<SEC-DOCUMENT>0001570562-22-000067.txt : 20220303
<SEC-HEADER>0001570562-22-000067.hdr.sgml : 20220303
<ACCEPTANCE-DATETIME>20220303170208
ACCESSION NUMBER:		0001570562-22-000067
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220303
DATE AS OF CHANGE:		20220303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolus, Inc.
		CENTRAL INDEX KEY:			0001570562
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				461385614
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38381
		FILM NUMBER:		22710041

	BUSINESS ADDRESS:	
		STREET 1:		520 NEWPORT CENTER DRIVE
		STREET 2:		SUITE 1200
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
		BUSINESS PHONE:		(949) 284-4555

	MAIL ADDRESS:	
		STREET 1:		520 NEWPORT CENTER DRIVE
		STREET 2:		SUITE 1200
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>eols-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:4ac935c8-acd7-4078-a010-d8166688f707,g:62b990ab-d451-4f6d-92f0-709386d601f0,d:77038361ec4447b8be22639fec3c691b--><html xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:eols="http://www.evolus.com/20211231" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>eols-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl80L2ZyYWc6YTc2Y2EwNmJmZGExNDgwMDg0NjBmMWNjYjExNTYzMmYvdGFibGU6M2QwMTI5NGUwY2ZlNGNmNmEwOGI5OGJjMGQ2Y2EwMGYvdGFibGVyYW5nZTozZDAxMjk0ZTBjZmU0Y2Y2YTA4Yjk4YmMwZDZjYTAwZl8yLTEtMS0xLTI0Njk3_74df87d4-d24a-4062-9daf-7364c28aad83">false</ix:nonNumeric><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl80L2ZyYWc6YTc2Y2EwNmJmZGExNDgwMDg0NjBmMWNjYjExNTYzMmYvdGFibGU6M2QwMTI5NGUwY2ZlNGNmNmEwOGI5OGJjMGQ2Y2EwMGYvdGFibGVyYW5nZTozZDAxMjk0ZTBjZmU0Y2Y2YTA4Yjk4YmMwZDZjYTAwZl80LTEtMS0xLTI0Njk3_e8344e00-c296-477d-a1a1-bc689559faf6">2021</ix:nonNumeric><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl80L2ZyYWc6YTc2Y2EwNmJmZGExNDgwMDg0NjBmMWNjYjExNTYzMmYvdGFibGU6M2QwMTI5NGUwY2ZlNGNmNmEwOGI5OGJjMGQ2Y2EwMGYvdGFibGVyYW5nZTozZDAxMjk0ZTBjZmU0Y2Y2YTA4Yjk4YmMwZDZjYTAwZl81LTEtMS0xLTI0Njk3_5099efe3-41fe-4d4a-a40a-ca2369847dce">FY</ix:nonNumeric><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl80L2ZyYWc6YTc2Y2EwNmJmZGExNDgwMDg0NjBmMWNjYjExNTYzMmYvdGFibGU6M2QwMTI5NGUwY2ZlNGNmNmEwOGI5OGJjMGQ2Y2EwMGYvdGFibGVyYW5nZTozZDAxMjk0ZTBjZmU0Y2Y2YTA4Yjk4YmMwZDZjYTAwZl84LTEtMS0xLTI0Njk3_f21de7f7-160c-4a69-bd79-fb58af3b4f35">0001570562</ix:nonNumeric><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfOS0wLTEtMS0yNDY5Nw_88e79aa4-bc34-4d38-bbd8-aeec1c06ccdf">http://fasb.org/us-gaap/2021-01-31#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfOS0wLTEtMS0yNDY5Nw_bbfa6ccc-bec5-4fce-81ec-f28ff59e01f1">http://fasb.org/us-gaap/2021-01-31#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="i68cb09998d774788979c19e4685aad8f_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE3MzI_fb117ad8-2568-44c6-bb64-c540497d2484">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="eols-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fa2f71f5a7041d1ace4d871fe10e977_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iaa72dc4cee564575a0f6a6004820d124_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8935b4319e2d40ef96ac74a02189f082_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib874ac63dd264f8fabd518dd19e7db7a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4cecda8a60147e1a6dbe55bc70c5855_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff1ebb6d09924e6db55a5c3231e23615_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a339248c57c4c3fbb0a8c12261031e6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c58ee31658f47ddb1bed8a3b81a0f35_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8472362221cf41d88c702018e38d71e8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idebc0775b4d14420bd4c6971f6b63b0b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9be00354c46b4b8b96a26749f9c3e28d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb18fef826e14bf1b6a11208896433a1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic454c127b7694ec7929df6e51728c3f3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9496baa43c834ff9b11ec53efd6d7f91_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i618370635dad4cc09cde0158985bd9fc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff982f9041634290a7428662c88e90ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if065d88090344c76906d42f9e58f3946_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idac57e11cdc94016861bd9248bcdb528_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dae31c8b50a4ed9834cf14ad981a07f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b072e47c4674802bf86129ee1b3d043_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5bcb363afdf4b8db455485e8e2ad3fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic40c99d6b0a04616bf00bfc233eced25_D20210228-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-28</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55331949261b40a1b1fb09e4158cee28_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib797f956941d4495ae3f6f4926ca7cd1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae9c7ae95d9f43cbb4015233b65597a5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida8a057d5f3b4f8999abff6725b2469f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9bdbef71f2046fc80639fa5cacb44eb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19668eba2a9a432cbae4ec0e6254aa0e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b39b85b47cc450fbde4206b76345039_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i191b278dcfec47f3972561e051202c15_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide759804fa684555b30ad8d92e40dd8f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e49ab226c6f4296b8a462ca4e5b73d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7f853492f874d82b33dd9c2cb1fff79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba22e2b749b44db0bac4acb2ea8a9073_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0eed27f558fa49d5b84d4d3ba1bfef2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i861bdd7e206b435b912b799375902ac9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7a53a744c7f48d4bb28c1d16000d70f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb4365e9adeb459aa371d09c5f6def3f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia43c0d4587004db0b6f491872654d03a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic59095e4226448ca90c7c028c530b46b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf213e710f77493dadadc321fcf59639_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1a49dbd0cdc4fa299c6fc4b349cd1c9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c22c52daf7d4250a52799a0d558499a_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b22c9a255f64ef69528be6cf90f2d57_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3dc0d8eadaf4cf7918bae649c0b4261_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8655593ec8584a3a81c2026e2ac5d7f4_D20230101-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdb8c8bf46044c1d94ceba9d58481dda_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib67b7815bf86448c836c0674ab2cd400_I20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67974a995ff142e8bcd737a314d25651_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87285d3792f541dfb0b8bd76edc9ed8b_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i369b3df3ec04419fa040ca2ec1d798db_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i581d900790a24282bf837c0e06b7b5f4_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f2ebd8bfca6432bb520e3b56fadc096_D20210601-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>eols:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="icdebbf3fdf644e34be10eab249d933bc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3bdecfb61f64eacb1bec28f7caef51c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia035180a7f3e4b968ed0e22107620141_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if89a2df2b8e54c8d8ee79434f9442e05_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1af8740f4504d02a822562858322d3f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic88608af4b8d44f29f8f6a890a3e0859_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia307b0175e9a4f089eff6272a567b599_D20210218-20210218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-18</xbrli:startDate><xbrli:endDate>2021-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e4a414b331e4768a456b40889b5bf16_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec7e63cb81e2460c81caf30e8a3ecb3e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a7d2bddc6cf450cb25bddf49c81a86d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id34ebca0dbac4892b9e26b1d887fc863_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41ae1e1c1bad4e168f9a39b7db9fc6ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fc31951483143dfaeb4fa1205ce3584_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6de2de54a6f5422793e33fa044c6ac61_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b5f19e8647e4e1294248e74152897f8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if36312ac79504238b5690df729b1f37c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc1dd5e647ea4c61b81e841d2fa58ac8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaadf7ebcb2440558c596d02aa4fe18d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i188292fb611741ec93ece11f8e4d57aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2126481ac7a74980a92e9285369775dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21f2ba8ba1854a108007d265c9b25d60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9646e12d03f4e54b9e9276d5b1d0f3a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id68d8821d04841b29a08745afac4b24a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c80b688d1614017ad7563e60cbf9695_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93faa46c660e429db8bd1d5c2859380e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81b74edf017e427b8f5b7fafd4bc3d1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17c0c8daaf4141d78d576fc09db214fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief25c158c2d14085a69e4a3d492bdfd3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95e8f96583894a6cb3bc3881f9f0ed7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="year"><xbrli:measure>eols:year</xbrli:measure></xbrli:unit><xbrli:context id="i44f0543f775c46f490919b75592c1ee5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i4297d135149943959e21307f69d5bb57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3723caf0d1864617b4ad156f12392622_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i239343ea90f94848ab298a3e8b49d754_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aa9cf7ce6924d97b753fab0a35caffd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a3026926537414c9e558b2f48c5ac00_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57c030fa26f84d46a809534c6d533f06_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecd7c427bcea41a68a2333c4ab2e58f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i135354304f194b65a202352820714058_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bcc0e46ed1c4cd4b910b9542aaeca6e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ef09bce4de74ec69fa66b0204b03c06_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bbaa2f404694cf09f8b1dd48adb8b5a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26cd83bcd422412f813d386ddac29197_D20190201-20190201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88606d7b76234da8a815ea40351a89f6_D20190201-20190201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58135f80c4e74590a70a971e21d37e1f_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i925e16da5e194d4986f670bfe115cfd7_I20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>eols:tranche</xbrli:measure></xbrli:unit><xbrli:context id="i96e618230e7d48238d27ef49600d13df_I20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0b2c7ebaf23495d8d1cc10fab315eb7_D20211214-20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-14</xbrli:startDate><xbrli:endDate>2021-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4f1ae42ca284ea69054431a374441c1_D20211214-20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-14</xbrli:startDate><xbrli:endDate>2021-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="payment"><xbrli:measure>eols:payment</xbrli:measure></xbrli:unit><xbrli:context id="i4ec3d79630cc4ba09ef1b19959bd91f0_D20211214-20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-14</xbrli:startDate><xbrli:endDate>2021-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i559b9a0d8aa547d0b36e58c3d536751e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id698b63e55694d648621289908e0dcbe_I20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e5503a1fc4a4988a8da895468afd601_I20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0449988c955c422a849943b6ec89fe73_I20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i709c7ab6d38744cca0fbeb034841964d_I20190315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="advance"><xbrli:measure>eols:advance</xbrli:measure></xbrli:unit><xbrli:context id="ie909f3b79bd4486daae42675b5641c62_I20190315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbb534318d9f4bd5bc4b81a523ac249b_I20190315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i458308c7266b440eb668d7481bd1e4b3_D20190315-20190315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-15</xbrli:startDate><xbrli:endDate>2019-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69e7efe2c2b144989db5533678b61c21_D20190315-20190315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-15</xbrli:startDate><xbrli:endDate>2019-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf71c87e895a46f09a7abf6657f2b04d_I20190315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97c0f553670c4c3495114a22bf868a2f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b43edc16c22483086f802b6b9cf884c_I20190315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cac7bab107947c89fb60b9a19aa1ed2_D20210104-20210104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaae348537d9a4136a16f6e54e4e524a6_I20200706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99d0525d0e434079b1d9eb140af4688c_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i639ff7637d4f4af7b61468f913b844be_D20201016-20201028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-16</xbrli:startDate><xbrli:endDate>2020-10-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="complaint"><xbrli:measure>eols:complaint</xbrli:measure></xbrli:unit><xbrli:context id="id67d131284974c959850a72560bf6292_D20201127-20201202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-27</xbrli:startDate><xbrli:endDate>2020-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>eols:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="ibb11d4e5afdb4c27ae1e67ee48ded284_D20210325-20210325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63f4e91998714dab927a5acf4a92ddb8_D20210326-20210326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-26</xbrli:startDate><xbrli:endDate>2021-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75496e7d4351422aa519e8a590bc554b_I20210326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic142d9a5a6964798b2bc095cf05edeb8_I20171121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0caf9e9143e34777b8ae279b103a9da1_D20171121-20171121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-21</xbrli:startDate><xbrli:endDate>2017-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i517a2340d6ac4cfb8363af7585980dcf_I20211121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7869351f7bde4260a08aa49ce4ef2470_I20201121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68cb09998d774788979c19e4685aad8f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id708d9ed50e54617af7629252e0fa1c6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecdda6aa05b04bfcab114de1346b4b98_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:RestrictedStockUnitsRSUsPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd29a6c578714db49b385b4f9e60b606_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:RestrictedStockUnitsRSUsPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef5563a248f47b9b87ca621a1f1eed8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:RestrictedStockUnitsRSUsMarketConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1da74bb1ddc84684bf5d405096cdedeb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:RestrictedStockUnitsRSUsMarketConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie061e2ccf1e04536b767f55687880f70_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia803156cd5cc4477b4ba2e43f8f8880d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1328d543a76b4257a15411d3fc978c8d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35d707ed76cb4921a043c6af35bf1696_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42f7ff0b06244a60a0750a47b3a469a0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic78866655f1e4fb7a2d18ed23eaca432_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88950351bb5049948706e070a4d2f1ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb1c0ae2c17f459f9a60df92e9ad83ba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4b758b9624b4b0996306bc2eeaddce7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i422b9466ee0c476e8729e37ee5d9e9d1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68cbcb58dbd347d186d56f67bdc0d88b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i258260be7e354c3dabf4d4df2ee981e1_I20210218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58d3338bb29342a7bea51d1b86c744ea_I20230915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9886998085bb48b9b58c8a53127543d0_I20240915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib98c7c392d2f4eaf8e8ab779dee845dd_I20250915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i002a56e0c1ec4c04b5999635912fcdc8_D20210323-20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-23</xbrli:startDate><xbrli:endDate>2021-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75469af343584e09847fb0027c3e78c7_D20210323-20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-23</xbrli:startDate><xbrli:endDate>2021-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if65ecdee742e445f89295c829f75efac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff738c7de2844195a714ca1b57f846c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa6947c0461b47158a26475a99eabf01_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4b16f01a5f7415687373739c3bf5523_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a37e00a5294439283de4636c2dc8b56_D20171214-20171214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-14</xbrli:startDate><xbrli:endDate>2017-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib72da45d6b9e4dfd9eaea3fd7a90255c_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i77038361ec4447b8be22639fec3c691b_1"></div><div style="min-height:9pt;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNDk4_d9286a33-6ae7-438f-a11e-f1defd658898">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNDk1_8aa7e4eb-9f5f-4e93-bcbc-4eac1840e2fd">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">For the fiscal year ended&#160;<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zMjk4NTM0ODg2OTI4_6d3ac15a-b300-400c-8d1e-f7dc8c2c5c9b"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zMjk4NTM0ODg2OTI4_3b045ff2-414d-43e0-b828-5b1172095d0c">December 31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">or</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNTA3_04bd61ad-1d1a-4cc7-8018-88f9824949f1">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to      </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">                  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNTAz_53ca8415-9bc3-4fb1-a9d5-1ba613010af4">001-38381</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNDk5_bb927288-6cc7-4112-ad32-878c411ebf2e">EVOLUS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YTQ2NjQ3NjNlMDIzNDk4ZGEwODhhNjRlM2FlNThjNWIvdGFibGVyYW5nZTphNDY2NDc2M2UwMjM0OThkYTA4OGE2NGUzYWU1OGM1Yl8wLTAtMS0xLTI0Njk3_abb789d5-6e78-4496-84c2-e9ea914391ce">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YTQ2NjQ3NjNlMDIzNDk4ZGEwODhhNjRlM2FlNThjNWIvdGFibGVyYW5nZTphNDY2NDc2M2UwMjM0OThkYTA4OGE2NGUzYWU1OGM1Yl8wLTItMS0xLTI0Njk3_5e39c71a-c0fa-49b3-9be4-ee23250693e3">46-1385614</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(State or other jurisdiction of <br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification Number)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YTQ2NjQ3NjNlMDIzNDk4ZGEwODhhNjRlM2FlNThjNWIvdGFibGVyYW5nZTphNDY2NDc2M2UwMjM0OThkYTA4OGE2NGUzYWU1OGM1Yl8yLTEtMS0xLTI0Njk3L3RleHRyZWdpb246YTEyZWJiMTAxYmZhNDZjNzlkZTU4MDg0OTdlY2EzMzFfNA_b4f380c2-8808-445a-a505-2204882db4b1">520 Newport Center Dr., Suite 1200</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YTQ2NjQ3NjNlMDIzNDk4ZGEwODhhNjRlM2FlNThjNWIvdGFibGVyYW5nZTphNDY2NDc2M2UwMjM0OThkYTA4OGE2NGUzYWU1OGM1Yl8yLTEtMS0xLTI0Njk3L3RleHRyZWdpb246YTEyZWJiMTAxYmZhNDZjNzlkZTU4MDg0OTdlY2EzMzFfNw_8f646d3a-2efe-4e50-8420-e76703de28bb">Newport Beach</ix:nonNumeric>, <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YTQ2NjQ3NjNlMDIzNDk4ZGEwODhhNjRlM2FlNThjNWIvdGFibGVyYW5nZTphNDY2NDc2M2UwMjM0OThkYTA4OGE2NGUzYWU1OGM1Yl8yLTEtMS0xLTI0Njk3L3RleHRyZWdpb246YTEyZWJiMTAxYmZhNDZjNzlkZTU4MDg0OTdlY2EzMzFfMTE_5cc76cef-182d-4aa1-8f95-26e9da3fccfa">California</ix:nonNumeric> <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YTQ2NjQ3NjNlMDIzNDk4ZGEwODhhNjRlM2FlNThjNWIvdGFibGVyYW5nZTphNDY2NDc2M2UwMjM0OThkYTA4OGE2NGUzYWU1OGM1Yl8yLTEtMS0xLTI0Njk3L3RleHRyZWdpb246YTEyZWJiMTAxYmZhNDZjNzlkZTU4MDg0OTdlY2EzMzFfMTQ_ea5dc133-298c-4eca-a799-58ea1257fd87">92660</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YTQ2NjQ3NjNlMDIzNDk4ZGEwODhhNjRlM2FlNThjNWIvdGFibGVyYW5nZTphNDY2NDc2M2UwMjM0OThkYTA4OGE2NGUzYWU1OGM1Yl8yLTEtMS0xLTI0Njk3L3RleHRyZWdpb246YTEyZWJiMTAxYmZhNDZjNzlkZTU4MDg0OTdlY2EzMzFfMTg_39dc62b6-7a7e-41f1-a8be-ef5e39860ea6">949</ix:nonNumeric>) <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YTQ2NjQ3NjNlMDIzNDk4ZGEwODhhNjRlM2FlNThjNWIvdGFibGVyYW5nZTphNDY2NDc2M2UwMjM0OThkYTA4OGE2NGUzYWU1OGM1Yl8yLTEtMS0xLTI0Njk3L3RleHRyZWdpb246YTEyZWJiMTAxYmZhNDZjNzlkZTU4MDg0OTdlY2EzMzFfMjI_8cfcbf75-de9c-48aa-930f-792698cdc192">284-4555</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6Y2E1NzQxZTRmODU3NGZkMmI5ZTlmMGQ1NmI4NGQ2YzEvdGFibGVyYW5nZTpjYTU3NDFlNGY4NTc0ZmQyYjllOWYwZDU2Yjg0ZDZjMV8yLTAtMS0xLTI0Njk3_7b0d2378-723c-493c-902c-785a1ee81a52">Common Stock, $0.00001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6Y2E1NzQxZTRmODU3NGZkMmI5ZTlmMGQ1NmI4NGQ2YzEvdGFibGVyYW5nZTpjYTU3NDFlNGY4NTc0ZmQyYjllOWYwZDU2Yjg0ZDZjMV8yLTEtMS0xLTI0Njk3_533ff849-5c19-4f30-ac3d-db7f8f6386cd">EOLS</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6Y2E1NzQxZTRmODU3NGZkMmI5ZTlmMGQ1NmI4NGQ2YzEvdGFibGVyYW5nZTpjYTU3NDFlNGY4NTc0ZmQyYjllOWYwZDU2Yjg0ZDZjMV8yLTItMS0xLTI0Njk3_5428be29-5d88-499b-b540-1c6622b635c8">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#9744; <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNTA1_72744ac7-e12a-48ba-89c2-c25c0adbfeb4">No</ix:nonNumeric>&#160;&#9746;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNTA0_e3d67385-967a-456b-be6c-5c6734515af3">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNDk3_e84c041d-553a-477f-83b9-8df5e227f275">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be&#160;submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNTAw_867c4a2d-9f08-41f9-97c1-59bd722489e0">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.834%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YzdjMzhkZThlZmI5NDk1YmEzZjRkMjljNjFmOTM5MDEvdGFibGVyYW5nZTpjN2MzOGRlOGVmYjk0OTViYTNmNGQyOWM2MWY5MzkwMV8yLTAtMS0xLTI0Njk3_1536bf97-e22c-440c-9631-7f32c294ce23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YzdjMzhkZThlZmI5NDk1YmEzZjRkMjljNjFmOTM5MDEvdGFibGVyYW5nZTpjN2MzOGRlOGVmYjk0OTViYTNmNGQyOWM2MWY5MzkwMV8yLTMtMS0xLTI0Njk3_14aef32c-223f-40dd-8e7a-f1a3a8c4fe4e">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YzdjMzhkZThlZmI5NDk1YmEzZjRkMjljNjFmOTM5MDEvdGFibGVyYW5nZTpjN2MzOGRlOGVmYjk0OTViYTNmNGQyOWM2MWY5MzkwMV8zLTMtMS0xLTI0Njk3_a58136e4-718f-4003-b9c9-c01b5919236e">&#9746;</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityExTransitionPeriod" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNDk2_e577062b-ac89-451e-8408-05a9a96ff4e5">&#9746;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes &#9744;    No  <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNTAx_8276c257-33d9-401f-bb64-680440762b74">&#9746;</ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zMjk4NTM0ODg2OTQ2_ca85489e-9ef6-45a6-b157-a53078b6e8c8">&#9746;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was approximately $<ix:nonFraction unitRef="usd" contextRef="i4fa2f71f5a7041d1ace4d871fe10e977_I20210630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8yODkw_63546625-21df-4bf2-8c51-408ebb78f88e">423.2</ix:nonFraction>&#160;million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Global Market of $12.65&#160;per share for such date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of February&#160;28, 2022, <ix:nonFraction unitRef="shares" contextRef="iaa72dc4cee564575a0f6a6004820d124_I20220228" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8xMDk5NTExNjMxMzI2_ac19b21a-a6d5-4f9d-9974-e96535e33189">55,694,452</ix:nonFraction> shares of the registrant&#8217;s sole class of common stock were outstanding.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span><br/></span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:9pt;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNTAy_83e7ed89-93dc-43f0-9d25-fd0f7d6e537e" escape="true">Portions of the registrant's Proxy Statement for the 2022 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December&#160;31, 2021.</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLUS, INC.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_19">14</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_22">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_25">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_28">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_31">44</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_37">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_40">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_40">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_43">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_67">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_67">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_70">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_70">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_133">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_133">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_136">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_136">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_139">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_139">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_1099511629303">Disclosure Regarding Foreign Jurisdictions that Prevent Inspection</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_1099511629303">95</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART III</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_145">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_145">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_148">Executive Compensation </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_148">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_151">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_151">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_154">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_154">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_157">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_157">99</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART IV</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_163">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_163">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_166">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_166">103</a></span></div></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#3216ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#3216ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_169">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;margin-top:6pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Special Note Regarding Forward-Looking Statements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve risks and uncertainties, including statements based on our current expectations, assumptions, estimates and projections about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, or other comparable terms intended to identify statements about the future. The forward-looking statements included herein are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to, those made below under &#8220;Summary of Risk Factors&#8221; and in Item 1A Risk Factors in this Annual Report.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider these risks, as well as the additional risks described in other documents we file with the SEC in the future, including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which may from time to time amend, supplement or supersede the risks and uncertainties we disclose. We also operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements included herein are based on current expectations of our management based on available information and are believed to be reasonable. In light of the significant risks and uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should read this Annual Report on Form 10-K and the other documents we file with the SEC with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by the cautionary statements referenced above.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in our securities involves various risks and you are urged to carefully consider the risks discussed under Item 1A &#8220;Risk Factors,&#8221; in this Annual Report on Form 10-K prior to making an investment in our securities. If any of the risks below or in Item 1A &#8220;Risk Factors&#8221; occurs, our business could be materially and adversely affected. As more fully described in Item 1A &#8220;Risk Factors&#8221;, the principal risks and uncertainties that may affect our business, financial condition and results of operations include, but are not limited to, the following:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently depend entirely on the successful commercialization of our only product, Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If we are unable to successfully market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we may not generate sufficient revenue to continue our business.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a limited operating history and have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We have only one approved product, which, together with our limited operating history, makes it difficult to assess our future viability.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may require additional financing to fund our future operations, and a failure to obtain additional capital when so needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our operations.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we or our counterparties do not comply with the terms of our settlement agreements with Medytox, Inc., or Medytox, and Allergan Limited, Allergan, Inc. and Allergan Pharmaceuticals Ireland, or, collectively, Allergan, we may face litigation or lose our ability to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which would materially and adversely affect our ability to carry out our business and our financial condition and ability to continue as a going concern.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The terms of the Medytox/Allergan Settlement Agreements with Medytox and Allergan will reduce our profitability and may affect the extent of any discounts we may offer to our customers.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business, financial condition and operations have been, and may in the future be, adversely affected by the COVID-19 outbreak or other similar outbreaks.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on the license and supply agreement, as amended, with Daewoong, which we refer to as the Daewoong Agreement, to provide us with exclusive rights to distribute Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in certain territories. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect our development and commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure to successfully in-license, acquire, develop and market additional product candidates or approved products would impair our ability to grow our business.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">faces, and any of our future product candidates will face, significant competition and our failure to effectively compete may prevent us from achieving significant market penetration and expansion.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may fail to achieve the broad degree of physician adoption and use or consumer demand necessary for commercial success.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to market Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is limited to use for the treatment of glabellar lines, and if we want to expand the indications for which we market Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we will need to obtain additional regulatory approvals, which will be expensive and may not be granted.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third party claims of intellectual property infringement may prevent or delay our commercialization efforts and interrupt our supply of products.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we or any of our current or future licensors, including Daewoong, are unable to maintain, obtain or protect intellectual property rights related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any of our future product candidates, we may not be able to compete effectively in our market.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need to increase the size of our organization, including our sales and marketing capabilities in order to further market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and we may experience difficulties in managing this growth.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on our digital technology and applications and our business and operations would suffer in the event of computer system failures or breach by hackers.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to extensive government regulation, and we may face delays in or not obtain regulatory approval of our product candidates and our compliance with ongoing regulatory requirements may result in significant additional expense, limit or delay regulatory approval or subject us to penalties if we fail to comply.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context indicates otherwise, as used in this Annual Report on Form 10-K, the terms &#8220;Evolus,&#8221; &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Evolus, Inc., a Delaware corporation, and our subsidiaries taken as a whole, unless otherwise noted. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EVOLUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Evolux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are three of our trademarks that are used in this Annual Report on Form 10-K. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the trade name in the United States for our approved product with non-proprietary name, prabotulinumtoxinA-xvfs. The product has different trade names outside of the United States, but is referred to throughout this Annual Report on Form 10-K as Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Annual Report on Form 10-K also includes trademarks, trade names and service marks that are the property of other organizations, such as BOTOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BOTOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cosmetic, which we refer to throughout this Annual Report on Form 10-K as BOTOX. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K may appear without the &#174; and &#8482; symbols, but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I</span></div><div id="i77038361ec4447b8be22639fec3c691b_16"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;Business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first commercial product is Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is a proprietary 900 kilodalton, or kDa, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. Our primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. We believe we offer customers and consumers a compelling value proposition with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Currently, BOTOX (onabotulinumtoxinA) is the neurotoxin market leader, and prior to the approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was the only known 900 kDa botulinum toxin type A complex approved in the United States. We believe aesthetic physicians generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we received the approval of our first product Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration, or FDA. In May 2019, we commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States, and our net product revenue totaled $99.0 million for fiscal year 2021 and $34.7 million for the fourth quarter of 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we announced the initiation of a Phase II clinical trial designed to investigate a higher strength dose of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the glabellar lines. We plan to enroll our first patient in the clinical trial during the first quarter of 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, we received approval from Health Canada&#160;for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age.&#160;We began marketing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada in October 2019 through our distribution partner, Clarion Medical Technologies, Inc., or Clarion, and our net service revenue totaled $0.7 million for fiscal year 2021. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received approval from the European Commission, to market Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in all 27 European Union, or EU, member states plus the United Kingdom, Iceland, Norway and Liechtenstein. In January 2021, we received a positive decision from the European Commission to add the 50 unit product to the existing approval obtained in September 2019. We plan to launch Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe in select countries during the third quarter of 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received acceptance of our submission to the Australian Therapeutics Good Administration, or TGA, for regulatory approval of our neurotoxin in Australia in the first quarter of 2022. We expect to receive full TGA regulatory approval and launch the product in Australia in 2023.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Market </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary market is self-pay aesthetic healthcare, which includes medical products purchased by physicians that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. By focusing on the self-pay medical aesthetics market, we believe we are not exposed to reimbursement risk associated with a reliance on payments from such third-party payors, and we are subject to fewer regulations that place limits on the types of marketing and other interactions we have with physicians.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to Medical Insight&#8217;s The Global Aesthetic Market Study, within the self-pay aesthetic market, the global aesthetic neurotoxin market is estimated to grow to approximately $5.5 billion in 2025. The U.S. aesthetic neurotoxin market is expected to grow to approximately $2.9 billion in 2025. According to Clarivate Aesthetic Injectables Market Insights, the European aesthetic neurotoxin market is expected to grow to approximately $621 million in 2025.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the growth in the medical aesthetics market is driven by a number of factors, including:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased use by millennials who are increasingly seeking medical aesthetic treatments and utilizing neurotoxins as an entry point for aesthetic procedures due to their minimally invasive nature;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an aging population together with an increasing life expectancy, which is resulting in more consumers with a desire for improved appearance and well-being over a longer period of time; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rising disposable income, with the U.S. Bureau of Economic Analysis reporting that real disposable income in the United States increased approximately 21% from December 2012 to December 2021;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">growing awareness, utilization and acceptance of elective or minimally invasive aesthetic procedures;&#160;and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued innovation and improved accessibility to these treatments due to an increase in the number of physicians who perform these procedures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the multiple age groups that receive aesthetic neurotoxin treatments, we strategically focus our marketing efforts on the millennial segment which is the largest cohort in the U.S. population. In 2019 there were estimated to be approximately 73 million millennials, defined as individuals born between 1981 and 1996. We believe that approximately 1.7 million females between the age of 30 and 39, which includes many individuals we define as millennials, are considering neurotoxins in the next twelve months.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Competitive Strengths </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer physicians and consumers a compelling value proposition because:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> offers the market the first known 900 kDa neurotoxin alternative to BOTOX.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The manufacture of both Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BOTOX starts with a 900 kDa complex, includes adding the excipients human serum albumin, or HSA, and sodium chloride, and finishes by vacuum drying. We believe Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the only known neurotoxin product in the United States with a 900 kDa neurotoxin complex other than BOTOX. We also believe an important component of competitiveness in the neurotoxin market relates to the characteristics associated with the 900 kDa complex and the potential of the accessory proteins to increase the effectiveness of the active toxin portion of the complex.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Enhanced level of physician-customer interaction through a self-pay, aesthetic-only marketing strategy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have elected to specifically target the self-pay aesthetic market. With a reduced regulatory burden compared to third-party payor reimbursed therapeutic products, there is a number of benefits that market participants in reimbursed markets are unable to achieve, such as an enhanced level of interaction with our physician-customers. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the only U.S. neurotoxin without a therapeutic indication. We believe pursuing an aesthetic-only non-reimbursed product strategy creates meaningful strategic advantages in the United States, including pricing and marketing flexibility. We utilize this flexibility to drive market adoption through programs such as promotional events, experience product programs and pricing strategies.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We offer a unique technology platform.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We provide a simple, personal and connected experience for physicians utilizing our proprietary technology platform. We have built and continue to improve our platform with the goal of limiting friction and enhancing the overall experience for physicians and ultimately consumers. We are modernizing the customer engagement with our proprietary &#8220;Evolus Practice&#8221; app. We not only leverage technology for operational efficiency, but more importantly, to enhance a customer&#8217;s experience. The combination of a highly specialized sales force and our technology platform is an effective and competitive model. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Results from our TRANSPARENCY global clinical program in more than 2,100 patients provides robust data to physicians evaluating the purchase of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe the comprehensive TRANSPARENCY clinical data set, including a head-to-head Phase III study comparing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BOTOX, provides physicians with confidence in recommending Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to their patients.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We have strong relationships with aesthetic key opinion leaders, or KOLs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have established relationships with aesthetic KOLs as a result of our management team&#8217;s industry experience and engagement of our clinical trial investigators. KOLs are important information resources to the general physician-customer market due to their clinical expertise, academic reputations, active clinical practices and their status as medical innovators. The broader physician community often looks to KOLs for their experience with products and procedures as part of their new product and procedure adoption process.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Our management team has significant experience and expertise in medical aesthetics.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our management team has extensive experience in self-pay healthcare markets, in the development, market launch and commercialization of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">major medical products, execution and integration of business development transactions, identification of and partnerships with KOLs, and understanding of the regulatory environment of the healthcare markets. Key members of our leadership team have also served in relevant senior leadership positions with leading aesthetic companies.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States with our own specialty sales organization now consisting of over 70 positions between representatives, management and other sales employees and in Canada through our distribution partner, Clarion. We plan to launch in select European countries during the third quarter of 2022. We plan to expand our product offerings over time through in-licensing, partnerships and acquisitions and by launching our products internationally. The key components of our strategy are:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pursue an aesthetic-only strategy to enhance marketing and pricing flexibility along with improving transparency for our customers.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leverage our strong KOL relationships to assist in scientific presentations, publications, and other methods to drive success of our commercial launch of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Launch directly or partner outside of the United States to reach and serve physicians and consumers in those territories. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leverage our differentiated digital platform to efficiently open new accounts, personalize the purchasing process and efficiently deploy marketing programs at scale.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Establish a leading medical aesthetics company with a diversified product offering by in-licensing technology, developing partnerships and potentially acquiring products.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Overview</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an injectable formulation of a 900 kDa botulinum toxin type A complex designed to address the needs of the large and growing facial aesthetics market.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contains a 900 kDa botulinum toxin type A complex produced by the bacterium </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clostridium botulinum.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The active part of the neurotoxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins that we believe help with the function of the active portion of the toxin. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has the same mechanism of action as other type A botulinum toxins. When injected intramuscularly at therapeutic doses, botulinum toxin causes a chemical denervation of the muscle resulting in localized reduction of muscle activity. Botulinum toxin type A specifically blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSPARENCY: Evolus Clinical Development for Glabellar Lines</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TRANSPARENCY was a comprehensive five-study clinical development program for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and was used to meet the regulatory requirements for a Biologics License Application, or BLA, in the United States, a Marketing Authorisation Application, or MAA, in the EU, and a New Drug Submission, or NDS, in Canada, for the treatment of moderate to severe glabellar lines. The TRANSPARENCY program, which was developed in consultation with the FDA, Canadian, and European regulatory bodies, included three multicenter, randomized, double-blinded, controlled, single dose Phase III studies titled EV-001, EV-002 and EVB-003. Treatment of the Glabellar lines was based on a 4-point photonumeric Glabellar Line Scale, or GLS, where 0=no lines, 1=mild lines, 2=moderate lines and 3=severe lines.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Phase III Clinical Trials </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Composite End Point Versus Placebo</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The two identical U.S. Phase III studies, EV-001 and EV-002 (the &#8220;U.S. Phase III Studies&#8221;), enrolled a combined 654 adults who had moderate to severe glabellar lines at maximum frown. Subjects were randomly assigned in a 3:1 ratio to receive a single treatment of either Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or placebo. The primary efficacy endpoint was defined as the proportion of subjects classified as responders on Day 30. A subject was considered a responder only if both the investigator and the subject independently agreed that there was a 2 point improvement or greater on the GLS from Day 0 to Day 30 at maximum frown. This type of endpoint where both the investigator and subject must agree is known as a composite endpoint.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both of the U.S. Phase III studies met the primary endpoint of superiority over placebo. The percentages of responders in the intent to treat population were:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">EV-001: 1.2% placebo, 67.5% Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with an absolute difference between the groups of 66.3%, 95% CI (59.0, 72.4)</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">EV-002: 1.3% placebo, 70.4% Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with an absolute difference between the groups of 69.1%, 95% CI (61.5, 75.1)</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EU Phase III Clinical Trials &#8211; Head-to-Head Comparison of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, Botox and Placebo</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EVB-003 study was the third Phase III safety and efficacy study in the TRANSPARENCY Program and compared the efficacy of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Botox and Placebo. The study was conducted in Europe and Canada and enrolled 540 adults who (i) the investigator assessed to have moderate to severe glabellar lines and (ii) who felt their glabellar lines had an important psychological impact, such as on their mood, anxiety or depressive symptoms. Subjects were randomly assigned in a 5:5:1 ratio to receive a single treatment of 20 units of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 20 units of BOTOX or placebo.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary efficacy endpoint was defined as the proportion of subjects classified as responders on Day 30. A responder was a subject with a GLS score of 0 or 1, as assessed by the investigator at maximum frown. The primary analysis of the primary efficacy endpoint in the EVB-003 study showed the superiority of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over placebo, and established non-inferiority of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to BOTOX. The percentages of responders for the primary efficacy endpoint were:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">4.2% in the placebo group, 95% CI (0.0, 9.8);</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">82.8% in the BOTOX group, 95% CI (78.1, 87.5); and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">87.2% in the Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> group, 95% CI (83.0, 91.5).</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A confidence interval, or CI, is a range of values in which, statistically, there is a specified level of confidence where the result lies. As an example, in the results above for this Phase III study, the results indicate that there is a 95% level of confidence that the responder rate for placebo was between 0.0% and 9.8%, which we express as: 95% CI (0.0, 9.8). </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The absolute differences between the treatment groups were:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">83.1% between Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and placebo groups, 95% CI (70.3, 89.4), (p&lt;0.001), indicating Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was superior to placebo; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">4.4% between Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BOTOX groups, 95% CI (-1.9, 10.8), with non&#8209;inferiority of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> versus BOTOX concluded based on the lower bound of the 95% CI for the absolute difference exceeding -10.0%.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:47.931%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EU Phase III Primary Endpoint - Responder Rates at Maximum Frown on Day 30 (GLS = 0 or 1) by Investigator Assessment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EU Phase III Primary Endpoint - Non-Inferiority, at Maximum Frown on Day 30 by Investigator Assessment</span></td></tr><tr style="height:141pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="eols-20211231_g1.jpg" alt="eols-20211231_g1.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="eols-20211231_g2.jpg" alt="eols-20211231_g2.jpg" style="height:129px;margin-bottom:5pt;vertical-align:text-bottom;width:325px"/></div></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EU and Canadian Phase III Trial - Adverse Event Rate Summary</span></div><div style="margin-bottom:9pt;text-align:center"><img src="eols-20211231_g3.jpg" alt="eols-20211231_g3.jpg" style="height:166px;margin-bottom:5pt;vertical-align:text-bottom;width:348px"/></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EU and Canadian Phase III Trial - Select Secondary Endpoints</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:132pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="eols-20211231_g4.jpg" alt="eols-20211231_g4.jpg" style="height:169px;margin-bottom:5pt;vertical-align:text-bottom;width:522px"/></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*P-Value Placebo vs Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &lt;0.001</span></div></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSPARENCY Safety Evaluations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Safety was studied across all five studies that made up the TRANSPARENCY Clinical Program. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was relatively well tolerated with no drug related serious adverse events, or SAEs. Most adverse events were mild and the labeling information for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lists the most common adverse reactions as headache (9.3%), eyelid ptosis (2.0%), upper respiratory tract infections (3%) and increase white blood cell count (1%).</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase II &#8220;Extra Strength&#8221; Clinical Trial</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we announced the initiation of a Phase II clinical trial designed to investigate a higher strength dose of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the glabellar lines. This planned glabellar line study is a controlled, randomized, prospective, double blind, three-arm trial following patients out to a maximum of 12 months. Three-arms will be enrolled: the currently approved 20 units of BOTOX and 20 units of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> compared to 40 units of &#8220;extra strength&#8221; Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Study initiation activity has begun with an open Investigational New Drug (&#8220;IND&#8221;) application and the first patient is expected to be enrolled in the first quarter of 2022. We anticipate completing the study in the first half of 2023.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Daewoong Pharmaceuticals Co. Ltd., or Daewoong, manufactures and supplies Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to us. Daewoong has over 70 years of experience manufacturing pharmaceutical products and is one of the largest pharmaceutical companies in South Korea. Daewoong constructed a facility in South Korea where Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is produced. We believe this facility will be sufficient to meet demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the foreseeable future. The FDA conducted a current Good Manufacturing Practice, or cGMP, and pre-approval inspection of the facility in November 2017 in connection with our Biologics License Application, or BLA, for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The UK Medicines and Healthcare Products Regulatory Agency, or MHRA, also completed an inspection of the manufacturing facility in February 2018 in connection with our Marketing Authorisation Application, or MAA. The U.S. FDA approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in February 2019 included approval to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at Daewoong&#8217;s facility.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Daewoong License and Supply Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, we entered into the Daewoong Agreement, pursuant to which Daewoong agreed to manufacture and supply Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and grant us an exclusive license to import, distribute, promote, market, develop, offer for sale and otherwise commercialize and exploit Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for aesthetic indications in the United States, EU, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, Russia, certain members of the Commonwealth of Independent States, or CIS, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Under the Daewoong Agreement, we are required to make certain minimum annual purchases in order to maintain the exclusivity of the license. If we fail to meet these purchase requirements, Daewoong may, at its option, convert the exclusive license for such covered territory to a non-exclusive license. These minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and our future market share in various jurisdictions. Under the Daewoong Agreement, Daewoong is responsible for all costs related to the manufacturing of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including costs related to the operation and upkeep of its manufacturing facility, and we are responsible for all costs related to obtaining regulatory approval, including clinical expenses, and commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the Daewoong Agreement expires September 30, 2023, and automatically renews for unlimited additional three-year terms if we meet certain performance requirements. The Daewoong Agreement will terminate (A) upon written notice by either us or Daewoong upon a continuing default that remains uncured within 90 days (or 30 days for a payment default) by the other party, or (B) without notice upon the bankruptcy or insolvency of our company.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Daewoong Agreement, we are the sole owner of any marketing authorization and clinical trial results we pursue in a covered territory. However, if we do not renew the Daewoong Agreement or upon termination of the Daewoong Agreement due to a breach by us, we are obligated to transfer our rights to Daewoong.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of Settlement Agreements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we settled litigation claims related to a complaint against us filed by Allergan, Inc. and Allergan Limited (together, &#8220;Allergan&#8221;) and Medytox, Inc. (&#8220;Medytox&#8221;) in the U.S. International Trade Commission related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;ITC Action&#8221;) and certain related matters by entering into a Settlement and License Agreement with Medytox and Allergan, which we refer to as the U.S. Settlement Agreement, and another Settlement and License Agreement with Medytox which we refer to as the ROW Settlement Agreement. We refer to the U.S. Settlement Agreement and the ROW Settlement Agreement collectively as the Medytox/Allergan Settlement Agreements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Medytox/Allergan Settlement Agreements, we agreed to (i) make cash payments of $35.0&#160;million in multiple payments over two years to Allergan and Medytox, of which we paid the first payment of $15.0&#160;million in the third quarter of 2021 and $15.0&#160;million during the first quarter of 2022, with final payment of $5.0 million due in 2023, (ii) pay to Allergan and Medytox royalties on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on a certain dollar amount per vial sold of Licensed Products by or on our behalf in the United States, from December 16, 2020 to September 16, 2022, (iii) from December 16, 2020 to September 16, 2022, pay Medytox a low-double digit royalty on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sold by us or on our behalf in territories we have licensed outside the United States, and (iv) beginning September 16, 2022 to September 16, 2032, we will pay Medytox a mid-single digit royalty percentage on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and all territories we have licensed outside the United States. We also issued 6,762,652 shares of our common stock to Medytox.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary competitors are companies offering injectable dose forms of botulinum toxin. There are only four approved injectable botulinum toxin type A neurotoxins in the United States, including Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. There are also other injectable botulinum toxin type A products being developed for the U.S. market. We believe the primary competing products in this market include BOTOX, Dysport and Xeomin:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BOTOX, marketed by Allergan plc, or Allergan, received FDA approval in 2002 for glabellar lines. Allergan (now AbbVie) was the first company to market neurotoxins for aesthetic purposes.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dysport, marketed by Galderma S.A., or Galderma, received FDA approval in 2009 for glabellar lines.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Xeomin, marketed by Merz Pharma GmbH &amp; Co., or Merz, received FDA approval in 2011 for glabellar lines.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also aware that Revance Therapeutics, Inc. has submitted a BLA to the FDA for an injectable botulinum toxin type A neurotoxin and in October 2021 received a Complete Response Letter from the FDA. Additionally, Hugel Inc., has submitted </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a BLA to the FDA for an injectable botulinum toxin type A neurotoxin. If either BLA is approved, we expect the competition in the U.S. injectable botulinum toxin market to further increase. Most of our primary competitors are also approved to sell injectable botulinum toxin type A neurotoxins in Europe and other markets that we may enter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the companies commercializing and developing neurotoxins, there are other products and treatments that may indirectly compete with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, such as dermal fillers, laser treatments, brow lifts, chemical peels, fat injections and cold therapy. We compete with various companies that have products in these medical aesthetic categories. Among these companies are Allergan (now AbbVie), Sanofi, Sun Pharma, Valeant Pharmaceuticals International, Inc., or Valeant, Mentor Worldwide LLC, a division of Johnson &amp; Johnson, Merz, Galderma, and Skinceuticals, a division of L&#8217;Oreal SA. In addition, we are aware of other companies also developing and/or marketing products in one or more of our target markets, including competing injectable botulinum toxin type A formulations that are in various phases of development in North America for the treatment of glabellar lines. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into the U.S. aesthetic neurotoxin market in May 2019. Given the limited history of the commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the impact of the COVID-19 outbreak and the impact of the ITC remedial orders, we have not observed significant seasonality in our net revenues to date. However, we are aware that historically the aesthetic neurotoxin market experiences higher revenue in the second and fourth calendar quarters as compared to the first and third calendar quarters. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation in the United States</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly regulated industry that is subject to significant federal, state, local and foreign regulation. Our business has been, and will continue to be, subject to a variety of laws including the Federal Food Drug and Cosmetic Act, or FFDCA, and the Public Health Service Act, or the PHS Act, among others. Biologics and medical devices are subject to regulation under the FFDCA and PHS Act.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, cosmetics, dietary supplements, biopharmaceutical products and medical devices are subject to extensive regulation by the FDA. The FFDCA, PHS Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, regulatory approval, license or clearance, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of these products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending license or marketing applications, warning letters and other enforcement actions, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Marketing Approval</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an investigative new drug application, or IND, which must become effective before human clinical trials may begin;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed biological product for its intended use, according to the FDA&#8217;s regulations, commonly referred to as good clinical practices, or GCPs, and any additional requirements including those for the protection of human research subjects and their health and other personal information;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">purity and potency from results of nonclinical testing and clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preserve the biological product&#8217;s identity, strength, quality and purity and, if applicable, the FDA&#8217;s current good tissue practices for the use of human cellular and tissue products;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential FDA audits of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the BLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a BLA is approved, a product is subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Adverse event reporting and submission of periodic reports is required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase IV testing, Risk Evaluation and Mitigation Strategies, or REMS, and surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control as well as product manufacturing, packaging and labeling procedures must continue to conform to cGMP after approval. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the agency inspects manufacturing facilities to assess compliance with applicable regulations such as cGMP and the Quality System Regulation. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulation of the Healthcare Industry</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we do not currently have plans for our neurotoxin product to be covered by insurance or government reimbursement programs, if we were to offer reimbursable products, we could be subject to federal laws and regulations covering reimbursable products, such as the Anti-Kickback Statute, Stark Law and Physician Payment Sunshine Act. These laws that may affect our ability to operate include, but are not limited to:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Anti-Kickback Statute, which prohibit persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce either the referral of an individual, or furnishing or arranging for a good or service, for which payment may be made under a federal healthcare program;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Federal False Claims Act which imposes civil and criminal liability on individuals and entities who submit, or cause to be submitted, false or fraudulent claims for payment to the government;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), which prohibits certain payments made to foreign government officials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services relating to healthcare matters; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Federal Physician Payments Sunshine Act, and its implementing regulations, which require that certain manufacturers of drugs, medical devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program (with certain exceptions) to report to the CMS </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information related to certain payments or other transfers of value made or distributed to physicians, which is defined broadly to include other healthcare providers, teaching hospitals, and ownership and investment interests held by physicians and their immediate family members; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">State and foreign law equivalents of the foregoing and state laws regarding pharmaceutical company marketing compliance, reporting and disclosure obligations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of these laws, regulations, rules or policies or any other law or governmental regulation, or if interpretations of the foregoing change, we may be subject to civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation in Europe</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Economic Area, or EEA (which is composed of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein), medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are two types of MAs:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the EMA and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we are a biotechnology medicinal products company, we are eligible for a Community MA under the Centralized Procedure.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation Outside of the United States and Europe</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States and EU, we may be subject to a variety of regulations in other jurisdictions governing manufacturing, clinical trials, commercial sales and distribution of our future products. Whether or not we obtain FDA approval or MA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval or MA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Data Privacy and Security Laws and Regulations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to data privacy and security regulation by the federal government, states and non-U.S. jurisdictions in which we conduct our business. For example, HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221; those independent contractors or agents of covered entities that create, receive, maintain, transmit or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state and non-U.S. laws, including the General Data Protection Regulation adopted by the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EU, govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns. We also remain subject to federal or state privacy-related laws that are more restrictive than the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties. For example, the Federal Trade Commission uses its consumer protection authority to initiate enforcement actions in response to alleged privacy and data security violations. Further, certain states have proposed or enacted legislation that will create new data privacy and security obligations for certain entities, such as the California Consumer Privacy Act, or CCPA, which came into effect January 1, 2020 and was recently amended and expanded by the California Privacy Rights Act, or the CRPA, passed on November 3, 2020. The CCPA and CPRA, among other things, create new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also created a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. It remains unclear what, if any, additional modifications will be made to the CPRA by the California legislature or how it will be interpreted. Therefore, the effects of the CCPA and CPRA are significant and will likely require us to modify our data processing practices and may cause us to incur substantial costs and expenses to comply, particularly given our base of operations in California.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Regulation</span></div><div style="margin-bottom:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous foreign, federal, state, and local environmental, health and safety laws and regulations relating to, among other matters, safe working conditions, manufacturing practices, fire hazard control, product stewardship and end-of-life handling or disposition of products, and environmental protection, including those governing the generation, storage, handling, use, transportation and disposal of hazardous or potentially hazardous substances and biological materials. We believe that we have been and remain in substantial compliance with all applicable environmental laws and regulations and that we currently have no liabilities under such environmental requirements that could reasonably be expected to materially harm our business, results of operations or financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had 167 employees, all of whom are full-time in the United States and United Kingdom, and 69% of our full-time employees were women. None of our employees are represented by labor unions or covered by collective bargaining agreements, and we have never experienced any work stoppage. We believe we have good relations with our employees.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Attracting and Developing Talent</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our future success largely depends upon our continued ability to attract and retain highly qualified management and technical personnel. Talent management is critical to our ability to execute on our long-term growth strategy. To facilitate talent attraction and retention, we strive to make our company a safe and rewarding workplace, with opportunities for our employees to grow and develop in their careers, supported by strong compensation and benefits, and by programs that build connections among our employees. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation and Benefits</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To attract, retain and recognize talent, we aim to ensure merit-based, equitable compensation practices and strive to provide competitive compensation and benefit packages to our employees. Our compensation package includes competitive base pay, an annual performance bonus, long-term incentive awards, health care and retirement benefits, paid time off and family leave, among others.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health, Safety and Wellness</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to the health, safety and wellness of our employees. In response to the COVID-19 pandemic, we implemented changes that we determined were in the best interest of our employees, as well as the communities in which we operate, and which comply with government regulations. This included requiring our employees and sales professionals to work remotely when required by local jurisdictions, limiting non-essential travel and minimizing in-person work-related meetings.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inclusion and Belonging</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We promote an inclusive culture that values equity, opportunity, and respect. In 2019, we formed a Culture &amp; Belonging Council comprised of our employees. This council has a vision to create and foster a culture that reflects diversity and inclusion so that each of our employees has a sense of belonging as their authentic, unique selves. In support of our inclusive culture, we provide unconscious bias training to strengthen employee awareness and strive to recruit a diverse talent pool across all levels of the organization. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at&#160;520 Newport Center Drive, Suite 1200, Newport Beach, California 92660,&#160;and our telephone number is (949) 284-4555. Our website address is www.evolus.com. We do not incorporate the information on or accessible through our website into this Annual Report on Form 10-K, and you should not consider any information on, or that can be accessed through, our website a part of this Annual Report on Form 10-K or any other filing we make with the SEC. We are an emerging growth company under the Jumpstart Our Business Startups Act of 2012 and also a smaller reporting company, and therefore we are subject to reduced public company reporting requirements. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available, free of charge, on our website at www.evolus.com our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to such reports, as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC. All such reports are also available free of charge via EDGAR through the SEC website at www.sec.gov.&#160;We do not incorporate the information on or accessible through these websites into this Annual Report on Form 10-K, and you should not consider any information on, or that can be accessed through, these websites a part of this Annual Report on Form 10-K or any other filing we make with the SEC.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An investment in our company involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all the other information in this Annual Report on Form 10-K, including Item 7&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the financial statements and the notes thereto included in Item 8 &#8220;Financial Statements and Supplementary Data.&#8221; If any of the following risks actually occurs, our business, reputation, financial condition, results of operations, revenue, and future prospects could be seriously harmed. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. Unless otherwise indicated, references to our business being seriously harmed in these risk factors will include harm to our business, reputation, financial condition, results of operations, revenue and future prospects. In that event, the market price of our common stock could decline, and you could lose part or all of your investment.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Strategy</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently depend entirely on the successful commercialization of our only product, Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">. If we are unable to successfully market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, we may not generate sufficient revenue to continue our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have only one product, Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and our business presently depends entirely on our ability to successfully commercialize it in a timely manner. While the product was commercially launched in the United States in May 2019 and through a distribution partner in Canada in October 2019, we have a limited history of generating revenue for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our near-term prospects, including our ability to generate revenue, as well as our future growth, depend entirely on the successful commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will depend on a number of factors, including our ability to successfully market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, whether alone or in collaboration with others, including our ability to hire, retain and train sales representatives in the United States. Our ability to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also dependent on the willingness of consumers to pay for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relative to other discretionary items, especially during economically challenging times. Additional factors necessary for the successful commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include the availability, perceived advantages, relative cost, relative safety of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and relative efficacy of competing products, the timing of new product introductions by our competitors, and the sales and marketing tactics of our competitors, including bundling of multiple products, in response to our launch of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors, many of which are beyond our control, in a timely manner or at all, we could experience significant issues commercializing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Further, we may never be able to successfully market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates. In addition, our experience as a commercial company is limited. Accordingly, we may not be able to generate sufficient revenue through the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates to continue our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history and have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We have only one product and limited commercial sales, which, together with our limited operating history, makes it difficult to assess our future viability. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a performance beauty company with a limited operating history. To date, we have invested substantially all of our efforts and financial resources in the clinical development, regulatory approval, and commercial launch of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is currently our only product. We began selling Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States in May 2019 and through a distribution partner in Canada in October 2019 and have a limited history of generating revenue. While we recorded a profit for the three months ended March 31, 2021, largely as a result of a payment received from our partner, Daewoong, we were not profitable and have incurred losses in each year since our inception in 2012. We have a limited operating history upon which you can evaluate our business and prospects. Consequently, any predictions about our future success, performance or viability may not be as accurate as they could be if we had a longer operating history or greater experience commercializing a product. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in the medical aesthetics field. We continue to incur significant expenses related to the commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have recorded net losses of $46.8 million and $163.0 million for the years ended December&#160;31, 2021 and 2020, respectively, and had an accumulated deficit as of December&#160;31, 2021 of $422.9 million. We expect to continue to incur losses for the foreseeable future. Our ability to achieve revenue and profitability is dependent on our ability to successfully market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, may adversely affect the market price of our common stock and our ability to raise capital and continue operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may require additional financing to fund our future operations, and a failure to obtain additional capital when so needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have utilized substantial amounts of cash since our inception in order to conduct clinical development to support regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States, EU and Canada and in connection with the launch of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and Canada. We expect that we will continue to expend substantial resources for the foreseeable future in order to continue to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and for the clinical development of any additional product candidates we may choose to pursue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the near term, we expect to make payments for expenditures associated with our settlement agreements with Medytox and Allergan, including a $15.0 million payment due in the first quarter of 2022 and $5.0 million in 2023, a portion of which will be reimbursed to us by Daewoong. Additionally, we expect to expend resources furthering the development and continuation of our marketing programs and commercialization infrastructure in connection with commercializing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within and outside of the United States. In the long term, our expenditures will include costs associated with the continued commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any of our future product candidates, including our proposed higher strength dose of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, such as research and development, conducting preclinical studies and clinical trials and manufacturing and supplying as well as marketing and selling any products approved for sale. We expect to incur additional costs as we continue to operate as a public company, hire additional personnel and expand our operations. Because the commercialization expenditures needed to meet our sales objectives are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We may in the future, also, acquire other companies or products which may be costly and which may require additional capital to operate. In addition, other unanticipated costs may arise. Accordingly, our actual cash needs may exceed our expectations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to raise additional capital through marketing and distribution arrangements, royalty financing arrangements, or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings or offerings of securities convertible into our equity, the ownership interest of our existing stockholders will be diluted and the terms of any such securities may have a preference over our common stock. Debt financing, receivables financing and royalty financing may also be coupled with an equity component, such as warrants to purchase our capital stock, which could also result in dilution of our existing stockholders&#8217; ownership, and such dilution may be material. Additionally, if we raise additional capital through debt financing, we will have increased fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures to meet specified financial ratios, and other operational restrictions, any of which could restrict our ability to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates or operate as a business and may result in liens being placed on our assets. If we were to default on any of our indebtedness, we could lose such assets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we do not achieve specified minimum sales targets under the Daewoong Agreement, we will lose exclusivity of the license that we have been granted under the Daewoong Agreement. In addition, if we are unable to raise additional capital when required or on acceptable terms, we will be required to take actions to address our liquidity needs which may include the following: significantly reduce operating expenses and delay, reduce the scope of or discontinue some of our development programs, commercialization efforts or other aspects of our business plan, out-license intellectual property rights to our product candidates and sell unsecured assets, or a combination of the above. As a result, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and may have a material adverse effect on our business, results of operations, financial condition and/or our ability to fund our scheduled obligations on a timely basis or at all.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our counterparties do not comply with the terms of our settlement agreements with Medytox, Inc., or Medytox, and Allergan Limited, Allergan, Inc. and Allergan Pharmaceuticals Ireland, or, collectively, Allergan, we may face litigation or lose our ability to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">which would materially and adversely affect our ability to carry out our business and our financial condition and ability to continue as a going concern. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, we entered into a Settlement and License Agreement with Allergan and Medytox, which we refer to as the U.S. Settlement Agreement, and into another Settlement and License Agreement with Medytox only, which we refer to as the ROW Settlement Agreement. Collectively, we refer to the U.S. Settlement Agreement and the ROW Settlement Agreement as the Medytox/Allergan Settlement Agreements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Medytox/Allergan Settlement Agreements we obtained (i) a license to commercialize, manufacture and to have manufactured for us certain products identified in the Medytox/Allergan Settlement Agreements, including Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Licensed Products&#8221;), in the United States and other territories where we license Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ii) the dismissal of outstanding litigation against us, including the ITC Action, a rescission of the related remedial orders, and the dismissal of a civil case in the Superior Court of California against us, which we refer to together with any claims (including claims brought in Korean courts) with a common nexus of fact as the Medytox/Allergan Actions, and (iii) releases of claims against us for the Medytox/Allergan Actions. In exchange, we agreed to (i) make payments of $35.0 million in multiple payments over two years to Allergan and Medytox, of which we have paid $30.0 million, (ii) from December 16, 2020 to September 16, 2022, pay to Allergan and Medytox certain royalties on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on a specified dollar amount per vial sold of the Licensed Products by or on behalf of the us in the United States, (iii) from December 16, 2020 to September 16, 2022, pay to Medytox a low-double digit royalty on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sold by us or on our behalf in territories we have licensed outside the United States, (iv) from September 16, 2022 to September 16, 2032, pay to Medytox a mid-single digit royalty percentage on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and all territories we have licensed outside the United States, (v) issue to Medytox 6,762,652 shares of our common stock, which we issued on February 18 2021, and (vi) enter into a Registration Rights Agreement pursuant to which we granted certain registration rights to Medytox with respect to such shares of common stock beginning as of March 31, 2022. In addition, under the Medytox/Allergan Settlement Agreements we made certain representations and warranties and agreed to positive and negative covenants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we fail to comply with the terms of the Medytox/Allergan Settlement Agreements, subject to applicable cure periods, Allergan and Medytox would have the ability to terminate the Medytox/Allergan Settlement Agreements and thereby cancel the licenses granted to us and re-institute litigation against us. Any litigation may result in remedies against our products, resulting in either an injunction prohibiting our sales, or with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, any of which would materially and adversely affect our ability to generate revenue from Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to carry out our business, and to continue as a going concern.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if Medytox or Allergan fail to comply with the terms of the Medytox/Allergan Settlement Agreements and comply with the covenants and agreements under the Medytox/Allergan Settlement Agreements, it could materially and adversely affect our ability to generate revenue from Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to carry out our business, and to continue as a going concern. We would also be required to engage in costly and time consuming litigation in order to enforce our rights under the Medytox/Allergan Settlement Agreements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The terms of the Medytox/Allergan Settlement Agreements will reduce our profitability until the royalty obligations expire, and may affect the extent of any discounts we may offer to our customers.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the royalty payments that we are required to pay under the Medytox/Allergan Settlement Agreements, our profitability will be impacted for the period that we are required to pay royalties. We may be able to offset a portion of the loss of profitability by decreasing any discount to customers on Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to discounts we provided to customers prior to the Medytox/Allergan Settlement Agreements. If we reduce discounts for any customers, their volume of purchases may decrease which would have a material and adverse effect on our business and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business, financial condition and operations have been, and may in the future be, adversely affected by the COVID-19 outbreak or other similar outbreaks.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak and pandemic of the novel coronavirus that was first detected in 2019, known as COVID-19, has had, and may continue to have, material adverse effects on our business, financial condition, results of operations and cash flows. Other similar outbreaks of contagious diseases in the future could have a similar material adverse effect on our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak, and restrictions intended to slow the spread of COVID-19, including quarantines, government-mandated actions, stay-at-home orders and other restrictions, has adversely affected our business in a number of ways. For example, the spread of COVID-19 in the United States has resulted in travel restrictions impacting our sales professionals and closures of our customers&#8217; businesses, which adversely affected our sales and operations, particularly in 2020 and periods of 2021. If similar or other restrictions are imposed in the future in response COVID-19 outbreaks or outbreaks of other contagious disease, our sales and operations may be adversely affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, surges of COVID-19 outbreaks or other outbreaks of contagious disease, including closures of our customers&#8217; businesses, may impact our ability to enroll patients in our ongoing and future clinical programs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other negative impacts of the COVID-19 outbreak or other similar outbreaks could include the availability of our key personnel, temporary closures of our office or the facilities of our business partners, customers, third party service providers or other vendors, and the interruption of our supply chain, distribution channels, liquidity and capital or financial markets, including increased inflation. Any of these events may result in a period of business disruption and in reduced sales and operations. In addition, any disruption and volatility in the global capital markets may increase our cost of capital and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adversely affect our ability to access financing when and on terms that we desire. Any of these events could have a material adverse effect on our business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is utilized in elective procedures, the costs of which are borne by the consumer and not third-party payors. As a result of the COVID-19 outbreak and restrictions to slow its spread, these elective procedures declined dramatically in 2020 due to closures of our customers&#8217; businesses and as many customers are deferring their procedures. Even after the current COVID-19 pandemic subsides, we may continue to experience negative impacts to our business and financial results if consumers continue to defer or avoid altogether elective procedures to administer Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to the continued perceived risk of infection or concern of a resurgence of the COVID-19 outbreak, including new and more contagious and/or vaccine resistant variants, as well as COVID-19&#8217;s global economic impact, including decreases in consumer discretionary spending and any economic slowdown or recession that may occur in the future.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Significant increases in unemployment stemming from the pandemic have also occurred which may impact consumer discretionary spending. Furthermore, the discretionary nature of aesthetic medical procedures may be particularly vulnerable to unfavorable economic conditions. Because we do not expect Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of glabellar lines to be reimbursed by any government or third-party payor, our only product is and will continue to be paid for directly by the consumer. Demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is accordingly tied to the discretionary spending levels of our targeted consumer population. A severe or prolonged economic downturn could result in a variety of risks to our business, including a decline in the discretionary spending of our target consumer population, which could lead to a weakened demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates. A severe or prolonged economic downturn may also affect our ability to raise additional capital when needed on acceptable terms, if at all, and could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our products. Inflation in the markets we serve could similarly impact our revenues, as consumer spending power could decline. Any of the foregoing could harm our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our business strategy was developed based on a number of important assumptions about the self-pay healthcare market. For example, we believe that the number of self-pay healthcare procedures will increase in the future. However, these trends are uncertain and limited sources exist to obtain reliable market data. Therefore, sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any of our future product candidates could differ materially from our projections if our assumptions are incorrect.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> faces, and any of our future product candidates will face, significant competition and our failure to effectively compete may prevent us from achieving significant market penetration and expansion. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved for use in facial aesthetic medicine. The facial aesthetic market is highly competitive and dynamic and is characterized by rapid and substantial technological development and product innovations. We have received regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of glabellar lines and launched commercially in the United States and through a distribution partner in Canada. We anticipate that Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will face significant competition from other facial aesthetic products, such as other injectable and topical botulinum toxins and dermal fillers. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may also compete with unapproved and off-label treatments. Many of our potential competitors, including Allergan, and now AbbVie Inc., which acquired Allergan, who first launched BOTOX for cosmetic uses in 2002 and has since maintained the highest market share position in the aesthetic neurotoxin market with its BOTOX product, are large, experienced companies that enjoy significant competitive advantages, such as substantially greater financial resources enabling them to, among other things, market and discount aggressively. Competitors may also have greater brand recognition for their products, larger sales forces and larger aesthetic product portfolios allowing the companies to bundle products to provide customers more choices and to further discount their products. Additionally, our competitors have greater existing market share in the aesthetic neurotoxin product market and long-standing customer loyalty programs and sales contracts with large customers which creates established business and financial relationships with customers, aesthetic societies and universities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These competitors may also try to compete with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on price both directly, through rebates and promotional programs to high volume physicians and coupons to consumers, and indirectly, through attractive product bundling with complimentary products, such as dermal fillers that offer convenience and an effectively lower price compared to the total price of purchasing each product separately. These companies may also seek to compete based on their longer operating history. Larger companies may be better capitalized than us and, accordingly, are able to offer greater customer loyalty benefits to encourage repeat use of their products and finance a sustained global advertising campaign to compete with our commercialization efforts at launch. A number of our larger competitors also have access to a significant amount of studies and publications that they could use to compete with us.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the long term, we expect to expand our focus to the broader self-pay healthcare market. Competitors and other parties may seek to impact regulatory approval of our future product applications through the filing of citizen petitions or other similar documents, which could require costly and time-consuming responses to the regulatory agencies. Larger competitors could seek to prevent or delay our commercialization efforts via costly litigation which can be lengthy and expensive and serve to distract our management team&#8217;s attention. We could face competition from other sources as well, including academic institutions, governmental agencies and public and private research institutions. In addition, we are aware of other companies also developing and/or marketing products in one or more of our target markets, including competing injectable botulinum toxin type A formulations that are currently in Phase III clinical development in North America for the treatment of glabellar lines. For example, Revance Therapeutics, Inc. has submitted a biologics license application, or BLA, to the FDA for an injectable botulinum toxin type A neurotoxin and in October 2021 received a Complete Response Letter from the FDA. Additionally, Hugel Inc., has submitted a BLA to the FDA for an injectable botulinum toxin type A neurotoxin. If either BLA is approved, we expect the competition in the U.S. injectable botulinum toxin market to further increase. We would face similar risks with respect to any future product candidates that we may seek to develop or commercialize in the broader self-pay healthcare market. Successful competitors in that market have the ability to effectively discover, obtain patents, develop, test and obtain regulatory approvals for products, as well as the ability to effectively commercialize, market and promote approved products, including communicating the effectiveness, safety and value of products to actual and prospective customers and medical staff.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy of competing in the aesthetic neurotoxin market is dependent on the marketing and pricing flexibility that we believe is afforded to a company with a portfolio limited to self-pay healthcare, comprised of products and procedures that are not reimbursed by third-party payors. In the event that regulations applicable to reimbursed products are changed to apply to self-pay healthcare products, we would no longer have this flexibility and we may not be able to compete as effectively with our competitors which may have a material effect on our business, financial condition and results of operations. Additionally, as a result of the royalty payments that we are required to pay under the Medytox/Allergan Settlement Agreements, we may not be able to discount Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the extent that we previously provided discounts to customers without impacting our gross profit margins. If we increase prices for any customers, their volume of purchases may decrease which would have a material and adverse effect on our business and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, competitors may develop new technologies within the aesthetic market that may be superior in safety and efficacy to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or offer alternatives to the use of toxins, including surgical and radio frequency techniques. To compete successfully in the aesthetic market, we will have to demonstrate that Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is at least as safe and effective as current products sold by our competitors. Competition in the aesthetic market could result in price-cutting and reduced profit margins, any of which would harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to less stringent regulatory requirements, there are many more aesthetic products and procedures available for use in international markets than are approved for use in the United States. There are also fewer limitations on the claims that our competitors in international markets can make about the effectiveness of their products and the manner in which they can market them. As a result, we expect to face more competition in these markets than in the United States.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could also be reduced or eliminated if our competitors develop and commercialize products that are safer, are more effective, have fewer or less severe side effects, are more convenient or are less expensive than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any other product that we may develop. Our competitors also may obtain FDA or other regulatory approval for these products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market, which may create additional barriers to successfully commercializing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any future product candidates and attracting physician and consumer demand.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> may fail to achieve the broad degree of physician adoption and use or consumer demand necessary for continued commercial success. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may fail to gain sufficient market acceptance by physicians, consumers and others in the medical aesthetics community to continue to grow our net revenues. The continued commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any future product candidates, including a proposed higher strength dose of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, will depend significantly on the broad adoption and use of the resulting product by physicians for approved indications, including, in the case of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the treatment of glabellar lines and other aesthetic indications that we may seek to pursue. We are aware that other companies are seeking to develop alternative products and treatments, any of which could impact the demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree and rate of physician adoption of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any future product candidates depend on a number of factors, including the cost, profitability to our customers, consumer demand, characteristics and effectiveness of the product. Our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">success will also depend our ability to create compelling marketing programs, training of our customers and ability to overcome any biases physicians or consumers may have toward the use, safety and efficacy of existing products over Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Moreover, our competitors may utilize negative selling efforts or offer more compelling marketing or discounting programs than we are able to offer, including by bundling multiple aesthetic products to provide a more comprehensive offering than we can as Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is currently our sole product.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in its clinical trials, Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was clinically tested and compared to BOTOX. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the only known neurotoxin product in the United States with a 900 kDa complex other than BOTOX. We believe that aesthetic physicians&#8217; familiarity with the 900 kDa complex&#8217;s handling, preparation and dosing will more easily facilitate incorporation of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> into their practices. However, the ease of integration of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> into a physician&#8217;s practice may not be as seamless as we anticipate.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to consumer demand, the treatment of glabellar lines with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an elective procedure, the cost of which must be borne by the consumer, and we do not expect costs related to the treatment to be reimbursable through any third-party payor, such as Medicaid, Medicare or commercial insurance. The decision by a consumer to undergo treatment with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of glabellar lines or other aesthetic indications that we may pursue may be influenced by a number of factors, including the cost, efficacy, safety, perception, marketing programs for, and physician recommendations of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> versus competitive products or procedures. Moreover, consumer demand may fluctuate over time as a result of consumer sentiment about the benefits and risks of aesthetic procedures generally and Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in particular, changes in demographics and social trends, and general consumer confidence and consumer discretionary spending, which may be impacted by the COVID-19 outbreak, economic and political conditions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates fail to achieve the broad degree of physician adoption necessary for commercial success or the requisite consumer demand, our operating results and financial condition will be adversely affected, which may delay, prevent or limit our ability to generate revenue and continue our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to market Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> is limited to use for the treatment of glabellar lines, and if we want to expand the indications for which we market Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, we will need to obtain additional regulatory approvals, which will be expensive and may not be granted. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received regulatory approval for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States for the treatment of moderate to severe glabellar lines. The terms of that approval restrict our ability to market or advertise Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for other indications, which could limit physician and consumer adoption. Under the U.S. Federal Food Drug and Cosmetic Act, we may generally only market Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for approved indications. Many of our competitors have received approval of multiple aesthetic and therapeutic indications for their neurotoxin products and may be able to market such products for use in a way we cannot. For example, we are aware that one of our competitors, Allergan (now AbbVie), has obtained and plans to obtain additional indications for its neurotoxin product within medical aesthetics and, therefore, is able to market its product across a greater number of indications than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If we are unable to obtain approval for indications in addition to our approval for glabellar lines, our marketing efforts for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will be severely limited. As a result, we may not generate physician and consumer demand or approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on our digital technology and applications and our business and operations would suffer in the event of computer system failures or breach by hackers.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are reliant on our digital technology, including our Evolus Practice App, which allows customers to open a new account, order Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pay invoices and engage with our customer experience team and medical affairs representatives. In the event that our digital technology is unable to function in the manner it was designed or at all, we would experience difficulty processing customer orders and requests in a timely manner or at all which would have a material adverse effect on our business, results of operations and financial condition. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The systems underlying our digital technology may not be adequately designed or may not operate with the reliability and redundancy necessary to avoid performance delays or outages that could be harmful to our business. If our digital technology is unavailable when customers attempt to access them, or if they do not load as quickly as expected, users may not use our technology as often in the future, or at all, and our ability to sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through a more limited sales force may be disrupted and we may not realize the efficiencies of leveraging our digital technology, any of which could adversely affect our business and financial performance. As the number of users of our digital technology continues to grow we will need an increasing amount of technical infrastructure, including network capacity and computing power, to continue to satisfy our needs. It is possible that we may fail to continue to effectively scale and grow our technical infrastructure to accommodate </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these increased demands, which may adversely affect our customers&#8217; experience with our digital technology which may decrease our revenue and harm our results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to disruption or damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyberattacks or cyber intrusions, insider threats, persons who access our systems in an authorized manner, or inadvertent misconfiguration of our systems. The risk of a security incident or system disruption, particularly through cyberattacks or cyber intrusions, including by computer hackers, foreign governments and cybercriminals, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Interruptions in our operations caused by such an event could result in a material disruption of our current or future product development programs. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, government files or penalties and other harm to our business and our competitive position. Interruptions in our operations caused by such an event could also result in a material disruption in our relationship with our customers. For example, if our Evolus Practice App were rendered inoperable, we would have to process orders by telephone or otherwise which may result in slower processing times and harm to our reputation.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, a computer security incident that affects our systems or results in the unauthorized access to financial information, personally identifiable information (PII), customer information or data, including credit card transaction data, or other sensitive information, could materially damage our reputation. In addition, such a security incident may require notification to governmental agencies, the media or individuals pursuant to various international, federal and state privacy and security laws, including the General Data Protection Regulation (GDPR); the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Clinical Health Act of 2009, and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. Additionally, the regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve, and a number of states have adopted laws and regulations that may affect our privacy and data security practices regarding the use, disclosure and protection of PII. For example, the California Consumer Privacy Act, among other things, has created new individual privacy rights and imposes increased obligations on companies handling PII. In the event of a security incident, we would also be exposed to the risk of litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyberattacks and other related security incidents.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or any other product candidate for which we seek approval as a biologic may face competition sooner than anticipated.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the enactment of the Biologics Price Competition and Innovation Act of 2009, or the BPCI Act, as part of the Patient Protection and Affordable Care Act, an abbreviated pathway for the approval of biosimilar or interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics. Under the BPCI Act, an application for a biosimilar product cannot be approved by the FDA until twelve years after the original branded product was approved under a Biologics License Application, or BLA. The law is complex and is still being interpreted and implemented by the FDA. For example, one company has filed a Citizen Petition requesting that the FDA not apply the BPCI Act to pre-enactment BLAs. As a result, its ultimate impact, implementation and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the BPCI Act may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> should qualify for the twelve-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider any of our product candidates to be a reference product for competing products, potentially creating the opportunity for competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are found to have improperly promoted off-label uses, or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, significant fines, penalties, sanctions, or product liability claims, and our image and reputation within the industry and marketplace could be harmed. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about pharmaceutical products, such as Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or other similar regulatory authorities as reflected in the product&#8217;s approved labeling. Physicians could use Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on their patients in a manner that is inconsistent with the approved label of the treatment of moderate to severe glabellar lines, potentially including for the treatment of other aesthetic or therapeutic indications. If we are found to have promoted such off-label uses, we may receive warning letters from and be subject to other enforcement actions by the FDA, the European Medicines Agency, or EMA, and other regulatory agencies, and become subject to significant liability, which would materially harm our business. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management&#8217;s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The FDA has also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed in order to resolve FDA enforcement actions. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject to FDA prohibitions or other restrictions on the sale or marketing of our products and other operations or significant fines and penalties, and the imposition of these sanctions could also affect our reputation and position within the industry. In addition, regulatory authorities outside the United States may impose similar fines, penalties or sanctions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians may also misuse Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates are misused or used with improper techniques or are determined to cause or contribute to consumer harm, we may become subject to costly litigation by our customers or their patients. Product liability claims could divert management&#8217;s attention from our core business, be expensive to defend, result in sizable damage awards against us that may not be covered by insurance and subject us to negative publicity resulting in reduced sales of our products. Furthermore, the use of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates for indications other than those cleared by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and consumers. Any of these events could harm our business and results of operations and cause our stock price to decline. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or any of our future product candidates may cause serious or undesirable side effects or possess other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of approved labeling, result in post-approval regulatory action or in product liability lawsuits.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unforeseen side effects from Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or our future product candidates could arise either during clinical development or after marketing such product. Undesirable side effects caused by product candidates could cause us or regulatory authorities to interrupt, modify, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA or similar regulatory authorities. Results of clinical trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, trials could be suspended or terminated and the FDA, the EMA or similar regulatory authorities could order us to cease further development of or deny approval of product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in product liability claims. Any of these occurrences may harm our business, financial condition, operating results and prospects.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if we or others identify undesirable side effects, or other previously unknown problems, caused by Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or any of our future product candidates, after obtaining regulatory approval in the United States or other jurisdictions, a number of potentially negative consequences could result, including regulatory authorities withdrawing approval or limiting the marketing of our products, requiring a recall of the product, requiring additional warnings on our product labeling or medication guides or instituting Risk Evaluation and Mitigation Strategies, or REMS. In order to mitigate these risks, regulatory authorities may require additional costly clinical trials or costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. As a result of any of these actions our sales of the product may decrease significantly, we may be required to expend material amounts to comply with any requirements of the regulatory authorities, we could be sued in a product liability lawsuit and held liable for harm caused to patients, and our brand and reputation may suffer.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any of our future product </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted against us under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources and result in decreased demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates or products we may develop, termination of clinical trial sites or entire trial programs, injury to our reputation and significant negative media attention, withdrawal of clinical trial participants or cancellation of clinical trials and significant costs and diversion management&#8217;s time to defend the related litigation.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future products that we develop. We currently carry product liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above events could prevent us from achieving or maintaining market acceptance of the affected product, negatively impact our revenues and could substantially increase the costs of commercializing our products. The demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could also be negatively impacted by any adverse effects of a competitor&#8217;s product or treatment.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to successfully in-license, acquire, develop and market additional product candidates or approved products would impair our ability to grow our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although most of our effort is focused on the commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a key element of our long-term strategy is to in-license, acquire, develop, market and commercialize a portfolio of products to serve the self-pay aesthetic market. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is currently our sole product. Our competitors are currently able to bundle multiple aesthetic products to provide a more comprehensive offering than we can as a single product company. Because our internal research and development capabilities are limited, we may be dependent upon pharmaceutical and other companies, academic scientists and other researchers to sell or license products or technology to us. The success of this strategy depends partly upon our ability to identify and select promising aesthetic product candidates and products, negotiate licensing or acquisition agreements with their current owners and finance these arrangements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing, sales and other resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidates that we acquire may require additional development efforts prior to commercial sale, including preclinical or clinical testing and approval by the FDA, the EMA and other similar regulatory authorities. All product candidates are prone to risks of failure during product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, any approved products that we acquire may not be manufactured or sold profitably or achieve market acceptance.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to increase the size of our organization, including our sales and marketing capabilities in order to further market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and we may experience difficulties in managing this growth.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had 167 employees, all of whom constituted full-time employees. Our management and personnel, systems and facilities currently in place may not be adequate to support future growth. Our need to effectively execute our growth strategy requires that we identify, recruit, retain, incentivize and integrate any additional employees to effectively manage any future clinical trials, manage our internal development efforts effectively while carrying out our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contractual obligations to third parties, and continue to improve our operational, financial and management controls, reporting systems and procedures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks in building and managing a sales organization whether internally or by utilizing third parties, including our ability to retain and incentivize qualified individuals, provide adequate training to sales and marketing personnel, generate sufficient sales leads, effectively manage a geographically dispersed sales and marketing team, adequately provide complementary products to be offered by sales personnel, which may otherwise put us at a competitive disadvantage relative to companies with more extensive product lines, and handle any unforeseen costs and expenses. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our limited financial resources and our limited experience in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our development and strategic objectives or disrupt our operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our international operations will expose us to risks, and failure to manage these risks may adversely affect our operating results and financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have operations in the United States and are planning to have international operations, including launching in Europe in 2022. International operations are subject to a number of inherent risks, and our future results could be adversely affected by a number of factors, including differences in demand for our products due to local requirements or preferences, the difficulty of hiring and managing employees with cultural and geographic differences and the costs of complying with differing regulatory requirements. Additionally, we may experience difficulties and increased costs due to differences in laws related to enforcing contracts, protecting intellectual property, taxes, tariffs and export regulations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international operations will also subject us to risks related to multiple, conflicting and changing laws and regulations such as privacy regulations, including the GDPR, tax laws, export and import restrictions, employment laws, immigration laws, labor laws, regulatory requirements and other governmental approvals, permits and licenses. Additionally, we will face heightened risk of unfair or corrupt business practices in certain geographies and of improper or fraudulent sales arrangements that may impact financial results and result in restatements of, or irregularities in, financial statements. These and other factors could harm our ability to gain future revenue and, consequently, materially impact our business, operating results and financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to attract and keep senior management and key scientific personnel, we may be unable to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> successfully, or any future products we develop. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management. We believe that our future success is highly dependent upon the contributions of our senior management, particularly David Moatazedi, our President, Chief Executive Officer and member of our board of directors, Lauren Silvernail, our Chief Financial Officer and Executive Vice President, Corporate Development, Rui Avelar, our Chief Medical Officer and Head of R&amp;D, and Crystal Muilenburg, our Chief Marketing Officer, as well as other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future products we develop. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we could experience difficulties attracting and retaining qualified employees in the future. For example, competition for qualified personnel in the pharmaceuticals and aesthetic medicine field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information or that their former employers own their research output. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our strategy of focusing exclusively on the self-pay healthcare market may limit our ability to increase sales or achieve profitability.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to focus exclusively on the self-pay healthcare market. This focus may limit our ability to increase sales or achieve profitability. For example, to maintain our business model, we have chosen not to offer products or services available in the broader healthcare market that are reimbursed by third-party payors such as Medicare, Medicaid or commercial insurance. This eliminates our ability to offer a substantial number of products and indications for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, under the Daewoong Agreement our rights to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are limited to cosmetic indications. Daewoong has subsequently licensed the rights to the therapeutic indications to a third party. As a result, we do not have the ability to expand the permitted uses of botulinum toxin products for therapeutic indications.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the only U.S. neurotoxin without a therapeutic indication, although other companies may seek to develop a similar product in the future. We believe pursuing an aesthetic-only non-reimbursed product strategy allows for meaningful strategic advantages in the United States, including pricing and marketing flexibility. However, physicians may choose to not pass any cost benefits received by them due to such pricing flexibility to their patients. In addition, companies offering aesthetic products competitive to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, whether they pursue an aesthetic-only non-reimbursed product strategy or not, may nonetheless try to compete with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on price both directly through rebates, promotional programs and coupons and indirectly through attractive product bundling and customer loyalty programs. Our business, financial results and future prospects will be materially harmed if we cannot generate sufficient consumer demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials, and we and our third-party manufacturer and supplier must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development and manufacturing activities in the future may, and Daewoong&#8217;s manufacturing and supplying activities presently do, involve the controlled storage, use and disposal of hazardous materials, including botulinum toxin type A, a key component of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and other hazardous compounds. We and Daewoong are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at Daewoong&#8217;s facilities pending their use and disposal. We and Daewoong cannot eliminate the risk of contamination, which could cause an interruption of Daewoong&#8217;s manufacturing processes, our commercialization efforts, business operations and environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, manufacture, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by Daewoong for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, this may not eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may use third-party collaborators to help us develop, validate or commercialize any new products, and our ability to commercialize such products could be impaired or delayed if these collaborations are unsuccessful. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may license or selectively pursue strategic collaborations for the development, validation and commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any future product candidates. In any third-party collaboration, we would be dependent upon the success of the collaborators in performing their responsibilities and their continued cooperation. Our collaborators may not cooperate with us or perform their obligations under our agreements with them. Our collaborators may choose to pursue alternative technologies in preference to those being developed in collaboration with us. The development, validation and commercialization of our product candidates will be delayed if collaborators fail to conduct their responsibilities in a timely manner or in accordance with applicable regulatory requirements or if they breach or terminate their collaboration agreements with us. Disputes with our collaborators could also impair our reputation or result in development delays, decreased revenues and litigation expenses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to consumers, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates or bring them to market and generate revenue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. Under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. As of December&#160;31, 2021, we had $273.8 million of federal NOLs and $169.3 million of state NOLs available to offset our future taxable income, if any. As of December&#160;31, 2021, we had federal research and development credit carryforwards of $2.9 million. These federal and state NOLs and federal research and development tax credit carryforwards expire at various dates beginning in 2034. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Planned discontinuation of LIBOR could have an adverse impact on operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had $71.2 million of outstanding indebtedness that bears interest at a floating rate using London Interbank Offered Rate ("LIBOR") as the applicable reference rate. LIBOR has been the subject of regulatory guidance and proposals for reform. In March 2021, the United Kingdom's Financial Conduct Authority, the authority that regulates LIBOR, and ICE Benchmark Administration (&#8220;IBA&#8221;), the authority that administers LIBOR, announced that the publication of one-week and two-month USD LIBOR maturities and the non-USD LIBOR maturities will cease immediately after December 31, 2021, with the publication of overnight, one-, three-, six-, and 12-month USD LIBOR ceasing immediately after June 30, 2023. The United States Federal Reserve also issued a statement advising banks to stop new USD LIBOR issuances by the end of 2021. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in, or the planned discontinuation of, LIBOR would cause changes in how interest is calculated on our floating rate debt including our term loans. Recent proposals for LIBOR reforms may result in the establishment of new methods of calculating LIBOR or the establishment of one or more alternative benchmark rates. Our floating rate debt instruments, including our term loans, provide for alternate interest rate calculations if LIBOR is no longer widely available or should the alternative interest rate prove more favorable. At this time, no consensus exists as to what rate or rates will become accepted alternatives to LIBOR, although the U.S. Federal Reserve, in connection with the Alternative Reference Rates Committee, a steering committee comprised of large U.S. financial institutions, is considering replacing U.S. dollar LIBOR with the Secured Overnight Financing Rate (&#8220;SOFR&#8221;). In addition, recent New York state legislation effectively codified the use of SOFR as the alternative to LIBOR in the absence of another chosen replacement rate, which may affect contracts governed by New York state law, including our Credit Agreement. SOFR is calculated based on short-term repurchase agreements, backed by Treasury securities. SOFR is observed and backward looking, which stands in contrast with LIBOR under the current methodology, which is an estimated forward-looking rate and relies, to some degree, on the expert judgment of submitting panel members. Given the inherent differences between LIBOR and SOFR or any other alternative benchmark rate that may be established, there are many uncertainties regarding a transition from LIBOR, including, but not limited to, the need to amend our debt instruments with LIBOR as the referenced rate and how this will impact our cost of variable rate debt. We will also need to consider any new contracts and if whether they should reference an alternative benchmark rate or include suggested fallback language, as published by the Alternative Reference Rates Committee. The consequences of these </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developments with respect to LIBOR cannot be entirely predicted and span multiple future periods but could result in an increase in the cost of our variable rate debt which may be detrimental to our financial position or operating results.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationship with Daewoong</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on the license and supply agreement, the Daewoong Agreement, with Daewoong to provide us exclusive rights to distribute Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> in certain territories. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect our development or commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Daewoong Agreement, as it has been amended from time to time, we have secured an exclusive license from Daewoong, a South Korean pharmaceutical manufacturer, to import, distribute, promote, market, develop, offer for sale and otherwise commercialize and exploit Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for aesthetic indications in the United States, EU, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, Russia, certain members of the Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. The Daewoong Agreement imposes on us obligations relating to exclusivity, territorial rights, development, commercialization, funding, payment, diligence, sublicensing, intellectual property protection and other matters. We are obligated to conduct development activities, obtain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and obtain from Daewoong all of our product supply requirements for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, under the Daewoong Agreement, we are required to submit our commercialization plan to a joint steering committee, or JSC, comprised of an equal number of development and commercial representatives from Daewoong and us, for review and input. Although the Daewoong Agreement provides us with final decision-making power regarding the marketing, promotion, sale and/or distribution of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, any disagreement among the JSC would be referred to Daewoong&#8217;s and our respective senior management for resolution if the JSC is unable to reach a decision within thirty days, which may result in a delay in our ability to implement our commercialization plan or harm our working relationship with Daewoong. If we fail to achieve minimum annual purchase targets of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the Daewoong Agreement, Daewoong may, at its sole option, elect to convert the exclusive license to a non-exclusive license. In light of the COVID-19 outbreak and the potential loss of our ability to discount the product to levels previously provided as a result of the Medytox/Allergan Settlement Agreements, it may become more difficult for us to achieve the minimum annual purchase targets for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which may result in the license being converted to a non-exclusive license.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the Daewoong Agreement will expire on September 30, 2023 in any of the aforementioned territories. The Daewoong Agreement will renew for unlimited additional three-year terms after the expiration of the initial term, only if we meet certain performance requirements during the initial term or preceding renewal term, as applicable. We or Daewoong may terminate the Daewoong Agreement if the other party breaches any of its duties or obligations and such breach continues without cure for ninety days, or thirty days in the case of a payment breach, or if we declare bankruptcy or assign our business for the benefit of creditors. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages to Daewoong and Daewoong may have the right to terminate our license. In addition, if any of the regulatory milestones or other cash payments become due under the terms of the Daewoong Agreement, we may not have sufficient funds available to meet our obligations, which would allow Daewoong to terminate the Daewoong Agreement. Any termination or loss of rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect our ability to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which in turn would have a material adverse effect on our business, operating results and prospects. If we were to lose our rights under the Daewoong Agreement, we believe it would be difficult for us to find an alternative supplier of a botulinum toxin type A complex. In addition, to the extent the alternative supplier has not secured regulatory approvals in a jurisdiction, we would have to expend significant resources to obtain regulatory approvals that may never be obtained or require several years to obtain, which could significantly delay commercialization. We may be unable to raise additional capital to fund our operations during this extended time on terms acceptable to us or at all. Additionally, if we experience delays as a result of a dispute with Daewoong, the demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could be materially and adversely affected.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently rely solely on Daewoong to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, and as such, any production or other problems with Daewoong could adversely affect us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend solely upon Daewoong for the manufacturing of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Although alternative sources of supply may exist, the number of third-party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for and qualify alternative suppliers, which could have a material adverse effect on our business. Suppliers of any new product candidate would be required to qualify under </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable regulatory requirements and would need to have sufficient rights under applicable intellectual property laws to the method of manufacturing the product candidate. Obtaining the necessary FDA approvals or other qualifications under applicable regulatory requirements and ensuring non-infringement of third-party intellectual property rights could result in a significant interruption of supply and could require the new manufacturer to bear significant additional costs which may be passed on to us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our reliance on Daewoong entails additional risks, including reliance on Daewoong for regulatory compliance and quality assurance, the possible breach of the Daewoong Agreement by Daewoong, and the possible termination or nonrenewal of the Daewoong Agreement at a time that is costly or inconvenient for us. Our failure, or the failure of Daewoong, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our dependence on Daewoong also subjects us to all of the risks related to Daewoong&#8217;s business, which are all generally beyond our control. Daewoong&#8217;s ability to perform its obligations under the Daewoong Agreement is dependent on Daewoong&#8217;s operational and financial health, which could be negatively impacted by several factors, including changes in the economic, political and legislative conditions in South Korea and the broader region in general and the ability of Daewoong to continue to successfully attract customers and compete in its market. Furthermore, Daewoong&#8217;s recently constructed manufacturing facility is Daewoong&#8217;s only facility meeting FDA and EMA, current Good Manufacturing Requirements, or cGMPs. Daewoong&#8217;s lack of familiarity with, or inability to effectively operate, the facility and produce products of consistent quality, may harm our ability to compete in our market.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, although we are ultimately responsible for ensuring compliance with regulatory requirements such as cGMPs, we are dependent on Daewoong for day-to-day compliance with cGMP for production of drug substance and finished products. Facilities used by Daewoong to produce the drug substance and materials or finished products for commercial sale must pass inspection and be approved by the FDA and other relevant regulatory authorities. If the safety of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is compromised due to a failure to adhere to applicable laws or for other reasons, we may not be able to successfully commercialize our product and we may be held liable for injuries sustained as a result. In addition, the manufacturing facilities of certain of our suppliers are located outside of the United States. This may give rise to difficulties in importing our product into the United States or other countries as a result of, among other things, regulatory agency approval requirements, taxes, tariffs, local import requirements such as import duties or inspections, incomplete or inaccurate import documentation or defective packaging. Any of these factors could adversely impact our ability to effectively market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure or refusal by Daewoong or any other third party to supply Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any other product candidates or products that we may develop could delay, prevent or impair our clinical development or commercialization efforts.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, Daewoong developed the manufacturing process for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and manufactures Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in a recently constructed facility located in South Korea. If this facility were to be damaged, destroyed or otherwise unable to operate or comply with regulatory requirements, whether due to earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters, public health emergencies (such as the COVID-19 outbreak) employee malfeasance, terrorist acts, power outages or otherwise, or if operations at the facility is disrupted for any other reason, such an event could jeopardize Daewoong&#8217;s ability to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as promptly as we or our customers expect or possibly at all. If Daewoong is unable to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within a timeframe that meets our and our customers&#8217; expectations, our business, prospects, financial results and reputation could be materially harmed. Any disaster recovery and business continuity plans that we and Daewoong have in place or put in place may not be adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of our or Daewoong&#8217;s lack of disaster recovery and business continuity plans, or the adequacy thereof, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We forecast the demand for commercial quantities of our products, and if our forecasts are inaccurate, we may experience delays in shipments, increased inventory costs or inventory levels, and reduced cash flow.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong. Pursuant to the Daewoong Agreement, we submit forecasts of anticipated product orders to Daewoong and may, from time to time, submit purchase orders on the basis of these forecasting requirements. Our limited historical experience may not provide us with enough data to accurately predict future demand. In addition, we expect Daewoong to manufacture its own product, Nabota, a botulinum toxin formulation, from this facility for sale in the South Korean market and other markets in which we do not have exclusive rights. If our business significantly expands, our demand for commercial products would increase and Daewoong may be unable to meet our increased demand. In addition, our product will have fixed future expiration dates. If we overestimate requirements for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we will have excess inventory, which may have to be disposed of if such inventory exceeds approved expiration dates, which would result in lost revenues </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and increase our expenses. If we underestimate requirements for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we may have inadequate inventory, which could interrupt, delay or prevent delivery of our products to our customers. Any of these occurrences would negatively affect our financial performance.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our commercialization efforts and interrupt our supply of products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the proprietary rights of third parties. Competitors in the field of dermatology, aesthetic medicine and neurotoxins have developed large portfolios of patents and patent applications in fields relating to our business. In particular, there are patents held by third parties that relate to the treatment with neurotoxin-based products for the indication we are currently marketing. There may also be patent applications that have been filed but not published that, when issued as patents, could be asserted against us. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the technology, medical device and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter-party reexamination proceedings before the U.S. Patent and Trademark Office, or USPTO. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As the technology, medical device and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we or any of our current or future licensors, including Daewoong, are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, methods of manufacture or methods for treatment related to the use or manufacture of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license under the applicable patents or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our methods of use, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to claims of patent infringement, third parties may bring claims against us asserting misappropriation of proprietary technology or other information in the development, manufacture and commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any of our future product candidates. Defense of such a claim would require dedicated time and resources, which time and resources could otherwise be used by us toward the maintenance of our own intellectual property and the development and commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any of our future product candidates or by any of our current or future licensors for operational upkeep and manufacturing of our products. For example, prior to entering into the Medytox/Allergan Settlement Agreements, we were a defendant in a lawsuit brought by Medytox in the Superior Court of the State of California, or the Medytox Litigation, and a respondent in an action filed by Allergan and Medytox in the U.S. International Trade Commission, each alleging, among other things, that Daewoong stole Medytox&#8217;s botulinum toxin bacterial strain, or the BTX strain, that Daewoong misappropriated certain trade secrets of Medytox, including the process used to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (which Medytox claims is similar to its biopharmaceutical drug, Meditoxin) using the BTX strain, and that Daewoong thereby interfered with Medytox&#8217;s plan to license Meditoxin to us, or the Medytox Litigation. Each of the Medytox Litigation and the ITC Action diverted the attention of our senior management and were costly, in terms of legal costs and the ultimate payments and royalties to be paid under the Medytox/Allergan Settlement Agreements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us or any of our current or future licensors may request and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement, we or any of our current or future licensors may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties which may not be commercially or more available, pay royalties or redesign our infringing products or manufacturing processes, which may be impossible or require substantial time and monetary expenditure. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research, manufacture clinical trial supplies or allow commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. Similarly, third-party patents could exist that might be enforced against our products, resulting in either an injunction prohibiting our sales, or with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or any of our current or future licensors, including Daewoong, are unable to maintain, obtain or protect intellectual property rights related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or any of our future product candidates, we may not be able to compete effectively in our market.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our current licensor, Daewoong, currently rely upon a combination of trademarks, trade secret protection, confidentiality agreements and proprietary know-how. Botulinum toxin cannot be patented, as it is produced by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clostridium</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">botulinum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a gram-positive, rod-shaped, anaerobic, spore-forming, motile bacterium with the ability to produce the neurotoxin botulinum. Only the manufacturing process for botulinum toxin can be patented, for which Daewoong has obtained a U.S. patent. Our trade secrets and other confidential proprietary information and those of our licensors could be disclosed or competitors could otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we or any of our current or future licensors may encounter significant problems in protecting and defending our or their intellectual property both in the United States and internationally. If we or any of our current or future licensors are unable to prevent material disclosure of the non-patented intellectual property related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could adversely affect our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection afforded by trademarks, confidentiality agreements and proprietary know-how, we may in the future rely upon in-licensed patents for any future product offerings. The strength of patents we may in-license in the technology and healthcare fields involves complex legal and scientific questions and can be uncertain. The patent applications that we may in-license may fail to result in issued patents with claims that cover any of our future product candidates in the United States or in other foreign countries, and the issued patents that we may in-license may be declared invalid or unenforceable. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are reliant on the ability of Daewoong, as the licensor of our only product, and will be reliant on future licensors of any future product candidates, to maintain their intellectual property and protect their intellectual property against misappropriation, infringement or other violation. We may not have primary control over our future licensors&#8217; patent prosecution activities. Furthermore, we may not be allowed to comment on prosecution strategies, and patent applications may be abandoned by the patent owner without our knowledge or consent. With respect to patents that are issued to our licensors, or patents that may be issued on patent applications, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. As a licensee, we are reliant on Daewoong and our future licensors to defend any third-party claims. Our licensors may not defend or prosecute such actions as vigorously or in the manner that we would have if entitled to do so, and we will be subject to any judgment or settlement resulting from such actions. Also, a third-party may challenge the validity of our in-licensing transactions. Furthermore, even if they are unchallenged, any of our future in-licensed patents and patent applications may not adequately protect the licensors or our intellectual property or prevent others from designing around their or our claims.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our intellectual property or the patents and other intellectual property of our licensors, which could be expensive and time-consuming. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our intellectual property, including any future patents we may acquire, or the patents and other intellectual property of our licensors, including Daewoong. As a result, we or any of our current or future licensors may be required to file infringement claims to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or any of our current or future licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant an injunction against an infringer are not satisfied. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse determination of any litigation or other proceedings could put one or more of such patents at risk of being invalidated or interpreted narrowly. Interference, derivation or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with respect to any of our future patent applications or those of our licensors or collaborators. Litigation or USPTO proceedings brought by us or any of our current or future licensors may fail </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or may be invoked against us or our licensors by third parties. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs and distraction to our management or the management of any of our current or future licensors, including Daewoong. We may not be able, alone or with any of our current or future licensors or collaborators, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation longer than we could. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, or in-license needed technology or other product candidates. There could also be public announcements of the results of the hearing, motions, or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States and in some cases may even force us to grant a compulsory license to competitors or other third parties. Consequently, we may not be able to prevent third parties from using our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in domestic and foreign intellectual property laws. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, collaborators, consultants, advisors and other third parties. We expect to enter into confidentiality and invention assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts within and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ individuals who were previously employed at other pharmaceutical or medical aesthetic companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. We may not be successful in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Any litigation or the threat thereof may adversely affect our ability to hire employees. A loss of key personnel or their work product could diminish or prevent our ability to commercialize product candidates, which could have an adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold intellectual property, including patent rights that are important or necessary to the development of our future product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we are using trademarks or trade names that are confusingly similar to their marks. If any third party were able to establish that our trademarks or trade names were infringing their marks, that third party may be able to block our ability to use the infringing trademark or trade name. In addition, if a third party were to bring such a claim, we would be required to dedicate time and resources to fight the claim, which time and resources could otherwise be used toward the maintenance of our own intellectual property.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may request and obtain injunctive or other equitable relief, which could prevent our ability to use the subject trademarks or trade names. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement. We may be required to re-brand one or more of our products, product candidates, or services offered under the infringing trademark or trade name, which may require substantial time and monetary expenditure. Third parties could claim senior rights in marks which might be enforced against our use of trademarks or trade names, resulting in either an injunction prohibiting our sales under those trademarks or trade names.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and products are subject to extensive government regulation. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to extensive, complex, costly and evolving regulation by federal and state governmental authorities in the United States, the EU, Canada and other countries, principally by the FDA, the U.S. Drug Enforcement Administration, the Centers for Disease Control and Prevention, the EMA and other similar regulatory authorities. Daewoong is also subject to extensive regulation by the FDA and the South Korean regulatory authorities as well as other regulatory authorities. Our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">failure to comply with all applicable regulatory requirements, or Daewoong&#8217;s failure to comply with applicable regulatory requirements, including those promulgated under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and the Controlled Substances Act, may subject us to operating restrictions and criminal prosecution, monetary penalties and other enforcement or administrative actions, including, sanctions, warnings, product seizures, recalls, fines, injunctions, suspension, revocation of approvals, or exclusion from future participation in the Medicare and Medicaid programs. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following regulatory approval, we, and our direct and indirect suppliers, including Daewoong, remain subject to the periodic inspection of our plants and facilities, review of production processes, and testing of our products to confirm that we are in compliance with all applicable regulations. Adverse findings during regulatory inspections may result in requirements that we implement REMS programs, requirements that we complete government mandated clinical trials, and government enforcement actions including those relating to labeling, advertising, marketing and promotion, as well as regulations governing manufacturing controls. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not obtain regulatory approval for the commercialization of any future product candidates. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug and biologic products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, with regulations differing from country to country. If we, our products or the manufacturing facilities for our products fail to comply with applicable regulatory requirements, a regulatory agency may:</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on the marketing or manufacturing of the product, suspend or withdraw product approvals or revoke necessary licenses;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue warning letters, show cause notices or untitled letters describing alleged violations, which may be publicly available;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commence criminal investigations and prosecutions;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose injunctions;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose other civil or criminal penalties;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or refuse to approve pending applications or supplements to approved applications filed by us;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to permit drugs or active ingredients to be imported or exported;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or impose restrictions on operations, including costly new manufacturing requirements; or </span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us to initiate a product recall.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA, the EMA or other similar foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we and our collaborators believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA and other similar regulatory authorities. Administering product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA, the EMA or other similar regulatory authorities delaying or denying approval of a product candidate for any or all targeted indications. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approval of a BLA or BLA supplement, marketing authorization application, or MAA, or other product approval is not guaranteed, and the approval process is expensive and may take several years. The FDA, the EMA and other regulatory authorities have substantial discretion in the approval process. Despite the time and expense expended, failure can occur at any stage, and we could encounter problems that cause us to abandon, modify or repeat clinical trials, or perform additional preclinical studies and clinical trials. The number of preclinical studies and clinical trials that will be required for the FDA, the EMA or other regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. The FDA, the EMA and other regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including the following:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be deemed safe, effective, pure or potent;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data from preclinical studies and clinical trials may not be deemed sufficient;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities might not approve our third-party manufacturers&#8217; processes or facilities; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deficiencies in the formulation, quality control, labeling, or specifications of a product candidate or in response to citizen petitions or similar documents filed in connection with the product candidate;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general requirements intended to address risks associated with a class of drugs, such as a new REMS requirement for neurotoxins;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the enactment of new laws or promulgation of new regulations that change the approval requirements; or</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities may change their approval policies or adopt new regulations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain approval, our business and results of operations will be materially and adversely harmed. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, limit or delay regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any other approved products are subject to continual regulatory review by the FDA, the EMA and other similar regulatory authorities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we or our collaborators receive for any future product candidates may also be subject to limitations on the approved indications for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the product. In addition, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any other future product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP requirements and compliance with good clinical practice, or GCP, requirements, for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; fines, warning letters or holds on clinical trials; refusal by the FDA, the EMA or other similar regulatory authorities to approve pending applications or supplements to approved applications filed by us or our strategic collaborators or suspension or revocation of product license approvals; product seizure or detention or refusal to permit the import or export of products; and injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain regulatory approvals in foreign jurisdictions for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or any future product candidates, we will be </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">unable to market our products outside of the United States. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we are and will be subject to a variety of foreign regulations governing manufacturing, clinical trials, commercial sales and distribution of our future products. Whether or not we obtain FDA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file, we may not receive necessary approvals to commercialize our products in markets outside of the United States. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or any future products may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so, we could be subject to sanctions that would materially harm our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some participants in our clinical trials have reported adverse events after being treated with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If we are successful in commercializing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any other product candidate, the FDA and other regulatory agency regulations require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events that we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA, the EMA or other similar regulatory authorities could take action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance of future products. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may in the future be subject to various U.S. federal and state laws pertaining to health care fraud and abuse, including anti-kickback, self-referral, false claims and fraud laws, and any violations by us of such laws could result in fines or other penalties. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we do not expect that Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will subject us to the various U.S. federal and most state laws intended to prevent health care fraud and abuse, we may in the future become subject to such laws. The Anti-Kickback Statute prohibits the offer, receipt, or payment of remuneration in exchange for or to induce the referral of patients or the use of products or services that would be paid for in whole or part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced price items and services. Many states have similar laws that apply to their state health care programs as well as private payors. Violations of anti-kickback and other applicable laws can result in exclusion from federal health care programs and substantial civil and criminal penalties. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal False Claims Act, or FCA, imposes liability on persons who, among other things, present or cause to be presented false or fraudulent claims for payment by a federal health care program. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims. Some state law equivalents of the above federal laws, such as the Anti-Kickback Statute and FCA, apply to items or services regardless of whether the good or service was reimbursed by a government program, so called all-payor laws. These all-payor laws could apply to our sales and marketing activities even if the Anti-Kickback Statute and FCA laws are inapplicable.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our marketing or other arrangements were determined to violate anti-kickback or related laws, including the FCA or an all-payor law, then we could be subject to penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment or the curtailment or restructuring of our operations, any of which could materially and adversely affect our ability to operate our business and our financial results. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and federal authorities have aggressively targeted pharmaceutical companies for alleged violations of these anti-fraud statutes, based on improper research or consulting contracts with doctors, certain marketing arrangements with pharmacies and other healthcare providers that rely on volume-based pricing, off-label marketing schemes, and other improper </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">promotional practices. Companies targeted in such prosecutions have paid substantial fines, have been ordered to implement extensive corrective action plans, and have in many cases become subject to consent decrees severely restricting the manner in which they conduct their business, among other consequences. Additionally, federal and state regulators have brought criminal actions against individual employees responsible for alleged violations. If we become the target of such an investigation or prosecution based on our contractual relationships with providers or institutions, or our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the FCPA and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. Our internal control policies and procedures may not protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislative or regulatory healthcare reforms in the United States and other countries may make it more difficult and costly for us to obtain regulatory clearance or approval of any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation is drafted and introduced in the U.S. Congress or other countries that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, regulations and guidance are often revised or reinterpreted by the FDA and other regulatory authorities in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future product candidates. Such changes could, among other things, require changes to manufacturing or marketing methods, changes to product labeling or promotional materials, recall, replacement, or discontinuance of one or more of our products; and additional recordkeeping.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationship with Alphaeon and Alphaeon 1, LLC</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain of our directors may have actual or potential conflicts of interest because of their ownership of debt and equity securities in AEON Biopharma, Inc., or AEON, and Alphaeon 1, LLC and their positions with AEON and Alphaeon 1, LLC. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our initial public offering in 2018, we were wholly owned by AEON (previously known as ALPHAEON Corp.). In January 2020, AEON transferred all of their stock ownership in us to Alphaeon 1, LLC. As of December&#160;31, 2021, Alphaeon 1, LLC owned 10.9% of our outstanding shares of common stock. Vikram Malik, Simone Blank, and Robert Hayman serve on our board of directors. Such directors or entities they are affiliated with currently own and may in the future own equity, debt or convertible debt of AEON and Alphaeon 1, LLC, which we refer to collectively as the Alphaeon entities. These individuals&#8217; or entities&#8217; holdings of debt or equity securities, options to purchase shares of Alphaeon entities or other equity awards in the Alphaeon entities may be significant for some of these persons or entities compared to these persons&#8217; or entities&#8217; total assets. Additionally, each of Mr. Malik, and Ms. Blank serve on the board of directors of Alphaeon and board of managers of Alphaeon 1, LLC. Their positions at the Alphaeon entities and the ownership of any Alphaeon entity equity, debt or equity awards may create, or may create the appearance of, conflicts of interest when these directors are faced with decisions that could have different implications for the Alphaeon entities than the decisions have for us. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decisions include corporate opportunities; the impact that operating decisions for our business may have on the Alphaeon entities&#8217; consolidated financial statements; the impact that operating or capital decisions (including the incurrence of indebtedness) for our business may have on the Alphaeon entities&#8217; current or future indebtedness or the covenants under that indebtedness; the timing and amount of financing efforts, whether they are debt or equity, and the amount of resulting dilution to existing shareholders; business combinations involving us; our dividend policy; and management stock ownership.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, disputes may arise between Alphaeon entities and us relating to our past and ongoing relationship, and these potential conflicts of interest may make it more difficult for us to favorably resolve such disputes, including those related to:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">indemnification and other matters arising from our initial public offering;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other disposal by Alphaeon 1, LLC of all or a portion of its ownership interest in us; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business combinations involving us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to resolve any potential conflicts, and even if we do, the resolution may be less favorable to us than if we were dealing with an unaffiliated party. While we are not controlled by the Alphaeon entities, we may not have the leverage to negotiate amendments to these agreements, if required, on terms as favorable to us as those we would negotiate with an unaffiliated third party.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AEON and its directors and officers will have limited liability to us or you for breach of fiduciary duty. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that, subject to any contractual provision to the contrary, AEON has no obligation to refrain from: engaging in the same or similar business activities or lines of business as we do; doing business with any of our clients or consumers; or employing or otherwise engaging any of our officers or employees.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides for the allocation of certain corporate opportunities between us and AEON. Under these provisions, neither AEON nor its other affiliates, nor any of their officers, directors, agents, stockholders, members, partners and subsidiaries, will have any obligation to present to us certain corporate opportunities. For example, a director or officer of our company who also serves as a director, officer or employee of AEON or any of its other affiliates may present to AEON certain acquisitions, in-licenses, potential development programs or other opportunities that may be complementary to our business, if he or she was not offered such corporate opportunity in his or her capacity as our director or officer, and, as a result, such opportunities may not be available to us. To the extent attractive corporate opportunities are allocated to AEON or its other affiliates instead of to us, we may not be able to benefit from these opportunities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under our certificate of incorporation, neither AEON nor any officer or director of AEON, except as provided in our certificate of incorporation, will be liable to us or to our stockholders for breach of any fiduciary or other duty by reason of any of these activities. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, AEON no longer held any shares of our stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medytox, Alphaeon 1, LLC and Daewoong each own a significant portion of our common stock and may exert significant control over our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had 55,576,988 shares of common stock issued and outstanding as of December&#160;31, 2021. As of December&#160;31, 2021, Medytox owned 13.4% of our outstanding shares of common stock, Alphaeon 1, LLC owned 10.9% of our outstanding shares of common stock, and Daewoong owned 5.6% of our outstanding shares of common stock. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This concentrated ownership position may provide any one of Medytox, Alphaeon 1, LLC or Daewoong with influence in determining the outcome of corporate actions requiring stockholder approval, including the election and removal of directors. The significant stock ownership by Medytox, Alphaeon 1, LLC and Daewoong may also discourage transactions involving a change-of-control of our company, including transactions in which you as a holder of our common stock might otherwise receive a premium for your shares.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities class action and derivative lawsuits have been filed against us and certain of our officers and directors, which could result in substantial costs and could divert management attention.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in Part I, Item 3 &#8220;Legal Proceedings,&#8221; we and certain of our officers have been named as defendants in a securities class action lawsuit and we are a nominal defendant in derivative lawsuits filed against certain of our officers and directors. We maintain director and officer&#8217;s insurance coverage and continue to engage in vigorous defense of such litigation. If we are not successful in our defense of such litigation, we could be forced to make significant payments to or other settlements with our stockholders and their lawyers outside of our insurance coverage, and such payments or settlement arrangements could have a material adverse effect on our business, operating results or financial condition. We may also be the target of this type of litigation in the future, as companies that have experienced volatility in the market price of their stock have been subject to securities act litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the claims asserted in these lawsuits are not successful, the litigation could result in substantial costs and significant adverse impact on our reputation and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, operating results or financial condition.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The trading price of our common stock has been volatile, and purchasers of our common stock could incur substantial losses. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price is volatile. For example, the closing price of our common stock during the year ended December 31, 2021 has ranged from a low of $3.20 to a high of $16.51. The stock market in general and the market for earlier-stage pharmaceutical and medical aesthetic companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, some of which are beyond our control, including: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introductions and announcements of new technologies and products by us, any commercialization partners or our competitors, and the timing of these introductions and announcements;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">success or failure of competitive products or medical aesthetic products generally;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of results of clinical trials or regulatory approval or disapproval of product candidates;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, licenses, strategic partnerships, new product approvals and introductions, joint ventures or capital commitments;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall financial market conditions for the pharmaceutical and biopharmaceutical sectors and issuance of securities analysts&#8217; reports or recommendations;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated safety concerns related to the use of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any of our future products;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any termination or loss of rights under the Daewoong Agreement;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other U.S. or foreign regulatory or legal actions or changes affecting us or our industry;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments concerning our manufacturer or any future strategic partnerships;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments affecting our compliance with the Medytox/Allergan Settlement Agreements or Daewoong&#8217;s ability to satisfy its reimbursement obligations to us with respect to the royalties payable to Medytox and Allergan;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments concerning litigation pending against us;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial estimates or guidance, including our ability to meet our future revenue and operating profit or loss estimates or guidance;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the public&#8217;s reaction to our earnings releases, other public announcements and filings with the SEC;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rumors and market speculation involving us or other companies in our industry;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">short selling of our common stock or the publication of opinions regarding our business prospects in a manner that is designed to create negative market momentum;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of substantial amounts of our stock by Medytox, Alphaeon 1 LLC, Daewoong or other significant stockholders or our insiders, or the expectation that such sales might occur;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">news reports relating to trends, concerns and other issues in medical aesthetics market or the pharmaceutical or biopharmaceutical industry;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating and stock performance of other companies that investors deem comparable to us and overall performance of the equity markets;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel, including our Chief Executive Officer, Chief Financial Officer, Chief Medical Officer and Chief Marketing Officer; </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property, product liability or other litigation against us, our manufacturer or other parties on which we rely or litigation against our general industry;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our capital structure, such as future issuances of securities and the incurrence of additional debt;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting standards, policies, guidelines, interpretations or principles; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic conditions in the markets in which we operate, including those related to COVID-19; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the market for pharmaceutical, biotechnology and medical aesthetics companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may affect the market price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the overall market and the market prices of a particular company&#8217;s securities, securities class action litigation has often been instituted against that company. We may become the target of this type of litigation in the future. Securities litigation, if instituted against us, could result in substantial costs and divert our management&#8217;s attention and resources from our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of our common stock by us, Medytox, Alphaeon 1, LLC, Daewoong or others, or the perception that such sales may occur, could depress the market price of our common stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales by us of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could significantly reduce the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as discussed above, each of Medytox, Alphaeon 1, LLC and Daewoong owns a significant portion of our outstanding shares of common stock. Subject to the restrictions described in the paragraph below, future sales of these shares in the public market will be subject to certain contractual limitations in the case of shares of our common stock owned by Medytox and the volume and other restrictions of Rule 144 under the Securities Act for so long as Medytox or Alphaeon 1, LLC are deemed to be our affiliate, unless the shares to be sold are registered with the SEC. Additionally, the shares of common stock held by Medytox are subject to contractual restrictions on transfer that, subject to certain limited exceptions such as transfers to affiliates prohibit Medytox from transferring more than 25% of the shares it holds prior to September 16, 2023, more than 50% of the shares it holds prior to September 16, 2024 and more than 75% of the shares it holds prior to September 16, 2025, with such contractual restrictions terminating on September 16, 2025. The sale by Medytox, Alphaeon 1, LLC or Daewoong of a substantial number of shares of our common stock, or a perception that such sales could occur, could significantly reduce the market price of our common stock. For example, in September 2021, Alphaeon 1, LLC sold 2,597,475 shares of our common stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed a registration statement with the SEC covering shares of our common stock available for future issuance under our&#160;2017 Omnibus Incentive Plan and may file future registration statements covering shares of our common stock for future issuance under any future plans. Upon effectiveness of such registration statements, any shares subsequently issued under such plans will be eligible for sale in the public market, except to the extent that they are restricted by the contractual arrangements discussed above and subject to compliance with Rule 144 in the case of our affiliates. Sales of a large number of the shares issued under these plans in the public market, or a perception that such sales could occur, could significantly reduce the market price of our common stock. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our certificate of incorporation and bylaws, as well as Delaware law, could discourage a takeover.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation, bylaws and Delaware law contain provisions that might enable our management to resist a takeover and might make it more difficult for an investor to acquire a substantial block of our common stock. These include the following provisions:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">permit our board of directors to issue shares of preferred stock, with any rights, preferences and privileges as they may designate, without stockholder approval, which could be used to dilute the ownership of a hostile bidder significantly;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that the authorized number of directors may be changed only by resolution of our board of directors and that a director may only be removed for cause by the affirmative vote of the holders of at least 66 2/3% of our voting stock;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divide our board of directors into three classes, with each class serving staggered three-year terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of our company;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors, which may delay the ability of our stockholders to force consideration by our company of a take-over proposal or to take certain corporate actions, including the removal of directors.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject to Section 203 of the General Corporation Law of the State of Delaware, or the DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This provision could have the effect of delaying or preventing a change-of-control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation designates the Court of Chancery of the State of Delaware as the&#160;sole and exclusive forum&#160;for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the&#160;sole and exclusive forum&#160;for all &#8220;internal corporate claims.&#8221; &#8220;Internal corporate claims&#8221; are claims that are based upon a violation of a duty by a current or former director, officer or stockholder in such capacity, or as to which Title 8 of the DGCL confers jurisdiction upon the Court of Chancery of the State of Delaware, or the Court of Chancery, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. For example, this choice of forum provision would not apply to claims brought pursuant to the Exchange Act or the Securities Act of 1933, as amended, or any other claim for which the federal courts have exclusive jurisdiction. Any person purchasing or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to this provision of our certificate of incorporation. The choice of forum provision in our certificate of incorporation will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This choice of forum provision may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision of our certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation and bylaws provide that we can indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. Separate indemnity agreements have been issued with each director and executive officer.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as permitted by Section 145 of the DGCL, our bylaws and our indemnification agreements that we have entered into with our directors and officers, among other things provide that:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have indemnified our directors and officers for serving us in those capacities, or for serving as a director, officer, employee or agent of other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that we may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interest and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will be required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rights conferred in our bylaws will not be exclusive. We may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an &#8220;emerging growth company,&#8221; and the reduced reporting requirements available to emerging growth companies could make our common stock less attractive to investors.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We qualify as an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we remain an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies. These provisions include, but are not limited to:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">being permitted to have only two years of audited financial statements and only two years of related selected financial data and management&#8217;s discussion and analysis of financial condition and results of operations disclosure;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an exemption from compliance with the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced disclosure about executive compensation arrangements in our periodic reports, registration statements and proxy statements; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exemptions from the requirements to seek non-binding advisory votes on executive compensation or golden parachute arrangements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we take advantage of any of these exemptions, the information that we provide stockholders may be different than what is available with respect to other public companies. Investors may find our common stock less attractive because </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including exemption from compliance with the auditor attestation requirements of Section 404(b) as long as we do not otherwise also qualify as an &#8220;accelerated filer&#8221; or &#8220;large accelerated filer&#8221; for SEC reporting purposes and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. Investors could find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our trading price may be more volatile.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders may, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts publish unfavorable research about our business or decrease the frequency or cease to provide coverage of our company, our stock price and trading volume could decline.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends in part on the research and reports that equity research analysts publish about us and our business. If one or more of the equity research analysts who cover us downgrades our common stock or issues other unfavorable commentary or research the price of our common stock may decline. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause the trading price or trading volume of our common stock to decline.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future, and the payment of dividends is also restricted under our credit facility. The payment of dividends on our common stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as our board of directors may consider relevant. If we do not pay dividends, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The requirements of being a public company may strain our resources, divert management&#8217;s attention and affect our ability to attract and retain executive management and qualified board members.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Nasdaq Marketplace Rules and other applicable securities rules and regulations. Complying with these rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources, particularly after we are no longer an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may need to hire more employees in the future or engage outside consultants to assist us in complying with these requirements, which will increase our costs and expenses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased selling, general and administrative expenses and a diversion of our management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i77038361ec4447b8be22639fec3c691b_25"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Properties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters is located at 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660, in a facility that we lease, encompassing approximately 17,758 square feet of space. The lease for this facility expires on January 31, 2025. We believe our facilities are sufficient for our current needs. When our lease expires, we may exercise our renewal option or look for additional or alternate space for our operations, and we believe that suitable additional or alternative space will be available in the future on commercially reasonable terms.</span></div><div id="i77038361ec4447b8be22639fec3c691b_28"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;Legal Proceedings.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Class Action Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16 and 28, 2020, two putative securities class action complaints were filed in the U.S. District Court for the Southern District of New York by Evolus shareholders Armin Malakouti and Clinton Cox, respectively, naming the Company and certain of its officers as defendants. The complaints assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, claiming that the defendants made false and materially misleading statements and failed to disclose material adverse facts related to the Company&#8217;s acquisition of the right to sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the complaint against the Company filed by Allergan and Medytox in the U.S. International Trade Commission related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which we refer to as the ITC Action, and risks related to the ITC Action. The complaints assert a putative class period of February 1, 2019 to July 6, 2020. The court consolidated the actions on November 13, 2020, under the caption In re Evolus Inc. Securities Litigation, No. 1:20-cv-08647 (PGG). On September 17, 2021, the court appointed a lead plaintiff and lead counsel. On November 17, 2021, the lead plaintiff filed an amended class action complaint against the Company, three of its officers, and Alphaeon Corporation, the Company&#8217;s former majority shareholder. On January 18, 2022, the Company and the officer defendants served their motion to dismiss the amended complaint, which is scheduled to be fully briefed on June 16, 2022.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Derivative Lawsuit</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2020 and December 2, 2020, two putative Evolus shareholders filed substantially similar shareholder derivative actions in the U.S. District Court for the Southern District of New York against certain of the Company&#8217;s officers and directors as defendants. The complaints alleged substantially similar facts as those in the Securities Class Action and assert claims for, among other things, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of Section 14(a) of the Exchange Act and for contribution under Sections 10(b) and 21(D) of the Exchange Act. On December 29, 2020, the plaintiffs filed a joint stipulation to consolidate their actions and on February 5, 2021, the court consolidated the action under the caption</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re Evolus, Inc. Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-09986-PPG, and adjourned defendants&#8217; time to move, answer or otherwise respond to the complaints. On September 20, 2021, the court so-ordered the parties&#8217; stipulated stay of the consolidated derivative suit pending the court&#8217;s decision on the defendants&#8217; motion to dismiss the Securities Class Action.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional suits will be filed, or additional allegations will be made by stockholders, with respect to these same or similar or other matters and also naming the Company and/or its officers and directors as defendants. The Company believes that the complaints are without merit and intends to vigorously defend against it. However, the outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss and accordingly has not accrued any liability associated with this action.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Books and Records Demand</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, the Company received a letter from a putative stockholder demanding inspection of specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law. The Company was subsequently informed that the stockholder sold his shares of the Company&#8217;s common stock. On October 13, 2021, the Company received a substantially similar demand to inspect specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law from another putative stockholder. The subject of the demand is substantially similar to the allegations in the putative securities class action and derivative complaints described above. The Company responded to that demand on December 17, 2021.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Legal Matters</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the legal proceedings set forth above, from time to time, we may be subject to other legal proceedings and claims in the ordinary course of business.</span></div><div id="i77038361ec4447b8be22639fec3c691b_31"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i77038361ec4447b8be22639fec3c691b_34"></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II</span></div><div id="i77038361ec4447b8be22639fec3c691b_37"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. &#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has been listed and traded on the Nasdaq under the symbol &#8220;EOLS&#8221; since February 12, 2018. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;February&#160;28, 2022, we had approximately 30&#160;holders of record of our common stock. This number does not include beneficial owners whose shares were held in street name. The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our capital stock and we do not currently intend to pay any cash dividends on our capital stock for the foreseeable future. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, tax considerations, legal or contractual restrictions, business prospects, the requirements of current or then-existing debt instruments, general economic conditions and other factors our board of directors may deem relevant. The payment of dividends is also restricted under our credit facility.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From January 1, 2021 to December&#160;31, 2021, the period covered by this Annual Report on Form 10-K, we did not issue any unregistered securities except as previously disclosed in those certain Current Report on Form 8-K filed with the SEC on February 19, 2021 and March 23, 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made no purchases of our equity securities during the fourth quarter of the year ended December&#160;31, 2021.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_40"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;[Reserved].</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_43"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion contains management&#8217;s discussion and analysis of our financial condition and results of operations and should be read together with the historical financial statements and the notes thereto included in Item 8 &#8220;Financial Statements and Supplementary Data&#8221; and included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs and involve numerous risks and uncertainties, including but not limited to those described in the Item 1A &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K. Actual results may differ materially from those contained in any forward-looking statements. You should carefully read &#8220;Special Note Regarding Forward-Looking Statements&#8221; and Item 1A &#8220;Risk Factors.&#8221;</span></div><div id="i77038361ec4447b8be22639fec3c691b_46"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. In February 2019, we received the approval of our first product Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration, or FDA. In May 2019, we commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. Our primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. We believe we offer customers and consumers a compelling value proposition with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Currently, onabotulinumtoxinA (BOTOX) is the neurotoxin market leader, and prior to the approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was the only known 900 kDa botulinum toxin type A complex approved in the United States. We believe aesthetic physicians generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, we received approval from Health Canada&#160;for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age.&#160;We began marketing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada in October 2019 through our distribution partner Clarion Medical Technologies, Inc., or Clarion. In September 2019, we also received approval from the European Commission, to market the product in all 27 European Union, or EU, member states plus the United Kingdom, Iceland, Norway and Liechtenstein. In January 2021, we received a positive decision from the European Commission to add the 50 unit product to the approval obtained in September 2019. We plan to launch Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe in the third quarter of 2022. We received acceptance of our submission to the Australian Therapeutics Good Administration, or TGA, for regulatory approval of our neurotoxin product in Australia in the first quarter of 2022. We expect to receive full TGA regulatory approval and launch the product in Australia in 2023.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we announced the initiation of a Phase II clinical trial designed to investigate a higher strength dose of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the frown lines. We plan to enroll our first patient in the clinical trial in the first quarter of 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of Settlement Agreements</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we settled litigation claims related to a complaint against us filed by Allergan, Inc. and Allergan Limited (together, &#8220;Allergan&#8221;) and Medytox, Inc. (&#8220;Medytox&#8221;) in the U.S. International Trade Commission related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;ITC Action&#8221;) and certain related matters by entering into a Settlement and License Agreement with Medytox and Allergan, which we refer to as the U.S. Settlement Agreement, and another Settlement and License Agreement with Medytox which we refer to as the ROW Settlement Agreement. We refer to the U.S. Settlement Agreement and the ROW Settlement Agreement collectively as the Medytox/Allergan Settlement Agreements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Medytox/Allergan Settlement Agreements, we agreed to (i) make cash payments of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$35.0&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in multiple payments over two years to Allergan and Medytox, of which we paid the first payment of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the third quarter of 2021 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the first quarter of 2022, with final payment of $5.0 million due in 2023, (ii) pay to Allergan and Medytox royalties on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on a certain dollar amount per vial sold of the Licensed Products by or on our behalf in the United States, from December 16, 2020 to September 16, 2022, (iii) from December 16, 2020 to September 16, 2022, pay Medytox a low-double digit royalty on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sold by us or on our behalf in territories we have licensed outside the United States, and (iv) from September 16, 2022 to September 16, 2032, pay Medytox a mid-single digit royalty percentage on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and all territories we have licensed outside the United States. We also issued 6,762,652 shares of our common stock to Medytox.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in March 2021, we entered into a Confidential Settlement and Release Agreement and certain related agreements with Daewoong Pharmaceutical Co. Ltd. (&#8220;Daewoong&#8221;), which we refer to as the Daewoong Arrangement, under which Daewoong paid us $25.5 million in April 2021, cancelled all remaining milestone payments up to $10.5 million in aggregate under the Daewoong Arrangement and agreed to reimburse us certain amounts (calculated on a dollar amount per vials sold basis in the United States) for sales of certain products with respect to which we are required to pay Medytox and Allergan royalties pursuant to the U.S. Settlement Agreement. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details on the litigation settlement agreements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the royalty payments that we are required to pay under the Medytox/Allergan Settlement Agreements, after giving effect to the offset of a certain portion thereof that will be reimbursed to us under the Daewoong Arrangement, we expect that our cost of sales and gross profit margin will be materially negatively impacted through September 2022 and negatively impacted to a lesser extent from September 2022 to September 2032.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Pharmakon Term Loans</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2021, we entered into a loan agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and Biopharma Credit PLC (collectively, &#8220;Pharmakon&#8221;). Pursuant to the terms of the agreement, Pharmakon agreed to make term loans to us in two tranches (&#8220;Pharmakon Term Loans&#8221;). The first tranche of $75.0 million was funded on December 29, 2021. The second tranche of $50.0 million may be drawn at our election no later than December 31, 2022, subject to the terms and conditions of the Pharmakon Term Loans. As of March&#160;3, 2022, we have not drawn the second tranche. The Pharmakon Term Loans will mature on the sixth year anniversary of the closing date of the first tranche. See &#8220;&#8212;Liquidity and Capital Resources&#8212;The Pharmakon Term Loans&#8221; for further information.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Daewoong Convertible Note</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2020, pursuant to a Convertible Promissory Note Purchase Agreement with Daewoong, we issued to Daewoong a Convertible Promissory Note for the principal amount of $40.0 million, which we refer to as the Daewoong Convertible Note, which was funded on July 30, 2020. On March&#160;23, 2021, the outstanding principal balance, together with all accrued and unpaid interest thereon, in the amount of $40.8 million was converted, at the conversion price of $13.00 per share, into the right to receive 3,136,869 shares of our common stock under the Conversion Agreement. See &#8220;&#8212;Liquidity and Capital Resources&#8212;The Daewoong Convertible Note&#8221; for further information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Royalties and Notes Payable to Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make the following future payments to the founders of Evolus, which we refer to as the Evolus Founders: quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These obligations terminate in the quarter following the 10-year anniversary of the first commercial sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. The fair value of the obligations are valued quarterly and are referred to in our financial statements as the contingent royalty obligation. In November 2021, we also paid $20.0 million to satisfy in full a promissory note that matured in November 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Impact</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing COVID-19 outbreak and restrictions intended to slow its spread resulted in temporary business closures for many of our customers starting in mid-March 2020, which negatively affected our sales during the first half of 2020. Starting in June 2020, we experienced an increase in sales that continued throughout the rest of 2020 and into 2021 as many states started easing restrictions on elective procedures and many of our customers re-opened their businesses. The COVID-19 pandemic has the potential to negatively impact our supply chain through reduced availability of commercial transport, which can impact our ability to distribute Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our customers.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and its effects continue to evolve, with developments including fluctuations in the rate of infections during 2021 and 2022 as a result of new and more contagious and/or vaccine resistant variants of the virus, which have led, and may lead in the future, to further government restrictions to combat increasing rates of infection. We continue to monitor the evolving situation and guidance from international and domestic authorities, including federal, state and local public health authorities and may take actions based on their recommendations. In these circumstances, there may be developments outside our control requiring us to adjust our operating plan. As such, given the dynamic nature of this situation, we cannot reasonably estimate the full impact of COVID-19 on our financial condition, results of operations or cash flows in the future.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Use of Adjusted Gross Profit Margin</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted gross profit and adjusted gross profit margin are not required by, nor presented in accordance with United States generally accepted accounting principles, or GAAP. Adjusted gross profit is defined as total net revenues less product cost of sales, excluding the one-time settlement payment from Daewoong and amortization of an intangible asset. Adjusted gross profit margin is calculated as adjusted gross profit divided by total net revenues. Management believes that adjusted gross profit margin is an important measure for investors because management uses adjusted gross profit margin as a key performance indicator to evaluate the profitability of sales without giving effect to costs that are not core to our cost of sales, such as the settlement payment from Daewoong and the amortization of an intangible asset. Adjusted gross profit margin should not be considered a measure of financial performance under GAAP, and the items excluded from adjusted gross profit margin should not be considered in isolation or as alternatives to financial statement data presented in the financial statements as an indicator of financial performance or liquidity. As adjusted gross profit margin is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, has limitations as an analytical tool and may not be comparable to other similarly titled measures of other companies. </span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are reconciliations of adjusted gross profit to gross profit, the most directly comparable to GAAP measure, and adjusted gross profit margin to gross profit margin, the most directly comparable GAAP measure:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.511%"><tr><td style="width:1.0%"></td><td style="width:76.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product cost of sales (excludes amortization of intangible assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement payment from Daewoong</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of distribution right intangible asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross profit margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">79.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">62.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Settlement payment from Daewoong</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Amortization of distribution right intangible asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Adjusted gross profit margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_49"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December 31, 2021 and 2020</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.477%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product cost of sales (excludes amortization of intangible assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement payment from Daewoong</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation to Evolus Founders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlement expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from extinguishment of debts, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Revenues</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently operate in one reportable segment and all of our net revenues are derived from sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Net revenues consist of revenues, net of adjustments primarily for customer rebates, coupon program, rewards related to the consumer loyalty program and co-branded marketing programs. Revenues are recognized when the control of the promised goods is transferred to the customer in an amount that reflects the consideration allocated to the related performance obligations and to which we expect to be entitled in exchange for those products or services. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales increased by $43.1 million, or 76.3%, to $99.7 million for the year ended December 31, 2021 from $56.5 million for the year ended December 31, 2020, with a majority of the increase attributable to higher sales volume and the rest to a higher net average selling price of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. We anticipate our continued sales growth will depend on our ability to grow our customer base and increase purchases by our current customers.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Cost of Sales</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product cost of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales, excluding amortization of intangible assets, primarily&#160;consisted of the cost of inventory purchased from Daewoong. In addition, during the period from December 2020 to September 2022, product cost of sales, excluding amortization of intangible assets, also included certain royalties on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> payable to Medytox and Allergan pursuant to the Medytox/Allergan Settlement Agreements, partially offset by reimbursement receivable from Daewoong pursuant to the Daewoong Arrangement with respect to such royalties.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product cost of sales, excluding amortization of intangible assets, increased by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$25.2 million, or 137.9%,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$43.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for&#160;the&#160;year ended December 31, 2021 from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$18.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily due to higher sales volume and the additional net royalties under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements, offset by payments we receive under the Daewoong Arrangement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We anticipate that our product cost of sales will fluctuate in line with changes in revenues.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Settlement Payment from Daewoong</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we recorded a one-time settlement receipt of $25.5 million from Daewoong in connection with the Daewoong Settlement Agreement.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross Profit Margin</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross profit margin was 79.0% and 62.4% for the years ended December 31, 2021 and 2020, respectively. Our adjusted gross profit margin, calculated as total net revenues less product cost of sales, excluding amortization of intangible assets and the one-time settlement payments from Daewoong, as a percentage of net revenues was&#160;56.3%&#160;and 67.6% for the&#160;years ended December 31, 2021 and December&#160;31, 2020, respectively. We anticipate our gross profit margin and adjusted gross profit margin will be impacted negatively and materially through September 2022, offset by payments we receive under the Daewoong Arrangement, and to a lesser degree for ten years thereafter, by our payments under the Medytox/Allergan Settlement Agreements. We also anticipate our gross profit margin and adjusted gross profit margin will fluctuate as we implement various marketing programs that may affect the average selling price for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and as we expand internationally.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses&#160;increased by&#160;$13.9 million, or 14.1%,&#160;to&#160;$112.1 million&#160;for the&#160;year ended December 31, 2021&#160;from&#160;$98.2 million&#160;for the&#160;year ended December 31, 2020, primarily resulting from increasing our commercial activities, including direct-to-consumer marketing, partially offset by reduced personnel costs. Selling, general and administrative expenses may fluctuate in the future primarily due to potential changes in marketing strategies and future launches internationally.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses&#160;increased by&#160;$0.3 million, or 19.9%,&#160;to&#160;$2.1 million&#160;for the&#160;year ended December 31, 2021&#160;from&#160;$1.7 million&#160;for the&#160;year ended December 31, 2020. The increase was primarily attributable to increased clinical activities. We expect that our overall research and development expense will increase as we conduct the Phase II Extra Strength clinical trial in 2022 and if and when we seek to develop further product candidates and as we pursue regulatory approvals in other jurisdictions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revaluation of Contingent Royalty Obligation Payable to Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the fair value of the contingent royalty obligation payable to Evolus Founders is recorded in operating expenses in each reporting period. During the&#160;years ended December 31, 2021&#160;and 2020, the revaluation charge of&#160;$6.3 million&#160;and&#160;gain of $2.0 million, respectively, were primarily driven by changes in management assumptions relating to revenue forecasts, the discount rate used </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iming of cash flows. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization&#160;decreased by $1.4 million, or 20.0%,&#160;to&#160;$5.6 million&#160;for the&#160;year ended December 31, 2021&#160;from $7.0 million for the&#160;year ended December 31, 2020 due to the decrease in amortization of the distribution right asset related </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to&#160;Jeuveau</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;over 20 years as well as amortization of the internal-use software costs.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Settlement Expenses</span></div><div style="margin-bottom:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to settlement agreements we entered into with Allergan and Medytox in connection with the settlement of claims relating to certain intellectual property disputes related to Jeuveau</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in February 2021, we recorded a charge in operating expenses and related liability of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$83.4 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in December 2020, which consisted of $35.0 million in deferred cash payments and $48.4 million from the issuance of 6,762,652 of shares of our common stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring Costs</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs during the year ended December 31, 2020 primarily included $3.0 million of termination benefits relating to actions we took to separate more than 100 employees to preserve liquidity and minimize the impact of COVID-19 on our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Operating Expense, Net</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating expenses, net, decreased by&#160;$8.5 million, or 85.9%,&#160;to&#160;$1.4 million&#160;for the&#160;year ended December 31, 2021&#160;from $9.9 million&#160;for the&#160;year ended December 31, 2020, primarily due to lower interest expense resulting from the repayment of the long-term debt from Oxford Finance, LLC in January 2021 and the conversion of the Daewoong Convertible Note in March 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes (Benefit) Expense</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense&#160;was de minimis&#160;for the&#160;year ended December 31, 2021&#160;compared to $0.1 million for the&#160;year ended December 31, 2020. This was primarily attributable to the decrease in state income taxes.</span></div><div id="i77038361ec4447b8be22639fec3c691b_52"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had cash and cash equivalents of $146.3 million, positive working capital of $121.1 million and stockholders&#8217; equity of $81.9 million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a limited history of generating revenues and began shipping Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in May 2019. As of December&#160;31, 2021, we had an accumulated deficit of $422.9 million. We incurred net losses of $46.8 million and $163.0 million in the years ended December 31, 2021 and 2020, respectively. We used net cash of $33.4 million and $57.9 million in operating activities for the twelve months ended December 31, 2021 and 2020, respectively. We expect to continue to incur significant expenses for the foreseeable future as we increase marketing efforts for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and maintain our regulatory approvals.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Follow-On Public Offering</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we completed a follow-on public offering and sold 10,350,000 shares of our common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,350,000 shares of our common stock at a price to the public of $9.50 per share. We received net proceeds of approximately $92.4&#160;million from the offering, after deducting underwriting discounts and commissions, excluding other offering expenses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;At-the-market&#8221; Offerings of Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we entered into an &#8220;at-the-market&#8221; sales agreement with SVB Leerink LLC (the &#8220;Sales Agent&#8221;) pursuant to which shares of our common stock may be sold from time to time for aggregate gross proceeds of up to $75.0 million (the &#8220;ATM Program&#8221;). The Sales Agent is entitled to compensation, at a commission rate equal to 3.0% of the gross proceeds from the sale of our common shares under the ATM Program.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the twelve months ended December 31, 2021, we sold a total of 934,367 shares of our common stock pursuant to the ATM Program at the prevailing market prices for total net proceeds of $10.9&#160;million and paid total commissions of $0.3&#160;million to the Sales Agent.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Pharmakon Term Loans</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2021, we entered into a loan agreement with Pharmakon. Pursuant to the terms of the agreement, Pharmakon agreed to make term loans to us in two tranches. The first tranche of $75.0&#160;million was funded on December 29, 2021. The second tranche of $50.0&#160;million may be drawn at our election no later than December 31, 2022. We received net proceeds of approximately $68.7&#160;million from Pharmakon, after issuance costs and debt discounts. As of March&#160;3, 2022, we have not drawn the second tranche. We shall make 12 equal quarterly payments of principal on the outstanding Pharmakon Term Loans commencing in March 2025 and continuing through the maturity date. The Pharmakon Term Loans will mature on the sixth year anniversary of the closing date of the first tranche. The term loan bears an annual interest rate equal to the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Dollar LIBOR rate (subject to a LIBOR rate floor of 1.0%) plus 8.5%, and matures in December 2027. The proceeds of the Pharmakon Term Loans will be used to fund the Company&#8217;s general corporate and working capital requirements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Royalties and Promissory Note Payable to the Evolus Founders</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make the following future payments to the founders of Evolus, which we refer to as the Evolus Founders: quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These obligations terminate in the quarter after the 10-year anniversary of the first commercial sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. The fair value of the obligations is valued quarterly and is referred to in our financial statements as the contingent royalty obligation. In November 2021, we also paid $20.0&#160;million to satisfy in full a promissory note that matured in November 2021.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, we recorded an aggregate balance of $44.7 million and $41.5 million, respectively, on our balance sheet for the royalty payment obligation.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Oxford Loan and Security Agreement</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2019, we entered into a Loan and Security Agreement, or the credit facility, with Oxford Finance, LLC, as collateral agent, or Oxford, and the lenders party thereto from time to time, pursuant to which the lender would make term loans available to us of up to $100.0 million. The credit facility provided that the term loans would be funded in two advances. The first tranche of $75.0 million was funded on the closing date, and the second tranche of $25.0 million was never drawn. The credit facility bore an annual interest rate equal to the greater of 9.5%, or the 30-day U.S. Dollar LIBOR rate plus 7.0%. We agreed to pay interest-only for the first 36 months until May 2022, followed by a 23-month amortization period.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2021, we entered into a letter agreement with Oxford, pursuant to which (i) we paid Oxford </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$76.4 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or the Payoff Amount, to discharge in full all outstanding obligations, included accrued interest, under the Loan and Security Agreement, and (ii) effective upon such repayment, the Loan and Security Agreement, and all unfunded commitments thereunder, guarantees and other security interests granted to Oxford, and all other obligations of and restrictions on us under the Loan and Security Agreement, terminated.</span></div><div style="margin-bottom:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition to entering into the letter agreement, Oxford agreed to waive a total of approximately $4.3 million of fees comprised of (i) approximately $2.8 million of the Final Payment (as defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6. Term Loans</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (ii) the prepayment fee of $1.5 million otherwise payable pursuant to the terms of the Loan and Security Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Daewoong Convertible Note</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2020, we entered into a Convertible Promissory Note Purchase Agreement with Daewoong for the purchase and sale of a Convertible Promissory Note for the principal amount of $40.0 million, which we refer to as the Daewoong Convertible Note, which was funded on July 30, 2020. Additionally, on July 6, 2020, we, Daewoong, and Oxford entered into a Subordination Agreement pursuant to which the Convertible Note would be subordinated to our obligations under the Loan and Security Agreement with Oxford and us.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Convertible Note bore interest at a rate of 3.0% payable semi-annually in arrears on June 30th and December 31st of each year and was scheduled to mature on July 30, 2025, subject to earlier conversion as provided below. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, pursuant to the Conversion Agreement with Daewoong, the outstanding principal balance, including interest paid in kind, that was added to the outstanding principal under the terms of the Daewoong Convertible Note, together with all accrued and unpaid interest thereon, in the amount of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$40.8&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was converted into 3,136,869 shares of our common stock, at the conversion price of $13.00 per share.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Settlement</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2021, upon entering into the Medytox/Allergan Settlement Agreements, we agreed to pay to Allergan and Medytox $35.0&#160;million in multiple payments over two years, of which we paid $15.0 million in the third quarter of 2021 and $15.0 million during the first quarter of 2022, with final payment of $5.0 million due in 2023. We also issued 6,762,652 shares of common stock to Medytox. In addition, during the period from December 16, 2020 to September 16, 2022, we agreed to pay to Allergan and Medytox royalties on the sale of Jeuveau</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on a certain dollar amount per vial sold in the United States, and a low-double digit royalty on net sales of Jeuveau</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sold in other Evolus territories. During the period from </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 17, 2022 to September 16, 2032, we agreed to pay to Medytox a mid-single digit royalty percentage on all net sales of Jeuveau</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The royalty payments will be made quarterly.</span></div><div style="margin-bottom:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in &#8220;&#8212;Overview&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of Settlement Agreements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; on March 23, 2021, upon entering the Daewoong Arrangement, Daewoong paid us $25.5 million in April 2021, cancelled all remaining milestone payments up to $10.5 million in aggregate under the Daewoong Arrangement and agreed to reimburse us certain amounts (calculated on a dollar amount per vials sold basis in the United States) for sales of certain products with respect to which we are required to pay Medytox and Allergan royalties pursuant to the U.S. Settlement Agreement. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Supply Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Agreement includes certain minimum annual purchases we are required to make in order to maintain the exclusivity of the license. We may, however, meet these minimum purchase obligations by achieving certain market share in its covered territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and our future market share in various jurisdictions.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Leases</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters in Newport Beach, California is under a five-year non-cancelable operating lease, which expires on January 31, 2025 with an option to extend the term for an additional&#160;60 months. Lease payments increase based on an annual rent escalation clause that occurs on each February 1 anniversary. We&#160;may, under certain circumstances, terminate the lease on the&#160;36 months&#160;anniversary of the lease commencement date by providing a written notice&#160;12 months&#160;prior to such anniversary and paying a termination fee&#160;equal to six months basic rent plus certain other expenses.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current and Future Capital Requirements</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our current capital resources, which consist of cash and cash equivalents, cash generated from operations, and cash available under the Pharmakon Term Loans, as well as the public debt and equity markets, will be sufficient to satisfy both our short-term and long-term cash requirements for working capital to support our daily operations and meet commitments under our contractual obligations with third parties. This includes our obligation to make an additional $15.0 million payment pursuant to the Medytox/Allergan Settlement Agreements in the first quarter of 2022.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based our projections of capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources, which consist of cash and cash equivalents, cash generated from operations, and cash available under the Pharmakon Term Loans, as well as the public debt and equity markets, sooner than we expect. Our cash requirements depend on numerous factors, including but not limited to the impact of any potential disruptions to our supply chain resulting from the COVID-19 pandemic, inflation and other long-term commitments and contingencies. Because of the numerous risks and uncertainties associated with research, development and commercialization of our products, we are unable to estimate the exact amount of our operating capital requirements. Any future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and amounts of the royalty and other payments payable in connection with the Medytox/Allergan Settlement Agreements and the reimbursement receivable from Daewoong in connection with the Daewoong Arrangement;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amounts of the royalty payable to the Evolus Founders;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of any future product candidates we may develop or acquire;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and costs of any ongoing or future clinical programs we may conduct;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to forecast demand for our products, scale our supply to meet that demand and manage working capital effectively;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our product or any future product candidates and any products we successfully commercialize, including costs associated with our supply chain; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates are approved or cleared for sale, including marketing, sales and distribution costs;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of maintaining a sales force, the productivity of that sales force, and the market acceptance of our products;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements that we may enter into; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any product liability or other lawsuits related to our products; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of any current litigation, including our ongoing securities class action lawsuit and shareholder derivative lawsuit;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expenses needed to attract and retain skilled personnel; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing intellectual property and any other future intellectual litigation we may be involved in; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount of sales of any future approved or cleared products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.339%"><tr><td style="width:1.0%"></td><td style="width:64.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.166%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #231f20;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #231f20;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #231f20;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #231f20;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #231f20;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:4.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:4.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Activities </span></div><div style="margin-bottom:9pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, operating activities used $33.4 million of cash, which primarily resulted from our net loss of $46.8 million as adjusted for certain non-cash charges including $9.6 million of stock-based compensation expense, $0.6 million of provision of allowance for doubtful accounts, $0.9 million of amortization of debt discount and issuance costs, $5.6 million of depreciation and amortization and $6.3 million in revaluation of our contingent royalty obligation. In addition, net operating assets and liabilities changed by $11.5 million primarily driven by $15.0 million of accrued litigation settlement expenses and various timing of inventory purchases and payments, collections from customers and payments to vendors.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, operating activities used $57.9 million of cash, which primarily resulted from our net loss of $163.1 million as adjusted for certain non-cash charges including $10.6 million of stock-based compensation expense, $2.1 million of provision of allowance for doubtful accounts, $2.7 million of amortization of debt discount and issuance costs, $7.0 million of depreciation and amortization and $48.4 million of non-cash portion of accrued settlement expenses, partially offset by a gain of $2.0 million in revaluation of our contingent royalty obligation In addition, net operating assets and liabilities changed by $35.6 million primarily driven by $35.0 million of accrued litigation settlement expenses and various timing of inventory purchases and payments, collections from customers and payments to vendors.</span></div><div style="margin-bottom:9pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investing Activities </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities was $4.0 million for the&#160;year ended December 31, 2021 compared to $12.2 million of cash provided&#160;for the year ended December 31, 2020. The change in cash used in investing activities was attributable to maturities of short-term investments with no new purchases during the year ended December 31, 2021.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities increased by $34.7 million to $73.1 million for the&#160;year ended December 31, 2021 from $38.3 million for the year ended December 31, 2020. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the&#160;year ended December 31, 2021, cash provided by financing activities resulted from the net proceeds from our follow-on offering of $92.4 million, sales of $10.9 million of our common shares under the ATM Program, and $72.0 million net proceeds from long-term debt with Pharmakon, offset by the repayment of long-term debt with Oxford of $76.3 million and repayment of the promissory note payable to Evolus Founders of $20.0 million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, cash provided by financing activities consisted of the $40.0 million proceeds from the Convertible Note in July 2020, partially offset by a $1.1 million in royalty and milestone payments to Evolus Founders.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indebtedness</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Liquidity and Capital Resources</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for a description of our Pharmakon Term Loans.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our material cash requirements from known contractual and other obligations primarily consist of (i) principal and interest payments related to our Pharmakon Term Loans (future interest payments on our outstanding Pharmakon Term Loans total approximately $33.5 million, with $7.2 million due within twelve months), (ii) quarterly royalty payments to the Evolus Founders of a low single digit percentage of net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (these obligations terminate in the quarter after the 10-year anniversary of the first commercial sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States), (iii) $15.0 million during the first quarter of 2022, and a final payment of $5.0 million due in 2023 related to the Medytox/Allergan Settlement Agreements, (iv) quarterly royalty payments to Allergan and Medytox on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the period from December 16, 2020 to September 16, 2022 based on a certain dollar amount per vial sold in the United States, and a low-double digit royalty on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sold in other Evolus territories (during the period from September 17, 2022 to September 16, 2032, we agreed to pay to Medytox a mid-single digit royalty percentage on all net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and (v) obligations under operating leases related to our office spaces.</span></div><div><span><br/></span></div><div id="i77038361ec4447b8be22639fec3c691b_61"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosure of contingent assets and liabilities, revenue and expenses at the date of the financial statements as well as the expenses incurred during the reporting period. Generally, we base our estimates on historical experience and on various other assumptions in accordance with GAAP that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions and such differences could be material to the financial position and results of operations. On an ongoing basis, we evaluate our estimates and assumptions in light of changes in circumstances, facts and experience. </span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are more fully described in the notes to our financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies to be most critical for fully understanding and evaluating our financial condition and results of operations, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration to which we expect to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when (or as) we satisfy the performance obligations. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account for revenue recognition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and service revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through a distribution partner in Canada. For product revenue, we&#160;recognize revenue when control of&#160;Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;is transferred </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to a customer upon receipt. For service revenue, we are determined to be the agent in the distribution of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Canada and record the sale as service revenue on a net basis.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues are recorded net of sales-related adjustments, wherever applicable, for the volume rebates, coupon program, consumer loyalty program and co-branded marketing programs. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volume rebates are contractually offered to certain customers, and the rebates payable to each customer are determined based on the contract and quarterly purchase volumes, which are readily available. The coupon program ended in June 2020, and all unredeemed coupons were expired. The consumer loyalty program allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and redeem the rewards for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward, or Reward, that the customer might redeem in the future. The standalone selling price of the Reward is measured based on historical sales data, estimated average selling price of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time of redemption, expected customer and consumer participation rates in the loyalty program, and estimated number of qualifying treatments to be performed by customers. We do not believe there is a reasonable likelihood that there will be a material change in the future estimates or assumptions we use to establish the liability for the Reward. However, if the actual customer and consumer participation rates and number of qualifying treatments in any future periods materially differ from the estimates, we may be exposed to adjustments that could be material. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue, and when customers redeem the Reward and the related product is delivered, the deferred revenue is reversed and included in net revenues. Through the co-branded marketing programs, eligible customers with a certain level of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchases receive advertising co-branded with us. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is sold to customers, the invoice price is allocated between the product sold and the advertisement. The standalone selling price of the advertisement is measured based on estimated market value of similar advertisement adjusted for the customer&#8217;s portion of the advertisement. The portion of invoice price allocated to the advertisement is initially recorded as deferred revenue, and when the advertisement airs, the deferred revenue is recognized in net revenues at that time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at the invoiced amount and do not bear interest. We assess the probability that we will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. On a recurring basis, we estimate the amounts of receivables considered uncollectible to reflect an allowance for doubtful accounts.&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Royalty Obligation to the Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of the contingent royalty obligation payable to the Evolus Founders under the Amended Purchase Agreement based on significant unobservable inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined each period end and recorded in operating expenses in the statements of operations and comprehensive loss and in the current and non-current liabilities in the balance sheets. The significant unobservable input assumptions that can significantly change the fair value includes (i) projected net revenues during the payment period, (ii) the discount rate and (iii) the timing of payments. Significant increases (decreases) in the discount rate would result in a significantly lower (higher) fair value measurement, which could materially impact the fair value reported on the balance sheet.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. We review goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. We perform an annual qualitative assessment of goodwill in the fourth quarter each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, we perform a two-step process. The first step involves comparing the fair value of our reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, we have determined that there is one reporting unit. There has been no impairment of goodwill for any of the periods presented.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are consisted of a definite-lived distribution right of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and capitalized internal-use software. The distribution right is amortized over the period the asset is expected to contribute to our future cash flows. We determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&#160;20&#160;years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&#160;two years&#160;upon being placed in service.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. We also review the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was&#160;no&#160;material impairment of long-lived assets for any periods presented.</span></div><div id="i77038361ec4447b8be22639fec3c691b_64"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued and Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We describe the recently issued accounting pronouncements that apply to us in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Summary of Significant Accounting Policies-Recent Accounting Pronouncements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_67"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.  Quantitative and Qualitative Disclosure About Market Risk.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_70"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.&#160; &#160;&#160;&#160;&#160;Financial Statements and Supplementary Data.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:10pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Financial Statements</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_73">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83MC9mcmFnOjQ4NmMwZjUwODBkZTQ4OGM5N2Y4MzhmZTY2OGI3YmQ5L3RhYmxlOjRiNmViMjViMDNiMjQwODc5NjIzYmQ3ZWY3OTM5NzkxL3RhYmxlcmFuZ2U6NGI2ZWIyNWIwM2IyNDA4Nzk2MjNiZDdlZjc5Mzk3OTFfMS0wLTEtMS0zOTIxOC90ZXh0cmVnaW9uOjcwMTc3NzMyZjExNjRhZjJhMTU3ZjVhOTYxMmNmNDk3XzMyOTg1MzQ4ODM0MTA_9ff647d4-2077-488a-a759-cfa2f14a8707">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_73">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_70">Financial Statements:</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_76">Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_76">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_82">Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_82">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_85">Statements of Stockholders&#8217; Equity (Deficit)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_85">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_88">Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_88">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_91">Notes to Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_91">66</a></span></div></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_73"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Evolus, Inc. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying balance sheets of Evolus, Inc. (the Company) as of December 31, 2021 and 2020, the related statements of operations and comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"><tr><td style="width:1.0%"></td><td style="width:60.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83My9mcmFnOmMyOGUxNDNiMDBkMTQyOTQ5ZGVhYThiNzMxNTE4N2Q5L3RhYmxlOjhjYzZhYjU0MzliZjRjNzY4YmY5ZmE2NWYzNzVhNDY1L3RhYmxlcmFuZ2U6OGNjNmFiNTQzOWJmNGM3NjhiZjlmYTY1ZjM3NWE0NjVfMC0xLTEtMS0zOTIyMi90ZXh0cmVnaW9uOjVkY2MwOTZlZjAzMDQzM2M4MTA1MTVlMjE2Mjg5N2E1XzMyOTg1MzQ4ODMzNzA_ea406d11-2b3d-41a7-9110-1712883cfdd5">Ernst &amp; Young LLP</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2017.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83My9mcmFnOmMyOGUxNDNiMDBkMTQyOTQ5ZGVhYThiNzMxNTE4N2Q5L3RleHRyZWdpb246YzI4ZTE0M2IwMGQxNDI5NDlkZWFhOGI3MzE1MTg3ZDlfMzI5ODUzNDg4Njc1NQ_20539ded-907d-4afa-ba7e-af5fb67cc74d">Irvine, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;3, 2022 </span></div><div style="margin-bottom:9pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_76"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except par value and share data)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:70.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.863%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.866%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNC0xLTEtMS0yNDY5Nw_8d8d466f-d942-480a-8042-7a8187b1f693">146,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNC0zLTEtMS0yNDY5Nw_75410dad-5ab0-4bdb-94c4-2439e8eed353">102,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNS0xLTEtMS0yNDY5Nw_c72884e1-ea77-4738-8e65-af3faa19139a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNS0zLTEtMS0yNDY5Nw_b73c1ec3-0241-4688-8545-0218a03f607f">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNi0xLTEtMS0yNDY5Nw_f6d88153-a4bc-47a7-841e-33a8d8de9ea9">14,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNi0zLTEtMS0yNDY5Nw_de1db430-5a9e-426b-999d-a77e2b0aae0e">9,680</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNy0xLTEtMS0yNDY5Nw_d4fc6836-66da-48ef-904b-09b88d8f4a24">1,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNy0zLTEtMS0yNDY5Nw_147cd452-7f86-49ed-9bd9-223681c3ac5d">3,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfOC0xLTEtMS0yNDY5Nw_d2872fc1-a55c-4d58-8698-ca3db7716301">5,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfOC0zLTEtMS0yNDY5Nw_ccfad016-6437-4159-b3dc-e4d8e7b16ac1">4,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfOS0xLTEtMS0zMDM3Nw_c0fa29da-be43-40cd-8242-f7af7bc4c634">11,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfOS0zLTEtMS0yNzk0Ng_2e932be6-a0ec-44be-ac4c-eb9436e3787a">2,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfOS0xLTEtMS0yNDY5Nw_956aa0cf-7b7a-4fd4-975c-3528454c828c">178,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfOS0zLTEtMS0yNDY5Nw_0961f8e7-f244-4f6a-8a71-1cfde362ac6c">127,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTAtMS0xLTEtMjQ2OTc_485778f8-5fa2-4948-af72-930072a64986">1,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTAtMy0xLTEtMjQ2OTc_58c616ca-936b-44c5-81a9-0296daf699a1">1,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTItMS0xLTEtMjQ2OTc_2481c940-0a9b-46be-a3f8-495d2a6e5a25">2,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTItMy0xLTEtMjQ2OTc_6128b558-796f-43c8-b416-a3de8c3c14f6">3,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTMtMS0xLTEtMjQ2OTc_50c28993-f1df-48e5-b018-d2ce7743d30b">50,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTMtMy0xLTEtMjQ2OTc_d6a761d4-6ef1-4553-b6e2-9bc96f9eb827">55,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTQtMS0xLTEtMjQ2OTc_d03f1f77-9daa-48ec-ad25-7ebf675195dc">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTQtMy0xLTEtMjQ2OTc_9ec99555-e907-48ed-b5bd-6f765fa2e342">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTUtMS0xLTEtMjQ2OTc_888a0625-7353-4c05-9655-78c3feb337a4">2,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTUtMy0xLTEtMjQ2OTc_4c2d3b07-320c-4e15-8edb-a6fa2f070973">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTYtMS0xLTEtMjQ2OTc_81e79c82-8508-4593-9b65-7fe2aa291879">257,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTYtMy0xLTEtMjQ2OTc_dff6e78e-d689-4f82-af85-1a16cfdd4bc7">209,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTktMS0xLTEtMjQ2OTc_cd574ec4-a524-4448-a90f-d25623dec31b">6,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTktMy0xLTEtMjQ2OTc_2f5822f5-3728-46cc-a512-3c1345f25a1c">9,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjItMS0xLTEtMjQ2OTc_25400266-9e3d-47e1-8c7f-d409d1fff152">29,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjItMy0xLTEtMjQ2OTc_2847f1fa-22f3-474f-9828-8073200994cf">9,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued litigation settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjMtMS0xLTEtMjQ2OTc_86b9e62c-1705-4bd8-8770-1b1eb8af7436">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjMtMy0xLTEtMjQ2OTc_25d84597-d20e-47b5-9d16-617fd0c19505">63,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjQtMS0xLTEtMjQ2OTc_03440f0b-fbcd-4ab5-a13a-95d7349c9443">1,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjQtMy0xLTEtMjQ2OTc_140338db-20eb-4c62-b530-a5dae3028715">1,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjUtMS0xLTEtMjQ2OTc_10821f8c-6823-44dd-980e-08c38343d7ec">5,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjUtMy0xLTEtMjQ2OTc_82e103aa-11ba-4172-9ae4-fe1d5b76e41b">3,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promissory note payable to Evolus Founders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjYtMS0xLTEtMjQ2OTc_55ada439-39e8-4481-87dc-8c2af7469ae9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjYtMy0xLTEtMjQ2OTc_bc39979d-5b0c-4bb7-a75d-d0ad6cc00574">19,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, net of discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:SecuredDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjctMS0xLTEtMjQ2OTc_a4d5b46a-99dd-4132-bb54-4eff9c2cd528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:SecuredDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjctMy0xLTEtMjQ2OTc_37be1a17-1cea-4e54-bd11-de2581837057">74,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjgtMS0xLTEtMjQ2OTc_d9e2ad6d-863c-4c02-ba23-310671b0316f">57,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjgtMy0xLTEtMjQ2OTc_33a1e85f-0915-4d26-9d1a-864701081d04">180,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued litigation settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LitigationReserveNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjktMS0xLTEtMjQ2OTc_7a042829-d316-47dc-a28d-6163ba515657">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:LitigationReserveNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjktMy0xLTEtMjQ2OTc_9acb5a4f-51c4-406d-891d-9068089b4cea">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzAtMS0xLTEtMjQ2OTc_5a25241f-3189-4ae5-aca5-6f58dec88f5a">2,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzAtMy0xLTEtMjQ2OTc_a73d22a6-c5d2-48fe-ac27-7b812b237613">3,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzEtMS0xLTEtMjQ2OTc_46f6041f-385c-4c9a-ab29-8e317ad12461">39,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzEtMy0xLTEtMjQ2OTc_90990c2c-ee44-46e6-a201-451d2d5eca46">38,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, net of discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:SecuredLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzMtMS0xLTEtMzc1OTI_7874359c-ca3c-4e5b-9b37-dcd97e75797f">71,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:SecuredLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzMtMy0xLTEtMzc1OTI_650f8d3a-9456-42e1-9afa-19e10127bbeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzQtMS0xLTEtMjQ2OTc_a36059e1-0101-406d-b716-d9c7dab1c239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzQtMy0xLTEtMjQ2OTc_b705426c-edee-403e-845d-d556da40174a">40,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzUtMS0xLTEtMjQ2OTc_74a6dc48-874a-4c45-90be-31856674d7df">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzUtMy0xLTEtMjQ2OTc_d5ffe047-e3ce-47c3-988f-4deece566790">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzYtMS0xLTEtMjQ2OTc_aa887844-a6f5-4de9-a86d-59dfc323ee69">175,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzYtMy0xLTEtMjQ2OTc_227d0d2b-af48-4f40-87ca-5c652ba9bf07">282,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzctMS0xLTEtMjQ2OTc_2738e5ec-5176-4313-a7f2-9a37b7812eff"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzctMy0xLTEtMjQ2OTc_7993e775-a787-4361-b3ea-2f8d5b542512"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjpmYTJiNzUxMTI5NzU0MzRhOGVmNzQyYmNhOTIxNDJiN18yMQ_893bc3a2-78bd-40cf-b0e8-692ccde811b8"><ix:nonFraction unitRef="usdPerShare" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjpmYTJiNzUxMTI5NzU0MzRhOGVmNzQyYmNhOTIxNDJiN18yMQ_df503efc-cfca-44f5-9eae-fb64da60ffc3">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjpmYTJiNzUxMTI5NzU0MzRhOGVmNzQyYmNhOTIxNDJiN18zNQ_139dc042-42d4-40cc-848f-2316e8d4e8ba"><ix:nonFraction unitRef="shares" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjpmYTJiNzUxMTI5NzU0MzRhOGVmNzQyYmNhOTIxNDJiN18zNQ_4814a95c-e7d2-4608-a225-f7def44a78da">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjpmYTJiNzUxMTI5NzU0MzRhOGVmNzQyYmNhOTIxNDJiN181Nw_1116df36-1b41-4fcd-81f2-784318712a93"><ix:nonFraction unitRef="shares" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjpmYTJiNzUxMTI5NzU0MzRhOGVmNzQyYmNhOTIxNDJiN181Nw_32984a35-ee88-440a-be6f-8b95946942c7"><ix:nonFraction unitRef="shares" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjpmYTJiNzUxMTI5NzU0MzRhOGVmNzQyYmNhOTIxNDJiN181Nw_b9f65947-b46e-4911-98c1-8fa7cc378b73"><ix:nonFraction unitRef="shares" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjpmYTJiNzUxMTI5NzU0MzRhOGVmNzQyYmNhOTIxNDJiN181Nw_c1d30c2f-bf3b-4e1d-b529-8472c9b416f4">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMS0xLTEtMjQ2OTc_519d7c46-901a-48c9-b474-470bbff315f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMy0xLTEtMjQ2OTc_030d0ce3-f3be-46a7-b419-f533411b615c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjozNjMxMzJiMzBmMGE0YmEwYjg2NTQ2NzE0ZDExNDliYV8xOA_28ff7473-ec30-492d-a495-290dc565d76a"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjozNjMxMzJiMzBmMGE0YmEwYjg2NTQ2NzE0ZDExNDliYV8xOA_3c288fea-c326-4f33-bb0c-5c15a0c74b1e">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjozNjMxMzJiMzBmMGE0YmEwYjg2NTQ2NzE0ZDExNDliYV8zMg_54c3811a-6a51-4143-9748-72382377ec17"><ix:nonFraction unitRef="shares" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjozNjMxMzJiMzBmMGE0YmEwYjg2NTQ2NzE0ZDExNDliYV8zMg_af3ac09c-c2b7-45e2-a71b-24ff2bd96dfa">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjozNjMxMzJiMzBmMGE0YmEwYjg2NTQ2NzE0ZDExNDliYV8xNjQ5MjY3NDQxODU1_806dcf99-f8a9-46c7-9438-e079f7ae4bd8"><ix:nonFraction unitRef="shares" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjozNjMxMzJiMzBmMGE0YmEwYjg2NTQ2NzE0ZDExNDliYV8xNjQ5MjY3NDQxODU1_bba46a71-0684-417f-9da1-de05dac3f583">55,576,988</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjozNjMxMzJiMzBmMGE0YmEwYjg2NTQ2NzE0ZDExNDliYV8xNjQ5MjY3NDQxODU5_227f836f-dc57-4573-99cb-9525600e6bf2"><ix:nonFraction unitRef="shares" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjozNjMxMzJiMzBmMGE0YmEwYjg2NTQ2NzE0ZDExNDliYV8xNjQ5MjY3NDQxODU5_44b1464a-f022-49c5-83da-0df241bced77">33,749,228</ix:nonFraction></ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> shares issued and outstanding at December&#160;31, 2021 and December&#160;31, 2020, re</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">spectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMS0xLTEtMjQ2OTc_f8e5dd36-c6d6-44e8-b6a4-3caec159d9f2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMy0xLTEtMjQ2OTc_5adc8181-465f-4d4b-8e28-3431a37d77ce">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDItMS0xLTEtMjQ2OTc_30746a3c-230b-4d98-a27f-e446139db3b8">504,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDItMy0xLTEtMjQ2OTc_575a1a1d-674e-435c-9fb4-44ce7c8a3d6a">303,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDQtMS0xLTEtMjQ2OTc_d69e93e6-74ac-493c-b6d2-08cc2d3f0310">422,882</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDQtMy0xLTEtMjQ2OTc_1c70a4bc-02ee-4e40-98e7-7de3b8ccfac3">376,072</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity (deficit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDUtMS0xLTEtMjQ2OTc_4f135843-f85e-4631-8123-18eb7132e6ab">81,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDUtMy0xLTEtMjQ2OTc_c8cf20e5-bdff-4d67-a2a1-a6fdb2e0fde5">72,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 41.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity (deficit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDYtMS0xLTEtMjQ2OTc_308040b4-8d50-47c8-b6b1-02a60263df0b">257,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDYtMy0xLTEtMjQ2OTc_6a538440-bfae-4698-8d8c-08b3fc751028">209,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_82"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Operations and Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.477%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8935b4319e2d40ef96ac74a02189f082_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfNC0xLTEtMS0yNDY5Nw_33719b85-9ce4-4259-a7ae-f76f09f12152">98,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib874ac63dd264f8fabd518dd19e7db7a_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfNC0zLTEtMS0yNDY5Nw_fc10a82f-41bd-478f-9aef-8600d2a6672e">55,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4cecda8a60147e1a6dbe55bc70c5855_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfNS0xLTEtMS0yNDY5Nw_62332eca-1cb7-43a0-8331-106f69378ae9">702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1ebb6d09924e6db55a5c3231e23615_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfNS0zLTEtMS0yNDY5Nw_a17dac92-ed62-4f3f-acf1-f3b5743b9c45">738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfNi0xLTEtMS0yNDY5Nw_a5fcc44a-9b26-4799-8736-b8115657252d">99,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfNi0zLTEtMS0yNDY5Nw_a6ece64b-8935-483b-98d2-7fa67fe7345a">56,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfOS0wLTEtMS0yNDY5Nw_88e79aa4-bc34-4d38-bbd8-aeec1c06ccdf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfOS0wLTEtMS0yNDY5Nw_bbfa6ccc-bec5-4fce-81ec-f28ff59e01f1">Product cost of sales (excludes amortization of intangible assets)</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfOS0xLTEtMS0yNDY5Nw_e3f31cc5-3434-4c4e-8bcb-f823e56288e4">43,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfOS0zLTEtMS0yNDY5Nw_ad2459ab-517c-451c-bbd6-2d588984b45d">18,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement payment from Daewoong</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTAtMS0xLTEtMzQ4Mzk_bb846b4a-0789-4f87-af8b-219983bb0b48">25,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTAtMy0xLTEtMzQ4Mzk_f8fb2171-22c2-42aa-ac48-83727688e5fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTAtMS0xLTEtMjQ2OTc_a92481fb-2f3f-4c80-bdf6-d89939c75508">112,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTAtMy0xLTEtMjQ2OTc_342f645e-e86d-47b0-9b9d-ff4857586670">98,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTEtMS0xLTEtMjQ2OTc_b0cf94d9-6581-4e7f-b126-245378ad6abc">2,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTEtMy0xLTEtMjQ2OTc_5728ffcd-eda9-479d-9960-ae8ce4ad0b80">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation to Evolus Founders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTItMS0xLTEtMjQ2OTc_29ba470d-48b0-4f9e-816d-b27a393ecef0">6,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTItMy0xLTEtMjQ2OTc_6ceaa7d1-6626-4e21-a1fc-14c13f404094">2,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTMtMS0xLTEtMjQ2OTc_43c83079-ab82-4627-a7ce-ff3ad05502d9">5,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTMtMy0xLTEtMjQ2OTc_8cd03709-dbaf-4726-9dc0-370ba53bd45f">7,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlement expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTQtMS0xLTEtMjQ2OTc_a771b460-d925-4313-b9dc-3fe2fced1271">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTQtMy0xLTEtMjQ2OTc_2a0511ba-f098-4b45-8035-45a63178bc81">83,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTUtMS0xLTEtMjQ2OTc_ac5bf79c-4e96-43c4-a644-c5c5ca8d7ee5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTUtMy0xLTEtMjQ2OTc_81e0245a-e9f6-42e1-b282-de672a921f25">2,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTYtMS0xLTEtMjQ2OTc_f600d468-4343-450a-ab5c-4c57366f5323">144,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTYtMy0xLTEtMjQ2OTc_d1d238e2-13ed-4d22-89d2-14ab303a2a0c">209,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTctMS0xLTEtMjQ2OTc_fb84da04-c7ee-4775-92cb-03041d371707">44,405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTctMy0xLTEtMjQ2OTc_55a108e2-0937-4884-aa68-fa84a84fec56">153,068</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTktMS0xLTEtMjQ2OTc_0a983321-90b4-4b2c-82c4-5973c4788e89">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTktMy0xLTEtMjQ2OTc_b31497bc-212d-4cdd-8015-276956e36149">635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjAtMS0xLTEtMjQ2OTc_8f3575a2-3a32-4849-95ec-3ec2b57de2c5">1,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjAtMy0xLTEtMjQ2OTc_ba52fc41-5c4a-4db0-901d-078ae79176ef">10,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from extinguishment of debts, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjEtMS0xLTEtMjg3ODk_f0f9be40-4b85-4243-a339-42fcb91e3712">968</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjEtMy0xLTEtMjg3OTY_100569a5-0ce6-489b-986c-ac009467cc16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjItMS0xLTEtMjQ2OTc_bf4165f7-94ae-4215-b444-40c96225819f">46,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjItMy0xLTEtMjQ2OTc_3528ebd0-6e26-410b-9b34-3fbbce70eec8">162,936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjMtMS0xLTEtMjQ2OTc_c63770f3-92ea-425c-8432-c7f6422f7479">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjMtMy0xLTEtMjQ2OTc_4c5ee0dc-6c67-4fa4-a1f6-d7a1eb3699b8">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjQtMS0xLTEtMjQ2OTc_cb1d55ba-ccd7-4fc6-9b1b-77b3ab9891a8">46,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjQtMy0xLTEtMjQ2OTc_e18d7bcf-f85b-42e4-9051-c07f43981587">163,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive gain:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjYtMS0xLTEtMjQ2OTc_9751c160-8a39-4933-a7bf-e228d6db753f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjYtMy0xLTEtMjQ2OTc_c0787e46-87cc-4436-b519-32b6e20594e3">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjctMS0xLTEtMjQ2OTc_1ad9c99a-0ac3-4ad0-9835-66408b10e72e">46,810</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjctMy0xLTEtMjQ2OTc_a652c052-9c27-4e3b-b249-a392dcfc6908">163,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjgtMS0xLTEtMjQ2OTc_33e11ff9-220d-4ca2-964c-19fdbfa92a24"><ix:nonFraction unitRef="usdPerShare" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjgtMS0xLTEtMjQ2OTc_8c4979f8-f2c9-4157-b559-b9628085fac7">0.94</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjgtMy0xLTEtMjQ2OTc_15522681-abac-4412-a309-4b0483c7c7e3"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjgtMy0xLTEtMjQ2OTc_5e44196f-bbb6-4226-98ca-00ca3692237c">4.83</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjktMS0xLTEtMjQ2OTc_0b505e87-7bc8-4db3-9d90-b236e6b3e75d"><ix:nonFraction unitRef="shares" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjktMS0xLTEtMjQ2OTc_83b334dc-924c-4a80-abfe-910c8a977fc1">49,773,101</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjktMy0xLTEtMjQ2OTc_72fdaa4d-c268-4212-a635-a7684fbd2511"><ix:nonFraction unitRef="shares" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjktMy0xLTEtMjQ2OTc_733a1629-7f95-429e-803b-be760f8429b1">33,737,838</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_85"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Stockholders&#8217; Equity (Deficit)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.768%"><tr><td style="width:1.0%"></td><td style="width:39.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other Comprehensive Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a339248c57c4c3fbb0a8c12261031e6_I20191231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOC0xLTEtMS0yNDY5Nw_2d9dd743-0bd5-4a00-a466-5d67913131a7">&#8212;</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a339248c57c4c3fbb0a8c12261031e6_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOC0zLTEtMS0yNDY5Nw_12a6c83a-9b5e-4d7a-b2fb-25be693b21c1">&#8212;</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c58ee31658f47ddb1bed8a3b81a0f35_I20191231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOC01LTEtMS0yNDY5Nw_1b615c64-863c-4cfd-a7b7-231cd15139e2">33,562,665</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c58ee31658f47ddb1bed8a3b81a0f35_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOC03LTEtMS0yNDY5Nw_04646d39-8bf3-449f-b25b-59be84ce5c5e">1</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8472362221cf41d88c702018e38d71e8_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOC05LTEtMS0yNDY5Nw_5d13bc1f-4a9e-4517-b674-57cbc5c79447">292,509</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idebc0775b4d14420bd4c6971f6b63b0b_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOC0xMS0xLTEtMjQ2OTc_1dfd270e-fa41-42ed-9948-76d879fe8744">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9be00354c46b4b8b96a26749f9c3e28d_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOC0xMy0xLTEtMjQ2OTc_060d5136-a5fe-4c59-9fd4-677de26366e2">213,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb18fef826e14bf1b6a11208896433a1_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOC0xNS0xLTEtMjQ2OTc_06c4f7db-e22e-4185-9ec8-8614d41618d5">79,457</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the incentive equity plan</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic454c127b7694ec7929df6e51728c3f3_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOS01LTEtMS0yNDY5Nw_96bad6ec-d31a-4d6e-8630-7fd6a4536b7d">186,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9496baa43c834ff9b11ec53efd6d7f91_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOS05LTEtMS0yNDY5Nw_dfa89c5b-fafd-48e7-9d0e-f331aaf12c0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOS0xNS0xLTEtMjQ2OTc_9e84f5ea-7ff4-4729-8bc2-29485c40571c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9496baa43c834ff9b11ec53efd6d7f91_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTAtOS0xLTEtMjQ2OTc_b8c50d46-f1ba-49df-ac8a-1225bab2bfb4">10,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTAtMTUtMS0xLTI0Njk3_51ec4631-39c4-4894-b31c-23dd22d32f1a">10,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i618370635dad4cc09cde0158985bd9fc_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTEtMTMtMS0xLTI0Njk3_92f5be58-1db2-4b18-b166-5baf8d96de3b">163,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTEtMTUtMS0xLTI0Njk3_749b252a-0e08-4943-a60a-3e93d7506bed">163,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff982f9041634290a7428662c88e90ce_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTItMTEtMS0xLTI0Njk3_064ddb2b-c7da-4a40-b4d0-e779bcd8908e">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTItMTUtMS0xLTI0Njk3_810b8ef2-1057-4500-8fb2-6b3c66d9e37f">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if065d88090344c76906d42f9e58f3946_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTMtMS0xLTEtMjQ2OTc_0b051c83-c29d-4906-aa51-52f90ee8be0d">&#8212;</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if065d88090344c76906d42f9e58f3946_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTMtMy0xLTEtMjQ2OTc_5202f5a9-c097-4be4-bb3c-ab4a5082dcaa">&#8212;</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idac57e11cdc94016861bd9248bcdb528_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTMtNS0xLTEtMjQ2OTc_e63dd452-c00d-4ae5-9ef5-42a39737cd0e">33,749,228</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idac57e11cdc94016861bd9248bcdb528_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTMtNy0xLTEtMjQ2OTc_11df84c0-ba8d-4466-88e9-0a7f0e8346e3">1</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dae31c8b50a4ed9834cf14ad981a07f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTMtOS0xLTEtMjQ2OTc_ef66c670-c34f-49c7-975b-e0697ea0bcc6">303,113</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b072e47c4674802bf86129ee1b3d043_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTMtMTEtMS0xLTI0Njk3_ccc1938c-6ea7-4d00-9e79-19e9a0c729f1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bcb363afdf4b8db455485e8e2ad3fa_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTMtMTMtMS0xLTI0Njk3_db2a653e-8905-495b-bd02-3cc530159798">376,072</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTMtMTUtMS0xLTI0Njk3_effbd372-3cd9-4ac4-994e-a497c5daace6">72,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with litigation settlement</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic40c99d6b0a04616bf00bfc233eced25_D20210228-20210228" decimals="INF" name="eols:StockIssuedDuringPeriodSharesLitigationSettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTQtNS0xLTEtMjg1MDM_98e09eb6-f2a5-4627-ba49-75ac75801968">6,762,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55331949261b40a1b1fb09e4158cee28_D20210101-20211231" decimals="-3" name="eols:StockIssuedDuringPeriodValuesLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTQtOS0xLTEtMjg1MDM_1adab10a-f5d5-44ab-ad13-9dff66b52f5f">48,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="eols:StockIssuedDuringPeriodValuesLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTQtMTUtMS0xLTI4NTAz_f248486d-cf5e-475f-a6b0-db6afa5a5e5a">48,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for conversion of convertible note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib797f956941d4495ae3f6f4926ca7cd1_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTUtNS0xLTEtMjg1MDM_4061fd94-7cc8-44d6-b50c-22f2ca1459cf">3,136,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55331949261b40a1b1fb09e4158cee28_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTUtOS0xLTEtMjg1MDM_6ece05e9-35b4-49a5-9a89-88e7d711fc0e">39,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTUtMTUtMS0xLTI4NTAz_50bed79b-64c0-4470-9b60-1f59c361373c">39,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon follow-on offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae9c7ae95d9f43cbb4015233b65597a5_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTYtNS0xLTEtMjg1MDM_1b5ca9b8-2925-4daa-8956-88cd1638afa3">10,350,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida8a057d5f3b4f8999abff6725b2469f_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTYtOS0xLTEtMjg1MDM_d6e6bc4c-2597-4b17-86c0-532fac778285">92,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9bdbef71f2046fc80639fa5cacb44eb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTYtMTUtMS0xLTI4NTAz_1e9bba52-f851-4c04-b2b2-75d4f9f6eeb6">92,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under &#8220;at-the-market&#8221; (ATM) program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19668eba2a9a432cbae4ec0e6254aa0e_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTctNS0xLTEtMjg1MDM_e079cc17-af93-4f78-8118-b0b1cd869fbc">934,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b39b85b47cc450fbde4206b76345039_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTctOS0xLTEtMjg1MDM_33c67f7a-5a82-4d1d-8307-187e07a7790b">10,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191b278dcfec47f3972561e051202c15_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTctMTUtMS0xLTI4NTAz_6971fbb9-49be-4065-a476-da47db783925">10,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the incentive equity plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib797f956941d4495ae3f6f4926ca7cd1_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTQtNS0xLTEtMjgyOTQ_08a1eea7-0bb2-47b5-be14-6f5b0786b866">643,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55331949261b40a1b1fb09e4158cee28_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTQtOS0xLTEtMjgzMzY_c7a9199c-31e4-40ba-883d-0fb2ded755e7">655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTgtMTUtMS0xLTMwMzg2_b3d888e7-4ab2-4f8d-b837-313c3e02f265">655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55331949261b40a1b1fb09e4158cee28_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTUtOS0xLTEtMjgzNTI_e2f833ec-3779-41da-82ad-d9db1907dbbb">9,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTktMTUtMS0xLTMwMzg2_d2ccea12-7c8d-45c3-a18e-6fdbd0cc5ce5">9,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide759804fa684555b30ad8d92e40dd8f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTYtMTMtMS0xLTI4MzY3_8549450d-0c11-4f7d-8608-1a82ec52e8b1">46,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjAtMTUtMS0xLTMwMzg2_06c3707d-b262-4b5c-b9c1-fc05d71fc0be">46,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e49ab226c6f4296b8a462ca4e5b73d2_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjItMS0xLTEtMzAzOTM_171d74fb-f424-4577-9b35-9055ca26d423">&#8212;</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e49ab226c6f4296b8a462ca4e5b73d2_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjItMy0xLTEtMzAzOTM_339a3e1c-5ea0-484a-b7c0-e7c6c794739b">&#8212;</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7f853492f874d82b33dd9c2cb1fff79_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjItNS0xLTEtMzAzOTM_08823764-9219-4c9a-b4d1-917c1bbde309">55,576,988</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7f853492f874d82b33dd9c2cb1fff79_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjItNy0xLTEtMzAzOTM_3aec663d-d132-4b5b-aee4-433465f8921d">1</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba22e2b749b44db0bac4acb2ea8a9073_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjItOS0xLTEtMzAzOTM_88d7faf9-d0bb-4f6e-a15c-a1775bee261c">504,757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed27f558fa49d5b84d4d3ba1bfef2d_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjItMTEtMS0xLTMwMzkz_d3356777-81b0-41f6-adcd-70a63ae85d96">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i861bdd7e206b435b912b799375902ac9_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjItMTMtMS0xLTMwMzkz_0b5cab24-c2d0-4057-9922-1905e7410da8">422,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjItMTUtMS0xLTMwMzkz_2ae63d5d-d1ec-4bb7-b202-66c20b84f15a">81,876</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_88"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Cash Flows </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.477%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMy0xLTEtMS0yNDY5Nw_0b7510aa-b117-4476-8c58-d2c897befad9">46,810</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMy0zLTEtMS0yNDY5Nw_4edf637f-29a2-4f12-9483-d814fb570f51">163,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNS0xLTEtMS0yNDY5Nw_788476a3-673c-4ea3-b2c7-f6d9621380f3">5,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNS0zLTEtMS0yNDY5Nw_572e3ac0-e871-423c-9d99-927a0683a3cf">7,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNi0xLTEtMS0yNDY5Nw_828c941c-61d7-4fe0-a0ec-8fcd132b636b">9,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNi0zLTEtMS0yNDY5Nw_3bf62583-3529-44f7-b79f-7b590b23f1cb">10,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for bad debts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNy0xLTEtMS0yNDY5Nw_af1f29f6-a0fe-45f9-9c5d-1ab233822743">589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNy0zLTEtMS0yNDY5Nw_72515e65-f86b-4853-ae70-b94022a1582b">2,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of discount on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfOC0xLTEtMS0yNDY5Nw_83c2970e-cf57-4e1e-b4a1-cba463eec2b0">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfOC0zLTEtMS0yNDY5Nw_c1b9172f-311c-4ffb-9567-657e0714c610">427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="eols:OperatingLeaseRightofUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfOS0xLTEtMS0yNDY5Nw_c7fcbf36-f707-4db6-b799-1f7b0e2a99b5">692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="eols:OperatingLeaseRightofUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfOS0zLTEtMS0yNDY5Nw_b66476fd-e77c-4c8f-b5ee-e98ae454f765">654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTAtMS0xLTEtMjQ2OTc_c3971061-55db-4ed4-bb67-ff810f80bef1">941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTAtMy0xLTEtMjQ2OTc_7230a9f2-c623-4a0b-802c-2f2f1e77dccc">2,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Paid-in-kind interest on convertible note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTEtMS0xLTEtMjQ2OTc_ec1511f5-856c-4fb7-9c39-03d567b4b670">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTEtMy0xLTEtMjQ2OTc_06be0994-9a61-46c3-a796-e6cca4a02b3f">506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTItMS0xLTEtMjQ2OTc_0a9d99fc-411a-483d-b036-4dad41e2b2b0">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTItMy0xLTEtMjQ2OTc_2e4fe1f8-bca2-4017-bdfc-e2c62ccc1004">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation to Evolus Founders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTMtMS0xLTEtMjQ2OTc_f8c3fa8d-97da-44bf-8615-b187c0b6db1b">6,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTMtMy0xLTEtMjQ2OTc_a798ed79-7961-4de7-84f1-dc15d592ce2b">2,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from extinguishment of debts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTQtMS0xLTEtMzQxMjY_d18fd243-a18f-4f0c-8d2c-00377c9d968a">968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTQtMy0xLTEtMzQxMjY_ce56270c-04ce-42c5-9f0a-73840e5948c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash portion of accrued settlement expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="eols:AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTQtMS0xLTEtMjQ2OTc_d688ea9b-a7bb-49d4-8d1b-584fc1cc5b3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="eols:AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTQtMy0xLTEtMjQ2OTc_d80e2a68-be5f-45d6-b61f-935848c00c56">48,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTYtMS0xLTEtMjQ2OTc_61a9ed37-7cc2-47d8-9ff2-5f688e79f1bc">2,979</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTYtMy0xLTEtMjQ2OTc_c0e9a1a3-8c04-48c7-807d-903b16e8298c">4,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTctMS0xLTEtMjQ2OTc_e5d9e321-b5d9-443c-b6a8-3f5709778eb6">5,566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTctMy0xLTEtMjQ2OTc_8bb282e5-a8dc-411e-b144-6edae642df4f">1,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTgtMS0xLTEtMjQ2OTc_6f1d7da4-6c96-47d0-916f-91b70a61f94a">7,264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTgtMy0xLTEtMjQ2OTc_52562fb9-90c6-4aa0-9ee2-46030477ed23">1,690</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTktMS0xLTEtMjQ2OTc_cba0ed2a-6451-4ca3-9a84-72523695d7ec">787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTktMy0xLTEtMjQ2OTc_c59eee1c-7c3d-4b5d-956a-8b0f16b9c532">2,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjAtMS0xLTEtMjQ2OTc_4bb55979-e5fe-4140-9ca8-0ef4ff9c7875">20,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjAtMy0xLTEtMjQ2OTc_c5a3748a-076f-4062-918e-c63da44eb7f3">4,248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued litigation settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="eols:IncreaseDecreaseInAccruedLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjEtMS0xLTEtMjQ2OTc_83b626ad-797a-4d31-8cfe-afb8f8695503">15,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="eols:IncreaseDecreaseInAccruedLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjEtMy0xLTEtMjQ2OTc_d8f0b5d0-6909-4820-9708-ba3e86f9b0b5">35,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="eols:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjItMS0xLTEtMjQ2OTc_9908326a-8740-4a40-b0d8-a9aaee0f9b53">838</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="eols:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjItMy0xLTEtMjQ2OTc_04ec1c36-ba8e-4812-a51c-937fafea21da">734</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjMtMS0xLTEtMjQ2OTc_508acecb-943a-4d23-a714-e41f7327b013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjMtMy0xLTEtMjQ2OTc_0208d526-d102-478f-a018-28e023fab7c2">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 39.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjQtMS0xLTEtMjQ2OTc_c4b6f351-d9c2-496a-9848-3da41bd2ac43">33,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjQtMy0xLTEtMjQ2OTc_5566de41-9306-47e8-abc1-43a237532240">57,871</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjYtMS0xLTEtMjQ2OTc_fb8fb32a-4a50-49c9-8998-9481679a5990">393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjYtMy0xLTEtMjQ2OTc_3f259f82-ede2-407e-8561-219761ebb04f">815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjctMS0xLTEtMjQ2OTc_5e1649da-2fbf-48c8-a318-5393c148c9be">577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForSoftware" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjctMy0xLTEtMjQ2OTc_e9ca6759-1ea3-4ffd-b149-33aaca9858c7">2,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjgtMS0xLTEtMjQ2OTc_206e4fa4-b8b2-4c18-86c4-8a3bb057231a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjgtMy0xLTEtMjQ2OTc_46ffb0b6-13b4-4d1e-8fe4-b0cdf6f71e23">74,668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturities of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjktMS0xLTEtMjQ2OTc_a1175e4e-00fd-41b5-bd9b-d33391c1ee9b">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjktMy0xLTEtMjQ2OTc_96eb8ff6-130e-4189-942e-b80f0517600e">90,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 39.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzAtMS0xLTEtMjQ2OTc_32f62352-c7ac-45a2-bd21-40f6c0e54783">4,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzAtMy0xLTEtMjQ2OTc_46124ba9-8aad-410f-8439-2c9dad58cd89">12,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of long term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzItMS0xLTEtMzQwNjg_69a241db-cb59-4fa4-be7a-d3c4ad3eba95">76,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzItMy0xLTEtMzQwNjg_570b772f-21d5-458a-a017-9f6e502ffa50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of promissory note payable to Evolus Founders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzQtMS0xLTEtNDA5OTM_f80ddebe-ea6f-4b3e-b536-45833aa842b2">20,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzQtMy0xLTEtNDA5OTM_3520650d-e8fb-4479-9c65-225d82c2c456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of contingent royalty obligation to Evolus Founders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="eols:PaymentsOfContingentRoyaltyObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzItMS0xLTEtMjQ2OTc_34a97664-7e3f-452c-91c5-9e095b93d8b4">3,097</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="eols:PaymentsOfContingentRoyaltyObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzItMy0xLTEtMjQ2OTc_0822e66a-8bea-4493-8cae-87074fc22f4a">1,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of convertible note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzMtMS0xLTEtMjQ2OTc_ae89578d-62b4-4ea0-b80a-9f891d2cd6d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzMtMy0xLTEtMjQ2OTc_914d45a4-16fd-4b96-bf4e-9808c24d312d">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt, net of discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzUtMS0xLTEtMjQ2OTc_4b6c2b7e-16dc-4102-836a-f2a66c6b2112">71,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzUtMy0xLTEtMjQ2OTc_1015a4d0-9513-4d44-926d-c69b0a2ed4dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments for debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzYtMS0xLTEtMjQ2OTc_0f3fb7da-0df1-4826-98f1-e7dc047bca6d">3,263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzYtMy0xLTEtMjQ2OTc_37c041d9-4794-4490-a973-d1cd65198e66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment for debt obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzctMS0xLTEtMjQ2OTc_3a9c3bff-9b53-472e-95dd-f2c9d295f5b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzctMy0xLTEtMjQ2OTc_9364cefd-796b-496c-b89a-0f614b35454e">523</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from follow-on offering, net of underwriting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9bdbef71f2046fc80639fa5cacb44eb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzgtMS0xLTEtMjQ2OTc_de6f7b17-8bfc-4f50-8af1-810277f30c66">92,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7a53a744c7f48d4bb28c1d16000d70f_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzgtMy0xLTEtMjQ2OTc_a3017c93-ed9d-4e2e-b5c6-020181765171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments for offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzktMS0xLTEtMjQ2OTc_c83b08ca-efbc-4244-8ad6-0bb85f3a44dd">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzktMy0xLTEtMjQ2OTc_0aeea0f1-3955-4320-b3f2-a308d47a7bfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with incentive equity plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDAtMS0xLTEtMjQ2OTc_9367de95-7cc1-49ee-95d4-bb61958db75f">655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDAtMy0xLTEtMjQ2OTc_872c86e5-c608-425b-be1a-440c6967223b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from ATM sales of shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191b278dcfec47f3972561e051202c15_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDItMS0xLTEtMzQwODk_5ece6db1-90e3-428a-8f49-3954716abab0">10,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb4365e9adeb459aa371d09c5f6def3f_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDItMy0xLTEtMzQxMTY_135427ff-bc85-4080-bdb6-dcd2f99e95dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 39.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDEtMS0xLTEtMjQ2OTc_d445ac5a-ef10-4940-9767-8fb4238fb920">73,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDEtMy0xLTEtMjQ2OTc_76cb8ede-acbc-491c-9cb1-abe985b61d59">38,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDMtMS0xLTEtMjQ2OTc_3451f208-7852-4b9b-a1dd-a38057550e0b">43,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDMtMy0xLTEtMjQ2OTc_b37d3e14-da88-420c-b12d-86d42b21350d">7,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDQtMS0xLTEtMjQ2OTc_76fdbca1-ab44-4598-bf4b-90fb60cc2b17">102,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb18fef826e14bf1b6a11208896433a1_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDQtMy0xLTEtMjQ2OTc_e99e2b84-b9ed-4c04-91b9-ed53f0f72fc3">109,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDUtMS0xLTEtMjQ2OTc_cdc11b78-4844-410a-9e68-c11e40b9da7e">146,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDUtMy0xLTEtMjQ2OTc_f525bf99-6ae6-4d29-b315-ea1f1901b4dc">102,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3.7pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Cash Flows (Continued)</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:3.7pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="margin-top:8.7pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfMy0xLTEtMS0yNDY5Nw_936916b6-6c9f-44e0-a5fa-7ad73d3bcb47">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfMy0zLTEtMS0yNDY5Nw_dbe97218-5f6c-4c99-a3e7-aecd617dc489">7,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfNC0xLTEtMS0yNDY5Nw_c942fcee-c39b-4a8b-9e50-a01608e39506">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfNC0zLTEtMS0yNDY5Nw_a966c462-4244-4b2c-bc06-c705f60fca58">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash investing and financing information</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of convertible note to equity</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfNi0xLTEtMS0yNDY5Nw_da4c0375-7851-4184-9094-9d3d5ac69b1a">39,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfNi0zLTEtMS0yNDY5Nw_a3f8aede-1571-448d-87bf-ce7f05da9170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in exchange for litigation settlement expense</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="eols:StockIssuedForAccruedLitigationSettlementExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfNy0xLTEtMS0yNDY5Nw_fc893de9-105c-4836-9da8-5876d8e98b7b">48,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="eols:StockIssuedForAccruedLitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfNy0zLTEtMS0yNDY5Nw_2462140c-e9eb-405a-92e3-488f5dc92cf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized software recorded in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfOC0xLTEtMS0yNDY5Nw_285d6609-a915-4fac-9e91-3f94db80310d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfOC0zLTEtMS0yNDY5Nw_f0deb605-d977-4efb-9571-d10278d26c16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3.7pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="margin-top:3.7pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_91"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div><span><br/></span></div><div id="i77038361ec4447b8be22639fec3c691b_94"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfNjY4Mw_288af611-4ae7-4a3c-86ca-e5de0c1956e0" continuedAt="i27f25516401d44c38d90786ee5413739" escape="true">Description of Business </ix:nonNumeric></span></div><ix:continuation id="i27f25516401d44c38d90786ee5413739" continuedAt="i3dba4678705946b5947943dc18acee2c"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolus, Inc., (&#8220;Evolus&#8221; or the &#8220;Company&#8221;) is a performance beauty company focused on delivering products in the self-pay aesthetic market. The Company received the approval of its first product Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in February 2019. The product was also approved by Health Canada in August 2018 and the European Commission (&#8220;EC&#8221;) in September 2019. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States in May 2019 and in Canada through a distribution partner in October 2019. The Company currently generates all of its net revenues from Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is headquartered in Newport Beach, California.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared on a basis that assumes that the Company will continue as a going concern, and do not include any adjustments that may result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company&#8217;s assets and the satisfaction of the Company&#8217;s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has incurred recurring net operating losses and negative cash flows from operating activities and management expects operating losses and negative cash flows to continue for at least the next 12 months. As of December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMjg1Nw_8d8d466f-d942-480a-8042-7a8187b1f693">146,256</ix:nonFraction> in cash and cash equivalents and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMjk1Mw_d69e93e6-74ac-493c-b6d2-08cc2d3f0310">422,882</ix:nonFraction>. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company entered into a $<ix:nonFraction unitRef="usd" contextRef="ia43c0d4587004db0b6f491872654d03a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTA5OTUxMTY2MDU3Mg_9303f5ff-01cf-403a-b34d-fbaa96b56b87">125,000</ix:nonFraction> Term Loan agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and Biopharma Credit PLC (collectively, &#8220;Pharmakon&#8221;). The first tranche of $<ix:nonFraction unitRef="usd" contextRef="ic59095e4226448ca90c7c028c530b46b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTA5OTUxMTY2MDc0Ng_f3f0a4d2-3a5f-4348-9705-358a14ef15f4">75,000</ix:nonFraction> was funded on December 29, 2021. The second tranche of $<ix:nonFraction unitRef="usd" contextRef="iaf213e710f77493dadadc321fcf59639_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTA5OTUxMTY2MDgwNQ_e4fc726f-bb7f-4342-944b-4f17e48c9f5b">50,000</ix:nonFraction> may be drawn at the Company&#8217;s election no later than December 31, 2022, subject to the terms and conditions of the loan agreement. As of December&#160;31, 2021, the Company has not drawn the second tranche. The Company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ia1a49dbd0cdc4fa299c6fc4b349cd1c9_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTA5OTUxMTY2MTA0OA_4aa28b57-2a58-4f5f-95d4-528e934ca146">68,695</ix:nonFraction> from Pharmakon, after issuance costs and debt discounts. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6. Term Loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company and Oxford Finance LLC (&#8220;Oxford&#8221;) entered into an agreement, pursuant to which the Company paid Oxford $<ix:nonFraction unitRef="usd" contextRef="i9c22c52daf7d4250a52799a0d558499a_D20210101-20210131" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTY0OTI2NzQ1NjQzOA_63e4d6cf-5c48-430e-b1a7-149a5851cf2d">76,447</ix:nonFraction> to pay off the Oxford Term Loan. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6. Term Loans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company, Medytox, Inc. (&#8220;Medytox&#8221;), Allergan, Inc. and Allergan Limited (together, &#8220;Allergan&#8221;) entered into settlement agreements in connection with the International Trade Commission (&#8220;ITC&#8221;) action, for which the Company agreed to pay $<ix:nonFraction unitRef="usd" contextRef="i6b22c9a255f64ef69528be6cf90f2d57_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTY0OTI2NzQ1Njc3OQ_ac30d780-4777-49e5-abed-6e079218d311">15,000</ix:nonFraction> in 2021, $<ix:nonFraction unitRef="usd" contextRef="ie3dc0d8eadaf4cf7918bae649c0b4261_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTY0OTI2NzQ1Njc5Mg_3143eaf7-cd30-490b-a9bb-d35fa77f0a38">15,000</ix:nonFraction> in 2022 and $<ix:nonFraction unitRef="usd" contextRef="i8655593ec8584a3a81c2026e2ac5d7f4_D20230101-20231231" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTY0OTI2NzQ1NjgwOA_01b4e8bc-a988-4543-bdfc-8c97097267b0">5,000</ix:nonFraction> in 2023 with additional terms including specified royalty payments as described below and in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company and Daewoong entered into certain agreements, pursuant to which Daewoong (1) paid the Company $<ix:nonFraction unitRef="usd" contextRef="ibdb8c8bf46044c1d94ceba9d58481dda_D20210401-20210430" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTY0OTI2NzQ1Nzc4NQ_ea8018bf-44c3-43df-8edf-08ac1b0b5b09">25,500</ix:nonFraction> in April 2021 and (2) agreed to reimburse the Company certain amounts with respect to the royalties payable to Medytox and Allergan, among other terms. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information. In addition, in March 2021 the outstanding Daewoong Convertible Note (as such term is defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Daewoong Convertible Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), including accrued interest, in the amount of $<ix:nonFraction unitRef="usd" contextRef="ib67b7815bf86448c836c0674ab2cd400_I20210323" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMzg0ODI5MDcxNTcwOA_8c83e1d8-b357-405a-8bbb-b86865f13dd4">40,779</ix:nonFraction> was converted into <ix:nonFraction unitRef="shares" contextRef="i67974a995ff142e8bcd737a314d25651_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMzg0ODI5MDcxNTcyNg_c3cd713f-2461-4c6e-b548-bdbf8ad75cd4">3,136,869</ix:nonFraction> shares of the Company&#8217;s common stock. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Daewoong Convertible Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company completed a follow-on public offering and issued <ix:nonFraction unitRef="shares" contextRef="i87285d3792f541dfb0b8bd76edc9ed8b_D20210401-20210430" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMzg0ODI5MDcwNzAzMw_38327937-d86b-4f0c-aba4-ee5aca0a863b">10,350,000</ix:nonFraction> shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i369b3df3ec04419fa040ca2ec1d798db_D20210401-20210430" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMzg0ODI5MDcxNTc0Ng_db73e69f-fbeb-4895-89d8-0ab7c70c5e47">1,350,000</ix:nonFraction> shares of common stock, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i581d900790a24282bf837c0e06b7b5f4_I20210430" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMzg0ODI5MDcxNTc1Nw_5406e129-051f-4b8e-8c9e-044ca62e0436">9.50</ix:nonFraction> per share. The Company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i87285d3792f541dfb0b8bd76edc9ed8b_D20210401-20210430" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMzg0ODI5MDcxNTczNw_f1ca0685-34f6-4ff9-993c-fd502308c55c">92,426</ix:nonFraction> from the offering, after deducting underwriting discounts and commissions, excluding other offering expenses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June, July and August 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i3f2ebd8bfca6432bb520e3b56fadc096_D20210601-20210831" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMzg0ODI5MDcxNTc2NA_05e96378-4da1-463a-8e40-6796bb00e1e1">934,367</ix:nonFraction> common shares at the prevailing market prices for total net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i3f2ebd8bfca6432bb520e3b56fadc096_D20210601-20210831" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMzg0ODI5MDcxNTcxNw_17349bc1-c217-4fb3-87fe-be81568549e2">10,910</ix:nonFraction> under the existing &#8220;at-the-market&#8221; sales agreement. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10. Stockholders&#8217; Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional details. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3dba4678705946b5947943dc18acee2c">The Company believes that its current capital resources, which consist of cash and cash equivalents, will be sufficient to fund operations through at least the next twelve months based on its expected cash needs. The Company may be required to raise additional capital to fund future operations through entering into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its controllable and variable expenditures and current rate of spending through reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals.</ix:continuation></span></div><div id="i77038361ec4447b8be22639fec3c691b_97"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NzU_1c2f8f3e-e6bc-4f44-81a5-503ff7682b64" continuedAt="i7e06935c90f542c68ee9e6a4c0225ba6" escape="true">Basis of Presentation and Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="i7e06935c90f542c68ee9e6a4c0225ba6" continuedAt="i778f6fcc8ca04ad5bc77849840cbad95"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NzA_21c8b528-fbb5-4383-8aaf-6c8531c02b3c" continuedAt="i6f44028253124e0d89e75bc3ce6f3472" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6f44028253124e0d89e75bc3ce6f3472">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</ix:continuation> </span></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNTQ5NzU1ODE4MzQ0Ng_68858edf-d438-4e74-9451-a17d4110d2c6" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain comparative amounts for prior year have been reclassified to conform to current year presentations. Such reclassifications did not affect net income or retained earnings.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NzY_f627393a-25f0-4176-9441-eb42a0355317" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make certain estimates and assumptions in order to prepare financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company&#8217;s most significant estimates relate to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations, stock-based compensation and royalty obligations, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#8217;s actual results could differ materially from those estimates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the full impact of&#160;the COVID-19&#160;outbreak is unknown and cannot be reasonably estimated. However, where possible, management has made appropriate accounting estimates with respect to certain accounting matters, which include the fair value of royalty obligations, allowance for doubtful accounts, inventory valuation and impairment assessments of goodwill and other long-lived assets, based on the facts and circumstances available as of the reporting date. The Company&#8217;s future assessment of the magnitude and duration of&#160;the COVID-19 outbreak, as well as other factors, could result in material impacts to the Company&#8217;s financial statements in future reporting periods.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NTE_67956f29-418d-485b-8118-f2de06641b36" continuedAt="i575eba78fef94a36a094eda76856bace" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, Evolus and Daewoong Pharmaceutical Co. Ltd. (&#8220;Daewoong&#8221;) entered into an agreement (the &#8220;Daewoong Agreement&#8221;), pursuant to which the Company received an exclusive distribution license to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, Russia, certain members of the Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the United States in May 2019 and in Canada through its distribution partner in October 2019 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&#8217;s business and its financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i778f6fcc8ca04ad5bc77849840cbad95" continuedAt="ie8bcb700f93a44febbf6ae35cd8ffc42"><ix:continuation id="i575eba78fef94a36a094eda76856bace" continuedAt="i1456bc7d28e343dc8a8ceafa093d1864"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company&#8217;s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by physicians and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak and restrictions intended to slow the spread of COVID-19, including quarantines, government-mandated actions, stay-at-home orders and other restrictions,&#160;have adversely affected the Company&#8217;s business in a number of ways, which have resulted, and may continue to result, in a period of business disruption and in reduced sales and operations. In addition, any disruption and volatility in the global capital markets may increase the Company&#8217;s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and cash flows.</span></div></ix:continuation><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NTI_80ae1dcb-f106-4bf0-a8f6-4a24d86a05cc" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. The Company has determined that it operates in a single operating and reportable segment. The Company&#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</span></div></ix:nonNumeric><ix:continuation id="i1456bc7d28e343dc8a8ceafa093d1864"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company&#8217;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#8217;s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#8217; ability to pay.</span></div></ix:continuation><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NDY_c0cb6f7e-9a4d-4312-a446-801faed32734" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NDM_e5c9ee5b-005f-41c7-a885-e95c8a953a8a" continuedAt="ide8233dff5cc43f6b8f1b9c68fb8cd42" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company&#8217;s statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the statements of operations and comprehensive loss using the specific-identification method. </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="ie8bcb700f93a44febbf6ae35cd8ffc42" continuedAt="iff93560a6dab4b96bc8c83fc24386ec2"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ide8233dff5cc43f6b8f1b9c68fb8cd42">The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments.</ix:continuation></span></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4MzY_0613a1ad-4592-4979-a5cb-5bcf8a144d23" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of finished goods held for sale and distribution. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost is determined based on the estimated amount payable to the Company&#8217;s supplier after accounting for any reimbursement receivable pursuant to the Daewoong Settlement Agreement (as such term is defined, and such agreement is discussed, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), usin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g the first-in, first-out method with prioritization of the items with the earliest expiration dates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Inventory valuation reserves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for the periods presented. Adverse changes in assumptions utilized in the Company&#8217;s inventory reserve calculations could result in an increase to its inventory valuation reserves.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product cost of sales, excluding amortization of intangible assets, consisted of the inventory cost, and, for periods on or after December 16, 2020, included certain royalties on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> payable to Medytox and Allergan pursuant to the Medytox/Allergan Settlement Agreements (as such term is defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), as partially offset by reimbursement receivable from Daewoong pursuant to the Daewoong Settlement Agreement with respect to such royalties.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NDc_b8ad9840-84af-41d7-b054-d389abf64c82" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</span></div><div style="margin-bottom:9pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4Njc_f9421c44-29ac-43e0-abc0-9ea612688b9e" continuedAt="i22e86678020d41349a9f9fa7482e134a" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i22e86678020d41349a9f9fa7482e134a">Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of approximately <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzI5ODUzNDk3Mzg2Nw_adf48651-a74c-4ef0-a7e5-d48234ce4631">five years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the term of the related lease.</ix:continuation> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="iff93560a6dab4b96bc8c83fc24386ec2" continuedAt="ib646bce9b5f945b0a355d1f298d4117a"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4MzM_d2f96f50-3741-4e43-8d1b-e589aae2cb7b" continuedAt="i3e15366a9f024eb88830cb89a92de9d5" escape="true">Goodwill</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3e15366a9f024eb88830cb89a92de9d5">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has <ix:nonFraction unitRef="reporting_unit" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTI1MzY_ed830b77-7a10-45db-9b37-03aeb4a7eae6">one</ix:nonFraction> reporting unit.</ix:continuation> There was <ix:nonFraction unitRef="usd" contextRef="icdebbf3fdf644e34be10eab249d933bc_D20190101-20191231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTI1NjU_2ff4e77e-6514-4b11-a064-6218b766d466"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTI1NjU_8d694f23-b51b-4a2d-8fb1-25cf0ba1eed2"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTI1NjU_bf860f36-322f-44bd-a4b0-2da32811785b">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of goodwill for any of the periods presented.</span></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NTg_7859c22e-31a8-4820-b349-0082b7eb66ad" continuedAt="i4c3b84f238cf4f7da925f53ff71dad83" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon FDA approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in February 2019, the in process research and development (&#8220;IPR&amp;D&#8221;) related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;was evaluated as completed and reclassified to a definite-lived distribution right intangible asset, which is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&#160;<ix:nonNumeric contextRef="ic3bdecfb61f64eacb1bec28f7caef51c_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTMyNDk_d254ef37-4422-4003-8862-530c3f585d54">20</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&#160;<ix:nonNumeric contextRef="ia035180a7f3e4b968ed0e22107620141_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTM3MDc_ad38901e-7a29-466e-8d60-c7b4e239ec67">two years</ix:nonNumeric>&#160;upon being placed in service.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4c3b84f238cf4f7da925f53ff71dad83">The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was <ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTQ2NTY_06e82ab4-6099-4f6d-9c14-a278023ef0f5"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTQ2NTY_1b6dbd09-8518-408e-bf14-52f7ccaee1ad"><ix:nonFraction unitRef="usd" contextRef="icdebbf3fdf644e34be10eab249d933bc_D20190101-20191231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTQ2NTY_5c7180a3-4551-44ee-a6a7-eebd2ff76a9e">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> material impairment of long-lived assets for any periods presented</ix:continuation>.</span></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4Mzc_acd4edb7-a5c8-4090-8a0c-508bffd0e31f" continuedAt="iec5fc4c95c194975a0e1a8ccbdc89555" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;), at the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#8220;ROU&#8221;) asset which represents the Company&#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancelable period of the lease and may include options to extend or terminate the lease </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="ib646bce9b5f945b0a355d1f298d4117a" continuedAt="i9eae4d3947294045a6df162c9c836a92"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iec5fc4c95c194975a0e1a8ccbdc89555">when it is reasonably certain that the Company will exercise such options. The Company&#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of&#160;December&#160;31, 2021.</ix:continuation></span></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NDQ_0690ed2a-b1df-4c47-9999-ea11e2c4efb6" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Royalty Obligation Payable to the Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable are determined at each reporting period end and recorded in operating expenses in the accompanying statements of operations and comprehensive loss and as a liability in the accompanying balance sheets. </span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Promissory Note Payable to the Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2018, the Company recognized a promissory note payable at present value using a discount rate for similar rated debt securities. Discount amortization related to the promissory note is recorded in interest expense in the accompanying statements of operations and comprehensive loss with a corresponding increase to the liabilities in the accompanying balance sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:DebtPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NjM_e80ddf27-e49b-4af7-a974-6c7a3f3d0201" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Debt</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt represents the debt balance with Pharmakon as of December&#160;31, 2021 and Oxford as of December&#160;31, 2020 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6. Term Loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, net of debt issuance costs. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are amortized into interest expense over the term of the debt.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4Nzg_f5e15e50-275b-4147-9e50-b92e4eb604ea" continuedAt="id19e47f1f393406e8a5b873482a17f5d" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates product revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and service revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through a distribution partner in Canada.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Canada as it does not control the product before control is transferred to a customer. The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i9eae4d3947294045a6df162c9c836a92" continuedAt="i66355409603544d4a01d62d65f7d89d9"><ix:continuation id="id19e47f1f393406e8a5b873482a17f5d" continuedAt="ic54c6fb4146c4ab89e9e036f66339f32"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the amount of consideration expected to be received. For the years ended December 31, 2021 and 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="if89a2df2b8e54c8d8ee79434f9442e05_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMjA5NjE_8ca5ad8f-9f76-474b-8e24-d5e97607d03a">702</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia1af8740f4504d02a822562858322d3f_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTcxODMzOA_f70fc496-c955-4608-aeab-bade7c435c5f">738</ix:nonFraction>, respectively, of revenues related to international sales. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross-to-Net Revenue Adjustments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides customers with discounts, such as trade and volume discounts and prompt pay discounts, that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, primarily for the volume based rebates, coupons, consumer loyalty programs and co-branded marketing programs. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Volume-based Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Coupons</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company issued customers coupons redeemable into gift cards funded by the Company for the benefit of patients. The coupons were accounted for as variable consideration. The Company estimated coupon redemption rates based on historical data and future expectations. The coupons were accrued based on estimated redemption rates and the volume of products purchased and were recorded as a reduction to revenues on product delivery. All issued coupons expired on June 30, 2020.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Consumer Loyalty Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; In May 2020, the Company launched a consumer loyalty program, which allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and redeem the rewards for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward (&#8220;Reward&#8221;) that the customer might redeem in the future. The standalone selling price of the Reward is measured based on historical sales data, estimated average selling price of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time of redemption, expected customer and consumer participation rates in the loyalty program, and estimated number of qualifying treatments to be performed by customers. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue. Subsequently, when customers redeem the Reward and the related product is delivered, the deferred revenue is recognized in net revenues at that time.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Co-Branded Marketing Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company offers eligible customers with a certain level of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> purchases to receive advertising co-branded with the Company. The co-branded advertising represents a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the advertisement. The standalone selling price of the advertisement is measured based on the estimated market value of similar advertisement adjusted for the customer&#8217;s portion of the advertisement. The portion of invoice price allocated to the advertisement is initially recorded as deferred revenue. Subsequently, when the advertisement airs, the deferred revenue is recognized in net revenues at that time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract balances</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration becomes unconditional. The Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of&#160;December&#160;31, 2021 and 2020, all amounts included in accounts receivable, net on the accompanying balance sheets are related to contracts with customers.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any contract assets nor unbilled receivables as of&#160;December&#160;31, 2021 or 2020. Sales commissions are included in selling, general and administrative expenses when incurred.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients primarily under the rebate and coupon programs and deferred revenue associated with Rewards under the consumer loyalty program and co-</span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i66355409603544d4a01d62d65f7d89d9" continuedAt="ifb16e18583764c6594a28f52e5dcd30e"><ix:continuation id="ic54c6fb4146c4ab89e9e036f66339f32"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">branded marketing programs. The Company&#8217;s contract liabilities are included in accounts payable and accrued expenses in the accompanying balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the accrued revenue contract liabilities, primarily related to volume-based rebates, consumer loyalty program, and co-branded media programs, were $<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5ODE4NA_745516b1-faaf-45fc-8587-805ceac5a12a">7,934</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5ODE5Mg_1df0ef73-81ce-4a07-9cd7-8f9b8e433167">3,081</ix:nonFraction>, respectively, which were recorded in accrued expenses in the accompanying balance sheets. For the years ended December 31, 2021 and 2020, provisions for rebate, coupon, consumer loyalty programs, and co-branded media programs were $<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="eols:RebatesAndCouponsCreditsAndPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5ODQwNQ_1cabb32b-ed1f-4cb5-9613-46c4bcb4f9dc">16,139</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="eols:RebatesAndCouponsCreditsAndPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5ODQxMw_1b3fe53e-082a-48cc-bbbc-669d28a09a4f">16,896</ix:nonFraction>, respectively, which were offset by related payments, redemptions and adjustments of $<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5ODUwMg_5e50799e-1a6b-4dc6-b4bd-42d87b5a161a">11,286</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5ODUxMA_0469a9e2-f585-4b96-a0e9-1f067b5109ff">15,524</ix:nonFraction>, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the&#160;years ended December 31, 2021 and 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzg0ODI5MDc0OTM5MQ_2cde9984-81ee-49a1-8bc4-5dfbad393ea3">2,802</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzg0ODI5MDc0OTM5OQ_cc922ef4-7e50-46ef-8ac1-90952d9a37a6">0</ix:nonFraction>, respectively, of revenue related to amounts included in contract liabilities at the beginning of the period and did not recognize any revenue related to changes in transaction prices regarding its contracts with customers from previous periods.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collectability</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.&#160;The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of December 31, 2021 and 2020, allowance for doubtful accounts was $<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTcxODA2Ng_540ac6e0-a115-47fa-afe4-6d6d8db5c013">2,385</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTcxODA3NA_2575a921-0442-4c69-b2e6-b5508c118b67">2,118</ix:nonFraction>, respectively. For the years ended December 31, 2021 and 2020, provision for bad debts was $<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTcxODE1NA_af1f29f6-a0fe-45f9-9c5d-1ab233822743">589</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTcxODE2Ng_72515e65-f86b-4853-ae70-b94022a1582b">2,066</ix:nonFraction>, respectively, and the write-off amount was $<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTcxODE4NA_9956ea6d-4110-4fd4-8521-95578f95f52b">322</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTcxODE3OA_9882bf83-1e63-4a0a-932d-9b62aa26218c">335</ix:nonFraction>, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Practical Expedients</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.</span></div></ix:continuation><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NDU_9575e4fb-eda2-47e1-9fb1-0b8257fed385" escape="true"><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Settlement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, upon entering into certain agreements to settle intellectual property disputes relating to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company agreed to pay to Allergan and Medytox </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ic88608af4b8d44f29f8f6a890a3e0859_I20210228" decimals="-3" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5ODg0NA_e4632a7c-76ea-4795-8b7a-beb2ede47ca2">35,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in multiple payments over <ix:nonNumeric contextRef="ia307b0175e9a4f089eff6272a567b599_D20210218-20210218" name="eols:LossContingencySettlementAgreementPaymentTerms" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5ODg1Nw_6d5ab27c-6fbc-4f63-955b-e1a8d93251f4">two years</ix:nonNumeric>, of which $<ix:nonFraction unitRef="usd" contextRef="i7e4a414b331e4768a456b40889b5bf16_D20210701-20210930" decimals="-3" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzg0ODI5MDc2NjI5OA_ad1c59d2-ab76-4248-9566-5a8a609571d2">15,000</ix:nonFraction> was paid in the third quarter of 2021 and $<ix:nonFraction unitRef="usd" contextRef="iec7e63cb81e2460c81caf30e8a3ecb3e_D20220101-20220331" decimals="-3" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzg0ODI5MDc2NjMwNw_adaa4cb7-045c-4f7d-8411-d1830786ec56">15,000</ix:nonFraction> was paid in the first quarter of 2022, and issued <ix:nonFraction unitRef="shares" contextRef="ic40c99d6b0a04616bf00bfc233eced25_D20210228-20210228" decimals="INF" name="eols:StockIssuedDuringPeriodSharesLitigationSettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5NjcwNA_98e09eb6-f2a5-4627-ba49-75ac75801968">6,762,652</ix:nonFraction> shares of its common stock to Medytox. In addition, for the period from December 16, 2020 to September 16, 2022, the Company agreed to pay to Allergan and Medytox a royalty on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on a certain dollar amount per vial sold in the United States and a low-double digit royalty on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sold in other Evolus territories. For the period from September 17, 2022 to September 16, 2032, the Company agreed to pay to Medytox a mid-single digit royalty percentage on all net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The royalty payments are made quarterly and recorded as product cost of sales on the accompanying statements of operations and comprehensive loss in the periods the royalties are incurred.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The settlement agreements resulted in an $<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY3OTIxMg_2a0511ba-f098-4b45-8035-45a63178bc81">83,421</ix:nonFraction> charge for the year ended December&#160;31, 2020, which consisted of $<ix:nonFraction unitRef="usd" contextRef="i3a7d2bddc6cf450cb25bddf49c81a86d_I20201231" decimals="-3" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMjg3NTk_8d118999-93df-48d9-a083-fe8fb00adcdf">35,000</ix:nonFraction> in deferred cash payments and $<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMjg3ODM_cc25f872-6a7b-4a15-ab91-3a74a023c7ae">48,421</ix:nonFraction> from the issuance of <ix:nonFraction unitRef="shares" contextRef="ic40c99d6b0a04616bf00bfc233eced25_D20210228-20210228" decimals="INF" name="eols:StockIssuedDuringPeriodSharesLitigationSettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5NjcwOA_98e09eb6-f2a5-4627-ba49-75ac75801968">6,762,652</ix:nonFraction> shares of the Company&#8217;s common stock in February </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="ifb16e18583764c6594a28f52e5dcd30e" continuedAt="iec4accb2a60e47c2a5df9bd622cd4f50"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021. In the year ended December 31, 2021, the Company made cash payments of $<ix:nonFraction unitRef="usd" contextRef="i6b22c9a255f64ef69528be6cf90f2d57_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzg0ODI5MDc0OTQyMQ_55b5550e-8184-4f30-a9fa-09ebb20e72c6">15,000</ix:nonFraction> to Medytox and Allergan. As of December&#160;31, 2021, a current liability of $<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMjkwMTc_fb7ea66a-609f-4034-8507-fa7ec73ec9c0">15,000</ix:nonFraction> and non-current liability of $<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LitigationReserveNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMjkwNDk_7a042829-d316-47dc-a28d-6163ba515657">5,000</ix:nonFraction> were recorded in the accompanying balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in March 2021, Daewoong and the Company entered into certain agreements, pursuant to which Daewoong agreed to pay the Company an amount equal to $<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzg0ODI5MDc0OTQwMw_f45258b2-48a8-4a79-863f-3eb7fbfb173b">25,500</ix:nonFraction>, which was recorded as a settlement payment from Daewoong and included as part of cost of sales on the accompanying statements of operations and comprehensive loss for the year ended December 31, 2021. For the period from December 16, 2020 to September 16, 2022, Daewoong also agreed to reimburse the Company certain amounts with respect to the royalties payable to Medytox and Allergan. This reimbursement is received quarterly and recorded as an offset to the related royalties to Medytox and Allergan in the product cost of sales on the accompanying statements of operations and comprehensive loss.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the details of all litigation settlement agreements.</span></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4Mzk_74d363bf-098c-4b4e-a0be-68f9e95a4456" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate, and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) is based on the fair value on the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the balance sheets and in the selling, general and administrative or research and development expenses in the statements of operations and comprehensive loss.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzg0ODI5MDc1ODI5Nw_d1261128-0701-4975-b3f3-267b3e1ff8c1" continuedAt="id0c00a6c59b743a6bffb080bea7bfe6c" escape="true">Advertising Costs</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id0c00a6c59b743a6bffb080bea7bfe6c">Advertising costs are expensed as incurred and primarily include costs related to social media ads and co-branded marketing programs. Advertising costs are included in selling, general and administrative expenses.</ix:continuation> For the years ended December 31, 2021 and 2020, the Company incurred advertising costs of $<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY4ODc2Ng_23766db8-1e6e-40f9-802e-57d598e3d6db">16,391</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY4ODc3NA_f4e2597d-12fb-4d84-beff-4915dea1a11e">4,979</ix:nonFraction>, respectively.</span></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NjA_7971fe35-d41b-4262-b12f-12372a0ac6da" continuedAt="icd0d8f7faf494ba1b6b102f73210a3a8" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. </span></div><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its statement of operations and comprehensive loss.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="iec4accb2a60e47c2a5df9bd622cd4f50" continuedAt="ib633972671fc490b95a0463cb69fa358"><ix:continuation id="icd0d8f7faf494ba1b6b102f73210a3a8"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&#160;50%&#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. The Company does not expect that changes to state tax laws through December&#160;31, 2021 to materially impact its financial statements.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NTY_7303416f-1a93-4cf5-b3ce-e6ebf4d4f566" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. The dilutive effect of stock options and restricted stock units is computed under the treasury stock method. The dilutive effect of the Daewoong Convertible Note is computed under the if-converted method. Potentially dilutive securities are excluded from the computations of diluted net loss per share if their effect would be antidilutive.</span></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and 2020, excluded from the dilutive net loss per share computation were stock options of <ix:nonFraction unitRef="shares" contextRef="id34ebca0dbac4892b9e26b1d887fc863_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTY0OTI2NzUwMzg0OA_0a6d196c-2ddc-4cb9-b304-35039821fa0d">3,922,286</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i41ae1e1c1bad4e168f9a39b7db9fc6ce_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTY0OTI2NzUwMzg1NA_05939937-3bd6-4e44-a03d-b7fb6a149f2b">4,407,498</ix:nonFraction>, respectively, non-vested RSUs of <ix:nonFraction unitRef="shares" contextRef="i1fc31951483143dfaeb4fa1205ce3584_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY4MjMzOA_bac9ec71-af08-4e5b-a75a-13b42c630d2f">1,926,467</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6de2de54a6f5422793e33fa044c6ac61_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY4MjM0MQ_0813652c-6951-4dde-a20f-2cad4c501e62">1,173,741</ix:nonFraction>, respectively, and <ix:nonFraction unitRef="shares" contextRef="i3b5f19e8647e4e1294248e74152897f8_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY4MzUwNA_1fce593a-fdfe-4d33-971a-6b7dc59423e6">0</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="if36312ac79504238b5690df729b1f37c_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzUzMjM_5ef9f47e-ebf4-4efd-8409-1c9e05987b81">3,076,923</ix:nonFraction>, shares issuable upon conversion of the Daewoong Convertible Note, respectively, because their inclusion would have been anti-dilutive. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.</span></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NjE_ecdf43b7-b4ab-4fa5-9591-0abc45c60efc" continuedAt="ibf451c4ea696466da4d9061b690653d9" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Pronouncements</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provisions remove certain exceptions including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020 and interim periods therein. The Company has adopted the guidance on the effective date of January 1, 2021. There are no material impacts to the financial statements as a result of this adoption.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements&#160;Issued But Not&#160;Adopted&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="ib633972671fc490b95a0463cb69fa358"><ix:continuation id="ibf451c4ea696466da4d9061b690653d9"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other (Topic 350):&#160;Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January&#160;1, 2023. The standard requires prospective application. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact on its financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU No. 2016-13, the FASB issued ASU 2018-19,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 326, Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU does not change the core principle of the guidance in ASU No. 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&#160;The FASB also subsequently issued ASU No. 2019-04 which did not change the core principle of the guidance in ASU No. 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January 1, 2023. The Company is in the process of determining the effects the adoption will have on its financial statements and reviewing credit loss models to assess the impact of the adoption of the standard on the financial statements. Based on initial assessments, the Company believes that while adoption will modify the way it analyzes financial instruments, it does not expect adoption of this guidance will have a material impact to its financial statements.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and in January 2021, the FASB issued ASU No. 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope (&#8220;ASU 2021-01&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Both ASU No. 2020-04 and ASU No. 2021-01 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or another reference rate expected to be discontinued because of reference rate reform. ASU No. 2020-04 and ASU No. 2021-01 are effective upon issuance for contract modifications and hedging relationships, and the Company is allowed to elect to apply the amendments prospectively through December 31, 2022. The Company does not expect adoption of this guidance will have a material impact on its financial statements.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This update will increase transparency of government assistance received by most business entities by requiring the disclosure of: (1) the types of transactions; (2) the accounting for the transactions; and, (3) the effect of the transactions on a business entity&#8217;s financial statements. ASU No. 2021-10 is effective for financial statements issued for annual periods beginning after December 15, 2021, with early application permitted. The Company does not expect adoption of this guidance will have a material impact on its financial statements.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_100"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzMwMjI_f6ad7183-4063-402b-8339-e9fdcdc46b69" continuedAt="ibc25a079526e4b01b1a53de1001cb470" escape="true">Fair Value Measurements and Short-Term Investments </ix:nonNumeric></span></div><ix:continuation id="ibc25a079526e4b01b1a53de1001cb470" continuedAt="i9b7dc0aec55041acad4cabd175dba111"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-Term Investments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company did not hold any short-term investments. <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzMwMTg_974d9664-b11c-487e-afdf-79789a51cf76" continuedAt="i1ccd21753a5e4544a7c550bbd2204025" escape="true">As of December&#160;31, 2020, all of the Company&#8217;s investments had remaining maturities of less than 12 months. The following is a summary of the Company&#8217;s short-term investments, considered available-for-sale, as of December&#160;31, 2020:</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><ix:continuation id="i1ccd21753a5e4544a7c550bbd2204025"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:52.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1dd5e647ea4c61b81e841d2fa58ac8_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZToxZDA3YWYyNTUzMzY0MTgyOTczMTE1ZmQzNmFhZWZhNi90YWJsZXJhbmdlOjFkMDdhZjI1NTMzNjQxODI5NzMxMTVmZDM2YWFlZmE2XzQtMS0xLTEtMjQ2OTc_e07c135f-6dd9-4130-8a48-50a0f4550d01">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1dd5e647ea4c61b81e841d2fa58ac8_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZToxZDA3YWYyNTUzMzY0MTgyOTczMTE1ZmQzNmFhZWZhNi90YWJsZXJhbmdlOjFkMDdhZjI1NTMzNjQxODI5NzMxMTVmZDM2YWFlZmE2XzQtMy0xLTEtMjQ2OTc_47772e67-5b84-4186-ba0a-dd9364ba9bbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1dd5e647ea4c61b81e841d2fa58ac8_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZToxZDA3YWYyNTUzMzY0MTgyOTczMTE1ZmQzNmFhZWZhNi90YWJsZXJhbmdlOjFkMDdhZjI1NTMzNjQxODI5NzMxMTVmZDM2YWFlZmE2XzQtNS0xLTEtMjQ2OTc_315c7d3f-50aa-47c7-860d-32280ae9cbbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1dd5e647ea4c61b81e841d2fa58ac8_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZToxZDA3YWYyNTUzMzY0MTgyOTczMTE1ZmQzNmFhZWZhNi90YWJsZXJhbmdlOjFkMDdhZjI1NTMzNjQxODI5NzMxMTVmZDM2YWFlZmE2XzQtNy0xLTEtMjQ2OTc_e64af5af-a35e-4499-a728-97e6de7273f6">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzMwMTQ_f0ba9a7e-157e-43f8-804b-c495c9d396b3" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:52.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaadf7ebcb2440558c596d02aa4fe18d_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpkZmNhZmU2YzRmN2U0NTc1OWY1ZTM1MDU5ZjYyMjc2Zi90YWJsZXJhbmdlOmRmY2FmZTZjNGY3ZTQ1NzU5ZjVlMzUwNTlmNjIyNzZmXzUtMS0xLTEtMjQ2OTc_16b66496-ec1c-4c29-8510-389311104b27">44,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i188292fb611741ec93ece11f8e4d57aa_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpkZmNhZmU2YzRmN2U0NTc1OWY1ZTM1MDU5ZjYyMjc2Zi90YWJsZXJhbmdlOmRmY2FmZTZjNGY3ZTQ1NzU5ZjVlMzUwNTlmNjIyNzZmXzUtMy0xLTEtMjQ2OTc_1374bd8a-baa4-47fc-b38a-45867a99062b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2126481ac7a74980a92e9285369775dc_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpkZmNhZmU2YzRmN2U0NTc1OWY1ZTM1MDU5ZjYyMjc2Zi90YWJsZXJhbmdlOmRmY2FmZTZjNGY3ZTQ1NzU5ZjVlMzUwNTlmNjIyNzZmXzUtNS0xLTEtMjQ2OTc_a2c54b17-fe2f-4269-85f8-d0b95c6b84c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21f2ba8ba1854a108007d265c9b25d60_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpkZmNhZmU2YzRmN2U0NTc1OWY1ZTM1MDU5ZjYyMjc2Zi90YWJsZXJhbmdlOmRmY2FmZTZjNGY3ZTQ1NzU5ZjVlMzUwNTlmNjIyNzZmXzUtNy0xLTEtMjQ2OTc_2361f4d0-177f-444f-bd54-7b048367e577">44,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:52.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1dd5e647ea4c61b81e841d2fa58ac8_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpiMmQ4OTA5YTY0YjQ0ZTNmYmIyMjIzZmE5NDExMmIxOC90YWJsZXJhbmdlOmIyZDg5MDlhNjRiNDRlM2ZiYjIyMjNmYTk0MTEyYjE4XzMtMS0xLTEtMjQ2OTc_b5925fab-71f9-419c-b78a-a960887c54f4">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9646e12d03f4e54b9e9276d5b1d0f3a_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpiMmQ4OTA5YTY0YjQ0ZTNmYmIyMjIzZmE5NDExMmIxOC90YWJsZXJhbmdlOmIyZDg5MDlhNjRiNDRlM2ZiYjIyMjNmYTk0MTEyYjE4XzMtMy0xLTEtMjQ2OTc_7dce9da0-e5c4-4f09-ab5a-d94526ca394e">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id68d8821d04841b29a08745afac4b24a_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpiMmQ4OTA5YTY0YjQ0ZTNmYmIyMjIzZmE5NDExMmIxOC90YWJsZXJhbmdlOmIyZDg5MDlhNjRiNDRlM2ZiYjIyMjNmYTk0MTEyYjE4XzMtNS0xLTEtMjQ2OTc_caf129d6-d503-4837-a321-0a1603106fa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c80b688d1614017ad7563e60cbf9695_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpiMmQ4OTA5YTY0YjQ0ZTNmYmIyMjIzZmE5NDExMmIxOC90YWJsZXJhbmdlOmIyZDg5MDlhNjRiNDRlM2ZiYjIyMjNmYTk0MTEyYjE4XzMtNy0xLTEtMjQ2OTc_b7547b16-64b9-4860-9fa1-5b4fdf2cc214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93faa46c660e429db8bd1d5c2859380e_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpiMmQ4OTA5YTY0YjQ0ZTNmYmIyMjIzZmE5NDExMmIxOC90YWJsZXJhbmdlOmIyZDg5MDlhNjRiNDRlM2ZiYjIyMjNmYTk0MTEyYjE4XzUtMS0xLTEtMjQ2OTc_2000b058-8cfa-4fd7-8703-c2d8a8ec3ba5">41,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b74edf017e427b8f5b7fafd4bc3d1b_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpiMmQ4OTA5YTY0YjQ0ZTNmYmIyMjIzZmE5NDExMmIxOC90YWJsZXJhbmdlOmIyZDg5MDlhNjRiNDRlM2ZiYjIyMjNmYTk0MTEyYjE4XzUtMy0xLTEtMjQ2OTc_d492fb01-710b-4b3d-b4ea-587d470388d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c0c8daaf4141d78d576fc09db214fe_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpiMmQ4OTA5YTY0YjQ0ZTNmYmIyMjIzZmE5NDExMmIxOC90YWJsZXJhbmdlOmIyZDg5MDlhNjRiNDRlM2ZiYjIyMjNmYTk0MTEyYjE4XzUtNS0xLTEtMjQ2OTc_1a9888e3-b80e-4e68-a744-2e80d752e577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief25c158c2d14085a69e4a3d492bdfd3_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpiMmQ4OTA5YTY0YjQ0ZTNmYmIyMjIzZmE5NDExMmIxOC90YWJsZXJhbmdlOmIyZDg5MDlhNjRiNDRlM2ZiYjIyMjNmYTk0MTEyYjE4XzUtNy0xLTEtMjQ2OTc_a232eae6-a543-4f10-a857-5a362c3072a6">41,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the&#160;year ended December 31, 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the contingent royalty obligation payable to the Evolus Founders based on Level 3 inputs using a discounted cash flows method. The significant unobservable input assumptions that can significantly change the fair value include (i) projected amount and timing of net revenues during the payment period, which terminates in the quarter following the <ix:nonFraction unitRef="year" contextRef="i95e8f96583894a6cb3bc3881f9f0ed7d_I20211231" decimals="INF" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzEyNDI_03fa3d3f-375a-42e3-9203-f3e8fd0d80c9">10</ix:nonFraction>-year anniversary of the first commercial sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States, (ii) the discount rate and (iii) the timing of payments. During the years ended December 31, 2021 and 2020, the Company utilized discount rates between <ix:nonFraction unitRef="number" contextRef="i44f0543f775c46f490919b75592c1ee5_I20201231" decimals="INF" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzE0NDg_96786f26-7959-40dc-891d-d5cad26a650e"><ix:nonFraction unitRef="number" contextRef="i4297d135149943959e21307f69d5bb57_I20211231" decimals="INF" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzE0NDg_b45242c8-32db-4396-941a-8bf67071f2e9">13.0</ix:nonFraction></ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3723caf0d1864617b4ad156f12392622_I20201231" decimals="INF" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzE0NTU_3018d156-47c0-49d2-9f1f-a8fbeda32091"><ix:nonFraction unitRef="number" contextRef="i239343ea90f94848ab298a3e8b49d754_I20211231" decimals="INF" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzE0NTU_d8c2befd-1178-4c25-bef7-87aada76cfb0">20.0</ix:nonFraction></ix:nonFraction>%, reflecting changes in the Company&#8217;s risk profile. Net revenue projections are also updated to reflect changes in the timing of expected sales. Significant increases (decreases) in the discount rate would result in a significantly lower (higher) fair value measurement, which could materially impact the fair value reported on the balance sheet.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i9b7dc0aec55041acad4cabd175dba111"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzMwMjU_51e8d44f-f86c-470f-b83c-d1c1888069b9" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTphZjI5MDlhMDE4MDM0MTEyODQ3NDllYTFkNGFiNmMxNy90YWJsZXJhbmdlOmFmMjkwOWEwMTgwMzQxMTI4NDc0OWVhMWQ0YWI2YzE3XzItMS0xLTEtMjQ2OTc_f0a35048-ba4b-4835-8c35-8ee1a6628370">41,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb18fef826e14bf1b6a11208896433a1_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTphZjI5MDlhMDE4MDM0MTEyODQ3NDllYTFkNGFiNmMxNy90YWJsZXJhbmdlOmFmMjkwOWEwMTgwMzQxMTI4NDc0OWVhMWQ0YWI2YzE3XzItMy0xLTEtMjQ2OTc_1fdadd4e-fd32-4c83-86db-22a4e4e03c10">44,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTphZjI5MDlhMDE4MDM0MTEyODQ3NDllYTFkNGFiNmMxNy90YWJsZXJhbmdlOmFmMjkwOWEwMTgwMzQxMTI4NDc0OWVhMWQ0YWI2YzE3XzMtMS0xLTEtMjQ2OTc_5e59c741-d734-4135-b8fa-a23cce2f0dcd">3,097</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTphZjI5MDlhMDE4MDM0MTEyODQ3NDllYTFkNGFiNmMxNy90YWJsZXJhbmdlOmFmMjkwOWEwMTgwMzQxMTI4NDc0OWVhMWQ0YWI2YzE3XzMtMy0xLTEtMjQ2OTc_b2750db9-1f64-43bd-bdc2-912281c77b0a">1,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recorded in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTphZjI5MDlhMDE4MDM0MTEyODQ3NDllYTFkNGFiNmMxNy90YWJsZXJhbmdlOmFmMjkwOWEwMTgwMzQxMTI4NDc0OWVhMWQ0YWI2YzE3XzQtMS0xLTEtMjQ2OTc_ff4c010d-dac1-4abe-9e8a-7257712cdfd4">6,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTphZjI5MDlhMDE4MDM0MTEyODQ3NDllYTFkNGFiNmMxNy90YWJsZXJhbmdlOmFmMjkwOWEwMTgwMzQxMTI4NDc0OWVhMWQ0YWI2YzE3XzQtMy0xLTEtMjQ2OTc_2aff2ca7-8881-45de-a90c-d7cbdf9ffdec">2,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTphZjI5MDlhMDE4MDM0MTEyODQ3NDllYTFkNGFiNmMxNy90YWJsZXJhbmdlOmFmMjkwOWEwMTgwMzQxMTI4NDc0OWVhMWQ0YWI2YzE3XzUtMS0xLTEtMjQ2OTc_3f03405d-6eb9-4e8e-ab7c-7daae503657e">44,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTphZjI5MDlhMDE4MDM0MTEyODQ3NDllYTFkNGFiNmMxNy90YWJsZXJhbmdlOmFmMjkwOWEwMTgwMzQxMTI4NDc0OWVhMWQ0YWI2YzE3XzUtMy0xLTEtMjQ2OTc_df1b5c1b-af80-46ac-9e4c-2ab437dfd1b6">41,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Assets and Liabilities</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, short-term available-for-sale debt securities, accounts receivable, accounts payable, accrued expenses, lease liabilities, and long-term debt. The carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of the promissory note payable to the Evolus Founders, long-term debt and operating lease liabilities using the discounted cash flow analysis based on the interest rates for similar rated debt securities (Level 2). As of December 31, 2021, the fair value of the long-term debt was $<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzE2NDkyNjc0NDUxOTU_d750404b-814a-431f-b0a0-dd3850aee394">75,448</ix:nonFraction>. As of December&#160;31, 2020, the fair value of the contingent promissory note and long-term debt was estimated to be $<ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzI4OTI_51b12262-f9fe-4d4c-b4f2-d75a9cae440c">19,284</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzI4OTk_80a78a7c-1cef-413e-93c2-faa5273c7fd2">76,368</ix:nonFraction>, respectively. The fair value of operating lease liabilities&#160;as of December&#160;31, 2021 and 2020 approximated their carrying value.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_103"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE4ODY_57590ba4-bac6-4270-b6c8-871c2b217cbe" continuedAt="ic362e6e363ca472087a1096c71bd74b1" escape="true">Goodwill and Intangible Assets </ix:nonNumeric></span></div><ix:continuation id="ic362e6e363ca472087a1096c71bd74b1" continuedAt="idb60c745b2b44f41a434db0cd238ca41"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE4ODA_661176ab-8481-4fc6-9976-59de5653f73c" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:30.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.849%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution right</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic3bdecfb61f64eacb1bec28f7caef51c_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzMtMS0xLTEtMjQ2OTc_66ea53cd-913f-4541-9b5f-4d5b64841350">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aa9cf7ce6924d97b753fab0a35caffd_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzMtMy0xLTEtMjQ2OTc_fb3f06e2-4bd5-4211-b75a-6f45197d70dc">59,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9aa9cf7ce6924d97b753fab0a35caffd_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzMtNS0xLTEtMjQ2OTc_523a3665-1521-4a77-a8dd-05e787e22033">8,589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aa9cf7ce6924d97b753fab0a35caffd_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzMtNy0xLTEtMjQ2OTc_6f3a6214-8bfd-4e2a-9627-cd20ce6f2b86">50,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a3026926537414c9e558b2f48c5ac00_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzQtMS0xLTEtMjQ2OTc_1bf41e4c-79f9-4f05-96cf-b68dba82bea0">2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c030fa26f84d46a809534c6d533f06_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzQtMy0xLTEtMjQ2OTc_257d9961-2c38-4114-ad66-0801eae34718">7,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c030fa26f84d46a809534c6d533f06_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzQtNS0xLTEtMjQ2OTc_e5476c58-7345-4a34-b264-7f2689d23ae4">7,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c030fa26f84d46a809534c6d533f06_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzQtNy0xLTEtMjQ2OTc_8f170da9-fead-4dca-82dc-1cfc9285108b">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzUtMy0xLTEtMjQ2OTc_4a94cf4a-ced0-4cd5-9c65-9a746d71d7b6">66,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzUtNS0xLTEtMjQ2OTc_d5c03b33-90ab-40d4-9df7-3f567eb09cfd">15,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzUtNy0xLTEtMjQ2OTc_5fdaabf5-5222-40ad-9255-baaa99b847cf">50,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzctMy0xLTEtMjQ2OTc_cd17a90e-e6ae-4851-a4d6-f59068fd9ec9">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzctNy0xLTEtMjQ2OTc_6d78cf7a-250f-4102-8328-e92822d405a7">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="eols:IntangibleAssetsGrossIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzgtMy0xLTEtMjQ2OTc_6acd0a46-e1ee-4b2a-8e4c-5e64746bd826">87,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzgtNS0xLTEtMjQ2OTc_5a45e39e-0a5e-4f49-864c-996ad61ad861">15,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzgtNy0xLTEtMjQ2OTc_3d1a83a3-67c8-4cfc-8add-742e0f959066">71,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.837%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.896%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution right</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iecd7c427bcea41a68a2333c4ab2e58f4_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzMtMS0xLTEtMjQ2OTc_6a6cfa48-6891-49ed-92a9-a8052cf5a11b">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135354304f194b65a202352820714058_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzMtMy0xLTEtMjQ2OTc_664c291f-316b-4bf3-a4a2-5a0acc592bad">59,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i135354304f194b65a202352820714058_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzMtNS0xLTEtMjQ2OTc_ffac1cb6-fa31-4b31-a1d6-76cc94131003">5,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135354304f194b65a202352820714058_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzMtNy0xLTEtMjQ2OTc_27f8f939-c6a7-47e2-aff0-f0a6c02ef51a">53,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5bcc0e46ed1c4cd4b910b9542aaeca6e_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzQtMS0xLTEtMjQ2OTc_7e98d9de-00fa-4c74-a055-7e287480fa37">2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef09bce4de74ec69fa66b0204b03c06_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzQtMy0xLTEtMjQ2OTc_b3d73ecd-4710-4ca4-a4f1-a6dc006bee3a">6,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ef09bce4de74ec69fa66b0204b03c06_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzQtNS0xLTEtMjQ2OTc_ee236dd7-6b68-47b4-b037-64e0bac0ae5e">4,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef09bce4de74ec69fa66b0204b03c06_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzQtNy0xLTEtMjQ2OTc_f0a62185-4955-46b8-8e0d-236344394099">1,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzUtMy0xLTEtMjQ2OTc_03a84a44-8b5e-47ad-a383-f4b7e6a60ef8">65,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzUtNS0xLTEtMjQ2OTc_3b59655f-9038-4407-a5ac-5da688b5e871">10,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzUtNy0xLTEtMjQ2OTc_c72be905-b088-49d6-8f8a-5777748eb9e2">55,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzctMy0xLTEtMjQ2OTc_3141a7bf-aff7-413c-b9d7-77ad498d6b1d">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzctNy0xLTEtMjQ2OTc_7adf1286-99ef-47c1-b74d-6997618e1d54">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="eols:IntangibleAssetsGrossIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzgtMy0xLTEtMjQ2OTc_0fc82f61-7270-475e-86e3-da17b61de950">86,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzgtNS0xLTEtMjQ2OTc_0dd30b9c-f3fb-4572-a590-6690ea2b164b">10,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzgtNy0xLTEtMjQ2OTc_e68f42e9-7cd2-4fb0-a511-11087855d872">76,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Intangible assets with indefinite lives have an indeterminable average life.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE4Nzg_e57352f5-dc9f-4b8c-93f1-f73c9980c787" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;December&#160;31, 2021 that are subject to amortization:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.142%"><tr><td style="width:1.0%"></td><td style="width:55.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.869%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3ZjI2OTc1YThjNzM0ODY0OGJkMTk2YTg4YjZlOTYwZC90YWJsZXJhbmdlOjdmMjY5NzVhOGM3MzQ4NjQ4YmQxOTZhODhiNmU5NjBkXzItMS0xLTEtMjQ2OTc_0ad1357a-7603-40bf-a5b3-2c0ef165786e">3,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3ZjI2OTc1YThjNzM0ODY0OGJkMTk2YTg4YjZlOTYwZC90YWJsZXJhbmdlOjdmMjY5NzVhOGM3MzQ4NjQ4YmQxOTZhODhiNmU5NjBkXzMtMS0xLTEtMjQ2OTc_9deb1f23-ae8a-4b8c-b9da-2800a312a80d">3,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3ZjI2OTc1YThjNzM0ODY0OGJkMTk2YTg4YjZlOTYwZC90YWJsZXJhbmdlOjdmMjY5NzVhOGM3MzQ4NjQ4YmQxOTZhODhiNmU5NjBkXzQtMS0xLTEtMjQ2OTc_249f2489-f7be-4057-81a5-fb9d02fc277f">2,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3ZjI2OTc1YThjNzM0ODY0OGJkMTk2YTg4YjZlOTYwZC90YWJsZXJhbmdlOjdmMjY5NzVhOGM3MzQ4NjQ4YmQxOTZhODhiNmU5NjBkXzUtMS0xLTEtMjQ2OTc_c7d38ee0-d31f-4350-8a16-94d4c9aa0295">2,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3ZjI2OTc1YThjNzM0ODY0OGJkMTk2YTg4YjZlOTYwZC90YWJsZXJhbmdlOjdmMjY5NzVhOGM3MzQ4NjQ4YmQxOTZhODhiNmU5NjBkXzUtMS0xLTEtMzA0NTk_717c2948-8959-4671-a492-7b39f90599c7">2,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3ZjI2OTc1YThjNzM0ODY0OGJkMTk2YTg4YjZlOTYwZC90YWJsZXJhbmdlOjdmMjY5NzVhOGM3MzQ4NjQ4YmQxOTZhODhiNmU5NjBkXzYtMS0xLTEtMjQ2OTc_71152e05-820e-442c-86f8-34851af1151b">35,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3ZjI2OTc1YThjNzM0ODY0OGJkMTk2YTg4YjZlOTYwZC90YWJsZXJhbmdlOjdmMjY5NzVhOGM3MzQ4NjQ4YmQxOTZhODhiNmU5NjBkXzctMS0xLTEtMjQ2OTc_ad5bfcf1-2e32-45b1-8597-721b8de2d8a2">50,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution right represents the license and associated distribution right to develop Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the initial term of which expires in September 2023 and is automatically extended for unlimited additional <ix:nonNumeric contextRef="i3bbaa2f404694cf09f8b1dd48adb8b5a_D20210101-20211231" name="eols:AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE4ODQ_88907c01-f858-4d03-8101-31a86f78a67d">three-year</ix:nonNumeric> terms provided that the Company meets certain performance requirements. Additionally, upon FDA approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;on February 1, 2019, the IPR&amp;D project was completed and reclassified as a definite-lived distribution right intangible asset, which is amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="i26cd83bcd422412f813d386ddac29197_D20190201-20190201" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzk2MA_5886100f-8b9b-43dd-9093-c42f4366abd6">20</ix:nonNumeric> years. The Company paid Daewoong a $<ix:nonFraction unitRef="usd" contextRef="i88606d7b76234da8a815ea40351a89f6_D20190201-20190201" decimals="-3" name="eols:MilestonePaymentsForIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzk5Mg_594c519a-64ae-42b2-9f73-3d673a73849e">2,000</ix:nonFraction> milestone payment, pursuant to the Daewoong Agreement, which increased the cost basis of the distribution. In connection with EU approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company paid a $<ix:nonFraction unitRef="usd" contextRef="i58135f80c4e74590a70a971e21d37e1f_D20191001-20191231" decimals="-3" name="eols:MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzExNjg_71e2cfa2-a3e0-48a2-9c36-8b166e46f9ac">1,000</ix:nonFraction> milestone payment to Daewoong in the fourth quarter of fiscal year 2019, which increased the cost basis of the distribution right. Under the Daewoong Arrangement (as defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), there is no additional cash consideration due to Daewoong. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idb60c745b2b44f41a434db0cd238ca41">For the years ended December 31, 2021 and 2020, the Company capitalized $<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:CapitalizedComputerSoftwareAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE0OTg_912a6d1d-7cfd-4bc1-a777-78615cd5a3d9">633</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE1MDU_a48c0e9d-eb0a-49b6-9872-97f1fa97488d">2,266</ix:nonFraction>, respectively, related to costs of computer software developed for internal use. The software is amortized over a <ix:nonNumeric contextRef="i2a3026926537414c9e558b2f48c5ac00_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE4Nzk_ec9a77dc-6d2d-433d-9707-2d6677ee2a44">two-year</ix:nonNumeric> period using the straight-line method. For the years ended December 31, 2021 and 2020, total intangible assets amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE3MzY_5a6aea43-8064-433d-a856-083bb6131470">5,305</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE3NDM_02fa01e7-ce5d-473d-bedb-ef8e37b0da09">3,635</ix:nonFraction>, respectively, was recorded within depreciation and amortization on the accompanying statements of operations and comprehensive loss.</ix:continuation></span></div><div id="i77038361ec4447b8be22639fec3c691b_106"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90ZXh0cmVnaW9uOjE5YTdjNWIwMjdkODRhOGJiMWJjMjZkYjJiNzE4NjRiXzc5_47da6775-20e4-4e65-8cb6-50dddcf21559" continuedAt="i67cc13eb7ba54c6481064504f8687f0d" escape="true">Accrued Expenses </ix:nonNumeric></span></div><ix:continuation id="i67cc13eb7ba54c6481064504f8687f0d"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90ZXh0cmVnaW9uOjE5YTdjNWIwMjdkODRhOGJiMWJjMjZkYjJiNzE4NjRiXzc3_5d3e799a-b1e6-47f3-b634-d8cd53131e76" escape="true"><div style="margin-bottom:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties under the Medytox/Allergan Settlement Agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzItMS0xLTEtMzA0Njc_553d8011-defc-49cf-b3f5-423983fb7041">12,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzItMy0xLTEtMzA0Njc_8f01036a-3aeb-410b-91e1-96477e4dd873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzItMS0xLTEtMjQ2OTc_b04b690b-48d1-49b2-aafb-441085627fa4">6,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzItMy0xLTEtMjQ2OTc_5b46f3e9-3c5f-498b-a163-6544d2108b9f">4,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued revenue contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzMtMS0xLTEtMjQ2OTc_745516b1-faaf-45fc-8587-805ceac5a12a">7,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzMtMy0xLTEtMjQ2OTc_1df0ef73-81ce-4a07-9cd7-8f9b8e433167">3,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzQtMS0xLTEtMjQ2OTc_081630a2-cd67-474d-ab39-f238ae824784">595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzQtMy0xLTEtMjQ2OTc_2fd70cff-8387-48d0-bce0-26904ed08912">895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzUtMS0xLTEtMjQ2OTc_bea16e4c-dc1f-479e-8ffe-3d1e79e1ba63">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzUtMy0xLTEtMjQ2OTc_d22745c1-5606-44fd-83a1-2fdfdf13c90f">1,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzYtMS0xLTEtMjQ2OTc_67a63f46-cd7b-4f9e-b523-e72f96e9282d">29,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzYtMy0xLTEtMjQ2OTc_4f55957f-65d5-4b10-8db5-eb7da0c60f94">9,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i77038361ec4447b8be22639fec3c691b_1437"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV84MjQ2MzM3MjMwMDk0_be7ccbc1-50fe-4f0c-bea7-1be4afbfe813" continuedAt="i9ab1bf4f38b04f558a9fc9906afe2211" escape="true">Term Loans</ix:nonNumeric></span></div><ix:continuation id="i9ab1bf4f38b04f558a9fc9906afe2211" continuedAt="iea653348aef243f9a4e26976e96e5483"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmakon Term Loans</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2021, the Company entered into a loan agreement with Pharmakon. Pursuant to the terms of the agreement, Pharmakon agreed to make term loans to the Company in <ix:nonFraction unitRef="tranche" contextRef="i925e16da5e194d4986f670bfe115cfd7_I20211214" decimals="INF" name="eols:DebtInstrumentNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjQ1ODUz_9d3cb6a8-c3e4-47c4-a658-59b91863b500">two</ix:nonFraction> tranches (&#8220;Pharmakon Term Loans&#8221;). The first tranche of $<ix:nonFraction unitRef="usd" contextRef="ic59095e4226448ca90c7c028c530b46b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjQyNTA5_f3f0a4d2-3a5f-4348-9705-358a14ef15f4">75,000</ix:nonFraction> was funded on December 29, 2021. The second tranche of $<ix:nonFraction unitRef="usd" contextRef="iaf213e710f77493dadadc321fcf59639_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjQyNTI5_e4fc726f-bb7f-4342-944b-4f17e48c9f5b">50,000</ix:nonFraction> may be drawn at the Company&#8217;s election no later than December 31, 2022. As of December&#160;31, 2021, the Company has not drawn the second tranche. The Pharmakon Term Loans will mature on the sixth year anniversary of the closing date of the first tranche (&#8220;Maturity Date&#8221;). </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Term Loans accrue interest at a per annum rate equal to the 3-month U.S. Dollar LIBOR rate (subject to a LIBOR rate floor of <ix:nonFraction unitRef="number" contextRef="i96e618230e7d48238d27ef49600d13df_I20211214" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjY2NTk2_46ca1116-f1ea-473b-a7cc-6332cff2acf0">1.0</ix:nonFraction>%) plus <ix:nonFraction unitRef="number" contextRef="ia0b2c7ebaf23495d8d1cc10fab315eb7_D20211214-20211214" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjQyNTQ1_6101e7cf-631b-4c69-ad12-1198585d55cf">8.5</ix:nonFraction>% per annum; provided that, upon a public statement or publication of information in certain circumstances that LIBOR has ceased or will cease to be provided or be representative or the occurrence of an early opt-in determination by the collateral agent, the Pharmakon Term Loans will be amended to provide for an alternative to the 3-month U.S. Dollar LIBOR rate established by the lenders holding a majority of the outstanding Pharmakon Term Loans, giving due consideration to the selection or recommendation of a replacement rate or mechanism for determining such rate by any applicable governmental authority or the then-prevailing market conventions. The Company agreed to make <ix:nonFraction unitRef="payment" contextRef="if4f1ae42ca284ea69054431a374441c1_D20211214-20211214" decimals="INF" name="eols:DebtInstrumentNumberOfPeriodicPaymentsPrincipal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8zMjk4NTM0OTA1MTA3_2f92eb0e-132f-433e-a531-0ccf202d7746">12</ix:nonFraction> equal quarterly payments of principal on the outstanding Pharmakon Term Loans commencing on or immediately following the <ix:nonNumeric contextRef="i4ec3d79630cc4ba09ef1b19959bd91f0_D20211214-20211214" name="eols:DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjQ2MDc2_919a6916-5b86-404d-a93b-a28c24ef161f">39</ix:nonNumeric>th-month anniversary of the funding date of the first tranche continuing through the Maturity Date.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may elect to prepay all amounts, not less than $<ix:nonFraction unitRef="usd" contextRef="i559b9a0d8aa547d0b36e58c3d536751e_I20211231" decimals="-3" name="eols:DebtInstrumentPrepaymentAmountThreshold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV82MDQ3MzEzOTgzNjg0_adfba3b4-232b-4385-8ed3-eab5df6d6d60">20,000</ix:nonFraction>, owed prior to the Maturity Date. Prepayments of the first tranche prior to the second anniversary of the closing date of the first tranche and prepayments of the second tranche prior to the second anniversary of the date on which the second tranche is drawn by the Company will be accompanied by a make whole amount equal to the sum of all interest that would have accrued through such second anniversary. Prepayments of the Pharmakon Term Loans will also be accompanied by a prepayment premium equal to the principal amount so prepaid multiplied by <ix:nonFraction unitRef="number" contextRef="id698b63e55694d648621289908e0dcbe_I20211214" decimals="INF" name="eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjQ5MjA3_dcd282cf-a998-4187-9748-b137c9c1208f">3.0</ix:nonFraction>% if made prior to the third anniversary of the closing date of the first tranche, <ix:nonFraction unitRef="number" contextRef="i3e5503a1fc4a4988a8da895468afd601_I20211214" decimals="2" name="eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjQ5MjE1_f7cfa451-13c6-4dd6-a206-9ba9ce6de340">2.0</ix:nonFraction>% if made on or after the third anniversary of the closing date of the first tranche but prior to the fourth anniversary of the closing date of the first tranche, and <ix:nonFraction unitRef="number" contextRef="i0449988c955c422a849943b6ec89fe73_I20211214" decimals="2" name="eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjQ5MjIz_222682fe-6ec1-49ef-9906-1b082de8a797">1.0</ix:nonFraction>% if made on or after the fourth anniversary of the closing date of the first tranche but prior to the Maturity Date. If the Pharmakon Term Loans are accelerated following the occurrence of an event of default, including a material adverse change, the Company is required to immediately pay Pharmakon an amount equal to the sum of all outstanding principal, unpaid interest, and applicable make whole and prepayment premiums.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Term Loans are secured by substantially all of the Company&#8217;s assets. The Pharmakon Term Loans contain customary affirmative and restrictive covenants and representations and warranties. The affirmative covenants include, </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="iea653348aef243f9a4e26976e96e5483" continuedAt="if97a272b7c4b4c698077940fd3ec7bb7"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">among others, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. The restrictive covenants include, among others, incurring certain additional indebtedness, consummating certain change in control transactions, or incurring any non- permitted lien or other encumbrance on the Company&#8217;s assets, without Pharmakon&#8217;s prior written consent. The Pharmakon Term Loans do not contain covenants requiring the Company to maintain a minimum cash threshold or minimum revenues or earnings. As of December&#160;31, 2021, the Company was in compliance with its debt covenants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing date of the first tranche, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i96e618230e7d48238d27ef49600d13df_I20211214" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjUxNTA1_76d481aa-94f8-49c0-8dee-95063209080b">3,042</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i96e618230e7d48238d27ef49600d13df_I20211214" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjUxNTEz_1cef67b1-119d-48af-b630-01f0bcfe99a1">3,263</ix:nonFraction> in debt discounts and issuance costs related to the Pharmakon Term Loans, respectively. Debt discounts and issuance costs related to the entire Pharmakon Term Loans have been allocated pro rata between the funded and unfunded portions. Debt discounts and issuance costs allocated to the first tranche of $<ix:nonFraction unitRef="usd" contextRef="ic59095e4226448ca90c7c028c530b46b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjUxMjQy_f3f0a4d2-3a5f-4348-9705-358a14ef15f4">75,000</ix:nonFraction> have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. As of December&#160;31, 2021, the borrowings outstanding under the Pharmakon Term Loans were classified as long-term debt in the accompanying balance sheets. Debt discounts and issuance costs associated with the unfunded tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. The overall effective interest rate was approximately <ix:nonFraction unitRef="number" contextRef="ia43c0d4587004db0b6f491872654d03a_I20211231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjUxNDc4_eaf692c0-28c2-49ef-b74a-4dea8964d10a">10.89</ix:nonFraction>% as of December&#160;31, 2021.</span></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8zODQ4MjkwNzIxNjQ1_e02c47f1-f381-4f05-aa76-f4ce389f5132" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.476%"><tr><td style="width:1.0%"></td><td style="width:68.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.582%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF8xLTEtMS0xLTM5MDQ2_8089ff7b-cfcd-441f-a1fe-3fbd7383529e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF8yLTEtMS0xLTM5MDQ2_21f9af8e-72ae-4b2e-8cab-5186c51057db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF8zLTEtMS0xLTM5MDQ2_9b734015-8ddc-48e9-9741-fd0a1caacb44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF80LTEtMS0xLTM5MDQ2_9cebb421-4a8f-43b0-b756-8bf5cc28f981">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF81LTEtMS0xLTM5MDQ2_06ee7995-3930-45b8-a746-eaaad29b533f">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF82LTEtMS0xLTM5MDQ2_fbb89175-5be9-4076-a672-a4ed34d58446">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF83LTEtMS0xLTM5MDQ2_ae8320d5-4d24-4da6-bb04-3dbf2df03546">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discounts and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF84LTEtMS0xLTM5MDQ2_12d13705-ef15-48d9-92ad-7b35e5e55777">3,778</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net of discounts and issuance costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF85LTEtMS0xLTM5MDQ4_6a7a6992-48c9-4ea0-96a2-362527546e00">71,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oxford Term Loans</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2019, the Company entered into a Loan and Security Agreement with Oxford (the &#8220;Loan Agreement&#8221;), providing for a credit facility of up to $<ix:nonFraction unitRef="usd" contextRef="i709c7ab6d38744cca0fbeb034841964d_I20190315" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3MTk1Mw_e8790f97-73b6-4b70-a2f2-8a8f03317199">100,000</ix:nonFraction>. Pursuant to the terms of the credit facility, the lender extended term loans (the &#8220;Oxford Term Loan&#8221;), available in <ix:nonFraction unitRef="advance" contextRef="i709c7ab6d38744cca0fbeb034841964d_I20190315" decimals="INF" name="eols:LineofCreditFacilityNumberofAdvances" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3MjA3NA_d7c40baa-7b0a-4237-a603-a4a1e7430cd6">two</ix:nonFraction> advances, to the Company. The first tranche of $<ix:nonFraction unitRef="usd" contextRef="ie909f3b79bd4486daae42675b5641c62_I20190315" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3MjEyNQ_8ddbba87-ec0b-4368-87be-7b6a2ed8100d">75,000</ix:nonFraction> was funded on the closing date. The second tranche of $<ix:nonFraction unitRef="usd" contextRef="ifbb534318d9f4bd5bc4b81a523ac249b_I20190315" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3MjE4Mw_b76d8188-dde3-493a-beec-ddb861745643">25,000</ix:nonFraction> was not drawn. The credit facility bore an annual interest rate equal to the greater of <ix:nonFraction unitRef="number" contextRef="i709c7ab6d38744cca0fbeb034841964d_I20190315" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3MjI3NQ_db1e4a20-4fab-4b31-985c-36d611f24749">9.5</ix:nonFraction>%, or the 30-day U.S. Dollar LIBOR rate plus <ix:nonFraction unitRef="number" contextRef="i458308c7266b440eb668d7481bd1e4b3_D20190315-20190315" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3MjMyMg_5f675b7e-45da-4c34-93d5-0bd405d1c045">7.0</ix:nonFraction>%. The Company agreed to pay interest-only for the first <ix:nonNumeric contextRef="i69e7efe2c2b144989db5533678b61c21_D20190315-20190315" name="eols:DebtInstrumentPeriodOfInterestOnlyPayments" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV82MDQ3MzEzOTgzNzAw_f0978877-b941-4aa6-8746-533a35afe77a">36</ix:nonNumeric> months until May 2022, followed by a <ix:nonNumeric contextRef="i69e7efe2c2b144989db5533678b61c21_D20190315-20190315" name="eols:DebtInstrumentAmortizationPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV82MDQ3MzEzOTgzNjQy_85a842b4-8de5-4e52-90d7-d9d01106b911">23</ix:nonNumeric> months amortization period.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing date, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="idf71c87e895a46f09a7abf6657f2b04d_I20190315" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjU5MzIw_ddfeddc0-9fcf-4fcb-9194-6b4c0232be2b">1,094</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="idf71c87e895a46f09a7abf6657f2b04d_I20190315" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjU5MzI4_c6c90353-2f30-400a-8af4-ede313c66d1d">2,205</ix:nonFraction> in debt discounts and issuance costs related to the Oxford Term Loan, respectively. Debt&#160;discounts and issuance costs related to the entire Oxford Term Loan have been allocated pro rata between the funded and unfunded portions. Debt&#160;discounts and issuance costs related to the Oxford Term Loan have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. The overall effective interest rate was approximately <ix:nonFraction unitRef="number" contextRef="i97c0f553670c4c3495114a22bf868a2f_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjU5ODEy_6777cd5b-93e0-4a23-b4bd-8235715ef5f1">11.6</ix:nonFraction>% as of December&#160;31, 2020. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the earliest to occur of the maturity date, the acceleration of the Oxford Term Loan, or the prepayment of the Oxford Term Loan, the Company was required to pay to Oxford a final payment of <ix:nonFraction unitRef="number" contextRef="i9b43edc16c22483086f802b6b9cf884c_I20190315" decimals="INF" name="eols:DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3MjY0OQ_e38e4f48-2347-4997-96ca-29cc0dc1802a">5.5</ix:nonFraction>% of the full principal amount of the Oxford Term Loan funded (&#8220;Final Payment&#8221;). The Company could elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee was also paid, which would be equal to <ix:nonFraction unitRef="number" contextRef="i9b43edc16c22483086f802b6b9cf884c_I20190315" decimals="INF" name="eols:DebtInstrumentPrepaymentFeePercentageYearTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3Mjg4MQ_81a89e4e-0300-4739-9ef2-211648ec7ccf">2.0</ix:nonFraction>% of the amount prepaid if the prepayment occurred after March 15, 2020 and on or prior to March 15, 2021, or <ix:nonFraction unitRef="number" contextRef="i9b43edc16c22483086f802b6b9cf884c_I20190315" decimals="INF" name="eols:DebtInstrumentPrepaymentFeePercentageThereafter" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3Mjk5Mw_b1cfeeb8-4453-44c8-a126-37fe85d07cf1">1.0</ix:nonFraction>% of the amount prepaid if the prepayment occurred thereafter (&#8220;Prepayment Fee&#8221;).</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if97a272b7c4b4c698077940fd3ec7bb7" continuedAt="iba7e1ed8468f4b12ac5d59bfc1615832">On January 4, 2021, the Company and Oxford entered into an agreement (&#8220;Payoff Letter&#8221;), pursuant to which (i) the Company paid Oxford $<ix:nonFraction unitRef="usd" contextRef="i4cac7bab107947c89fb60b9a19aa1ed2_D20210104-20210104" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3Mzc2MQ_2cdbbad6-e8cc-4477-9a71-6878efc82e4c">76,447</ix:nonFraction> to discharge in full all outstanding obligations, including accrued interest by and between Oxford, in its capacity as collateral agent and lender, and the Company, and (ii) effective upon such repayment, the Loan Agreement, and all unfunded commitments thereunder, guarantees and other security interests granted to Oxford in connection with the Loan Agreement and all other obligations of and restrictions on the Company under the Loan Agreement, terminated. As a condition to entering into the Payoff Letter, Oxford agreed to waive a total of $<ix:nonFraction unitRef="usd" contextRef="i4cac7bab107947c89fb60b9a19aa1ed2_D20210104-20210104" decimals="-3" name="eols:DebtInstrumentFeeAmountWaived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3NDMxMQ_799a189e-a568-4f29-948c-2343f158eacd">4,300</ix:nonFraction> of fees comprised of (i) $<ix:nonFraction unitRef="usd" contextRef="i4cac7bab107947c89fb60b9a19aa1ed2_D20210104-20210104" decimals="-3" name="eols:DebtInstrumentOfFinalPaymentAmountWaived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3NDM0MA_59277322-8889-4ee1-b1dc-76b8b1306933">2,800</ix:nonFraction> of the Final Payment and (ii) the Prepayment Fee of $<ix:nonFraction unitRef="usd" contextRef="i4cac7bab107947c89fb60b9a19aa1ed2_D20210104-20210104" decimals="-3" name="eols:DebtInstrumentPrepaymentFeeAmountWaived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3NDM5Ng_ae92d07e-5158-49ff-8fbb-9a35ebd57d20">1,500</ix:nonFraction>. As a result, the Company recorded a loss of $<ix:nonFraction unitRef="usd" contextRef="i4cac7bab107947c89fb60b9a19aa1ed2_D20210104-20210104" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV82MDQ3MzEzOTgzNjkz_3e935901-ce77-44c6-839d-0ff9d96e1db9">1,939</ix:nonFraction> in extinguishment of debts, net on the accompanying statements of operations and comprehensive loss.</ix:continuation></span></div><div id="i77038361ec4447b8be22639fec3c691b_112"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7.<ix:continuation id="iba7e1ed8468f4b12ac5d59bfc1615832" continuedAt="ie0fc362e215e477385a25f3655a9d87e"> Daewoong Convertible Note</ix:continuation></span></div><ix:continuation id="ie0fc362e215e477385a25f3655a9d87e"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2020, the Company entered into a Convertible Promissory Note Purchase Agreement with Daewoong for the principal amount of $<ix:nonFraction unitRef="usd" contextRef="iaae348537d9a4136a16f6e54e4e524a6_I20200706" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTIvZnJhZzo0OWRhZGUyYjA4YmE0MTI5YTc0MTU4YWMzYjYwZmM2Yy90ZXh0cmVnaW9uOjQ5ZGFkZTJiMDhiYTQxMjlhNzQxNThhYzNiNjBmYzZjXzIwMg_975826bd-2491-471d-900f-1259e3991238">40,000</ix:nonFraction> (the &#8220;Daewoong Convertible Note&#8221;), which was funded on July 30, 2020. Additionally, on July 6, 2020, the Company, Daewoong and Oxford entered into a Subordination Agreement pursuant to which the Daewoong Convertible Note was subordinated to the Company&#8217;s obligations under the Loan Agreement.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Convertible Note bore interest at a rate of <ix:nonFraction unitRef="number" contextRef="iaae348537d9a4136a16f6e54e4e524a6_I20200706" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTIvZnJhZzo0OWRhZGUyYjA4YmE0MTI5YTc0MTU4YWMzYjYwZmM2Yy90ZXh0cmVnaW9uOjQ5ZGFkZTJiMDhiYTQxMjlhNzQxNThhYzNiNjBmYzZjXzY1Nw_f59d05dc-0c33-4a59-9934-41dbe9133dff">3.0</ix:nonFraction>% payable semi-annually in arrears on June 30th and December 31st of each year and was to mature on July 30, 2025, subject to earlier conversion as provided below. Interest was initially paid in kind by adding the accrued amount thereof to the outstanding principal amount on a semi-annual basis on June 30th and December 31st of each calendar year for so long as any principal amount under the Oxford Term Loan remained outstanding and the Subordination Agreement was not terminated. Interest became payable in cash after the Oxford Term Loan was repaid in full, and the Subordination Agreement was terminated on January 4, 2021. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;23, 2021, the outstanding principal balance including all accrued and unpaid interest thereon, of $<ix:nonFraction unitRef="usd" contextRef="ib67b7815bf86448c836c0674ab2cd400_I20210323" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTIvZnJhZzo0OWRhZGUyYjA4YmE0MTI5YTc0MTU4YWMzYjYwZmM2Yy90ZXh0cmVnaW9uOjQ5ZGFkZTJiMDhiYTQxMjlhNzQxNThhYzNiNjBmYzZjXzEwOTk1MTE2MzYwMTk_8c83e1d8-b357-405a-8bbb-b86865f13dd4">40,779</ix:nonFraction> was converted into <ix:nonFraction unitRef="shares" contextRef="i67974a995ff142e8bcd737a314d25651_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTIvZnJhZzo0OWRhZGUyYjA4YmE0MTI5YTc0MTU4YWMzYjYwZmM2Yy90ZXh0cmVnaW9uOjQ5ZGFkZTJiMDhiYTQxMjlhNzQxNThhYzNiNjBmYzZjXzEwOTk1MTE2MzYwMTU_c3cd713f-2461-4c6e-b548-bdbf8ad75cd4">3,136,869</ix:nonFraction> shares of the Company&#8217;s common stock under the Conversion Agreement at the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib67b7815bf86448c836c0674ab2cd400_I20210323" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTIvZnJhZzo0OWRhZGUyYjA4YmE0MTI5YTc0MTU4YWMzYjYwZmM2Yy90ZXh0cmVnaW9uOjQ5ZGFkZTJiMDhiYTQxMjlhNzQxNThhYzNiNjBmYzZjXzEwOTk1MTE2MzYxMDQ_1aae903e-25cd-4d08-aa75-03e90f96b824">13.00</ix:nonFraction> per share. The conversion was accounted for as an extinguishment of debt resulting in a gain of $<ix:nonFraction unitRef="usd" contextRef="i99d0525d0e434079b1d9eb140af4688c_D20210301-20210331" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTIvZnJhZzo0OWRhZGUyYjA4YmE0MTI5YTc0MTU4YWMzYjYwZmM2Yy90ZXh0cmVnaW9uOjQ5ZGFkZTJiMDhiYTQxMjlhNzQxNThhYzNiNjBmYzZjXzYwNDczMTM5NjEwMTQ_d6bd1789-ec46-4f46-804a-eb3d43897c1e">971</ix:nonFraction>, which is recorded in loss from extinguishment of debts, net on the accompanying statements of operations and comprehensive loss. The Daewoong Convertible Note was not registered, and the shares of the Company&#8217;s common stock issued upon conversion of the Daewoong Convertible Note have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the details of the Conversion Agreement.</span></div></ix:continuation><div id="i77038361ec4447b8be22639fec3c691b_115"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90ZXh0cmVnaW9uOjIwNjM0MTFhYzMwODRkYjI5ZWM3NGY3YjI5NzVmOTNiXzI5Mzk_414f6ff0-30ed-4736-b335-a9454b401ba1" continuedAt="i09fcc75d9bbc4069a19fdeb3703d7f61" escape="true">Operating Leases</ix:nonNumeric></span></div><ix:continuation id="i09fcc75d9bbc4069a19fdeb3703d7f61" continuedAt="ic23ea9c7c3a248e6ad03fdfb72bebb57"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s corporate headquarters in Newport Beach, California is leased under a <ix:nonNumeric contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90ZXh0cmVnaW9uOjIwNjM0MTFhYzMwODRkYjI5ZWM3NGY3YjI5NzVmOTNiXzMyOTg1MzQ4ODY5NjE_6362e68a-4fb0-4fc1-a45f-67f17c980ed8">five-year</ix:nonNumeric> non-cancelable operating lease, which expires on January 31, 2025. Lease payments increase each year on February 1 based on an annual rent escalation clause. The Company may, under certain circumstances, terminate the lease on the <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="eols:LesseeOperatingLeaseTerminationPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90ZXh0cmVnaW9uOjIwNjM0MTFhYzMwODRkYjI5ZWM3NGY3YjI5NzVmOTNiXzYzNA_c987593e-73e6-40bb-97d3-6bf673764297">36</ix:nonNumeric>-month anniversary of the lease commencement date by providing a written notice <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="eols:LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90ZXh0cmVnaW9uOjIwNjM0MTFhYzMwODRkYjI5ZWM3NGY3YjI5NzVmOTNiXzcxNg_055c1fb4-81d2-403c-ae76-6cb3464dd11f">12</ix:nonNumeric> months prior to such anniversary and paying a termination fee&#160;equal to <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="eols:LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90ZXh0cmVnaW9uOjIwNjM0MTFhYzMwODRkYjI5ZWM3NGY3YjI5NzVmOTNiXzc4Mw_805db418-69ba-4d4d-8a25-1dae3e37f77a">six months</ix:nonNumeric> basic rent plus certain other expenses. The Company has an option to extend the term of the lease for an additional <ix:nonNumeric contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90ZXh0cmVnaW9uOjIwNjM0MTFhYzMwODRkYjI5ZWM3NGY3YjI5NzVmOTNiXzkwMg_da8545ed-76e8-43d7-93c7-7101c47d37ee">60</ix:nonNumeric> months, which is not recognized as part of its ROU assets and lease liabilities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease agreement does not contain any residual value guarantees or material restrictive covenants. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU assets if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial implications of a decision to extend or not to extend a lease&#160;in&#160;determining&#160;if the renewal option is reasonably certain to be exercised.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="ic23ea9c7c3a248e6ad03fdfb72bebb57"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90ZXh0cmVnaW9uOjIwNjM0MTFhYzMwODRkYjI5ZWM3NGY3YjI5NzVmOTNiXzI5NDA_cffc4ca2-4305-42ba-84ac-f805d7cb1f7a" continuedAt="i5401b873f3774fa7a224f7023588609e" escape="true">he components of operating lease expense are as follows:</ix:nonNumeric></span></div><ix:continuation id="i5401b873f3774fa7a224f7023588609e"><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.154%"><tr><td style="width:1.0%"></td><td style="width:62.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTo3YTY4MzEyNTYyODA0ZDc3YmUzZGJmYzExYzZiNzY4Ni90YWJsZXJhbmdlOjdhNjgzMTI1NjI4MDRkNzdiZTNkYmZjMTFjNmI3Njg2XzItMS0xLTEtMjQ2OTc_2b9af4a6-b0d7-4fb8-94f0-6afec3c4fdc2">1,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTo3YTY4MzEyNTYyODA0ZDc3YmUzZGJmYzExYzZiNzY4Ni90YWJsZXJhbmdlOjdhNjgzMTI1NjI4MDRkNzdiZTNkYmZjMTFjNmI3Njg2XzItMy0xLTEtMjQ2OTc_95445bf1-59f3-4057-b574-effa204667e1">1,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTo3YTY4MzEyNTYyODA0ZDc3YmUzZGJmYzExYzZiNzY4Ni90YWJsZXJhbmdlOjdhNjgzMTI1NjI4MDRkNzdiZTNkYmZjMTFjNmI3Njg2XzMtMS0xLTEtMjQ2OTc_912cdef7-6482-42ed-9f22-a99f443b6c3d">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTo3YTY4MzEyNTYyODA0ZDc3YmUzZGJmYzExYzZiNzY4Ni90YWJsZXJhbmdlOjdhNjgzMTI1NjI4MDRkNzdiZTNkYmZjMTFjNmI3Njg2XzMtMy0xLTEtMjQ2OTc_cfe998cb-687c-4e32-804d-65593976d62b">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTo3YTY4MzEyNTYyODA0ZDc3YmUzZGJmYzExYzZiNzY4Ni90YWJsZXJhbmdlOjdhNjgzMTI1NjI4MDRkNzdiZTNkYmZjMTFjNmI3Njg2XzQtMS0xLTEtMjQ2OTc_7e1ff44c-56db-4c75-a4d4-a60a3cd26a9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTo3YTY4MzEyNTYyODA0ZDc3YmUzZGJmYzExYzZiNzY4Ni90YWJsZXJhbmdlOjdhNjgzMTI1NjI4MDRkNzdiZTNkYmZjMTFjNmI3Njg2XzQtMy0xLTEtMjQ2OTc_6bfcf153-6b77-4060-8824-5f5dca67c2c8">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTo3YTY4MzEyNTYyODA0ZDc3YmUzZGJmYzExYzZiNzY4Ni90YWJsZXJhbmdlOjdhNjgzMTI1NjI4MDRkNzdiZTNkYmZjMTFjNmI3Njg2XzUtMS0xLTEtMjQ2OTc_aa59fbcc-5dab-4161-b004-697b40d5f824">1,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTo3YTY4MzEyNTYyODA0ZDc3YmUzZGJmYzExYzZiNzY4Ni90YWJsZXJhbmdlOjdhNjgzMTI1NjI4MDRkNzdiZTNkYmZjMTFjNmI3Njg2XzUtMy0xLTEtMjQ2OTc_0a459fc2-ed24-48b2-a1b4-dbcb2dd7f320">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term and discount rate are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.154%"><tr><td style="width:1.0%"></td><td style="width:62.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTozYTJjNDRjNzQ4NjQ0MWRlYWUyNmVhOWQwMmE0N2NlZi90YWJsZXJhbmdlOjNhMmM0NGM3NDg2NDQxZGVhZTI2ZWE5ZDAyYTQ3Y2VmXzItMS0xLTEtMzk2ODQ_5e6a5510-7f6a-4e6b-907e-8227dba41d0d">3.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTozYTJjNDRjNzQ4NjQ0MWRlYWUyNmVhOWQwMmE0N2NlZi90YWJsZXJhbmdlOjNhMmM0NGM3NDg2NDQxZGVhZTI2ZWE5ZDAyYTQ3Y2VmXzItMy0xLTEtMzk2ODQ_51cfe10b-88da-4dc6-a35e-3c74b5ad94e4">4.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTozYTJjNDRjNzQ4NjQ0MWRlYWUyNmVhOWQwMmE0N2NlZi90YWJsZXJhbmdlOjNhMmM0NGM3NDg2NDQxZGVhZTI2ZWE5ZDAyYTQ3Y2VmXzMtMS0xLTEtMzk2ODQ_9eba11d8-5202-4c99-bbe7-a2585fd1b9a1">9.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTozYTJjNDRjNzQ4NjQ0MWRlYWUyNmVhOWQwMmE0N2NlZi90YWJsZXJhbmdlOjNhMmM0NGM3NDg2NDQxZGVhZTI2ZWE5ZDAyYTQ3Y2VmXzMtMy0xLTEtMzk2ODQ_d0f97f0e-225e-4133-af84-b2b4675fb562">9.4</ix:nonFraction>%</span></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease&#160;expenses were included in the selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss. Operating lease right-of-use assets and related current and noncurrent operating lease liabilities are presented in the accompanying balance sheets. </span></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90ZXh0cmVnaW9uOjIwNjM0MTFhYzMwODRkYjI5ZWM3NGY3YjI5NzVmOTNiXzI5NDE_aaef9730-9049-41b0-98f0-8f2b273eeec8" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the future minimum payments under the operating lease agreements with non-cancelable terms as of December&#160;31, 2021:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.327%"><tr><td style="width:1.0%"></td><td style="width:76.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTowM2FkMmNlOTQ0ZDk0ZjY5YjBkMGNiMzhlMWZiNmRlZC90YWJsZXJhbmdlOjAzYWQyY2U5NDRkOTRmNjliMGQwY2IzOGUxZmI2ZGVkXzItMS0xLTEtMjQ2OTc_51ad2912-0d13-4d00-94ab-2d9308a8564e">1,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTowM2FkMmNlOTQ0ZDk0ZjY5YjBkMGNiMzhlMWZiNmRlZC90YWJsZXJhbmdlOjAzYWQyY2U5NDRkOTRmNjliMGQwY2IzOGUxZmI2ZGVkXzMtMS0xLTEtMjQ2OTc_88b794e6-33cc-46ca-b54d-f11fac8a4280">1,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTowM2FkMmNlOTQ0ZDk0ZjY5YjBkMGNiMzhlMWZiNmRlZC90YWJsZXJhbmdlOjAzYWQyY2U5NDRkOTRmNjliMGQwY2IzOGUxZmI2ZGVkXzQtMS0xLTEtMjQ2OTc_d16244eb-a3c6-4ffd-b8b5-1966bf8a75cf">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTowM2FkMmNlOTQ0ZDk0ZjY5YjBkMGNiMzhlMWZiNmRlZC90YWJsZXJhbmdlOjAzYWQyY2U5NDRkOTRmNjliMGQwY2IzOGUxZmI2ZGVkXzUtMS0xLTEtMjQ2OTc_8eb0f090-56bc-4e2d-bb13-3bda7568b947">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTowM2FkMmNlOTQ0ZDk0ZjY5YjBkMGNiMzhlMWZiNmRlZC90YWJsZXJhbmdlOjAzYWQyY2U5NDRkOTRmNjliMGQwY2IzOGUxZmI2ZGVkXzYtMS0xLTEtMjQ2OTc_d9e79110-d58a-4284-82ad-ec017c028cbc">4,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTowM2FkMmNlOTQ0ZDk0ZjY5YjBkMGNiMzhlMWZiNmRlZC90YWJsZXJhbmdlOjAzYWQyY2U5NDRkOTRmNjliMGQwY2IzOGUxZmI2ZGVkXzctMS0xLTEtMjQ2OTc_865c5d95-3848-4be7-9114-e3f141aa987d">556</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTowM2FkMmNlOTQ0ZDk0ZjY5YjBkMGNiMzhlMWZiNmRlZC90YWJsZXJhbmdlOjAzYWQyY2U5NDRkOTRmNjliMGQwY2IzOGUxZmI2ZGVkXzgtMS0xLTEtMjQ2OTc_18a2124e-334b-470e-9f74-320766e0fe11">3,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i77038361ec4447b8be22639fec3c691b_118"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTgvZnJhZzplMTJjODc2MjJiNjA0NmFkYTQwNGUyMDhiMjZiMDRhNC90ZXh0cmVnaW9uOmUxMmM4NzYyMmI2MDQ2YWRhNDA0ZTIwOGIyNmIwNGE0XzIwNzUy_e172672c-31e6-4b82-b627-417b652b3388" continuedAt="i612f83466333483daaf1bb809533e407" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i612f83466333483daaf1bb809533e407" continuedAt="i521e37e07db5410ea9fe2c27c4265fda"><div style="margin-bottom:10pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately $<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTgvZnJhZzplMTJjODc2MjJiNjA0NmFkYTQwNGUyMDhiMjZiMDRhNC90ZXh0cmVnaW9uOmUxMmM4NzYyMmI2MDQ2YWRhNDA0ZTIwOGIyNmIwNGE0XzE5MQ_e204d948-8b60-40eb-b709-7b09dad2a389">2,012</ix:nonFraction>. Certain minimum purchase commitments related to the purchase of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are described below.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Supply Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Agreement includes certain minimum annual purchases that the Company is required to make in order to maintain the exclusivity of the license. The Company may, however, meet these minimum purchase obligations by achieving certain market share in its covered territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i521e37e07db5410ea9fe2c27c4265fda" continuedAt="icdca7adf252e4133b04939d970207616"><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. <ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTgvZnJhZzplMTJjODc2MjJiNjA0NmFkYTQwNGUyMDhiMjZiMDRhNC90ZXh0cmVnaW9uOmUxMmM4NzYyMmI2MDQ2YWRhNDA0ZTIwOGIyNmIwNGE0XzE3Mjk_69ced800-0313-4728-abf8-370178059516"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTgvZnJhZzplMTJjODc2MjJiNjA0NmFkYTQwNGUyMDhiMjZiMDRhNC90ZXh0cmVnaW9uOmUxMmM4NzYyMmI2MDQ2YWRhNDA0ZTIwOGIyNmIwNGE0XzE3Mjk_7b05bafd-d509-4bd8-bc4d-bb10841ef0eb">No</ix:nonFraction></ix:nonFraction> amounts were accrued as of December&#160;31, 2021 and 2020.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16 and 28, 2020, <ix:nonFraction unitRef="complaint" contextRef="i639ff7637d4f4af7b61468f913b844be_D20201016-20201028" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTgvZnJhZzplMTJjODc2MjJiNjA0NmFkYTQwNGUyMDhiMjZiMDRhNC90ZXh0cmVnaW9uOmUxMmM4NzYyMmI2MDQ2YWRhNDA0ZTIwOGIyNmIwNGE0XzE2ODE3_9d5f8def-6639-46f1-a450-5e4abfdb45d3">two</ix:nonFraction> putative securities class action complaints were filed in the U.S. District Court for the Southern District of New York by Evolus shareholders Armin Malakouti and Clinton Cox, respectively, naming the Company and certain of its officers as defendants. The complaints assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, claiming that the defendants made false and materially misleading statements and failed to disclose material adverse facts related to the Company&#8217;s acquisition of the right to sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the complaint against the Company filed by Allergan and Medytox in the U.S. International Trade Commission related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;ITC Action&#8221;), and risks related to the ITC Action. The complaints assert a putative class period of February 1, 2019 to July 6, 2020. The court consolidated the actions on November 13, 2020, under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-08647 (PGG). On September 17, 2021, the court appointed a lead plaintiff and lead counsel. On November 17, 2021, the lead plaintiff filed an amended class action complaint against the Company, three of its officers, and Alphaeon Corporation, the Company&#8217;s former majority shareholder. On January 18, 2022, the Company and the officer defendants served their motion to dismiss the amended complaint, which is scheduled to be fully briefed on June 16, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2020 and December 2, 2020, <ix:nonFraction unitRef="plaintiff" contextRef="id67d131284974c959850a72560bf6292_D20201127-20201202" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTgvZnJhZzplMTJjODc2MjJiNjA0NmFkYTQwNGUyMDhiMjZiMDRhNC90ZXh0cmVnaW9uOmUxMmM4NzYyMmI2MDQ2YWRhNDA0ZTIwOGIyNmIwNGE0XzE4MDc2_3c4f59e3-02e2-40c7-9dc2-05e264e7f395">two</ix:nonFraction> putative Evolus shareholders filed substantially similar shareholder derivative actions in the U.S. District Court for the Southern District of New York against certain of the Company&#8217;s officers and directors as defendants. The complaints alleged substantially similar facts as those in the Securities Class Action and assert claims for, among other things, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of Section 14(a) of the Exchange Act and for contribution under Sections 10(b) and 21(D) of the Exchange Act. On December 29, 2020, the plaintiffs filed a joint stipulation to consolidate their actions and on February 5, 2021, the court consolidated the action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus, Inc. Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-09986-PPG, and adjourned defendants&#8217; time to move, answer or otherwise respond to the complaints. On September 20, 2021, the court so-ordered the parties&#8217; stipulated stay of the consolidated derivative suit pending the court&#8217;s decision on the defendants&#8217; motion to dismiss the Securities Class Action.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional suits will be filed, or additional allegations will be made by stockholders, with respect to these same or similar or other matters and also naming the Company and/or its officers and directors as defendants. The Company believes that the complaints are without merit and intends to vigorously defend against it. However, the outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss and accordingly has not accrued any liability associated with this action.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Books and Records Demand</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, the Company received a letter from a putative stockholder demanding inspection of specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law. The Company was subsequently informed that the stockholder sold his shares of the Company&#8217;s common stock. On October 13, 2021, the Company received a substantially similar demand to inspect specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law from another putative stockholder. The subject of the demand is substantially similar to the allegations in the putative securities class action and derivative complaints described above. The Company responded to that demand on December 17, 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Legal Matters</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is, from time to time, involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="icdca7adf252e4133b04939d970207616" continuedAt="ie7ff6cb152f74f8493b1f7051cbae611"><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&#8217;s financial results for that period.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. <ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTgvZnJhZzplMTJjODc2MjJiNjA0NmFkYTQwNGUyMDhiMjZiMDRhNC90ZXh0cmVnaW9uOmUxMmM4NzYyMmI2MDQ2YWRhNDA0ZTIwOGIyNmIwNGE0XzYwNDczMTM5OTE2MDI_05028225-8ff0-41b0-972f-1afe1a0b727e">No</ix:nonFraction> amounts were accrued as of December&#160;31, 2021.</span></div></ix:continuation><div><span><br/></span></div><div id="i77038361ec4447b8be22639fec3c691b_121"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU4NTU_aa6b2c3f-185d-4584-ae78-6ca85df3e9e8" continuedAt="ic229ff4dd7cd43e5954b10a00df777bf" escape="true">Stockholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="ic229ff4dd7cd43e5954b10a00df777bf" continuedAt="i86795e0e16ac4a8faae26ae317d60912"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="shares" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzY4_b8c9f883-e19e-431a-b2f9-bd9375cb436e">10,000,000</ix:nonFraction> authorized shares of preferred stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEyOA_967958f4-55d6-410f-bf6b-a851cf556fab">0.00001</ix:nonFraction> per share. As of December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE1Mg_10e03a40-ddca-46d8-b476-49d6c02606cd"><ix:nonFraction unitRef="shares" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE1Mg_87c0c877-5f32-406a-9b00-2e162f07e8eb">no</ix:nonFraction></ix:nonFraction> shares of its preferred stock were issued and outstanding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="shares" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzIxMw_3f51e8db-b0ae-4fc5-b520-2fd1677fc5c6">100,000,000</ix:nonFraction> authorized shares of common stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzI3MA_0fbf0733-bf07-4ce0-9166-79a2e61ee3bb">0.00001</ix:nonFraction> per share. As of December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2NDA4OTE_806dcf99-f8a9-46c7-9438-e079f7ae4bd8"><ix:nonFraction unitRef="shares" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2NDA4OTE_bba46a71-0684-417f-9da1-de05dac3f583">55,576,988</ix:nonFraction></ix:nonFraction> shares of its common stock were issued and outstanding.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="ic40c99d6b0a04616bf00bfc233eced25_D20210228-20210228" decimals="INF" name="eols:StockIssuedDuringPeriodSharesLitigationSettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2NDE2MDQ_98e09eb6-f2a5-4627-ba49-75ac75801968">6,762,652</ix:nonFraction> shares of its common stock to Medytox pursuant to the Share Issuance Agreement. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="ibb11d4e5afdb4c27ae1e67ee48ded284_D20210325-20210325" decimals="INF" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2MzM5MDE_ff4708ce-89d3-4eed-ac5d-5646cc2975d8">3,136,869</ix:nonFraction> shares of its common stock to Daewoong in connection with the conversion of Daewoong Convertible Note. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Daewoong Convertible Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company completed a follow-on public offering and issued <ix:nonFraction unitRef="shares" contextRef="i87285d3792f541dfb0b8bd76edc9ed8b_D20210401-20210430" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2MzQxMjQ_ccb1b13e-aad9-4ff9-b24e-3a5ccd3de6fb">10,350,000</ix:nonFraction> shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i369b3df3ec04419fa040ca2ec1d798db_D20210401-20210430" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2MzQyNTQ_fe771b96-89b8-4c61-b639-ca1088a1fee2">1,350,000</ix:nonFraction> shares of common stock, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i581d900790a24282bf837c0e06b7b5f4_I20210430" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2MzQzMTA_7cfdb2f3-7f32-4acf-9d6d-08c5e316b8f3">9.50</ix:nonFraction> per share. The Company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i87285d3792f541dfb0b8bd76edc9ed8b_D20210401-20210430" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2MzQzNzY_52ae306a-8a73-424d-8326-b85ea46cdd15">92,426</ix:nonFraction> from the offering, after deducting underwriting discounts and commissions, excluding other offering expenses.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8220;At-the-market&#8221; Offerings of Common Stock</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2021, the Company entered into an &#8220;at-the-market&#8221; sales agreement with SVB Leerink LLC (the &#8220;Sales Agent&#8221;) pursuant to which shares of the Company&#8217;s common stock may be sold from time to time for aggregate gross proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="i63f4e91998714dab927a5acf4a92ddb8_D20210326-20210326" decimals="-3" name="eols:SaleOfStockMaximumConsiderationReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzgyNDYzMzcyMjE0MTY_c008a1ce-163b-4fa2-b597-28c52c1dacd1">75,000</ix:nonFraction> (the &#8220;ATM Program&#8221;). The Sales Agent is entitled to compensation, at a commission rate equal to <ix:nonFraction unitRef="number" contextRef="i75496e7d4351422aa519e8a590bc554b_I20210326" decimals="3" name="eols:SaleOfStockCommissionPaymentUponGrossProceedsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzgyNDYzMzcyMjE0MjU_c4416aed-3f87-4cc0-af6f-e05ac95b0ba6">3.0</ix:nonFraction>% of the gross proceeds from sales of the Company&#8217;s common shares under the ATM Program.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, the Company sold a total of <ix:nonFraction unitRef="shares" contextRef="i19668eba2a9a432cbae4ec0e6254aa0e_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2NDA0OTg_e079cc17-af93-4f78-8118-b0b1cd869fbc">934,367</ix:nonFraction> shares of its common stock pursuant to the ATM Program at the prevailing market prices for total net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i8b39b85b47cc450fbde4206b76345039_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2NDA1MDI_33c67f7a-5a82-4d1d-8307-187e07a7790b">10,910</ix:nonFraction> and paid total commissions of $<ix:nonFraction unitRef="usd" contextRef="i191b278dcfec47f3972561e051202c15_D20210101-20211231" decimals="-3" name="eols:SaleOfStockCommissionPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzM4NDgyOTA3MTAzMDM_dde0d6e5-f141-421e-aa5e-f4e870267612">337</ix:nonFraction> to the Sales Agent.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Omnibus Incentive Plan and Stock-based Compensation Allocation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2017 Omnibus Incentive Plan (the &#8220;Plan&#8221;) provides for the grant of incentive options to employees of the Company, and for the grant of non-statutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&#8217;s officers, directors, consultants and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is <ix:nonFraction unitRef="shares" contextRef="ic142d9a5a6964798b2bc095cf05edeb8_I20171121" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwMDk_bf2ace62-a168-496b-8677-0bac18c673d5">4,361,291</ix:nonFraction> shares, plus an annual increase on each anniversary of November 21, 2017 equal to <ix:nonFraction unitRef="number" contextRef="i0caf9e9143e34777b8ae279b103a9da1_D20171121-20171121" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTQ_72553e1e-d3d0-418c-bdd8-c8c1ab8f2d1b">4.0</ix:nonFraction>% of the total issued and outstanding shares of the Company&#8217;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&#8217;s board of directors). On November 21, 2021 and 2020, an additional <ix:nonFraction unitRef="shares" contextRef="i517a2340d6ac4cfb8363af7585980dcf_I20211121" decimals="INF" name="eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEzMzA_4731c7d4-b071-498e-8203-5e1b1b9af747">2,223,080</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i7869351f7bde4260a08aa49ce4ef2470_I20201121" decimals="INF" name="eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEzNDQ_7db6fe88-849e-4b53-816f-a981edc8c5a5">1,349,969</ix:nonFraction> shares, respectively, were reserved under the evergreen provision of the Plan. As of December&#160;31, 2021, the Company had an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE0Nzg_3035e4d2-461f-4aec-b20c-32e0cffcde6c">3,361,247</ix:nonFraction> shares of its common stock available for future issuance under the Plan.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i86795e0e16ac4a8faae26ae317d60912" continuedAt="i48f33cf9b0a24c41afb8235c06524cb9"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Award Activity and Balances</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options are granted at exercise prices based on the Company&#8217;s common stock price on the date of grant. The options and RSU grants generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE3MzI_fb117ad8-2568-44c6-bb64-c540497d2484">one</span>-to <ix:nonNumeric contextRef="id708d9ed50e54617af7629252e0fa1c6_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU4NjQ_e4c7bd23-78d4-4c7c-ae8b-ee1b206d4ae1">four-year</ix:nonNumeric> period. There have been <ix:nonFraction unitRef="shares" contextRef="iecdda6aa05b04bfcab114de1346b4b98_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE3NzA_067f6e3a-a3c4-4939-a5fb-4c6e1de311c3"><ix:nonFraction unitRef="shares" contextRef="ifd29a6c578714db49b385b4f9e60b606_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE3NzA_1dccebcf-f089-4ec9-b00a-2f093df771bd"><ix:nonFraction unitRef="shares" contextRef="i8ef5563a248f47b9b87ca621a1f1eed8_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE3NzA_dd8e157b-a378-4f53-bed4-819eb7ba47f0"><ix:nonFraction unitRef="shares" contextRef="i1da74bb1ddc84684bf5d405096cdedeb_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE3NzA_e2a529f5-5619-44b4-bbb1-f5e6744acb8e">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> awards granted with performance conditions or market conditions for the periods presented. The options have a contractual term of <ix:nonNumeric contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE5MDM_bf95c68a-4d11-4a0b-a0d8-3ea5cb1900be">ten years</ix:nonNumeric>. The fair value of options is estimated using the Black&#8209;Scholes option pricing model, which has various inputs, including the grant date common share price, exercise price, risk&#8209;free interest rate, volatility, expected life and dividend yield. The change of any of these inputs could significantly impact the determination of the fair value of the Company&#8217;s options as well as significantly impact its results of operations. The fair value of RSU grants is determined at the grant date based on the common share price. The Company records stock-based compensation expense net of actual forfeitures when they occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant assumptions used in the Black-Scholes option-pricing are as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company has limited data regarding company&#8209;specific historical or implied volatility of its share price. Consequently, the Company estimates its volatility based on the average historical volatility of the stock price from a set of peer companies and its own stock performance, since our shares do not have sufficient trading history. Management considers factors such as stage of life cycle, competitors, size, market capitalization and financial leverage in the selection of similar entities.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The expected term represents the period of time in which the options granted are expected to be outstanding. The Company estimates the expected term of options with consideration of vesting date, contractual term, and historical experience. The expected term of &#8220;plain vanilla&#8221; options is estimated based on the midpoint between the vesting date and the end of the contractual term under the simplified method permitted by the SEC implementation guidance. The weighted&#8209;average expected term of the Company&#8217;s options is approximately <ix:nonNumeric contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" name="eols:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzM2NDQ_b1349f70-b1e8-4918-bd7a-db196f4625c9">six years</ix:nonNumeric>.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk&#8209;Free Rate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The risk&#8209;free interest rate is selected based upon the implied yields in effect at the time of the option grant on U.S. Treasury zero&#8209;coupon issues with a term approximately equal to the expected life of the option being valued.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dividends.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company does not anticipate paying cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield rate of <ix:nonFraction unitRef="number" contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzQwNTE_7fe7c5e5-8f63-4542-aed9-9219d0c0bdee">zero</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU4NTc_feedcadd-a3b9-48ae-a640-a2e39f4c8de4" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-averages for assumptions used in determining the fair value of stock options granted were as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo1N2ZiNjY3ZjM4OTM0YzhkYTMzOTBmMjA3ZGY4MjRhYS90YWJsZXJhbmdlOjU3ZmI2NjdmMzg5MzRjOGRhMzM5MGYyMDdkZjgyNGFhXzItMS0xLTEtMjQ2OTc_0785c25e-8581-47cb-933d-53474c3ab710">78.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo1N2ZiNjY3ZjM4OTM0YzhkYTMzOTBmMjA3ZGY4MjRhYS90YWJsZXJhbmdlOjU3ZmI2NjdmMzg5MzRjOGRhMzM5MGYyMDdkZjgyNGFhXzItMy0xLTEtMjQ2OTc_63fc07c2-8a67-42d7-bba4-f5e411ae2649">61.2</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo1N2ZiNjY3ZjM4OTM0YzhkYTMzOTBmMjA3ZGY4MjRhYS90YWJsZXJhbmdlOjU3ZmI2NjdmMzg5MzRjOGRhMzM5MGYyMDdkZjgyNGFhXzMtMS0xLTEtMjQ2OTc_fb8f2bd7-816d-4fe4-b874-da3942dd2daa">1.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo1N2ZiNjY3ZjM4OTM0YzhkYTMzOTBmMjA3ZGY4MjRhYS90YWJsZXJhbmdlOjU3ZmI2NjdmMzg5MzRjOGRhMzM5MGYyMDdkZjgyNGFhXzMtMy0xLTEtMjQ2OTc_799aa29d-625a-4aa2-a4d8-6c938d49f0fb">1.4</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo1N2ZiNjY3ZjM4OTM0YzhkYTMzOTBmMjA3ZGY4MjRhYS90YWJsZXJhbmdlOjU3ZmI2NjdmMzg5MzRjOGRhMzM5MGYyMDdkZjgyNGFhXzQtMS0xLTEtMjQ2OTc_48ef3528-0633-4379-ba80-ec370d84e600">6.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo1N2ZiNjY3ZjM4OTM0YzhkYTMzOTBmMjA3ZGY4MjRhYS90YWJsZXJhbmdlOjU3ZmI2NjdmMzg5MzRjOGRhMzM5MGYyMDdkZjgyNGFhXzQtMy0xLTEtMjQ2OTc_ff504856-d5ea-4140-ba91-3ceb1b847d0c">6.14</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo1N2ZiNjY3ZjM4OTM0YzhkYTMzOTBmMjA3ZGY4MjRhYS90YWJsZXJhbmdlOjU3ZmI2NjdmMzg5MzRjOGRhMzM5MGYyMDdkZjgyNGFhXzUtMS0xLTEtMjQ2OTc_6634a732-1a15-4755-b3f3-dbb94074357a">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo1N2ZiNjY3ZjM4OTM0YzhkYTMzOTBmMjA3ZGY4MjRhYS90YWJsZXJhbmdlOjU3ZmI2NjdmMzg5MzRjOGRhMzM5MGYyMDdkZjgyNGFhXzUtMy0xLTEtMjQ2OTc_c96677ac-9543-4fe0-9447-c6aa8f40a2d0">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i48f33cf9b0a24c41afb8235c06524cb9" continuedAt="i70e8eb939b694ef4a52dc14d10098503"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU4NTg_b362b1c8-6b56-4cc3-9707-1bbb6473dbb5" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the Plan for the year ended December 31, 2021 and 2020, is presented below:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:41.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.784%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Terms (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie061e2ccf1e04536b767f55687880f70_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzktMS0xLTEtMjQ2OTc_685f1c9d-2aa1-4a4c-aacd-f2ba29b956c9">3,977,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie061e2ccf1e04536b767f55687880f70_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzktMy0xLTEtMjQ2OTc_8d8cac20-3875-4f95-a2a5-25a5e43ffb0f">14.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia803156cd5cc4477b4ba2e43f8f8880d_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzktNS0xLTEtMjQ2OTc_74d73774-15a0-46fa-bed0-0eb80d62d946">8.51</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie061e2ccf1e04536b767f55687880f70_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzktNy0xLTEtMjQ2OTc_9614ca21-195c-4484-af93-2510c0d6fb0a">7,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzEwLTEtMS0xLTI0Njk3_aff63884-49f4-436f-99ab-e8f6977b22ef">1,322,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzEwLTMtMS0xLTI0Njk3_5ca80612-81b0-4e72-ba17-5b97fb04721b">8.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzExLTEtMS0xLTI0Njk3_c5a7c468-4e6f-49c5-8b9a-bb9e89af39d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzExLTMtMS0xLTI0Njk3_cffa8957-a8da-4825-b67a-e0c240239147"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzEyLTEtMS0xLTI0Njk3_74f8c4c3-b7c6-4db4-8496-eca1eb4a5758">892,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzEyLTMtMS0xLTI0Njk3_c781689c-6211-482d-8590-9c6cc64fd2d3">15.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1328d543a76b4257a15411d3fc978c8d_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzEzLTEtMS0xLTI0Njk3_a5837f47-b59d-4f8b-beb9-dc3c73eb0cd0">4,407,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1328d543a76b4257a15411d3fc978c8d_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzEzLTMtMS0xLTI0Njk3_f9b09dc4-2e1b-4bb9-938a-2bbe0a69d6d5">12.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzEzLTUtMS0xLTI0Njk3_0a220dbc-02dd-4d7f-af5e-beef0e7543e4">7.66</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1328d543a76b4257a15411d3fc978c8d_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzEzLTctMS0xLTI0Njk3_81e84da3-82ef-4821-8106-b8c9a94fa1a2">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE0LTEtMS0xLTMyMjA5_090dd20c-2c6f-4b55-b6cd-307aa4a386e4">357,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE0LTMtMS0xLTM0MzU4_f648b7ed-9518-4664-94eb-8b12722119ab">9.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE1LTEtMS0xLTMyMjA5_c390393d-a2be-4152-8c41-8f2a1dd158fe">99,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE1LTMtMS0xLTM0MzY2_8d4ec85e-eaaa-4a2e-b380-a5d561a24514">9.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE2LTEtMS0xLTMyMjA5_95277614-54a6-4b87-a69b-4ca352f83b36">742,902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE2LTMtMS0xLTM0MzY2_38342790-49e1-4651-aaa1-91b51d9a4014">16.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE3LTEtMS0xLTMyMjEx_d6871710-5e01-41e2-bf4a-f0526894b26f">3,922,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE3LTMtMS0xLTMyMjE2_7ef3484a-0242-4950-9779-6743784ccae0">11.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE3LTUtMS0xLTMyMjE4_d87cd6e6-f007-4981-9616-7c58a47a5c11">7.10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE3LTctMS0xLTMyMjIw_a1e05aef-2277-4431-aef0-4038aaeff4bc">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE0LTEtMS0xLTI0Njk3_2aab1567-c47e-462a-af1a-30d727611b79">2,316,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE0LTMtMS0xLTI0Njk3_6d0797fe-9931-4a44-b70c-eba953b4d10f">11.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE0LTUtMS0xLTI0Njk3_10833fd8-58dd-4193-9801-f2885b99d95b">6.67</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE0LTctMS0xLTI0Njk3_cd977c43-1bc0-4a0c-b9e1-163af47a044a">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE1LTEtMS0xLTI0Njk3_73579d32-747f-4255-b64d-28740d45878b">3,922,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE1LTMtMS0xLTI0Njk3_c1deee7b-9618-497b-80c2-370ea92cc225">11.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE1LTUtMS0xLTI0Njk3_1674a06f-4b92-4904-8c27-8621a9ec13c0">7.10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE1LTctMS0xLTI0Njk3_67cade09-ffd6-4151-bd2c-8bcecb1cf71e">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of outstanding and exercisable options represents the excess of the fair market value of our common stock over the exercise price of underlying options as of&#160;December&#160;31, 2021 and 2020. The total intrinsic value of options exercised during the year ended December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2NDE1MDI_53ae9a07-0278-4531-bdbe-cb62a928a886">200</ix:nonFraction>. There were <ix:nonFraction unitRef="shares" contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzYwNDczMTM5NjY2MDk_69f1fdf3-2d94-4fb2-a276-1ea94836aa6b">no</ix:nonFraction> options exercised during the year ended December&#160;31, 2020. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, the Company recorded expenses related to stock options of $<ix:nonFraction unitRef="usd" contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzQ2NTU_f1b8ca53-d308-4b44-b8db-3c6472a846f2">5,302</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzQ2NjI_031c2416-01bc-4485-9a5e-8aadd54331a0">7,968</ix:nonFraction>, respectively. As of&#160;December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzQ3MDA_ed2950e2-97ef-4b57-92cb-6d95462bb53e">6,358</ix:nonFraction> of total unrecognized compensation cost, net of actual forfeitures, related to stock option-based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&#160;<ix:nonNumeric contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzQ5MjM_6b3fa762-dc29-42ac-9c90-c6bb0dd92710">1.68</ix:nonNumeric> years. </span></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU4NjA_68f85bc4-bcc1-4e4f-8f8c-e62f7105661c" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity under the Plan for the year ended December 31, 2021 and 2020, is presented below:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42f7ff0b06244a60a0750a47b3a469a0_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzgtMS0xLTEtMjQ2OTc_c5e9a8a6-c28e-4a4e-83ec-1cc87dc95605">229,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i42f7ff0b06244a60a0750a47b3a469a0_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzgtMy0xLTEtMjQ2OTc_b86b01df-c44e-4cf6-b4e8-ba2e0a443490">15.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzktMS0xLTEtMjQ2OTc_dfff72a9-586d-426c-84aa-79f5ad856f96">1,301,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzktMy0xLTEtMjQ2OTc_3fbac9bf-c1c0-4628-99f1-f8794a7194ae">5.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzEwLTEtMS0xLTI0Njk3_5bdbfa77-5ab4-4c0d-b7eb-e124d6963822">186,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzEwLTMtMS0xLTI0Njk3_2490cb8f-93cd-4065-8433-639cabfe3af4">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzExLTEtMS0xLTI0Njk3_7ea18fb6-e61f-4d69-84f1-d7d9ff1cdff0">170,698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzExLTMtMS0xLTI0Njk3_45da0f30-592b-4414-be51-15041b64bfd4">7.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic78866655f1e4fb7a2d18ed23eaca432_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzEyLTEtMS0xLTI0Njk3_e0ec1200-66e8-44e8-b2e4-9cafcacd9af6">1,173,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic78866655f1e4fb7a2d18ed23eaca432_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzEyLTMtMS0xLTI0Njk3_5142bd82-a045-490c-b0a3-ccc7ae808e0d">6.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzEzLTEtMS0xLTMyMjAw_98aec670-b86d-4eb1-8009-8023be8ca45c">1,850,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzEzLTMtMS0xLTMyMjA0_5160b265-b74b-4e43-a6c8-6e953d4d3c80">7.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzE0LTEtMS0xLTMyMjAw_3e32f1af-2f19-4a58-94b4-f59eb0e1a1e8">566,788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzE0LTMtMS0xLTMyMjA0_1d9b9126-4a68-4062-aaf3-6274227ce8fa">5.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzE1LTEtMS0xLTMyMjAw_82356123-e7b6-43f4-8970-1a52611d254e">530,729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzE1LTMtMS0xLTMyMjA0_f6cb12c8-ff90-40f4-9640-5ba59932b027">7.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88950351bb5049948706e070a4d2f1ba_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzE2LTEtMS0xLTMyMTk4_d62a51e2-61bd-421e-9593-05be5087c0f7">1,926,467</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88950351bb5049948706e070a4d2f1ba_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzE2LTMtMS0xLTMyMTk4_7c80661a-8c05-4988-a504-549f918a2811">8.06</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, the Company recorded expenses related to restricted stock units of $<ix:nonFraction unitRef="usd" contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzUwOTk_d29014d6-8f25-4d2c-b83b-a21b15b7bad6">4,274</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzUxMDY_ce2bad86-4861-4a91-8660-5154824a77dc">2,615</ix:nonFraction>, respectively. Total fair value of RSUs vested during the years ended December 31, 2021 and 2020 was </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i70e8eb939b694ef4a52dc14d10098503" continuedAt="i618bae55c36a487fbe7d11d57a031fd9"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzUxODE_97aec235-fb69-45e3-a109-cd1581a50a7e">5,892</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzUxODg_aaaddcd1-9cac-4967-8cdf-d4215b28ac77">1,980</ix:nonFraction>, respectively. As of&#160;December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i88950351bb5049948706e070a4d2f1ba_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzUyMjY_de22436a-1c85-4a3a-9408-aedad5de05b2">11,768</ix:nonFraction> of total unrecognized compensation cost, net of actual forfeitures, related to RSU-based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&#160;<ix:nonNumeric contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU0NDA_d722d8c2-be90-4916-9f56-ac88bc3675aa">2.87</ix:nonNumeric> years. </span></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU4Njc_26e1dc0f-785a-47a1-ba93-33202329d687" escape="true"><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense arising from the above Plan:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb1c0ae2c17f459f9a60df92e9ad83ba_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTpkMjU5OTY3MjAwMjA0ZGExOGI2NWZiYjQzZjk5ZGMyYS90YWJsZXJhbmdlOmQyNTk5NjcyMDAyMDRkYTE4YjY1ZmJiNDNmOTlkYzJhXzItMS0xLTEtMjQ2OTc_44c281ac-cf26-4dda-abfc-97b4d0c80d2b">9,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b758b9624b4b0996306bc2eeaddce7_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTpkMjU5OTY3MjAwMjA0ZGExOGI2NWZiYjQzZjk5ZGMyYS90YWJsZXJhbmdlOmQyNTk5NjcyMDAyMDRkYTE4YjY1ZmJiNDNmOTlkYzJhXzItMy0xLTEtMjQ2OTc_6b4356bf-9ae5-43c4-ad3d-71180dbc0592">10,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i422b9466ee0c476e8729e37ee5d9e9d1_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTpkMjU5OTY3MjAwMjA0ZGExOGI2NWZiYjQzZjk5ZGMyYS90YWJsZXJhbmdlOmQyNTk5NjcyMDAyMDRkYTE4YjY1ZmJiNDNmOTlkYzJhXzMtMS0xLTEtMjQ2OTc_0a6b357f-7bb3-4be9-bf65-f9fb69a6d90a">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68cbcb58dbd347d186d56f67bdc0d88b_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTpkMjU5OTY3MjAwMjA0ZGExOGI2NWZiYjQzZjk5ZGMyYS90YWJsZXJhbmdlOmQyNTk5NjcyMDAyMDRkYTE4YjY1ZmJiNDNmOTlkYzJhXzMtMy0xLTEtMjQ2OTc_47044bab-a7e5-4424-ac24-dac218ca518c">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTpkMjU5OTY3MjAwMjA0ZGExOGI2NWZiYjQzZjk5ZGMyYS90YWJsZXJhbmdlOmQyNTk5NjcyMDAyMDRkYTE4YjY1ZmJiNDNmOTlkYzJhXzQtMS0xLTEtMjQ2OTc_f0bc4dd9-6f09-4790-9afc-05a833331118">9,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTpkMjU5OTY3MjAwMjA0ZGExOGI2NWZiYjQzZjk5ZGMyYS90YWJsZXJhbmdlOmQyNTk5NjcyMDAyMDRkYTE4YjY1ZmJiNDNmOTlkYzJhXzQtMy0xLTEtMjQ2OTc_e90fb2db-e851-49ad-864d-37ef7c51c790">10,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt"><ix:continuation id="i618bae55c36a487fbe7d11d57a031fd9" continuedAt="i7e1655e4a78c400a8b394ec40524f152"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during the years ended December 31, 2021 and 2020, the Company capitalized $<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="eols:AllocatedShareBasedCompensationExpenseCapitalized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU2MDA_c3f9684d-501b-4394-851e-2681d274da6e">63</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="eols:AllocatedShareBasedCompensationExpenseCapitalized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU2MDg_7e5a93f6-de25-40ae-bdf7-1fa1ae4c9993">21</ix:nonFraction>, respectively, of stock-based compensation expense in capitalized software. Capitalized software is a component of intangible assets and is presented in the accompanying balance sheets. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7e1655e4a78c400a8b394ec40524f152"> for capitalized software information.</ix:continuation> </span></div><div id="i77038361ec4447b8be22639fec3c691b_1474"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11.<ix:continuation id="ie7ff6cb152f74f8493b1f7051cbae611" continuedAt="iad132a8abcbc4dc7b9cb6b5deb6ea0f5"> Medytox/Allergan Settlement Agreements and Daewoong Arrangement</ix:continuation></span></div><ix:continuation id="iad132a8abcbc4dc7b9cb6b5deb6ea0f5" continuedAt="ia129f73622ed4e7487d754bce9dd5c91"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medytox/Allergan Settlement Agreements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Settlement Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company, Allergan and Medytox entered into a Settlement and License Agreement (the &#8220;U.S. Settlement Agreement&#8221;), pursuant to which, among other things: (i) Allergan and Medytox agreed to file a petition requesting the remedial orders related to the ITC Action be rescinded with respect to the Company; (ii) Medytox agreed to dismiss substantially similar litigation in California against the Company; (iii) the Company, on the one hand, and Medytox and Allergan, on the other hand, agreed to mutually release certain claims they may have against one another and their respective affiliates, (iv) Allergan and Medytox granted to the Company and its agents a license to manufacture and commercialize certain products identified in the U.S. Settlement Agreement, including Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Licensed Products&#8221;), in the United States during the 21 month period that, pursuant to the ITC Action, the Company was restricted from, among other things, selling, marketing, or promoting such imported Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States (the &#8220;Restricted Period&#8221;); (v) the Company agreed to pay to Allergan and Medytox $<ix:nonFraction unitRef="usd" contextRef="i258260be7e354c3dabf4d4df2ee981e1_I20210218" decimals="-3" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjI5MDk0_49e645b8-8d84-4ec5-bdd4-b3dbc549f458">35,000</ix:nonFraction> in multiple payments over <ix:nonNumeric contextRef="ia307b0175e9a4f089eff6272a567b599_D20210218-20210218" name="eols:LossContingencySettlementAgreementPaymentTerms" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjI5MTI0_6d5ab27c-6fbc-4f63-955b-e1a8d93251f4">two years</ix:nonNumeric>, of which the Company paid the first cash payment of $<ix:nonFraction unitRef="usd" contextRef="i7e4a414b331e4768a456b40889b5bf16_D20210701-20210930" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjI5MTgx_5f19366a-3a61-489a-bb51-a026c46dfb09">15,000</ix:nonFraction> in the third quarter of 2021 and the second payment of $<ix:nonFraction unitRef="usd" contextRef="iec7e63cb81e2460c81caf30e8a3ecb3e_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8zODQ4MjkwNzA3MTM4_b83f8346-042b-4256-91ee-3c2029c8cfab">15,000</ix:nonFraction> in the first quarter of 2022; and (vi) during the Restricted Period, the Company agreed to pay to Allergan and Medytox certain confidential royalties on the sale of Licensed Products, calculated on dollar amount per vial sold of Licensed Products by or on behalf of the Company in the United States.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ROW Settlement Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company and Medytox entered into a Settlement and License Agreement (the &#8220;ROW Settlement Agreement&#8221; and, together with the U.S. Settlement Agreement, the &#8220;Medytox/Allergan Settlement Agreements&#8221;), pursuant to which, among other things: (i) the Company and Medytox agreed to mutually release certain claims they may have against one another and their respective affiliates; (ii) Medytox granted to the Company and its agents a license to manufacture and commercialize the Licensed Products, in Canada, the European Union, Switzerland, member countries and cooperating countries of the European Economic Area, Russia, certain members of the Commonwealth of Independent States, South Africa, Australia and Japan (the &#8220;ROW Territories&#8221;) during the Restricted Period; (iii) Medytox granted to the Company and its agents a fully paid up license to manufacture and commercialize the Licensed Products in the ROW Territories and the United States from the end of the Restricted Period (the &#8220;Medytox License Period&#8221;); (iv) the Company and Medytox agreed to enter into the Share Issuance Agreement (as defined below) pursuant to which the Company issued <ix:nonFraction unitRef="shares" contextRef="ic40c99d6b0a04616bf00bfc233eced25_D20210228-20210228" decimals="INF" name="eols:StockIssuedDuringPeriodSharesLitigationSettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjM3NjI4_98e09eb6-f2a5-4627-ba49-75ac75801968">6,762,652</ix:nonFraction> shares (the &#8220;Settlement Shares&#8221;) of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i258260be7e354c3dabf4d4df2ee981e1_I20210218" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjMwNzY0_9947b5a8-0ab6-4c0c-a23a-0a10380a632e">0.00001</ix:nonFraction> per share, to Medytox; (v) the Company and Medytox agreed to enter into the Registration Rights Agreement (as defined below), pursuant to which the Company granted certain registration rights to Medytox with respect to the Settlement Shares; (vi) during the Restricted Period, the Company agreed to pay Medytox a confidential low-double digit royalty on net sales of the Licensed Products sold by or on behalf of the Company in the ROW Territories; and (vii) during the Medytox License Period, the Company </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="ia129f73622ed4e7487d754bce9dd5c91" continuedAt="i45e9858558734ae8a677ea4bf3a36006"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreed to pay Medytox a confidential mid-single digit royalty percentage on net sales of the Licensed Products sold by or on behalf of the Company in the United States and the ROW Territories.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share Issuance Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the ROW Settlement Agreement, the Company and Medytox entered into a Share Issuance Agreement effective February 18, 2021 (the &#8220;Share Issuance Agreement&#8221;). Pursuant to the Share Issuance Agreement and subject to the terms and conditions set forth therein, among other things, the Company issued to Medytox the Settlement Shares to enter into the ROW Settlement Agreement and in consideration for Medytox&#8217;s representations, warranties, and other agreements set forth in the Share Issuance Agreement. The Settlement Shares are subject to contractual restrictions on transfer that, subject to certain limited exceptions such as transfers to affiliates, prevented Medytox from transferring any shares of common stock prior to February 16, 2022 and, thereafter, prohibit Medytox from transferring more than <ix:nonFraction unitRef="number" contextRef="i58d3338bb29342a7bea51d1b86c744ea_I20230915" decimals="2" name="eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjMyMzI4_ef714d71-05e2-4b3c-ab55-43a6f1b3179e">25</ix:nonFraction>% of the shares it holds prior to September 16, 2023, more than <ix:nonFraction unitRef="number" contextRef="i9886998085bb48b9b58c8a53127543d0_I20240915" decimals="2" name="eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjMyMzk0_feb505de-5fe2-40e1-a59b-c16b5282dd05">50</ix:nonFraction>% of the shares it holds prior to September 16, 2024 and more than <ix:nonFraction unitRef="number" contextRef="ib98c7c392d2f4eaf8e8ab779dee845dd_I20250915" decimals="2" name="eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjMyNDYz_be4317e6-d006-4d9a-a122-2f9211537461">75</ix:nonFraction>% of the shares it holds prior to September 16, 2025, with such contractual restrictions terminating on September 16, 2025.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registration Rights Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the ROW Settlement Agreement, the Company and Medytox also entered into a Registration Rights Agreement effective February 18, 2021 (the &#8220;Registration Rights Agreement&#8221;). Pursuant to the Registration Rights Agreement, among other things, the Company agreed, after March 31, 2022, (i) to comply with certain requests by Medytox to register for sale, under the Securities Act, the Settlement Shares, and (ii) to include the Settlement Shares in certain registrations by the Company of its securities for sale under the Securities Act, to the extent requested by Medytox, in each case subject to certain customary conditions, exceptions and limitations as set forth in the Registration Rights Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Medytox&#8217;s registration rights under the Registration Rights Agreement will terminate at such time that Medytox is able to sell all of the Settlement Shares over a three-month period, or less, pursuant to an exemption to registration under the Securities Act.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daewoong Arrangement</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Daewoong Arrangement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, the Company and Daewoong entered into a Confidential Settlement and Release Agreement (the &#8220;Daewoong Arrangement&#8221;), pursuant to which, among other things: (i) Daewoong agreed to (a) pay to the Company an amount equal to $<ix:nonFraction unitRef="usd" contextRef="i002a56e0c1ec4c04b5999635912fcdc8_D20210323-20210323" decimals="-3" name="us-gaap:LongTermPurchaseCommitmentAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjM0NTI1_c3e66004-7e9c-4813-ac28-f1c0786042cf">25,500</ix:nonFraction>, which the Company received in April 2021, (b) pay certain legal fees incurred by the Company&#8217;s litigation counsel in connection with its defense of the ITC Action (including any appeal of the resulting remedial orders), (c) cancel all remaining milestone payments, totaling $<ix:nonFraction unitRef="usd" contextRef="i002a56e0c1ec4c04b5999635912fcdc8_D20210323-20210323" decimals="-3" name="eols:MilestonePaymentInConnectionWithAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjM0ODAz_fa63c3cf-0d15-41aa-b36b-c884b1befff9">10,500</ix:nonFraction> in aggregate, and (d) reimburse the Company certain amounts (calculated on a dollar amount per vials sold basis in the United States) for sales of certain products with respect to which the Company is required to pay Medytox and Allergan royalties pursuant to the U.S. Settlement Agreement; and (ii) the Company agreed to (a) release, on behalf of itself and certain of its affiliates and representatives, certain claims they may have against Daewoong related to the allegations made in or the subject matter of the Medytox/Allergan Actions, or any orders, remedies and losses resulting from the Medytox/Allergan Actions, and (b) coordinate with Daewoong on certain matters related to the Medytox/Allergan Actions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conversion Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Daewoong Arrangement, the Company and Daewoong also entered into a Convertible Promissory Note Conversion Agreement (the &#8220;Conversion Agreement&#8221;), pursuant to which, among other things, (i) the principal balance under the Daewoong Convertible Note, together with all accrued and unpaid interest thereon, in the amount of $<ix:nonFraction unitRef="usd" contextRef="ib67b7815bf86448c836c0674ab2cd400_I20210323" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjM1OTAz_6ee35dac-3819-433a-b8c5-f9f4afc7b09f">40,779</ix:nonFraction> was converted into <ix:nonFraction unitRef="shares" contextRef="ibb11d4e5afdb4c27ae1e67ee48ded284_D20210325-20210325" decimals="INF" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjM1OTY5_ff4708ce-89d3-4eed-ac5d-5646cc2975d8">3,136,869</ix:nonFraction> shares of Common Stock at the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib67b7815bf86448c836c0674ab2cd400_I20210323" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjM3ODc1_dbce3a2c-e214-4651-922f-8d8de9d859dc">13.00</ix:nonFraction> per share (the &#8220;Conversion Shares&#8221;); and (ii) the Daewoong Convertible Note was deemed cancelled and satisfied in full in connection with such conversion.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the conversion, shares owned by Daewoong, together with its affiliates and attribution parties, did not exceed <ix:nonFraction unitRef="number" contextRef="i75469af343584e09847fb0027c3e78c7_D20210323-20210323" decimals="INF" name="eols:DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjM2MjU4_018d6157-51af-41ef-8082-39921928854d">9.99</ix:nonFraction>% of the Company&#8217;s then outstanding common shares immediately following such issuance, as required under the terms of the Daewoong Convertible Note. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i45e9858558734ae8a677ea4bf3a36006"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Daewoong Agreement Amendment</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Daewoong Arrangement, on March 23, 2021, the Company and Daewoong also entered into the Third Amendment to the Supply Agreement (the &#8220;Daewoong Agreement Amendment&#8221;). Pursuant to the Daewoong Agreement Amendment, the parties amended the Daewoong Agreement to (i) expand the territory within which the Company may distribute Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to certain countries in Europe, (ii) reduce the period of time with respect to which the Company is required to deliver binding forecasts to Daewoong; (iii) introduce certain limitations on Daewoong&#8217;s ability to convert the Company&#8217;s exclusive license for certain territories to a non-exclusive license in the event the Company fails to meet certain minimum purchase requirements for such territory; (iv) adjust the minimum purchase requirements and reduce the transfer price per vial of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> applicable to various territories, (v) require that any Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> supplied by Daewoong match certain shelf-life thresholds, and (vi) prohibit the Company from sharing certain confidential information of Daewoong with Medytox or its affiliates or representatives.</span></div></ix:continuation><div id="i77038361ec4447b8be22639fec3c691b_124"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjQvZnJhZzoyOGJmMWMyNGU2NDI0YTFmOTQ1YmVmYzJiZGVlNzZlNi90ZXh0cmVnaW9uOjI4YmYxYzI0ZTY0MjRhMWY5NDViZWZjMmJkZWU3NmU2XzE4OQ_8a23a722-c3c5-4d79-921a-4c417f5a2eaf" continuedAt="ifa895079ad3d4de094c3a2a2c55ac1fb" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifa895079ad3d4de094c3a2a2c55ac1fb">The Company maintains a defined contribution&#160;401(k) plan covering substantially all employees. Matching contributions totaled $<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjQvZnJhZzoyOGJmMWMyNGU2NDI0YTFmOTQ1YmVmYzJiZGVlNzZlNi90ZXh0cmVnaW9uOjI4YmYxYzI0ZTY0MjRhMWY5NDViZWZjMmJkZWU3NmU2XzE2Mg_ae0b96b8-ff76-4b88-b88c-d53521ab61e6">481</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjQvZnJhZzoyOGJmMWMyNGU2NDI0YTFmOTQ1YmVmYzJiZGVlNzZlNi90ZXh0cmVnaW9uOjI4YmYxYzI0ZTY0MjRhMWY5NDViZWZjMmJkZWU3NmU2XzE2OQ_788fbbab-0ba9-4f04-a609-642b3ddf4b88">524</ix:nonFraction>&#160;for the years ended December 31, 2021 and 2020, respectively.</ix:continuation></span></div><div id="i77038361ec4447b8be22639fec3c691b_127"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzYxMTQ_a75f91b9-ab26-47d6-8577-10919d9adb7f" continuedAt="i9cee5c8dd08941c4b8caeb7335f5d4b6" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="i9cee5c8dd08941c4b8caeb7335f5d4b6" continuedAt="i43ca528b64d9466eb01cbc135fb24f2e"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loss before income taxes was entirely generated from its U.S. operations. <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzYxMDc_42d8268b-ccef-408e-b3d0-d2a106be7181" continuedAt="ifea35e016dc74e4d96565258fd1adc27" escape="true">The current and deferred expense is as follows:</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><ix:continuation id="ifea35e016dc74e4d96565258fd1adc27"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzMtMS0xLTEtMjQ2OTc_f6dc0a8c-85db-4a38-b6be-ed841cd84dd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzMtMy0xLTEtMjQ2OTc_5397415a-2c76-4215-8127-76bacf5eb246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzQtMS0xLTEtMjQ2OTc_3e9e3b21-bf9b-4a8f-a276-9686c4327b97">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzQtMy0xLTEtMjQ2OTc_e37e3485-2d8a-483b-a444-c409934ca91a">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzYtMS0xLTEtMjQ2OTc_d86df0fc-a2e3-4e5b-aeff-6655eef11487">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzYtMy0xLTEtMjQ2OTc_6b300b04-444b-4228-8c5d-8421ec08288c">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred (benefit) provision:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzgtMS0xLTEtMjQ2OTc_6a7e541b-ac35-4ccb-98bd-d74abff8bce3">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzgtMy0xLTEtMjQ2OTc_c82039a0-be21-484a-bce9-4cbe6e5a8c66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzktMS0xLTEtMjQ2OTc_5ab380a0-9d4e-4038-aca3-7ea0fda9aabd">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzktMy0xLTEtMjQ2OTc_dedcceb0-fb96-4cb8-9748-20a1e5cab3f2">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred provision (benefit) </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzExLTEtMS0xLTI0Njk3_01d802b9-e6df-45c2-960a-3928c4ec152d">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzExLTMtMS0xLTI0Njk3_42d01d76-a1a1-4f11-a3ea-63f196afb092">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision (benefit) for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzEyLTEtMS0xLTI0Njk3_d0b9318b-f971-4d1f-91bb-97cb7162d1e0">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzEyLTMtMS0xLTI0Njk3_bf647c7f-0058-4d36-9698-222548554420">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has federal net operating loss (&#8220;NOL&#8221;) carryforwards of $<ix:nonFraction unitRef="usd" contextRef="if65ecdee742e445f89295c829f75efac_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzI0NA_8b816ad7-54e6-4575-8620-c09ba12472f2">273,776</ix:nonFraction>, of which $<ix:nonFraction unitRef="usd" contextRef="if65ecdee742e445f89295c829f75efac_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzI1Nw_8fc0abe9-da84-43b1-b0d4-9438e67d2b93">72,579</ix:nonFraction> will begin to expire in 2034. The federal NOLs generated in 2018 and in the subsequent years in the amount of $<ix:nonFraction unitRef="usd" contextRef="if65ecdee742e445f89295c829f75efac_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzM3MA_c2fc38bf-be0f-4871-8952-e94fac175d9e">201,197</ix:nonFraction> have an indefinite carryforward period. As of December&#160;31, 2021,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company has state NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="iff738c7de2844195a714ca1b57f846c6_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzQ2Ng_329818dc-6e9d-4431-bd4b-83ffec0acfa8">169,332</ix:nonFraction>, which will begin to expire in 2038. As of December&#160;31, 2021, the Company has federal research and development (&#8220;R&amp;D&#8221;) credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="iaa6947c0461b47158a26475a99eabf01_I20211231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzU5Nw_c7420ffa-2d4d-448b-8c9a-a3740b9667f1">2,929</ix:nonFraction>, which will begin to expire in 2034. The Company also has California R&amp;D credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="id4b16f01a5f7415687373739c3bf5523_I20211231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzY5Nw_e748c618-5ea5-41b4-a29b-3b03aeb9aafc">2,918</ix:nonFraction>, which has an indefinite carryforward period. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOL and the R&amp;D credit carryforwards generated by the Company in tax years ended February 11, 2018 and prior have been included in the consolidated and unitary income tax returns of Alphaeon Corporation (&#8220;Alphaeon&#8221;). After the Company left Alphaeon consolidated and unitary income tax group on February 11, 2018, the Company files its own standalone income tax returns. Deferred tax assets in the accompanying financial statements reflect the Company's standalone tax attributes that are reportable on its own income tax returns.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, if a company experiences a greater than 50 percentage point aggregate change in ownership of certain significant stockholders over a three-year period, utilization of its pre-change NOL carryforwards and R&amp;D credit carryforwards is subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state laws. The annual limitation generally is determined by multiplying the value of the Company&#8217;s stock at the time of such ownership change, subject to certain adjustments, by the applicable long-term tax-exempt rate. The annual limitations may </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i43ca528b64d9466eb01cbc135fb24f2e" continuedAt="i3d379db0d87940569c5bfa57eee74f5f"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result in the expiration of NOL and R&amp;D credit carryforwards before utilization and may be material. The Company has started but has not completed an analysis to determine whether its NOL and R&amp;D credits generated through December&#160;31, 2021 are likely to be limited by Section&#160;382 and 383. The Company anticipates that an ownership change as defined under Section&#160;382 may have occurred and that the resulting limitation would significantly reduce the Company&#8217;s ability to utilize its NOL and R&amp;D credit carryforwards before they expire. Additionally, future ownership changes under Section&#160;382 and 383 may also limit the Company's ability to fully utilize any remaining tax benefits. The Company&#8217;s net deferred income tax assets have been offset by a valuation allowance. Therefore, any resulting reduction to the Company&#8217;s NOL and R&amp;D credit carryforwards once the analysis is complete will be offset by a corresponding reduction of the valuation allowance and there would be no impact on the Company&#8217;s balance sheet, statement of operations, or cash flows.</span></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzYxMTc_8ba3c80e-15cb-47b8-b186-0ffe08b39a17" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred tax assets and liabilities were as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:57.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzMtMS0xLTEtMjQ2OTc_2bd8cadc-c448-4fef-85e0-6049163a3b2f">67,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzMtMy0xLTEtMjQ2OTc_1c1c41fa-95ac-444e-99a7-b88fcbc57573">60,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzQtMS0xLTEtMjQ2OTc_c555e9c1-39a2-4e27-993f-fcb9ec8f3fe5">2,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzQtMy0xLTEtMjQ2OTc_bf0d0f83-e6f8-4529-9747-7ddaa7b660aa">3,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other deferred assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzUtMS0xLTEtMjQ2OTc_7848fb99-4e55-471b-aa2e-553a6b9c7c38">2,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzUtMy0xLTEtMjQ2OTc_67a7d11c-d32f-450d-b200-1ee647dfa8ef">2,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzYtMS0xLTEtMjQ2OTc_96a250fd-799f-4baf-a10f-588053506630">4,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzYtMy0xLTEtMjQ2OTc_220e781a-eda9-4c54-955d-2f5a6a19fcfb">2,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="eols:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzctMS0xLTEtMjQ2OTc_b17a5e89-91d7-4bf2-a133-ebfeac8cc000">893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="eols:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzctMy0xLTEtMjQ2OTc_7a0e312f-df3a-4b7c-b178-96371db7fa09">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzgtMS0xLTEtMjQ2OTc_00c6ad5f-2442-408f-bbc9-c744d5e450bb">20,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzgtMy0xLTEtMjQ2OTc_b1f5b34e-2a56-4ae9-bb01-c3c680fe5dd4">21,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzEwLTEtMS0xLTI0Njk3_c084ea87-8dd2-4949-b8a1-d91c9fa6748f">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzEwLTMtMS0xLTI0Njk3_01231ded-44d0-429d-926b-b096b8f9ec40">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzExLTEtMS0xLTI0Njk3_883c1c76-d1f1-4a90-bdba-cb3a9c80052c">85,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzExLTMtMS0xLTI0Njk3_da7f7144-3c34-4b2d-a42f-b075351d931e">78,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzEyLTEtMS0xLTI0Njk3_409a40cd-c6a9-4e80-9395-3a9486417b70">12,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzEyLTMtMS0xLTI0Njk3_fd7d459b-d48f-4280-af4b-2e32cbdcf9a3">13,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE0LTEtMS0xLTI0Njk3_4d579acf-bf73-4248-8270-a99b2c8ba5b3">11,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE0LTMtMS0xLTI0Njk3_30abe92d-d566-4223-8348-69b033bacab9">12,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE1LTEtMS0xLTI0Njk3_b1ba59ae-0190-4229-9771-08c3fee60487">690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE1LTMtMS0xLTI0Njk3_98f1a9f4-f8b6-4d74-9b51-595653622039">873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE2LTEtMS0xLTI0Njk3_780b5d65-2628-4411-9a93-ea1b4a78e94d">192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE2LTMtMS0xLTI0Njk3_4a01a411-ee63-4c00-8eb4-1b458f6abc24">249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE3LTEtMS0xLTI0Njk3_25c57e01-d2b8-4d71-8529-9bc7ba434cc3">12,410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE3LTMtMS0xLTI0Njk3_d0f91215-7ac8-4285-a155-c43962f9aab8">13,362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income taxes</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE4LTEtMS0xLTI0Njk3_baaee1db-e832-4dc6-9280-a0c4d5dd3c29">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE4LTMtMS0xLTI0Njk3_3cbcf38c-2e02-450f-abe9-5acdda79a1ef">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzYxMTA_166f4c7e-017b-4db5-a6ca-1edc469725bc" continuedAt="i5a38f5fb2eb3459586c51ba5a88e87a7" escape="true">A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i3d379db0d87940569c5bfa57eee74f5f"><div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><ix:continuation id="i5a38f5fb2eb3459586c51ba5a88e87a7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:57.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzItMS0xLTEtMjQ2OTc_34d1473f-af86-460f-aaa3-930710596cb9">9,832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzItMy0xLTEtMjQ2OTc_cf9efdc5-8cb2-431d-9b88-fb4bb1d3269a">34,217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of Federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzMtMS0xLTEtMjQ2OTc_480b49e6-c596-4e83-aa3d-ad5b1d68e97e">1,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzMtMy0xLTEtMjQ2OTc_ca3e12c8-256e-4745-88be-74ad7a1ccfa0">7,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzUtMS0xLTEtMjQ2OTc_a62d871a-94c6-4f8c-a73b-e31cfdfe05f1">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzUtMy0xLTEtMjQ2OTc_503c13f6-b33e-4e7d-bf9f-5a087db271b2">513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meals and entertainment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzYtMS0xLTEtMjQ2OTc_f574edf4-ecc9-453a-9663-e9b570f56734">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzYtMy0xLTEtMjQ2OTc_4a67ef9a-6e45-44fa-9672-aa5ed430ddef">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzctMS0xLTEtMjQ2OTc_487f8b39-3f7f-413f-9ac2-aabb47f315c7">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzctMy0xLTEtMjQ2OTc_b950759b-9a31-4d7c-bdbf-e83e2cf6e336">242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers' compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="eols:EffectiveIncomeTaxRateReconciliationOfficersCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzgtMS0xLTEtMjQ2OTc_ea703a6c-b3f4-44b7-a710-f8273573f181">2,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="eols:EffectiveIncomeTaxRateReconciliationOfficersCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzgtMy0xLTEtMjQ2OTc_0a076daf-addf-4122-af92-0417f197a32a">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzktMS0xLTEtMjQ2OTc_dd825bba-84da-4f2f-be17-e66d87718b5c">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzktMy0xLTEtMjQ2OTc_4a38ed41-223e-4dd0-a1be-345590752874">616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzEwLTEtMS0xLTI0Njk3_5720a47f-4a0e-4745-ace1-aa41385dd84f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzEwLTMtMS0xLTI0Njk3_a17dc206-7b35-443f-84c7-36e2398facbc">147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory note - debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="eols:EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzExLTEtMS0xLTI0Njk3_2539da7c-fe29-4ab4-81a7-c42fd2557a94">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" sign="-" name="eols:EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzExLTMtMS0xLTI0Njk3_57feaabd-6e63-4b44-a819-67b19b2b7a18">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingenciesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzEyLTEtMS0xLTI0Njk3_e295e9aa-9fe7-445f-a902-ceea6a6062a7">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingenciesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzEyLTMtMS0xLTI0Njk3_21422a96-fc6e-444b-a8b2-864a81826c61">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzEzLTEtMS0xLTI0Njk3_5507a4b0-60c4-4cb8-869a-a1875e695dcb">7,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzEzLTMtMS0xLTI0Njk3_3da1248c-1595-4e36-8470-348f45d6f137">41,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzE0LTEtMS0xLTI0Njk3_b156f9f0-9431-439b-9146-6471de172fd2">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzE0LTMtMS0xLTI0Njk3_5f84bb76-6eb6-4d04-b2f0-fc0613068e17">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzYxMTE_49feedae-1607-4e01-be33-8b6cc31dc945" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:57.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTphNmUwNjc2MjM2NWE0NmY2OWQ2YWQyZGY0YzI0NGQyNy90YWJsZXJhbmdlOmE2ZTA2NzYyMzY1YTQ2ZjY5ZDZhZDJkZjRjMjQ0ZDI3XzItMS0xLTEtMjQ2OTc_db8d48da-f6fb-4bd7-beba-bf684fb98c8b">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb18fef826e14bf1b6a11208896433a1_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTphNmUwNjc2MjM2NWE0NmY2OWQ2YWQyZGY0YzI0NGQyNy90YWJsZXJhbmdlOmE2ZTA2NzYyMzY1YTQ2ZjY5ZDZhZDJkZjRjMjQ0ZDI3XzItMy0xLTEtMjQ2OTc_84bdc2d9-6e31-40b1-89c4-8651925e72ae">2,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTphNmUwNjc2MjM2NWE0NmY2OWQ2YWQyZGY0YzI0NGQyNy90YWJsZXJhbmdlOmE2ZTA2NzYyMzY1YTQ2ZjY5ZDZhZDJkZjRjMjQ0ZDI3XzQtMS0xLTEtMjQ2OTc_ff23f6fd-4c98-4714-8211-14fddbb3d991">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTphNmUwNjc2MjM2NWE0NmY2OWQ2YWQyZGY0YzI0NGQyNy90YWJsZXJhbmdlOmE2ZTA2NzYyMzY1YTQ2ZjY5ZDZhZDJkZjRjMjQ0ZDI3XzQtMy0xLTEtMjQ2OTc_3ea2d93b-9b81-4c97-91ff-65876259cabd">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTphNmUwNjc2MjM2NWE0NmY2OWQ2YWQyZGY0YzI0NGQyNy90YWJsZXJhbmdlOmE2ZTA2NzYyMzY1YTQ2ZjY5ZDZhZDJkZjRjMjQ0ZDI3XzctMS0xLTEtMjQ2OTc_023ef668-13b6-44b9-ba68-9134ad7ebdb0">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTphNmUwNjc2MjM2NWE0NmY2OWQ2YWQyZGY0YzI0NGQyNy90YWJsZXJhbmdlOmE2ZTA2NzYyMzY1YTQ2ZjY5ZDZhZDJkZjRjMjQ0ZDI3XzctMy0xLTEtMjQ2OTc_9d4c08e7-e171-4980-8440-c9a12022d294">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has considered the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above. The Company&#8217;s effective income tax rate would not be impacted if the unrecognized tax benefits are recognized. Additional amounts in the summary rollforward could impact the Company&#8217;s effective tax rate if it did not maintain a full valuation allowance on its net deferred tax assets. The Company does not expect its unrecognized tax benefits to change significantly over the next 12&#160;months.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There were <ix:nonFraction unitRef="usd" contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzQ3MDQ_b3e44634-5efb-4562-882d-853de0c373a2"><ix:nonFraction unitRef="usd" contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzQ3MDQ_e26246fd-411e-4f1b-adb1-6c3b66b17263">no</ix:nonFraction></ix:nonFraction> accrued interest and penalties associated with uncertain tax positions as of December&#160;31, 2021 and 2020. The Company&#8217;s tax returns for all years since inception are open for audit. </span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;). The Cares Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions which are expected to impact the Company&#8217;s financial statements include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. There was no material impact on its financial position, results of operations, or cash flows related to the CARES Act.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2020, the United States enacted the Consolidated Appropriations Act, which extended many of the benefits of the CARES Act that were scheduled to expire. The Company noted no material impacts due to the Consolidated Appropriations Act on its financial statements and related disclosures.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_130"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14. <ix:nonNumeric contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMzAvZnJhZzpiZDliZWY3MmZlZWQ0ODkxYjYxNmUwY2Q5ZjNkYjdkMS90ZXh0cmVnaW9uOmJkOWJlZjcyZmVlZDQ4OTFiNjE2ZTBjZDlmM2RiN2QxXzc5MDg_40c7c2fa-986f-4971-b940-a76f1574f182" continuedAt="idd86b7a8df8b445d8967614218fd4684" escape="true">Related Party Transactions</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idd86b7a8df8b445d8967614218fd4684" continuedAt="i3a3a2d052776450699f8afa1571ba6b2"> </ix:continuation></span></div><ix:continuation id="i3a3a2d052776450699f8afa1571ba6b2"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payment Obligations Related to the Acquisition by Alphaeon</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was acquired by Strathspey Crown Holdings Group, LLC (&#8220;SCH&#8221;) in 2013 and subsequently by its subsidiary, Alphaeon Corporation (&#8220;Alphaeon&#8221;), by means of a stock purchase agreement (&#8220;Stock Purchase Agreement&#8221;) pursuant to which Alphaeon assumed certain payment obligations related to the acquisition. On December 14, 2017, the Stock Purchase Agreement was amended (&#8220;Amended Stock Purchase Agreement&#8221;), and, as a result, effective upon the closing of the Company&#8217;s IPO, the Company assumed all of Alphaeon&#8217;s payment obligations under the Amended Stock Purchase Agreement. </span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended Stock Purchase Agreement, the payment obligations to the Evolus founders consists of: quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The obligations terminate in the quarter following the&#160;<ix:nonNumeric contextRef="i9a37e00a5294439283de4636c2dc8b56_D20171214-20171214" name="eols:RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMzAvZnJhZzpiZDliZWY3MmZlZWQ0ODkxYjYxNmUwY2Q5ZjNkYjdkMS90ZXh0cmVnaW9uOmJkOWJlZjcyZmVlZDQ4OTFiNjE2ZTBjZDlmM2RiN2QxXzEwOTk1MTE2NDYwNDM_204f8b17-5fd5-4b99-b594-2d4ec03659ce">10</ix:nonNumeric>-year anniversary of the first commercial sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the United States. In November 2021, we paid $<ix:nonFraction unitRef="usd" contextRef="ib72da45d6b9e4dfd9eaea3fd7a90255c_D20211101-20211130" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMzAvZnJhZzpiZDliZWY3MmZlZWQ0ODkxYjYxNmUwY2Q5ZjNkYjdkMS90ZXh0cmVnaW9uOmJkOWJlZjcyZmVlZDQ4OTFiNjE2ZTBjZDlmM2RiN2QxXzIwOTU_21f68e42-c4d7-4bac-b3a6-32c4c2839770">20,000</ix:nonFraction>&#160;to satisfy in full a promissory note that matured in November 2021. Under the Amended Stock Purchase Agreement, the Company recorded the fair value of all revised payment obligations owed to the Evolus Founders. See&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Fair Value Measurements and Short-Term Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for more information about the Company&#8217;s accounting thereof.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Related Party Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2021, the Company and Medytox entered into a Settlement and License Agreement (the &#8220;ROW Settlement Agreement&#8221; and, together with the U.S. Settlement Agreement, the &#8220;Medytox/Allergan Settlement Agreements&#8221;), pursuant to which, among other things, the Company issued <ix:nonFraction unitRef="shares" contextRef="ic40c99d6b0a04616bf00bfc233eced25_D20210228-20210228" decimals="INF" name="eols:StockIssuedDuringPeriodSharesLitigationSettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMzAvZnJhZzpiZDliZWY3MmZlZWQ0ODkxYjYxNmUwY2Q5ZjNkYjdkMS90ZXh0cmVnaW9uOmJkOWJlZjcyZmVlZDQ4OTFiNjE2ZTBjZDlmM2RiN2QxXzE2NDkyNjc0NTc5Mjg_98e09eb6-f2a5-4627-ba49-75ac75801968">6,762,652</ix:nonFraction> shares (the &#8220;Settlement Shares&#8221;) of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i258260be7e354c3dabf4d4df2ee981e1_I20210218" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMzAvZnJhZzpiZDliZWY3MmZlZWQ0ODkxYjYxNmUwY2Q5ZjNkYjdkMS90ZXh0cmVnaW9uOmJkOWJlZjcyZmVlZDQ4OTFiNjE2ZTBjZDlmM2RiN2QxXzE2NDkyNjc0NTgwMDY_9947b5a8-0ab6-4c0c-a23a-0a10380a632e">0.00001</ix:nonFraction> per share, to Medytox. See&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for more information about the Company&#8217;s accounting thereof.</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, the Company and Daewoong entered into a Confidential Settlement and Release Agreement (the &#8220;Daewoong Settlement Agreement&#8221;) and a Convertible Promissory Note Conversion Agreement (the &#8220;Conversion Agreement&#8221;). Pursuant to the Conversion Agreement, among other things, (i) the principal balance under the Daewoong Convertible Note, together with all accrued and unpaid interest thereon, in the amount of $<ix:nonFraction unitRef="usd" contextRef="ib67b7815bf86448c836c0674ab2cd400_I20210323" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMzAvZnJhZzpiZDliZWY3MmZlZWQ0ODkxYjYxNmUwY2Q5ZjNkYjdkMS90ZXh0cmVnaW9uOmJkOWJlZjcyZmVlZDQ4OTFiNjE2ZTBjZDlmM2RiN2QxXzE2NDkyNjc0NTcyNzM_6ee35dac-3819-433a-b8c5-f9f4afc7b09f">40,779</ix:nonFraction> was converted, at the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib67b7815bf86448c836c0674ab2cd400_I20210323" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMzAvZnJhZzpiZDliZWY3MmZlZWQ0ODkxYjYxNmUwY2Q5ZjNkYjdkMS90ZXh0cmVnaW9uOmJkOWJlZjcyZmVlZDQ4OTFiNjE2ZTBjZDlmM2RiN2QxXzE2NDkyNjc0NTczMTk_dbce3a2c-e214-4651-922f-8d8de9d859dc">13.00</ix:nonFraction> per share, into <ix:nonFraction unitRef="shares" contextRef="ibb11d4e5afdb4c27ae1e67ee48ded284_D20210325-20210325" decimals="INF" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMzAvZnJhZzpiZDliZWY3MmZlZWQ0ODkxYjYxNmUwY2Q5ZjNkYjdkMS90ZXh0cmVnaW9uOmJkOWJlZjcyZmVlZDQ4OTFiNjE2ZTBjZDlmM2RiN2QxXzE2NDkyNjc0NTczMzk_ff4708ce-89d3-4eed-ac5d-5646cc2975d8">3,136,869</ix:nonFraction> shares of Common Stock (the &#8220;Conversion Shares&#8221;); and (ii) the Daewoong Convertible Note was deemed cancelled and satisfied in full in connection with such conversion. See&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for more information about the Company&#8217;s accounting thereof.</span></div></ix:continuation><div style="padding-right:9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_133"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. &#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i77038361ec4447b8be22639fec3c691b_136"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, our principal executive and principal financial officers, respectively, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended, as of the end of the period covered by this Annual Report on Form 10-K. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of December&#160;31, 2021, our disclosure controls and procedures were effective (a)&#160;to ensure that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (b)&#160;to include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Under the supervision and with the participation of senior management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our internal control over financial reporting based on the framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on the evaluation under that framework and applicable SEC rules, our management concluded that our internal control over financial reporting was effective as of December&#160;31, 2021.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm on our internal control over financial reporting due to an exemption established pursuant to the JOBS Act for &#8220;emerging growth companies.&#8221;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended December&#160;31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations of Internal Controls</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well&#160;designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management overriding of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div id="i77038361ec4447b8be22639fec3c691b_139"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.  Other Information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_1099511629303"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.  Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i77038361ec4447b8be22639fec3c691b_142"></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information required by Part&#160;III is omitted from this annual report on Form&#160;10&#8209;K and is incorporated herein by reference to our definitive Proxy Statement for our 2022 Annual Meeting of Stockholders (&#8220;Proxy Statement&#8221;), which we intend to file pursuant to Regulation&#160;14A of the Securities Exchange Act of 1934, as amended, within 120&#160;days after December&#160;31, 2021.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.  Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as disclosed below with respect to our Code of Conduct, the information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2022 Annual Meeting of Stockholders.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a Code of Conduct applicable to all directors, officers and employees of the Company. We have posted the Code of Business Conduct on our website at www.evolus.com. We will post any amendments to the Code of Conduct on our website. In accordance with the requirements of the SEC and Nasdaq, we will also post waivers applicable to any of our officers or directors from provisions of the Code of Conduct on our website.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_148"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.  Executive Compensation.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2022 Annual Meeting of Stockholders.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain of Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2022 Annual Meeting of Stockholders.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_154"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.  Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2022 Annual Meeting of Stockholders.</span></div><div id="i77038361ec4447b8be22639fec3c691b_157"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.  Principal Accounting Fees and Services.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2022 Annual Meeting of Stockholders.</span></div><div id="i77038361ec4447b8be22639fec3c691b_160"></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part IV</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.  Exhibits, Financial Statement Schedules. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following documents are filed as part of this Annual Report on Form 10-K:</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1) Financial Statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Item 8 &#8220;Financial Statements and Supplementary Data&#8221; elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2) Financial Statement Schedules.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> None. Financial statement schedules have been omitted because they are not applicable.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3) Exhibits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following exhibits are filed (or incorporated by reference herein) as part of this Annual Report on Form&#160;10-K:</span></div><div style="margin-bottom:10pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed Herewith<br/>(x)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018001474/exhibit318-k21218.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018001474/exhibit318-k21218.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/12/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018001474/exhibit328-k21218.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018001474/exhibit328-k21218.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/12/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit41s-1a1.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit41s-1a1.htm">Specimen certificate evidencing shares of common stock of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/25/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit42s-1.htm">4.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit42s-1.htm">Stockholders&#8217; Agreement, dated as of December 14, 2017, by and among ALPHAEON Corporation, Dental Innovations BVBA, Longitude Venture Partners II, L.P. and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit4312312110k.htm">4.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit4312312110k.htm">Description of Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex41.htm">4.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex41.htm">Registration Rights Agreement, dated February 18, 2021, by and between Evolus Inc. and Medytox, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/12/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit101s-1.htm">10.1&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit101s-1.htm">Stock Purchase Agreement, dated as of September 30, 2014, by and between Strathspey Crown Holdings, LLC and ALPHAEON Corporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit102s-1.htm">10.2&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit102s-1.htm">Amendment to Stock Purchase Agreement, dated as of September 30, 2014, by and between Strathspey Crown Holdings, LLC and ALPHAEON Corporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit103s-1.htm">10.3&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit103s-1.htm">License and Supply Agreement, dated as of September 30, 2013, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit104s-1.htm">10.4&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit104s-1.htm">First Amendment to License and Supply Agreement, dated as of February 26, 2014, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit105s-1.htm">10.5&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit105s-1.htm">Second Amendment to License and Supply Agreement, dated as of July 15, 2014, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit106s-1.htm">10.6+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit106s-1.htm">2017 Omnibus Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit107s-1.htm">10.7+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit107s-1.htm">Form of Option Award Agreement under 2017 Omnibus Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit108s-1.htm">10.8+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit108s-1.htm">Form of Dueling Option Award Agreement under 2017 Omnibus Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit109s-1.htm">10.9+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit109s-1.htm">Form of Restricted Shares Award Agreement under 2017 Omnibus Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1010s-1.htm">10.10+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1010s-1.htm">Form of RSU Award Agreement under 2017 Omnibus Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056220000061/exhibit101112311910k.htm">10.11+</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056220000061/exhibit101112311910k.htm">Form of RSU Award Agreement under 2017 Omnibus Incentive Plan (Updated 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit1011s-1a.htm">10.12+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit1011s-1a.htm">Form of Indemnification Agreement by and between the Registrant and its directors and officers.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/25/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1020s-1.htm">10.14&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1020s-1.htm">Second Amendment to Stock Purchase Agreement, dated as of December 14, 2017, by and among SCH-AEON, LLC (f/k/a Strathspey Crown Holdings, LLC), ALPHAEON Corporation, the Registrant and J. Christopher Marmo, as Contributors&#8217; Representative, and acknowledged by the parties listed as Contributors on the signature pages thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1029s-1.htm">10.17+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1029s-1.htm">Employment Agreement, dated as of May 6, 2018, by and between David Moatazedi and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-226186</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/16/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1030s-1.htm">10.18+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1030s-1.htm">Employment Agreement, dated as of May 29, 2018, by and between Lauren Silvernail and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-226186</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/16/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056219000038/exhibit1031.htm">10.19+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056219000038/exhibit1031.htm">Employment Agreement, dated August 15, 2018, by and between Rui Avelar and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/20/19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102012312110k.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102012312110k.htm">20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102012312110k.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102012312110k.htm">Employment Agreement, dated February 25, 2021, by and between Crystal Muilenburg and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056219000085/ticlease.htm">10.21</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056219000085/ticlease.htm">Lease, dated as of May 15, 2019, between the Registrant and 520 Newport Center Drive LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/21/19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000102/ex11032621.htm">10.22</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000102/ex11032621.htm">Sales Agreement, dated March 26, 2021, by and between Evolus, Inc. and SVB Leerink LLC as Sales Agent.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/26/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex102.htm">10.23&#8225;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex102.htm">Settlement and License Agreement, dated February 18, 2021, by and among Evolus, Inc., Allergan Limited, Allergan, Inc., Allergan Pharmaceuticals Ireland and Medytox, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/12/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex103.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex103.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex103.htm">&#8225;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex103.htm">Settlement and License Agreement, dated February 18, 2021, by and between Evolus, Inc. and Medytox, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/12/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex104.htm">10.25</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex104.htm">Share Issuance Agreement, dated February 18, 2021, by and between Evolus Inc. and Medytox, Inc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex104.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/12/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex105.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex105.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex105.htm">&#8225;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex105.htm">Confidential Settlement and Release Agreement, dated March 23, 2021, by and between Evolus, Inc. and Daewoong Pharmaceutical Co. Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/12/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex106.htm">10.27</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex106.htm">Convertible Promissory Note Conversion Agreement, dated March 23, 2021, by and between Evolus, Inc. and Daewoong Pharmaceutical Co. Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/12/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex107.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex107.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex107.htm">&#8225;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex107.htm">Third Amendment to Supply Agreement, dated March 23, 2021, by and between Evolus, Inc. and Daewoong Pharmaceutical Co. Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/12/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000177/ex101121421.htm">10.29&#8225;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056221000177/ex101121421.htm">Loan Agreement, dated as of December 14, 2021, by and among Evolus, Inc. (as Borrower and a Credit Party), BioPharma Credit PLC (as Collateral Agent), BPCR Limited Partnership (as a Lender), and BioPharma Credit Investments V (Master) LP (as a Lender).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/14/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit21112312110k.htm">21.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit21112312110k.htm">List of Subsidiaries.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit23112312110k.htm">23.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit23112312110k.htm">Consent of  independent registered public accounting firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_169">24.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_169">Power of Attorney (included on signature page).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31112312110k.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31112312110k.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31212312110k.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31212312110k.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32112312110k.htm">32.1#</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32112312110k.htm">Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:0.1%"></td><td style="width:2.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.389%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Registrant has omitted and filed separately with the Securities and Exchange Commission portions of the exhibit pursuant to a confidential treatment request under Rule 406 promulgated under the Securities Act of 1933, as amended, or the Securities Act.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information in Exhibit 32.1 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Annual Report on Form 10-K), unless the Registrant specifically incorporates the foregoing information into those documents by reference.</span></td></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_166"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="i77038361ec4447b8be22639fec3c691b_169"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March&#160;3, 2022.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.005%"><tr><td style="width:1.0%"></td><td style="width:8.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.866%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EVOLUS, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ David Moatazedi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Moatazedi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The undersigned directors and officers of Evolus, Inc. constitute and appoint David Moatazedi and Lauren P. Silvernail, and each of them, as their true and lawful attorneys and agents with power of substitution, to do any and all acts and things in our name and behalf in our capacities as directors and officers and to execute any and all instruments for us and in our names in the capacities indicated below, which said attorneys and agents may deem necessary or advisable to enable said corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations and requirements of the Securities and Exchange Commission, in connection with this Annual Report on Form&#160;10-K, including specifically but without limitation, power and authority to sign for us or any of us in our names in the capacities indicated below, any and all amendments hereto; and we do hereby ratify and confirm all that said attorneys and agents shall do or cause to be done by virtue hereof.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:28.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ David Moatazedi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member of the Board of Directors</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Moatazedi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lauren P. Silvernail</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and<br/>Executive Vice President of Corporate Development<br/>(Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lauren P. Silvernail</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Vikram Malik</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vikram Malik</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Simone Blank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Simone Blank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert Hayman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert Hayman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Gill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Gill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter C. Farrell, Ph.D., AM.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter C. Farrell, Ph.D., AM.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77038361ec4447b8be22639fec3c691b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:28.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Karah Parschauer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karah Parschauer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brady Stewart</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brady Stewart</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>exhibit4312312110k.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib20c66e514ad42b78573367e508b9cb4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.3</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF CAPITAL STOCK</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the rights of our common stock and preferred stock, certain provisions of our certificate of incorporation and our bylaws, and applicable law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our certificate of incorporation and bylaws, copies of which are filed as exhibits to our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our authorized capital stock consists of&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">100,000,000 shares of common stock, par value $0.00001 per share&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">10,000,000 shares of preferred stock, par value $0.00001 per share.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there were 55,576,988 outstanding shares of our common stock. As of that date, there were outstanding options to purchase 3,922,286 shares of our common stock and 1,926,467 shares of common stock issuable upon the vesting and settlement of restricted stock units.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the rights of holders of our common stock&#58;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of our common stock are entitled to one vote per share. The number of authorized shares of common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of our capital stock entitled to vote, irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law, or DGCL.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to preferences that may be applicable to the holders of outstanding shares of preferred stock, the holders of common stock are entitled to share equally, on a per share basis, in any dividends when, as and if declared by our board of directors out of assets legally available for dividends (except that in the event a dividend or distribution is paid in the form of common stock (or rights to acquire such stock), then holders of common stock shall receive common stock (or rights to acquire such stock, as the case may be).</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a Delaware corporation, we are subject to certain restrictions on dividends under the DGCL. Generally, a Delaware corporation may only pay dividends either out of &#8220;surplus&#8221; or out of the current or the immediately preceding year's net profits. Surplus is defined as the excess, if any, at any given time, of the total assets of a corporation over its total liabilities and statutory capital. The value of a corporation&#8217;s assets can be measured in a number of ways and may not necessarily equal their book value.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidation Rights</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon our liquidation, dissolution or winding up, after satisfaction of all our liabilities and the payment of any liquidation preference of any outstanding preferred stock, the holders of shares of common stock will be entitled to share equally, on a per share basis, in all of our assets legally remaining for distribution after payment of all debt and other liabilities.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redemption Rights</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no redemption or sinking fund provisions applicable to our common stock.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preemptive Rights and Conversion Rights</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no preemptive or conversion rights applicable to our common stock.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no shares of our preferred stock outstanding, but our board of directors is authorized, without further action by our stockholders, to create and issue one or more series of preferred stock and to fix the rights, powers, preferences and privileges thereof. Among other rights, our board of directors may determine, without further vote or action by our stockholders&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">the number of shares constituting the series and the distinctive designation of the series&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">the dividend rate on the shares of the series, whether dividends will be cumulative, and if so, from which date or dates, and the relative rights of priority, if any, of payment of dividends on shares of the series&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">whether the series will have voting rights in addition to the voting rights provided by law and, if so, the terms of the voting rights&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">whether the series will have conversion privileges and, if so, the terms and conditions of conversion&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">whether or not the shares of the series will be redeemable or exchangeable, and, if so, the dates, terms and conditions of redemption or exchange, as the case may be&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">whether the series will have a sinking fund for the redemption or purchase of shares of that series, and, if so, the terms and amount of the sinking fund&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">the rights of the shares of the series in the event of our voluntary or involuntary liquidation, dissolution or winding up and the relative rights or priority, if any, of payment of shares of the series.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any future issuance of shares of preferred stock, or the issuance of rights to purchase shares of preferred stock, could, among other things, decrease the amount of earnings and assets available for distribution to the holders of common stock or could adversely affect the rights and powers, including voting rights, of the holders of the common stock.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registration Rights</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alphaeon</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2017, we entered into a stockholders&#8217; agreement with ALPHAEON Corporation, or Alphaeon, Dental Innovations BVBA, or DI, as collateral agent, and Longitude Venture Partners II, L.P., or Longitude, as a secured party, that provided Alphaeon (and upon an event of default by Alphaeon under certain convertible bridge note and convertible promissory notes then-outstanding, DI and Longitude) with registration rights relating to shares of our common stock held by Alphaeon (and then-pledged to DI and Longitude). Subsequent to December 31, 2019, Alphaeon changed its name to AEON-Biopharma, Inc. but we continue to refer to the renamed AEON-Biopharma, Inc. as Alphaeon.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the stockholders&#8217; agreement, certain stockholders party thereto may request that we register for resale all or a portion of their shares of common stock. Certain stockholders party thereto may also request that we file an automatic shelf registration statement on Form S-3 that covers the registrable securities requested to be registered, to the extent we are eligible to do so. Depending on certain conditions, and in addition to other exclusions, we may defer a demand registration for up to 90 days in any twelve-month period.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that we propose to register any of our securities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), either for our account or for the account of our other security holders, the stockholders party to the stockholders&#8217; agreement are entitled to certain piggyback registration rights allowing them to include their shares in the registration, subject to certain marketing and other limitations. As a result, whenever we propose to file a registration statement under the Securities Act, the stockholders party to the stockholders&#8217; agreement are entitled to notice of the registration and the right to include their shares in such registration.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stockholders&#8217; agreement provides that we must pay all registration expenses (other than the underwriting discounts and commissions) in connection with effecting any demand registration or shelf registration. The stockholders&#8217; agreement contains customary indemnification and contribution provisions by us for the benefit of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the stockholders party thereto and their affiliates and, in limited situations, by the stockholders party thereto for the benefit of us and any underwriters with respect to written information furnished to us by such stockholders and stated by such stockholders to be specifically included in any registration statement, prospectus or related document.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registration rights remain in effect with respect to any shares covered by the stockholders&#8217; agreement until (i) all such shares have been sold pursuant to an effective registration statement under the Securities Act, or (ii) such time as Rule 144 or </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">another similar exemption under the Securities Act is available for the sale of all of the shares without limitation during a three-month period without registration. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Alphaeon distributed a certain number of shares of our common stock that it held to certain of its noteholders in exchange for the extinguishment of outstanding debt obligations. As part of that distribution, such noteholders, including DI and Alpha International Investment Ltd., became parties to the stockholders&#8217; agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, Alphaeon transferred a certain number of shares of our common stock that it held to its majority stockholder, Strathspey Crown Holdings Group, LLC, or SCH. As part of that transaction, SCH became a party to the stockholders&#8217; agreement. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2019, Alphaeon contributed all of the remaining shares of our common stock that it held in us to Alphaeon 1, LLC. As part of that contribution, Alphaeon 1, LLC became a party to the stockholders&#8217; agreement and succeeded to all of Alphaeon&#8217;s rights thereunder.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medytox</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, in connection with a settlement and license agreement we entered into with Medytox, Inc., or Medytox, we entered into the following agreements with Medytox&#58; (i) the share issuance agreement (as described below) pursuant to which we issued 6,762,652 shares (the &#8220;Settlement Shares&#8221;) of our common stock, par value $0.00001 per share, to Medytox&#59; and (ii) a registration rights agreement (as described below), pursuant to which granted certain registration rights to Medytox with respect to the Settlement Shares.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the registration rights agreement, at any time after March 31, 2022, certain stockholders party thereto may request that we register for resale all or a portion of their shares of common stock. Certain stockholders party thereto may also request that we file an automatic shelf registration statement on Form S-3 that covers the registrable securities requested to be registered, to the extent we are eligible to do so. Depending on certain conditions, and in addition to other exclusions, we may defer a demand registration for up to 90 days in any twelve-month period.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that we propose to register any of our securities under the Securities Act, either for our account or for the account of our other security holders, the stockholders party to the registration rights agreement are entitled to certain piggyback registration rights allowing them to include their shares in the registration, subject to certain marketing and other limitations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, whenever we propose to file a registration statement under the Securities Act, the stockholders party to the registration rights agreement are entitled to notice of the registration and the right to include their shares in such registration.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registration rights agreement provides that we must pay all registration expenses (other than the underwriting discounts and commissions) in connection with effecting any demand registration or shelf registration. The registration rights agreement contains customary indemnification and contribution provisions by us for the benefit of the stockholders party thereto and their affiliates and, in limited situations, by the stockholders party thereto for the benefit of us and any underwriters with respect to written information furnished to us by such stockholders and stated by such stockholders to be specifically included in any registration statement, prospectus or related document.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registration rights remain in effect with respect to the Settlement Shares covered by the share issuance agreement until (i) all such shares have been sold pursuant to an effective registration statement under the Securities Act, or (ii) such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of the shares without limitation during a three-month period without registration.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-Takeover Effects of Provisions of our Certificate of Incorporation, Bylaws and Delaware Law</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delaware Anti-Takeover Law</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to Section 203 of the DGCL, or Section 203. Section 203 generally prohibits a public Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years following the time that such stockholder became an interested stockholder, unless&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">prior to such time the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">at or subsequent to such time the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2&#47;3% of the outstanding voting stock which is not owned by the interested stockholder.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, Section 203 defines a business combination to include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">any merger or consolidation involving the corporation and the interested stockholder&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, Section 203 defines an interested stockholder as any entity (other than the corporation and any direct or indirect majority-owned subsidiary of the corporation) or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with, associated with or controlling or controlled by such entity or person.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate of Incorporation and Bylaws</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provisions of our certificate of incorporation and bylaws may make a change-of-control of our company more difficult and could delay, defer or prevent a tender offer or other takeover attempt that a stockholder might consider to be in its best interest, including takeover attempts that might result in the payment of a premium to stockholders over the market price for their shares. These provisions also may promote the continuity of our management by making it more difficult for a person to remove or change the incumbent members of our board of directors.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Authorized but Unissued Shares&#59; Undesignated Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The authorized but unissued shares of our common stock will be available for future issuance without stockholder approval, subject to applicable law and the Nasdaq Marketplace Rules. These additional shares may be used for a variety of corporate purposes, including future public offerings to raise additional capital, acquisitions and employee benefit plans. In addition, our board of directors may authorize, without stockholder approval, the issuance of undesignated preferred stock with voting rights or other rights or preferences designated from time to time by our board of directors (including the right to approve an acquisition or other change in our control). The existence of authorized but unissued shares of common stock or preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Election and Removal of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our board of directors will consist of not less than five nor more than nine directors. The exact number of directors will be fixed from time to time only by resolution of our board of directors. Our board of directors currently has seven members.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that directors may be removed only for cause and only by the affirmative vote of holders of at least 66 2&#47;3% of our then outstanding voting stock. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Classified Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our certificate of incorporation provides that our board of directors is classified with approximately one-third of the directors elected each year. The authorized number of directors may be changed only by resolution of the board of directors. The directors are divided into three classes, designated class I, class II and class III. Each class consists, as nearly as may be possible, of one-third of the total number of directors constituting the entire board of directors. At each annual meeting of stockholders, successors to the class of directors whose term expires at that annual meeting will be elected until the third annual meeting of stockholders next succeeding the elections or until their successors are duly elected and qualified or until their earlier death, resignation or removal. In addition, if the number of directors is changed, any </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase or decrease will be apportioned by our board of directors among the classes so as to maintain the number of directors in each class as nearly equal as possible, and any additional director of any class elected to fill a vacancy resulting from an increase in such class or from the removal from office, death, disability, resignation or disqualification of a director or other cause will hold office for a term that will coincide with the remaining term of that class, but in no case will a decrease in the number of directors have the effect of removing or shortening the term of any incumbent director.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Director Vacancies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our certificate of incorporation authorizes only our board of directors to fill vacant directorships.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">No Cumulative Voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our certificate of incorporation provides that stockholders do not have the right to cumulate votes in the election of directors (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose).</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Special Meetings of Stockholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our certificate of incorporation and bylaws provide that special meetings of our stockholders may only be called by the chairman of the board, our Chief Executive Officer or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advance Notice Procedures for Director Nominations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our bylaws establish advance notice procedures for stockholders seeking to nominate candidates for election as directors at an annual or special meeting of stockholders. Although our bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates to be elected at an annual meeting, our bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Action by Written Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our certificate of incorporation provides that any action required or permitted to be taken by the stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by any consent in writing in lieu of a meeting of such stockholders, subject to the rights of the holders of any series of preferred stock.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amending Our Certificate of Incorporation and Bylaws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our certificate of incorporation and bylaws may be amended by the affirmative vote of the holders of at least 66 2&#47;3% of the voting power of our then-outstanding common stock. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exclusive Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery shall be the sole and exclusive forum for all &#8220;internal corporate claims.&#8221; &#8220;Internal corporate claims&#8221; are claims, (i) that are based upon a violation of a duty by a current or former director or officer or stockholder in such capacity, or (ii) as to which Title 8 of the DGCL confers jurisdiction upon the Court of Chancery, except for, as to each of (i) and (ii) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. This exclusive forum provision is intended to apply to claims arising under Delaware state law and would not apply to claims brought pursuant to the Securities Exchange Act of 1934, as amended, or the Securities Act, or any other claim for which the federal courts have exclusive jurisdiction. The exclusive forum provision in our certificate of incorporation will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conflicts of Interest</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the corporation or its officers, directors or stockholders. Our certificate of incorporation, to the maximum extent permitted from time to time by Delaware law, renounces any interest or expectancy that we have in, or right to be offered an opportunity to participate in, specified business opportunities that are from time to time presented to Alphaeon or any of its officers, directors, stockholders, agents, members, partners, subsidiaries (other than our company) and affiliates, other than those directors and officers of our company who are offered business opportunities in their capacity as directors and officers of our company, or the specified parties. Our certificate of incorporation provides that, to the fullest extent permitted by law, none of the specified parties will have any duty to refrain from engaging in a corporate opportunity that we might reasonably be deemed to have pursued or had the ability or desire to pursue if granted the opportunity to do so. In addition, to the fullest extent permitted by law, in the event that any of the specified parties acquire knowledge of a potential transaction or other business opportunity which may be a corporate opportunity for itself or himself or its or his affiliates or for us, such person will have no duty to communicate or offer such transaction or business opportunity to us and they may take any such opportunity for themselves or offer it to another person or entity. Our certificate of incorporation does not renounce our interest in any business opportunity that is offered to a director or officer of our company in his or her capacity as a director or officer of our company. To the fullest extent permitted by law, no business opportunity will be deemed to be a potential corporate opportunity for us </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unless we would be permitted to undertake the opportunity under our certificate of incorporation, we have sufficient financial resources to undertake the opportunity and the opportunity would be in line with our business.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nasdaq Global Market Listing</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;EOLS.&#8221;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transfer Agent and Registrar</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#8217;s address is 250 Royall Street, Canton, Massachusetts 02021.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>3
<FILENAME>exhibit102012312110k.htm
<DESCRIPTION>EX-10.20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6c3ef2776cc1429c87201824bdea01b1_38"></div><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.25pt;padding-left:0.52pt;padding-right:0.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">This Employment Agreement is between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Evolus, Inc.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> a Delaware corporation (the &#8220;Company&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Crystal Muilenburg,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> an individual (&#8220;Employee.&#8221;) This Agreement is entered into effective as of February 25, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Effective Date&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">.   This Agreement amends and restates the terms of the Offer Letter, dated February 20, 2019, between Employee and the Company.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">POSITION AND RESPONSIBILITIES</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:22.68pt">Position. Employee shall be employed by the Company to render services to the Company in the position of Chief Marketing Officer of the Company. Employee shall report directly to the President and Chief Executive Officer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:121%">CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8221;). Employee shall use her good faith efforts to perform such duties and responsibilities and shall have such authorities as are normally related to such positions in accordance with the standards of the industry and any additional duties of an executive nature the CEO now or hereafter assigns to Employee consistent with her position as the Company&#8217;s Chief Marketing Officer. </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">The principal place of Employee&#8217;s employment under this Agreement shall be Orange County, California (the &#8220;</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Company Offices</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8221;).</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22pt">Other Activities.  During her employment with the Company, Employee shall (i) devote substantially all of Employee&#8217;s business time and energy to the performance of Employee&#8217;s duties for the Company and (ii) hold no other employment. </font></div><div><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">COMPENSATION AND BENEFITS</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:22.68pt">Base Salary. In consideration of the services to be rendered under this Agreement, effective March 1, 2021, the Company shall pay Employee a salary at the rate of Three Hundred Ninety Thousand ($390,000) per year (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8221;). The Base Salary shall be paid in accordance with the Company&#8217;s regularly established payroll practice.  Employee&#8217;s Base Salary shall be reviewed from time to time (not less frequently than annually commencing in 2022) in accordance with the established procedures of the Company for adjusting salaries for similarly situated employees and may be increased, but not decreased in the sole discretion of the Board.</font></div><div style="padding-left:5pt;padding-right:5.85pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:22pt">Annual Bonus. Beginning as of the Effective Date, Employee&#8217;s target opportunity for her annual incentive bonus, as determined by the Board in its reasonable discretion (the &#8220;Annual Bonus&#8221;) will be equal to 40% of the Base Salary based on 100% achievement of key performance indicators for Employee and the Company as determined by the Board in its sole discretion and communicated to Employee.  The terms of any written Annual Bonus plan developed by the Board shall govern any Annual Bonus that may be paid.  Any Annual Bonus shall be paid in all events within two and one-half months after the end of the year in which such Annual Bonus becomes earned, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:121%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> that no Annual Bonus shall be considered earned or payable unless, subject to Section 5(c), Employee has remained continuously employed through the payment date of the Annual Bonus.</font></div><div style="padding-left:41.05pt;padding-right:5.75pt"><font><br></font></div><div style="padding-left:5.05pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:22.63pt">Equity. Employee shall be eligible to participate in the Company&#8217;s 2017 Omnibus Incentive Plan on the same terms and conditions as other similarly situated senior executives of the Company, in accordance with the Plan, as may be amended from time to time.</font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">1</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5pt;padding-right:6.5pt;text-indent:31pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:31pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:27.68pt">Benefits. Employee shall be eligible to participate in the benefits made generally available by the Company to its other senior executives, in accordance with the benefit plans established by the Company, and as may be amended from time to time in the Company&#8217;s sole discretion.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-indent:31pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.01pt">Vacation. Employee&#8217;s vacation and other paid time off shall be governed by the Company&#8217;s usual policies applicable to senior management employees.</font></div><div style="margin-top:0.15pt;text-indent:31pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-indent:31pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:27pt">Expenses. The Company shall reimburse Employee for reasonable business expenses incurred, and for any other approved expenses incurred, in the performance of Employee&#8217;s duties hereunder in accordance with the Company&#8217;s customary expense reimbursement guidelines.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-indent:35.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:22.5pt">Employment Policy. As an employee of the Company, Employee shall be subject to and abide by the Company&#8217;s policies, procedures, practices, rules and regulations as adopted or as amended from time to time in the Company&#8217;s sole discretion.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-indent:35.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:25.17pt">Indemnification. Employee shall be covered under a directors&#8217; and officers&#8217; liability insurance policy paid for by the Company both during and after (while there remains any potential liability to Employee) the termination of Employee&#8217;s employment to the extent that the Company maintains such a liability insurance policy now or in the future for its active officers and directors. In addition, concurrently herewith the Company and Employee are entering into an Indemnification Agreement. </font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">AT-WILL EMPLOYMENT&#59; TERMINATION BY COMPANY</font></div><div style="padding-left:41pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:22.68pt">Termination for Cause.  Employee&#8217;s employment under this Agreement shall commence on the Effective Date and shall continue indefinitely for no specific term.  The Company may terminate Employee&#8217;s employment with the Company at will at any time upon written notice, with or without Cause or advance notice, for any reason or no reason at all, notwithstanding anything to the contrary contained in or arising from any statements, policies or practices of the Company relating to the employment, discipline or termination of its employees.  For purposes of this Agreement, &#8220;Cause&#8221; shall mean any of the following&#58; (a) the commission of any act of fraud, embezzlement or willful dishonesty by Employee which adversely affects the business of the Company&#59; (b) any unauthorized use or disclosure by Employee of confidential information or trade secrets of the Company&#59; (c) the refusal or omission by Employee to perform any lawful duties properly required of her under this Agreement, provided that any such failure or refusal has been communicated to Employee in writing and Employee has been provided a reasonable opportunity to correct it, if correction is possible&#59; (d) any act or omission by Employee involving malfeasance or gross negligence in the performance of Employee&#8217;s duties to, or material deviation from any of the policies or directives of, the Company, provided, however, that in the case of deviations from policies or directives, (i) the Company must give Employee notice of such deviations within thirty (30) days of the Company becoming aware of such an occurrence, (ii) Employee must be given thirty (30) days to cure or correct the deviation, if curable, and (iii) Employee may only be terminated if the deviation remains uncured after thirty (30) days, if curable, following written notice and upon the approval of the Board of Directors&#59; (e) conduct on the part of Employee which constitutes the breach of any statutory or </font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5pt;padding-right:5.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">common law duty of loyalty to the Company&#59; or (f) any illegal act by Employee which the Board determines adversely affects the business of the Company, or any felony committed by Employee, as evidenced by conviction thereof.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:22pt">Termination upon Death.  Employee&#8217;s employment under this Agreement shall terminate automatically upon Employee&#8217;s death. </font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">TERMINATION BY EMPLOYEE</font></div><div style="padding-left:5pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Employee may terminate employment with the Company at any time upon written notice for any reason or no reason at all, with or without Good Reason.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Reason&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall mean any of the following which is not corrected by the Company within thirty (30) days after the Company has received written notice from Employee referring to this Section 4 and specifying the circumstances purportedly constituting Good Reason and the correction sought (such notice to be given within thirty (30) days after the occurrence of such circumstance)&#58; (a) a material diminution in Employee&#8217;s title, duties, authorities, or responsibilities&#59; (b) a material reduction in Employee&#8217;s Base Salary or Annual Bonus opportunity&#59; (c) requiring Employee to relocate her principal place of business more than 30 miles outside of the Orange County, California (excluding reasonable amounts of time that Employee will work at the Company&#8217;s offices in Santa Barbara, California)&#59; or (d) a material breach by the Company of any provision of this Agreement or any other agreement between the Company and Employee.  Notwithstanding the foregoing, a termination of Employee&#8217;s employment with the Company shall not constitute a termination for Good Reason unless such termination occurs not more than ninety (90) days following the initial existence of the condition claimed to constitute good reason. </font></div><div style="padding-left:5pt"><font><br></font></div><div style="margin-top:3.45pt;padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">TERMINATION OBLIGATIONS</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.68pt">Termination of Employment.  Employee&#8217;s right to compensation and benefits under this Agreement, if any, upon termination of employment shall be determined in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22pt">All Terminations of Employment. Upon any termination of employment, Employee shall be entitled to prompt and full payment of all earned but unpaid Base Salary, accrued but unused vacation, and any Annual Bonus that has become fully earned and payable under this Agreement for the year preceding the year in which the date of termination occurs, regardless of whether the payment date of the Annual Bonus for the preceding year is scheduled to occur after Employee&#8217;s termination date (collectively, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Accrued Benefits&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).  Except as provided in Section 5(c), Employee&#8217;s rights following a termination of employment with respect to any benefits, incentives or awards provided to Employee pursuant to the terms of any plan, program or arrangement sponsored or maintained by the Company, whether tax-qualified or not, which are not specifically addressed herein, shall be subject to the terms of such plan, program or arrangement, and this Agreement shall have no effect upon such terms except as specifically provided herein. Employee&#8217;s rights following a termination of employment with respect to the Stock Option and any other stock option or equity-based award that may be hereafter granted to Employee shall be governed by the applicable award agreement. Company acknowledges that any rights Employee may have to indemnification for actions taken as an officer or director under Company&#8217;s charter, other arrangements and its insurance policies shall not be forfeited or terminated with respect to any actions or omissions prior to any termination of employment.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.68pt">Termination of Employment by Company without Cause or by Employee for Good Reason. If the Company terminates Employee&#8217;s employment under this Agreement for any </font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">3</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5pt;padding-right:5.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">reason other than Cause, or Employee terminates her employment under this Agreement for Good Reason, and Employee enters into a release as provided in Section 5(e) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Qualified Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then in addition to the Accrued Benefits,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee shall be entitled to (i) a gross amount, minus appropriate withholding and payroll deductions, equal to (a) in the case of a Qualified Termination that occurs in connection with or within 12 months after Change in Control (as such term is defined in the Plan), 12 months of Employee&#8217;s then current Base Salary, payable in a lump sum within 60 days of Employee&#8217;s execution of a mutually agreeable release, or (b) in the case of any other Qualified Termination, 6 months of Employee&#8217;s then current Base Salary, payable in equal installments through the Company&#8217;s regular payroll over the 6 month period following the Employee&#8217;s date of termination, plus the continuation of health benefits for 6 months&#59; and (ii) a gross amount equal to the Annual Bonus (if any) that Employee would have earned for the calendar year in which the termination of her employment occurs based on the target level of achievement, pro-rated based on the number of full months Employee was employed in that calendar year of her employment, minus appropriate withholding and payroll deductions, payable at the time the Company normally pays Annual Bonuses after the close of the fiscal year in which Employee&#8217;s employment terminates.  <br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22pt">Other Terminations.  Upon termination of Employee&#8217;s employment by Company for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or by Employee for any reason other than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Employee shall be entitled only to the compensation and benefits provided in Section 5(b) and no severance compensation and benefits.  </font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.68pt">Release. Any and all amounts payable and benefits or additional rights provided pursuant to this Agreement upon a termination of employment beyond the Accrued Benefits (including any post-termination benefits or amounts under this Agreement) shall only be payable if Employee delivers to the Company and does not revoke a general release of claims in favor of the Company in the form acceptable to the Company, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> such release does not purport to&#58; (i) revoke any of the rights provided pursuant to this Agreement or rights to continued indemnification for actions taken as an officer or director prior to the termination of employment&#59; or (ii) impose upon Employee any new or additional restrictive covenants that do not otherwise survive the termination of Employee&#8217;s employment. Such release must be executed and delivered (and no longer subject to revocation, if applicable) within 45 days following the termination of employment (or such longer period to the extent required by law). Any payments of severance that would otherwise be made during the period before the release becomes effective (i.e., not more than 52 days after the date of termination of employment) shall instead be made on the first regular payroll date after the date the release becomes effective.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:2.8pt;padding-left:5pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.01pt">Resignation and Cooperation.  Upon any termination of employment, Employee shall be deemed to have resigned from all offices and directorships then held with the Company, including any such positions with its subsidiaries. Following a termination of employment, Employee shall cooperate reasonably in the orderly transfer of her duties to other employees. Employee shall also reasonably (after taking into account Employee&#8217;s post-termination responsibilities and obligations) cooperate with the Company in the defense of any action brought by any third party against the Company that relates to Employee&#8217;s employment by the Company.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">4</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:22pt">Continuing Obligations. Employee understands and agrees that Employee&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">Sections 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">herein (including the exhibits and schedules described therein) shall survive a termination of employment and the termination of this Agreement.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">INVENTIONS AND PROPRIETARY INFORMATION&#59; PROHIBITION ON THIRD PARTY INFORMATION</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Employee agrees to sign and be bound by the terms of the Company&#8217;s standard employee proprietary information and invention assignment agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">ARBITRATION</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee agrees to sign and be bound by the terms of the Company&#8217;s standard employee Arbitration Agreement.</font></div><div><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">ATTORNEYS&#8217; FEES AND COSTS</font></div><div style="padding-left:5pt"><font><br></font></div><div style="margin-top:2.8pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In any dispute arising from or relating to this Agreement or Employee&#8217;s hiring, employment, compensation, benefits, or termination, the prevailing party shall be entitled to recover its attorneys&#8217; fees and costs.</font></div><div style="padding-left:5pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">AMENDMENTS&#59; WAIVERS&#59; REMEDIES</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">This Agreement may not be amended or waived except by a writing signed by Employee and by a duty authorized representative of the Company other than Employee. Failure to exercise any right under this Agreement shall not constitute a waiver of such right. Any waiver of any breach of this Agreement shall not operate as a waiver of any subsequent breaches. All rights or remedies specified for a party herein shall be cumulative and in addition to all other rights and remedies of the party hereunder or under applicable law.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">ASSIGNMENT&#59; BINDING EFFECT</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.68pt">Assignment. The performance of Employee is personal hereunder, and Employee agrees that Employee shall have no right to assign and shall not assign or purport to assign any rights or obligations under this Agreement. This Agreement may be assigned or transferred by the Company&#59; and nothing in this Agreement shall prevent the consolidation, merger or sale of the Company or a sale of any or all or substantially all of its assets.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22pt">Binding Effect. Subject to the foregoing restriction on assignment by Employee, this Agreement shall inure to the benefit of and be binding upon each of the parties&#59; the affiliates, officers, directors, agents, successors and assigns of the Company&#59; and the heirs, devisees, spouses, legal representatives and successors of Employee.</font></div><div style="padding-left:41pt;padding-right:5.75pt"><font><br></font></div><div style="margin-top:2.8pt;padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">NOTICES</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">All notices or other communications required or permitted hereunder shall be made in writing and shall be deemed to have been duly given if delivered&#58; (a) by hand&#59; (b) by a nationally recognized overnight courier service&#59; or (c) by United States first class registered or certified mail, return receipt requested, to the principal address of the other party, as set forth below. The date of notice shall be deemed to be the earlier of (i) actual receipt of notice by any permitted </font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">5</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5pt;padding-right:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">means, or (ii) five business days following dispatch by overnight delivery service or the United States Mail. Employee shall be obligated to notify the Company in writing of any change in Employee&#8217;s address. Notice of change of address shall be effective only when done in accordance with this paragraph.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company&#8217;s Notice Address&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">520 Newport Center Dr., Suite 1200</font></div><div style="margin-top:0.65pt;padding-left:41pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Newport Beach, CA 92660</font></div><div style="margin-top:0.65pt;padding-left:41pt;padding-right:320.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58;  Legal</font></div><div style="margin-top:2.3pt;padding-left:41pt;padding-right:-65.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:206%">Employee&#8217;s Notice&#58; to Employee at her address on file in the Company&#8217;s payroll records </font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">SEVERABILITY</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">If any provision of this Agreement shall be held by a court or arbitrator to be invalid, unenforceable or void, such provision shall be enforced to the fullest extent permitted by law, and the remainder of this Agreement shall remain in full force and effect. In the event that the time period or scope of any provision is declared by a court or arbitrator of competent jurisdiction to exceed the maximum time period or scope that such court or arbitrator deems enforceable, then such court or arbitrator shall reduce the time period or scope to the maximum time period or scope permitted by law.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">TAX MATTERS</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:22.68pt">Withholding. Any and all amounts payable under this Agreement or otherwise shall be subject to, and the Company may withhold from such amounts, any federal, state, local or other taxes as may be required to be withheld pursuant to any applicable law or regulation.</font></div><div style="padding-left:5pt;padding-right:5.85pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:22pt">Section 409A Compliance.</font></div><div><font><br></font></div><div style="margin-top:3.85pt;padding-left:5pt;padding-right:5.7pt;text-indent:71.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.61pt">The intent of the parties hereto is that payments and benefits under this Agreement be exempt from (to the extent possible) Section 409A (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of the Internal Revenue Code of 1986 and the regulations and guidance promulgated thereunder, as amended (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith. To the extent that any provision hereof is modified in order to comply with Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to the parties hereto of the applicable provision without violating the provisions of Section 409A. </font></div><div style="margin-top:3.85pt;padding-left:77pt;padding-right:5.7pt;text-indent:71.5pt"><font><br></font></div><div style="margin-top:3.25pt;padding-left:5pt;padding-right:5.8pt;text-indent:71.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%;padding-left:18.7pt">A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits that constitute &#8220;nonqualified deferred compensation&#8221; under Section 409A upon or following a termination of employment unless such termination is also a &#8220;separation from service&#8221; within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean &#8220;separation from service.&#8221;</font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">6</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.35pt;text-indent:71.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-indent:71.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.79pt">To the extent that reimbursements or other in-kind benefits under this Agreement constitute &#8220;nonqualified deferred compensation&#8221; for purposes of Section 409A, (A) all expenses or other reimbursements hereunder shall be made on or prior to the last day of the taxable year following the taxable year in which such expenses were incurred by Employee, (B) any right to reimbursement or in- kind benefits shall not be subject to liquidation or exchange for another benefit and (C) no such reimbursement, expenses eligible for reimbursement or in-kind benefits provided in any taxable year shall in any way affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year.</font></div><div style="text-indent:71.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-indent:71.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.36pt">For purposes of Section 409A, Employee&#8217;s right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days, the actual date of payment within the specified period shall be at the sole discretion of the Board.</font></div><div style="margin-top:0.35pt;text-indent:71.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-indent:71.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.27pt">Notwithstanding any other provision of this Agreement to the contrary, in no event shall any payment under this Agreement that constitutes &#8220;nonqualified deferred compensation&#8221; for purposes of Section 409A be subject to offset by any other amount unless otherwise permitted by Section 409A.</font></div><div style="margin-top:0.05pt;text-indent:71.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-indent:71.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.36pt">Notwithstanding any other provision of this Agreement, to the extent required to avoid the imposition of tax, penalties or interest under Section 409A, amounts that would otherwise be payable and benefits that would otherwise be provided under this Agreement during the six-month period immediately following a termination of employment shall instead be paid on the first payroll date after the six (6)-month anniversary of the termination of employment (or Employee&#8217;s death, if earlier).</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:22.68pt">Section 280G. </font></div><div style="padding-left:41pt;padding-right:5.85pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-indent:71.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.61pt">Notwithstanding anything contained in this Agreement to the contrary, to the extent that the payments and benefits provided under this Agreement and benefits provided to, or for the benefit of, Employee under any other Company plan or agreement (such payments or benefits are collectively referred to as the &#8220;Benefits&#8221;) would be subject to the excise tax (the &#8220;Excise Tax&#8221;) imposed under Section 4999 of the Code, the Benefits shall be reduced (but not below zero) if and to the extent that a reduction in the Benefits would result in Employee retaining a larger amount, on an after-tax basis (taking into account federal, state and local income taxes and the Excise Tax), than if Employee received all of the Benefits (such reduced amount is referred to hereinafter as the &#8220;Limited Benefit Amount&#8221;).  Unless Employee shall have given prior written notice specifying a different order to the Company to effectuate the Limited Benefit Amount, any such notice consistent with the requirements of Section 409A of the Code to avoid the imputation of any tax, penalty or interest thereunder, the Company shall reduce or eliminate the Benefits by first reducing or eliminating amounts which are payable from any cash severance, then from any payment in respect of an equity award that is not covered by Treas. Reg. Section 1.280G-1 Q&#47;A-24(b) or (c), then from any payment in respect of an equity award that is covered by Treas. Reg. Section 1.280G-1 Q&#47;A-24(c), in each case in reverse order beginning with payments or benefits which are to be paid the farthest in time from the Determination (as defined below).  Any notice given by Employee pursuant to the preceding </font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">7</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5pt;padding-right:5.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">sentence shall take precedence over the provisions of any other plan, arrangement or agreement governing Employee&#8217;s rights and entitlements to any benefits or compensation.</font></div><div style="padding-left:76.5pt;padding-right:5.85pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-indent:71.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.7pt">A determination as to whether the Benefits shall be reduced to the Limited Benefit Amount pursuant to this Agreement and the amount of such Limited Benefit Amount shall be made by the Company&#8217;s independent public accountants or another certified public accounting firm or executive compensation consulting firm of national reputation designated by the Company and acceptable to Employee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Firm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) at the Company&#8217;s expense.  The Firm shall provide its determination (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), together with detailed supporting calculations and documentation to the Company and Employee within ten (10) business days of the date of termination of Employee&#8217;s employment, if applicable, or such other time as reasonably requested by the Company or Employee.  </font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">GOVERNING LAW</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement shall be governed by and construed in accordance with the laws of the State of California.</font></div><div style="padding-left:5pt;padding-right:5.8pt;text-indent:36pt"><font><br></font></div><div style="margin-top:2.8pt;padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">INTERPRETATION</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.8pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">This Agreement shall be construed as a whole, according to its fair meaning, and not in favor of or against any party. Sections and section headings contained in this Agreement are for reference purposes only and shall not affect in any manner the meaning or interpretation of this Agreement. Whenever the context requires, references to the singular shall include the plural and the plural the singular.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">OBLIGATIONS SURVIVE TERMINATION OF EMPLOYMENT</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each party agrees that any and all of such party&#8217;s obligations under this Agreement, including any agreement contemplated hereby, shall survive a termination of employment.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">COUNTERPARTS</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.9pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement may be executed in any number of counterparts, and the signature pages may be transmitted by pdf or electronic means, each of which shall be deemed an original of this Agreement, but all of which together shall constitute one and the same instrument.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">AUTHORITY</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.8pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Each party represents and warrants that such party has the right, power and authority to enter into and execute this Agreement and to perform and discharge all of the obligations hereunder&#59; and that this Agreement constitutes the valid and legally binding agreement and obligation of such party and is enforceable in accordance with its terms.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">ENTIRE AGREEMENT</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">This Agreement is intended to be the final, complete and exclusive statement of the terms of Employee&#8217;s employment by the Company and may not be contradicted by evidence of any prior or contemporaneous statements or agreements, except for agreements specifically </font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">8</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">referenced herein (including the agreements referenced in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Sections 6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:121%">7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">above). To the extent that the practices, policies or procedures of the Company, now or in the future, apply to Employee and are inconsistent with the terms of this Agreement, the provisions of this Agreement shall control. Any subsequent change in Employee&#8217;s duties, position or compensation shall not affect the validity or scope of this Agreement.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">EMPLOYEE ACKNOWLEDGEMENT</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">EMPLOYEE ACKNOWLEDGES THAT EMPLOYEE HAS HAD THE OPPORTUNITY TO CONSULT LEGAL COUNSEL CONCERNING THIS AGREEMENT, THAT EMPLOYEE HAS READ AND UNDERSTANDS THE AGREEMENT, THAT EMPLOYEE IS FULLY AWARE OF ITS LEGAL EFFECT AND THAT EMPLOYEE HAS ENTERED INTO IT FREELY BASED ON EMPLOYEE&#8217;S OWN JUDGMENT AND NOT ON ANY REPRESENTATIONS OR PROMISES OTHER THAN THOSE CONTAINED IN THIS AGREEMENT.</font></div><div style="padding-left:6pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div style="margin-top:3.25pt;padding-left:5.57pt;padding-right:5.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:122%">&#91;The remainder of this page has intentionally been left blank.  The signature page follows on the next page.&#93;</font></div><div><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">9</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.25pt;padding-left:5pt;padding-right:6.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">By signing below, each of the parties hereto acknowledges and agrees to all of the terms of this Employment Agreement, effective as of the Effective Date.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Crystal Muilenburg (&#8220;Employee&#8221;)</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sign name&#58; &#47;s&#47; Crystal Muilenburg&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLUS, INC., a Delaware Corporation (the &#8220;Company&#8221;)</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sign name&#58; &#47;s&#47; David Moatazedi&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print name&#58; David Moatazedi&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; President and Chief Executive Officer&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:3.85pt;text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">10</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>exhibit21112312110k.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id9c81293c031426da3f8f4c04d44c435_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:138%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">EVOLUS, INC.</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:138%">LIST OF SUBSIDIARIES</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.194%"><tr><td style="width:1.0%"></td><td style="width:43.013%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation or Organization</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Evolus Pharma Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Evolus Pharma BV</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Evolus International Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">United Kingdom</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>exhibit23112312110k.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i24788c70596145b88c0da447e62769d3_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;23.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-223068), pertaining to the Evolus, Inc. 2017 Omnibus Incentive Plan of Evolus, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-229184), pertaining to the Evolus, Inc. 2017 Omnibus Incentive Plan of Evolus, Inc., </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-236620), pertaining to the Evolus, Inc. 2017 Omnibus Incentive Plan of Evolus, Inc., </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-254746), pertaining to the Evolus, Inc. 2017 Omnibus Incentive Plan of Evolus, Inc., and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-3 No. 333-230466) of Evolus, Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of our report dated March&#160;3, 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">with respect to the financial statements of Evolus, Inc. included in this Annual Report (Form 10-K) of Evolus, Inc. for the year ended December&#160;31, 2021.</font></div><div style="margin-bottom:8pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:58.477%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ernst &#38; Young LLP</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Irvine, California&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;3, 2022 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>exhibit31112312110k.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3db646cc5967470ab7590a0a4ff27ddb_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Moatazedi, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">I have reviewed this Annual Report on Form 10-K of Evolus, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such&#160;internal control over financial reporting, or caused such&#160;internal control over financial reporting&#160;to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.460%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 3, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; David Moatazedi</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Moatazedi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>exhibit31212312110k.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if55d063f517e41f28862f8d41db673ed_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Lauren Silvernail, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">I have reviewed this Annual Report on Form 10-K of Evolus, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such&#160;internal control over financial reporting, or caused such&#160;internal control over financial reporting&#160;to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 3, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Lauren Silvernail</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lauren Silvernail</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Executive Vice President, Corporate Development</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>exhibit32112312110k.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7bc6eade319f484ea23b6e9c0f513e77_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#167; 1350 AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the undersigned hereby certifies, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, in his or her capacity as an officer of Evolus, Inc., that, to his or her knowledge&#58;</font></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Annual Report on Form&#160;10-K of Evolus, Inc. for the fiscal year ended December&#160;31, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Evolus, Inc.</font></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:43.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 3, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; David Moatazedi</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Moatazedi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 3, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Lauren Silvernail</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lauren Silvernail</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Executive Vice President, Corporate Development</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>eols-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4ac935c8-acd7-4078-a010-d8166688f707,g:62b990ab-d451-4f6d-92f0-709386d601f0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:eols="http://www.evolus.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolus.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.evolus.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.evolus.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://www.evolus.com/role/BalanceSheets">
        <link:definition>1001003 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.evolus.com/role/BalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofOperationsandComprehensiveLoss" roleURI="http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss">
        <link:definition>1003005 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofStockholdersEquityDeficit" roleURI="http://www.evolus.com/role/StatementsofStockholdersEquityDeficit">
        <link:definition>1004006 - Statement - Statements of Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlows" roleURI="http://www.evolus.com/role/StatementsofCashFlows">
        <link:definition>1005007 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.evolus.com/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://www.evolus.com/role/DescriptionofBusinessDetails">
        <link:definition>2402401 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2405402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandShortTermInvestments" roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestments">
        <link:definition>2106103 - Disclosure - Fair Value Measurements and Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandShortTermInvestmentsTables" roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables">
        <link:definition>2307301 - Disclosure - Fair Value Measurements and Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails">
        <link:definition>2408403 - Disclosure - Fair Value Measurements and Short-Term Investments - Short-term Investments Available for Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandShortTermInvestmentsNarrativeDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails">
        <link:definition>2409404 - Disclosure - Fair Value Measurements and Short-Term Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>2410405 - Disclosure - Fair Value Measurements and Short-Term Investments - Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandShortTermInvestmentsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails">
        <link:definition>2411406 - Disclosure - Fair Value Measurements and Short-Term Investments - Reconciliation of Fair Value Measurement of Contingent Royalty Obligation Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssets">
        <link:definition>2112104 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2313302 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails">
        <link:definition>2414407 - Disclosure - Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails">
        <link:definition>2415408 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>2416409 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.evolus.com/role/AccruedExpenses">
        <link:definition>2117105 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.evolus.com/role/AccruedExpensesTables">
        <link:definition>2318303 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.evolus.com/role/AccruedExpensesDetails">
        <link:definition>2419410 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoans" roleURI="http://www.evolus.com/role/TermLoans">
        <link:definition>2120106 - Disclosure - Term Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoansTables" roleURI="http://www.evolus.com/role/TermLoansTables">
        <link:definition>2321304 - Disclosure - Term Loans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoansPharmakonTermLoansDetails" roleURI="http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails">
        <link:definition>2422411 - Disclosure - Term Loans - Pharmakon Term Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoansScheduleofLongTermDebtMaturitiesDetails" roleURI="http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails">
        <link:definition>2423412 - Disclosure - Term Loans - Schedule of Long Term Debt Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoansOxfordTermLoansDetails" roleURI="http://www.evolus.com/role/TermLoansOxfordTermLoansDetails">
        <link:definition>2424413 - Disclosure - Term Loans - Oxford Term Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DaewoongConvertibleNote" roleURI="http://www.evolus.com/role/DaewoongConvertibleNote">
        <link:definition>2125107 - Disclosure - Daewoong Convertible Note</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DaewoongConvertibleNoteDetails" roleURI="http://www.evolus.com/role/DaewoongConvertibleNoteDetails">
        <link:definition>2426414 - Disclosure - Daewoong Convertible Note (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeases" roleURI="http://www.evolus.com/role/OperatingLeases">
        <link:definition>2127108 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTables" roleURI="http://www.evolus.com/role/OperatingLeasesTables">
        <link:definition>2328305 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesNarrativeDetails" roleURI="http://www.evolus.com/role/OperatingLeasesNarrativeDetails">
        <link:definition>2429415 - Disclosure - Operating Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails" roleURI="http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails">
        <link:definition>2430416 - Disclosure - Operating Leases - Components of Lease Expense and Other Quantitative Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails" roleURI="http://www.evolus.com/role/OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails">
        <link:definition>2431417 - Disclosure - Operating Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails" roleURI="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails">
        <link:definition>2432418 - Disclosure - Operating Leases - Maturity of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>2432418 - Disclosure - Operating Leases - Maturity of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.evolus.com/role/CommitmentsandContingencies">
        <link:definition>2133109 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesDetails" roleURI="http://www.evolus.com/role/CommitmentandContingenciesDetails">
        <link:definition>2434419 - Disclosure - Commitment and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.evolus.com/role/StockholdersEquity">
        <link:definition>2135110 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.evolus.com/role/StockholdersEquityTables">
        <link:definition>2336306 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.evolus.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2437420 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityValuationAssumptionsDetails" roleURI="http://www.evolus.com/role/StockholdersEquityValuationAssumptionsDetails">
        <link:definition>2438421 - Disclosure - Stockholders' Equity - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofStockOptionActivityDetails" roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails">
        <link:definition>2439422 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofRestrictedStockUnitActivityDetails" roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails">
        <link:definition>2440423 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockbasedCompensationExpenseDetails" roleURI="http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails">
        <link:definition>2441424 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedytoxAllerganSettlementAgreementsandDaewoongArrangement" roleURI="http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangement">
        <link:definition>2142111 - Disclosure - Medytox/Allergan Settlement Agreements and Daewoong Arrangement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails" roleURI="http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails">
        <link:definition>2443425 - Disclosure - Medytox/Allergan Settlement Agreements and Daewoong Arrangement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.evolus.com/role/EmployeeBenefitPlan">
        <link:definition>2144112 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://www.evolus.com/role/EmployeeBenefitPlanDetails">
        <link:definition>2445426 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.evolus.com/role/IncomeTaxes">
        <link:definition>2146113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.evolus.com/role/IncomeTaxesTables">
        <link:definition>2347307 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails" roleURI="http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails">
        <link:definition>2448427 - Disclosure - Income Taxes - Components of Current and Deferred Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.evolus.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2449428 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2450429 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofEffectiveTaxDetails" roleURI="http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails">
        <link:definition>2451430 - Disclosure - Income Taxes - Reconciliation of Effective Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsDetails" roleURI="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails">
        <link:definition>2452431 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.evolus.com/role/RelatedPartyTransactions">
        <link:definition>2153114 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.evolus.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2454432 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" abstract="false" name="MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" abstract="false" name="DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eols_OxfordTermLoansMember" abstract="true" name="OxfordTermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentFeeAmountWaived" abstract="false" name="DebtInstrumentPrepaymentFeeAmountWaived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_FollowOnOfferingMember" abstract="true" name="FollowOnOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_ContingentRoyaltyObligationMember" abstract="true" name="ContingentRoyaltyObligationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_IntangibleAssetsGrossIncludingGoodwill" abstract="false" name="IntangibleAssetsGrossIncludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DaewoongAgreementMember" abstract="true" name="DaewoongAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_TermOneMember" abstract="true" name="TermOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_OxfordTermLoanFacilityMember" abstract="true" name="OxfordTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_StockIssuedDuringPeriodValuesLitigationSettlement" abstract="false" name="StockIssuedDuringPeriodValuesLitigationSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_RestrictedStockUnitsRSUsMarketConditionsMember" abstract="true" name="RestrictedStockUnitsRSUsMarketConditionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_DebtInstrumentNumberOfTranches" abstract="false" name="DebtInstrumentNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_StockIssuedForAccruedLitigationSettlementExpense" abstract="false" name="StockIssuedForAccruedLitigationSettlementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_SaleOfStockMaximumConsiderationReceivable" abstract="false" name="SaleOfStockMaximumConsiderationReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" abstract="false" name="AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_RebatesAndCouponsCreditsAndPayments" abstract="false" name="RebatesAndCouponsCreditsAndPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentAmountThreshold" abstract="false" name="DebtInstrumentPrepaymentAmountThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" abstract="false" name="EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" abstract="false" name="RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_TermLoanFacilityTrancheOneMember" abstract="true" name="TermLoanFacilityTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" abstract="false" name="ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_AllocatedShareBasedCompensationExpenseCapitalized" abstract="false" name="AllocatedShareBasedCompensationExpenseCapitalized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal" abstract="false" name="DebtInstrumentNumberOfPeriodicPaymentsPrincipal" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" abstract="false" name="DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_PharmakonTermLoansOneMember" abstract="true" name="PharmakonTermLoansOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_DebtInstrumentFeeAmountWaived" abstract="false" name="DebtInstrumentFeeAmountWaived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_EvolusIncMember" abstract="true" name="EvolusIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" abstract="false" name="SaleOfStockCommissionPaymentUponGrossProceedsPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eols_LineofCreditFacilityNumberofAdvances" abstract="false" name="LineofCreditFacilityNumberofAdvances" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" abstract="false" name="CommonStockAdditionalCapitalSharesReservedforFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eols_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" abstract="false" name="PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentTermsAxis" abstract="true" name="DebtInstrumentPrepaymentTermsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="eols_IncreaseDecreaseInAccruedLitigationSettlement" abstract="false" name="IncreaseDecreaseInAccruedLitigationSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_TermLoanFacilityTrancheTwoMember" abstract="true" name="TermLoanFacilityTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_TermTwoMember" abstract="true" name="TermTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_PaymentsOfContingentRoyaltyObligation" abstract="false" name="PaymentsOfContingentRoyaltyObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DebtInstrumentPeriodOfInterestOnlyPayments" abstract="false" name="DebtInstrumentPeriodOfInterestOnlyPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" abstract="false" name="ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_SCHAEONLLCMember" abstract="true" name="SCHAEONLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_MilestonePaymentsForIntangibleAssets" abstract="false" name="MilestonePaymentsForIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear" abstract="false" name="ShareIssuanceAgreementPercentageOfShareDisposePerYear" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eols_ATMSalesAgreementMember" abstract="true" name="ATMSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" abstract="false" name="LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_PharmakonTermLoansTwoMember" abstract="true" name="PharmakonTermLoansTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentFeePercentageYearTwo" abstract="false" name="DebtInstrumentPrepaymentFeePercentageYearTwo" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eols_MilestonePaymentInConnectionWithAgreement" abstract="false" name="MilestonePaymentInConnectionWithAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_PharmakonTermLoansMember" abstract="true" name="PharmakonTermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_TermThreeMember" abstract="true" name="TermThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="eols_LossContingencySettlementAgreementPaymentTerms" abstract="false" name="LossContingencySettlementAgreementPaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_LesseeOperatingLeaseTerminationPeriod" abstract="false" name="LesseeOperatingLeaseTerminationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" abstract="true" name="RestrictedStockUnitsRSUsPerformanceConditionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentFeePercentageThereafter" abstract="false" name="DebtInstrumentPrepaymentFeePercentageThereafter" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" abstract="false" name="LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_DebtInstrumentOfFinalPaymentAmountWaived" abstract="false" name="DebtInstrumentOfFinalPaymentAmountWaived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DebtInstrumentAmortizationPeriod" abstract="false" name="DebtInstrumentAmortizationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_DaewoongConvertibleNoteMember" abstract="true" name="DaewoongConvertibleNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation" abstract="false" name="EffectiveIncomeTaxRateReconciliationOfficersCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" abstract="false" name="EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentTermsDomain" abstract="true" name="DebtInstrumentPrepaymentTermsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_OperatingLeaseRightofUseAssetAmortization" abstract="false" name="OperatingLeaseRightofUseAssetAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_StockIssuedDuringPeriodSharesLitigationSettlement" abstract="false" name="StockIssuedDuringPeriodSharesLitigationSettlement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" abstract="false" name="DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" abstract="false" name="DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses" abstract="false" name="AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_IntellectualPropertyDisputesJeuveauMember" abstract="true" name="IntellectualPropertyDisputesJeuveauMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_SaleOfStockCommissionPaid" abstract="false" name="SaleOfStockCommissionPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>eols-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4ac935c8-acd7-4078-a010-d8166688f707,g:62b990ab-d451-4f6d-92f0-709386d601f0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolus.com/role/BalanceSheets" xlink:type="simple" xlink:href="eols-20211231.xsd#BalanceSheets"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6abf08e1-36f6-44d9-9c19-84577fe9054b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_81ed1fba-9dc1-4c4d-ae18-e68af382231b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6abf08e1-36f6-44d9-9c19-84577fe9054b" xlink:to="loc_us-gaap_AssetsCurrent_81ed1fba-9dc1-4c4d-ae18-e68af382231b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cee96eea-8605-4408-afe6-85781801dbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6abf08e1-36f6-44d9-9c19-84577fe9054b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cee96eea-8605-4408-afe6-85781801dbdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8ab3f685-e93a-41c0-ae3e-8811ad7b0f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6abf08e1-36f6-44d9-9c19-84577fe9054b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8ab3f685-e93a-41c0-ae3e-8811ad7b0f79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6ce90b9e-68e3-4290-95b9-b75110f96174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6abf08e1-36f6-44d9-9c19-84577fe9054b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6ce90b9e-68e3-4290-95b9-b75110f96174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_42376543-3147-4702-bb31-239dc9b16eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6abf08e1-36f6-44d9-9c19-84577fe9054b" xlink:to="loc_us-gaap_Goodwill_42376543-3147-4702-bb31-239dc9b16eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a076766d-4585-444a-9923-88970e64ae6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6abf08e1-36f6-44d9-9c19-84577fe9054b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a076766d-4585-444a-9923-88970e64ae6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4c90df39-ebf8-4acc-a7ee-85cdae1c3070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9f396420-acf7-496b-9311-c6a2af894877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4c90df39-ebf8-4acc-a7ee-85cdae1c3070" xlink:to="loc_us-gaap_StockholdersEquity_9f396420-acf7-496b-9311-c6a2af894877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ac83cb4a-8f58-4099-b186-ee985cfc2144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4c90df39-ebf8-4acc-a7ee-85cdae1c3070" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ac83cb4a-8f58-4099-b186-ee985cfc2144" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9e941b89-1ebf-44ec-a7fb-b653e7417964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4c90df39-ebf8-4acc-a7ee-85cdae1c3070" xlink:to="loc_us-gaap_Liabilities_9e941b89-1ebf-44ec-a7fb-b653e7417964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_17ae4a01-4c50-4642-8a1d-89228e0cc2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0ccc03ed-37f5-4c44-bc3a-4e1c6af81c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_17ae4a01-4c50-4642-8a1d-89228e0cc2bf" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0ccc03ed-37f5-4c44-bc3a-4e1c6af81c97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_188c8521-1f93-444b-8a45-4d6daa91da54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_17ae4a01-4c50-4642-8a1d-89228e0cc2bf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_188c8521-1f93-444b-8a45-4d6daa91da54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1293e13d-815d-4e20-a31f-a79e13ff7956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_17ae4a01-4c50-4642-8a1d-89228e0cc2bf" xlink:to="loc_us-gaap_InventoryNet_1293e13d-815d-4e20-a31f-a79e13ff7956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a96aa0cb-24f7-4b3a-8210-9020ca1421c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_17ae4a01-4c50-4642-8a1d-89228e0cc2bf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a96aa0cb-24f7-4b3a-8210-9020ca1421c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_24644353-31f8-4c51-93af-1cb6e2097f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_17ae4a01-4c50-4642-8a1d-89228e0cc2bf" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_24644353-31f8-4c51-93af-1cb6e2097f9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_b5a10760-1058-4d77-a695-29e2403a12c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_17ae4a01-4c50-4642-8a1d-89228e0cc2bf" xlink:to="loc_us-gaap_OtherAssetsCurrent_b5a10760-1058-4d77-a695-29e2403a12c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0b93cc00-900c-4bff-848c-0c9ac2743f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9fbf560c-4c52-4c53-b993-7aa1645c4648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0b93cc00-900c-4bff-848c-0c9ac2743f4d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9fbf560c-4c52-4c53-b993-7aa1645c4648" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_73c8ff5e-5759-4f78-b6e9-63ec3e742afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0b93cc00-900c-4bff-848c-0c9ac2743f4d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_73c8ff5e-5759-4f78-b6e9-63ec3e742afd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e351b06e-aad4-4204-9830-6e2cd7217306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0b93cc00-900c-4bff-848c-0c9ac2743f4d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e351b06e-aad4-4204-9830-6e2cd7217306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_5aecfb6d-5d13-4928-922b-f17ab08fe6ee" xlink:href="eols-20211231.xsd#eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0b93cc00-900c-4bff-848c-0c9ac2743f4d" xlink:to="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_5aecfb6d-5d13-4928-922b-f17ab08fe6ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtCurrent_f7f236ba-8b18-42cc-8fd4-066c05d11608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0b93cc00-900c-4bff-848c-0c9ac2743f4d" xlink:to="loc_us-gaap_SecuredDebtCurrent_f7f236ba-8b18-42cc-8fd4-066c05d11608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_74ce12bd-baa7-4c73-a5ad-6a83574fde8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0b93cc00-900c-4bff-848c-0c9ac2743f4d" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_74ce12bd-baa7-4c73-a5ad-6a83574fde8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_92f107bb-f366-46e6-9525-431ab06f6712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0b93cc00-900c-4bff-848c-0c9ac2743f4d" xlink:to="loc_us-gaap_LitigationReserveCurrent_92f107bb-f366-46e6-9525-431ab06f6712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_572e4a4b-7665-411f-ac1e-6cc9fcdc4708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_eb954196-7a64-4cf3-aaf5-7c4f8da7fa89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_572e4a4b-7665-411f-ac1e-6cc9fcdc4708" xlink:to="loc_us-gaap_PreferredStockValue_eb954196-7a64-4cf3-aaf5-7c4f8da7fa89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9528de88-3e66-42c6-a6f5-32b8b9ad8086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_572e4a4b-7665-411f-ac1e-6cc9fcdc4708" xlink:to="loc_us-gaap_CommonStockValue_9528de88-3e66-42c6-a6f5-32b8b9ad8086" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_459cf002-9186-4c43-aa96-c1f0bcaf202f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_572e4a4b-7665-411f-ac1e-6cc9fcdc4708" xlink:to="loc_us-gaap_AdditionalPaidInCapital_459cf002-9186-4c43-aa96-c1f0bcaf202f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_725fb46a-a53b-42c8-8643-d7f78816a11f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_572e4a4b-7665-411f-ac1e-6cc9fcdc4708" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_725fb46a-a53b-42c8-8643-d7f78816a11f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d80d9a93-c68b-4381-9fa3-ca0351449d69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9cd67b26-f9bb-4981-b6a5-b9e93a697b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d80d9a93-c68b-4381-9fa3-ca0351449d69" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9cd67b26-f9bb-4981-b6a5-b9e93a697b9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e652d1d1-bf61-4de3-afe3-b9b66eca2679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d80d9a93-c68b-4381-9fa3-ca0351449d69" xlink:to="loc_us-gaap_LiabilitiesCurrent_e652d1d1-bf61-4de3-afe3-b9b66eca2679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent_31bf9859-5377-412f-9b60-74fa0bbe4a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d80d9a93-c68b-4381-9fa3-ca0351449d69" xlink:to="loc_us-gaap_LitigationReserveNoncurrent_31bf9859-5377-412f-9b60-74fa0bbe4a8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_2667465b-f9ad-4d69-9346-d0a78bcc48b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d80d9a93-c68b-4381-9fa3-ca0351449d69" xlink:to="loc_us-gaap_ContractualObligation_2667465b-f9ad-4d69-9346-d0a78bcc48b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_577df66d-d5a8-42b0-82c6-a122dcb99f95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d80d9a93-c68b-4381-9fa3-ca0351449d69" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_577df66d-d5a8-42b0-82c6-a122dcb99f95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_4b110e3f-8959-4945-85c3-99b4890faf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d80d9a93-c68b-4381-9fa3-ca0351449d69" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_4b110e3f-8959-4945-85c3-99b4890faf5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_22ed33fd-7355-49c1-8638-ecd4b8933178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d80d9a93-c68b-4381-9fa3-ca0351449d69" xlink:to="loc_us-gaap_SecuredLongTermDebt_22ed33fd-7355-49c1-8638-ecd4b8933178" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="eols-20211231.xsd#StatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6b5b8f02-a7cf-4036-bc9a-7e31537769fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4d9b4e18-666c-4f24-a058-b4834c99c145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6b5b8f02-a7cf-4036-bc9a-7e31537769fa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4d9b4e18-666c-4f24-a058-b4834c99c145" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2d292ffb-9dd7-4b3d-8eb7-878bc7a30989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6b5b8f02-a7cf-4036-bc9a-7e31537769fa" xlink:to="loc_us-gaap_CostsAndExpenses_2d292ffb-9dd7-4b3d-8eb7-878bc7a30989" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_045728df-ffba-4141-be8c-1f0b1cc6ea7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1757a4c2-8467-46de-b285-cecee882a151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_045728df-ffba-4141-be8c-1f0b1cc6ea7c" xlink:to="loc_us-gaap_NetIncomeLoss_1757a4c2-8467-46de-b285-cecee882a151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2caf3e08-51a2-41ff-904c-3afaa99e1bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_045728df-ffba-4141-be8c-1f0b1cc6ea7c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2caf3e08-51a2-41ff-904c-3afaa99e1bfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c961cfc2-27f8-48e3-bf7b-91e8d8d11be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9fcac91b-b966-4d4f-a67c-47f264d02239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c961cfc2-27f8-48e3-bf7b-91e8d8d11be9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9fcac91b-b966-4d4f-a67c-47f264d02239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d47b5dfe-5b31-4339-b224-b9d078ffac67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c961cfc2-27f8-48e3-bf7b-91e8d8d11be9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d47b5dfe-5b31-4339-b224-b9d078ffac67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f398bd9d-43ce-4486-9859-77f11502832b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c961cfc2-27f8-48e3-bf7b-91e8d8d11be9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f398bd9d-43ce-4486-9859-77f11502832b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_58068da3-aa4c-4a5a-89ac-24db1fb46188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c961cfc2-27f8-48e3-bf7b-91e8d8d11be9" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_58068da3-aa4c-4a5a-89ac-24db1fb46188" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_4a5979a9-b3df-45c0-b1b6-42b2941ae203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c961cfc2-27f8-48e3-bf7b-91e8d8d11be9" xlink:to="loc_us-gaap_LitigationSettlementExpense_4a5979a9-b3df-45c0-b1b6-42b2941ae203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ac7dc8fc-f5f1-479f-9cb5-a27ea0d097c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c961cfc2-27f8-48e3-bf7b-91e8d8d11be9" xlink:to="loc_us-gaap_RestructuringCharges_ac7dc8fc-f5f1-479f-9cb5-a27ea0d097c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ff21e8c0-3fed-4baa-8689-d29e5fcb257f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c961cfc2-27f8-48e3-bf7b-91e8d8d11be9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ff21e8c0-3fed-4baa-8689-d29e5fcb257f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9df545f0-51e0-4f63-8d39-eddf96588154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c961cfc2-27f8-48e3-bf7b-91e8d8d11be9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9df545f0-51e0-4f63-8d39-eddf96588154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_101b336b-b784-4f18-a2b8-d61b38e4ed5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cce4ed71-8579-4856-ac99-01efefe1b279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_101b336b-b784-4f18-a2b8-d61b38e4ed5b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cce4ed71-8579-4856-ac99-01efefe1b279" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ab32d9b6-e69c-41d5-98ad-4909c7d5cb35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_101b336b-b784-4f18-a2b8-d61b38e4ed5b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ab32d9b6-e69c-41d5-98ad-4909c7d5cb35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2c613559-cc4f-4ab3-be68-55a06706832a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ce62a730-911c-422b-80b6-c31303fc43bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2c613559-cc4f-4ab3-be68-55a06706832a" xlink:to="loc_us-gaap_OperatingIncomeLoss_ce62a730-911c-422b-80b6-c31303fc43bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_dd175dba-b586-41bc-82fb-a1e9f6b18a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2c613559-cc4f-4ab3-be68-55a06706832a" xlink:to="loc_us-gaap_InvestmentIncomeNet_dd175dba-b586-41bc-82fb-a1e9f6b18a50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f08a94d0-c82e-4e7a-81cd-7e2cf795661b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2c613559-cc4f-4ab3-be68-55a06706832a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f08a94d0-c82e-4e7a-81cd-7e2cf795661b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f9c8dae3-6d23-4026-90e1-2f24e9903630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2c613559-cc4f-4ab3-be68-55a06706832a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f9c8dae3-6d23-4026-90e1-2f24e9903630" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="eols-20211231.xsd#StatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_262c749e-ef88-4a85-a689-0db460a9a292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_86291aff-b307-4947-8d0e-11ac5488fb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_262c749e-ef88-4a85-a689-0db460a9a292" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_86291aff-b307-4947-8d0e-11ac5488fb6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_07b4c92d-5f2d-4772-961d-04d104ca2f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForSoftware"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_262c749e-ef88-4a85-a689-0db460a9a292" xlink:to="loc_us-gaap_PaymentsForSoftware_07b4c92d-5f2d-4772-961d-04d104ca2f09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_36b1ae31-3d3e-481c-8673-e080bc9572c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_262c749e-ef88-4a85-a689-0db460a9a292" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_36b1ae31-3d3e-481c-8673-e080bc9572c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_c7c8e786-d0bf-4ed0-a1fb-b83f00330ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_262c749e-ef88-4a85-a689-0db460a9a292" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_c7c8e786-d0bf-4ed0-a1fb-b83f00330ce6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_68b81b9a-c104-4fc5-a53a-fc64d3304ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_68b81b9a-c104-4fc5-a53a-fc64d3304ded" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_950539db-8d70-4547-ac6c-90dd3b08ed35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_950539db-8d70-4547-ac6c-90dd3b08ed35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c8ae04e3-c1cf-4ef0-9b67-d50e2ddc3de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c8ae04e3-c1cf-4ef0-9b67-d50e2ddc3de0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9fb61518-4f5f-4af9-8ae2-54757e20abbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9fb61518-4f5f-4af9-8ae2-54757e20abbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_2af79d63-742e-40af-9419-9a2e5b0ae2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_us-gaap_PaidInKindInterest_2af79d63-742e-40af-9419-9a2e5b0ae2a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_5cb998e9-e424-4339-90a2-d513549a4642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_5cb998e9-e424-4339-90a2-d513549a4642" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8a31d741-9e27-4417-ae20-26c180bc58e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8a31d741-9e27-4417-ae20-26c180bc58e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e2fd0c24-1b79-49e7-af3a-f5e6c748f075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_us-gaap_NetIncomeLoss_e2fd0c24-1b79-49e7-af3a-f5e6c748f075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement_e0d604f6-4825-4297-ab37-e0a0e6d3a036" xlink:href="eols-20211231.xsd#eols_IncreaseDecreaseInAccruedLitigationSettlement"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement_e0d604f6-4825-4297-ab37-e0a0e6d3a036" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OperatingLeaseRightofUseAssetAmortization_ad3ebe0a-b741-4bc6-a841-fe6775f72c1a" xlink:href="eols-20211231.xsd#eols_OperatingLeaseRightofUseAssetAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_eols_OperatingLeaseRightofUseAssetAmortization_ad3ebe0a-b741-4bc6-a841-fe6775f72c1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_887a1802-e248-4d4f-b17f-6e08fe3c59fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_887a1802-e248-4d4f-b17f-6e08fe3c59fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_75b22f4b-3b7f-400e-a476-1f374733721f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_75b22f4b-3b7f-400e-a476-1f374733721f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7bac96d9-79a6-42d3-bbef-07a312edd885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7bac96d9-79a6-42d3-bbef-07a312edd885" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d7c81783-db71-4652-adff-a7825e5da796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d7c81783-db71-4652-adff-a7825e5da796" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1c0a289c-7a1f-47f8-aa26-24841fe222fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1c0a289c-7a1f-47f8-aa26-24841fe222fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_efbc4641-d93a-4c19-92ee-7f8788151709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_efbc4641-d93a-4c19-92ee-7f8788151709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5e4d6216-d78f-4ef3-aa3a-194ee9dd4f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5e4d6216-d78f-4ef3-aa3a-194ee9dd4f88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_589d24fb-e608-4641-bae4-ac379c8bab74" xlink:href="eols-20211231.xsd#eols_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_589d24fb-e608-4641-bae4-ac379c8bab74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fbc5ef18-b5d7-43b2-80da-c0a90ac29de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_us-gaap_ShareBasedCompensation_fbc5ef18-b5d7-43b2-80da-c0a90ac29de9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses_4fa7094a-f179-494c-95a4-9637cd34fa24" xlink:href="eols-20211231.xsd#eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab109fb2-496c-4c1d-841f-fa5acf4fc281" xlink:to="loc_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses_4fa7094a-f179-494c-95a4-9637cd34fa24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ebb3c766-f4cf-42c8-b25e-1129cd3d4d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2776184c-4c5c-4e1f-b531-eee96f9996c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ebb3c766-f4cf-42c8-b25e-1129cd3d4d71" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2776184c-4c5c-4e1f-b531-eee96f9996c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_609d02a9-95c8-44fd-b2fb-5c109a3a1584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ebb3c766-f4cf-42c8-b25e-1129cd3d4d71" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_609d02a9-95c8-44fd-b2fb-5c109a3a1584" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f6ecd84-da98-4d85-bdd5-a18a3cf6ade5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ebb3c766-f4cf-42c8-b25e-1129cd3d4d71" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f6ecd84-da98-4d85-bdd5-a18a3cf6ade5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07b0bf8-8552-4132-b0ad-4b636ed98b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_47caaa0d-b16d-4bfb-b0fc-903398932c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07b0bf8-8552-4132-b0ad-4b636ed98b11" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_47caaa0d-b16d-4bfb-b0fc-903398932c03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_3b7748fb-f4cc-47f6-86b7-08e23fc4dc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07b0bf8-8552-4132-b0ad-4b636ed98b11" xlink:to="loc_us-gaap_RepaymentsOfDebt_3b7748fb-f4cc-47f6-86b7-08e23fc4dc2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_af1a410b-c4ad-480f-9dd1-8f9561c841e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07b0bf8-8552-4132-b0ad-4b636ed98b11" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_af1a410b-c4ad-480f-9dd1-8f9561c841e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7099f3b6-12cc-4248-bc9a-58cdcb0dca4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07b0bf8-8552-4132-b0ad-4b636ed98b11" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7099f3b6-12cc-4248-bc9a-58cdcb0dca4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_16bd73fa-8d68-42b6-b5a9-499e16c681bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07b0bf8-8552-4132-b0ad-4b636ed98b11" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_16bd73fa-8d68-42b6-b5a9-499e16c681bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_da71dddf-b111-4c93-864d-a2021728d9b5" xlink:href="eols-20211231.xsd#eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07b0bf8-8552-4132-b0ad-4b636ed98b11" xlink:to="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_da71dddf-b111-4c93-864d-a2021728d9b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation_97c80f9d-cc55-4fd5-861d-119dc7f8c57d" xlink:href="eols-20211231.xsd#eols_PaymentsOfContingentRoyaltyObligation"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07b0bf8-8552-4132-b0ad-4b636ed98b11" xlink:to="loc_eols_PaymentsOfContingentRoyaltyObligation_97c80f9d-cc55-4fd5-861d-119dc7f8c57d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3080bccc-61b2-4a90-bac3-174baf7a1609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07b0bf8-8552-4132-b0ad-4b636ed98b11" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3080bccc-61b2-4a90-bac3-174baf7a1609" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_d36cf269-87c3-49ce-abf3-3986cdd609ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07b0bf8-8552-4132-b0ad-4b636ed98b11" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_d36cf269-87c3-49ce-abf3-3986cdd609ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_490fb7fb-8f5f-4bf8-a85b-6a96038b70e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07b0bf8-8552-4132-b0ad-4b636ed98b11" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_490fb7fb-8f5f-4bf8-a85b-6a96038b70e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_58043225-212e-47df-8baf-9293112176da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4768b12e-1525-481b-aacc-b3b66df45992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_58043225-212e-47df-8baf-9293112176da" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4768b12e-1525-481b-aacc-b3b66df45992" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_57a00cff-939b-4d15-9c53-a8a9f461d4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_58043225-212e-47df-8baf-9293112176da" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_57a00cff-939b-4d15-9c53-a8a9f461d4c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0aae45c8-6418-492e-872d-b87246d8ef3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_58043225-212e-47df-8baf-9293112176da" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0aae45c8-6418-492e-872d-b87246d8ef3c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_213f1062-3c2a-41b2-af37-c9a93158da40" xlink:href="eols-20211231.xsd#eols_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ef5bd217-0d4f-40b5-9003-129630aab316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_IntangibleAssetsGrossIncludingGoodwill_213f1062-3c2a-41b2-af37-c9a93158da40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ef5bd217-0d4f-40b5-9003-129630aab316" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d85506a6-5e5c-4b30-85b0-b49fca2b57eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_IntangibleAssetsGrossIncludingGoodwill_213f1062-3c2a-41b2-af37-c9a93158da40" xlink:to="loc_us-gaap_Goodwill_d85506a6-5e5c-4b30-85b0-b49fca2b57eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_43eb0908-7059-438f-8fd4-2b30c96344b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97a7f6e7-7294-491e-a6e7-08029bc016e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_43eb0908-7059-438f-8fd4-2b30c96344b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97a7f6e7-7294-491e-a6e7-08029bc016e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_019e5c44-db8a-426e-98af-da5ca5e8868a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_43eb0908-7059-438f-8fd4-2b30c96344b4" xlink:to="loc_us-gaap_Goodwill_019e5c44-db8a-426e-98af-da5ca5e8868a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5fa19949-2dc3-46a8-a078-8baa74947d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4d16e157-7235-49e6-979b-56108e25965e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5fa19949-2dc3-46a8-a078-8baa74947d8a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4d16e157-7235-49e6-979b-56108e25965e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d5868b57-89f9-4dae-90db-463a2efae608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5fa19949-2dc3-46a8-a078-8baa74947d8a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d5868b57-89f9-4dae-90db-463a2efae608" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_188de180-5d0d-4320-a1bc-611977e01ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7a76dba6-e29b-4936-8659-544bab0f4ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_188de180-5d0d-4320-a1bc-611977e01ea2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7a76dba6-e29b-4936-8659-544bab0f4ffa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b722b4a8-2551-402e-a5c1-3ff461dd6343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_188de180-5d0d-4320-a1bc-611977e01ea2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b722b4a8-2551-402e-a5c1-3ff461dd6343" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_50d6fd3d-17a6-42e6-95cd-4c32f304d713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_188de180-5d0d-4320-a1bc-611977e01ea2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_50d6fd3d-17a6-42e6-95cd-4c32f304d713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cceffc13-7cab-4863-94d9-bde3d6bfad69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_188de180-5d0d-4320-a1bc-611977e01ea2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cceffc13-7cab-4863-94d9-bde3d6bfad69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_af5229c0-1faf-49be-aea6-8055a81c31ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_188de180-5d0d-4320-a1bc-611977e01ea2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_af5229c0-1faf-49be-aea6-8055a81c31ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_b1c36113-182c-4fdf-a4b7-ecb686b3f9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_188de180-5d0d-4320-a1bc-611977e01ea2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_b1c36113-182c-4fdf-a4b7-ecb686b3f9fb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7a93a64d-ff0f-4483-8c08-52d7d85674a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_d5ef832c-e27c-4895-9aae-6edb5aa8fa26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7a93a64d-ff0f-4483-8c08-52d7d85674a5" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_d5ef832c-e27c-4895-9aae-6edb5aa8fa26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5f289bf3-3159-418d-8abd-cc0ba6a86326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7a93a64d-ff0f-4483-8c08-52d7d85674a5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5f289bf3-3159-418d-8abd-cc0ba6a86326" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_77e7ed19-9a3d-4ea7-885d-a0124da220c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7a93a64d-ff0f-4483-8c08-52d7d85674a5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_77e7ed19-9a3d-4ea7-885d-a0124da220c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e94a2e34-d13b-4bc3-ad5d-3c637dec0df0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7a93a64d-ff0f-4483-8c08-52d7d85674a5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e94a2e34-d13b-4bc3-ad5d-3c637dec0df0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_8d0f2a64-e170-424b-bf66-a29528018a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7a93a64d-ff0f-4483-8c08-52d7d85674a5" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_8d0f2a64-e170-424b-bf66-a29528018a83" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#TermLoansScheduleofLongTermDebtMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_99a528ff-057f-4d8e-80bb-21c1164ae693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_60e64758-545a-4ba1-9c78-3c0cd41bf555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_99a528ff-057f-4d8e-80bb-21c1164ae693" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_60e64758-545a-4ba1-9c78-3c0cd41bf555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_bb22596e-6699-4d81-8f30-6fb93a465e54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_99a528ff-057f-4d8e-80bb-21c1164ae693" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_bb22596e-6699-4d81-8f30-6fb93a465e54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1d3cac12-ed4c-4fb0-aac1-681176884fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9d877758-31b3-41f0-bc89-ee9db13c796b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1d3cac12-ed4c-4fb0-aac1-681176884fd8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9d877758-31b3-41f0-bc89-ee9db13c796b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_bfc42d78-f613-4eb6-8a93-17913ac660df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1d3cac12-ed4c-4fb0-aac1-681176884fd8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_bfc42d78-f613-4eb6-8a93-17913ac660df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_28b9aa1d-e9ec-412b-bb7e-2e55fb077f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1d3cac12-ed4c-4fb0-aac1-681176884fd8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_28b9aa1d-e9ec-412b-bb7e-2e55fb077f56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f441c1c6-b1e9-4fad-a0ce-ef8e5e55ec57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1d3cac12-ed4c-4fb0-aac1-681176884fd8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f441c1c6-b1e9-4fad-a0ce-ef8e5e55ec57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_a8a6e4ef-5645-4922-a39b-29741a1e261d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1d3cac12-ed4c-4fb0-aac1-681176884fd8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_a8a6e4ef-5645-4922-a39b-29741a1e261d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ff493563-c5ff-477a-a1e5-0652236c2061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1d3cac12-ed4c-4fb0-aac1-681176884fd8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ff493563-c5ff-477a-a1e5-0652236c2061" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_d31ab68f-3e4b-47ab-bd1d-f66dbe4c2e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_41e6daa5-4625-4d4a-9b59-52533ad4336e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_d31ab68f-3e4b-47ab-bd1d-f66dbe4c2e1e" xlink:to="loc_us-gaap_OperatingLeaseCost_41e6daa5-4625-4d4a-9b59-52533ad4336e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_9b1cea3d-8a07-4a8e-80dd-1b1913d09176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_d31ab68f-3e4b-47ab-bd1d-f66dbe4c2e1e" xlink:to="loc_us-gaap_VariableLeaseCost_9b1cea3d-8a07-4a8e-80dd-1b1913d09176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_65789bf9-371f-478d-bfe1-ce835b4f3a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_d31ab68f-3e4b-47ab-bd1d-f66dbe4c2e1e" xlink:to="loc_us-gaap_ShortTermLeaseCost_65789bf9-371f-478d-bfe1-ce835b4f3a80" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d7fe2039-63b6-46c8-ba85-7878ebbbd396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_89993726-8095-4d92-8a37-b0dfa9611565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d7fe2039-63b6-46c8-ba85-7878ebbbd396" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_89993726-8095-4d92-8a37-b0dfa9611565" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_aea60ba6-29d3-4295-8d0b-b3ddecb080b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d7fe2039-63b6-46c8-ba85-7878ebbbd396" xlink:to="loc_us-gaap_OperatingLeaseLiability_aea60ba6-29d3-4295-8d0b-b3ddecb080b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="eols-20211231.xsd#OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_194eeb16-1e87-41ce-828b-3974c0a6aa8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_080af557-5fbd-45ab-982d-f3dcfb1801ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_194eeb16-1e87-41ce-828b-3974c0a6aa8f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_080af557-5fbd-45ab-982d-f3dcfb1801ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_089f2bb9-5796-41a3-955b-9b8949287233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_194eeb16-1e87-41ce-828b-3974c0a6aa8f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_089f2bb9-5796-41a3-955b-9b8949287233" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_020a2ac2-8671-483b-b215-950e64faebd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_194eeb16-1e87-41ce-828b-3974c0a6aa8f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_020a2ac2-8671-483b-b215-950e64faebd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_841c377e-9ebe-452c-b7cb-ff1e20540006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_194eeb16-1e87-41ce-828b-3974c0a6aa8f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_841c377e-9ebe-452c-b7cb-ff1e20540006" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e83b9ba8-032b-40a8-99d5-1e6ab465d423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_55bddf00-069a-4e66-a4d5-8d86b08e4683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e83b9ba8-032b-40a8-99d5-1e6ab465d423" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_55bddf00-069a-4e66-a4d5-8d86b08e4683" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_dae8dfab-72a5-4e48-a9c9-fc516971a068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e83b9ba8-032b-40a8-99d5-1e6ab465d423" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_dae8dfab-72a5-4e48-a9c9-fc516971a068" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_65bd0f90-a6a4-4e8a-9301-9477e9bdd06c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_503e14cb-a43d-42bd-b1dd-944439421db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_65bd0f90-a6a4-4e8a-9301-9477e9bdd06c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_503e14cb-a43d-42bd-b1dd-944439421db3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ff36cafe-3460-4b78-ad9f-1b453ecee3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_65bd0f90-a6a4-4e8a-9301-9477e9bdd06c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ff36cafe-3460-4b78-ad9f-1b453ecee3c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_32f61dc9-a42c-457a-83d4-5e009074ba14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1fe1634b-c584-4429-b600-58d359b1f50c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_32f61dc9-a42c-457a-83d4-5e009074ba14" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1fe1634b-c584-4429-b600-58d359b1f50c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e7c07f0f-48e8-492e-8a2f-e518b883eb31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_32f61dc9-a42c-457a-83d4-5e009074ba14" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e7c07f0f-48e8-492e-8a2f-e518b883eb31" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_db16cb01-dd36-400c-b2af-b0ead73ba5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f5153b8b-5ff0-4540-bcfb-582433c5ac6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_db16cb01-dd36-400c-b2af-b0ead73ba5d8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f5153b8b-5ff0-4540-bcfb-582433c5ac6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b154875d-8b13-43b0-9cb5-d34061c89218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_db16cb01-dd36-400c-b2af-b0ead73ba5d8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b154875d-8b13-43b0-9cb5-d34061c89218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_a0ebe1d9-85a9-45fd-b42f-440593e1ad02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_db16cb01-dd36-400c-b2af-b0ead73ba5d8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_a0ebe1d9-85a9-45fd-b42f-440593e1ad02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_cdafb1cd-d915-4114-b0a9-8ecdc629f66e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_db16cb01-dd36-400c-b2af-b0ead73ba5d8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_cdafb1cd-d915-4114-b0a9-8ecdc629f66e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DeferredTaxAssetsOperatingLeaseLiabilities_b01a4598-22c0-4cdc-8eec-df1bce72e0e7" xlink:href="eols-20211231.xsd#eols_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_db16cb01-dd36-400c-b2af-b0ead73ba5d8" xlink:to="loc_eols_DeferredTaxAssetsOperatingLeaseLiabilities_b01a4598-22c0-4cdc-8eec-df1bce72e0e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4f5e5f53-5d8c-4062-94cf-862b43d41d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_db16cb01-dd36-400c-b2af-b0ead73ba5d8" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4f5e5f53-5d8c-4062-94cf-862b43d41d8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_982e258f-c6f3-4e10-836c-2f5b6cba3af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_db16cb01-dd36-400c-b2af-b0ead73ba5d8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_982e258f-c6f3-4e10-836c-2f5b6cba3af7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_8a565fd9-f72a-4a5f-a244-52ed4705585f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_db16cb01-dd36-400c-b2af-b0ead73ba5d8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_8a565fd9-f72a-4a5f-a244-52ed4705585f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_c1c03749-311a-45b0-9c25-0c747fb25678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0794de28-4e50-46bc-bdaa-4a32bdce5cce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_c1c03749-311a-45b0-9c25-0c747fb25678" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_0794de28-4e50-46bc-bdaa-4a32bdce5cce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_bd91cb28-1d18-4942-949a-c9fa518a326b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_c1c03749-311a-45b0-9c25-0c747fb25678" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_bd91cb28-1d18-4942-949a-c9fa518a326b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_baac451b-be12-48f0-aca5-a79101719afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_dfc73cfd-b416-4893-962b-51444bd42e34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_baac451b-be12-48f0-aca5-a79101719afc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_dfc73cfd-b416-4893-962b-51444bd42e34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_439a6bf2-53a2-489f-b9e1-9284c1229211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_baac451b-be12-48f0-aca5-a79101719afc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_439a6bf2-53a2-489f-b9e1-9284c1229211" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_83831e21-b64e-4aa5-af8c-8b2827453407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_baac451b-be12-48f0-aca5-a79101719afc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_83831e21-b64e-4aa5-af8c-8b2827453407" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#IncomeTaxesReconciliationofEffectiveTaxDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bb537d38-1162-458b-8cc6-bae02dfb1c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ed18df33-20c0-4218-b85e-11df88a7ac3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bb537d38-1162-458b-8cc6-bae02dfb1c99" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ed18df33-20c0-4218-b85e-11df88a7ac3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6e4edfc9-60a7-4d51-a2bb-3c96f5297015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bb537d38-1162-458b-8cc6-bae02dfb1c99" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6e4edfc9-60a7-4d51-a2bb-3c96f5297015" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_f1023992-2ea8-4cd2-8d58-e0644812c3db" xlink:href="eols-20211231.xsd#eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bb537d38-1162-458b-8cc6-bae02dfb1c99" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_f1023992-2ea8-4cd2-8d58-e0644812c3db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_bf80d9ee-ffbf-4b48-8e33-c4f6f6fdb1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bb537d38-1162-458b-8cc6-bae02dfb1c99" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_bf80d9ee-ffbf-4b48-8e33-c4f6f6fdb1ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_846f5a7b-c908-43a7-aaa5-0c2e4aeecf08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bb537d38-1162-458b-8cc6-bae02dfb1c99" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_846f5a7b-c908-43a7-aaa5-0c2e4aeecf08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_80f9df3a-80b4-462a-905a-ed5fadcc8d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bb537d38-1162-458b-8cc6-bae02dfb1c99" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_80f9df3a-80b4-462a-905a-ed5fadcc8d3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_e9422a77-0681-4344-b712-0677a95e1cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bb537d38-1162-458b-8cc6-bae02dfb1c99" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_e9422a77-0681-4344-b712-0677a95e1cec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_be5a03bc-0912-469c-804c-1dcf7a3e7bf3" xlink:href="eols-20211231.xsd#eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bb537d38-1162-458b-8cc6-bae02dfb1c99" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_be5a03bc-0912-469c-804c-1dcf7a3e7bf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_98cad55a-e3b9-4355-b3b4-7e53ecda5179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bb537d38-1162-458b-8cc6-bae02dfb1c99" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_98cad55a-e3b9-4355-b3b4-7e53ecda5179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4ad5362e-6f54-49d4-89f2-fdb478d22f43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bb537d38-1162-458b-8cc6-bae02dfb1c99" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4ad5362e-6f54-49d4-89f2-fdb478d22f43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation_1e8d4ebe-e263-44ef-9a37-ee9d2b6b04bf" xlink:href="eols-20211231.xsd#eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bb537d38-1162-458b-8cc6-bae02dfb1c99" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation_1e8d4ebe-e263-44ef-9a37-ee9d2b6b04bf" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>eols-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4ac935c8-acd7-4078-a010-d8166688f707,g:62b990ab-d451-4f6d-92f0-709386d601f0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="eols-20211231.xsd#StatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="ic737da932cbc4ce7844dd6067f9b79ef_StatementsofOperationsandComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9d13c3d6-605e-46ef-ad34-53e7966b67e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_RevenuesAbstract_9d13c3d6-605e-46ef-ad34-53e7966b67e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06ec0f19-ef59-4283-b7c6-a58f99d8e495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_9d13c3d6-605e-46ef-ad34-53e7966b67e4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06ec0f19-ef59-4283-b7c6-a58f99d8e495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_705e0eda-9231-48e6-936d-2a092637878b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_705e0eda-9231-48e6-936d-2a092637878b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_19708b2b-b7ed-43c8-add7-62e0d7471ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_19708b2b-b7ed-43c8-add7-62e0d7471ffd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a226b730-832e-43d8-97c0-1d1b36979551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a226b730-832e-43d8-97c0-1d1b36979551" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_dedb3699-8f49-4712-bf97-b2ecdeee2503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_dedb3699-8f49-4712-bf97-b2ecdeee2503" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_69dfd54c-9a3f-4434-91ea-1637721a857d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_69dfd54c-9a3f-4434-91ea-1637721a857d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_161d4bc3-321e-4fb3-9fc7-2af671fd32aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_161d4bc3-321e-4fb3-9fc7-2af671fd32aa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_bdad3cb9-e923-4dda-9607-e8ea40844962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_LitigationSettlementExpense_bdad3cb9-e923-4dda-9607-e8ea40844962" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0005901f-3c41-4f76-84be-18cf9b701ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_RestructuringCharges_0005901f-3c41-4f76-84be-18cf9b701ca1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_78d05250-261b-4bee-9431-e5bd7365cd67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_CostsAndExpenses_78d05250-261b-4bee-9431-e5bd7365cd67" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6c128e34-e539-4f62-a143-19fcf54bfa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_OperatingIncomeLoss_6c128e34-e539-4f62-a143-19fcf54bfa8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b8e9bfd1-99cd-4bff-9f2f-8f9a2adf95e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b8e9bfd1-99cd-4bff-9f2f-8f9a2adf95e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_b34b2e44-bb40-4b31-94bd-e67530250a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b8e9bfd1-99cd-4bff-9f2f-8f9a2adf95e9" xlink:to="loc_us-gaap_InvestmentIncomeNet_b34b2e44-bb40-4b31-94bd-e67530250a27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1fb08891-ed4c-45b2-bb9f-69ef453c8e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b8e9bfd1-99cd-4bff-9f2f-8f9a2adf95e9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1fb08891-ed4c-45b2-bb9f-69ef453c8e00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_96fd6ce2-dff3-4d3f-877e-321b8cb95443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b8e9bfd1-99cd-4bff-9f2f-8f9a2adf95e9" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_96fd6ce2-dff3-4d3f-877e-321b8cb95443" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_61aa3923-78a9-4dab-9c4a-ee73171b5ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_61aa3923-78a9-4dab-9c4a-ee73171b5ad9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_65722c98-2902-4fde-9844-80b9acfbaf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_65722c98-2902-4fde-9844-80b9acfbaf2d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7ef87171-1862-43b2-afbb-f9faf4fa374f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_NetIncomeLoss_7ef87171-1862-43b2-afbb-f9faf4fa374f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_aa695dc7-bbf8-4b2e-a663-9209adcac0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_aa695dc7-bbf8-4b2e-a663-9209adcac0a9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b710b33d-ca41-4547-9fea-a276be9342c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_aa695dc7-bbf8-4b2e-a663-9209adcac0a9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b710b33d-ca41-4547-9fea-a276be9342c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8f920930-ca67-4330-97c1-261fae9e870c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_8f920930-ca67-4330-97c1-261fae9e870c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_afec7409-3d6e-46c0-8b5f-fd33651f6786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_EarningsPerShareBasic_afec7409-3d6e-46c0-8b5f-fd33651f6786" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_19bfa03c-2ea8-49a6-ad03-ddc555bcbf70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_19bfa03c-2ea8-49a6-ad03-ddc555bcbf70" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_09473644-84cd-44df-907b-4878f5e220ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_09473644-84cd-44df-907b-4878f5e220ce" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3ffecb68-a3d5-44d4-abe6-bf274130f337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3ffecb68-a3d5-44d4-abe6-bf274130f337" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_4fb5c420-f137-42f9-b4e5-64e84e444d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_4fb5c420-f137-42f9-b4e5-64e84e444d26" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d124808f-14f6-47ed-8068-d09cd6abc73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_StatementTable_d124808f-14f6-47ed-8068-d09cd6abc73b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d3005b4a-50cb-4412-a0ee-423f88f931c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d124808f-14f6-47ed-8068-d09cd6abc73b" xlink:to="loc_srt_ProductOrServiceAxis_d3005b4a-50cb-4412-a0ee-423f88f931c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d3005b4a-50cb-4412-a0ee-423f88f931c3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d3005b4a-50cb-4412-a0ee-423f88f931c3" xlink:to="loc_srt_ProductsAndServicesDomain_d3005b4a-50cb-4412-a0ee-423f88f931c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_270d7e37-5d21-46e0-977e-9a7548b9b42c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d3005b4a-50cb-4412-a0ee-423f88f931c3" xlink:to="loc_srt_ProductsAndServicesDomain_270d7e37-5d21-46e0-977e-9a7548b9b42c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_fa59beb6-822f-44cb-b52c-269a2057f57b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_270d7e37-5d21-46e0-977e-9a7548b9b42c" xlink:to="loc_us-gaap_ProductMember_fa59beb6-822f-44cb-b52c-269a2057f57b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_fdaca54c-0c4f-4c31-9c43-5999195ff590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_270d7e37-5d21-46e0-977e-9a7548b9b42c" xlink:to="loc_us-gaap_ServiceMember_fdaca54c-0c4f-4c31-9c43-5999195ff590" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="eols-20211231.xsd#StatementsofStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StatementsofStockholdersEquityDeficit" xlink:type="extended" id="ic45384913cae4d478791384a8b8d2f03_StatementsofStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8425b9aa-1ff0-4e0b-b00c-bdaf90746e52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8425b9aa-1ff0-4e0b-b00c-bdaf90746e52" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_12915e92-d284-4c59-9303-aa213ffc4773" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_SharesIssued_12915e92-d284-4c59-9303-aa213ffc4773" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b2c69e8c-15d0-4a11-a77c-9d8db8de33bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_StockholdersEquity_b2c69e8c-15d0-4a11-a77c-9d8db8de33bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_c2e9d704-881e-40cc-b8f9-9ef21ce4886c" xlink:href="eols-20211231.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_c2e9d704-881e-40cc-b8f9-9ef21ce4886c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodValuesLitigationSettlement_e2711f91-7ed5-4404-bd2e-dffdf06738dd" xlink:href="eols-20211231.xsd#eols_StockIssuedDuringPeriodValuesLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_eols_StockIssuedDuringPeriodValuesLitigationSettlement_e2711f91-7ed5-4404-bd2e-dffdf06738dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f27d195a-198d-435b-bb28-7f9f87b41eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f27d195a-198d-435b-bb28-7f9f87b41eca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0a0cd84f-844a-498d-b2d5-6d64b594950a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0a0cd84f-844a-498d-b2d5-6d64b594950a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d4264185-e8de-4e76-be33-706ec6085d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d4264185-e8de-4e76-be33-706ec6085d60" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27d0f5ea-a475-400b-a965-5e61310e646b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27d0f5ea-a475-400b-a965-5e61310e646b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f919326e-6c8c-44a0-950d-c8f714376864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f919326e-6c8c-44a0-950d-c8f714376864" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f47b3032-7a98-4576-93d8-be9ba435e84f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_NetIncomeLoss_f47b3032-7a98-4576-93d8-be9ba435e84f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9562943d-fbaf-46ec-ad1a-570209f35657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9562943d-fbaf-46ec-ad1a-570209f35657" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_20bc9361-2c9f-4cec-b17a-64be9740f504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b4f75314-8362-4421-8900-cc9bb59420e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d6caa97c-a751-488f-8b3b-076442f26850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8425b9aa-1ff0-4e0b-b00c-bdaf90746e52" xlink:to="loc_us-gaap_StatementTable_d6caa97c-a751-488f-8b3b-076442f26850" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d3167d6e-5e40-410e-a20c-e532287bd30e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d6caa97c-a751-488f-8b3b-076442f26850" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d3167d6e-5e40-410e-a20c-e532287bd30e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d3167d6e-5e40-410e-a20c-e532287bd30e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3167d6e-5e40-410e-a20c-e532287bd30e" xlink:to="loc_us-gaap_EquityComponentDomain_d3167d6e-5e40-410e-a20c-e532287bd30e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_42d6b92f-22c7-434f-a151-8b92dea79d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3167d6e-5e40-410e-a20c-e532287bd30e" xlink:to="loc_us-gaap_EquityComponentDomain_42d6b92f-22c7-434f-a151-8b92dea79d7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d1b1e482-dca3-4105-8aff-0e9294be5c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42d6b92f-22c7-434f-a151-8b92dea79d7a" xlink:to="loc_us-gaap_PreferredStockMember_d1b1e482-dca3-4105-8aff-0e9294be5c80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9cd0707b-51dc-4de7-8dfe-1f9a33e85933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42d6b92f-22c7-434f-a151-8b92dea79d7a" xlink:to="loc_us-gaap_CommonStockMember_9cd0707b-51dc-4de7-8dfe-1f9a33e85933" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_991e86ac-dbda-432a-94c5-c40f5653dada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42d6b92f-22c7-434f-a151-8b92dea79d7a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_991e86ac-dbda-432a-94c5-c40f5653dada" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_53f63647-d3c2-425d-9acc-ec5622ac4560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42d6b92f-22c7-434f-a151-8b92dea79d7a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_53f63647-d3c2-425d-9acc-ec5622ac4560" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_db00c526-9bde-4e81-96a7-53c57d6d137c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42d6b92f-22c7-434f-a151-8b92dea79d7a" xlink:to="loc_us-gaap_RetainedEarningsMember_db00c526-9bde-4e81-96a7-53c57d6d137c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4e8e22f2-6d81-4dc6-b21c-ae814b2b2aad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d6caa97c-a751-488f-8b3b-076442f26850" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4e8e22f2-6d81-4dc6-b21c-ae814b2b2aad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4e8e22f2-6d81-4dc6-b21c-ae814b2b2aad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4e8e22f2-6d81-4dc6-b21c-ae814b2b2aad" xlink:to="loc_us-gaap_ClassOfStockDomain_4e8e22f2-6d81-4dc6-b21c-ae814b2b2aad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_330338e9-61ec-461b-b814-b4986e30ecb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4e8e22f2-6d81-4dc6-b21c-ae814b2b2aad" xlink:to="loc_us-gaap_ClassOfStockDomain_330338e9-61ec-461b-b814-b4986e30ecb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_268555c9-00d9-4139-ac99-9befed56629d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_330338e9-61ec-461b-b814-b4986e30ecb2" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_268555c9-00d9-4139-ac99-9befed56629d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4770df23-f6d3-416d-83dc-23aaf6d9b219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d6caa97c-a751-488f-8b3b-076442f26850" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4770df23-f6d3-416d-83dc-23aaf6d9b219" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4770df23-f6d3-416d-83dc-23aaf6d9b219_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4770df23-f6d3-416d-83dc-23aaf6d9b219" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4770df23-f6d3-416d-83dc-23aaf6d9b219_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c132e22-30ef-4865-946e-26da146dfe05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4770df23-f6d3-416d-83dc-23aaf6d9b219" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c132e22-30ef-4865-946e-26da146dfe05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FollowOnOfferingMember_761072a4-ae1d-45e8-b72a-c7ac47fdd959" xlink:href="eols-20211231.xsd#eols_FollowOnOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c132e22-30ef-4865-946e-26da146dfe05" xlink:to="loc_eols_FollowOnOfferingMember_761072a4-ae1d-45e8-b72a-c7ac47fdd959" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember_5f6210dd-6bf2-441c-be35-eb6829186514" xlink:href="eols-20211231.xsd#eols_ATMSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c132e22-30ef-4865-946e-26da146dfe05" xlink:to="loc_eols_ATMSalesAgreementMember_5f6210dd-6bf2-441c-be35-eb6829186514" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="eols-20211231.xsd#StatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StatementsofCashFlows" xlink:type="extended" id="i1bb65d5e24ae4074b44754186b0e4a57_StatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7860ad2c-8231-4534-a6af-e625119e5ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7860ad2c-8231-4534-a6af-e625119e5ec6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_21c9330b-3aef-45b1-856c-16c7a2601a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7860ad2c-8231-4534-a6af-e625119e5ec6" xlink:to="loc_us-gaap_NetIncomeLoss_21c9330b-3aef-45b1-856c-16c7a2601a75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7860ad2c-8231-4534-a6af-e625119e5ec6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2b792941-c41c-4941-ad0d-e4eeb5bd6608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2b792941-c41c-4941-ad0d-e4eeb5bd6608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c04c4eec-c64a-46ce-ac48-ca79e2606347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_ShareBasedCompensation_c04c4eec-c64a-46ce-ac48-ca79e2606347" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_9e43e546-2d06-4968-84f7-e4ac96ee92bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_9e43e546-2d06-4968-84f7-e4ac96ee92bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a6beaa7f-5645-4e60-a8c6-a883f73e62dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a6beaa7f-5645-4e60-a8c6-a883f73e62dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OperatingLeaseRightofUseAssetAmortization_f6d7d0ef-9ebb-4f06-a107-a14cc184222a" xlink:href="eols-20211231.xsd#eols_OperatingLeaseRightofUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_eols_OperatingLeaseRightofUseAssetAmortization_f6d7d0ef-9ebb-4f06-a107-a14cc184222a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4ba6bfb3-f704-436c-9fba-3fc411132f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4ba6bfb3-f704-436c-9fba-3fc411132f4c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_f292e611-6765-4db0-9d42-c22fd0247eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_PaidInKindInterest_f292e611-6765-4db0-9d42-c22fd0247eba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5d519f2b-d710-4f1e-8c0c-0746726f6514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5d519f2b-d710-4f1e-8c0c-0746726f6514" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8ec35e99-6337-4d64-a5cb-6fca15af0fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8ec35e99-6337-4d64-a5cb-6fca15af0fb9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_de045ba1-41b3-4c09-b5a8-55a5644f1ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_de045ba1-41b3-4c09-b5a8-55a5644f1ed1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses_81058f80-f948-41fd-8ab1-9a1568b68029" xlink:href="eols-20211231.xsd#eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses_81058f80-f948-41fd-8ab1-9a1568b68029" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c11495be-1537-4cf6-91e7-4a21ed3a3364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c11495be-1537-4cf6-91e7-4a21ed3a3364" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cb42fa7e-f677-4725-b171-9170aae69837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cb42fa7e-f677-4725-b171-9170aae69837" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d4433e36-4de8-4a89-91da-985c9e61c05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d4433e36-4de8-4a89-91da-985c9e61c05f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_45bce733-ac13-457a-87fa-603b8b5bee2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_45bce733-ac13-457a-87fa-603b8b5bee2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_326789ea-e17f-4b50-b055-7be4a8cc220d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_326789ea-e17f-4b50-b055-7be4a8cc220d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement_24afce95-3ef9-4c91-831c-3cc825bd222b" xlink:href="eols-20211231.xsd#eols_IncreaseDecreaseInAccruedLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:to="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement_24afce95-3ef9-4c91-831c-3cc825bd222b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_f6acc9fb-1186-4894-8e2d-db85a7083888" xlink:href="eols-20211231.xsd#eols_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:to="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_f6acc9fb-1186-4894-8e2d-db85a7083888" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_22c92d82-5cfc-48f0-adda-271e1cccde3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_22c92d82-5cfc-48f0-adda-271e1cccde3e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9ac8b3d3-9cf3-4402-a080-84c7ca8182f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7860ad2c-8231-4534-a6af-e625119e5ec6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9ac8b3d3-9cf3-4402-a080-84c7ca8182f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_82312da4-a117-4cf5-a38e-88920e28b6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_82312da4-a117-4cf5-a38e-88920e28b6c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9a87c39b-a4d9-42ae-ab0a-d25aa988d757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_82312da4-a117-4cf5-a38e-88920e28b6c6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9a87c39b-a4d9-42ae-ab0a-d25aa988d757" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_1ae6c049-04cd-4294-b7b2-53222e44f336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForSoftware"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_82312da4-a117-4cf5-a38e-88920e28b6c6" xlink:to="loc_us-gaap_PaymentsForSoftware_1ae6c049-04cd-4294-b7b2-53222e44f336" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_2e701d3a-37a8-44e5-87fb-16a34a247ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_82312da4-a117-4cf5-a38e-88920e28b6c6" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_2e701d3a-37a8-44e5-87fb-16a34a247ec5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_e3b55d77-599f-41ad-be7d-ff8384b24030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_82312da4-a117-4cf5-a38e-88920e28b6c6" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_e3b55d77-599f-41ad-be7d-ff8384b24030" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c484fb6b-f887-4bec-93da-215d04db0e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_82312da4-a117-4cf5-a38e-88920e28b6c6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c484fb6b-f887-4bec-93da-215d04db0e83" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_1ea105b1-1a00-490b-b0da-1c59ad2f9956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_RepaymentsOfDebt_1ea105b1-1a00-490b-b0da-1c59ad2f9956" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_11f46f5e-a006-43cd-aa9d-e8582c9048f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_11f46f5e-a006-43cd-aa9d-e8582c9048f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation_9eede4c3-b119-4648-af77-bf20555d9fdd" xlink:href="eols-20211231.xsd#eols_PaymentsOfContingentRoyaltyObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_eols_PaymentsOfContingentRoyaltyObligation_9eede4c3-b119-4648-af77-bf20555d9fdd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_0a0fc045-8bcb-4373-9a28-14214312113b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_0a0fc045-8bcb-4373-9a28-14214312113b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_17b1a959-291d-4ec8-b0d8-0a5791b97f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_17b1a959-291d-4ec8-b0d8-0a5791b97f8f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1654432d-77f8-42ca-8054-f258bc703878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1654432d-77f8-42ca-8054-f258bc703878" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_0e7e91af-458e-4cfb-b2e0-4db7accf4634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_0e7e91af-458e-4cfb-b2e0-4db7accf4634" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_873c7ff4-a580-4218-8c13-62fb0434bc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_873c7ff4-a580-4218-8c13-62fb0434bc3f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_25033500-bbb7-4c8c-a86f-e2b913c97504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_25033500-bbb7-4c8c-a86f-e2b913c97504" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_2d9ba184-0a2f-4d97-8484-92483455193d" xlink:href="eols-20211231.xsd#eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_2d9ba184-0a2f-4d97-8484-92483455193d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_96d2c20f-0914-4873-91f2-a3ff28ab08ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_96d2c20f-0914-4873-91f2-a3ff28ab08ec" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_344020eb-3109-4fc5-9002-ec499f48c595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_344020eb-3109-4fc5-9002-ec499f48c595" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d2859fc9-27b6-4f8a-bf9e-607fde9f3644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d2859fc9-27b6-4f8a-bf9e-607fde9f3644" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1892b220-f049-46db-80e6-3e2e9914baa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_296a8325-d706-4b14-84ca-d43666890d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_296a8325-d706-4b14-84ca-d43666890d7d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_f4f5f59e-3638-4a57-a373-162a0f8cef9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_296a8325-d706-4b14-84ca-d43666890d7d" xlink:to="loc_us-gaap_InterestPaidNet_f4f5f59e-3638-4a57-a373-162a0f8cef9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_23e8a18c-992b-427b-997c-d462ca1bbd36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_296a8325-d706-4b14-84ca-d43666890d7d" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_23e8a18c-992b-427b-997c-d462ca1bbd36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e91f896b-d952-426b-be29-3a0df05512f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e91f896b-d952-426b-be29-3a0df05512f9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_ce7234ee-368d-4d12-aef3-92159b2027f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e91f896b-d952-426b-be29-3a0df05512f9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_ce7234ee-368d-4d12-aef3-92159b2027f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedForAccruedLitigationSettlementExpense_198f4c90-b124-4555-b47d-4490917771bb" xlink:href="eols-20211231.xsd#eols_StockIssuedForAccruedLitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e91f896b-d952-426b-be29-3a0df05512f9" xlink:to="loc_eols_StockIssuedForAccruedLitigationSettlementExpense_198f4c90-b124-4555-b47d-4490917771bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_35c76286-cfc6-44e3-af60-4db169aefb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e91f896b-d952-426b-be29-3a0df05512f9" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_35c76286-cfc6-44e3-af60-4db169aefb1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_44917de0-8e63-4357-8045-39fb5438fc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:to="loc_us-gaap_StatementTable_44917de0-8e63-4357-8045-39fb5438fc9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b2207da9-1716-4452-ae21-a672eb2fb60e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_44917de0-8e63-4357-8045-39fb5438fc9f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b2207da9-1716-4452-ae21-a672eb2fb60e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b2207da9-1716-4452-ae21-a672eb2fb60e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b2207da9-1716-4452-ae21-a672eb2fb60e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b2207da9-1716-4452-ae21-a672eb2fb60e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b059b50a-1127-4726-a725-dbf66f727519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b2207da9-1716-4452-ae21-a672eb2fb60e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b059b50a-1127-4726-a725-dbf66f727519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FollowOnOfferingMember_de57c1fd-95bf-4acf-9fb5-70ca5ac94e55" xlink:href="eols-20211231.xsd#eols_FollowOnOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b059b50a-1127-4726-a725-dbf66f727519" xlink:to="loc_eols_FollowOnOfferingMember_de57c1fd-95bf-4acf-9fb5-70ca5ac94e55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember_00a3a0cd-3238-4b1b-89d3-c8da8eb1911c" xlink:href="eols-20211231.xsd#eols_ATMSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b059b50a-1127-4726-a725-dbf66f727519" xlink:to="loc_eols_ATMSalesAgreementMember_00a3a0cd-3238-4b1b-89d3-c8da8eb1911c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#DescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/DescriptionofBusinessDetails" xlink:type="extended" id="id54594e4469248858abd0d617dd3ec7b_DescriptionofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b485d3ef-4e37-4b6a-bae2-9d2d16b9b977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b485d3ef-4e37-4b6a-bae2-9d2d16b9b977" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0fd1715c-659f-4456-b36a-8b382fc72215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0fd1715c-659f-4456-b36a-8b382fc72215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0e2b76e8-1ff2-4ba3-9c85-40456402858f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0e2b76e8-1ff2-4ba3-9c85-40456402858f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_0e2d4620-cb1a-4127-897b-58a34e3f9314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_0e2d4620-cb1a-4127-897b-58a34e3f9314" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_05b445a5-f1a0-43a9-b0db-1d146e329030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_05b445a5-f1a0-43a9-b0db-1d146e329030" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_8ed82097-614e-4bfc-a701-8fb5ff13f145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_8ed82097-614e-4bfc-a701-8fb5ff13f145" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_faeca765-7de8-48e7-941b-fad15a2ac734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_faeca765-7de8-48e7-941b-fad15a2ac734" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_67995164-9b5f-4e9c-88f3-79700ba67986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_ConvertibleDebt_67995164-9b5f-4e9c-88f3-79700ba67986" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_4900b193-ca22-45d8-b924-5fc10b9aeb22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_4900b193-ca22-45d8-b924-5fc10b9aeb22" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_213c7b21-787b-4466-9efc-b79fcddb88f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_213c7b21-787b-4466-9efc-b79fcddb88f6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_bcdced65-7526-4451-848c-289cda7892f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_bcdced65-7526-4451-848c-289cda7892f6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2285e90a-f7e1-4570-910c-15743c32ce98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2285e90a-f7e1-4570-910c-15743c32ce98" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_82a4039e-0415-4da5-9819-aa7e967a0626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:to="loc_us-gaap_DebtInstrumentAxis_82a4039e-0415-4da5-9819-aa7e967a0626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_82a4039e-0415-4da5-9819-aa7e967a0626_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_82a4039e-0415-4da5-9819-aa7e967a0626" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_82a4039e-0415-4da5-9819-aa7e967a0626_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_08806e40-4694-4991-bf20-cd64749548a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_82a4039e-0415-4da5-9819-aa7e967a0626" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_08806e40-4694-4991-bf20-cd64749548a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember_dc6b7927-2d27-4925-b6a5-5f1e8eb1e336" xlink:href="eols-20211231.xsd#eols_PharmakonTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08806e40-4694-4991-bf20-cd64749548a4" xlink:to="loc_eols_PharmakonTermLoansMember_dc6b7927-2d27-4925-b6a5-5f1e8eb1e336" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansOneMember_5be6f5a7-1ccf-42a8-ba4c-1b3296b28f80" xlink:href="eols-20211231.xsd#eols_PharmakonTermLoansOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_PharmakonTermLoansMember_dc6b7927-2d27-4925-b6a5-5f1e8eb1e336" xlink:to="loc_eols_PharmakonTermLoansOneMember_5be6f5a7-1ccf-42a8-ba4c-1b3296b28f80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansTwoMember_f5531d2f-783f-4261-90d0-9a6bcf91cd1e" xlink:href="eols-20211231.xsd#eols_PharmakonTermLoansTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_PharmakonTermLoansMember_dc6b7927-2d27-4925-b6a5-5f1e8eb1e336" xlink:to="loc_eols_PharmakonTermLoansTwoMember_f5531d2f-783f-4261-90d0-9a6bcf91cd1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoanFacilityMember_fc290760-4457-4074-b235-6ae179698ec4" xlink:href="eols-20211231.xsd#eols_OxfordTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08806e40-4694-4991-bf20-cd64749548a4" xlink:to="loc_eols_OxfordTermLoanFacilityMember_fc290760-4457-4074-b235-6ae179698ec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember_905bb1b6-5233-488c-b88f-7dca74240685" xlink:href="eols-20211231.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08806e40-4694-4991-bf20-cd64749548a4" xlink:to="loc_eols_DaewoongConvertibleNoteMember_905bb1b6-5233-488c-b88f-7dca74240685" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d46bb640-94be-4613-ae2f-12d5ea2dfee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d46bb640-94be-4613-ae2f-12d5ea2dfee8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d46bb640-94be-4613-ae2f-12d5ea2dfee8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d46bb640-94be-4613-ae2f-12d5ea2dfee8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d46bb640-94be-4613-ae2f-12d5ea2dfee8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0e9428bb-2bfb-4776-a736-af37b002f8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d46bb640-94be-4613-ae2f-12d5ea2dfee8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0e9428bb-2bfb-4776-a736-af37b002f8d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_7412ee08-3a02-46d7-a6fc-70d1dc3439a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0e9428bb-2bfb-4776-a736-af37b002f8d5" xlink:to="loc_us-gaap_SecuredDebtMember_7412ee08-3a02-46d7-a6fc-70d1dc3439a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_dd9bfaa6-0b7b-461d-bfd0-b77e5980d036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0e9428bb-2bfb-4776-a736-af37b002f8d5" xlink:to="loc_us-gaap_ConvertibleDebtMember_dd9bfaa6-0b7b-461d-bfd0-b77e5980d036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_3155250c-cda5-4e8b-ab6c-8653074e9faa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:to="loc_srt_LitigationCaseAxis_3155250c-cda5-4e8b-ab6c-8653074e9faa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_3155250c-cda5-4e8b-ab6c-8653074e9faa_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_3155250c-cda5-4e8b-ab6c-8653074e9faa" xlink:to="loc_srt_LitigationCaseTypeDomain_3155250c-cda5-4e8b-ab6c-8653074e9faa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_58df84b7-d2da-4499-b886-cfcab6f41507" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_3155250c-cda5-4e8b-ab6c-8653074e9faa" xlink:to="loc_srt_LitigationCaseTypeDomain_58df84b7-d2da-4499-b886-cfcab6f41507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_c8288448-afcc-4e49-87fa-d9c9ac6166c9" xlink:href="eols-20211231.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_58df84b7-d2da-4499-b886-cfcab6f41507" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_c8288448-afcc-4e49-87fa-d9c9ac6166c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_6b8d59c1-49a4-42cf-8374-fd7f8d585cb7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:to="loc_srt_StatementScenarioAxis_6b8d59c1-49a4-42cf-8374-fd7f8d585cb7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6b8d59c1-49a4-42cf-8374-fd7f8d585cb7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_6b8d59c1-49a4-42cf-8374-fd7f8d585cb7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6b8d59c1-49a4-42cf-8374-fd7f8d585cb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c96d1d38-4da6-4209-a446-98c21aa3f429" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_6b8d59c1-49a4-42cf-8374-fd7f8d585cb7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c96d1d38-4da6-4209-a446-98c21aa3f429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_8ed8ca42-1cf5-473e-b175-5926be87d686" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_c96d1d38-4da6-4209-a446-98c21aa3f429" xlink:to="loc_srt_ScenarioForecastMember_8ed8ca42-1cf5-473e-b175-5926be87d686" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d15a51f8-b25e-48e6-acbf-da7cd5870f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d15a51f8-b25e-48e6-acbf-da7cd5870f2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d15a51f8-b25e-48e6-acbf-da7cd5870f2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d15a51f8-b25e-48e6-acbf-da7cd5870f2c" xlink:to="loc_us-gaap_EquityComponentDomain_d15a51f8-b25e-48e6-acbf-da7cd5870f2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3cf59e62-e5ce-4870-99cd-365c824efabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d15a51f8-b25e-48e6-acbf-da7cd5870f2c" xlink:to="loc_us-gaap_EquityComponentDomain_3cf59e62-e5ce-4870-99cd-365c824efabf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e6de6927-d8c3-43c1-96f8-0e183907ac9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3cf59e62-e5ce-4870-99cd-365c824efabf" xlink:to="loc_us-gaap_CommonStockMember_e6de6927-d8c3-43c1-96f8-0e183907ac9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9e30483c-3eca-463b-a68f-a2741cc5d7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9e30483c-3eca-463b-a68f-a2741cc5d7d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9e30483c-3eca-463b-a68f-a2741cc5d7d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9e30483c-3eca-463b-a68f-a2741cc5d7d3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9e30483c-3eca-463b-a68f-a2741cc5d7d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_99a61639-2058-42b4-bd1a-dba3e260475e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9e30483c-3eca-463b-a68f-a2741cc5d7d3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_99a61639-2058-42b4-bd1a-dba3e260475e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PublicStockOfferingMember_fa27dad6-0394-4b41-b04d-41a4b386bf1f" xlink:href="eols-20211231.xsd#eols_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_99a61639-2058-42b4-bd1a-dba3e260475e" xlink:to="loc_eols_PublicStockOfferingMember_fa27dad6-0394-4b41-b04d-41a4b386bf1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_803bc2d3-ef93-4749-b359-541ea1dc87f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_99a61639-2058-42b4-bd1a-dba3e260475e" xlink:to="loc_us-gaap_OverAllotmentOptionMember_803bc2d3-ef93-4749-b359-541ea1dc87f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember_770f3bd9-304f-4f60-86df-0a9edcec1e0a" xlink:href="eols-20211231.xsd#eols_ATMSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_99a61639-2058-42b4-bd1a-dba3e260475e" xlink:to="loc_eols_ATMSalesAgreementMember_770f3bd9-304f-4f60-86df-0a9edcec1e0a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i315765ed3c7744dba3c057251075a1d7_BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a1e3d615-875d-4f72-9cf6-7663a2c9f56e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a1e3d615-875d-4f72-9cf6-7663a2c9f56e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_86c10ded-2fa1-4fdc-a906-45b51c9d27c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_86c10ded-2fa1-4fdc-a906-45b51c9d27c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_815ccd92-03e2-46a0-b03a-dcc33a349717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_NumberOfReportingUnits_815ccd92-03e2-46a0-b03a-dcc33a349717" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_22d88094-22db-41d6-98ae-4308e5cc974f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_22d88094-22db-41d6-98ae-4308e5cc974f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_92df7994-3579-4348-8bb1-0ce01f55c4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_92df7994-3579-4348-8bb1-0ce01f55c4c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c28973fb-4ce0-41bb-ab14-a828e33ff355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c28973fb-4ce0-41bb-ab14-a828e33ff355" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6e9eae7-f637-4e06-88fc-6f09f55b2b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6e9eae7-f637-4e06-88fc-6f09f55b2b3a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9c340023-2bdb-4c49-8798-0bf40fc87923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9c340023-2bdb-4c49-8798-0bf40fc87923" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RebatesAndCouponsCreditsAndPayments_b578b421-cc23-4f56-8049-3a7a07d8018b" xlink:href="eols-20211231.xsd#eols_RebatesAndCouponsCreditsAndPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_eols_RebatesAndCouponsCreditsAndPayments_b578b421-cc23-4f56-8049-3a7a07d8018b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_7e868094-0923-4045-b201-26fc8b7bb2bf" xlink:href="eols-20211231.xsd#eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_7e868094-0923-4045-b201-26fc8b7bb2bf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d37a4d09-e119-4beb-9a55-af069fd54e67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d37a4d09-e119-4beb-9a55-af069fd54e67" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4ed73c4d-3470-47a3-8a07-519fd1f3806a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4ed73c4d-3470-47a3-8a07-519fd1f3806a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementPaymentTerms_f92d14cc-418d-415a-a356-d7f953a7da1f" xlink:href="eols-20211231.xsd#eols_LossContingencySettlementAgreementPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_eols_LossContingencySettlementAgreementPaymentTerms_f92d14cc-418d-415a-a356-d7f953a7da1f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_f7daf08c-fe0b-4fce-90c9-72aa431bc8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_f7daf08c-fe0b-4fce-90c9-72aa431bc8d2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_16b109d7-3371-4bc9-8769-93e7bf9dfa15" xlink:href="eols-20211231.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_16b109d7-3371-4bc9-8769-93e7bf9dfa15" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_66212cf5-2570-4adf-af31-9036027e9d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_LitigationSettlementExpense_66212cf5-2570-4adf-af31-9036027e9d47" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_ad4b609b-ee48-4b4d-b377-d4dae62c879a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_ad4b609b-ee48-4b4d-b377-d4dae62c879a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_577bc199-0379-410f-a605-286ffc00ec5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_LitigationReserveCurrent_577bc199-0379-410f-a605-286ffc00ec5d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent_8876942f-a93d-4a71-8741-011ae27e2f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_LitigationReserveNoncurrent_8876942f-a93d-4a71-8741-011ae27e2f5c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_2196d874-0864-4646-9ac2-5009b073ec1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_AdvertisingExpense_2196d874-0864-4646-9ac2-5009b073ec1f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_737ccd5c-cb8c-4cce-b54c-6abd344d9378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_737ccd5c-cb8c-4cce-b54c-6abd344d9378" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_c289bf3f-fc8f-41db-a9a1-270427c62ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_c289bf3f-fc8f-41db-a9a1-270427c62ca8" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_7bb02905-a1d9-4393-b1c2-719e4441e201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_7bb02905-a1d9-4393-b1c2-719e4441e201" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_d251ce02-7e1e-4268-b559-9b46d86dab7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_d251ce02-7e1e-4268-b559-9b46d86dab7b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ad036a1-a37c-4418-8109-364a40933c76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ad036a1-a37c-4418-8109-364a40933c76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8ad036a1-a37c-4418-8109-364a40933c76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ad036a1-a37c-4418-8109-364a40933c76" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8ad036a1-a37c-4418-8109-364a40933c76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2d415bf-9ecc-4524-8865-3ad0867f6a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ad036a1-a37c-4418-8109-364a40933c76" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2d415bf-9ecc-4524-8865-3ad0867f6a85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_cc128f08-7205-4b16-95e7-2286571d376a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2d415bf-9ecc-4524-8865-3ad0867f6a85" xlink:to="loc_us-gaap_DistributionRightsMember_cc128f08-7205-4b16-95e7-2286571d376a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_84d0b154-2fb9-4502-87d2-26f9fc1cb939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2d415bf-9ecc-4524-8865-3ad0867f6a85" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_84d0b154-2fb9-4502-87d2-26f9fc1cb939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_521ba40d-da18-49ab-b2f9-09e790c31280" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:to="loc_srt_ProductOrServiceAxis_521ba40d-da18-49ab-b2f9-09e790c31280" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_521ba40d-da18-49ab-b2f9-09e790c31280_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_521ba40d-da18-49ab-b2f9-09e790c31280" xlink:to="loc_srt_ProductsAndServicesDomain_521ba40d-da18-49ab-b2f9-09e790c31280_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6eb01643-121c-4d14-b524-a7a38b4e284b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_521ba40d-da18-49ab-b2f9-09e790c31280" xlink:to="loc_srt_ProductsAndServicesDomain_6eb01643-121c-4d14-b524-a7a38b4e284b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_de98db7a-fbf1-4bdb-9662-9b41642d0d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6eb01643-121c-4d14-b524-a7a38b4e284b" xlink:to="loc_us-gaap_ServiceMember_de98db7a-fbf1-4bdb-9662-9b41642d0d7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_57eaf90d-87d8-4b07-be64-742e5ed80bd7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:to="loc_srt_StatementGeographicalAxis_57eaf90d-87d8-4b07-be64-742e5ed80bd7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_57eaf90d-87d8-4b07-be64-742e5ed80bd7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_57eaf90d-87d8-4b07-be64-742e5ed80bd7" xlink:to="loc_srt_SegmentGeographicalDomain_57eaf90d-87d8-4b07-be64-742e5ed80bd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9204c6be-38ba-4f8a-9420-8535f43dd970" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_57eaf90d-87d8-4b07-be64-742e5ed80bd7" xlink:to="loc_srt_SegmentGeographicalDomain_9204c6be-38ba-4f8a-9420-8535f43dd970" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_c25aaa81-30cf-4929-9343-f8a155d035a0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9204c6be-38ba-4f8a-9420-8535f43dd970" xlink:to="loc_country_CA_c25aaa81-30cf-4929-9343-f8a155d035a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_94496524-edec-4f0c-a32c-bb124398242b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:to="loc_srt_LitigationCaseAxis_94496524-edec-4f0c-a32c-bb124398242b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_94496524-edec-4f0c-a32c-bb124398242b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_94496524-edec-4f0c-a32c-bb124398242b" xlink:to="loc_srt_LitigationCaseTypeDomain_94496524-edec-4f0c-a32c-bb124398242b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1f99f95d-49cd-46ea-b56f-d334e5b6a3d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_94496524-edec-4f0c-a32c-bb124398242b" xlink:to="loc_srt_LitigationCaseTypeDomain_1f99f95d-49cd-46ea-b56f-d334e5b6a3d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_bc0dfab6-752f-4a8d-aa8f-b55bd081eb5c" xlink:href="eols-20211231.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1f99f95d-49cd-46ea-b56f-d334e5b6a3d3" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_bc0dfab6-752f-4a8d-aa8f-b55bd081eb5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_db7b2742-9790-4882-bf01-684a5f094fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_db7b2742-9790-4882-bf01-684a5f094fd5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_db7b2742-9790-4882-bf01-684a5f094fd5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_db7b2742-9790-4882-bf01-684a5f094fd5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_db7b2742-9790-4882-bf01-684a5f094fd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9e93f307-9ba7-4b3e-97a1-bd0384f8d8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_db7b2742-9790-4882-bf01-684a5f094fd5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9e93f307-9ba7-4b3e-97a1-bd0384f8d8a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f048ea0b-07cb-4c3b-b66c-c620ed4830d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9e93f307-9ba7-4b3e-97a1-bd0384f8d8a5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f048ea0b-07cb-4c3b-b66c-c620ed4830d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_05090499-dc28-4f9e-a97a-f2edbaa3009e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9e93f307-9ba7-4b3e-97a1-bd0384f8d8a5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_05090499-dc28-4f9e-a97a-f2edbaa3009e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_f91ae7cf-4e85-4314-bb59-54978698005f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9e93f307-9ba7-4b3e-97a1-bd0384f8d8a5" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_f91ae7cf-4e85-4314-bb59-54978698005f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_05d08318-0666-4ed8-abe2-0ffa595de280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_05d08318-0666-4ed8-abe2-0ffa595de280" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_05d08318-0666-4ed8-abe2-0ffa595de280_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_05d08318-0666-4ed8-abe2-0ffa595de280" xlink:to="loc_us-gaap_EquityComponentDomain_05d08318-0666-4ed8-abe2-0ffa595de280_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b474b294-4a4d-4245-9fc1-dd555b91227b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_05d08318-0666-4ed8-abe2-0ffa595de280" xlink:to="loc_us-gaap_EquityComponentDomain_b474b294-4a4d-4245-9fc1-dd555b91227b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_33d00d0a-c26f-4d91-8289-c9dcf1b7e14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b474b294-4a4d-4245-9fc1-dd555b91227b" xlink:to="loc_us-gaap_CommonStockMember_33d00d0a-c26f-4d91-8289-c9dcf1b7e14a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b37039bb-82e0-4b54-8440-aba3ce2daf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b37039bb-82e0-4b54-8440-aba3ce2daf4b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b37039bb-82e0-4b54-8440-aba3ce2daf4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b37039bb-82e0-4b54-8440-aba3ce2daf4b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b37039bb-82e0-4b54-8440-aba3ce2daf4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_58d473bb-c3e1-49ff-a4e0-0a2de005e5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b37039bb-82e0-4b54-8440-aba3ce2daf4b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_58d473bb-c3e1-49ff-a4e0-0a2de005e5c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_77af8b03-24a4-4e1d-a55f-c149e0e3e4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_58d473bb-c3e1-49ff-a4e0-0a2de005e5c7" xlink:to="loc_us-gaap_SubsequentEventMember_77af8b03-24a4-4e1d-a55f-c149e0e3e4b2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails" xlink:type="extended" id="i92d2754e28084c96951bd93d70bb4704_FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_359fcbcf-29be-49a7-9f61-0a487bc71a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_28bd5def-8786-4e5c-af7c-315ff8f16692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_359fcbcf-29be-49a7-9f61-0a487bc71a0e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_28bd5def-8786-4e5c-af7c-315ff8f16692" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_5d325b14-b013-4df7-963d-0a84a003ec39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_359fcbcf-29be-49a7-9f61-0a487bc71a0e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_5d325b14-b013-4df7-963d-0a84a003ec39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_55e7d225-ec5d-42e4-97c5-af1beccc387e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_5d325b14-b013-4df7-963d-0a84a003ec39" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_55e7d225-ec5d-42e4-97c5-af1beccc387e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9fb2f897-f777-456d-8f4b-4e7a097714ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_5d325b14-b013-4df7-963d-0a84a003ec39" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9fb2f897-f777-456d-8f4b-4e7a097714ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_963ec34c-8a54-4946-9269-279937429394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_359fcbcf-29be-49a7-9f61-0a487bc71a0e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_963ec34c-8a54-4946-9269-279937429394" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_94236bb5-add9-4e8c-bcaa-74be8141f5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_359fcbcf-29be-49a7-9f61-0a487bc71a0e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_94236bb5-add9-4e8c-bcaa-74be8141f5e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_513e55b9-e205-495c-9546-623f71de62af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_94236bb5-add9-4e8c-bcaa-74be8141f5e1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_513e55b9-e205-495c-9546-623f71de62af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_513e55b9-e205-495c-9546-623f71de62af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_513e55b9-e205-495c-9546-623f71de62af" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_513e55b9-e205-495c-9546-623f71de62af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_312a99a5-4939-4a46-ba1d-aa7b0aaa7fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_513e55b9-e205-495c-9546-623f71de62af" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_312a99a5-4939-4a46-ba1d-aa7b0aaa7fb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_25e00e43-b3f6-4eab-8a64-0794cfff4326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_312a99a5-4939-4a46-ba1d-aa7b0aaa7fb8" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_25e00e43-b3f6-4eab-8a64-0794cfff4326" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails" xlink:type="extended" id="i4c0c81272608489893ea9c09472263ae_FairValueMeasurementsandShortTermInvestmentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f97d0675-d18d-427e-bf65-349663e47ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_d6390ecc-fcbc-4113-956d-5a6ec2c79788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f97d0675-d18d-427e-bf65-349663e47ee5" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_d6390ecc-fcbc-4113-956d-5a6ec2c79788" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_1334088e-a1c4-4151-bf92-e6ddd1d28751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f97d0675-d18d-427e-bf65-349663e47ee5" xlink:to="loc_us-gaap_LongTermDebtFairValue_1334088e-a1c4-4151-bf92-e6ddd1d28751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_904902b4-aaf6-4707-9414-232cbcc927c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f97d0675-d18d-427e-bf65-349663e47ee5" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_904902b4-aaf6-4707-9414-232cbcc927c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13cb814-3384-4ec0-90e4-a4f953523799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f97d0675-d18d-427e-bf65-349663e47ee5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13cb814-3384-4ec0-90e4-a4f953523799" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_af29459a-cb8a-46cb-93fc-df25a4557f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13cb814-3384-4ec0-90e4-a4f953523799" xlink:to="loc_us-gaap_FinancialInstrumentAxis_af29459a-cb8a-46cb-93fc-df25a4557f7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_af29459a-cb8a-46cb-93fc-df25a4557f7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_af29459a-cb8a-46cb-93fc-df25a4557f7d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_af29459a-cb8a-46cb-93fc-df25a4557f7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ba1f23-0fa0-44c7-b170-4481d575078b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_af29459a-cb8a-46cb-93fc-df25a4557f7d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ba1f23-0fa0-44c7-b170-4481d575078b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationMember_a458b1d8-cc53-40b2-b501-ce0bd6c7f176" xlink:href="eols-20211231.xsd#eols_ContingentRoyaltyObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ba1f23-0fa0-44c7-b170-4481d575078b" xlink:to="loc_eols_ContingentRoyaltyObligationMember_a458b1d8-cc53-40b2-b501-ce0bd6c7f176" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_49b05173-9437-41fa-b435-fad38ed91bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13cb814-3384-4ec0-90e4-a4f953523799" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_49b05173-9437-41fa-b435-fad38ed91bcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_49b05173-9437-41fa-b435-fad38ed91bcc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_49b05173-9437-41fa-b435-fad38ed91bcc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_49b05173-9437-41fa-b435-fad38ed91bcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_19aa8b69-4b0c-49b5-90c7-5664937b3f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_49b05173-9437-41fa-b435-fad38ed91bcc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_19aa8b69-4b0c-49b5-90c7-5664937b3f36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_d77ee66c-341e-4a46-be87-cf49fd38b7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_19aa8b69-4b0c-49b5-90c7-5664937b3f36" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_d77ee66c-341e-4a46-be87-cf49fd38b7e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_7ea2f98e-3904-434e-8a11-2dc543942848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_19aa8b69-4b0c-49b5-90c7-5664937b3f36" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_7ea2f98e-3904-434e-8a11-2dc543942848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_77f193e9-26b8-46dc-bd0b-d7998a721377" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13cb814-3384-4ec0-90e4-a4f953523799" xlink:to="loc_srt_RangeAxis_77f193e9-26b8-46dc-bd0b-d7998a721377" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_77f193e9-26b8-46dc-bd0b-d7998a721377_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_77f193e9-26b8-46dc-bd0b-d7998a721377" xlink:to="loc_srt_RangeMember_77f193e9-26b8-46dc-bd0b-d7998a721377_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b8a4126f-14b5-4dde-8a4d-f58805bbd691" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_77f193e9-26b8-46dc-bd0b-d7998a721377" xlink:to="loc_srt_RangeMember_b8a4126f-14b5-4dde-8a4d-f58805bbd691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2ec936dd-3c3a-45f1-be24-3f3387a9558f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b8a4126f-14b5-4dde-8a4d-f58805bbd691" xlink:to="loc_srt_MinimumMember_2ec936dd-3c3a-45f1-be24-3f3387a9558f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d66aec6c-1641-4cfb-a326-70c7a91d6816" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b8a4126f-14b5-4dde-8a4d-f58805bbd691" xlink:to="loc_srt_MaximumMember_d66aec6c-1641-4cfb-a326-70c7a91d6816" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="ia5e44c827d5d41cd8eab090b30db43cd_FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56ec7f05-f90a-4ebc-b2c8-d386590a5bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4bffa439-4337-4388-a026-c475e87c3c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56ec7f05-f90a-4ebc-b2c8-d386590a5bab" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4bffa439-4337-4388-a026-c475e87c3c23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_f8a1dc14-7dd1-445f-9574-32493e5af84e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56ec7f05-f90a-4ebc-b2c8-d386590a5bab" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_f8a1dc14-7dd1-445f-9574-32493e5af84e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_373b48d7-800a-4801-94b4-9177bb2f5d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56ec7f05-f90a-4ebc-b2c8-d386590a5bab" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_373b48d7-800a-4801-94b4-9177bb2f5d72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_bba24dd7-80f0-4bdb-9df2-0199a3b64cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_373b48d7-800a-4801-94b4-9177bb2f5d72" xlink:to="loc_us-gaap_FinancialInstrumentAxis_bba24dd7-80f0-4bdb-9df2-0199a3b64cec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bba24dd7-80f0-4bdb-9df2-0199a3b64cec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bba24dd7-80f0-4bdb-9df2-0199a3b64cec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bba24dd7-80f0-4bdb-9df2-0199a3b64cec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6bd4556-bbad-41fd-86fd-d4c63c0c55d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bba24dd7-80f0-4bdb-9df2-0199a3b64cec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6bd4556-bbad-41fd-86fd-d4c63c0c55d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_4af09519-e22f-4f3c-b98f-da182cb4d6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6bd4556-bbad-41fd-86fd-d4c63c0c55d4" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_4af09519-e22f-4f3c-b98f-da182cb4d6d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5af72043-6c2a-4dad-9fe9-b51e08ab9cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6bd4556-bbad-41fd-86fd-d4c63c0c55d4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5af72043-6c2a-4dad-9fe9-b51e08ab9cc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_478e09c9-05c5-4e0c-8378-70f2add0c838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_373b48d7-800a-4801-94b4-9177bb2f5d72" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_478e09c9-05c5-4e0c-8378-70f2add0c838" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_478e09c9-05c5-4e0c-8378-70f2add0c838_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_478e09c9-05c5-4e0c-8378-70f2add0c838" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_478e09c9-05c5-4e0c-8378-70f2add0c838_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_373042fb-f1da-4acd-bd25-ab2020a4c8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_478e09c9-05c5-4e0c-8378-70f2add0c838" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_373042fb-f1da-4acd-bd25-ab2020a4c8ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_63f340a3-e79e-4861-b93f-08f02b672994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_373042fb-f1da-4acd-bd25-ab2020a4c8ac" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_63f340a3-e79e-4861-b93f-08f02b672994" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f82eaf96-59d8-40b1-b04c-88c913c0645f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_373042fb-f1da-4acd-bd25-ab2020a4c8ac" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f82eaf96-59d8-40b1-b04c-88c913c0645f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5359fb8b-1630-40e4-bda0-359d8c37b76a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_373042fb-f1da-4acd-bd25-ab2020a4c8ac" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5359fb8b-1630-40e4-bda0-359d8c37b76a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended" id="ib9a30a9ddbe849df88b64a09164abe2a_GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e1595cf-c55f-461f-9bf3-568f264820c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_189936d0-c883-43ca-8cf3-a359a0ebf395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e1595cf-c55f-461f-9bf3-568f264820c2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_189936d0-c883-43ca-8cf3-a359a0ebf395" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d24ed215-6678-40d8-a281-af577a76e91e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_189936d0-c883-43ca-8cf3-a359a0ebf395" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d24ed215-6678-40d8-a281-af577a76e91e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2c649b51-2333-4f59-9a11-6c15bacea61f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_189936d0-c883-43ca-8cf3-a359a0ebf395" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2c649b51-2333-4f59-9a11-6c15bacea61f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2e837995-3c8b-4b7e-8eb9-2d47f727cc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_189936d0-c883-43ca-8cf3-a359a0ebf395" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2e837995-3c8b-4b7e-8eb9-2d47f727cc6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce6ce3f8-5f19-48a7-93e7-981440930d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_189936d0-c883-43ca-8cf3-a359a0ebf395" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce6ce3f8-5f19-48a7-93e7-981440930d73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_681094f5-6833-4608-883c-6c63bd5d8f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e1595cf-c55f-461f-9bf3-568f264820c2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_681094f5-6833-4608-883c-6c63bd5d8f54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c209adac-c557-4333-a26a-e7ae0e01b6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_681094f5-6833-4608-883c-6c63bd5d8f54" xlink:to="loc_us-gaap_Goodwill_c209adac-c557-4333-a26a-e7ae0e01b6c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_43214a15-8b17-415a-8729-cc2b8ad53cbe" xlink:href="eols-20211231.xsd#eols_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e1595cf-c55f-461f-9bf3-568f264820c2" xlink:to="loc_eols_IntangibleAssetsGrossIncludingGoodwill_43214a15-8b17-415a-8729-cc2b8ad53cbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_9949469a-d97b-4006-bfdf-ac2994914bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e1595cf-c55f-461f-9bf3-568f264820c2" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_9949469a-d97b-4006-bfdf-ac2994914bb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2c13124-6342-4582-a76e-15fb09c6a6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e1595cf-c55f-461f-9bf3-568f264820c2" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2c13124-6342-4582-a76e-15fb09c6a6b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ceb2123a-9d65-4cff-b7ae-2e89c2f8322d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2c13124-6342-4582-a76e-15fb09c6a6b5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ceb2123a-9d65-4cff-b7ae-2e89c2f8322d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ceb2123a-9d65-4cff-b7ae-2e89c2f8322d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ceb2123a-9d65-4cff-b7ae-2e89c2f8322d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ceb2123a-9d65-4cff-b7ae-2e89c2f8322d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4786217-9569-46ab-97ee-519b1b0129db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ceb2123a-9d65-4cff-b7ae-2e89c2f8322d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4786217-9569-46ab-97ee-519b1b0129db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_da7b59f5-397a-48d0-ac09-4841ebc8925a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4786217-9569-46ab-97ee-519b1b0129db" xlink:to="loc_us-gaap_DistributionRightsMember_da7b59f5-397a-48d0-ac09-4841ebc8925a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_b3160714-0f61-405f-81f8-74855cb11c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4786217-9569-46ab-97ee-519b1b0129db" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_b3160714-0f61-405f-81f8-74855cb11c42" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended" id="i169d8e0efe56425c89b3fe7f36a0b1d4_GoodwillandIntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_4fc28036-7de3-4091-b6cf-13d689c67de1" xlink:href="eols-20211231.xsd#eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:to="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_4fc28036-7de3-4091-b6cf-13d689c67de1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0d9d610e-c0c3-4bfa-922d-7f2c74efc195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0d9d610e-c0c3-4bfa-922d-7f2c74efc195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets_5edb96a5-916c-4007-9d7d-84e8f77af635" xlink:href="eols-20211231.xsd#eols_MilestonePaymentsForIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:to="loc_eols_MilestonePaymentsForIntangibleAssets_5edb96a5-916c-4007-9d7d-84e8f77af635" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_f05f3da6-a813-48c7-befc-7cb4b38725b8" xlink:href="eols-20211231.xsd#eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:to="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_f05f3da6-a813-48c7-befc-7cb4b38725b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_92d5c3e5-771f-46a8-a7c0-0599180e2fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_92d5c3e5-771f-46a8-a7c0-0599180e2fdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8fe0719c-44d9-425f-988d-c7c265371028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8fe0719c-44d9-425f-988d-c7c265371028" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_00b892a2-9a7d-487e-bbb3-f5dde791b464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_00b892a2-9a7d-487e-bbb3-f5dde791b464" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d34c51d5-30c4-4c5e-a571-e009ad29e135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d34c51d5-30c4-4c5e-a571-e009ad29e135" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f3bfeb83-61f2-4e18-b773-30cd1722395a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d34c51d5-30c4-4c5e-a571-e009ad29e135" xlink:to="loc_dei_LegalEntityAxis_f3bfeb83-61f2-4e18-b773-30cd1722395a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f3bfeb83-61f2-4e18-b773-30cd1722395a_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f3bfeb83-61f2-4e18-b773-30cd1722395a" xlink:to="loc_dei_EntityDomain_f3bfeb83-61f2-4e18-b773-30cd1722395a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_730c4b32-b9f7-4b7d-a1b4-037b5045e931" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f3bfeb83-61f2-4e18-b773-30cd1722395a" xlink:to="loc_dei_EntityDomain_730c4b32-b9f7-4b7d-a1b4-037b5045e931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SCHAEONLLCMember_355e51c0-4ba8-4bba-97c0-977c4ef3fb24" xlink:href="eols-20211231.xsd#eols_SCHAEONLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_730c4b32-b9f7-4b7d-a1b4-037b5045e931" xlink:to="loc_eols_SCHAEONLLCMember_355e51c0-4ba8-4bba-97c0-977c4ef3fb24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_010b0505-bde8-4f42-9bd5-07bb5b2c9632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d34c51d5-30c4-4c5e-a571-e009ad29e135" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_010b0505-bde8-4f42-9bd5-07bb5b2c9632" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_010b0505-bde8-4f42-9bd5-07bb5b2c9632_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_010b0505-bde8-4f42-9bd5-07bb5b2c9632" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_010b0505-bde8-4f42-9bd5-07bb5b2c9632_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee5495e5-37e3-47c4-8602-087fb9e9a3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_010b0505-bde8-4f42-9bd5-07bb5b2c9632" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee5495e5-37e3-47c4-8602-087fb9e9a3f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EvolusIncMember_9bb9b91a-31d0-4c9a-80c3-50d56593ffe2" xlink:href="eols-20211231.xsd#eols_EvolusIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee5495e5-37e3-47c4-8602-087fb9e9a3f2" xlink:to="loc_eols_EvolusIncMember_9bb9b91a-31d0-4c9a-80c3-50d56593ffe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81c92707-16ef-4c7c-a977-9d099701028b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d34c51d5-30c4-4c5e-a571-e009ad29e135" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81c92707-16ef-4c7c-a977-9d099701028b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81c92707-16ef-4c7c-a977-9d099701028b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81c92707-16ef-4c7c-a977-9d099701028b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81c92707-16ef-4c7c-a977-9d099701028b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bb49d3f0-f55a-4def-9f44-23ae6d0fd3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81c92707-16ef-4c7c-a977-9d099701028b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bb49d3f0-f55a-4def-9f44-23ae6d0fd3a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_28afc2c6-3cb2-4004-9a5c-f2217ed15258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bb49d3f0-f55a-4def-9f44-23ae6d0fd3a6" xlink:to="loc_us-gaap_DistributionRightsMember_28afc2c6-3cb2-4004-9a5c-f2217ed15258" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_a9e6954b-a3e5-4dd5-aa7d-d6660caa4343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bb49d3f0-f55a-4def-9f44-23ae6d0fd3a6" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_a9e6954b-a3e5-4dd5-aa7d-d6660caa4343" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#TermLoansPharmakonTermLoansDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails" xlink:type="extended" id="i0a303e206eb349cfbfee2df9263014df_TermLoansPharmakonTermLoansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfTranches_c230f907-15d1-426d-903a-785131804bde" xlink:href="eols-20211231.xsd#eols_DebtInstrumentNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_eols_DebtInstrumentNumberOfTranches_c230f907-15d1-426d-903a-785131804bde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_18040fe6-8d8f-456b-90cd-44911818a903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_18040fe6-8d8f-456b-90cd-44911818a903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9dd72ea7-bdae-4426-a8ad-9b5769c5350c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9dd72ea7-bdae-4426-a8ad-9b5769c5350c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b53dcb3f-70a0-4c42-80c1-c83c0d118401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b53dcb3f-70a0-4c42-80c1-c83c0d118401" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal_773aafeb-a325-4e93-89f3-91f1e409bac8" xlink:href="eols-20211231.xsd#eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal_773aafeb-a325-4e93-89f3-91f1e409bac8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod_6c84e8ec-c5cd-4aa5-8ceb-f6e93d826b32" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod_6c84e8ec-c5cd-4aa5-8ceb-f6e93d826b32" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentAmountThreshold_8379ec89-0144-47a2-bd2d-2e07e77317c4" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentAmountThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_eols_DebtInstrumentPrepaymentAmountThreshold_8379ec89-0144-47a2-bd2d-2e07e77317c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_011c2978-ad7e-4e28-bcce-05540d8ac599" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_011c2978-ad7e-4e28-bcce-05540d8ac599" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4941ea46-3f1e-4b6f-af42-eb05131f1467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4941ea46-3f1e-4b6f-af42-eb05131f1467" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_14f5aa5a-a9fc-41e2-adbe-e25abb953587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_14f5aa5a-a9fc-41e2-adbe-e25abb953587" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8be41012-7c77-4b15-89d8-e1d6d215ae95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8be41012-7c77-4b15-89d8-e1d6d215ae95" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d82c8d00-1f39-4a80-902b-aa6af1bdcf59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_us-gaap_DebtInstrumentTable_d82c8d00-1f39-4a80-902b-aa6af1bdcf59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0d5e6cf2-adba-4ac6-b57d-4b1e5af8e963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d82c8d00-1f39-4a80-902b-aa6af1bdcf59" xlink:to="loc_us-gaap_DebtInstrumentAxis_0d5e6cf2-adba-4ac6-b57d-4b1e5af8e963" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0d5e6cf2-adba-4ac6-b57d-4b1e5af8e963_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0d5e6cf2-adba-4ac6-b57d-4b1e5af8e963" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0d5e6cf2-adba-4ac6-b57d-4b1e5af8e963_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_90d8e173-1a00-4856-b588-fbd2b4389040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0d5e6cf2-adba-4ac6-b57d-4b1e5af8e963" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_90d8e173-1a00-4856-b588-fbd2b4389040" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember_fbe15f0f-042a-45ab-8ca1-3b182d45c759" xlink:href="eols-20211231.xsd#eols_PharmakonTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90d8e173-1a00-4856-b588-fbd2b4389040" xlink:to="loc_eols_PharmakonTermLoansMember_fbe15f0f-042a-45ab-8ca1-3b182d45c759" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansOneMember_5ce152ee-66a3-45d3-8cae-047dfeda9513" xlink:href="eols-20211231.xsd#eols_PharmakonTermLoansOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_PharmakonTermLoansMember_fbe15f0f-042a-45ab-8ca1-3b182d45c759" xlink:to="loc_eols_PharmakonTermLoansOneMember_5ce152ee-66a3-45d3-8cae-047dfeda9513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansTwoMember_9b375eab-5846-4ae9-a38d-7aacf47379c8" xlink:href="eols-20211231.xsd#eols_PharmakonTermLoansTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_PharmakonTermLoansMember_fbe15f0f-042a-45ab-8ca1-3b182d45c759" xlink:to="loc_eols_PharmakonTermLoansTwoMember_9b375eab-5846-4ae9-a38d-7aacf47379c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_000ce50b-2c9b-478a-a987-e9cb3fca37ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d82c8d00-1f39-4a80-902b-aa6af1bdcf59" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_000ce50b-2c9b-478a-a987-e9cb3fca37ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_000ce50b-2c9b-478a-a987-e9cb3fca37ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_000ce50b-2c9b-478a-a987-e9cb3fca37ef" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_000ce50b-2c9b-478a-a987-e9cb3fca37ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4b99d9ec-8829-4410-b971-f60feb36dd82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_000ce50b-2c9b-478a-a987-e9cb3fca37ef" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4b99d9ec-8829-4410-b971-f60feb36dd82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_44f7cb71-f4ce-476a-8dd0-0cd9273bd479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4b99d9ec-8829-4410-b971-f60feb36dd82" xlink:to="loc_us-gaap_SecuredDebtMember_44f7cb71-f4ce-476a-8dd0-0cd9273bd479" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_4af9d195-131b-48c3-9e13-02e81576be89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d82c8d00-1f39-4a80-902b-aa6af1bdcf59" xlink:to="loc_us-gaap_VariableRateAxis_4af9d195-131b-48c3-9e13-02e81576be89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4af9d195-131b-48c3-9e13-02e81576be89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_4af9d195-131b-48c3-9e13-02e81576be89" xlink:to="loc_us-gaap_VariableRateDomain_4af9d195-131b-48c3-9e13-02e81576be89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b1e7c9de-8073-471b-9588-b1dae79d836c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_4af9d195-131b-48c3-9e13-02e81576be89" xlink:to="loc_us-gaap_VariableRateDomain_b1e7c9de-8073-471b-9588-b1dae79d836c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7ab095b1-0081-4c91-92ce-4cafa99ce0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_b1e7c9de-8073-471b-9588-b1dae79d836c" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7ab095b1-0081-4c91-92ce-4cafa99ce0f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsAxis_23d7808c-bb9a-41d6-aab4-a9b1508a4b25" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentTermsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d82c8d00-1f39-4a80-902b-aa6af1bdcf59" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsAxis_23d7808c-bb9a-41d6-aab4-a9b1508a4b25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsDomain_23d7808c-bb9a-41d6-aab4-a9b1508a4b25_default" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsAxis_23d7808c-bb9a-41d6-aab4-a9b1508a4b25" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsDomain_23d7808c-bb9a-41d6-aab4-a9b1508a4b25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsDomain_298610be-b3fe-491e-822d-a145534a80c1" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsAxis_23d7808c-bb9a-41d6-aab4-a9b1508a4b25" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsDomain_298610be-b3fe-491e-822d-a145534a80c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermOneMember_d128b6e3-0292-431c-8e3b-6ef21eba3afc" xlink:href="eols-20211231.xsd#eols_TermOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_298610be-b3fe-491e-822d-a145534a80c1" xlink:to="loc_eols_TermOneMember_d128b6e3-0292-431c-8e3b-6ef21eba3afc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermTwoMember_b541d645-ea31-4ed1-b28b-af0402f43248" xlink:href="eols-20211231.xsd#eols_TermTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_298610be-b3fe-491e-822d-a145534a80c1" xlink:to="loc_eols_TermTwoMember_b541d645-ea31-4ed1-b28b-af0402f43248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermThreeMember_187355af-9dfd-46eb-b903-f1782317c0f2" xlink:href="eols-20211231.xsd#eols_TermThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_298610be-b3fe-491e-822d-a145534a80c1" xlink:to="loc_eols_TermThreeMember_187355af-9dfd-46eb-b903-f1782317c0f2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansOxfordTermLoansDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#TermLoansOxfordTermLoansDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/TermLoansOxfordTermLoansDetails" xlink:type="extended" id="id8c4c9dceacc483fb9aefd9362eca441_TermLoansOxfordTermLoansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b0772945-f09d-433b-9a95-3ccf293afb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b0772945-f09d-433b-9a95-3ccf293afb6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LineofCreditFacilityNumberofAdvances_ec2b6c25-eecd-4ee5-8b68-cab446bc1a18" xlink:href="eols-20211231.xsd#eols_LineofCreditFacilityNumberofAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_LineofCreditFacilityNumberofAdvances_ec2b6c25-eecd-4ee5-8b68-cab446bc1a18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d712899c-ee44-47ae-a8ed-ce9db4280cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d712899c-ee44-47ae-a8ed-ce9db4280cf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_32b19856-5c41-4f93-9a4b-1b12e228cb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_32b19856-5c41-4f93-9a4b-1b12e228cb46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_3a80860e-a2f9-4bac-b97d-2e03ae5a7806" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPeriodOfInterestOnlyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_3a80860e-a2f9-4bac-b97d-2e03ae5a7806" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentAmortizationPeriod_d36666d5-0ad3-42ce-93c0-7821035afadc" xlink:href="eols-20211231.xsd#eols_DebtInstrumentAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_DebtInstrumentAmortizationPeriod_d36666d5-0ad3-42ce-93c0-7821035afadc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9c511d1d-37b9-4c8e-87cf-5974e0c6a269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9c511d1d-37b9-4c8e-87cf-5974e0c6a269" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_405e778e-be84-4a25-a1d1-f2c1c862da9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_405e778e-be84-4a25-a1d1-f2c1c862da9a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_87a19df5-5302-4c43-a609-e308c7fd3b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_87a19df5-5302-4c43-a609-e308c7fd3b68" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_347679b4-bdd4-400e-87f6-3196a212dff9" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_347679b4-bdd4-400e-87f6-3196a212dff9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_9b1aa154-ad98-4bae-82dd-ca03b5cb5611" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentFeePercentageYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_9b1aa154-ad98-4bae-82dd-ca03b5cb5611" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_551efc9f-5f1a-45a5-bb20-f1a62391c396" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentFeePercentageThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_551efc9f-5f1a-45a5-bb20-f1a62391c396" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_f708a1c3-2ab8-4b83-a22e-20536ded1f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_f708a1c3-2ab8-4b83-a22e-20536ded1f56" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentFeeAmountWaived_748a0ef4-598d-470c-88f8-be186d726406" xlink:href="eols-20211231.xsd#eols_DebtInstrumentFeeAmountWaived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_DebtInstrumentFeeAmountWaived_748a0ef4-598d-470c-88f8-be186d726406" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentOfFinalPaymentAmountWaived_b202f650-a3c7-4756-8ca2-f7fe38dde25f" xlink:href="eols-20211231.xsd#eols_DebtInstrumentOfFinalPaymentAmountWaived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_DebtInstrumentOfFinalPaymentAmountWaived_b202f650-a3c7-4756-8ca2-f7fe38dde25f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeeAmountWaived_8d6aa287-0838-43af-ad54-6ff4ff4e16d3" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentFeeAmountWaived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_DebtInstrumentPrepaymentFeeAmountWaived_8d6aa287-0838-43af-ad54-6ff4ff4e16d3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_52430f2c-7eb7-4c5c-a67b-530cffe01fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_52430f2c-7eb7-4c5c-a67b-530cffe01fff" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6b1765f2-d318-4785-ada8-6868c2ee20cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_DebtInstrumentTable_6b1765f2-d318-4785-ada8-6868c2ee20cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_856e4917-7052-43b2-8db3-536b7f6dd76f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6b1765f2-d318-4785-ada8-6868c2ee20cd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_856e4917-7052-43b2-8db3-536b7f6dd76f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_856e4917-7052-43b2-8db3-536b7f6dd76f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_856e4917-7052-43b2-8db3-536b7f6dd76f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_856e4917-7052-43b2-8db3-536b7f6dd76f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cd68cb6c-1efa-4109-9d5c-ad0846f27433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_856e4917-7052-43b2-8db3-536b7f6dd76f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cd68cb6c-1efa-4109-9d5c-ad0846f27433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_cccd3cb3-d453-43cf-bb07-a358567d167e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cd68cb6c-1efa-4109-9d5c-ad0846f27433" xlink:to="loc_us-gaap_SecuredDebtMember_cccd3cb3-d453-43cf-bb07-a358567d167e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2df8f986-c991-4e34-8c15-a9aa9302c4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6b1765f2-d318-4785-ada8-6868c2ee20cd" xlink:to="loc_us-gaap_DebtInstrumentAxis_2df8f986-c991-4e34-8c15-a9aa9302c4b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2df8f986-c991-4e34-8c15-a9aa9302c4b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2df8f986-c991-4e34-8c15-a9aa9302c4b2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2df8f986-c991-4e34-8c15-a9aa9302c4b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_faa4d4dd-fa50-4db0-9cb3-13edbc13e18f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2df8f986-c991-4e34-8c15-a9aa9302c4b2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_faa4d4dd-fa50-4db0-9cb3-13edbc13e18f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermLoanFacilityTrancheOneMember_6c24ab2f-1b3f-45a4-bf1a-67e6a5d3b141" xlink:href="eols-20211231.xsd#eols_TermLoanFacilityTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_faa4d4dd-fa50-4db0-9cb3-13edbc13e18f" xlink:to="loc_eols_TermLoanFacilityTrancheOneMember_6c24ab2f-1b3f-45a4-bf1a-67e6a5d3b141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermLoanFacilityTrancheTwoMember_ff7fc826-2252-45a9-9776-b9524251e33a" xlink:href="eols-20211231.xsd#eols_TermLoanFacilityTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_faa4d4dd-fa50-4db0-9cb3-13edbc13e18f" xlink:to="loc_eols_TermLoanFacilityTrancheTwoMember_ff7fc826-2252-45a9-9776-b9524251e33a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermLoanFacilityMember_f7817d5e-fa57-4a63-a560-53a25e7faa7e" xlink:href="eols-20211231.xsd#eols_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_faa4d4dd-fa50-4db0-9cb3-13edbc13e18f" xlink:to="loc_eols_TermLoanFacilityMember_f7817d5e-fa57-4a63-a560-53a25e7faa7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoansMember_d7b86455-23ac-43cd-8f82-d241f8ab2a9a" xlink:href="eols-20211231.xsd#eols_OxfordTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_faa4d4dd-fa50-4db0-9cb3-13edbc13e18f" xlink:to="loc_eols_OxfordTermLoansMember_d7b86455-23ac-43cd-8f82-d241f8ab2a9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoanFacilityMember_da760b3c-8d4c-4f4b-808b-d9b77eb99cf9" xlink:href="eols-20211231.xsd#eols_OxfordTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_faa4d4dd-fa50-4db0-9cb3-13edbc13e18f" xlink:to="loc_eols_OxfordTermLoanFacilityMember_da760b3c-8d4c-4f4b-808b-d9b77eb99cf9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_8d1ac060-25b0-4e27-a920-b3b1ab566531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6b1765f2-d318-4785-ada8-6868c2ee20cd" xlink:to="loc_us-gaap_VariableRateAxis_8d1ac060-25b0-4e27-a920-b3b1ab566531" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8d1ac060-25b0-4e27-a920-b3b1ab566531_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_8d1ac060-25b0-4e27-a920-b3b1ab566531" xlink:to="loc_us-gaap_VariableRateDomain_8d1ac060-25b0-4e27-a920-b3b1ab566531_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_dfe2a176-48fc-4f31-bf7a-905a32b24eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_8d1ac060-25b0-4e27-a920-b3b1ab566531" xlink:to="loc_us-gaap_VariableRateDomain_dfe2a176-48fc-4f31-bf7a-905a32b24eb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_fdef5183-198a-46f4-bf1f-c885ddf512cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_dfe2a176-48fc-4f31-bf7a-905a32b24eb9" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_fdef5183-198a-46f4-bf1f-c885ddf512cc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/DaewoongConvertibleNoteDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#DaewoongConvertibleNoteDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/DaewoongConvertibleNoteDetails" xlink:type="extended" id="i7f2ec5e828ac4c5d9423b1d60f5d64d6_DaewoongConvertibleNoteDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_55d417ab-c3ab-4452-8c5b-a51444cdbd8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8db8dc91-94f3-4d88-a998-608a25425aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_55d417ab-c3ab-4452-8c5b-a51444cdbd8a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8db8dc91-94f3-4d88-a998-608a25425aba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fa61f1cf-7f7a-4407-bc7d-243b7fd53219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_55d417ab-c3ab-4452-8c5b-a51444cdbd8a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fa61f1cf-7f7a-4407-bc7d-243b7fd53219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_5a22224b-f325-4bc0-bb7b-3aa5a0191788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_55d417ab-c3ab-4452-8c5b-a51444cdbd8a" xlink:to="loc_us-gaap_ConvertibleDebt_5a22224b-f325-4bc0-bb7b-3aa5a0191788" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_d1bd7cad-57df-4190-a12c-6b3947d21dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_55d417ab-c3ab-4452-8c5b-a51444cdbd8a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_d1bd7cad-57df-4190-a12c-6b3947d21dbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_de52d060-c11d-45bc-a4b4-f2d70d1362f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_55d417ab-c3ab-4452-8c5b-a51444cdbd8a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_de52d060-c11d-45bc-a4b4-f2d70d1362f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1473167e-ffe2-42e9-a793-f3c00d889c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_55d417ab-c3ab-4452-8c5b-a51444cdbd8a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1473167e-ffe2-42e9-a793-f3c00d889c43" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_807700bd-43f3-4481-8cc9-18ce444c01bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_55d417ab-c3ab-4452-8c5b-a51444cdbd8a" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_807700bd-43f3-4481-8cc9-18ce444c01bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9eac5b9d-8ef3-456a-bb33-9f51d696ab14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_807700bd-43f3-4481-8cc9-18ce444c01bc" xlink:to="loc_us-gaap_DebtInstrumentAxis_9eac5b9d-8ef3-456a-bb33-9f51d696ab14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9eac5b9d-8ef3-456a-bb33-9f51d696ab14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9eac5b9d-8ef3-456a-bb33-9f51d696ab14" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9eac5b9d-8ef3-456a-bb33-9f51d696ab14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d81a944f-24e9-4309-a8a9-1af3bac34adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9eac5b9d-8ef3-456a-bb33-9f51d696ab14" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d81a944f-24e9-4309-a8a9-1af3bac34adf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember_02d2eb75-5f72-419d-89fd-44f376e51f1f" xlink:href="eols-20211231.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d81a944f-24e9-4309-a8a9-1af3bac34adf" xlink:to="loc_eols_DaewoongConvertibleNoteMember_02d2eb75-5f72-419d-89fd-44f376e51f1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2cb07c5f-dfd0-4b62-8d17-73671c9ccb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_807700bd-43f3-4481-8cc9-18ce444c01bc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2cb07c5f-dfd0-4b62-8d17-73671c9ccb3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2cb07c5f-dfd0-4b62-8d17-73671c9ccb3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2cb07c5f-dfd0-4b62-8d17-73671c9ccb3f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2cb07c5f-dfd0-4b62-8d17-73671c9ccb3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_59c9f743-e2df-4bf8-9689-9e66317d7601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2cb07c5f-dfd0-4b62-8d17-73671c9ccb3f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_59c9f743-e2df-4bf8-9689-9e66317d7601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_af0a94b5-ae15-482a-a945-7b4c056e17fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_59c9f743-e2df-4bf8-9689-9e66317d7601" xlink:to="loc_us-gaap_ConvertibleDebtMember_af0a94b5-ae15-482a-a945-7b4c056e17fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5dfd7e0e-0ef7-4e8a-9e0b-af24f2ae0f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_807700bd-43f3-4481-8cc9-18ce444c01bc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5dfd7e0e-0ef7-4e8a-9e0b-af24f2ae0f03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5dfd7e0e-0ef7-4e8a-9e0b-af24f2ae0f03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5dfd7e0e-0ef7-4e8a-9e0b-af24f2ae0f03" xlink:to="loc_us-gaap_EquityComponentDomain_5dfd7e0e-0ef7-4e8a-9e0b-af24f2ae0f03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_24d021fa-d97b-4376-8c7b-31da89a05854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5dfd7e0e-0ef7-4e8a-9e0b-af24f2ae0f03" xlink:to="loc_us-gaap_EquityComponentDomain_24d021fa-d97b-4376-8c7b-31da89a05854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4a01ff39-9d1d-4840-95c1-01f82eb15a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_24d021fa-d97b-4376-8c7b-31da89a05854" xlink:to="loc_us-gaap_CommonStockMember_4a01ff39-9d1d-4840-95c1-01f82eb15a95" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i17abfed15c274ac28220b1682d647db3_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e510e327-2e61-41f4-874b-ff19dbe1ecf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e510e327-2e61-41f4-874b-ff19dbe1ecf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0512bbdc-87ad-4d27-9e3a-3eb910c77820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0512bbdc-87ad-4d27-9e3a-3eb910c77820" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6edbaacc-0a51-4e56-9098-a8b71a4ab9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6edbaacc-0a51-4e56-9098-a8b71a4ab9bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6e03be57-24b3-4318-a86f-124eb7ffa836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6e03be57-24b3-4318-a86f-124eb7ffa836" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3a2bb63f-585a-4991-a313-2dd283e46275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3a2bb63f-585a-4991-a313-2dd283e46275" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fdaf048c-98f8-4638-af0f-471d17e97b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fdaf048c-98f8-4638-af0f-471d17e97b51" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_633645d0-6869-427d-af83-cb56c3c4c763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_CommonStockSharesIssued_633645d0-6869-427d-af83-cb56c3c4c763" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_8f24179a-527a-4aa2-a895-f69e5c2eed3b" xlink:href="eols-20211231.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_8f24179a-527a-4aa2-a895-f69e5c2eed3b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a3855e66-7329-4398-9ea8-9ee23369fe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a3855e66-7329-4398-9ea8-9ee23369fe2b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_7b60fc73-a4b0-4865-a90c-6890d777ef9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_7b60fc73-a4b0-4865-a90c-6890d777ef9c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e722df93-4ad2-4c38-9427-f3ab3a49f633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e722df93-4ad2-4c38-9427-f3ab3a49f633" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_85cf5489-c2c2-42f2-9caf-ab1e8736df8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_85cf5489-c2c2-42f2-9caf-ab1e8736df8f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5251dd21-c192-4ca3-9d0d-26522fc38b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5251dd21-c192-4ca3-9d0d-26522fc38b91" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockMaximumConsiderationReceivable_6f5e3a08-9252-4ca7-9fb3-4ca96f180ae3" xlink:href="eols-20211231.xsd#eols_SaleOfStockMaximumConsiderationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_eols_SaleOfStockMaximumConsiderationReceivable_6f5e3a08-9252-4ca7-9fb3-4ca96f180ae3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_3a269c70-e182-4895-ad01-b50d7ebfec25" xlink:href="eols-20211231.xsd#eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_3a269c70-e182-4895-ad01-b50d7ebfec25" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_102d3294-935b-4e36-b068-3a7b38533be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_102d3294-935b-4e36-b068-3a7b38533be2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_016c5eb0-4b80-44aa-a035-f991335e4239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_016c5eb0-4b80-44aa-a035-f991335e4239" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockCommissionPaid_dd4f7a04-9c52-48c0-82ef-1683cb3f4a2f" xlink:href="eols-20211231.xsd#eols_SaleOfStockCommissionPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_eols_SaleOfStockCommissionPaid_dd4f7a04-9c52-48c0-82ef-1683cb3f4a2f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a2677a09-57f7-4a65-87c6-ef6806778f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a2677a09-57f7-4a65-87c6-ef6806778f34" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_feeea32f-a7f0-4670-895f-478eca3c8c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_feeea32f-a7f0-4670-895f-478eca3c8c45" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_d1429bf9-8ac7-4a8c-809e-a8e5f5be7e02" xlink:href="eols-20211231.xsd#eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_d1429bf9-8ac7-4a8c-809e-a8e5f5be7e02" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e5b7e9d2-3667-4c17-b563-6caffcfe4634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e5b7e9d2-3667-4c17-b563-6caffcfe4634" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0530f183-cd09-4956-ad3b-62232cf2fc36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0530f183-cd09-4956-ad3b-62232cf2fc36" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4d9f5c1e-4df3-407c-9cd8-e492228182cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4d9f5c1e-4df3-407c-9cd8-e492228182cc" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5ed9ac03-30fd-466e-9221-119ce411825c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5ed9ac03-30fd-466e-9221-119ce411825c" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_f60887c1-5921-4a12-bc2f-f14f0455b935" xlink:href="eols-20211231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_f60887c1-5921-4a12-bc2f-f14f0455b935" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3208a3aa-93e3-42c9-8b73-27aa5fd06dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3208a3aa-93e3-42c9-8b73-27aa5fd06dd5" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6ac4f824-2555-4358-af0d-c8fb6d5e7ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6ac4f824-2555-4358-af0d-c8fb6d5e7ed2" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_58e2e6f0-8075-43a2-ad61-2d9952c53380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_58e2e6f0-8075-43a2-ad61-2d9952c53380" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_18ded734-d875-4050-a81d-93d1a4097355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_18ded734-d875-4050-a81d-93d1a4097355" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3b72f745-f0fe-4bdd-8a0e-abcceaf84e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3b72f745-f0fe-4bdd-8a0e-abcceaf84e83" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1c7c460b-0a3e-4229-8850-ecd56bcae018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1c7c460b-0a3e-4229-8850-ecd56bcae018" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1aaa8ba2-e822-4db8-8231-27a5f449cb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1aaa8ba2-e822-4db8-8231-27a5f449cb5f" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c451c988-aed6-4d32-bfe4-40359373ddb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c451c988-aed6-4d32-bfe4-40359373ddb6" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized_2d7294ee-2e96-47d8-b546-240d91d1d454" xlink:href="eols-20211231.xsd#eols_AllocatedShareBasedCompensationExpenseCapitalized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized_2d7294ee-2e96-47d8-b546-240d91d1d454" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f21c5095-a2eb-4f42-a95b-213d30721060" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:to="loc_srt_RangeAxis_f21c5095-a2eb-4f42-a95b-213d30721060" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f21c5095-a2eb-4f42-a95b-213d30721060_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f21c5095-a2eb-4f42-a95b-213d30721060" xlink:to="loc_srt_RangeMember_f21c5095-a2eb-4f42-a95b-213d30721060_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e2ae3580-fbb1-4b93-9f2c-a80cf661c07e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f21c5095-a2eb-4f42-a95b-213d30721060" xlink:to="loc_srt_RangeMember_e2ae3580-fbb1-4b93-9f2c-a80cf661c07e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_96de5240-51dd-4062-a090-79886bd540b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e2ae3580-fbb1-4b93-9f2c-a80cf661c07e" xlink:to="loc_srt_MinimumMember_96de5240-51dd-4062-a090-79886bd540b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_74490c0d-0808-455c-a144-736acf7d1d5a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e2ae3580-fbb1-4b93-9f2c-a80cf661c07e" xlink:to="loc_srt_MaximumMember_74490c0d-0808-455c-a144-736acf7d1d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e96546dc-e86d-4aee-818f-dcdcd6b7f520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:to="loc_us-gaap_AwardTypeAxis_e96546dc-e86d-4aee-818f-dcdcd6b7f520" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e96546dc-e86d-4aee-818f-dcdcd6b7f520_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e96546dc-e86d-4aee-818f-dcdcd6b7f520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e96546dc-e86d-4aee-818f-dcdcd6b7f520_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3900faba-6a45-494e-acc3-e27f08ec826a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e96546dc-e86d-4aee-818f-dcdcd6b7f520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3900faba-6a45-494e-acc3-e27f08ec826a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0ad06cf5-fb02-4f3e-bea6-b198874f123c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3900faba-6a45-494e-acc3-e27f08ec826a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0ad06cf5-fb02-4f3e-bea6-b198874f123c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_0d0c2e13-981a-4716-8c98-16aa338d7da8" xlink:href="eols-20211231.xsd#eols_RestrictedStockUnitsRSUsPerformanceConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_0ad06cf5-fb02-4f3e-bea6-b198874f123c" xlink:to="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_0d0c2e13-981a-4716-8c98-16aa338d7da8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember_a085f7e3-a1e7-4fec-8250-245c71390797" xlink:href="eols-20211231.xsd#eols_RestrictedStockUnitsRSUsMarketConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_0ad06cf5-fb02-4f3e-bea6-b198874f123c" xlink:to="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember_a085f7e3-a1e7-4fec-8250-245c71390797" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e9806cb7-552d-42e7-98dd-92a5687561b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3900faba-6a45-494e-acc3-e27f08ec826a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e9806cb7-552d-42e7-98dd-92a5687561b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c8b3456f-d130-432f-9555-fd2415b368ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c8b3456f-d130-432f-9555-fd2415b368ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8b3456f-d130-432f-9555-fd2415b368ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c8b3456f-d130-432f-9555-fd2415b368ee" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8b3456f-d130-432f-9555-fd2415b368ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3bb04ce8-f27f-48a9-b847-2b39e6404eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c8b3456f-d130-432f-9555-fd2415b368ee" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3bb04ce8-f27f-48a9-b847-2b39e6404eff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember_8b9b74e2-c6a5-4a12-84b9-d17ef007b458" xlink:href="eols-20211231.xsd#eols_ATMSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3bb04ce8-f27f-48a9-b847-2b39e6404eff" xlink:to="loc_eols_ATMSalesAgreementMember_8b9b74e2-c6a5-4a12-84b9-d17ef007b458" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PublicStockOfferingMember_49c7ba0f-4db5-479d-92b2-8be43e93e0c0" xlink:href="eols-20211231.xsd#eols_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3bb04ce8-f27f-48a9-b847-2b39e6404eff" xlink:to="loc_eols_PublicStockOfferingMember_49c7ba0f-4db5-479d-92b2-8be43e93e0c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_6c22ea9e-e524-49e5-8382-f1ec513cc8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3bb04ce8-f27f-48a9-b847-2b39e6404eff" xlink:to="loc_us-gaap_OverAllotmentOptionMember_6c22ea9e-e524-49e5-8382-f1ec513cc8ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_51682f0e-e579-412c-8655-f2937f6bb10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:to="loc_us-gaap_DebtInstrumentAxis_51682f0e-e579-412c-8655-f2937f6bb10a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_51682f0e-e579-412c-8655-f2937f6bb10a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_51682f0e-e579-412c-8655-f2937f6bb10a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_51682f0e-e579-412c-8655-f2937f6bb10a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8967125c-c5b8-43e9-bbd1-3046466b2e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_51682f0e-e579-412c-8655-f2937f6bb10a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8967125c-c5b8-43e9-bbd1-3046466b2e39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember_fd8b5c61-d933-465f-ac1e-accfc0b3f0fe" xlink:href="eols-20211231.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8967125c-c5b8-43e9-bbd1-3046466b2e39" xlink:to="loc_eols_DaewoongConvertibleNoteMember_fd8b5c61-d933-465f-ac1e-accfc0b3f0fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_35dda7d5-e005-4f1c-8e49-f1444ddb783d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_35dda7d5-e005-4f1c-8e49-f1444ddb783d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_35dda7d5-e005-4f1c-8e49-f1444ddb783d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_35dda7d5-e005-4f1c-8e49-f1444ddb783d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_35dda7d5-e005-4f1c-8e49-f1444ddb783d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d78b3b76-af72-4c41-bdd8-0c2124eb9edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_35dda7d5-e005-4f1c-8e49-f1444ddb783d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d78b3b76-af72-4c41-bdd8-0c2124eb9edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_bdaa8186-c777-4aac-a909-1b49c97a7df2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d78b3b76-af72-4c41-bdd8-0c2124eb9edb" xlink:to="loc_us-gaap_ConvertibleDebtMember_bdaa8186-c777-4aac-a909-1b49c97a7df2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_10b42ce4-63ab-4a55-bcc8-cd8ae29b01e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_10b42ce4-63ab-4a55-bcc8-cd8ae29b01e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_10b42ce4-63ab-4a55-bcc8-cd8ae29b01e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_10b42ce4-63ab-4a55-bcc8-cd8ae29b01e0" xlink:to="loc_us-gaap_EquityComponentDomain_10b42ce4-63ab-4a55-bcc8-cd8ae29b01e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_27b093ab-a3b3-4d82-be0b-f65401ab5a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_10b42ce4-63ab-4a55-bcc8-cd8ae29b01e0" xlink:to="loc_us-gaap_EquityComponentDomain_27b093ab-a3b3-4d82-be0b-f65401ab5a43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_55eeb76e-547b-432e-915e-f87d1524a19f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_27b093ab-a3b3-4d82-be0b-f65401ab5a43" xlink:to="loc_us-gaap_CommonStockMember_55eeb76e-547b-432e-915e-f87d1524a19f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f4cce317-d32e-434f-80d2-cfda84bc1707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_27b093ab-a3b3-4d82-be0b-f65401ab5a43" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f4cce317-d32e-434f-80d2-cfda84bc1707" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityValuationAssumptionsDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#StockholdersEquityValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityValuationAssumptionsDetails" xlink:type="extended" id="i6c0947fd0503428a82f7e22ee19c116a_StockholdersEquityValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f886b6da-d8b1-4dcb-ba1a-3df0f9773f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a19a44dd-9f65-4bd3-91cf-238e174d1656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f886b6da-d8b1-4dcb-ba1a-3df0f9773f2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a19a44dd-9f65-4bd3-91cf-238e174d1656" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4a3e343b-0e48-486b-88a1-c301797b54c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f886b6da-d8b1-4dcb-ba1a-3df0f9773f2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4a3e343b-0e48-486b-88a1-c301797b54c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_76e56b75-f847-4bd7-9c96-61b153c60687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f886b6da-d8b1-4dcb-ba1a-3df0f9773f2d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_76e56b75-f847-4bd7-9c96-61b153c60687" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3eacdd4f-e74c-417f-be6e-78febfb7887f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f886b6da-d8b1-4dcb-ba1a-3df0f9773f2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3eacdd4f-e74c-417f-be6e-78febfb7887f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12963f2e-3774-4e2b-a18d-5db3ed02be9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f886b6da-d8b1-4dcb-ba1a-3df0f9773f2d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12963f2e-3774-4e2b-a18d-5db3ed02be9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bde46ce2-0ff5-4ff4-9105-8ea9446ecb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12963f2e-3774-4e2b-a18d-5db3ed02be9d" xlink:to="loc_us-gaap_AwardTypeAxis_bde46ce2-0ff5-4ff4-9105-8ea9446ecb9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bde46ce2-0ff5-4ff4-9105-8ea9446ecb9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bde46ce2-0ff5-4ff4-9105-8ea9446ecb9a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bde46ce2-0ff5-4ff4-9105-8ea9446ecb9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb782fd7-007f-4aef-9d37-866db0be0f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bde46ce2-0ff5-4ff4-9105-8ea9446ecb9a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb782fd7-007f-4aef-9d37-866db0be0f27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dffdfd75-2d17-48e4-bfa8-5a4e5db6e692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb782fd7-007f-4aef-9d37-866db0be0f27" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dffdfd75-2d17-48e4-bfa8-5a4e5db6e692" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#StockholdersEquityScheduleofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="extended" id="i576c28c49a554162a59ad6268597775c_StockholdersEquityScheduleofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65125793-5f3f-41be-ab78-bca8d93a949e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65125793-5f3f-41be-ab78-bca8d93a949e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1942fc61-eb85-41db-933b-bb3e9e246f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65125793-5f3f-41be-ab78-bca8d93a949e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1942fc61-eb85-41db-933b-bb3e9e246f58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8dd3e469-0c70-4d25-b3da-d5cd11ee2558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65125793-5f3f-41be-ab78-bca8d93a949e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8dd3e469-0c70-4d25-b3da-d5cd11ee2558" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e4723051-acb3-4354-a66a-773cdf34b5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65125793-5f3f-41be-ab78-bca8d93a949e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e4723051-acb3-4354-a66a-773cdf34b5bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0fa29f67-0e8c-460d-86e0-f73c3a13e698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65125793-5f3f-41be-ab78-bca8d93a949e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0fa29f67-0e8c-460d-86e0-f73c3a13e698" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_494d7973-8d71-45a6-b3bc-c619a4792ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7eaf1dfe-8b8c-40e9-a012-2fe5f8dfa068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7eaf1dfe-8b8c-40e9-a012-2fe5f8dfa068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1db30061-b5f7-40a6-8b07-d04e8b396f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1db30061-b5f7-40a6-8b07-d04e8b396f42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20b2be14-b733-4603-99b8-98c82c6fa8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1db30061-b5f7-40a6-8b07-d04e8b396f42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20b2be14-b733-4603-99b8-98c82c6fa8fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ff3bf4de-306d-4a7f-9cb2-2e1fd6b19bde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1db30061-b5f7-40a6-8b07-d04e8b396f42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ff3bf4de-306d-4a7f-9cb2-2e1fd6b19bde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_11529fab-5b18-4d19-9f2c-fb4d4b05b464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1db30061-b5f7-40a6-8b07-d04e8b396f42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_11529fab-5b18-4d19-9f2c-fb4d4b05b464" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_569270c9-2672-4776-92d7-fcf03210c500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1db30061-b5f7-40a6-8b07-d04e8b396f42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_569270c9-2672-4776-92d7-fcf03210c500" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_90cb0d5c-a1a8-405f-9383-a3a051cea354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3718bdcf-1103-4e13-844d-d7417ca4ac79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3718bdcf-1103-4e13-844d-d7417ca4ac79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3463a838-f33b-4b5a-8b6d-e60bb9a5d24c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3463a838-f33b-4b5a-8b6d-e60bb9a5d24c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d7bf1ce9-01a5-4be4-989e-af3d93cd1f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3463a838-f33b-4b5a-8b6d-e60bb9a5d24c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d7bf1ce9-01a5-4be4-989e-af3d93cd1f6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0419bd2a-ac06-4514-a6a0-243fcce4b0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0419bd2a-ac06-4514-a6a0-243fcce4b0bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_6ab5fee0-30cf-491f-b285-e3b1b7ce629e" xlink:href="eols-20211231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_6ab5fee0-30cf-491f-b285-e3b1b7ce629e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d981a714-ba63-4733-b6a0-f5b64857fee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_6ab5fee0-30cf-491f-b285-e3b1b7ce629e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d981a714-ba63-4733-b6a0-f5b64857fee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2203ef41-034f-4603-8803-d386bc28ee33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8b0a67fa-2e20-4caf-84c7-a9c6e14c7a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8b0a67fa-2e20-4caf-84c7-a9c6e14c7a48" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7ebfa80f-d667-4fcd-8de0-e292d99a47fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7ebfa80f-d667-4fcd-8de0-e292d99a47fb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f4870079-5950-4b0c-9540-947eea1d3762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7ebfa80f-d667-4fcd-8de0-e292d99a47fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f4870079-5950-4b0c-9540-947eea1d3762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_db799175-bc6a-495e-ade5-9c92ec105ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7ebfa80f-d667-4fcd-8de0-e292d99a47fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_db799175-bc6a-495e-ade5-9c92ec105ec8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0370e8ec-d308-4d2a-8ab2-2ed9260b36cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7ebfa80f-d667-4fcd-8de0-e292d99a47fb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0370e8ec-d308-4d2a-8ab2-2ed9260b36cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_58ea2053-13d9-4213-b279-14b7de91625f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7ebfa80f-d667-4fcd-8de0-e292d99a47fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_58ea2053-13d9-4213-b279-14b7de91625f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01bce980-016b-492c-a07a-bece34e4dd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01bce980-016b-492c-a07a-bece34e4dd0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_db9ab32f-2d53-4f0f-8592-64ecf55d3444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01bce980-016b-492c-a07a-bece34e4dd0e" xlink:to="loc_us-gaap_AwardTypeAxis_db9ab32f-2d53-4f0f-8592-64ecf55d3444" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db9ab32f-2d53-4f0f-8592-64ecf55d3444_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_db9ab32f-2d53-4f0f-8592-64ecf55d3444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db9ab32f-2d53-4f0f-8592-64ecf55d3444_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c25f3489-a4bb-4f74-84b8-68a99a6d964f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_db9ab32f-2d53-4f0f-8592-64ecf55d3444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c25f3489-a4bb-4f74-84b8-68a99a6d964f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2bfca2f4-db70-44ee-9692-18bf1f087f55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c25f3489-a4bb-4f74-84b8-68a99a6d964f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2bfca2f4-db70-44ee-9692-18bf1f087f55" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails" xlink:type="extended" id="idb6e9024b1bc4a4fab011860ee905fb6_StockholdersEquityScheduleofRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47489192-6794-41a1-a10d-93658d024c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6237bcef-9bda-4e6e-886c-d32f7a6e5e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47489192-6794-41a1-a10d-93658d024c3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6237bcef-9bda-4e6e-886c-d32f7a6e5e96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_39ece3cd-e4dd-4df8-917f-9d08f76572dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6237bcef-9bda-4e6e-886c-d32f7a6e5e96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_39ece3cd-e4dd-4df8-917f-9d08f76572dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5874ebd6-2ab9-406d-b12a-d4161715aa04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6237bcef-9bda-4e6e-886c-d32f7a6e5e96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5874ebd6-2ab9-406d-b12a-d4161715aa04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_990656d8-e4a1-43ed-889d-834c424c1d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6237bcef-9bda-4e6e-886c-d32f7a6e5e96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_990656d8-e4a1-43ed-889d-834c424c1d4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d90bb2e6-bf65-44ea-b87f-758bd4f35a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6237bcef-9bda-4e6e-886c-d32f7a6e5e96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d90bb2e6-bf65-44ea-b87f-758bd4f35a57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b4c60bf-b1c2-490c-a82c-749b305eafab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16785c2f-a270-4744-88d1-b374d4bfd9af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47489192-6794-41a1-a10d-93658d024c3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16785c2f-a270-4744-88d1-b374d4bfd9af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5f767225-4ff2-4292-a511-d5db7c5376f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16785c2f-a270-4744-88d1-b374d4bfd9af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5f767225-4ff2-4292-a511-d5db7c5376f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8f4cd9c5-acf2-452c-8883-70258b0d1143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16785c2f-a270-4744-88d1-b374d4bfd9af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8f4cd9c5-acf2-452c-8883-70258b0d1143" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6eebd182-6478-4e94-94b7-e442cd1beb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16785c2f-a270-4744-88d1-b374d4bfd9af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6eebd182-6478-4e94-94b7-e442cd1beb0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_936288f8-808a-479c-a0b2-e9b28d7e09dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16785c2f-a270-4744-88d1-b374d4bfd9af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_936288f8-808a-479c-a0b2-e9b28d7e09dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5e04763b-d37d-4ce5-8406-d35ff1e394f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8798f325-7e35-4e09-a1dc-53b10c6562f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47489192-6794-41a1-a10d-93658d024c3d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8798f325-7e35-4e09-a1dc-53b10c6562f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_882b6870-35f2-49b0-b5e3-7cb94f4f2c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8798f325-7e35-4e09-a1dc-53b10c6562f6" xlink:to="loc_us-gaap_AwardTypeAxis_882b6870-35f2-49b0-b5e3-7cb94f4f2c97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_882b6870-35f2-49b0-b5e3-7cb94f4f2c97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_882b6870-35f2-49b0-b5e3-7cb94f4f2c97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_882b6870-35f2-49b0-b5e3-7cb94f4f2c97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c0b95c3-5120-4cd0-9597-a9bb6a561709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_882b6870-35f2-49b0-b5e3-7cb94f4f2c97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c0b95c3-5120-4cd0-9597-a9bb6a561709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_875b607f-fc06-4945-b5e0-71b543766c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c0b95c3-5120-4cd0-9597-a9bb6a561709" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_875b607f-fc06-4945-b5e0-71b543766c5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f67f41f8-2768-4383-a37f-4b89bee4270e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8798f325-7e35-4e09-a1dc-53b10c6562f6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f67f41f8-2768-4383-a37f-4b89bee4270e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f67f41f8-2768-4383-a37f-4b89bee4270e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f67f41f8-2768-4383-a37f-4b89bee4270e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f67f41f8-2768-4383-a37f-4b89bee4270e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_78c22fc0-6269-438a-ad0f-dc0c97995a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f67f41f8-2768-4383-a37f-4b89bee4270e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_78c22fc0-6269-438a-ad0f-dc0c97995a9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a914a365-1376-4123-8c99-d0f4d4ab3e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_78c22fc0-6269-438a-ad0f-dc0c97995a9a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a914a365-1376-4123-8c99-d0f4d4ab3e38" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#StockholdersEquityStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="extended" id="ida774734f5bf4e309dd3694d655c6bf1_StockholdersEquityStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f4a6149e-a2f0-45b3-b03a-dfb60f1409a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_44433e7f-a8a4-401a-b695-c3fcd10d0054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f4a6149e-a2f0-45b3-b03a-dfb60f1409a4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_44433e7f-a8a4-401a-b695-c3fcd10d0054" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_30b2ec8f-a08a-4237-8a24-6cf6b971ce53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f4a6149e-a2f0-45b3-b03a-dfb60f1409a4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_30b2ec8f-a08a-4237-8a24-6cf6b971ce53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d65b438c-7343-42e0-871c-07f6d2f2d7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_30b2ec8f-a08a-4237-8a24-6cf6b971ce53" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d65b438c-7343-42e0-871c-07f6d2f2d7ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d65b438c-7343-42e0-871c-07f6d2f2d7ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d65b438c-7343-42e0-871c-07f6d2f2d7ad" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d65b438c-7343-42e0-871c-07f6d2f2d7ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d44f511b-c0fa-4648-9e39-671caa01c250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d65b438c-7343-42e0-871c-07f6d2f2d7ad" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d44f511b-c0fa-4648-9e39-671caa01c250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_abc65808-2014-4389-a01a-5f6213bfec03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d44f511b-c0fa-4648-9e39-671caa01c250" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_abc65808-2014-4389-a01a-5f6213bfec03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_799e43d6-bc18-41ae-8141-6d4813f0af42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d44f511b-c0fa-4648-9e39-671caa01c250" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_799e43d6-bc18-41ae-8141-6d4813f0af42" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails" xlink:type="extended" id="i4dfb1a3436a9435a94418a7aca5646ed_MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_76e9623d-d853-4876-a9d3-41cedf9edc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_76e9623d-d853-4876-a9d3-41cedf9edc9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementPaymentTerms_8c926c02-9559-48ba-9159-dcf2afe166de" xlink:href="eols-20211231.xsd#eols_LossContingencySettlementAgreementPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_eols_LossContingencySettlementAgreementPaymentTerms_8c926c02-9559-48ba-9159-dcf2afe166de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_c3a65f56-35b3-4edb-b86f-2c677b57727d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_c3a65f56-35b3-4edb-b86f-2c677b57727d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_1ed6a0a3-1dc2-450f-9508-ce810a44e8cd" xlink:href="eols-20211231.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_1ed6a0a3-1dc2-450f-9508-ce810a44e8cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3d4f48fe-0f1b-4c25-be62-57bea8d7c01c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3d4f48fe-0f1b-4c25-be62-57bea8d7c01c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear_79ede4f3-527f-4417-b5e0-7fd6deb2f5fa" xlink:href="eols-20211231.xsd#eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear_79ede4f3-527f-4417-b5e0-7fd6deb2f5fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_3c3b4cc1-33be-4399-be11-47d5efab8dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_3c3b4cc1-33be-4399-be11-47d5efab8dc2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestonePaymentInConnectionWithAgreement_e4dd397b-a106-4b5a-aafd-64aaaa0355f8" xlink:href="eols-20211231.xsd#eols_MilestonePaymentInConnectionWithAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_eols_MilestonePaymentInConnectionWithAgreement_e4dd397b-a106-4b5a-aafd-64aaaa0355f8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_9312f101-f970-48fa-b782-8ad9c75e73ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_us-gaap_ConvertibleDebt_9312f101-f970-48fa-b782-8ad9c75e73ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_648a9759-87a2-42a7-8903-1238ccd87995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_648a9759-87a2-42a7-8903-1238ccd87995" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_e5de47c6-f924-4450-8e36-f0a4232055da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_e5de47c6-f924-4450-8e36-f0a4232055da" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned_9321da00-7877-4302-bc69-e37687168fe3" xlink:href="eols-20211231.xsd#eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned_9321da00-7877-4302-bc69-e37687168fe3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_31892936-72c3-482d-9868-bee4c57bbbab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:to="loc_srt_LitigationCaseAxis_31892936-72c3-482d-9868-bee4c57bbbab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_31892936-72c3-482d-9868-bee4c57bbbab_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_31892936-72c3-482d-9868-bee4c57bbbab" xlink:to="loc_srt_LitigationCaseTypeDomain_31892936-72c3-482d-9868-bee4c57bbbab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_92839df2-f829-415d-86bc-23f5430cc344" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_31892936-72c3-482d-9868-bee4c57bbbab" xlink:to="loc_srt_LitigationCaseTypeDomain_92839df2-f829-415d-86bc-23f5430cc344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_b32247d7-08cd-4849-a586-b3473fd3876b" xlink:href="eols-20211231.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_92839df2-f829-415d-86bc-23f5430cc344" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_b32247d7-08cd-4849-a586-b3473fd3876b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a69f8ec4-c7f5-4e90-8a72-1b9480c9d91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:to="loc_us-gaap_DebtInstrumentAxis_a69f8ec4-c7f5-4e90-8a72-1b9480c9d91a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a69f8ec4-c7f5-4e90-8a72-1b9480c9d91a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a69f8ec4-c7f5-4e90-8a72-1b9480c9d91a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a69f8ec4-c7f5-4e90-8a72-1b9480c9d91a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42647b16-4560-4100-9135-e23ad05ae0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a69f8ec4-c7f5-4e90-8a72-1b9480c9d91a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_42647b16-4560-4100-9135-e23ad05ae0c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongAgreementMember_b4c333f4-2b5d-482b-b4e5-32afed0609f2" xlink:href="eols-20211231.xsd#eols_DaewoongAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42647b16-4560-4100-9135-e23ad05ae0c7" xlink:to="loc_eols_DaewoongAgreementMember_b4c333f4-2b5d-482b-b4e5-32afed0609f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember_1a04083f-4f40-4d2c-82fa-8af89572834e" xlink:href="eols-20211231.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42647b16-4560-4100-9135-e23ad05ae0c7" xlink:to="loc_eols_DaewoongConvertibleNoteMember_1a04083f-4f40-4d2c-82fa-8af89572834e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9c2229e7-e41b-4968-9242-8b7637b0022a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9c2229e7-e41b-4968-9242-8b7637b0022a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9c2229e7-e41b-4968-9242-8b7637b0022a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9c2229e7-e41b-4968-9242-8b7637b0022a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9c2229e7-e41b-4968-9242-8b7637b0022a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e75d0bbf-e9a9-422c-bd65-95baa8ad24de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9c2229e7-e41b-4968-9242-8b7637b0022a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e75d0bbf-e9a9-422c-bd65-95baa8ad24de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_ff840578-c907-421b-9b4f-8ac353b3f274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e75d0bbf-e9a9-422c-bd65-95baa8ad24de" xlink:to="loc_us-gaap_ConvertibleDebtMember_ff840578-c907-421b-9b4f-8ac353b3f274" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e1982747-2994-4c97-965b-56653bb1599b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e1982747-2994-4c97-965b-56653bb1599b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e1982747-2994-4c97-965b-56653bb1599b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e1982747-2994-4c97-965b-56653bb1599b" xlink:to="loc_us-gaap_EquityComponentDomain_e1982747-2994-4c97-965b-56653bb1599b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6a711db5-4bc2-41b5-9682-13e131a113d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e1982747-2994-4c97-965b-56653bb1599b" xlink:to="loc_us-gaap_EquityComponentDomain_6a711db5-4bc2-41b5-9682-13e131a113d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c0c084b0-f33e-4997-b04d-ffb2b31d8096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6a711db5-4bc2-41b5-9682-13e131a113d3" xlink:to="loc_us-gaap_CommonStockMember_c0c084b0-f33e-4997-b04d-ffb2b31d8096" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b197fba1-3e4f-45ee-ac2b-4262559ac59f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:to="loc_srt_RangeAxis_b197fba1-3e4f-45ee-ac2b-4262559ac59f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b197fba1-3e4f-45ee-ac2b-4262559ac59f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b197fba1-3e4f-45ee-ac2b-4262559ac59f" xlink:to="loc_srt_RangeMember_b197fba1-3e4f-45ee-ac2b-4262559ac59f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_99bdf1e2-4520-445c-a0b0-cbfc5b1b3887" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b197fba1-3e4f-45ee-ac2b-4262559ac59f" xlink:to="loc_srt_RangeMember_99bdf1e2-4520-445c-a0b0-cbfc5b1b3887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5490631c-517e-44a9-a12b-f076cecac8f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_99bdf1e2-4520-445c-a0b0-cbfc5b1b3887" xlink:to="loc_srt_MaximumMember_5490631c-517e-44a9-a12b-f076cecac8f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_523ef8f2-f983-4063-92be-b4e0f8e49992" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:to="loc_srt_StatementScenarioAxis_523ef8f2-f983-4063-92be-b4e0f8e49992" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_523ef8f2-f983-4063-92be-b4e0f8e49992_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_523ef8f2-f983-4063-92be-b4e0f8e49992" xlink:to="loc_srt_ScenarioUnspecifiedDomain_523ef8f2-f983-4063-92be-b4e0f8e49992_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9c6d4928-b592-4fda-a990-88c8fc6eed32" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_523ef8f2-f983-4063-92be-b4e0f8e49992" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9c6d4928-b592-4fda-a990-88c8fc6eed32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_e71b3c44-0d1a-44fb-8d9a-deb74c497fd5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_9c6d4928-b592-4fda-a990-88c8fc6eed32" xlink:to="loc_srt_ScenarioForecastMember_e71b3c44-0d1a-44fb-8d9a-deb74c497fd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a8e819b8-5f52-4135-a565-0fdce9a45dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a8e819b8-5f52-4135-a565-0fdce9a45dfd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a8e819b8-5f52-4135-a565-0fdce9a45dfd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a8e819b8-5f52-4135-a565-0fdce9a45dfd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a8e819b8-5f52-4135-a565-0fdce9a45dfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c4ad60a9-fbc1-49ac-86ec-fb3995efb833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a8e819b8-5f52-4135-a565-0fdce9a45dfd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c4ad60a9-fbc1-49ac-86ec-fb3995efb833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5f1140e2-ceac-4d69-ae27-a7864080f59a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c4ad60a9-fbc1-49ac-86ec-fb3995efb833" xlink:to="loc_us-gaap_SubsequentEventMember_5f1140e2-ceac-4d69-ae27-a7864080f59a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="iafb30d0cc16f4d77bd74e602411d5f77_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_8296e435-4a97-4097-820e-8ba9c5ceec15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_143ee369-57ba-4887-813f-f10638d6ca02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_8296e435-4a97-4097-820e-8ba9c5ceec15" xlink:to="loc_us-gaap_OperatingLossCarryforwards_143ee369-57ba-4887-813f-f10638d6ca02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_ffc05b14-b88b-4b0a-9de2-aef2880535e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_8296e435-4a97-4097-820e-8ba9c5ceec15" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_ffc05b14-b88b-4b0a-9de2-aef2880535e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_1745e621-1590-4851-baf1-68686181eebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_8296e435-4a97-4097-820e-8ba9c5ceec15" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_1745e621-1590-4851-baf1-68686181eebb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_ba2561c4-10f9-4f6f-8e44-a6720e003e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_8296e435-4a97-4097-820e-8ba9c5ceec15" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_ba2561c4-10f9-4f6f-8e44-a6720e003e0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_4d9eb5f4-65af-4902-9e3a-1f7889de8609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_8296e435-4a97-4097-820e-8ba9c5ceec15" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_4d9eb5f4-65af-4902-9e3a-1f7889de8609" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_73031600-3985-4739-b054-0ee3a6c9531b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_8296e435-4a97-4097-820e-8ba9c5ceec15" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_73031600-3985-4739-b054-0ee3a6c9531b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f7cf63e2-dbc3-462e-b96c-831ec3bcfe81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_73031600-3985-4739-b054-0ee3a6c9531b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f7cf63e2-dbc3-462e-b96c-831ec3bcfe81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f7cf63e2-dbc3-462e-b96c-831ec3bcfe81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f7cf63e2-dbc3-462e-b96c-831ec3bcfe81" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f7cf63e2-dbc3-462e-b96c-831ec3bcfe81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_03be77dc-c37e-476b-977b-6164cc27b605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f7cf63e2-dbc3-462e-b96c-831ec3bcfe81" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_03be77dc-c37e-476b-977b-6164cc27b605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_04097027-a96c-4a79-a7fc-2a7073f3d84f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_03be77dc-c37e-476b-977b-6164cc27b605" xlink:to="loc_us-gaap_DomesticCountryMember_04097027-a96c-4a79-a7fc-2a7073f3d84f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_26a52433-adf4-41d2-9a57-476483bec40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_03be77dc-c37e-476b-977b-6164cc27b605" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_26a52433-adf4-41d2-9a57-476483bec40c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_64cbce9a-23a9-4ac6-bb5f-f25ac6041252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_73031600-3985-4739-b054-0ee3a6c9531b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_64cbce9a-23a9-4ac6-bb5f-f25ac6041252" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_64cbce9a-23a9-4ac6-bb5f-f25ac6041252_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_64cbce9a-23a9-4ac6-bb5f-f25ac6041252" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_64cbce9a-23a9-4ac6-bb5f-f25ac6041252_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_643e050b-6a92-4a69-9a06-96ac78fcfb59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_64cbce9a-23a9-4ac6-bb5f-f25ac6041252" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_643e050b-6a92-4a69-9a06-96ac78fcfb59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_eaf4e1cc-bb6c-4054-9075-d7773144581b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_643e050b-6a92-4a69-9a06-96ac78fcfb59" xlink:to="loc_us-gaap_ResearchMember_eaf4e1cc-bb6c-4054-9075-d7773144581b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i22013644984842c7bc75a0cd059770a9_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_4f7342ef-f447-4c73-8f90-9b025c4401e9" xlink:href="eols-20211231.xsd#eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:to="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_4f7342ef-f447-4c73-8f90-9b025c4401e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_3b44514f-a636-4843-a061-71b7c37fe51a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_3b44514f-a636-4843-a061-71b7c37fe51a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_9b126f39-3703-4519-952b-44e9efa2eb76" xlink:href="eols-20211231.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_9b126f39-3703-4519-952b-44e9efa2eb76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_75df47b8-0a0b-46a9-99c8-2187ca24190e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_75df47b8-0a0b-46a9-99c8-2187ca24190e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_d315228d-e6ca-4a2a-be69-853dd7787fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:to="loc_us-gaap_ConvertibleDebt_d315228d-e6ca-4a2a-be69-853dd7787fe5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_db99524e-d1f7-43d6-a6d6-67028aad07fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_db99524e-d1f7-43d6-a6d6-67028aad07fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_f0599b90-948e-4a09-b906-85a5e9f76d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_f0599b90-948e-4a09-b906-85a5e9f76d60" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e4439b72-62bf-447b-9555-ef9a2364629b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e4439b72-62bf-447b-9555-ef9a2364629b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4439b72-62bf-447b-9555-ef9a2364629b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e4439b72-62bf-447b-9555-ef9a2364629b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4439b72-62bf-447b-9555-ef9a2364629b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e50c755-b64d-4a64-8460-dff914fc7999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e4439b72-62bf-447b-9555-ef9a2364629b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e50c755-b64d-4a64-8460-dff914fc7999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EvolusIncMember_cccd6ffc-64c1-4e8e-981e-a597dbcc689b" xlink:href="eols-20211231.xsd#eols_EvolusIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e50c755-b64d-4a64-8460-dff914fc7999" xlink:to="loc_eols_EvolusIncMember_cccd6ffc-64c1-4e8e-981e-a597dbcc689b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_eb4a685d-5740-4104-884e-de9a3556c986" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:to="loc_dei_LegalEntityAxis_eb4a685d-5740-4104-884e-de9a3556c986" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_eb4a685d-5740-4104-884e-de9a3556c986_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_eb4a685d-5740-4104-884e-de9a3556c986" xlink:to="loc_dei_EntityDomain_eb4a685d-5740-4104-884e-de9a3556c986_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_75e44c1a-4398-456d-94fd-feadb9810797" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_eb4a685d-5740-4104-884e-de9a3556c986" xlink:to="loc_dei_EntityDomain_75e44c1a-4398-456d-94fd-feadb9810797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SCHAEONLLCMember_892e0b23-89fe-4faa-8e6b-a059702664a1" xlink:href="eols-20211231.xsd#eols_SCHAEONLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_75e44c1a-4398-456d-94fd-feadb9810797" xlink:to="loc_eols_SCHAEONLLCMember_892e0b23-89fe-4faa-8e6b-a059702664a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8f58e92d-b20f-4c0a-bbfe-721e9c780f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8f58e92d-b20f-4c0a-bbfe-721e9c780f98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8f58e92d-b20f-4c0a-bbfe-721e9c780f98_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8f58e92d-b20f-4c0a-bbfe-721e9c780f98" xlink:to="loc_us-gaap_EquityComponentDomain_8f58e92d-b20f-4c0a-bbfe-721e9c780f98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4d37b307-4d25-41dc-b1de-d585bba4425c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8f58e92d-b20f-4c0a-bbfe-721e9c780f98" xlink:to="loc_us-gaap_EquityComponentDomain_4d37b307-4d25-41dc-b1de-d585bba4425c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_311f9640-6ab1-479b-9040-4dabd32e90f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4d37b307-4d25-41dc-b1de-d585bba4425c" xlink:to="loc_us-gaap_CommonStockMember_311f9640-6ab1-479b-9040-4dabd32e90f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_bd3f275f-1b57-4deb-b332-7e89866852b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:to="loc_srt_LitigationCaseAxis_bd3f275f-1b57-4deb-b332-7e89866852b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_bd3f275f-1b57-4deb-b332-7e89866852b5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_bd3f275f-1b57-4deb-b332-7e89866852b5" xlink:to="loc_srt_LitigationCaseTypeDomain_bd3f275f-1b57-4deb-b332-7e89866852b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a578ddf5-25d2-4810-a669-1fcd1388b9f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_bd3f275f-1b57-4deb-b332-7e89866852b5" xlink:to="loc_srt_LitigationCaseTypeDomain_a578ddf5-25d2-4810-a669-1fcd1388b9f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_ac809dce-ef6f-41e3-b11e-b24c303dad90" xlink:href="eols-20211231.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a578ddf5-25d2-4810-a669-1fcd1388b9f5" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_ac809dce-ef6f-41e3-b11e-b24c303dad90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5e3eceb5-252a-46d2-9b0f-a0c144d77bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:to="loc_us-gaap_DebtInstrumentAxis_5e3eceb5-252a-46d2-9b0f-a0c144d77bcc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5e3eceb5-252a-46d2-9b0f-a0c144d77bcc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5e3eceb5-252a-46d2-9b0f-a0c144d77bcc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5e3eceb5-252a-46d2-9b0f-a0c144d77bcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_502a5552-51d0-4f90-a81f-82063c69a8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5e3eceb5-252a-46d2-9b0f-a0c144d77bcc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_502a5552-51d0-4f90-a81f-82063c69a8a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember_f3c54bc0-29ca-4e45-a4a4-7e5366ff308d" xlink:href="eols-20211231.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_502a5552-51d0-4f90-a81f-82063c69a8a0" xlink:to="loc_eols_DaewoongConvertibleNoteMember_f3c54bc0-29ca-4e45-a4a4-7e5366ff308d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1753c019-1142-4942-8b76-d1631d5e23fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1753c019-1142-4942-8b76-d1631d5e23fa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1753c019-1142-4942-8b76-d1631d5e23fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1753c019-1142-4942-8b76-d1631d5e23fa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1753c019-1142-4942-8b76-d1631d5e23fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8ca24f29-f2d4-4625-bc4c-98c670ea5696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1753c019-1142-4942-8b76-d1631d5e23fa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8ca24f29-f2d4-4625-bc4c-98c670ea5696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_efacc7d8-5d69-47b0-8ff8-ec5dedbc3575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8ca24f29-f2d4-4625-bc4c-98c670ea5696" xlink:to="loc_us-gaap_ConvertibleDebtMember_efacc7d8-5d69-47b0-8ff8-ec5dedbc3575" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>eols-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4ac935c8-acd7-4078-a010-d8166688f707,g:62b990ab-d451-4f6d-92f0-709386d601f0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_6c7946e9-ee6a-4b98-8cf6-a63b077d3285_terseLabel_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs Performance Conditions</link:label>
    <link:label id="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_label_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs), Performance Conditions [Member]</link:label>
    <link:label id="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_documentation_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs), Performance Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" xlink:href="eols-20211231.xsd#eols_RestrictedStockUnitsRSUsPerformanceConditionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" xlink:to="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_e7a1fa73-443f-444e-934c-2d1c779f817d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual, payments</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_a6fb9109-a9d2-49a8-adc8-377ed3290896_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PublicStockOfferingMember_e75e37af-b808-4688-a176-3e20ce8bd735_terseLabel_en-US" xlink:label="lab_eols_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_eols_PublicStockOfferingMember_label_en-US" xlink:label="lab_eols_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_eols_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_eols_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PublicStockOfferingMember" xlink:href="eols-20211231.xsd#eols_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PublicStockOfferingMember" xlink:to="lab_eols_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_52042614-8084-4f28-a310-a804d71afd8b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_a3bc890b-4473-42da-9dca-5d64c6af7db3_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e66057f8-95fc-4da4-9b6d-d33a787ff935_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0d4d73eb-29b9-4308-8ff0-268214baafeb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a79f93b7-770a-472d-8b2b-2df5cb5ae38b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c9f37f70-2d3c-4b77-a0af-2ec4c3ff43e0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_45b4a019-6d67-4a57-a91c-f624b280bc3e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d14a6589-68b9-4824-97ef-85164ad87187_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3f4ac2bb-72f7-4dca-8980-58c88de92e10_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b79965d3-4704-41ec-b4c9-c11a1ee34808_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_22b3efcc-d065-47d9-9559-eda5e1318bd4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_81772da8-4f4c-458c-87f3-9ab35b3d047e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_RebatesAndCouponsCreditsAndPayments_bfecfbcf-f463-4cd7-b944-cc22f5b28242_terseLabel_en-US" xlink:label="lab_eols_RebatesAndCouponsCreditsAndPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates and coupons, credits and payments</link:label>
    <link:label id="lab_eols_RebatesAndCouponsCreditsAndPayments_label_en-US" xlink:label="lab_eols_RebatesAndCouponsCreditsAndPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates And Coupons, Credits And Payments</link:label>
    <link:label id="lab_eols_RebatesAndCouponsCreditsAndPayments_documentation_en-US" xlink:label="lab_eols_RebatesAndCouponsCreditsAndPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates And Coupons, Credits And Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RebatesAndCouponsCreditsAndPayments" xlink:href="eols-20211231.xsd#eols_RebatesAndCouponsCreditsAndPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RebatesAndCouponsCreditsAndPayments" xlink:to="lab_eols_RebatesAndCouponsCreditsAndPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b2f25c50-235f-474b-82c7-126dd2dd1caf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_263b3549-e594-4a75-aadc-cfdb3a07fb15_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_23011188-d022-4337-81bf-79568001f54e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_a5581379-47d0-4bbd-baa2-729b32e90d51_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_abba0ca2-c1e4-45f4-9adc-0f6a9bd451dc_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8b9127e6-c329-455d-a577-421fff6e8d66_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_08fc989e-637b-4a26-9822-a1bcdcff4022_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_dd3462b6-c225-4687-8a7d-b59dc9c6013f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9b3c3cc3-ede3-4dbb-9a6d-478a99f01814_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9525b9bd-d1ee-48fe-8bcf-a226e916ac8d_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_80e066d9-4c2d-4f96-b17c-f0d0923efb01_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5d60e7c6-7a82-4c37-a9c9-e557ed2c8c18_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_51d532f6-6168-4a54-afcb-dddf6d494df8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DaewoongConvertibleNoteMember_d68516a5-bd82-432a-8251-8f77eb659d0f_terseLabel_en-US" xlink:label="lab_eols_DaewoongConvertibleNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daewoong Convertible Note</link:label>
    <link:label id="lab_eols_DaewoongConvertibleNoteMember_label_en-US" xlink:label="lab_eols_DaewoongConvertibleNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daewoong Convertible Note [Member]</link:label>
    <link:label id="lab_eols_DaewoongConvertibleNoteMember_documentation_en-US" xlink:label="lab_eols_DaewoongConvertibleNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daewoong Convertible Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember" xlink:href="eols-20211231.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DaewoongConvertibleNoteMember" xlink:to="lab_eols_DaewoongConvertibleNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_8de5fea2-4843-4c52-84f9-d3305d687260_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Meals and entertainment</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a95ceeb3-9385-422d-b31d-12634aa361e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_051c20ba-e619-4182-9c04-b07b4fbddc48_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt, net of discounts</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Other Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_8eeafb89-9e0d-4f4e-8bf3-f1f529141c22_terseLabel_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of contingent royalty obligation</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_label_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Revaluation Of Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_documentation_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Revaluation Of Contingent Royalty Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:href="eols-20211231.xsd#eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:to="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3618fa5f-5818-425e-9a2b-4b50d298ea23_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield rate of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c09955c6-bd34-40f9-a7c5-80f128d7b84d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_43ad0141-ef90-4c29-b0e3-d3e1f3c0b992_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c7e38cf5-7635-4cb7-a444-3190a5b83f7a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_99fa5df4-ac00-456f-a53e-4c5c5a50e150_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b9e87f53-6c89-4c87-93be-63399d84c6f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_085aeec3-eff0-4c6e-b67b-3799f2b0d0d8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1c56e17c-9f9c-412b-9117-7e9c182de98a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b3c08f05-e3d5-4ea5-8074-168315bab9ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_155fff44-6a1a-4e25-949a-73562bfa16ff_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_75740db1-2893-4d9f-af35-a387fd223816_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9366b209-8498-4d1a-91f6-ffe3ad5f6026_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_effe31f3-d3df-4fba-975d-0653e72b8774_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of contingent royalty obligation to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2851a6ac-2bd4-4632-981e-6c689e930116_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value recorded in operating expenses</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_f50b74e7-f74f-4705-b5fe-93e08855f4a0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Investments Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember_146b6c3d-6605-44ba-971c-858069f8eebb_terseLabel_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs Market Conditions</link:label>
    <link:label id="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember_label_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs), Market Conditions [Member]</link:label>
    <link:label id="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember_documentation_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs), Market Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember" xlink:href="eols-20211231.xsd#eols_RestrictedStockUnitsRSUsMarketConditionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember" xlink:to="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_69ecaff9-9230-46d2-bcf8-05a9b9614973_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_1df57227-6a1c-435f-b52f-760fc7fd4f46_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10164be2-b2ad-4d5e-8e15-cd38d8114736_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_c7381154-fd5c-4daf-9886-ac0f11383847_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement expenses</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_097aa26a-4245-46c5-afec-743f6926f81a_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_9bf4cbf4-8430-420b-9d5a-a3a482f9a85b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable operating lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d9ace77a-4605-4757-a355-6cf74dc8dc80_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_49ddddff-07ec-4122-b6ed-86928b65d81e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities excluded from the computation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_03e9dc6a-8c7a-4497-ba62-0345fda43f0d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ac599348-1d04-42e2-82eb-470be5da1750_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_65ac8549-55b1-4a08-b327-f08b1e840d53_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_409b6a41-504f-4419-b841-d1b8ff735bf4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2173ec2e-1f6f-4fdf-bc20-49b16328b2c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_16779ab7-2dde-4db7-b1ff-575e5f9a4327_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of awards vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_83b7e5a6-0182-474b-954f-4aae9c2168dd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bd38a633-d77a-41a5-b606-e00cfe47dcce_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for-sale securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d15bdf4-d4bf-4d89-81a0-3fbc7d27d3f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PharmakonTermLoansOneMember_9921d3ea-9079-491e-b759-476e0f546d5d_terseLabel_en-US" xlink:label="lab_eols_PharmakonTermLoansOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche A Loan</link:label>
    <link:label id="lab_eols_PharmakonTermLoansOneMember_label_en-US" xlink:label="lab_eols_PharmakonTermLoansOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loans One [Member]</link:label>
    <link:label id="lab_eols_PharmakonTermLoansOneMember_documentation_en-US" xlink:label="lab_eols_PharmakonTermLoansOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loans One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansOneMember" xlink:href="eols-20211231.xsd#eols_PharmakonTermLoansOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PharmakonTermLoansOneMember" xlink:to="lab_eols_PharmakonTermLoansOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bc92720b-3464-4b20-9c04-f4c3e8264dbe_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1118887e-ace0-4baf-82c1-d2c9409839b5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_3d56365c-bc1b-4dab-b6f9-5a487b0bd3a8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentAmountThreshold_0e4e62eb-d14c-4c72-b663-c0212365d1b3_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, prepayment amount threshold</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentAmountThreshold_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Amount Threshold</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentAmountThreshold_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Amount Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentAmountThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:to="lab_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a0fe758e-49df-499b-b502-ccb6d1ecba21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_90f88ad8-488f-4c2a-a258-d5aedbd2c8b5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_eead08ae-797b-4128-b359-e5adeac5365f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b693be24-7050-435f-a53d-1e8cb2cc83e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_6183c92f-213a-46da-9cb1-3c999dee437a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_994385cb-aaeb-4e15-868c-286cf3e01c77_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e3fcf42b-fb93-4056-b655-d86f78ecfb3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_86588507-d806-4b70-9b86-02b9327bcd1c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_5e69f260-5db2-408d-85f2-ecb831c1943a_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December&#160;31, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_873638ee-83d1-4634-8d36-c0b92a28fa32_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4a12896f-0b52-4789-9ff0-4d6ed56451b2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a9a5187c-09cc-4453-9f8c-43c61bc290d5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f68bbca5-8b1c-4a0a-b0e9-4608ed823ee2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_c917aeed-bfe1-4675-a870-052eda4444a5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a30dd3b6-e5f8-4a4f-97fe-2aae19939b26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_c4dc9739-7b76-46cb-8fe3-d8c5bd5bd32f_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_7d56853a-68da-4fa0-a97e-fce8cc9a7698_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3b7f7cd3-d8a9-4e72-ab52-9fa7dd5b2936_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a35238dc-ed25-4637-a8e9-72d901c7b5ce_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medytox/Allergan Settlement Agreements and Daewoong Arrangement</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_093ef376-1762-42b8-9dca-7e750e937dd9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for conversion of convertible note</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_9556441f-52e9-4370-a877-9e4eb8cd1836_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5a9845ff-8008-43cf-a322-6461c54f0b4f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e37d2d2c-d07d-4963-b624-9062cf3b95d4_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized software recorded in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_07199d36-d99c-430d-bc1e-c8851db6ef45_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_eef79d2d-c368-48db-a565-d03819a374fb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_ce6b62c0-298a-44b9-934a-b8096a144376_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ef57e507-ff53-48a0-823d-99347fed12bb_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveNoncurrent_46b6b2a0-0857-41e9-ac0f-2973e97a27fc_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserveNoncurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveNoncurrent" xlink:to="lab_us-gaap_LitigationReserveNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_1ebecd91-694f-4dc0-8565-8c910c522513_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8fd02c7b-08ab-4344-b24e-9b73972534c7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_6718f124-74b8-483a-9e93-8f650f36c283_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_27407493-6823-4e8c-8abb-4085eada9aac_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_faa4047d-415c-4a68-9f15-15765c1b6ec1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_ce2302ea-585a-44d5-8cd1-d5d68d07af8a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_18e0c342-d3b6-468c-b6c1-4f82d3477a60_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6220e7a5-1dfd-4413-ba10-dd0e70017130_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_178ea5cd-0026-42d9-b727-6d27a06460af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ee405b63-507d-4362-9866-092c9f63c2dc_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_906ebf5d-360e-41cd-9a1f-5972b3d1b5e4_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_afdb7cb7-e668-4d5d-8118-b04b96966124_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_f35ce315-4f7e-43e3-baf6-4c7e7c146e1b_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_57d0cece-a857-4509-89b0-57a3d06d4ca8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Obligation Payable and Promissory Note Payable to the Evolus Founders</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_53b50111-b17b-4d2a-8624-e2232ebbe9d0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1d388862-d9b5-4c42-896a-24b676da324f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_5401c15b-9e76-4bd0-b06a-cc9adf152d2d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contributions to 401(k) plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_78b8f408-c99e-49b1-9ccc-631ccfe83fd2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned_1b786b6d-0b7e-4f55-b5cf-e27df952a9de_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares beneficially own percentage</link:label>
    <link:label id="lab_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned_label_en-US" xlink:label="lab_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Percentage of Shares Beneficially Owned</link:label>
    <link:label id="lab_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned_documentation_en-US" xlink:label="lab_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Percentage of Shares Beneficially Owned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" xlink:href="eols-20211231.xsd#eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" xlink:to="lab_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_30638ce8-7a25-418a-b988-cf5ccf878c3d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_78c8cdf5-494d-4e0f-9948-f4104d212cec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares authorized under the plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_5f3aaa63-cef4-40ab-865e-a378ca11da1d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_3b4b2c66-80e2-4014-a583-e8410e13e7bc_terseLabel_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_label_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Obligation [Member]</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_documentation_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Obligation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationMember" xlink:href="eols-20211231.xsd#eols_ContingentRoyaltyObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentRoyaltyObligationMember" xlink:to="lab_eols_ContingentRoyaltyObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_f1dc19a5-65a1-4ace-bcf7-4ef2e455acb3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed asset depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_b3f5a68c-f338-4e4e-a633-d9e466fe38bb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_185fcf6e-6dda-477d-ac6e-5f8c543bf8f9_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_e28851f2-76cb-4a46-9cce-8d183648cd73_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_fbd2a665-ebb5-46d1-a45c-163944a79521_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_583e5e1c-a35e-41f8-9f3a-b280945daf70_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of secured debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PharmakonTermLoansMember_0e4375f1-20d4-4557-97c3-176f21192832_terseLabel_en-US" xlink:label="lab_eols_PharmakonTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loans</link:label>
    <link:label id="lab_eols_PharmakonTermLoansMember_label_en-US" xlink:label="lab_eols_PharmakonTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loans [Member]</link:label>
    <link:label id="lab_eols_PharmakonTermLoansMember_documentation_en-US" xlink:label="lab_eols_PharmakonTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember" xlink:href="eols-20211231.xsd#eols_PharmakonTermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PharmakonTermLoansMember" xlink:to="lab_eols_PharmakonTermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_d09829cb-f853-408f-954f-e20245a37b82_terseLabel_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of termination of first commercial sale</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_label_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Period Of Termination Of First Commercial Sale</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_documentation_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Period Of Termination Of First Commercial Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:href="eols-20211231.xsd#eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:to="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_860ff3fb-9ccc-4696-8ecc-dabc467faca6_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory note payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_4b058763-94fc-41be-a568-8b50bb371a43_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt, net of discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_60d52e67-d2a5-455d-9a45-ffceb082f400_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ad2e5abc-e643-4401-9661-1dd55d2a4cc8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1e124758-6452-4e95-a7bd-5a170bc0b7b7_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_e074b4c1-0700-4720-9316-c0f4533019e9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_75f21d9c-703d-4195-9b36-728051894ca5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SaleOfStockMaximumConsiderationReceivable_b82fc473-e2df-4915-a42a-ab6e8585a90b_verboseLabel_en-US" xlink:label="lab_eols_SaleOfStockMaximumConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consideration receivable</link:label>
    <link:label id="lab_eols_SaleOfStockMaximumConsiderationReceivable_label_en-US" xlink:label="lab_eols_SaleOfStockMaximumConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Consideration Receivable</link:label>
    <link:label id="lab_eols_SaleOfStockMaximumConsiderationReceivable_documentation_en-US" xlink:label="lab_eols_SaleOfStockMaximumConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Consideration Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockMaximumConsiderationReceivable" xlink:href="eols-20211231.xsd#eols_SaleOfStockMaximumConsiderationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SaleOfStockMaximumConsiderationReceivable" xlink:to="lab_eols_SaleOfStockMaximumConsiderationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_472d18c9-3bda-44fe-84bf-bf0fb5e13b1f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of Federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_b8fba608-f325-41a3-ad99-a129870cc3de_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software development</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_be940b09-e3b1-4e78-8a9a-89c9e9405024_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1a72c0ef-8b95-4e9b-984f-d6d9df9a37cb_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_95b94781-1720-4407-bedc-0202afdf3b4e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2e7b6d8b-6d0b-4e71-b398-a940e4b13f19_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_f1ff20fe-9267-47ad-83f3-0e2f1c97ba37_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_e0731f57-db9c-4547-9946-8e3aaa8014a2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_6465ba26-c835-4444-ab15-146188e65144_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued revenue contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_895a7e08-49c4-4d83-9819-77e0c7fb8ccd_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_80c98351-4cd0-435e-8a40-e7a76cafca3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_f032bccd-0ea1-4b25-b516-03cf6716a813_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service revenue</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_4205dc10-1e94-45a7-b648-908dc6e4f115_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ee100816-b120-4926-8d0c-b330688c2a9d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_cccbaa8f-4df8-4d99-bc8f-36ec79d61206_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7fee3f2b-5150-48c0-82d3-53b3cbdda009_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_d67c5ce1-4dae-4f22-a833-8bd6a3d1d8e7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_2040265f-1299-411f-b706-6de65d3e5925_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_a2729506-718e-4628-9145-6d66d14c50f3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7d820679-c8c8-4981-83fc-1aefbddf1b48_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_9f09aed5-f5e0-4c03-a552-b25c44687476_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-kind interest on convertible note</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_9c1c3284-2252-4e07-bc3a-6366bb2a310b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_StockIssuedForAccruedLitigationSettlementExpense_ded17c77-da47-4488-92d2-f39243b1e115_terseLabel_en-US" xlink:label="lab_eols_StockIssuedForAccruedLitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in exchange for litigation settlement expense</link:label>
    <link:label id="lab_eols_StockIssuedForAccruedLitigationSettlementExpense_label_en-US" xlink:label="lab_eols_StockIssuedForAccruedLitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued For Accrued Litigation Settlement Expense</link:label>
    <link:label id="lab_eols_StockIssuedForAccruedLitigationSettlementExpense_documentation_en-US" xlink:label="lab_eols_StockIssuedForAccruedLitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued For Accrued Litigation Settlement Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedForAccruedLitigationSettlementExpense" xlink:href="eols-20211231.xsd#eols_StockIssuedForAccruedLitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedForAccruedLitigationSettlementExpense" xlink:to="lab_eols_StockIssuedForAccruedLitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_c3034f12-b9ca-45b3-b343-2728436b3315_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_51594849-47c2-4a8e-b2bf-7770531e3daf_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of contingent royalty obligation to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bfc4e90d-7605-4485-a524-f44cf24d82c0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_f71dd86c-5ddd-48c7-a8da-c20dc2d0e9eb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other deferred assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_62c2e127-1212-48b6-8df7-6eb9f32ef8e0_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_2c4cde4a-4584-4059-975c-11632437599d_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_6043510b-6086-4022-b5fa-6465fba147a1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_242fb2dc-49b2-421b-90fe-2d246723a6d6_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_54be2201-383e-4cec-a244-44a6fc601efb_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_df001f63-2b14-46c6-b191-a169df90f97e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a9f6cdca-0d56-4199-8a10-fc58d8ca55ef_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_256cf477-906e-4638-9757-869e5a634b26_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_dedc836e-015a-4fc4-bbc0-62fcd88d4dce_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear_969df1d1-965e-4313-b46b-28f3d3da844d_terseLabel_en-US" xlink:label="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issuance agreement, percentage of share dispose per year</link:label>
    <link:label id="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear_label_en-US" xlink:label="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issuance Agreement, Percentage of Share Dispose Per Year</link:label>
    <link:label id="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear_documentation_en-US" xlink:label="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issuance Agreement, Percentage of Share Dispose Per Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear" xlink:href="eols-20211231.xsd#eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear" xlink:to="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_89bc0d8b-0093-46c2-b506-99ad32515a1c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_bbac4c69-35d4-4384-8fcc-299998cf6f9e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_9eb265c1-2de8-478f-bf58-2483ec552b59_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_122bc824-101f-4399-a51b-3086aa3a94e3_netLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_e569cb98-01c4-4e1a-a3cd-57b7dd33bb59_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daewoong Convertible Note</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_8fa34f0f-a5d5-4255-9938-282eb9bd7d1f_terseLabel_en-US" xlink:label="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension period</link:label>
    <link:label id="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_label_en-US" xlink:label="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Asset, Period Of Extension Of Terms Based On Certain Performance Requirements</link:label>
    <link:label id="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_documentation_en-US" xlink:label="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Asset, Period Of Extension Of Terms Based On Certain Performance Requirements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:href="eols-20211231.xsd#eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:to="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7d3f3416-c9e2-444c-9444-c8f0c68ccc01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Current and Deferred Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_bdd4c6c6-98f4-436a-b63f-16b237f1d07a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_5bbe02af-52c9-419d-bc43-8d42fc68d907_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_af75658b-f480-40cb-a33e-b59774e871e5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities_770ad30b-bfa1-42db-883e-1dfda5c5bbd4_terseLabel_en-US" xlink:label="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="eols-20211231.xsd#eols_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_TermLoanFacilityMember_c65f8f7a-44d5-43e1-9fcf-1eec35ac78e7_terseLabel_en-US" xlink:label="lab_eols_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_eols_TermLoanFacilityMember_label_en-US" xlink:label="lab_eols_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_eols_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_eols_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermLoanFacilityMember" xlink:href="eols-20211231.xsd#eols_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermLoanFacilityMember" xlink:to="lab_eols_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_281c4a22-aa47-4692-a90a-f0f3959ce422_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dad0312c-0179-4f18-af86-861471a4a450_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_af3624b5-e34a-4763-9a73-f51c74aae9b3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_092a5daa-2a5b-4112-940e-c75fb513a1a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e522ba66-7c98-4e8f-b3bc-e81235c5628b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_AuditInformationAbstract_label_en-US" xlink:label="lab_eols_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_eols_AuditInformationAbstract_documentation_en-US" xlink:label="lab_eols_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AuditInformationAbstract" xlink:href="eols-20211231.xsd#eols_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AuditInformationAbstract" xlink:to="lab_eols_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_ce179f61-3d58-416f-a969-7b546bc4add0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_b1198cad-fe6e-4461-99b1-e411f9134f65_terseLabel_en-US" xlink:label="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with incentive equity plan</link:label>
    <link:label id="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_label_en-US" xlink:label="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Payments For) Issuance Of Common Stock In Connection With Equity Incentive Plan</link:label>
    <link:label id="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_documentation_en-US" xlink:label="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Payments For) Issuance Of Common Stock In Connection With Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:href="eols-20211231.xsd#eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:to="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_c706cf11-e6a0-43c5-9320-13bff14968b9_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f79c02c7-a98d-4c24-b213-8af23426aa85_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d04ad7bf-4bcc-4d98-b3eb-5789fafbfc45_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_38f5584f-c90e-4582-8751-913c8d6e8193_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, $0.00001 par value; 100,000,000 shares authorized; 55,576,988 and 33,749,228 shares issued and outstanding at December&#160;31, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_70dabd46-9bc7-467f-86eb-4b76f5629430_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_85a16036-8863-44f6-8959-fb66ecefe4aa_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term purchase commitment, amount</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_abf3d55c-a8a2-42f9-b3e2-85f3085a4c8b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period for unrecognized costs to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bc5698df-00b5-44c3-8e5f-4d14791e1e75_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4e7b5109-1955-44f0-9655-f7a1e3c6db35_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0fc05460-2486-49e1-8edd-eb8da7b3c755_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_7090e9a8-ed2d-4065-bf4f-8838903d4316_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_7a0b1d1d-d798-4bf8-b2c3-12b97626ba25_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e3329263-e91c-4e77-9239-03c791eaf788_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_e7392bef-4a8a-4c5d-88a4-db9bd2b04c37_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_fe4b90d8-46dc-4837-996b-7d587be4b9b4_verboseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average expected term of options</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Term</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:href="eols-20211231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_5fc90fb6-b730-417e-b527-eb7830c7cb1c_terseLabel_en-US" xlink:label="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, commission payment upon gross proceeds</link:label>
    <link:label id="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_label_en-US" xlink:label="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Commission Payment Upon Gross Proceeds, Percentage</link:label>
    <link:label id="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_documentation_en-US" xlink:label="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Commission Payment Upon Gross Proceeds, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:href="eols-20211231.xsd#eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:to="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_bf71059b-1e98-457f-8ec8-7f9d142073f5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_2032e1f5-c8ff-4b77-ab28-ca1cf6747aa5_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b79e27f1-6e40-4b90-8e43-bfbd3573d6af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Key Assumptions Used to Determine Fair Value of Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_TermTwoMember_e7a114cd-bfed-4fd5-8cab-aa7ce0f10876_terseLabel_en-US" xlink:label="lab_eols_TermTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After the 3rd anniversary but prior to the 4th anniversary</link:label>
    <link:label id="lab_eols_TermTwoMember_label_en-US" xlink:label="lab_eols_TermTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Two [Member]</link:label>
    <link:label id="lab_eols_TermTwoMember_documentation_en-US" xlink:label="lab_eols_TermTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermTwoMember" xlink:href="eols-20211231.xsd#eols_TermTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermTwoMember" xlink:to="lab_eols_TermTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ab980ae3-4a20-4f8a-8c7e-1311f6a5f27e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_e4bf990d-8bdc-4f77-9aa5-168906aed33f_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_fa19e372-348a-48bd-9628-ae619d0047dd_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtCurrent_e8ef8894-e09a-4844-b17f-985b6df0fbe3_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, net of discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_SecuredDebtCurrent_label_en-US" xlink:label="lab_us-gaap_SecuredDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtCurrent" xlink:to="lab_us-gaap_SecuredDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_1e8c2424-88a5-4858-ba11-6373ef47fca5_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_2053ac24-5f3f-49d0-82ce-f5935912c80b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_6e66c5f9-20a6-4214-8bd9-4e10682087c2_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of interest only payments</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_label_en-US" xlink:label="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Period Of Interest Only Payments</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Period Of Interest Only Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPeriodOfInterestOnlyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:to="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_37246975-2f31-4f7f-a0c9-2b251e7047ab_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9386027d-4224-4d54-ae94-eda00ce4954b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList_a5a98de5-bd38-4825-be01-f2f76a90fab8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:to="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a11637c4-3b5b-41ec-ba53-5023516044fe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_105b41a9-7e4a-48c2-bfb9-a1cd2c63168e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_918ef2ea-42b9-4579-bf71-950dde4678b1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate net proceeds from stock offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9b70650e-e643-44e4-95a8-bd41f93f2268_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate net proceeds from stock offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_3ff3371d-1508-4cf9-9dff-a6317d6ef2c0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_ce52bcb1-2b15-4ab0-b5df-58215e19eb3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_e40a209d-7f3a-4d42-9761-f2f4c57b84d9_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_22c8e63f-d69a-4609-ab8e-59b12163c3a7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b5ce2ff0-36fb-4b1b-af33-51420b47853b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d94dd88a-e606-4d72-bfae-56cbf6ce403d_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e3f34c95-a26d-48c4-8e83-f341ae8b0c9e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_a585e834-a71c-4b6b-9f43-0c5bb36e6915_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties related to income tax matters</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_8a66f14b-cba4-4196-abee-445d37d24561_terseLabel_en-US" xlink:label="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_label_en-US" xlink:label="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_documentation_en-US" xlink:label="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:href="eols-20211231.xsd#eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:to="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_47e24793-53e1-4a4f-b1a3-1b46f6f5ce37_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation_0cf2f301-7025-49b9-b6f3-5eb06572a3a6_terseLabel_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officers' compensation</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation_label_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Officers' Compensation</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation_documentation_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Officers' Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation" xlink:href="eols-20211231.xsd#eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation" xlink:to="lab_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f9792305-598c-4bb7-b8e9-e35713e3f38f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provision:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsDomain_f0d067b5-cf78-40f6-a4e0-ccf50bc89a2e_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Terms [Domain]</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsDomain_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Terms [Domain]</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsDomain_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Terms [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsDomain" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentTermsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain" xlink:to="lab_eols_DebtInstrumentPrepaymentTermsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_OxfordTermLoanFacilityMember_bdb9e022-aedf-443f-9b6f-549137c964fa_terseLabel_en-US" xlink:label="lab_eols_OxfordTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan Facility</link:label>
    <link:label id="lab_eols_OxfordTermLoanFacilityMember_label_en-US" xlink:label="lab_eols_OxfordTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan Facility [Member]</link:label>
    <link:label id="lab_eols_OxfordTermLoanFacilityMember_documentation_en-US" xlink:label="lab_eols_OxfordTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan Facility Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoanFacilityMember" xlink:href="eols-20211231.xsd#eols_OxfordTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_OxfordTermLoanFacilityMember" xlink:to="lab_eols_OxfordTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3833efc5-c88a-4f02-ae3b-26ada0fcfcc2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_b553f489-126a-4304-83bc-ef93c6a1f8f3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a05ec41d-adeb-43d0-8ffb-a1aeb0ecf41a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_587a8ad3-0691-43e5-bb27-595fddb87ad5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, not subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_0d9d595e-4b22-4319-8a9a-dede6f35a251_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_dc21973d-ad66-436c-a723-a676b9a9b800_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4aa7a393-4626-4c9b-963e-72d499a6ca8d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_89dce23b-a08b-4bd5-9dbd-a175d296c57b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_33efb5a9-b193-4cc9-a348-1d720e9cc04a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4ef0d4c5-8189-408a-a2c6-841d4f2e2561_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b660245c-a187-4204-9ae7-c80921eb5156_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9d763bb2-990f-4074-b65a-78feef5a3b2a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentFeeAmountWaived_ecad67fb-e423-4bb3-bd2a-66e80221af3b_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentFeeAmountWaived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument fee amount comprised</link:label>
    <link:label id="lab_eols_DebtInstrumentFeeAmountWaived_label_en-US" xlink:label="lab_eols_DebtInstrumentFeeAmountWaived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Fee Amount Waived</link:label>
    <link:label id="lab_eols_DebtInstrumentFeeAmountWaived_documentation_en-US" xlink:label="lab_eols_DebtInstrumentFeeAmountWaived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Fee Amount Waived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentFeeAmountWaived" xlink:href="eols-20211231.xsd#eols_DebtInstrumentFeeAmountWaived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentFeeAmountWaived" xlink:to="lab_eols_DebtInstrumentFeeAmountWaived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6acf3d6c-255f-47d1-b67c-f6d6f34936ec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8cc93360-2e19-4fc2-a98e-889c6cef5600_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59276fd6-4a3e-4d0f-bedf-34469b61bdf8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b7068b60-115b-4d70-971c-3fc2b822928b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ae3c7673-7a2f-4081-a905-dfb16329e164_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_f8f8843a-0be3-4305-8f7f-4bfb5a594886_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0bdac5e0-f7a8-46e3-bdcb-c53e792117a5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_44f36187-7851-4e2f-86f0-9da85c55cfa4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_6b9646b7-dcf1-42bd-a324-94e49321e702_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_4d05baea-dfe9-44c4-932e-2e62fd349e8c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction amount in period</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_TermLoanFacilityTrancheOneMember_16620957-3497-4c15-a6d7-89ad0d9e4981_terseLabel_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First tranche</link:label>
    <link:label id="lab_eols_TermLoanFacilityTrancheOneMember_label_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility, Tranche One [Member]</link:label>
    <link:label id="lab_eols_TermLoanFacilityTrancheOneMember_documentation_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermLoanFacilityTrancheOneMember" xlink:href="eols-20211231.xsd#eols_TermLoanFacilityTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermLoanFacilityTrancheOneMember" xlink:to="lab_eols_TermLoanFacilityTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_bcc7baca-177e-45b1-93f8-a2110d9b01d9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_5e147c4d-df7e-4b78-b492-f949898bf726_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_5e44cd13-8334-4356-8c11-fb89bcf0c99d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSUs Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_6b765aeb-6200-43e1-95b8-74d15f44d1e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in state tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_eded49d4-eb53-4d15-8f7c-20de08c3af57_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f119e548-4225-4f02-80f3-d00b387d29f7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_b324c6fc-2ca6-4d24-a848-6d9232adbf90_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_06136abf-1176-4b4d-a359-ca1386a70b7c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_19ee13ed-3d2e-43ae-a152-d635a94f03df_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_982eeb74-320e-4e73-912e-22d2e5d871b0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_02a02c97-344f-4708-a7e5-1c34c337a73a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a27a3ba7-3ee8-449e-b408-b15ed4120fcd_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f5d0355d-6b5b-4972-af0e-34d40317071b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_220c23c8-3140-4cc0-91f0-6a164c049fdf_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_OperatingLeaseRightofUseAssetAmortization_bafe5c2a-fac5-4c84-b1ed-e93f4672efc4_terseLabel_en-US" xlink:label="lab_eols_OperatingLeaseRightofUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_eols_OperatingLeaseRightofUseAssetAmortization_label_en-US" xlink:label="lab_eols_OperatingLeaseRightofUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization</link:label>
    <link:label id="lab_eols_OperatingLeaseRightofUseAssetAmortization_documentation_en-US" xlink:label="lab_eols_OperatingLeaseRightofUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OperatingLeaseRightofUseAssetAmortization" xlink:href="eols-20211231.xsd#eols_OperatingLeaseRightofUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_OperatingLeaseRightofUseAssetAmortization" xlink:to="lab_eols_OperatingLeaseRightofUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_66aafc4c-add0-4f65-a8f9-507f7196d217_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_34c9e446-8b19-4874-9aee-fe23af4afce6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_95d34aab-b02c-4a07-a808-b58d67c6f9ca_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_57bc1f37-46eb-4020-8e13-bd272922901f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_bbf15f83-e8a1-424b-9464-853f4e5840ff_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7e550c69-5531-45e8-b97d-000fc7b6f104_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d3bc6e00-911d-410c-be12-c8566e0ff51b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_196ef87d-2bce-45c4-bdce-16e19a0f9f41_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e8e23ce9-9724-4be2-8d15-547fa4eb49eb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_30d0fa57-3a39-489e-bfd2-d74eb1e4adb1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8812f78e-a135-443f-b90f-8154bb750e20_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_732ea228-5954-4aee-b546-ba4e05999bbc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1026897b-b5c1-4be9-83e8-555e5f81fc00_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ed4662d7-3366-4abe-8e24-8b98ce39865e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_928d3c25-ec45-4b89-a109-0ae7815d0330_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c22b1fce-7368-47da-abc9-842f1d9cb7ee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_e7b051ec-c8c9-4069-bd79-8514868369c4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible note to equity</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_678dda43-374c-443d-a3ed-2c9b7b0cb1eb_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from extinguishment of debts, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f073ea1e-202b-4966-a2ba-37c12ebef9d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from extinguishment of debts, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_EvolusIncMember_1bb79a96-064d-4968-905b-558c840d3518_terseLabel_en-US" xlink:label="lab_eols_EvolusIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolus, Inc.</link:label>
    <link:label id="lab_eols_EvolusIncMember_label_en-US" xlink:label="lab_eols_EvolusIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolus, Inc [Member]</link:label>
    <link:label id="lab_eols_EvolusIncMember_documentation_en-US" xlink:label="lab_eols_EvolusIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolus, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EvolusIncMember" xlink:href="eols-20211231.xsd#eols_EvolusIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_EvolusIncMember" xlink:to="lab_eols_EvolusIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_98e2d653-ac2c-4cf0-b1b3-f27ef927e8c8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_c888f762-6455-478e-9e05-32b59419ad84_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_a6c658d7-9be1-41d6-8dd5-07da7b0fd7be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_a861440e-ef15-4c2f-bc17-9e00d4eab9e8_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of final payment of full principal amount</link:label>
    <link:label id="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_label_en-US" xlink:label="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Percentage Of Principal Amount, Balloon Payment</link:label>
    <link:label id="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Percentage Of Principal Amount, Balloon Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:to="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_b6aaa0bf-f226-4ab6-863f-03ad2c2d751e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_84535191-97ec-445c-8eab-eff0db41a136_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_df9e7369-55c8-4c8f-a17d-a55aa6fbcf52_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ae02c764-ce06-43c4-aa4d-9bd13aa3781e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_81d226c3-4619-4d32-be3f-95a15b65914f_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_3b5d9aca-8bdb-4ce3-b3d0-d50897678198_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_57d16590-a4f4-40f2-a7ca-b6d1e7000651_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred (benefit) provision:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_335a3b6d-27bd-4f99-bfeb-3391f0227511_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_OxfordTermLoansMember_6b78f0ea-7655-4871-aa85-96c877e0e7a3_terseLabel_en-US" xlink:label="lab_eols_OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loans</link:label>
    <link:label id="lab_eols_OxfordTermLoansMember_label_en-US" xlink:label="lab_eols_OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loans [Member]</link:label>
    <link:label id="lab_eols_OxfordTermLoansMember_documentation_en-US" xlink:label="lab_eols_OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoansMember" xlink:href="eols-20211231.xsd#eols_OxfordTermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_OxfordTermLoansMember" xlink:to="lab_eols_OxfordTermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PharmakonTermLoansTwoMember_4fab575c-9a66-472c-aa07-da93c72732c7_terseLabel_en-US" xlink:label="lab_eols_PharmakonTermLoansTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche B Loan</link:label>
    <link:label id="lab_eols_PharmakonTermLoansTwoMember_label_en-US" xlink:label="lab_eols_PharmakonTermLoansTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loans Two [Member]</link:label>
    <link:label id="lab_eols_PharmakonTermLoansTwoMember_documentation_en-US" xlink:label="lab_eols_PharmakonTermLoansTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loans Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansTwoMember" xlink:href="eols-20211231.xsd#eols_PharmakonTermLoansTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PharmakonTermLoansTwoMember" xlink:to="lab_eols_PharmakonTermLoansTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e429ed68-51a7-4356-a46a-16bc34fc96d6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3536fd5c-f17f-4635-9581-2f31b8722425_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_b046f605-978e-4df4-a95f-edb866396d43_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_34d0a4cb-c45d-44b3-900b-2a579e73ff44_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term of options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_0871ce85-38e4-48cf-9b34-520e8fcc969e_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_140bd25b-353a-4285-819e-8d084d284d5d_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a2522c6d-b3e5-4b43-9299-357138883b3a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_222fe8a6-94c4-4aea-811d-525abfb11244_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_cd707003-34a6-4b06-9f81-706cd24a39d2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses_6e366fea-6d7c-4c31-aa95-ca4ff080e883_terseLabel_en-US" xlink:label="lab_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash portion of accrued settlement expenses</link:label>
    <link:label id="lab_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses_label_en-US" xlink:label="lab_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments Of Non Cash Portion Of Accrued Settlement Expenses</link:label>
    <link:label id="lab_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses_documentation_en-US" xlink:label="lab_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments Of Non Cash Portion Of Accrued Settlement Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses" xlink:href="eols-20211231.xsd#eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses" xlink:to="lab_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_5219ac4e-5ab9-45bb-a2b5-823258a6d6b4_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_18b5346f-6ecc-43be-afb7-35a01823527d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a840f9e7-d1a6-4812-9356-22d500e9358a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_9b816067-d77f-4e81-9bef-ad29a0721e7a_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f0dbea45-2f72-4396-a2ee-8c983cb4f81e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_77246fec-54e7-4e4c-bf9c-33f8c547cb0a_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, net of discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_label_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Long-term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt" xlink:to="lab_us-gaap_SecuredLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7eb2290d-855e-43d2-be99-f9e2c445d316_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_TermThreeMember_f63b7525-af02-4c72-a02d-6cef73c42ce0_terseLabel_en-US" xlink:label="lab_eols_TermThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After the 4th anniversary</link:label>
    <link:label id="lab_eols_TermThreeMember_label_en-US" xlink:label="lab_eols_TermThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Three [Member]</link:label>
    <link:label id="lab_eols_TermThreeMember_documentation_en-US" xlink:label="lab_eols_TermThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermThreeMember" xlink:href="eols-20211231.xsd#eols_TermThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermThreeMember" xlink:to="lab_eols_TermThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_43f22cae-c10a-46c3-abaf-8b9a509d2292_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Fair Value Measurement for Contingent Royalty Obligation Payable</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_4e51f56e-466c-4a2a-af80-5e593a7b6b57_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal settlement</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_da98e867-3350-4f24-bee4-e403a4a17295_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent promissory note payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_ffeba05b-66b3-442b-af22-017de84c8ffb_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c3f54eb6-3e85-4b01-9d60-c61e09cf0f87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_34503d98-58d8-44ab-9073-3e57949e9c59_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_19e11449-1e63-49ef-a8e6-c408f7af5147_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c9e51f6a-cbb6-4eb8-bdd1-7e0b86de38f7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total provision (benefit) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_9777b3f0-8e49-477d-b955-482b4cd04ba3_terseLabel_en-US" xlink:label="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for provisions for accrued volume-based rebate and coupon liability</link:label>
    <link:label id="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_label_en-US" xlink:label="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Provisions For Accrued Volume-Based Rebate And Coupon Liability</link:label>
    <link:label id="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_documentation_en-US" xlink:label="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Provisions For Accrued Volume-Based Rebate, Coupon And Consumer Loyalty Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:href="eols-20211231.xsd#eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:to="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_81389e2d-426b-467c-a061-5ad0393643bb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_989453ca-277c-497c-8996-b293386307e2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d37c37c2-d555-4853-b029-afeb3bb3341e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_eada6501-002b-456e-8cfb-b9349636966f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_FollowOnOfferingMember_ecf7f046-a55c-4ba0-b918-11f2ae7af58e_terseLabel_en-US" xlink:label="lab_eols_FollowOnOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-on Offering</link:label>
    <link:label id="lab_eols_FollowOnOfferingMember_label_en-US" xlink:label="lab_eols_FollowOnOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Offering [Member]</link:label>
    <link:label id="lab_eols_FollowOnOfferingMember_documentation_en-US" xlink:label="lab_eols_FollowOnOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FollowOnOfferingMember" xlink:href="eols-20211231.xsd#eols_FollowOnOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_FollowOnOfferingMember" xlink:to="lab_eols_FollowOnOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_82fede18-03b4-4bf3-879b-951ba3334ef8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a70d02b-7836-4240-bf22-cedf00896c64_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3a3a0107-f306-48ed-aea7-092ccb3cdd87_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ea46b7ea-8a11-41d1-a50a-4d5c50b878b7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_23c0e333-df5f-4da9-9269-bc5d50b81f99_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_9a669901-a972-4623-862d-ea6878c9ad94_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5f5a37fe-7913-4a75-8a37-7fe359db2cbc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_ff962ef7-e5bd-41bd-9db4-e064be3fd28b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1da07ace-4783-4163-bebf-a1aee60ad6e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_05f50550-a547-41b5-9cc7-06bc70449d80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4ff1728d-5b17-4c57-a9be-10fd5fc6d8e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_70aed062-0549-4350-83af-5cabd0cb82ad_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_876d2f85-da1d-4e0f-b3da-a9baaeae7043_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_14b2e62a-01d9-4c54-9a59-dd4c36c7ef89_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b2469aa4-728f-4f4c-aee9-5324de528a4e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock option costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9459463e-692d-4ad9-a599-ac8e34bbeb12_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3651f05f-1c30-4ebe-81ca-03352dc2ff60_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ATMSalesAgreementMember_d766d99b-5c89-4c63-adb7-b149086accbc_terseLabel_en-US" xlink:label="lab_eols_ATMSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A T M Sales Agreement</link:label>
    <link:label id="lab_eols_ATMSalesAgreementMember_label_en-US" xlink:label="lab_eols_ATMSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A T M Sales Agreement [Member]</link:label>
    <link:label id="lab_eols_ATMSalesAgreementMember_documentation_en-US" xlink:label="lab_eols_ATMSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A T M Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember" xlink:href="eols-20211231.xsd#eols_ATMSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ATMSalesAgreementMember" xlink:to="lab_eols_ATMSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_23206404-2afd-48b1-a3dc-58ec741c93af_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_7636a10a-0ae8-4af8-98f5-74e07e774b7f_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_aa87d095-ca1a-42e3-bc44-f850da24a502_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_39da6479-3214-467f-8c29-2ad19e6157b3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized costs other than options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b7cbc5f4-d07d-48d3-ba64-7df7d0d3bf1b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_b88d28c9-5c44-4880-b245-b9d8d5656fb7_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term operating lease expense</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_MilestonePaymentsForIntangibleAssets_d0d9e213-645e-4877-abe3-a307f90d4dda_verboseLabel_en-US" xlink:label="lab_eols_MilestonePaymentsForIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment for intangible assets</link:label>
    <link:label id="lab_eols_MilestonePaymentsForIntangibleAssets_label_en-US" xlink:label="lab_eols_MilestonePaymentsForIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments For Intangible Assets</link:label>
    <link:label id="lab_eols_MilestonePaymentsForIntangibleAssets_documentation_en-US" xlink:label="lab_eols_MilestonePaymentsForIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments For Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets" xlink:href="eols-20211231.xsd#eols_MilestonePaymentsForIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestonePaymentsForIntangibleAssets" xlink:to="lab_eols_MilestonePaymentsForIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e54fb693-29a5-457a-a82f-270103ac00b4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_fbf2d896-f879-4308-9839-32f04814bd2a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_10c85cd8-39be-4f93-8adb-de93cbeecbbb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_52933414-c862-4182-ab64-bd2506883de1_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ec626b2a-8226-4980-924e-db9cbf03d863_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement payment from daewoong</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_54406a51-428d-43d1-9243-0cf4bb02bc17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_a81cc16d-d8a7-4c1b-a528-be8bb1fb66ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_123b63b9-5111-45dd-9695-fec597a03009_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ae0691f8-5799-442a-a71a-a5bf6b5b3d92_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79cec61c-419d-4c95-a34a-477a1be58ea1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_eb999f72-bb4e-486b-a28d-de6d4abe2058_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeeAmountWaived_2e55ba8e-74fe-4434-a0a1-188791454a33_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeeAmountWaived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument prepayment fee amount</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeeAmountWaived_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeeAmountWaived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Fee Amount, Waived</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeeAmountWaived_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeeAmountWaived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Fee Amount, Waived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeeAmountWaived" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentFeeAmountWaived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentFeeAmountWaived" xlink:to="lab_eols_DebtInstrumentPrepaymentFeeAmountWaived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_655bc2a3-0b1c-4dd9-bcdc-bbf4dee8ba05_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_b0006bd3-e175-4e53-8b85-3975b308ae92_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_7adb34e7-803a-42d0-8b4b-aab33b17d270_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_c3acc8c9-6576-4a08-8d3a-8da28e2b7e25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_365cd27b-d6a7-4dd1-8109-0df8b660b28a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_b8522aa4-86fb-4ff4-b7bf-f60c1f19c681_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_f98fd684-5e41-41d0-ae5d-fdbdcb841d6c_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8c22b7f7-feac-4bb0-a6cf-fb20f732c41b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_681ffa07-ec1d-4316-b4e5-291cf8521c4a_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful lives of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b5951425-29e9-4bef-b463-3aaa17adde01_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Life (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1aa61f5a-dc9e-46ad-91a7-91a0a128b0bc_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5453acff-e8ee-4936-9304-4d032fd6696b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7d67e2f-bb03-4c5e-8943-49719c10d58b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_fc810ad5-3bbc-428b-ac45-37141ad6a7dd_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0ed219d8-c61a-415b-9f5a-01a1ab01fb3d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7fee7302-3ad4-4a34-95d5-d463f4528fe7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_875d163b-c0d5-4bd8-aac1-f69b0576f7a9_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_24304027-dac9-4fb9-8f18-2781cbd8808c_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PaymentsOfContingentRoyaltyObligation_868dbe4c-75ba-49d0-9327-4e953005478c_negatedTerseLabel_en-US" xlink:label="lab_eols_PaymentsOfContingentRoyaltyObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent royalty obligation to Evolus Founders</link:label>
    <link:label id="lab_eols_PaymentsOfContingentRoyaltyObligation_label_en-US" xlink:label="lab_eols_PaymentsOfContingentRoyaltyObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_PaymentsOfContingentRoyaltyObligation_documentation_en-US" xlink:label="lab_eols_PaymentsOfContingentRoyaltyObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Contingent Royalty Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation" xlink:href="eols-20211231.xsd#eols_PaymentsOfContingentRoyaltyObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PaymentsOfContingentRoyaltyObligation" xlink:to="lab_eols_PaymentsOfContingentRoyaltyObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_56a5858d-d752-45ff-91e0-8ef078912583_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_e5b518a5-722e-447d-a523-1f69d0ec3442_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from follow-on offering, net of underwriting fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a8edd40d-1249-4414-acbd-a492222e0bda_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_699c1232-01e8-46df-8c5a-7ab6f9b4e935_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement payment from daewoong</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7fe3fd2e-5892-45dd-bf12-369d0d793df3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_e7a28c3c-4167-4cdc-a904-8d2a0c884e68_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, percentage of principal amount, prepaid multiplied</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Terms, Prepayment Multiple On Principal Amount</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Terms, Prepayment Multiple On Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:to="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_19cf74ee-13fa-4afc-b2a1-78f885425efb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain (Loss), before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_a6275dc3-1547-4a98-beb6-b86a5fcb5ee3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_f2968e70-b886-4be0-bec2-47fab48d70e8_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_c29e4ef2-6f0e-4847-94b0-695861c95566_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee percentage, thereafter</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Thereafter</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentFeePercentageThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:to="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_c4d95ce8-073e-43e0-8ded-4e446d65c8af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of promissory note payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4f073cc6-bec8-4340-977d-97b6329b19c2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f51bddcb-f05a-42a0-9462-f60f36563cc0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b2c75de4-1270-412e-9fde-b8a45760e2e3_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsAxis_8ddabe71-e6d9-406a-ac20-2f1be8229a1c_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Terms [Axis]</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsAxis_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Terms [Axis]</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsAxis_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsAxis" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentTermsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsAxis" xlink:to="lab_eols_DebtInstrumentPrepaymentTermsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ec454925-f6ff-4de0-b532-d4f127186fb6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_fc289179-4ba4-4dd6-8db9-bf89f3b43ffb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_MilestonePaymentInConnectionWithAgreement_0f632bdf-613f-4094-a60e-6c44eaff1012_terseLabel_en-US" xlink:label="lab_eols_MilestonePaymentInConnectionWithAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent milestone payment</link:label>
    <link:label id="lab_eols_MilestonePaymentInConnectionWithAgreement_label_en-US" xlink:label="lab_eols_MilestonePaymentInConnectionWithAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment In Connection With Agreement</link:label>
    <link:label id="lab_eols_MilestonePaymentInConnectionWithAgreement_documentation_en-US" xlink:label="lab_eols_MilestonePaymentInConnectionWithAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment In Connection With Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestonePaymentInConnectionWithAgreement" xlink:href="eols-20211231.xsd#eols_MilestonePaymentInConnectionWithAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestonePaymentInConnectionWithAgreement" xlink:to="lab_eols_MilestonePaymentInConnectionWithAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9acb43b3-9f69-41e1-a1ae-9de76fbc1401_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_c486a287-00ef-4aca-b0d7-7e388db3f860_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_3d636d6f-bfd4-4a64-aa86-265eb522086a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_d2e10ac5-45de-40a8-b3f6-7f744e7eadf1_terseLabel_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, equivalent rent termination period</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_label_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Fee, Period Of Rent Equivalent</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_documentation_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Fee, Period Of Rent Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:href="eols-20211231.xsd#eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:to="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e571f037-20ff-428e-af02-4a605b87dddf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_b1a7d3af-88cf-4925-b003-eeb5ae3d11b8_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LineofCreditFacilityNumberofAdvances_c79cfb13-e031-4ef0-a95c-ce95f6fcd381_terseLabel_en-US" xlink:label="lab_eols_LineofCreditFacilityNumberofAdvances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of advances</link:label>
    <link:label id="lab_eols_LineofCreditFacilityNumberofAdvances_label_en-US" xlink:label="lab_eols_LineofCreditFacilityNumberofAdvances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number of Advances</link:label>
    <link:label id="lab_eols_LineofCreditFacilityNumberofAdvances_documentation_en-US" xlink:label="lab_eols_LineofCreditFacilityNumberofAdvances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number of Advances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LineofCreditFacilityNumberofAdvances" xlink:href="eols-20211231.xsd#eols_LineofCreditFacilityNumberofAdvances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LineofCreditFacilityNumberofAdvances" xlink:to="lab_eols_LineofCreditFacilityNumberofAdvances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67a49cbe-93c4-4d1f-b979-69b9870ca30f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_b5c44fe2-b398-4ac4-8725-24294bdb5f86_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Composition of Lease Expense and Other Quantitative Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_530e267e-f954-4774-99bf-096fdea77b6d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_TermOneMember_c4cdf3db-6f16-49ee-a60b-180fb4f5401e_terseLabel_en-US" xlink:label="lab_eols_TermOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to the 3rd anniversary</link:label>
    <link:label id="lab_eols_TermOneMember_label_en-US" xlink:label="lab_eols_TermOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term One [Member]</link:label>
    <link:label id="lab_eols_TermOneMember_documentation_en-US" xlink:label="lab_eols_TermOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermOneMember" xlink:href="eols-20211231.xsd#eols_TermOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermOneMember" xlink:to="lab_eols_TermOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_d6f6aef1-da5b-478e-be62-8a014700a62e_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_0c9d684f-ef69-402b-ace1-33ea88ca4fa0_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7a136f62-a6b4-4711-a68e-192fc9c50b73_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding used to compute basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f5e66eef-6b42-4e7d-a631-5c40e4863b21_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_8395669e-8f42-4d10-b3ad-754ae76cf8b2_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_17179178-1d47-4621-a012-364c5e703f2f_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a6d00ff5-3c0d-4457-b555-1a10be0b960b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_b593d292-3d91-4342-b092-81c02b8e7a2e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering price per share (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_97408f57-6caa-4736-8848-61b939f9bd7a_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering price per share (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_3e562039-01d1-44b1-be31-601756bf797b_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_47b6d9ae-98d8-4498-b865-be28eed8128c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_15b8de41-9b0c-4fb0-8070-83050018e926_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_67b7db3f-f30c-4094-8627-8dc560903c5a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_122dc1fc-b118-4467-a779-f8b2d24fad34_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_348ad2a9-b408-4f47-b791-1cf477d400e7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_TermLoanFacilityTrancheTwoMember_cbcc442e-9811-4ee3-86d1-1ac84bf4490f_terseLabel_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility, Tranche Two</link:label>
    <link:label id="lab_eols_TermLoanFacilityTrancheTwoMember_label_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility, Tranche Two [Member]</link:label>
    <link:label id="lab_eols_TermLoanFacilityTrancheTwoMember_documentation_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermLoanFacilityTrancheTwoMember" xlink:href="eols-20211231.xsd#eols_TermLoanFacilityTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermLoanFacilityTrancheTwoMember" xlink:to="lab_eols_TermLoanFacilityTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8d4585bb-26da-490a-a007-64a832c775c0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive gain:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_bc03d1ac-9ac4-4992-b629-9911c8095e97_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_612b30d7-596d-407d-b31c-b95cdea5aa49_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_968e42a2-532f-4a38-8260-cda49fa7df96_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_c7012a18-1eac-43b8-a8d8-9169de19f47b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f3cd518-b60c-4d70-8b69-0dc84b0c5c92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_358619a7-e777-4237-aef3-b5298ef6c840_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for conversion of convertible note (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_dacd3c72-15f4-4136-9827-06522ca513ae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_5bcbec4e-c2ed-4867-ad09-067bfc616188_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_02a825b2-090b-47cf-9e75-7c6b10b05bdd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8e22b8f7-dc0a-4ffb-a750-b0c94a21d0ac_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements and Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DistributionRightsMember_074b57c2-98dd-483e-86c5-6d18f2547de0_terseLabel_en-US" xlink:label="lab_us-gaap_DistributionRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution right</link:label>
    <link:label id="lab_us-gaap_DistributionRightsMember_label_en-US" xlink:label="lab_us-gaap_DistributionRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionRightsMember" xlink:to="lab_us-gaap_DistributionRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_965e6d63-13a5-479a-9842-2bfb27815f0e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_35daba62-307e-4d7f-ab54-48c469d95934_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4cdf358e-b1c9-4860-8b7e-6d2c7be8154a_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e034a308-e609-4f08-b44a-4426c33277f8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7d7c2aaf-24ca-45ff-9823-3152ea651c4c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_990cdd2c-d3ba-48e0-8e2a-94eba2bb1998_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_7342471d-5c3e-4ae8-a7ef-da760d634739_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_acb672e0-0dca-467f-97fa-484a55a967f2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_b5b92dc6-4a2e-43ef-9a97-214b98f90e61_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible note</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d62b9193-36d1-462b-be53-b5703592d0c6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_348db0f7-016e-4224-b4b6-1212001014c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_3effd37f-4f82-4cf4-b728-0d98aa1f0e85_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties under the Medytox/Allergan Settlement Agreements</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_StockIssuedDuringPeriodValuesLitigationSettlement_cdfaf2d6-9ffa-4107-90c9-ea69de068204_terseLabel_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValuesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with litigation settlement</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodValuesLitigationSettlement_label_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValuesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Values Litigation Settlement</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodValuesLitigationSettlement_documentation_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValuesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Values, Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodValuesLitigationSettlement" xlink:href="eols-20211231.xsd#eols_StockIssuedDuringPeriodValuesLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedDuringPeriodValuesLitigationSettlement" xlink:to="lab_eols_StockIssuedDuringPeriodValuesLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_4cf81db8-746f-46fe-aa6d-07b58c9c9c20_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d7941491-51b8-42a5-aaa0-2a631236545f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85fbfb8c-c1c2-4996-9690-3ecc9aa0b76e_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_40afd7b5-200c-4504-a2bf-69e221c13a8c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product cost of sales (excludes amortization of intangible assets)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_6fc2355c-3ede-4371-8f4e-35a9a6cbb978_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f936fa81-11b1-410a-83b0-3f13df5578c6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_f9934332-ef2c-467b-b287-b6fbed671fea_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d23058a5-3cb4-4a21-b0e2-0acc55881cb6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_1b489df3-d395-4274-8e08-7b35395a37d4_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b4e295cd-1500-43ec-83e7-196b24e2007d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity CIK</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_f6da68e7-4365-4a43-8365-e061f55a75cb_terseLabel_en-US" xlink:label="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized share-based compensation expense</link:label>
    <link:label id="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_label_en-US" xlink:label="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Share-Based Compensation Expense Capitalized</link:label>
    <link:label id="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_documentation_en-US" xlink:label="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Share-Based Compensation Expense Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized" xlink:href="eols-20211231.xsd#eols_AllocatedShareBasedCompensationExpenseCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized" xlink:to="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_30695298-19ee-4c03-afc7-dc62f0b29767_terseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:href="eols-20211231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_641e25cf-df89-452a-8e57-bd4a709ccba5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c7077dc9-f4c7-41fe-bd4a-f766892f1f74_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_ff3f404d-b602-4403-a121-5d725229e588_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2479ef64-5bf9-4095-bd33-0ad9eb0421f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ed54dccd-cb7e-4422-951d-4c61001fd2f2_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing information</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_8a8e1131-8af6-4798-94eb-332077aa71fc_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3909ff37-97fc-42a1-b730-a25836434699_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_fe4f3cfa-125a-48ca-85e5-079b9a0fb956_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Future Amortization Expense of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_010c0650-ce76-4cdc-84c7-78544dd02010_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_c1932785-314e-45bb-b66b-879741583175_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_d21748a3-8563-41ec-8c04-0403c73874dc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for debt obligation</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_09b5aaae-9688-47c8-b4d3-7cb17f474cbd_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_09551772-6bfd-4188-b073-c8d24fffa1a8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_07d15760-916a-49f1-a9e4-71945bcb9488_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_fd28c16b-8655-414d-80e3-28a29d735618_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_123f9fe5-f99c-4ffd-b416-283986d81241_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_d7744e72-75dc-4ba2-8d3e-e61aaa35c59e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_728bc4d4-6714-4a61-9de3-d430765723e5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0608b6ba-2af2-4b2f-bba2-7381cf34c577_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_c7d38aed-7419-4dda-86c0-fe881f4cc0d9_terseLabel_en-US" xlink:label="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, period to provide written notice to terminate contract</link:label>
    <link:label id="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_label_en-US" xlink:label="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Period Of Written Notice Prior To Lease Terminate Date</link:label>
    <link:label id="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_documentation_en-US" xlink:label="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Period Of Written Notice Prior To Lease Terminate Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:href="eols-20211231.xsd#eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:to="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_IncreaseDecreaseInAccruedLitigationSettlement_bf295388-b0bc-4301-bc88-f7b2e3cfb3b1_verboseLabel_en-US" xlink:label="lab_eols_IncreaseDecreaseInAccruedLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation settlement</link:label>
    <link:label id="lab_eols_IncreaseDecreaseInAccruedLitigationSettlement_label_en-US" xlink:label="lab_eols_IncreaseDecreaseInAccruedLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Litigation Settlement</link:label>
    <link:label id="lab_eols_IncreaseDecreaseInAccruedLitigationSettlement_documentation_en-US" xlink:label="lab_eols_IncreaseDecreaseInAccruedLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement" xlink:href="eols-20211231.xsd#eols_IncreaseDecreaseInAccruedLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement" xlink:to="lab_eols_IncreaseDecreaseInAccruedLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SaleOfStockCommissionPaid_9389a202-a809-4b65-88ac-5ae0cbef45c5_terseLabel_en-US" xlink:label="lab_eols_SaleOfStockCommissionPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate net proceeds from stock offering</link:label>
    <link:label id="lab_eols_SaleOfStockCommissionPaid_label_en-US" xlink:label="lab_eols_SaleOfStockCommissionPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Paid</link:label>
    <link:label id="lab_eols_SaleOfStockCommissionPaid_documentation_en-US" xlink:label="lab_eols_SaleOfStockCommissionPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockCommissionPaid" xlink:href="eols-20211231.xsd#eols_SaleOfStockCommissionPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SaleOfStockCommissionPaid" xlink:to="lab_eols_SaleOfStockCommissionPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal_10048722-338c-4910-bbd5-4166e5ffe901_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of periodic payments</link:label>
    <link:label id="lab_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal_label_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number of Periodic Payments, Principal</link:label>
    <link:label id="lab_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal_documentation_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number of Periodic Payments, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal" xlink:href="eols-20211231.xsd#eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal" xlink:to="lab_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd0ec8a8-0c46-4d2e-8da7-9e4c974dc103_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_f75a38f7-03da-4928-8000-cd335fe6b6d6_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_9e578786-1296-47bb-99f4-37d9620d5668_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_0ae6b000-3560-42c3-b479-670f30267cd2_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1ec3db9d-30d6-46fe-a773-c513c66c6970_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term , Exercisable (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_a9b7a6df-6a2f-4a72-8cfd-a93044f32525_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net book value</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_f88704c6-a5dd-4b9e-aff5-f650a402eed2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_240fa60f-5fbf-4cf1-92bb-5a3aa35ee95e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d8d9ee92-f9a1-45e9-b632-dd84af674750_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_920aae25-225f-41e1-a0d5-47242617dd46_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of discount on short-term investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_da2f8ca4-aeca-45c3-a4f2-7c4c9a79dcb8_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_IntangibleAssetsGrossIncludingGoodwill_2c06e82e-40e0-4fe9-92fa-1f90d2c2977f_totalLabel_en-US" xlink:label="lab_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross (including goodwill)</link:label>
    <link:label id="lab_eols_IntangibleAssetsGrossIncludingGoodwill_label_en-US" xlink:label="lab_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:label id="lab_eols_IntangibleAssetsGrossIncludingGoodwill_documentation_en-US" xlink:label="lab_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:href="eols-20211231.xsd#eols_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:to="lab_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d084b76-e533-44df-bb2a-c4be6e48d3ca_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c7bd18ac-517d-4679-89a7-75cc1f29d123_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentOfFinalPaymentAmountWaived_85086d8e-559e-4526-a0e6-b2c990091801_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentOfFinalPaymentAmountWaived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument of principal amount payment</link:label>
    <link:label id="lab_eols_DebtInstrumentOfFinalPaymentAmountWaived_label_en-US" xlink:label="lab_eols_DebtInstrumentOfFinalPaymentAmountWaived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Of Final Payment Amount Waived</link:label>
    <link:label id="lab_eols_DebtInstrumentOfFinalPaymentAmountWaived_documentation_en-US" xlink:label="lab_eols_DebtInstrumentOfFinalPaymentAmountWaived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Of Final Payment Amount Waived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentOfFinalPaymentAmountWaived" xlink:href="eols-20211231.xsd#eols_DebtInstrumentOfFinalPaymentAmountWaived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentOfFinalPaymentAmountWaived" xlink:to="lab_eols_DebtInstrumentOfFinalPaymentAmountWaived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_2084d530-f1c5-4c48-aafe-cbde190d463e_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_7bcffa91-2bd6-4f64-9646-37bcd01f355d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_a7e4c493-02a1-4bbd-b7aa-abd97f788a05_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8b88306a-bae1-4d41-91f6-be971599b523_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3ee44abe-3134-46d0-b1d9-d510d574cd5c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_79021f54-0b93-4b3a-8b00-5fb50535cbf6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_f7a403de-75b9-4e8c-a9a8-d25d01e16ad8_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2b4a02c0-2a63-4f1c-a945-cd4c6a68b4d2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_98921375-7eba-4156-8652-5f991d374519_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6c1f1b64-ae48-49d3-933e-ed87d470f259_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d5f293d5-a2ea-46a9-bccb-87ab099d18e1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_7205adf4-2f78-4223-922b-020892315e68_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_1744bc69-fc39-445e-b073-5b47541f598f_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_67586cbb-2cf0-4b7a-ab98-67fa8d69c7bf_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_b41226e3-4240-4bcf-a3da-b912c1978acf_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationPeriod_74372b50-0916-4bf5-bb18-a121b27fbd12_terseLabel_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, termination period</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationPeriod_label_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationPeriod_documentation_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LesseeOperatingLeaseTerminationPeriod" xlink:href="eols-20211231.xsd#eols_LesseeOperatingLeaseTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LesseeOperatingLeaseTerminationPeriod" xlink:to="lab_eols_LesseeOperatingLeaseTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_95ea8ff0-7f2b-4a99-99f9-a71e1d7b83d1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_757bbfbd-7271-41d1-bb3b-45eca30ce183_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_db73f914-4237-4507-8c30-d4f89b46a9f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9e542476-fec8-4d81-8d70-77d9ba204681_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_85cd6e12-d730-413b-b8b4-76ddf4b58b6e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentAmortizationPeriod_d53b7da3-897c-494c-9539-002a66a5e08e_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period</link:label>
    <link:label id="lab_eols_DebtInstrumentAmortizationPeriod_label_en-US" xlink:label="lab_eols_DebtInstrumentAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Amortization Period</link:label>
    <link:label id="lab_eols_DebtInstrumentAmortizationPeriod_documentation_en-US" xlink:label="lab_eols_DebtInstrumentAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentAmortizationPeriod" xlink:href="eols-20211231.xsd#eols_DebtInstrumentAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentAmortizationPeriod" xlink:to="lab_eols_DebtInstrumentAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8dbd2d68-4651-4044-be33-35a49dbe46fa_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding used to compute diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_fe175f87-8834-47d4-9cf5-08c83f8157bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_e918d505-b90c-4dd3-b64c-894b629169b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_fc545e34-d78a-499e-b9d3-be250e32b5f8_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_47970953-3550-4df0-b059-0193a9e6831c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d9b3d29d-0a08-4569-978e-145205bf80c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_64f8348c-2ac8-47c3-9b21-ff2598ae12d7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f8de0512-7dcd-4834-bd8e-6a3a02403e6a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_b107317d-7ae8-4e97-83c8-2181be9a3ea4_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss, writeoff</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_30e8c14d-9c54-4bea-a124-5b4c1bdaeee8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod_3fbea17b-4f40-43cb-aa3c-e422080cbf25_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anniversary period</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod_label_en-US" xlink:label="lab_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Payment Commencement Period</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Payment Commencement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" xlink:to="lab_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_688ec713-8923-4ca2-948f-394a2ad4c7b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_354e4fa6-680f-40f1-9453-c2aa15d391ee_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_bffb7dd1-bf70-4d45-bf7f-9fb5b6763f2b_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_6ca6354c-9160-4791-aecc-6f7d3bc10e51_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_9579dcfd-eb2c-44ec-a9ce-d7b61cfa8423_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitment, amount</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18b5c642-b69e-450c-aba0-65a38a947183_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e16b954f-be26-4e26-a02c-c658a79868d6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9e033341-e4ab-4b89-aba3-7dc55e18c699_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2df06b29-1d4c-4253-b4fc-c9b42339592d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3f28233b-4bcb-4bbf-9757-9918fdead1b1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6fdce43d-bcf4-4938-bf27-4873528391de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ed7e35cc-6e46-4fdd-a8f3-f0a3bccd18e5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_cf0b63e5-c447-47b4-83d3-60d79e0ace2d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_bb0fce84-2f09-4813-be56-6f0399691ba9_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee percentage, year two</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Year Two</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentFeePercentageYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:to="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LossContingencySettlementAgreementPaymentTerms_3fd4e883-abd1-4f2a-9e28-c1317c4c4828_terseLabel_en-US" xlink:label="lab_eols_LossContingencySettlementAgreementPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement agreement, payment terms (in years)</link:label>
    <link:label id="lab_eols_LossContingencySettlementAgreementPaymentTerms_label_en-US" xlink:label="lab_eols_LossContingencySettlementAgreementPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreement, Payment Terms</link:label>
    <link:label id="lab_eols_LossContingencySettlementAgreementPaymentTerms_documentation_en-US" xlink:label="lab_eols_LossContingencySettlementAgreementPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreement, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementPaymentTerms" xlink:href="eols-20211231.xsd#eols_LossContingencySettlementAgreementPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LossContingencySettlementAgreementPaymentTerms" xlink:to="lab_eols_LossContingencySettlementAgreementPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2ef997d2-23fd-4b4a-9873-db0c587fd8a0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e505952b-2069-46db-97b4-48ddfd361c49_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_a01add3d-60cb-499b-b9ce-5264ce05209f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DeferredTaxAssetsOperatingLeaseLiabilities_fff84a8e-3584-4757-bf9e-1083b8618d5f_terseLabel_en-US" xlink:label="lab_eols_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_eols_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_eols_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Operating Lease Liabilities</link:label>
    <link:label id="lab_eols_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_eols_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="eols-20211231.xsd#eols_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_eols_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SCHAEONLLCMember_6199ffa2-8e27-4f44-b5c6-af07fcc3fc03_terseLabel_en-US" xlink:label="lab_eols_SCHAEONLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCH</link:label>
    <link:label id="lab_eols_SCHAEONLLCMember_label_en-US" xlink:label="lab_eols_SCHAEONLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCH-AEON, LLC [Member]</link:label>
    <link:label id="lab_eols_SCHAEONLLCMember_documentation_en-US" xlink:label="lab_eols_SCHAEONLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCH-AEON, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SCHAEONLLCMember" xlink:href="eols-20211231.xsd#eols_SCHAEONLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SCHAEONLLCMember" xlink:to="lab_eols_SCHAEONLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DaewoongAgreementMember_a81d73f0-81f9-4a8d-992f-d1dd390b3404_terseLabel_en-US" xlink:label="lab_eols_DaewoongAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daewoong Agreement</link:label>
    <link:label id="lab_eols_DaewoongAgreementMember_label_en-US" xlink:label="lab_eols_DaewoongAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daewoong Agreement [Member]</link:label>
    <link:label id="lab_eols_DaewoongAgreementMember_documentation_en-US" xlink:label="lab_eols_DaewoongAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daewoong Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongAgreementMember" xlink:href="eols-20211231.xsd#eols_DaewoongAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DaewoongAgreementMember" xlink:to="lab_eols_DaewoongAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_00fe7431-a814-44f5-97b2-668a0cff0727_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent promissory note payable</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_bbe12be3-ce85-40c4-9a47-d57cd78c40a7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2b5b10d0-8662-4f45-b246-6c5c60fcd300_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_182b2a53-9365-434a-8fb7-0c46594cba5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase percentage of maximum shares outstanding (equal to)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2f0f804e-0ca8-48a2-9ce4-e4ab593b5347_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_19e4d2d2-6204-4bc4-b565-a322dc6c56cd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_e3e00982-9ea0-43eb-b357-55c769a8ae2b_verboseLabel_en-US" xlink:label="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_label_en-US" xlink:label="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment In Connection With License And Supply Agreement</link:label>
    <link:label id="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_documentation_en-US" xlink:label="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment In Connection With License And Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" xlink:href="eols-20211231.xsd#eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" xlink:to="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_a29ab4cd-5961-4964-a407-16973f36751b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_9e108367-5d8a-48c0-b327-ea9a346aec3c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8d0e59bb-5ac6-4757-99b2-981881c26da7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_b36740a1-38f6-4010-959a-d09b0118a811_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_IntellectualPropertyDisputesJeuveauMember_05e28618-6048-43c9-a3c8-bb9af60f8056_terseLabel_en-US" xlink:label="lab_eols_IntellectualPropertyDisputesJeuveauMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property Disputes, Jeuveau</link:label>
    <link:label id="lab_eols_IntellectualPropertyDisputesJeuveauMember_label_en-US" xlink:label="lab_eols_IntellectualPropertyDisputesJeuveauMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property Disputes, Jeuveau [Member]</link:label>
    <link:label id="lab_eols_IntellectualPropertyDisputesJeuveauMember_documentation_en-US" xlink:label="lab_eols_IntellectualPropertyDisputesJeuveauMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property Disputes, Jeuveau</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember" xlink:href="eols-20211231.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_IntellectualPropertyDisputesJeuveauMember" xlink:to="lab_eols_IntellectualPropertyDisputesJeuveauMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_ccf5cb8c-409c-4df5-aae1-2f2e4c7908da_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b6306c6e-8777-4076-9ddc-895e680cb25f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement_2bb763a7-22d0-402c-acfb-4c66840da89f_terseLabel_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with litigation settlement (in shares)</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement_label_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Litigation Settlement</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement_documentation_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares, Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:href="eols-20211231.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:to="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_b9148181-8013-4ed1-9d05-c888e263c44c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_c1347c93-e928-4140-b7a4-a87ab6d4babc_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_ba7d89be-2a8b-4ce3-9bf5-d3e5ef8f9eb6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, new claims filed, number</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0662215f-2a28-432a-a2aa-8e31b8181b71_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForSoftware_ecf66977-991d-4ec6-a308-25a688e236c5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to capitalized software</link:label>
    <link:label id="lab_us-gaap_PaymentsForSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForSoftware" xlink:to="lab_us-gaap_PaymentsForSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_f2f0a1ae-24a4-49b8-8f85-1f605864d077_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_8f44f34e-9280-4577-9fa2-c109e3b111d3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_05767af8-7ce1-4349-ac4e-4240f22a8054_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_e472cf91-31b9-4d1a-b09d-4e09c65048d8_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Book Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d2a75e12-605e-476f-8a13-e5354def670b_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_42cf1c65-c9ce-4e55-83e0-4cc43eb991a2_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentNumberOfTranches_96612b2f-7f28-4c9a-8530-2ba284fcc0fa_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_eols_DebtInstrumentNumberOfTranches_label_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number of Tranches</link:label>
    <link:label id="lab_eols_DebtInstrumentNumberOfTranches_documentation_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfTranches" xlink:href="eols-20211231.xsd#eols_DebtInstrumentNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentNumberOfTranches" xlink:to="lab_eols_DebtInstrumentNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_bddcfca9-2fa7-4c81-b880-9a5de18be4ae_terseLabel_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory note - debt discount</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_label_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Promissory Note, Debt Discount</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_documentation_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Promissory Note, Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" xlink:href="eols-20211231.xsd#eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" xlink:to="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_4a9a55f2-05c1-4d91-bed2-2e569f88af60_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_0f71bf91-c68f-4389-a4b5-9bf5ef421935_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53e5ba76-72f5-4178-aebd-e146c2897ade_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_41c5b7db-f7ac-4b88-8a16-3eac8842230b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_c12867eb-c500-468d-9d9a-c6b53bc1cf20_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5a7da520-10ab-48f9-acf8-eb41ba6a84de_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_222fb7da-6d0f-45b1-b86c-988ddda4984e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_a7f014f4-cf5e-417d-b1c7-ed2aea5829c3_terseLabel_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_label_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Obligation Payable to Related Party, Current</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_documentation_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Obligation Payable to Related Party, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:href="eols-20211231.xsd#eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:to="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_af0b2bfb-8e30-447c-ac29-3b083f98a662_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_e17dfb71-abc7-4157-ae53-cced0054f348_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_c1d7f7fb-bc8a-48ae-ba0a-5dcead9fe0e2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred provision (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_91fc6b0b-d384-4b99-9ced-77226cc3ab1c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average remaining contractual term (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>eols-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4ac935c8-acd7-4078-a010-d8166688f707,g:62b990ab-d451-4f6d-92f0-709386d601f0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolus.com/role/Cover" xlink:type="simple" xlink:href="eols-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f1bf2c61-3f3d-456b-bf18-85f9fb84d0fd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_DocumentType_f1bf2c61-3f3d-456b-bf18-85f9fb84d0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_385cebdd-310d-4bf1-b0fe-59b1b44eacfc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_DocumentAnnualReport_385cebdd-310d-4bf1-b0fe-59b1b44eacfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_89f280cf-1ee1-4290-bb89-9243734db8cd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_DocumentPeriodEndDate_89f280cf-1ee1-4290-bb89-9243734db8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_077d142e-4846-45be-8ed7-6b4b028d19f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_CurrentFiscalYearEndDate_077d142e-4846-45be-8ed7-6b4b028d19f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7221b6d5-0f7a-4679-8df6-b1091d387e3e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_DocumentTransitionReport_7221b6d5-0f7a-4679-8df6-b1091d387e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_42845ce6-249e-447d-9d96-c61819e182e3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityFileNumber_42845ce6-249e-447d-9d96-c61819e182e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f64dd0a2-0f73-4acd-abf6-950e213e1b1a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityRegistrantName_f64dd0a2-0f73-4acd-abf6-950e213e1b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e9fe4708-c964-4079-9be5-5746d7f0893a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e9fe4708-c964-4079-9be5-5746d7f0893a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ca9fdfa1-25bd-4df3-b842-6cbe71551140" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityTaxIdentificationNumber_ca9fdfa1-25bd-4df3-b842-6cbe71551140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_57a98831-6877-4706-bc4e-ecb51d2d6040" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityAddressAddressLine1_57a98831-6877-4706-bc4e-ecb51d2d6040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5b371c0b-612d-476e-9bbe-35c2006d7736" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityAddressCityOrTown_5b371c0b-612d-476e-9bbe-35c2006d7736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_58cc948c-a7e8-4cb8-9f9c-58fe5855c0b9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityAddressStateOrProvince_58cc948c-a7e8-4cb8-9f9c-58fe5855c0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_40c7207b-0e1e-4ae4-86f7-e04098d35df8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityAddressPostalZipCode_40c7207b-0e1e-4ae4-86f7-e04098d35df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d48ce5ac-3722-462f-958c-70717e9807ec" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_CityAreaCode_d48ce5ac-3722-462f-958c-70717e9807ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_13664837-6a47-4429-a95f-0e0bf5f6ee80" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_LocalPhoneNumber_13664837-6a47-4429-a95f-0e0bf5f6ee80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_588a54e8-4eab-454f-9e58-404c97719b61" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_Security12bTitle_588a54e8-4eab-454f-9e58-404c97719b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b5cfdfd4-90a9-49ff-ac9f-53cac5681350" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_TradingSymbol_b5cfdfd4-90a9-49ff-ac9f-53cac5681350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_757a6291-a9e7-4ba9-801e-2c5a564d71a9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_SecurityExchangeName_757a6291-a9e7-4ba9-801e-2c5a564d71a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_030cef40-486f-4733-8c91-f1b95d6d21ba" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_030cef40-486f-4733-8c91-f1b95d6d21ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_f5247110-27c4-4010-a313-9fbc40a17f6e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityVoluntaryFilers_f5247110-27c4-4010-a313-9fbc40a17f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_cd53604f-0507-4229-89a2-fe6d8ad4ca12" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityCurrentReportingStatus_cd53604f-0507-4229-89a2-fe6d8ad4ca12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_26208695-24a7-490f-8003-3c8a6ad127d4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityInteractiveDataCurrent_26208695-24a7-490f-8003-3c8a6ad127d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f0ac116d-c7c2-4e3d-ac11-e98a4b59585c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityFilerCategory_f0ac116d-c7c2-4e3d-ac11-e98a4b59585c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_0dcb6d12-738e-4503-9f2e-0137002b9ab4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntitySmallBusiness_0dcb6d12-738e-4503-9f2e-0137002b9ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_43240c14-2d39-4b88-8c00-ea97a072b490" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityEmergingGrowthCompany_43240c14-2d39-4b88-8c00-ea97a072b490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_f0ba1f97-f2e6-44ba-96dd-f3f99b844fbe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityExTransitionPeriod_f0ba1f97-f2e6-44ba-96dd-f3f99b844fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_2ea8b302-7a75-47a0-8ba7-34f2b55ce0eb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_IcfrAuditorAttestationFlag_2ea8b302-7a75-47a0-8ba7-34f2b55ce0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_da3a09f4-aa83-4ad8-ae9a-cf8d1bedc60e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityShellCompany_da3a09f4-aa83-4ad8-ae9a-cf8d1bedc60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_87c7c3f1-dd3f-47e6-947f-f64ee85a7f2e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityPublicFloat_87c7c3f1-dd3f-47e6-947f-f64ee85a7f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f2e8ea63-3d21-49e8-a4c5-182cdec00b28" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f2e8ea63-3d21-49e8-a4c5-182cdec00b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_9984afd7-b5d2-472c-aa90-3bca7f10fdab" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_9984afd7-b5d2-472c-aa90-3bca7f10fdab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ad4ce658-d94d-4825-bb72-ab818d7e5ad6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_AmendmentFlag_ad4ce658-d94d-4825-bb72-ab818d7e5ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f136314f-e4ee-4189-92c5-f3ce4e8475c7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_DocumentFiscalYearFocus_f136314f-e4ee-4189-92c5-f3ce4e8475c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_05369945-4bde-447a-a19d-c16e5f683075" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_DocumentFiscalPeriodFocus_05369945-4bde-447a-a19d-c16e5f683075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a8b2b002-be36-41e9-b974-f5fe597b216d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34d85fb4-1271-455b-be4c-cb347f437069" xlink:to="loc_dei_EntityCentralIndexKey_a8b2b002-be36-41e9-b974-f5fe597b216d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/AuditInformation" xlink:type="simple" xlink:href="eols-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_eols_AuditInformationAbstract_2bb2a33d-b819-4990-ba4d-8b309f83f310" xlink:href="eols-20211231.xsd#eols_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_afae0172-6011-4ab2-8a18-787e98db00f0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AuditInformationAbstract_2bb2a33d-b819-4990-ba4d-8b309f83f310" xlink:to="loc_dei_AuditorFirmId_afae0172-6011-4ab2-8a18-787e98db00f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_efc8c96d-dbf7-43ce-9f0c-38da83da1404" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AuditInformationAbstract_2bb2a33d-b819-4990-ba4d-8b309f83f310" xlink:to="loc_dei_AuditorLocation_efc8c96d-dbf7-43ce-9f0c-38da83da1404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_dbb28336-ad46-4425-b594-bdbe23f39d81" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AuditInformationAbstract_2bb2a33d-b819-4990-ba4d-8b309f83f310" xlink:to="loc_dei_AuditorName_dbb28336-ad46-4425-b594-bdbe23f39d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/BalanceSheets" xlink:type="simple" xlink:href="eols-20211231.xsd#BalanceSheets"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_42d6305c-78b2-4a60-bfb3-92cb74a9fc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_20749b6d-8812-424f-9502-f70f6efded16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_42d6305c-78b2-4a60-bfb3-92cb74a9fc5c" xlink:to="loc_us-gaap_AssetsAbstract_20749b6d-8812-424f-9502-f70f6efded16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0e207d32-751e-41d3-b800-b319f91fbb67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20749b6d-8812-424f-9502-f70f6efded16" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0e207d32-751e-41d3-b800-b319f91fbb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_266fd4a3-b102-48b4-91f4-d74b6b1f54c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0e207d32-751e-41d3-b800-b319f91fbb67" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_266fd4a3-b102-48b4-91f4-d74b6b1f54c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4f9457c3-7f49-4b1b-b76e-55999b914bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0e207d32-751e-41d3-b800-b319f91fbb67" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4f9457c3-7f49-4b1b-b76e-55999b914bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_79c0c283-10f5-4109-b919-25b685f47e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0e207d32-751e-41d3-b800-b319f91fbb67" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_79c0c283-10f5-4109-b919-25b685f47e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0aeafcfa-75a0-447a-9760-f05edb5a3f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0e207d32-751e-41d3-b800-b319f91fbb67" xlink:to="loc_us-gaap_InventoryNet_0aeafcfa-75a0-447a-9760-f05edb5a3f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1e51a04e-3fcf-49f7-b02f-5935f58a6df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0e207d32-751e-41d3-b800-b319f91fbb67" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1e51a04e-3fcf-49f7-b02f-5935f58a6df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_71bcba4d-b998-47a6-95fe-544a95c9c9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0e207d32-751e-41d3-b800-b319f91fbb67" xlink:to="loc_us-gaap_OtherAssetsCurrent_71bcba4d-b998-47a6-95fe-544a95c9c9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_80154cbc-146b-4d8e-bd67-ab3f836607ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0e207d32-751e-41d3-b800-b319f91fbb67" xlink:to="loc_us-gaap_AssetsCurrent_80154cbc-146b-4d8e-bd67-ab3f836607ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a76f40e4-a507-4f70-b164-f4dbf62f5c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20749b6d-8812-424f-9502-f70f6efded16" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a76f40e4-a507-4f70-b164-f4dbf62f5c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2eb0758d-89fd-4992-88fd-53b2155d115f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20749b6d-8812-424f-9502-f70f6efded16" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2eb0758d-89fd-4992-88fd-53b2155d115f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6d83fca0-11c2-4641-b126-76d503b4e880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20749b6d-8812-424f-9502-f70f6efded16" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6d83fca0-11c2-4641-b126-76d503b4e880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2e02bc1d-833b-43b2-8354-117a616d6452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20749b6d-8812-424f-9502-f70f6efded16" xlink:to="loc_us-gaap_Goodwill_2e02bc1d-833b-43b2-8354-117a616d6452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ee77d524-23ab-4cf7-9e9f-b40afa071d31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20749b6d-8812-424f-9502-f70f6efded16" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ee77d524-23ab-4cf7-9e9f-b40afa071d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6a0b3cb2-c906-4b38-bb85-1975e251a721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20749b6d-8812-424f-9502-f70f6efded16" xlink:to="loc_us-gaap_Assets_6a0b3cb2-c906-4b38-bb85-1975e251a721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a146f4eb-f5d8-4a24-8ae1-fcece828e76f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_42d6305c-78b2-4a60-bfb3-92cb74a9fc5c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a146f4eb-f5d8-4a24-8ae1-fcece828e76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7b5104bb-b751-44d3-9032-8087e7faf427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a146f4eb-f5d8-4a24-8ae1-fcece828e76f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7b5104bb-b751-44d3-9032-8087e7faf427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c846c1be-1093-47e5-9fda-44c95143da46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7b5104bb-b751-44d3-9032-8087e7faf427" xlink:to="loc_us-gaap_AccountsPayableCurrent_c846c1be-1093-47e5-9fda-44c95143da46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_12082f20-0333-4a61-864e-2ca77213eb92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7b5104bb-b751-44d3-9032-8087e7faf427" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_12082f20-0333-4a61-864e-2ca77213eb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_d83cc75e-c0b5-4aa0-895b-a46913289472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7b5104bb-b751-44d3-9032-8087e7faf427" xlink:to="loc_us-gaap_LitigationReserveCurrent_d83cc75e-c0b5-4aa0-895b-a46913289472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7122fb3e-6100-4868-8aca-f85083188ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7b5104bb-b751-44d3-9032-8087e7faf427" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7122fb3e-6100-4868-8aca-f85083188ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_c3d3a5c5-982a-4683-a20e-00434d527553" xlink:href="eols-20211231.xsd#eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7b5104bb-b751-44d3-9032-8087e7faf427" xlink:to="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_c3d3a5c5-982a-4683-a20e-00434d527553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_9d15ca62-1338-4d0d-9533-e09b295d63d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7b5104bb-b751-44d3-9032-8087e7faf427" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_9d15ca62-1338-4d0d-9533-e09b295d63d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtCurrent_0ab7b15d-958c-4f4c-a741-54df6184b550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7b5104bb-b751-44d3-9032-8087e7faf427" xlink:to="loc_us-gaap_SecuredDebtCurrent_0ab7b15d-958c-4f4c-a741-54df6184b550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3207cbc3-38fe-4539-b67e-593700e17f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7b5104bb-b751-44d3-9032-8087e7faf427" xlink:to="loc_us-gaap_LiabilitiesCurrent_3207cbc3-38fe-4539-b67e-593700e17f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent_8940eeef-da62-4381-a88b-268a36d266f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a146f4eb-f5d8-4a24-8ae1-fcece828e76f" xlink:to="loc_us-gaap_LitigationReserveNoncurrent_8940eeef-da62-4381-a88b-268a36d266f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b8546468-5c5f-45e1-a874-2249d4b3ca6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a146f4eb-f5d8-4a24-8ae1-fcece828e76f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b8546468-5c5f-45e1-a874-2249d4b3ca6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_0cf9f580-b262-4128-a946-507a116cea91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a146f4eb-f5d8-4a24-8ae1-fcece828e76f" xlink:to="loc_us-gaap_ContractualObligation_0cf9f580-b262-4128-a946-507a116cea91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_7bb8f5fe-7cc5-4623-9b38-7b46de2e0d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a146f4eb-f5d8-4a24-8ae1-fcece828e76f" xlink:to="loc_us-gaap_SecuredLongTermDebt_7bb8f5fe-7cc5-4623-9b38-7b46de2e0d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_6874f1ff-a590-4a1a-bd98-a4736ba65ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a146f4eb-f5d8-4a24-8ae1-fcece828e76f" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_6874f1ff-a590-4a1a-bd98-a4736ba65ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_31892090-8f74-41d4-816a-dc58fb93df77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a146f4eb-f5d8-4a24-8ae1-fcece828e76f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_31892090-8f74-41d4-816a-dc58fb93df77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_696eeca8-492d-42c6-8a91-c5e203880610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a146f4eb-f5d8-4a24-8ae1-fcece828e76f" xlink:to="loc_us-gaap_Liabilities_696eeca8-492d-42c6-8a91-c5e203880610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e0f8ac7a-d5e8-4d82-8208-a8c50b55606c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a146f4eb-f5d8-4a24-8ae1-fcece828e76f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e0f8ac7a-d5e8-4d82-8208-a8c50b55606c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_946eb368-e8cf-49c0-a448-c8e04794efab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a146f4eb-f5d8-4a24-8ae1-fcece828e76f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_946eb368-e8cf-49c0-a448-c8e04794efab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_813535be-09bf-4e59-9984-0a30198b72f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_946eb368-e8cf-49c0-a448-c8e04794efab" xlink:to="loc_us-gaap_PreferredStockValue_813535be-09bf-4e59-9984-0a30198b72f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3f075911-a63a-494f-8cf5-4adc1225da74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_946eb368-e8cf-49c0-a448-c8e04794efab" xlink:to="loc_us-gaap_CommonStockValue_3f075911-a63a-494f-8cf5-4adc1225da74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_809d8b5c-b9f9-439f-9071-3f3fdca6e5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_946eb368-e8cf-49c0-a448-c8e04794efab" xlink:to="loc_us-gaap_AdditionalPaidInCapital_809d8b5c-b9f9-439f-9071-3f3fdca6e5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_341b4ee5-acd6-46c5-ba77-7016ec8ad8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_946eb368-e8cf-49c0-a448-c8e04794efab" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_341b4ee5-acd6-46c5-ba77-7016ec8ad8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e34dcb2d-fdf3-4f29-908a-99f3d429cf84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_946eb368-e8cf-49c0-a448-c8e04794efab" xlink:to="loc_us-gaap_StockholdersEquity_e34dcb2d-fdf3-4f29-908a-99f3d429cf84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_79aba0d5-c9d8-45f0-86c9-ee4218b6f4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a146f4eb-f5d8-4a24-8ae1-fcece828e76f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_79aba0d5-c9d8-45f0-86c9-ee4218b6f4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5df147ee-3250-4e36-9a85-6d4356ca16e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_42d6305c-78b2-4a60-bfb3-92cb74a9fc5c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5df147ee-3250-4e36-9a85-6d4356ca16e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="eols-20211231.xsd#BalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8d266837-4781-4219-be13-a331768db449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2dd3aa8f-6204-42d9-ac31-6616fd2dabd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8d266837-4781-4219-be13-a331768db449" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2dd3aa8f-6204-42d9-ac31-6616fd2dabd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fa97f4ce-1942-4a37-a054-3ac622fe30b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8d266837-4781-4219-be13-a331768db449" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fa97f4ce-1942-4a37-a054-3ac622fe30b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c6fb45ba-850b-4878-b3b4-d3d0d35dbf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8d266837-4781-4219-be13-a331768db449" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c6fb45ba-850b-4878-b3b4-d3d0d35dbf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ac3f0f30-c4dd-4d40-af92-f3f6f762341d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8d266837-4781-4219-be13-a331768db449" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ac3f0f30-c4dd-4d40-af92-f3f6f762341d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7105afad-4216-4f49-a31e-8cf0e4c32817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8d266837-4781-4219-be13-a331768db449" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7105afad-4216-4f49-a31e-8cf0e4c32817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fb912104-19d2-4368-8f6f-71334f3e29e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8d266837-4781-4219-be13-a331768db449" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fb912104-19d2-4368-8f6f-71334f3e29e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e3ddcc32-4e6d-42d2-9beb-8c547e087453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8d266837-4781-4219-be13-a331768db449" xlink:to="loc_us-gaap_CommonStockSharesIssued_e3ddcc32-4e6d-42d2-9beb-8c547e087453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_65233a36-fd2a-4333-a0a8-6350805e5790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8d266837-4781-4219-be13-a331768db449" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_65233a36-fd2a-4333-a0a8-6350805e5790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="eols-20211231.xsd#StatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b9c2b5b3-c9d1-4e23-a55f-5dae1ad02cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d124808f-14f6-47ed-8068-d09cd6abc73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b9c2b5b3-c9d1-4e23-a55f-5dae1ad02cc7" xlink:to="loc_us-gaap_StatementTable_d124808f-14f6-47ed-8068-d09cd6abc73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d3005b4a-50cb-4412-a0ee-423f88f931c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d124808f-14f6-47ed-8068-d09cd6abc73b" xlink:to="loc_srt_ProductOrServiceAxis_d3005b4a-50cb-4412-a0ee-423f88f931c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_270d7e37-5d21-46e0-977e-9a7548b9b42c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d3005b4a-50cb-4412-a0ee-423f88f931c3" xlink:to="loc_srt_ProductsAndServicesDomain_270d7e37-5d21-46e0-977e-9a7548b9b42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_fa59beb6-822f-44cb-b52c-269a2057f57b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_270d7e37-5d21-46e0-977e-9a7548b9b42c" xlink:to="loc_us-gaap_ProductMember_fa59beb6-822f-44cb-b52c-269a2057f57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_fdaca54c-0c4f-4c31-9c43-5999195ff590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_270d7e37-5d21-46e0-977e-9a7548b9b42c" xlink:to="loc_us-gaap_ServiceMember_fdaca54c-0c4f-4c31-9c43-5999195ff590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d124808f-14f6-47ed-8068-d09cd6abc73b" xlink:to="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9d13c3d6-605e-46ef-ad34-53e7966b67e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_RevenuesAbstract_9d13c3d6-605e-46ef-ad34-53e7966b67e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06ec0f19-ef59-4283-b7c6-a58f99d8e495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9d13c3d6-605e-46ef-ad34-53e7966b67e4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06ec0f19-ef59-4283-b7c6-a58f99d8e495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_705e0eda-9231-48e6-936d-2a092637878b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_705e0eda-9231-48e6-936d-2a092637878b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_19708b2b-b7ed-43c8-add7-62e0d7471ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_19708b2b-b7ed-43c8-add7-62e0d7471ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a226b730-832e-43d8-97c0-1d1b36979551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a226b730-832e-43d8-97c0-1d1b36979551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_dedb3699-8f49-4712-bf97-b2ecdeee2503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_dedb3699-8f49-4712-bf97-b2ecdeee2503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_69dfd54c-9a3f-4434-91ea-1637721a857d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_69dfd54c-9a3f-4434-91ea-1637721a857d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_161d4bc3-321e-4fb3-9fc7-2af671fd32aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_161d4bc3-321e-4fb3-9fc7-2af671fd32aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_bdad3cb9-e923-4dda-9607-e8ea40844962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_LitigationSettlementExpense_bdad3cb9-e923-4dda-9607-e8ea40844962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0005901f-3c41-4f76-84be-18cf9b701ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_RestructuringCharges_0005901f-3c41-4f76-84be-18cf9b701ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_78d05250-261b-4bee-9431-e5bd7365cd67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bdc34257-c6c3-4bfe-9bc6-6e219ba28742" xlink:to="loc_us-gaap_CostsAndExpenses_78d05250-261b-4bee-9431-e5bd7365cd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6c128e34-e539-4f62-a143-19fcf54bfa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_OperatingIncomeLoss_6c128e34-e539-4f62-a143-19fcf54bfa8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b8e9bfd1-99cd-4bff-9f2f-8f9a2adf95e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b8e9bfd1-99cd-4bff-9f2f-8f9a2adf95e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_b34b2e44-bb40-4b31-94bd-e67530250a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b8e9bfd1-99cd-4bff-9f2f-8f9a2adf95e9" xlink:to="loc_us-gaap_InvestmentIncomeNet_b34b2e44-bb40-4b31-94bd-e67530250a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1fb08891-ed4c-45b2-bb9f-69ef453c8e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b8e9bfd1-99cd-4bff-9f2f-8f9a2adf95e9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1fb08891-ed4c-45b2-bb9f-69ef453c8e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_96fd6ce2-dff3-4d3f-877e-321b8cb95443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_b8e9bfd1-99cd-4bff-9f2f-8f9a2adf95e9" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_96fd6ce2-dff3-4d3f-877e-321b8cb95443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_61aa3923-78a9-4dab-9c4a-ee73171b5ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_61aa3923-78a9-4dab-9c4a-ee73171b5ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_65722c98-2902-4fde-9844-80b9acfbaf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_65722c98-2902-4fde-9844-80b9acfbaf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7ef87171-1862-43b2-afbb-f9faf4fa374f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_NetIncomeLoss_7ef87171-1862-43b2-afbb-f9faf4fa374f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_aa695dc7-bbf8-4b2e-a663-9209adcac0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_aa695dc7-bbf8-4b2e-a663-9209adcac0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b710b33d-ca41-4547-9fea-a276be9342c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_aa695dc7-bbf8-4b2e-a663-9209adcac0a9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b710b33d-ca41-4547-9fea-a276be9342c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8f920930-ca67-4330-97c1-261fae9e870c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_8f920930-ca67-4330-97c1-261fae9e870c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_afec7409-3d6e-46c0-8b5f-fd33651f6786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_EarningsPerShareBasic_afec7409-3d6e-46c0-8b5f-fd33651f6786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_19bfa03c-2ea8-49a6-ad03-ddc555bcbf70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_19bfa03c-2ea8-49a6-ad03-ddc555bcbf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_09473644-84cd-44df-907b-4878f5e220ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_09473644-84cd-44df-907b-4878f5e220ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3ffecb68-a3d5-44d4-abe6-bf274130f337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3ffecb68-a3d5-44d4-abe6-bf274130f337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_4fb5c420-f137-42f9-b4e5-64e84e444d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb0f3136-b228-4e4e-b62b-cd8ef97d7ed4" xlink:to="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_4fb5c420-f137-42f9-b4e5-64e84e444d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="eols-20211231.xsd#StatementsofStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StatementsofStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a076c3cc-5f98-400f-b6a2-73885c6ab5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d6caa97c-a751-488f-8b3b-076442f26850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a076c3cc-5f98-400f-b6a2-73885c6ab5c7" xlink:to="loc_us-gaap_StatementTable_d6caa97c-a751-488f-8b3b-076442f26850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d3167d6e-5e40-410e-a20c-e532287bd30e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d6caa97c-a751-488f-8b3b-076442f26850" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d3167d6e-5e40-410e-a20c-e532287bd30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_42d6b92f-22c7-434f-a151-8b92dea79d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3167d6e-5e40-410e-a20c-e532287bd30e" xlink:to="loc_us-gaap_EquityComponentDomain_42d6b92f-22c7-434f-a151-8b92dea79d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d1b1e482-dca3-4105-8aff-0e9294be5c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42d6b92f-22c7-434f-a151-8b92dea79d7a" xlink:to="loc_us-gaap_PreferredStockMember_d1b1e482-dca3-4105-8aff-0e9294be5c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9cd0707b-51dc-4de7-8dfe-1f9a33e85933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42d6b92f-22c7-434f-a151-8b92dea79d7a" xlink:to="loc_us-gaap_CommonStockMember_9cd0707b-51dc-4de7-8dfe-1f9a33e85933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_991e86ac-dbda-432a-94c5-c40f5653dada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42d6b92f-22c7-434f-a151-8b92dea79d7a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_991e86ac-dbda-432a-94c5-c40f5653dada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_53f63647-d3c2-425d-9acc-ec5622ac4560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42d6b92f-22c7-434f-a151-8b92dea79d7a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_53f63647-d3c2-425d-9acc-ec5622ac4560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_db00c526-9bde-4e81-96a7-53c57d6d137c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42d6b92f-22c7-434f-a151-8b92dea79d7a" xlink:to="loc_us-gaap_RetainedEarningsMember_db00c526-9bde-4e81-96a7-53c57d6d137c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4e8e22f2-6d81-4dc6-b21c-ae814b2b2aad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d6caa97c-a751-488f-8b3b-076442f26850" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4e8e22f2-6d81-4dc6-b21c-ae814b2b2aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_330338e9-61ec-461b-b814-b4986e30ecb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4e8e22f2-6d81-4dc6-b21c-ae814b2b2aad" xlink:to="loc_us-gaap_ClassOfStockDomain_330338e9-61ec-461b-b814-b4986e30ecb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_268555c9-00d9-4139-ac99-9befed56629d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_330338e9-61ec-461b-b814-b4986e30ecb2" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_268555c9-00d9-4139-ac99-9befed56629d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4770df23-f6d3-416d-83dc-23aaf6d9b219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d6caa97c-a751-488f-8b3b-076442f26850" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4770df23-f6d3-416d-83dc-23aaf6d9b219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c132e22-30ef-4865-946e-26da146dfe05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4770df23-f6d3-416d-83dc-23aaf6d9b219" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c132e22-30ef-4865-946e-26da146dfe05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FollowOnOfferingMember_761072a4-ae1d-45e8-b72a-c7ac47fdd959" xlink:href="eols-20211231.xsd#eols_FollowOnOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c132e22-30ef-4865-946e-26da146dfe05" xlink:to="loc_eols_FollowOnOfferingMember_761072a4-ae1d-45e8-b72a-c7ac47fdd959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember_5f6210dd-6bf2-441c-be35-eb6829186514" xlink:href="eols-20211231.xsd#eols_ATMSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c132e22-30ef-4865-946e-26da146dfe05" xlink:to="loc_eols_ATMSalesAgreementMember_5f6210dd-6bf2-441c-be35-eb6829186514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8425b9aa-1ff0-4e0b-b00c-bdaf90746e52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d6caa97c-a751-488f-8b3b-076442f26850" xlink:to="loc_us-gaap_StatementLineItems_8425b9aa-1ff0-4e0b-b00c-bdaf90746e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8425b9aa-1ff0-4e0b-b00c-bdaf90746e52" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_12915e92-d284-4c59-9303-aa213ffc4773" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_SharesIssued_12915e92-d284-4c59-9303-aa213ffc4773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b2c69e8c-15d0-4a11-a77c-9d8db8de33bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_StockholdersEquity_b2c69e8c-15d0-4a11-a77c-9d8db8de33bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_c2e9d704-881e-40cc-b8f9-9ef21ce4886c" xlink:href="eols-20211231.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_c2e9d704-881e-40cc-b8f9-9ef21ce4886c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodValuesLitigationSettlement_e2711f91-7ed5-4404-bd2e-dffdf06738dd" xlink:href="eols-20211231.xsd#eols_StockIssuedDuringPeriodValuesLitigationSettlement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_eols_StockIssuedDuringPeriodValuesLitigationSettlement_e2711f91-7ed5-4404-bd2e-dffdf06738dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f27d195a-198d-435b-bb28-7f9f87b41eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f27d195a-198d-435b-bb28-7f9f87b41eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0a0cd84f-844a-498d-b2d5-6d64b594950a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0a0cd84f-844a-498d-b2d5-6d64b594950a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d4264185-e8de-4e76-be33-706ec6085d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d4264185-e8de-4e76-be33-706ec6085d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27d0f5ea-a475-400b-a965-5e61310e646b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27d0f5ea-a475-400b-a965-5e61310e646b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f919326e-6c8c-44a0-950d-c8f714376864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f919326e-6c8c-44a0-950d-c8f714376864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f47b3032-7a98-4576-93d8-be9ba435e84f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_NetIncomeLoss_f47b3032-7a98-4576-93d8-be9ba435e84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9562943d-fbaf-46ec-ad1a-570209f35657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9562943d-fbaf-46ec-ad1a-570209f35657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_20bc9361-2c9f-4cec-b17a-64be9740f504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_SharesIssued_20bc9361-2c9f-4cec-b17a-64be9740f504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b4f75314-8362-4421-8900-cc9bb59420e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89825e23-d038-484f-bf90-43f3b9ac01ba" xlink:to="loc_us-gaap_StockholdersEquity_b4f75314-8362-4421-8900-cc9bb59420e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="eols-20211231.xsd#StatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1cea2d6e-fc1f-4220-9dfb-0d06b0f66ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_44917de0-8e63-4357-8045-39fb5438fc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1cea2d6e-fc1f-4220-9dfb-0d06b0f66ae3" xlink:to="loc_us-gaap_StatementTable_44917de0-8e63-4357-8045-39fb5438fc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b2207da9-1716-4452-ae21-a672eb2fb60e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_44917de0-8e63-4357-8045-39fb5438fc9f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b2207da9-1716-4452-ae21-a672eb2fb60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b059b50a-1127-4726-a725-dbf66f727519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b2207da9-1716-4452-ae21-a672eb2fb60e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b059b50a-1127-4726-a725-dbf66f727519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FollowOnOfferingMember_de57c1fd-95bf-4acf-9fb5-70ca5ac94e55" xlink:href="eols-20211231.xsd#eols_FollowOnOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b059b50a-1127-4726-a725-dbf66f727519" xlink:to="loc_eols_FollowOnOfferingMember_de57c1fd-95bf-4acf-9fb5-70ca5ac94e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember_00a3a0cd-3238-4b1b-89d3-c8da8eb1911c" xlink:href="eols-20211231.xsd#eols_ATMSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b059b50a-1127-4726-a725-dbf66f727519" xlink:to="loc_eols_ATMSalesAgreementMember_00a3a0cd-3238-4b1b-89d3-c8da8eb1911c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_44917de0-8e63-4357-8045-39fb5438fc9f" xlink:to="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7860ad2c-8231-4534-a6af-e625119e5ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7860ad2c-8231-4534-a6af-e625119e5ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_21c9330b-3aef-45b1-856c-16c7a2601a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7860ad2c-8231-4534-a6af-e625119e5ec6" xlink:to="loc_us-gaap_NetIncomeLoss_21c9330b-3aef-45b1-856c-16c7a2601a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7860ad2c-8231-4534-a6af-e625119e5ec6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2b792941-c41c-4941-ad0d-e4eeb5bd6608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2b792941-c41c-4941-ad0d-e4eeb5bd6608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c04c4eec-c64a-46ce-ac48-ca79e2606347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_ShareBasedCompensation_c04c4eec-c64a-46ce-ac48-ca79e2606347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_9e43e546-2d06-4968-84f7-e4ac96ee92bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_9e43e546-2d06-4968-84f7-e4ac96ee92bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a6beaa7f-5645-4e60-a8c6-a883f73e62dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a6beaa7f-5645-4e60-a8c6-a883f73e62dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OperatingLeaseRightofUseAssetAmortization_f6d7d0ef-9ebb-4f06-a107-a14cc184222a" xlink:href="eols-20211231.xsd#eols_OperatingLeaseRightofUseAssetAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_eols_OperatingLeaseRightofUseAssetAmortization_f6d7d0ef-9ebb-4f06-a107-a14cc184222a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4ba6bfb3-f704-436c-9fba-3fc411132f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4ba6bfb3-f704-436c-9fba-3fc411132f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_f292e611-6765-4db0-9d42-c22fd0247eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_PaidInKindInterest_f292e611-6765-4db0-9d42-c22fd0247eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5d519f2b-d710-4f1e-8c0c-0746726f6514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5d519f2b-d710-4f1e-8c0c-0746726f6514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8ec35e99-6337-4d64-a5cb-6fca15af0fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8ec35e99-6337-4d64-a5cb-6fca15af0fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_de045ba1-41b3-4c09-b5a8-55a5644f1ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_de045ba1-41b3-4c09-b5a8-55a5644f1ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses_81058f80-f948-41fd-8ab1-9a1568b68029" xlink:href="eols-20211231.xsd#eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses_81058f80-f948-41fd-8ab1-9a1568b68029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f972ef7-df53-4651-a7fc-224a28dce797" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c11495be-1537-4cf6-91e7-4a21ed3a3364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c11495be-1537-4cf6-91e7-4a21ed3a3364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cb42fa7e-f677-4725-b171-9170aae69837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cb42fa7e-f677-4725-b171-9170aae69837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d4433e36-4de8-4a89-91da-985c9e61c05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d4433e36-4de8-4a89-91da-985c9e61c05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_45bce733-ac13-457a-87fa-603b8b5bee2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_45bce733-ac13-457a-87fa-603b8b5bee2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_326789ea-e17f-4b50-b055-7be4a8cc220d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_326789ea-e17f-4b50-b055-7be4a8cc220d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement_24afce95-3ef9-4c91-831c-3cc825bd222b" xlink:href="eols-20211231.xsd#eols_IncreaseDecreaseInAccruedLitigationSettlement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:to="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement_24afce95-3ef9-4c91-831c-3cc825bd222b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_f6acc9fb-1186-4894-8e2d-db85a7083888" xlink:href="eols-20211231.xsd#eols_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:to="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_f6acc9fb-1186-4894-8e2d-db85a7083888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_22c92d82-5cfc-48f0-adda-271e1cccde3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ea2c98f-d246-47e6-ba6f-2e7076a6326b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_22c92d82-5cfc-48f0-adda-271e1cccde3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9ac8b3d3-9cf3-4402-a080-84c7ca8182f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7860ad2c-8231-4534-a6af-e625119e5ec6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9ac8b3d3-9cf3-4402-a080-84c7ca8182f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_82312da4-a117-4cf5-a38e-88920e28b6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_82312da4-a117-4cf5-a38e-88920e28b6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9a87c39b-a4d9-42ae-ab0a-d25aa988d757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_82312da4-a117-4cf5-a38e-88920e28b6c6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9a87c39b-a4d9-42ae-ab0a-d25aa988d757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_1ae6c049-04cd-4294-b7b2-53222e44f336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForSoftware"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_82312da4-a117-4cf5-a38e-88920e28b6c6" xlink:to="loc_us-gaap_PaymentsForSoftware_1ae6c049-04cd-4294-b7b2-53222e44f336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_2e701d3a-37a8-44e5-87fb-16a34a247ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_82312da4-a117-4cf5-a38e-88920e28b6c6" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_2e701d3a-37a8-44e5-87fb-16a34a247ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_e3b55d77-599f-41ad-be7d-ff8384b24030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_82312da4-a117-4cf5-a38e-88920e28b6c6" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_e3b55d77-599f-41ad-be7d-ff8384b24030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c484fb6b-f887-4bec-93da-215d04db0e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_82312da4-a117-4cf5-a38e-88920e28b6c6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c484fb6b-f887-4bec-93da-215d04db0e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_1ea105b1-1a00-490b-b0da-1c59ad2f9956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_RepaymentsOfDebt_1ea105b1-1a00-490b-b0da-1c59ad2f9956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_11f46f5e-a006-43cd-aa9d-e8582c9048f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_11f46f5e-a006-43cd-aa9d-e8582c9048f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation_9eede4c3-b119-4648-af77-bf20555d9fdd" xlink:href="eols-20211231.xsd#eols_PaymentsOfContingentRoyaltyObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_eols_PaymentsOfContingentRoyaltyObligation_9eede4c3-b119-4648-af77-bf20555d9fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_0a0fc045-8bcb-4373-9a28-14214312113b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_0a0fc045-8bcb-4373-9a28-14214312113b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_17b1a959-291d-4ec8-b0d8-0a5791b97f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_17b1a959-291d-4ec8-b0d8-0a5791b97f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1654432d-77f8-42ca-8054-f258bc703878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1654432d-77f8-42ca-8054-f258bc703878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_0e7e91af-458e-4cfb-b2e0-4db7accf4634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_0e7e91af-458e-4cfb-b2e0-4db7accf4634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_873c7ff4-a580-4218-8c13-62fb0434bc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_873c7ff4-a580-4218-8c13-62fb0434bc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_25033500-bbb7-4c8c-a86f-e2b913c97504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_25033500-bbb7-4c8c-a86f-e2b913c97504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_2d9ba184-0a2f-4d97-8484-92483455193d" xlink:href="eols-20211231.xsd#eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_2d9ba184-0a2f-4d97-8484-92483455193d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_96d2c20f-0914-4873-91f2-a3ff28ab08ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ca1b7584-e097-4adf-be2a-5ee308ce06e2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_96d2c20f-0914-4873-91f2-a3ff28ab08ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_344020eb-3109-4fc5-9002-ec499f48c595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_344020eb-3109-4fc5-9002-ec499f48c595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d2859fc9-27b6-4f8a-bf9e-607fde9f3644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d2859fc9-27b6-4f8a-bf9e-607fde9f3644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1892b220-f049-46db-80e6-3e2e9914baa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1892b220-f049-46db-80e6-3e2e9914baa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_296a8325-d706-4b14-84ca-d43666890d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_296a8325-d706-4b14-84ca-d43666890d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_f4f5f59e-3638-4a57-a373-162a0f8cef9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_296a8325-d706-4b14-84ca-d43666890d7d" xlink:to="loc_us-gaap_InterestPaidNet_f4f5f59e-3638-4a57-a373-162a0f8cef9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_23e8a18c-992b-427b-997c-d462ca1bbd36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_296a8325-d706-4b14-84ca-d43666890d7d" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_23e8a18c-992b-427b-997c-d462ca1bbd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e91f896b-d952-426b-be29-3a0df05512f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ed89f80-227c-42c6-b7cd-9d9c433e8ea4" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e91f896b-d952-426b-be29-3a0df05512f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_ce7234ee-368d-4d12-aef3-92159b2027f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e91f896b-d952-426b-be29-3a0df05512f9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_ce7234ee-368d-4d12-aef3-92159b2027f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedForAccruedLitigationSettlementExpense_198f4c90-b124-4555-b47d-4490917771bb" xlink:href="eols-20211231.xsd#eols_StockIssuedForAccruedLitigationSettlementExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e91f896b-d952-426b-be29-3a0df05512f9" xlink:to="loc_eols_StockIssuedForAccruedLitigationSettlementExpense_198f4c90-b124-4555-b47d-4490917771bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_35c76286-cfc6-44e3-af60-4db169aefb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e91f896b-d952-426b-be29-3a0df05512f9" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_35c76286-cfc6-44e3-af60-4db169aefb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="eols-20211231.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_603b3ca7-f0c0-4b4a-8b1b-24ac1fe98f59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0ad32417-a99e-40a7-8ebb-7c39491b259b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_603b3ca7-f0c0-4b4a-8b1b-24ac1fe98f59" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0ad32417-a99e-40a7-8ebb-7c39491b259b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d38e2819-7fce-4078-9251-aba535e6ce3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d38e2819-7fce-4078-9251-aba535e6ce3c" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_82a4039e-0415-4da5-9819-aa7e967a0626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:to="loc_us-gaap_DebtInstrumentAxis_82a4039e-0415-4da5-9819-aa7e967a0626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_08806e40-4694-4991-bf20-cd64749548a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_82a4039e-0415-4da5-9819-aa7e967a0626" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_08806e40-4694-4991-bf20-cd64749548a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember_dc6b7927-2d27-4925-b6a5-5f1e8eb1e336" xlink:href="eols-20211231.xsd#eols_PharmakonTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08806e40-4694-4991-bf20-cd64749548a4" xlink:to="loc_eols_PharmakonTermLoansMember_dc6b7927-2d27-4925-b6a5-5f1e8eb1e336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansOneMember_5be6f5a7-1ccf-42a8-ba4c-1b3296b28f80" xlink:href="eols-20211231.xsd#eols_PharmakonTermLoansOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_PharmakonTermLoansMember_dc6b7927-2d27-4925-b6a5-5f1e8eb1e336" xlink:to="loc_eols_PharmakonTermLoansOneMember_5be6f5a7-1ccf-42a8-ba4c-1b3296b28f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansTwoMember_f5531d2f-783f-4261-90d0-9a6bcf91cd1e" xlink:href="eols-20211231.xsd#eols_PharmakonTermLoansTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_PharmakonTermLoansMember_dc6b7927-2d27-4925-b6a5-5f1e8eb1e336" xlink:to="loc_eols_PharmakonTermLoansTwoMember_f5531d2f-783f-4261-90d0-9a6bcf91cd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoanFacilityMember_fc290760-4457-4074-b235-6ae179698ec4" xlink:href="eols-20211231.xsd#eols_OxfordTermLoanFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08806e40-4694-4991-bf20-cd64749548a4" xlink:to="loc_eols_OxfordTermLoanFacilityMember_fc290760-4457-4074-b235-6ae179698ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember_905bb1b6-5233-488c-b88f-7dca74240685" xlink:href="eols-20211231.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08806e40-4694-4991-bf20-cd64749548a4" xlink:to="loc_eols_DaewoongConvertibleNoteMember_905bb1b6-5233-488c-b88f-7dca74240685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d46bb640-94be-4613-ae2f-12d5ea2dfee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d46bb640-94be-4613-ae2f-12d5ea2dfee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0e9428bb-2bfb-4776-a736-af37b002f8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d46bb640-94be-4613-ae2f-12d5ea2dfee8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0e9428bb-2bfb-4776-a736-af37b002f8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_7412ee08-3a02-46d7-a6fc-70d1dc3439a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0e9428bb-2bfb-4776-a736-af37b002f8d5" xlink:to="loc_us-gaap_SecuredDebtMember_7412ee08-3a02-46d7-a6fc-70d1dc3439a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_dd9bfaa6-0b7b-461d-bfd0-b77e5980d036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0e9428bb-2bfb-4776-a736-af37b002f8d5" xlink:to="loc_us-gaap_ConvertibleDebtMember_dd9bfaa6-0b7b-461d-bfd0-b77e5980d036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_3155250c-cda5-4e8b-ab6c-8653074e9faa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:to="loc_srt_LitigationCaseAxis_3155250c-cda5-4e8b-ab6c-8653074e9faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_58df84b7-d2da-4499-b886-cfcab6f41507" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_3155250c-cda5-4e8b-ab6c-8653074e9faa" xlink:to="loc_srt_LitigationCaseTypeDomain_58df84b7-d2da-4499-b886-cfcab6f41507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_c8288448-afcc-4e49-87fa-d9c9ac6166c9" xlink:href="eols-20211231.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_58df84b7-d2da-4499-b886-cfcab6f41507" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_c8288448-afcc-4e49-87fa-d9c9ac6166c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_6b8d59c1-49a4-42cf-8374-fd7f8d585cb7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:to="loc_srt_StatementScenarioAxis_6b8d59c1-49a4-42cf-8374-fd7f8d585cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c96d1d38-4da6-4209-a446-98c21aa3f429" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_6b8d59c1-49a4-42cf-8374-fd7f8d585cb7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c96d1d38-4da6-4209-a446-98c21aa3f429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_8ed8ca42-1cf5-473e-b175-5926be87d686" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_c96d1d38-4da6-4209-a446-98c21aa3f429" xlink:to="loc_srt_ScenarioForecastMember_8ed8ca42-1cf5-473e-b175-5926be87d686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d15a51f8-b25e-48e6-acbf-da7cd5870f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d15a51f8-b25e-48e6-acbf-da7cd5870f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3cf59e62-e5ce-4870-99cd-365c824efabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d15a51f8-b25e-48e6-acbf-da7cd5870f2c" xlink:to="loc_us-gaap_EquityComponentDomain_3cf59e62-e5ce-4870-99cd-365c824efabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e6de6927-d8c3-43c1-96f8-0e183907ac9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3cf59e62-e5ce-4870-99cd-365c824efabf" xlink:to="loc_us-gaap_CommonStockMember_e6de6927-d8c3-43c1-96f8-0e183907ac9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9e30483c-3eca-463b-a68f-a2741cc5d7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9e30483c-3eca-463b-a68f-a2741cc5d7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_99a61639-2058-42b4-bd1a-dba3e260475e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9e30483c-3eca-463b-a68f-a2741cc5d7d3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_99a61639-2058-42b4-bd1a-dba3e260475e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PublicStockOfferingMember_fa27dad6-0394-4b41-b04d-41a4b386bf1f" xlink:href="eols-20211231.xsd#eols_PublicStockOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_99a61639-2058-42b4-bd1a-dba3e260475e" xlink:to="loc_eols_PublicStockOfferingMember_fa27dad6-0394-4b41-b04d-41a4b386bf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_803bc2d3-ef93-4749-b359-541ea1dc87f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_99a61639-2058-42b4-bd1a-dba3e260475e" xlink:to="loc_us-gaap_OverAllotmentOptionMember_803bc2d3-ef93-4749-b359-541ea1dc87f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember_770f3bd9-304f-4f60-86df-0a9edcec1e0a" xlink:href="eols-20211231.xsd#eols_ATMSalesAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_99a61639-2058-42b4-bd1a-dba3e260475e" xlink:to="loc_eols_ATMSalesAgreementMember_770f3bd9-304f-4f60-86df-0a9edcec1e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_02696257-b9db-4398-be22-da45b3630065" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b485d3ef-4e37-4b6a-bae2-9d2d16b9b977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b485d3ef-4e37-4b6a-bae2-9d2d16b9b977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0fd1715c-659f-4456-b36a-8b382fc72215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0fd1715c-659f-4456-b36a-8b382fc72215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0e2b76e8-1ff2-4ba3-9c85-40456402858f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0e2b76e8-1ff2-4ba3-9c85-40456402858f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_0e2d4620-cb1a-4127-897b-58a34e3f9314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_0e2d4620-cb1a-4127-897b-58a34e3f9314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_05b445a5-f1a0-43a9-b0db-1d146e329030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_05b445a5-f1a0-43a9-b0db-1d146e329030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_8ed82097-614e-4bfc-a701-8fb5ff13f145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_8ed82097-614e-4bfc-a701-8fb5ff13f145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_faeca765-7de8-48e7-941b-fad15a2ac734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_faeca765-7de8-48e7-941b-fad15a2ac734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_67995164-9b5f-4e9c-88f3-79700ba67986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_ConvertibleDebt_67995164-9b5f-4e9c-88f3-79700ba67986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_4900b193-ca22-45d8-b924-5fc10b9aeb22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_4900b193-ca22-45d8-b924-5fc10b9aeb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_213c7b21-787b-4466-9efc-b79fcddb88f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_213c7b21-787b-4466-9efc-b79fcddb88f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_bcdced65-7526-4451-848c-289cda7892f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_bcdced65-7526-4451-848c-289cda7892f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2285e90a-f7e1-4570-910c-15743c32ce98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97bb231c-02b8-4561-b2c8-f0dc37252066" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2285e90a-f7e1-4570-910c-15743c32ce98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="eols-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cb647d86-c7a8-4ebe-a87e-428b1be8302c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b91f7fb9-8d5a-43bc-8e99-549870511ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb647d86-c7a8-4ebe-a87e-428b1be8302c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b91f7fb9-8d5a-43bc-8e99-549870511ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="eols-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_87846d40-4460-4aa6-8a1c-ca5d2c46549e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_87846d40-4460-4aa6-8a1c-ca5d2c46549e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_72bf1985-5208-40b0-b70c-59d8b324db11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_72bf1985-5208-40b0-b70c-59d8b324db11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_86285f6a-fcd6-46a4-a33e-0dae2e5c0fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_UseOfEstimates_86285f6a-fcd6-46a4-a33e-0dae2e5c0fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_37db880d-14fc-42b3-b4f8-e7fbbdb615da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_37db880d-14fc-42b3-b4f8-e7fbbdb615da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_342d92e9-c533-419c-8d1d-875ba8262029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_342d92e9-c533-419c-8d1d-875ba8262029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5a84be7d-af77-41e7-951f-66c5bc75c561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5a84be7d-af77-41e7-951f-66c5bc75c561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_178f0ccb-fa25-4c1c-8ba5-4e017d1e9de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_178f0ccb-fa25-4c1c-8ba5-4e017d1e9de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_a4717c55-327d-4ae7-a802-64cb5d9a264c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_a4717c55-327d-4ae7-a802-64cb5d9a264c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_401536c2-e86d-4d3a-b548-c29aacf1f5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_401536c2-e86d-4d3a-b548-c29aacf1f5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3bedb15c-a825-4ea2-8480-e0cc6374edcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3bedb15c-a825-4ea2-8480-e0cc6374edcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6eaf5d50-4137-477a-b470-3a89570698d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6eaf5d50-4137-477a-b470-3a89570698d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_4a67b373-5192-44ac-bb89-eed9aa093607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_4a67b373-5192-44ac-bb89-eed9aa093607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_1619765d-2d41-4443-80a1-fd2a251f6b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_1619765d-2d41-4443-80a1-fd2a251f6b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1e4019f3-dc5c-425a-ae45-1f889a0de779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1e4019f3-dc5c-425a-ae45-1f889a0de779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_80f60a84-bbd0-4627-a2a0-9b8714be37c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_DebtPolicyTextBlock_80f60a84-bbd0-4627-a2a0-9b8714be37c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_49a5c928-7819-47e2-ac09-4bf9b2700a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_49a5c928-7819-47e2-ac09-4bf9b2700a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_73257f3d-2d10-493f-9ae3-c1bd7711215c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_73257f3d-2d10-493f-9ae3-c1bd7711215c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_03800e1a-2e89-44d5-b02f-cd3b630f22bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_03800e1a-2e89-44d5-b02f-cd3b630f22bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_8e30453c-c92a-440d-a59e-c57695246214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_8e30453c-c92a-440d-a59e-c57695246214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_c9f8607d-fda2-4297-8941-cd1334998a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_c9f8607d-fda2-4297-8941-cd1334998a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_799eca47-54ff-40be-95e0-4bcb930d3a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_799eca47-54ff-40be-95e0-4bcb930d3a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_19d28524-7e86-49ef-afcc-d0b8047ccfd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a26f70f-776b-4fd9-851a-fa2add0503ca" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_19d28524-7e86-49ef-afcc-d0b8047ccfd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_14521fd8-c7a5-42ad-99c4-988de386e7db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14521fd8-c7a5-42ad-99c4-988de386e7db" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ad036a1-a37c-4418-8109-364a40933c76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ad036a1-a37c-4418-8109-364a40933c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2d415bf-9ecc-4524-8865-3ad0867f6a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ad036a1-a37c-4418-8109-364a40933c76" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2d415bf-9ecc-4524-8865-3ad0867f6a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_cc128f08-7205-4b16-95e7-2286571d376a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2d415bf-9ecc-4524-8865-3ad0867f6a85" xlink:to="loc_us-gaap_DistributionRightsMember_cc128f08-7205-4b16-95e7-2286571d376a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_84d0b154-2fb9-4502-87d2-26f9fc1cb939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2d415bf-9ecc-4524-8865-3ad0867f6a85" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_84d0b154-2fb9-4502-87d2-26f9fc1cb939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_521ba40d-da18-49ab-b2f9-09e790c31280" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:to="loc_srt_ProductOrServiceAxis_521ba40d-da18-49ab-b2f9-09e790c31280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6eb01643-121c-4d14-b524-a7a38b4e284b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_521ba40d-da18-49ab-b2f9-09e790c31280" xlink:to="loc_srt_ProductsAndServicesDomain_6eb01643-121c-4d14-b524-a7a38b4e284b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_de98db7a-fbf1-4bdb-9662-9b41642d0d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6eb01643-121c-4d14-b524-a7a38b4e284b" xlink:to="loc_us-gaap_ServiceMember_de98db7a-fbf1-4bdb-9662-9b41642d0d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_57eaf90d-87d8-4b07-be64-742e5ed80bd7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:to="loc_srt_StatementGeographicalAxis_57eaf90d-87d8-4b07-be64-742e5ed80bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9204c6be-38ba-4f8a-9420-8535f43dd970" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_57eaf90d-87d8-4b07-be64-742e5ed80bd7" xlink:to="loc_srt_SegmentGeographicalDomain_9204c6be-38ba-4f8a-9420-8535f43dd970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_c25aaa81-30cf-4929-9343-f8a155d035a0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9204c6be-38ba-4f8a-9420-8535f43dd970" xlink:to="loc_country_CA_c25aaa81-30cf-4929-9343-f8a155d035a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_94496524-edec-4f0c-a32c-bb124398242b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:to="loc_srt_LitigationCaseAxis_94496524-edec-4f0c-a32c-bb124398242b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1f99f95d-49cd-46ea-b56f-d334e5b6a3d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_94496524-edec-4f0c-a32c-bb124398242b" xlink:to="loc_srt_LitigationCaseTypeDomain_1f99f95d-49cd-46ea-b56f-d334e5b6a3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_bc0dfab6-752f-4a8d-aa8f-b55bd081eb5c" xlink:href="eols-20211231.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1f99f95d-49cd-46ea-b56f-d334e5b6a3d3" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_bc0dfab6-752f-4a8d-aa8f-b55bd081eb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_db7b2742-9790-4882-bf01-684a5f094fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_db7b2742-9790-4882-bf01-684a5f094fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9e93f307-9ba7-4b3e-97a1-bd0384f8d8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_db7b2742-9790-4882-bf01-684a5f094fd5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9e93f307-9ba7-4b3e-97a1-bd0384f8d8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f048ea0b-07cb-4c3b-b66c-c620ed4830d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9e93f307-9ba7-4b3e-97a1-bd0384f8d8a5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f048ea0b-07cb-4c3b-b66c-c620ed4830d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_05090499-dc28-4f9e-a97a-f2edbaa3009e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9e93f307-9ba7-4b3e-97a1-bd0384f8d8a5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_05090499-dc28-4f9e-a97a-f2edbaa3009e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_f91ae7cf-4e85-4314-bb59-54978698005f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9e93f307-9ba7-4b3e-97a1-bd0384f8d8a5" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_f91ae7cf-4e85-4314-bb59-54978698005f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_05d08318-0666-4ed8-abe2-0ffa595de280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_05d08318-0666-4ed8-abe2-0ffa595de280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b474b294-4a4d-4245-9fc1-dd555b91227b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_05d08318-0666-4ed8-abe2-0ffa595de280" xlink:to="loc_us-gaap_EquityComponentDomain_b474b294-4a4d-4245-9fc1-dd555b91227b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_33d00d0a-c26f-4d91-8289-c9dcf1b7e14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b474b294-4a4d-4245-9fc1-dd555b91227b" xlink:to="loc_us-gaap_CommonStockMember_33d00d0a-c26f-4d91-8289-c9dcf1b7e14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b37039bb-82e0-4b54-8440-aba3ce2daf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b37039bb-82e0-4b54-8440-aba3ce2daf4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_58d473bb-c3e1-49ff-a4e0-0a2de005e5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b37039bb-82e0-4b54-8440-aba3ce2daf4b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_58d473bb-c3e1-49ff-a4e0-0a2de005e5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_77af8b03-24a4-4e1d-a55f-c149e0e3e4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_58d473bb-c3e1-49ff-a4e0-0a2de005e5c7" xlink:to="loc_us-gaap_SubsequentEventMember_77af8b03-24a4-4e1d-a55f-c149e0e3e4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c67d99e9-e0d1-453b-9c7f-ecbfd321d484" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a1e3d615-875d-4f72-9cf6-7663a2c9f56e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a1e3d615-875d-4f72-9cf6-7663a2c9f56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_86c10ded-2fa1-4fdc-a906-45b51c9d27c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_86c10ded-2fa1-4fdc-a906-45b51c9d27c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_815ccd92-03e2-46a0-b03a-dcc33a349717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_NumberOfReportingUnits_815ccd92-03e2-46a0-b03a-dcc33a349717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_22d88094-22db-41d6-98ae-4308e5cc974f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_22d88094-22db-41d6-98ae-4308e5cc974f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_92df7994-3579-4348-8bb1-0ce01f55c4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_92df7994-3579-4348-8bb1-0ce01f55c4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c28973fb-4ce0-41bb-ab14-a828e33ff355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c28973fb-4ce0-41bb-ab14-a828e33ff355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6e9eae7-f637-4e06-88fc-6f09f55b2b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6e9eae7-f637-4e06-88fc-6f09f55b2b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9c340023-2bdb-4c49-8798-0bf40fc87923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9c340023-2bdb-4c49-8798-0bf40fc87923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RebatesAndCouponsCreditsAndPayments_b578b421-cc23-4f56-8049-3a7a07d8018b" xlink:href="eols-20211231.xsd#eols_RebatesAndCouponsCreditsAndPayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_eols_RebatesAndCouponsCreditsAndPayments_b578b421-cc23-4f56-8049-3a7a07d8018b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_7e868094-0923-4045-b201-26fc8b7bb2bf" xlink:href="eols-20211231.xsd#eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_7e868094-0923-4045-b201-26fc8b7bb2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d37a4d09-e119-4beb-9a55-af069fd54e67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d37a4d09-e119-4beb-9a55-af069fd54e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4ed73c4d-3470-47a3-8a07-519fd1f3806a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4ed73c4d-3470-47a3-8a07-519fd1f3806a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementPaymentTerms_f92d14cc-418d-415a-a356-d7f953a7da1f" xlink:href="eols-20211231.xsd#eols_LossContingencySettlementAgreementPaymentTerms"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_eols_LossContingencySettlementAgreementPaymentTerms_f92d14cc-418d-415a-a356-d7f953a7da1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_f7daf08c-fe0b-4fce-90c9-72aa431bc8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_f7daf08c-fe0b-4fce-90c9-72aa431bc8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_16b109d7-3371-4bc9-8769-93e7bf9dfa15" xlink:href="eols-20211231.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_16b109d7-3371-4bc9-8769-93e7bf9dfa15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_66212cf5-2570-4adf-af31-9036027e9d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_LitigationSettlementExpense_66212cf5-2570-4adf-af31-9036027e9d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_ad4b609b-ee48-4b4d-b377-d4dae62c879a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_ad4b609b-ee48-4b4d-b377-d4dae62c879a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_577bc199-0379-410f-a605-286ffc00ec5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_LitigationReserveCurrent_577bc199-0379-410f-a605-286ffc00ec5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent_8876942f-a93d-4a71-8741-011ae27e2f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_LitigationReserveNoncurrent_8876942f-a93d-4a71-8741-011ae27e2f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_2196d874-0864-4646-9ac2-5009b073ec1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_AdvertisingExpense_2196d874-0864-4646-9ac2-5009b073ec1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_737ccd5c-cb8c-4cce-b54c-6abd344d9378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_737ccd5c-cb8c-4cce-b54c-6abd344d9378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_c289bf3f-fc8f-41db-a9a1-270427c62ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_c289bf3f-fc8f-41db-a9a1-270427c62ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_7bb02905-a1d9-4393-b1c2-719e4441e201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_7bb02905-a1d9-4393-b1c2-719e4441e201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_d251ce02-7e1e-4268-b559-9b46d86dab7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a9529b01-b944-4716-a99a-acfb632b5d05" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_d251ce02-7e1e-4268-b559-9b46d86dab7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestments" xlink:type="simple" xlink:href="eols-20211231.xsd#FairValueMeasurementsandShortTermInvestments"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5bfad804-290d-4ed9-b8b2-bef92f7d27f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_efb0e2e9-24c6-4701-b47b-eafc62e98ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5bfad804-290d-4ed9-b8b2-bef92f7d27f2" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_efb0e2e9-24c6-4701-b47b-eafc62e98ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables" xlink:type="simple" xlink:href="eols-20211231.xsd#FairValueMeasurementsandShortTermInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_341532df-9c90-48d2-b449-14f8c2a9ffbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_f55b1295-5f48-4a62-954e-e548dfe3dbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_341532df-9c90-48d2-b449-14f8c2a9ffbd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_f55b1295-5f48-4a62-954e-e548dfe3dbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9eb71be0-4cad-4c86-9b9e-9ccf38aa8f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_341532df-9c90-48d2-b449-14f8c2a9ffbd" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9eb71be0-4cad-4c86-9b9e-9ccf38aa8f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1db3633c-84a6-431f-a24d-e0484d641169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_341532df-9c90-48d2-b449-14f8c2a9ffbd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1db3633c-84a6-431f-a24d-e0484d641169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2b8e95f6-94a8-442b-a8a1-b2e062d84f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_94236bb5-add9-4e8c-bcaa-74be8141f5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2b8e95f6-94a8-442b-a8a1-b2e062d84f48" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_94236bb5-add9-4e8c-bcaa-74be8141f5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_513e55b9-e205-495c-9546-623f71de62af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_94236bb5-add9-4e8c-bcaa-74be8141f5e1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_513e55b9-e205-495c-9546-623f71de62af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_312a99a5-4939-4a46-ba1d-aa7b0aaa7fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_513e55b9-e205-495c-9546-623f71de62af" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_312a99a5-4939-4a46-ba1d-aa7b0aaa7fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_25e00e43-b3f6-4eab-8a64-0794cfff4326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_312a99a5-4939-4a46-ba1d-aa7b0aaa7fb8" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_25e00e43-b3f6-4eab-8a64-0794cfff4326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_359fcbcf-29be-49a7-9f61-0a487bc71a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_94236bb5-add9-4e8c-bcaa-74be8141f5e1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_359fcbcf-29be-49a7-9f61-0a487bc71a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_28bd5def-8786-4e5c-af7c-315ff8f16692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_359fcbcf-29be-49a7-9f61-0a487bc71a0e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_28bd5def-8786-4e5c-af7c-315ff8f16692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_5d325b14-b013-4df7-963d-0a84a003ec39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_359fcbcf-29be-49a7-9f61-0a487bc71a0e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_5d325b14-b013-4df7-963d-0a84a003ec39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_55e7d225-ec5d-42e4-97c5-af1beccc387e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_5d325b14-b013-4df7-963d-0a84a003ec39" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_55e7d225-ec5d-42e4-97c5-af1beccc387e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9fb2f897-f777-456d-8f4b-4e7a097714ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_5d325b14-b013-4df7-963d-0a84a003ec39" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9fb2f897-f777-456d-8f4b-4e7a097714ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_963ec34c-8a54-4946-9269-279937429394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_359fcbcf-29be-49a7-9f61-0a487bc71a0e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_963ec34c-8a54-4946-9269-279937429394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7a1cd8c2-a348-45aa-9123-7285f1cee45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13cb814-3384-4ec0-90e4-a4f953523799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7a1cd8c2-a348-45aa-9123-7285f1cee45c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13cb814-3384-4ec0-90e4-a4f953523799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_af29459a-cb8a-46cb-93fc-df25a4557f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13cb814-3384-4ec0-90e4-a4f953523799" xlink:to="loc_us-gaap_FinancialInstrumentAxis_af29459a-cb8a-46cb-93fc-df25a4557f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ba1f23-0fa0-44c7-b170-4481d575078b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_af29459a-cb8a-46cb-93fc-df25a4557f7d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ba1f23-0fa0-44c7-b170-4481d575078b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationMember_a458b1d8-cc53-40b2-b501-ce0bd6c7f176" xlink:href="eols-20211231.xsd#eols_ContingentRoyaltyObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ba1f23-0fa0-44c7-b170-4481d575078b" xlink:to="loc_eols_ContingentRoyaltyObligationMember_a458b1d8-cc53-40b2-b501-ce0bd6c7f176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_49b05173-9437-41fa-b435-fad38ed91bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13cb814-3384-4ec0-90e4-a4f953523799" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_49b05173-9437-41fa-b435-fad38ed91bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_19aa8b69-4b0c-49b5-90c7-5664937b3f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_49b05173-9437-41fa-b435-fad38ed91bcc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_19aa8b69-4b0c-49b5-90c7-5664937b3f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_d77ee66c-341e-4a46-be87-cf49fd38b7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_19aa8b69-4b0c-49b5-90c7-5664937b3f36" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_d77ee66c-341e-4a46-be87-cf49fd38b7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_7ea2f98e-3904-434e-8a11-2dc543942848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_19aa8b69-4b0c-49b5-90c7-5664937b3f36" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_7ea2f98e-3904-434e-8a11-2dc543942848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_77f193e9-26b8-46dc-bd0b-d7998a721377" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13cb814-3384-4ec0-90e4-a4f953523799" xlink:to="loc_srt_RangeAxis_77f193e9-26b8-46dc-bd0b-d7998a721377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b8a4126f-14b5-4dde-8a4d-f58805bbd691" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_77f193e9-26b8-46dc-bd0b-d7998a721377" xlink:to="loc_srt_RangeMember_b8a4126f-14b5-4dde-8a4d-f58805bbd691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2ec936dd-3c3a-45f1-be24-3f3387a9558f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b8a4126f-14b5-4dde-8a4d-f58805bbd691" xlink:to="loc_srt_MinimumMember_2ec936dd-3c3a-45f1-be24-3f3387a9558f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d66aec6c-1641-4cfb-a326-70c7a91d6816" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b8a4126f-14b5-4dde-8a4d-f58805bbd691" xlink:to="loc_srt_MaximumMember_d66aec6c-1641-4cfb-a326-70c7a91d6816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f97d0675-d18d-427e-bf65-349663e47ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13cb814-3384-4ec0-90e4-a4f953523799" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f97d0675-d18d-427e-bf65-349663e47ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_d6390ecc-fcbc-4113-956d-5a6ec2c79788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f97d0675-d18d-427e-bf65-349663e47ee5" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_d6390ecc-fcbc-4113-956d-5a6ec2c79788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_1334088e-a1c4-4151-bf92-e6ddd1d28751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f97d0675-d18d-427e-bf65-349663e47ee5" xlink:to="loc_us-gaap_LongTermDebtFairValue_1334088e-a1c4-4151-bf92-e6ddd1d28751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_904902b4-aaf6-4707-9414-232cbcc927c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f97d0675-d18d-427e-bf65-349663e47ee5" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_904902b4-aaf6-4707-9414-232cbcc927c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d898ab8f-1220-4cfd-8bf6-47bbbc08d814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_373b48d7-800a-4801-94b4-9177bb2f5d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d898ab8f-1220-4cfd-8bf6-47bbbc08d814" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_373b48d7-800a-4801-94b4-9177bb2f5d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_bba24dd7-80f0-4bdb-9df2-0199a3b64cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_373b48d7-800a-4801-94b4-9177bb2f5d72" xlink:to="loc_us-gaap_FinancialInstrumentAxis_bba24dd7-80f0-4bdb-9df2-0199a3b64cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6bd4556-bbad-41fd-86fd-d4c63c0c55d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bba24dd7-80f0-4bdb-9df2-0199a3b64cec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6bd4556-bbad-41fd-86fd-d4c63c0c55d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_4af09519-e22f-4f3c-b98f-da182cb4d6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6bd4556-bbad-41fd-86fd-d4c63c0c55d4" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_4af09519-e22f-4f3c-b98f-da182cb4d6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5af72043-6c2a-4dad-9fe9-b51e08ab9cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6bd4556-bbad-41fd-86fd-d4c63c0c55d4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5af72043-6c2a-4dad-9fe9-b51e08ab9cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_478e09c9-05c5-4e0c-8378-70f2add0c838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_373b48d7-800a-4801-94b4-9177bb2f5d72" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_478e09c9-05c5-4e0c-8378-70f2add0c838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_373042fb-f1da-4acd-bd25-ab2020a4c8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_478e09c9-05c5-4e0c-8378-70f2add0c838" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_373042fb-f1da-4acd-bd25-ab2020a4c8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_63f340a3-e79e-4861-b93f-08f02b672994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_373042fb-f1da-4acd-bd25-ab2020a4c8ac" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_63f340a3-e79e-4861-b93f-08f02b672994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f82eaf96-59d8-40b1-b04c-88c913c0645f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_373042fb-f1da-4acd-bd25-ab2020a4c8ac" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f82eaf96-59d8-40b1-b04c-88c913c0645f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5359fb8b-1630-40e4-bda0-359d8c37b76a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_373042fb-f1da-4acd-bd25-ab2020a4c8ac" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5359fb8b-1630-40e4-bda0-359d8c37b76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56ec7f05-f90a-4ebc-b2c8-d386590a5bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_373b48d7-800a-4801-94b4-9177bb2f5d72" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56ec7f05-f90a-4ebc-b2c8-d386590a5bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4bffa439-4337-4388-a026-c475e87c3c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56ec7f05-f90a-4ebc-b2c8-d386590a5bab" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4bffa439-4337-4388-a026-c475e87c3c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_f8a1dc14-7dd1-445f-9574-32493e5af84e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56ec7f05-f90a-4ebc-b2c8-d386590a5bab" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_f8a1dc14-7dd1-445f-9574-32493e5af84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#FairValueMeasurementsandShortTermInvestmentsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f137b07e-ec09-4b82-99d4-febae72716ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d083e814-4276-4689-bc5e-d7a8772e6b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f137b07e-ec09-4b82-99d4-febae72716ec" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d083e814-4276-4689-bc5e-d7a8772e6b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_538e1db3-6b69-4919-9012-45a7f713bdb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d083e814-4276-4689-bc5e-d7a8772e6b4f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_538e1db3-6b69-4919-9012-45a7f713bdb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_ceab4b01-83f3-4209-ab8d-5fcb0fd94c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d083e814-4276-4689-bc5e-d7a8772e6b4f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_ceab4b01-83f3-4209-ab8d-5fcb0fd94c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2b595fc4-d0a7-46e3-9023-902949fb4627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d083e814-4276-4689-bc5e-d7a8772e6b4f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2b595fc4-d0a7-46e3-9023-902949fb4627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_94c3da26-ada4-46b6-a874-23e4aad5b06e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d083e814-4276-4689-bc5e-d7a8772e6b4f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_94c3da26-ada4-46b6-a874-23e4aad5b06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="eols-20211231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e6b620c8-9b2c-4f95-a25b-3f8fa9e6809e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6dc2779b-de8c-48b9-ac2e-a10a28fd743f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e6b620c8-9b2c-4f95-a25b-3f8fa9e6809e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6dc2779b-de8c-48b9-ac2e-a10a28fd743f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="eols-20211231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2f0865a7-232d-4b79-9160-a36c4506c5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_456fc4b3-1c1a-45e2-991a-6ac3dafffd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2f0865a7-232d-4b79-9160-a36c4506c5e1" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_456fc4b3-1c1a-45e2-991a-6ac3dafffd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_bd0585f8-b4bd-48e0-ba1c-d0960bbf8a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2f0865a7-232d-4b79-9160-a36c4506c5e1" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_bd0585f8-b4bd-48e0-ba1c-d0960bbf8a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_45faabca-949f-472a-9d2f-68c74c55c89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2c13124-6342-4582-a76e-15fb09c6a6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_45faabca-949f-472a-9d2f-68c74c55c89c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2c13124-6342-4582-a76e-15fb09c6a6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ceb2123a-9d65-4cff-b7ae-2e89c2f8322d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2c13124-6342-4582-a76e-15fb09c6a6b5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ceb2123a-9d65-4cff-b7ae-2e89c2f8322d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4786217-9569-46ab-97ee-519b1b0129db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ceb2123a-9d65-4cff-b7ae-2e89c2f8322d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4786217-9569-46ab-97ee-519b1b0129db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_da7b59f5-397a-48d0-ac09-4841ebc8925a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4786217-9569-46ab-97ee-519b1b0129db" xlink:to="loc_us-gaap_DistributionRightsMember_da7b59f5-397a-48d0-ac09-4841ebc8925a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_b3160714-0f61-405f-81f8-74855cb11c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4786217-9569-46ab-97ee-519b1b0129db" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_b3160714-0f61-405f-81f8-74855cb11c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e1595cf-c55f-461f-9bf3-568f264820c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2c13124-6342-4582-a76e-15fb09c6a6b5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e1595cf-c55f-461f-9bf3-568f264820c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_189936d0-c883-43ca-8cf3-a359a0ebf395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e1595cf-c55f-461f-9bf3-568f264820c2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_189936d0-c883-43ca-8cf3-a359a0ebf395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d24ed215-6678-40d8-a281-af577a76e91e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_189936d0-c883-43ca-8cf3-a359a0ebf395" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d24ed215-6678-40d8-a281-af577a76e91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2c649b51-2333-4f59-9a11-6c15bacea61f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_189936d0-c883-43ca-8cf3-a359a0ebf395" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2c649b51-2333-4f59-9a11-6c15bacea61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2e837995-3c8b-4b7e-8eb9-2d47f727cc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_189936d0-c883-43ca-8cf3-a359a0ebf395" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2e837995-3c8b-4b7e-8eb9-2d47f727cc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce6ce3f8-5f19-48a7-93e7-981440930d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_189936d0-c883-43ca-8cf3-a359a0ebf395" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce6ce3f8-5f19-48a7-93e7-981440930d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_681094f5-6833-4608-883c-6c63bd5d8f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e1595cf-c55f-461f-9bf3-568f264820c2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_681094f5-6833-4608-883c-6c63bd5d8f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c209adac-c557-4333-a26a-e7ae0e01b6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_681094f5-6833-4608-883c-6c63bd5d8f54" xlink:to="loc_us-gaap_Goodwill_c209adac-c557-4333-a26a-e7ae0e01b6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_43214a15-8b17-415a-8729-cc2b8ad53cbe" xlink:href="eols-20211231.xsd#eols_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e1595cf-c55f-461f-9bf3-568f264820c2" xlink:to="loc_eols_IntangibleAssetsGrossIncludingGoodwill_43214a15-8b17-415a-8729-cc2b8ad53cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_9949469a-d97b-4006-bfdf-ac2994914bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7e1595cf-c55f-461f-9bf3-568f264820c2" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_9949469a-d97b-4006-bfdf-ac2994914bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3349de08-033d-49a4-a9c6-bc832f5554e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2859b1ba-1af3-4369-a82c-564188d25d91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3349de08-033d-49a4-a9c6-bc832f5554e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2859b1ba-1af3-4369-a82c-564188d25d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_780dc6f3-452d-4355-93d7-38b168f8a2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3349de08-033d-49a4-a9c6-bc832f5554e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_780dc6f3-452d-4355-93d7-38b168f8a2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e2ebc0c0-fb3f-4e92-a2c2-7d25aae58cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3349de08-033d-49a4-a9c6-bc832f5554e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e2ebc0c0-fb3f-4e92-a2c2-7d25aae58cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_03ef7da2-29db-4f9c-88ea-2fed49d1e086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3349de08-033d-49a4-a9c6-bc832f5554e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_03ef7da2-29db-4f9c-88ea-2fed49d1e086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fe21e611-26bd-4333-807e-df64c5b4923b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3349de08-033d-49a4-a9c6-bc832f5554e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fe21e611-26bd-4333-807e-df64c5b4923b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_c8e1a966-f147-4bd5-ba09-38574247de56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3349de08-033d-49a4-a9c6-bc832f5554e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_c8e1a966-f147-4bd5-ba09-38574247de56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8f504ff7-2555-4c09-a398-23f4cc7944c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3349de08-033d-49a4-a9c6-bc832f5554e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8f504ff7-2555-4c09-a398-23f4cc7944c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4f868dd3-d9e5-4169-9e9d-8217210f8671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d34c51d5-30c4-4c5e-a571-e009ad29e135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4f868dd3-d9e5-4169-9e9d-8217210f8671" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d34c51d5-30c4-4c5e-a571-e009ad29e135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f3bfeb83-61f2-4e18-b773-30cd1722395a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d34c51d5-30c4-4c5e-a571-e009ad29e135" xlink:to="loc_dei_LegalEntityAxis_f3bfeb83-61f2-4e18-b773-30cd1722395a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_730c4b32-b9f7-4b7d-a1b4-037b5045e931" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f3bfeb83-61f2-4e18-b773-30cd1722395a" xlink:to="loc_dei_EntityDomain_730c4b32-b9f7-4b7d-a1b4-037b5045e931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SCHAEONLLCMember_355e51c0-4ba8-4bba-97c0-977c4ef3fb24" xlink:href="eols-20211231.xsd#eols_SCHAEONLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_730c4b32-b9f7-4b7d-a1b4-037b5045e931" xlink:to="loc_eols_SCHAEONLLCMember_355e51c0-4ba8-4bba-97c0-977c4ef3fb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_010b0505-bde8-4f42-9bd5-07bb5b2c9632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d34c51d5-30c4-4c5e-a571-e009ad29e135" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_010b0505-bde8-4f42-9bd5-07bb5b2c9632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee5495e5-37e3-47c4-8602-087fb9e9a3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_010b0505-bde8-4f42-9bd5-07bb5b2c9632" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee5495e5-37e3-47c4-8602-087fb9e9a3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EvolusIncMember_9bb9b91a-31d0-4c9a-80c3-50d56593ffe2" xlink:href="eols-20211231.xsd#eols_EvolusIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee5495e5-37e3-47c4-8602-087fb9e9a3f2" xlink:to="loc_eols_EvolusIncMember_9bb9b91a-31d0-4c9a-80c3-50d56593ffe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81c92707-16ef-4c7c-a977-9d099701028b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d34c51d5-30c4-4c5e-a571-e009ad29e135" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81c92707-16ef-4c7c-a977-9d099701028b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bb49d3f0-f55a-4def-9f44-23ae6d0fd3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81c92707-16ef-4c7c-a977-9d099701028b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bb49d3f0-f55a-4def-9f44-23ae6d0fd3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_28afc2c6-3cb2-4004-9a5c-f2217ed15258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bb49d3f0-f55a-4def-9f44-23ae6d0fd3a6" xlink:to="loc_us-gaap_DistributionRightsMember_28afc2c6-3cb2-4004-9a5c-f2217ed15258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_a9e6954b-a3e5-4dd5-aa7d-d6660caa4343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bb49d3f0-f55a-4def-9f44-23ae6d0fd3a6" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_a9e6954b-a3e5-4dd5-aa7d-d6660caa4343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d34c51d5-30c4-4c5e-a571-e009ad29e135" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_4fc28036-7de3-4091-b6cf-13d689c67de1" xlink:href="eols-20211231.xsd#eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:to="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_4fc28036-7de3-4091-b6cf-13d689c67de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0d9d610e-c0c3-4bfa-922d-7f2c74efc195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0d9d610e-c0c3-4bfa-922d-7f2c74efc195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets_5edb96a5-916c-4007-9d7d-84e8f77af635" xlink:href="eols-20211231.xsd#eols_MilestonePaymentsForIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:to="loc_eols_MilestonePaymentsForIntangibleAssets_5edb96a5-916c-4007-9d7d-84e8f77af635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_f05f3da6-a813-48c7-befc-7cb4b38725b8" xlink:href="eols-20211231.xsd#eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:to="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_f05f3da6-a813-48c7-befc-7cb4b38725b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_92d5c3e5-771f-46a8-a7c0-0599180e2fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_92d5c3e5-771f-46a8-a7c0-0599180e2fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8fe0719c-44d9-425f-988d-c7c265371028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8fe0719c-44d9-425f-988d-c7c265371028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_00b892a2-9a7d-487e-bbb3-f5dde791b464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6388ca5-a9e7-4e73-abd3-ffc50f90a249" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_00b892a2-9a7d-487e-bbb3-f5dde791b464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpenses" xlink:type="simple" xlink:href="eols-20211231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_14a92e93-9be7-4f62-8de7-2f9748c56735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_12b194f6-d6ad-4f89-83be-a06fc791c838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_14a92e93-9be7-4f62-8de7-2f9748c56735" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_12b194f6-d6ad-4f89-83be-a06fc791c838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="eols-20211231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_f209ae67-56e9-4b26-954a-f1e504de53c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_cc439bf0-f7fc-4b2d-b3c2-f5c3eeecd31b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f209ae67-56e9-4b26-954a-f1e504de53c3" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_cc439bf0-f7fc-4b2d-b3c2-f5c3eeecd31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_66c62ac2-7999-471e-ba91-7ba94f8bf49d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_99bf63ad-679c-43b6-be07-74d3dc2a8f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_66c62ac2-7999-471e-ba91-7ba94f8bf49d" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_99bf63ad-679c-43b6-be07-74d3dc2a8f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_53ac48da-9abe-4e21-945d-6fdd97b7d24c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_66c62ac2-7999-471e-ba91-7ba94f8bf49d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_53ac48da-9abe-4e21-945d-6fdd97b7d24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1cf28b00-67d8-4d33-96f3-680d96c248ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_66c62ac2-7999-471e-ba91-7ba94f8bf49d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1cf28b00-67d8-4d33-96f3-680d96c248ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_67d8e7fb-8784-44d9-ab8f-ab85a43f2184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_66c62ac2-7999-471e-ba91-7ba94f8bf49d" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_67d8e7fb-8784-44d9-ab8f-ab85a43f2184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_583243b1-b241-4179-84c5-9d14f0eccb22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_66c62ac2-7999-471e-ba91-7ba94f8bf49d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_583243b1-b241-4179-84c5-9d14f0eccb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_34229593-8df6-42d7-9482-1a826056cb14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_66c62ac2-7999-471e-ba91-7ba94f8bf49d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_34229593-8df6-42d7-9482-1a826056cb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoans" xlink:type="simple" xlink:href="eols-20211231.xsd#TermLoans"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/TermLoans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0b34374b-0045-47cf-8c03-dc528cfeb145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4983b4db-02e4-42f0-9492-5018ce003dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0b34374b-0045-47cf-8c03-dc528cfeb145" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4983b4db-02e4-42f0-9492-5018ce003dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansTables" xlink:type="simple" xlink:href="eols-20211231.xsd#TermLoansTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/TermLoansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5eb0530c-9e7d-4503-94cd-1bfed1a42547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ffe5ba31-9eba-4633-b6e1-6eb882553fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5eb0530c-9e7d-4503-94cd-1bfed1a42547" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ffe5ba31-9eba-4633-b6e1-6eb882553fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#TermLoansPharmakonTermLoansDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_088538ee-a6f2-49f4-a2f7-6c501714ad2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d82c8d00-1f39-4a80-902b-aa6af1bdcf59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_088538ee-a6f2-49f4-a2f7-6c501714ad2f" xlink:to="loc_us-gaap_DebtInstrumentTable_d82c8d00-1f39-4a80-902b-aa6af1bdcf59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0d5e6cf2-adba-4ac6-b57d-4b1e5af8e963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d82c8d00-1f39-4a80-902b-aa6af1bdcf59" xlink:to="loc_us-gaap_DebtInstrumentAxis_0d5e6cf2-adba-4ac6-b57d-4b1e5af8e963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_90d8e173-1a00-4856-b588-fbd2b4389040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0d5e6cf2-adba-4ac6-b57d-4b1e5af8e963" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_90d8e173-1a00-4856-b588-fbd2b4389040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember_fbe15f0f-042a-45ab-8ca1-3b182d45c759" xlink:href="eols-20211231.xsd#eols_PharmakonTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90d8e173-1a00-4856-b588-fbd2b4389040" xlink:to="loc_eols_PharmakonTermLoansMember_fbe15f0f-042a-45ab-8ca1-3b182d45c759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansOneMember_5ce152ee-66a3-45d3-8cae-047dfeda9513" xlink:href="eols-20211231.xsd#eols_PharmakonTermLoansOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_PharmakonTermLoansMember_fbe15f0f-042a-45ab-8ca1-3b182d45c759" xlink:to="loc_eols_PharmakonTermLoansOneMember_5ce152ee-66a3-45d3-8cae-047dfeda9513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansTwoMember_9b375eab-5846-4ae9-a38d-7aacf47379c8" xlink:href="eols-20211231.xsd#eols_PharmakonTermLoansTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_PharmakonTermLoansMember_fbe15f0f-042a-45ab-8ca1-3b182d45c759" xlink:to="loc_eols_PharmakonTermLoansTwoMember_9b375eab-5846-4ae9-a38d-7aacf47379c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_000ce50b-2c9b-478a-a987-e9cb3fca37ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d82c8d00-1f39-4a80-902b-aa6af1bdcf59" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_000ce50b-2c9b-478a-a987-e9cb3fca37ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4b99d9ec-8829-4410-b971-f60feb36dd82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_000ce50b-2c9b-478a-a987-e9cb3fca37ef" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4b99d9ec-8829-4410-b971-f60feb36dd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_44f7cb71-f4ce-476a-8dd0-0cd9273bd479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4b99d9ec-8829-4410-b971-f60feb36dd82" xlink:to="loc_us-gaap_SecuredDebtMember_44f7cb71-f4ce-476a-8dd0-0cd9273bd479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_4af9d195-131b-48c3-9e13-02e81576be89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d82c8d00-1f39-4a80-902b-aa6af1bdcf59" xlink:to="loc_us-gaap_VariableRateAxis_4af9d195-131b-48c3-9e13-02e81576be89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b1e7c9de-8073-471b-9588-b1dae79d836c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_4af9d195-131b-48c3-9e13-02e81576be89" xlink:to="loc_us-gaap_VariableRateDomain_b1e7c9de-8073-471b-9588-b1dae79d836c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7ab095b1-0081-4c91-92ce-4cafa99ce0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_b1e7c9de-8073-471b-9588-b1dae79d836c" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7ab095b1-0081-4c91-92ce-4cafa99ce0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsAxis_23d7808c-bb9a-41d6-aab4-a9b1508a4b25" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentTermsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d82c8d00-1f39-4a80-902b-aa6af1bdcf59" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsAxis_23d7808c-bb9a-41d6-aab4-a9b1508a4b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsDomain_298610be-b3fe-491e-822d-a145534a80c1" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentTermsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsAxis_23d7808c-bb9a-41d6-aab4-a9b1508a4b25" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsDomain_298610be-b3fe-491e-822d-a145534a80c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermOneMember_d128b6e3-0292-431c-8e3b-6ef21eba3afc" xlink:href="eols-20211231.xsd#eols_TermOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_298610be-b3fe-491e-822d-a145534a80c1" xlink:to="loc_eols_TermOneMember_d128b6e3-0292-431c-8e3b-6ef21eba3afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermTwoMember_b541d645-ea31-4ed1-b28b-af0402f43248" xlink:href="eols-20211231.xsd#eols_TermTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_298610be-b3fe-491e-822d-a145534a80c1" xlink:to="loc_eols_TermTwoMember_b541d645-ea31-4ed1-b28b-af0402f43248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermThreeMember_187355af-9dfd-46eb-b903-f1782317c0f2" xlink:href="eols-20211231.xsd#eols_TermThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_298610be-b3fe-491e-822d-a145534a80c1" xlink:to="loc_eols_TermThreeMember_187355af-9dfd-46eb-b903-f1782317c0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d82c8d00-1f39-4a80-902b-aa6af1bdcf59" xlink:to="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfTranches_c230f907-15d1-426d-903a-785131804bde" xlink:href="eols-20211231.xsd#eols_DebtInstrumentNumberOfTranches"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_eols_DebtInstrumentNumberOfTranches_c230f907-15d1-426d-903a-785131804bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_18040fe6-8d8f-456b-90cd-44911818a903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_18040fe6-8d8f-456b-90cd-44911818a903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9dd72ea7-bdae-4426-a8ad-9b5769c5350c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9dd72ea7-bdae-4426-a8ad-9b5769c5350c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b53dcb3f-70a0-4c42-80c1-c83c0d118401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b53dcb3f-70a0-4c42-80c1-c83c0d118401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal_773aafeb-a325-4e93-89f3-91f1e409bac8" xlink:href="eols-20211231.xsd#eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal_773aafeb-a325-4e93-89f3-91f1e409bac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod_6c84e8ec-c5cd-4aa5-8ceb-f6e93d826b32" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod_6c84e8ec-c5cd-4aa5-8ceb-f6e93d826b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentAmountThreshold_8379ec89-0144-47a2-bd2d-2e07e77317c4" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentAmountThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_eols_DebtInstrumentPrepaymentAmountThreshold_8379ec89-0144-47a2-bd2d-2e07e77317c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_011c2978-ad7e-4e28-bcce-05540d8ac599" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_011c2978-ad7e-4e28-bcce-05540d8ac599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4941ea46-3f1e-4b6f-af42-eb05131f1467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4941ea46-3f1e-4b6f-af42-eb05131f1467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_14f5aa5a-a9fc-41e2-adbe-e25abb953587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_14f5aa5a-a9fc-41e2-adbe-e25abb953587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8be41012-7c77-4b15-89d8-e1d6d215ae95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92b7b81c-3012-4b9e-bf44-573616094a1b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8be41012-7c77-4b15-89d8-e1d6d215ae95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#TermLoansScheduleofLongTermDebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_765e1091-1589-404f-99ea-2ccd72a19a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7e006ef0-11ad-4bc6-a113-4860ca32533f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_765e1091-1589-404f-99ea-2ccd72a19a1e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7e006ef0-11ad-4bc6-a113-4860ca32533f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d8f78887-8ae7-4c66-8c37-8dada6f4b088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_765e1091-1589-404f-99ea-2ccd72a19a1e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d8f78887-8ae7-4c66-8c37-8dada6f4b088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_fd8461be-d62e-4ceb-b3a5-fa3944b947e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_765e1091-1589-404f-99ea-2ccd72a19a1e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_fd8461be-d62e-4ceb-b3a5-fa3944b947e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_d0b7759b-1f7e-4f24-a257-5871c91b9724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_765e1091-1589-404f-99ea-2ccd72a19a1e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_d0b7759b-1f7e-4f24-a257-5871c91b9724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5ff4abdd-fd45-4ec3-937b-0abbb3c38814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_765e1091-1589-404f-99ea-2ccd72a19a1e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5ff4abdd-fd45-4ec3-937b-0abbb3c38814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_35142767-09a7-459a-b8e7-b0841aaa150c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_765e1091-1589-404f-99ea-2ccd72a19a1e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_35142767-09a7-459a-b8e7-b0841aaa150c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_028a86e7-25cc-44da-9862-40fbd46c1c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_765e1091-1589-404f-99ea-2ccd72a19a1e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_028a86e7-25cc-44da-9862-40fbd46c1c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0ffbe5d2-0456-4167-bc08-cd5b3f54a964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_765e1091-1589-404f-99ea-2ccd72a19a1e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0ffbe5d2-0456-4167-bc08-cd5b3f54a964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1483b614-d409-4ecb-a1dd-d24310d963e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_765e1091-1589-404f-99ea-2ccd72a19a1e" xlink:to="loc_us-gaap_LongTermDebt_1483b614-d409-4ecb-a1dd-d24310d963e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansOxfordTermLoansDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#TermLoansOxfordTermLoansDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/TermLoansOxfordTermLoansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_137922bc-8075-4215-a116-e6c7caeed601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6b1765f2-d318-4785-ada8-6868c2ee20cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_137922bc-8075-4215-a116-e6c7caeed601" xlink:to="loc_us-gaap_DebtInstrumentTable_6b1765f2-d318-4785-ada8-6868c2ee20cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_856e4917-7052-43b2-8db3-536b7f6dd76f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6b1765f2-d318-4785-ada8-6868c2ee20cd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_856e4917-7052-43b2-8db3-536b7f6dd76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cd68cb6c-1efa-4109-9d5c-ad0846f27433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_856e4917-7052-43b2-8db3-536b7f6dd76f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cd68cb6c-1efa-4109-9d5c-ad0846f27433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_cccd3cb3-d453-43cf-bb07-a358567d167e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cd68cb6c-1efa-4109-9d5c-ad0846f27433" xlink:to="loc_us-gaap_SecuredDebtMember_cccd3cb3-d453-43cf-bb07-a358567d167e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2df8f986-c991-4e34-8c15-a9aa9302c4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6b1765f2-d318-4785-ada8-6868c2ee20cd" xlink:to="loc_us-gaap_DebtInstrumentAxis_2df8f986-c991-4e34-8c15-a9aa9302c4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_faa4d4dd-fa50-4db0-9cb3-13edbc13e18f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2df8f986-c991-4e34-8c15-a9aa9302c4b2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_faa4d4dd-fa50-4db0-9cb3-13edbc13e18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermLoanFacilityTrancheOneMember_6c24ab2f-1b3f-45a4-bf1a-67e6a5d3b141" xlink:href="eols-20211231.xsd#eols_TermLoanFacilityTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_faa4d4dd-fa50-4db0-9cb3-13edbc13e18f" xlink:to="loc_eols_TermLoanFacilityTrancheOneMember_6c24ab2f-1b3f-45a4-bf1a-67e6a5d3b141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermLoanFacilityTrancheTwoMember_ff7fc826-2252-45a9-9776-b9524251e33a" xlink:href="eols-20211231.xsd#eols_TermLoanFacilityTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_faa4d4dd-fa50-4db0-9cb3-13edbc13e18f" xlink:to="loc_eols_TermLoanFacilityTrancheTwoMember_ff7fc826-2252-45a9-9776-b9524251e33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermLoanFacilityMember_f7817d5e-fa57-4a63-a560-53a25e7faa7e" xlink:href="eols-20211231.xsd#eols_TermLoanFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_faa4d4dd-fa50-4db0-9cb3-13edbc13e18f" xlink:to="loc_eols_TermLoanFacilityMember_f7817d5e-fa57-4a63-a560-53a25e7faa7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoansMember_d7b86455-23ac-43cd-8f82-d241f8ab2a9a" xlink:href="eols-20211231.xsd#eols_OxfordTermLoansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_faa4d4dd-fa50-4db0-9cb3-13edbc13e18f" xlink:to="loc_eols_OxfordTermLoansMember_d7b86455-23ac-43cd-8f82-d241f8ab2a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoanFacilityMember_da760b3c-8d4c-4f4b-808b-d9b77eb99cf9" xlink:href="eols-20211231.xsd#eols_OxfordTermLoanFacilityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_faa4d4dd-fa50-4db0-9cb3-13edbc13e18f" xlink:to="loc_eols_OxfordTermLoanFacilityMember_da760b3c-8d4c-4f4b-808b-d9b77eb99cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_8d1ac060-25b0-4e27-a920-b3b1ab566531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6b1765f2-d318-4785-ada8-6868c2ee20cd" xlink:to="loc_us-gaap_VariableRateAxis_8d1ac060-25b0-4e27-a920-b3b1ab566531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_dfe2a176-48fc-4f31-bf7a-905a32b24eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_8d1ac060-25b0-4e27-a920-b3b1ab566531" xlink:to="loc_us-gaap_VariableRateDomain_dfe2a176-48fc-4f31-bf7a-905a32b24eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_fdef5183-198a-46f4-bf1f-c885ddf512cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_dfe2a176-48fc-4f31-bf7a-905a32b24eb9" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_fdef5183-198a-46f4-bf1f-c885ddf512cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6b1765f2-d318-4785-ada8-6868c2ee20cd" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b0772945-f09d-433b-9a95-3ccf293afb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b0772945-f09d-433b-9a95-3ccf293afb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LineofCreditFacilityNumberofAdvances_ec2b6c25-eecd-4ee5-8b68-cab446bc1a18" xlink:href="eols-20211231.xsd#eols_LineofCreditFacilityNumberofAdvances"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_LineofCreditFacilityNumberofAdvances_ec2b6c25-eecd-4ee5-8b68-cab446bc1a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d712899c-ee44-47ae-a8ed-ce9db4280cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d712899c-ee44-47ae-a8ed-ce9db4280cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_32b19856-5c41-4f93-9a4b-1b12e228cb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_32b19856-5c41-4f93-9a4b-1b12e228cb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_3a80860e-a2f9-4bac-b97d-2e03ae5a7806" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPeriodOfInterestOnlyPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_3a80860e-a2f9-4bac-b97d-2e03ae5a7806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentAmortizationPeriod_d36666d5-0ad3-42ce-93c0-7821035afadc" xlink:href="eols-20211231.xsd#eols_DebtInstrumentAmortizationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_DebtInstrumentAmortizationPeriod_d36666d5-0ad3-42ce-93c0-7821035afadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9c511d1d-37b9-4c8e-87cf-5974e0c6a269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9c511d1d-37b9-4c8e-87cf-5974e0c6a269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_405e778e-be84-4a25-a1d1-f2c1c862da9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_405e778e-be84-4a25-a1d1-f2c1c862da9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_87a19df5-5302-4c43-a609-e308c7fd3b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_87a19df5-5302-4c43-a609-e308c7fd3b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_347679b4-bdd4-400e-87f6-3196a212dff9" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_347679b4-bdd4-400e-87f6-3196a212dff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_9b1aa154-ad98-4bae-82dd-ca03b5cb5611" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentFeePercentageYearTwo"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_9b1aa154-ad98-4bae-82dd-ca03b5cb5611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_551efc9f-5f1a-45a5-bb20-f1a62391c396" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentFeePercentageThereafter"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_551efc9f-5f1a-45a5-bb20-f1a62391c396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_f708a1c3-2ab8-4b83-a22e-20536ded1f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_f708a1c3-2ab8-4b83-a22e-20536ded1f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentFeeAmountWaived_748a0ef4-598d-470c-88f8-be186d726406" xlink:href="eols-20211231.xsd#eols_DebtInstrumentFeeAmountWaived"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_DebtInstrumentFeeAmountWaived_748a0ef4-598d-470c-88f8-be186d726406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentOfFinalPaymentAmountWaived_b202f650-a3c7-4756-8ca2-f7fe38dde25f" xlink:href="eols-20211231.xsd#eols_DebtInstrumentOfFinalPaymentAmountWaived"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_DebtInstrumentOfFinalPaymentAmountWaived_b202f650-a3c7-4756-8ca2-f7fe38dde25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeeAmountWaived_8d6aa287-0838-43af-ad54-6ff4ff4e16d3" xlink:href="eols-20211231.xsd#eols_DebtInstrumentPrepaymentFeeAmountWaived"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_eols_DebtInstrumentPrepaymentFeeAmountWaived_8d6aa287-0838-43af-ad54-6ff4ff4e16d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_52430f2c-7eb7-4c5c-a67b-530cffe01fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a80fe54-7ae5-45eb-9307-c0ac8209ab38" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_52430f2c-7eb7-4c5c-a67b-530cffe01fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/DaewoongConvertibleNote" xlink:type="simple" xlink:href="eols-20211231.xsd#DaewoongConvertibleNote"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/DaewoongConvertibleNote" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_afaba915-0cc7-4337-858b-5196147f4bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_c36a0ae7-73f7-4595-b4ea-9839ed09cd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_afaba915-0cc7-4337-858b-5196147f4bfe" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_c36a0ae7-73f7-4595-b4ea-9839ed09cd7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/DaewoongConvertibleNoteDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#DaewoongConvertibleNoteDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/DaewoongConvertibleNoteDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9db7685c-dfa8-450a-a211-d7d37065bf73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_807700bd-43f3-4481-8cc9-18ce444c01bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9db7685c-dfa8-450a-a211-d7d37065bf73" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_807700bd-43f3-4481-8cc9-18ce444c01bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9eac5b9d-8ef3-456a-bb33-9f51d696ab14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_807700bd-43f3-4481-8cc9-18ce444c01bc" xlink:to="loc_us-gaap_DebtInstrumentAxis_9eac5b9d-8ef3-456a-bb33-9f51d696ab14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d81a944f-24e9-4309-a8a9-1af3bac34adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9eac5b9d-8ef3-456a-bb33-9f51d696ab14" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d81a944f-24e9-4309-a8a9-1af3bac34adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember_02d2eb75-5f72-419d-89fd-44f376e51f1f" xlink:href="eols-20211231.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d81a944f-24e9-4309-a8a9-1af3bac34adf" xlink:to="loc_eols_DaewoongConvertibleNoteMember_02d2eb75-5f72-419d-89fd-44f376e51f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2cb07c5f-dfd0-4b62-8d17-73671c9ccb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_807700bd-43f3-4481-8cc9-18ce444c01bc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2cb07c5f-dfd0-4b62-8d17-73671c9ccb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_59c9f743-e2df-4bf8-9689-9e66317d7601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2cb07c5f-dfd0-4b62-8d17-73671c9ccb3f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_59c9f743-e2df-4bf8-9689-9e66317d7601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_af0a94b5-ae15-482a-a945-7b4c056e17fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_59c9f743-e2df-4bf8-9689-9e66317d7601" xlink:to="loc_us-gaap_ConvertibleDebtMember_af0a94b5-ae15-482a-a945-7b4c056e17fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5dfd7e0e-0ef7-4e8a-9e0b-af24f2ae0f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_807700bd-43f3-4481-8cc9-18ce444c01bc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5dfd7e0e-0ef7-4e8a-9e0b-af24f2ae0f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_24d021fa-d97b-4376-8c7b-31da89a05854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5dfd7e0e-0ef7-4e8a-9e0b-af24f2ae0f03" xlink:to="loc_us-gaap_EquityComponentDomain_24d021fa-d97b-4376-8c7b-31da89a05854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4a01ff39-9d1d-4840-95c1-01f82eb15a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_24d021fa-d97b-4376-8c7b-31da89a05854" xlink:to="loc_us-gaap_CommonStockMember_4a01ff39-9d1d-4840-95c1-01f82eb15a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_55d417ab-c3ab-4452-8c5b-a51444cdbd8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_807700bd-43f3-4481-8cc9-18ce444c01bc" xlink:to="loc_us-gaap_ShortTermDebtLineItems_55d417ab-c3ab-4452-8c5b-a51444cdbd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8db8dc91-94f3-4d88-a998-608a25425aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_55d417ab-c3ab-4452-8c5b-a51444cdbd8a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8db8dc91-94f3-4d88-a998-608a25425aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fa61f1cf-7f7a-4407-bc7d-243b7fd53219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_55d417ab-c3ab-4452-8c5b-a51444cdbd8a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fa61f1cf-7f7a-4407-bc7d-243b7fd53219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_5a22224b-f325-4bc0-bb7b-3aa5a0191788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_55d417ab-c3ab-4452-8c5b-a51444cdbd8a" xlink:to="loc_us-gaap_ConvertibleDebt_5a22224b-f325-4bc0-bb7b-3aa5a0191788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_d1bd7cad-57df-4190-a12c-6b3947d21dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_55d417ab-c3ab-4452-8c5b-a51444cdbd8a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_d1bd7cad-57df-4190-a12c-6b3947d21dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_de52d060-c11d-45bc-a4b4-f2d70d1362f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_55d417ab-c3ab-4452-8c5b-a51444cdbd8a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_de52d060-c11d-45bc-a4b4-f2d70d1362f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1473167e-ffe2-42e9-a793-f3c00d889c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_55d417ab-c3ab-4452-8c5b-a51444cdbd8a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1473167e-ffe2-42e9-a793-f3c00d889c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeases" xlink:type="simple" xlink:href="eols-20211231.xsd#OperatingLeases"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_efcf6490-6309-4377-834e-c9bf7768fbce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_c666cd2e-99e3-45f9-a51a-dbdae5c33844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_efcf6490-6309-4377-834e-c9bf7768fbce" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_c666cd2e-99e3-45f9-a51a-dbdae5c33844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="eols-20211231.xsd#OperatingLeasesTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_092932a7-16c9-43f5-ba61-94102c5e9721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_c04998a3-f1f4-4756-ac5c-18a8c1d298ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_092932a7-16c9-43f5-ba61-94102c5e9721" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_c04998a3-f1f4-4756-ac5c-18a8c1d298ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_066d41d6-2b65-44d8-9865-dd64915ce073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_092932a7-16c9-43f5-ba61-94102c5e9721" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_066d41d6-2b65-44d8-9865-dd64915ce073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesNarrativeDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#OperatingLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_84cfb7d7-8f92-44fc-9e08-559f1a6aa901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3d4a3705-c198-4121-8181-4667769e75fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_84cfb7d7-8f92-44fc-9e08-559f1a6aa901" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3d4a3705-c198-4121-8181-4667769e75fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LesseeOperatingLeaseTerminationPeriod_1532b089-d6a2-43d1-b6d4-faf0c6b94ae2" xlink:href="eols-20211231.xsd#eols_LesseeOperatingLeaseTerminationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_84cfb7d7-8f92-44fc-9e08-559f1a6aa901" xlink:to="loc_eols_LesseeOperatingLeaseTerminationPeriod_1532b089-d6a2-43d1-b6d4-faf0c6b94ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_a5d7a3e0-60ee-462b-8023-b81bfb38f534" xlink:href="eols-20211231.xsd#eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_84cfb7d7-8f92-44fc-9e08-559f1a6aa901" xlink:to="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_a5d7a3e0-60ee-462b-8023-b81bfb38f534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_3df4f8ec-c448-4eb6-a5f1-84d1dceec168" xlink:href="eols-20211231.xsd#eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_84cfb7d7-8f92-44fc-9e08-559f1a6aa901" xlink:to="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_3df4f8ec-c448-4eb6-a5f1-84d1dceec168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_dea7835b-8713-4aa3-87aa-b5b5e770b3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_84cfb7d7-8f92-44fc-9e08-559f1a6aa901" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_dea7835b-8713-4aa3-87aa-b5b5e770b3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6b74443e-d6a4-49c9-8b2a-5ba6df31f7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_7efd621a-9530-4b66-8510-afe5c04ca65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6b74443e-d6a4-49c9-8b2a-5ba6df31f7cd" xlink:to="loc_us-gaap_OperatingLeaseCost_7efd621a-9530-4b66-8510-afe5c04ca65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_54ec35e1-3fc5-40c5-b1c8-b56ffb37fdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6b74443e-d6a4-49c9-8b2a-5ba6df31f7cd" xlink:to="loc_us-gaap_VariableLeaseCost_54ec35e1-3fc5-40c5-b1c8-b56ffb37fdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_a72af809-1f2c-4cc2-8bfc-74ab85dccf4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6b74443e-d6a4-49c9-8b2a-5ba6df31f7cd" xlink:to="loc_us-gaap_ShortTermLeaseCost_a72af809-1f2c-4cc2-8bfc-74ab85dccf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_3fee1b28-0c12-4b7c-acd4-b60b76e26052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6b74443e-d6a4-49c9-8b2a-5ba6df31f7cd" xlink:to="loc_us-gaap_LeaseCost_3fee1b28-0c12-4b7c-acd4-b60b76e26052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_537fac66-ab4d-4611-b908-ee5579830a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d5bb2f6f-cbd3-416c-b419-38185c11ac64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_537fac66-ab4d-4611-b908-ee5579830a83" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d5bb2f6f-cbd3-416c-b419-38185c11ac64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_de59d284-a568-482d-b3f0-071ac8ccd95a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_537fac66-ab4d-4611-b908-ee5579830a83" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_de59d284-a568-482d-b3f0-071ac8ccd95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8af801f3-14b9-4b48-9c36-55fde78e9592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bc223703-5975-4944-b29a-1e1edfdfd0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8af801f3-14b9-4b48-9c36-55fde78e9592" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bc223703-5975-4944-b29a-1e1edfdfd0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2b0632e6-7f40-4dde-95da-df55d18d7aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8af801f3-14b9-4b48-9c36-55fde78e9592" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2b0632e6-7f40-4dde-95da-df55d18d7aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_336d86bf-552e-4fd2-8151-bdf58e406c72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8af801f3-14b9-4b48-9c36-55fde78e9592" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_336d86bf-552e-4fd2-8151-bdf58e406c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5794609b-96a8-416b-89e0-4752a3f426fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8af801f3-14b9-4b48-9c36-55fde78e9592" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5794609b-96a8-416b-89e0-4752a3f426fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e82967b2-327e-4890-80b9-107311a1cf35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8af801f3-14b9-4b48-9c36-55fde78e9592" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e82967b2-327e-4890-80b9-107311a1cf35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_961f6d1c-2812-471a-9afb-94525dbf8e71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8af801f3-14b9-4b48-9c36-55fde78e9592" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_961f6d1c-2812-471a-9afb-94525dbf8e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9ec81a18-9334-42e3-ae24-288f45d84fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8af801f3-14b9-4b48-9c36-55fde78e9592" xlink:to="loc_us-gaap_OperatingLeaseLiability_9ec81a18-9334-42e3-ae24-288f45d84fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="eols-20211231.xsd#OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="eols-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6ae5d64a-44a2-460c-a35c-2b1dbb57e96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4adfcc4b-8034-4203-ad29-4b2890b7752a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6ae5d64a-44a2-460c-a35c-2b1dbb57e96d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4adfcc4b-8034-4203-ad29-4b2890b7752a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#CommitmentandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_33bf7b84-99fc-4d51-a66b-c52f164bb4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_b9e41c31-9326-451e-9327-bd04dd3d1544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_33bf7b84-99fc-4d51-a66b-c52f164bb4c1" xlink:to="loc_us-gaap_PurchaseObligation_b9e41c31-9326-451e-9327-bd04dd3d1544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2a5972f8-db36-41e5-92e9-19ca0dcfb398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_33bf7b84-99fc-4d51-a66b-c52f164bb4c1" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2a5972f8-db36-41e5-92e9-19ca0dcfb398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_842cb7e0-d283-44b7-baa6-379fa9af25db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_33bf7b84-99fc-4d51-a66b-c52f164bb4c1" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_842cb7e0-d283-44b7-baa6-379fa9af25db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_1bbc8be1-7bb2-4c06-8a97-cb1e968d6822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_33bf7b84-99fc-4d51-a66b-c52f164bb4c1" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_1bbc8be1-7bb2-4c06-8a97-cb1e968d6822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquity" xlink:type="simple" xlink:href="eols-20211231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_12e99c85-8e31-4411-ba18-a999ae08ee0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_953fd201-1f25-4852-b8b0-ca4453b0c0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_12e99c85-8e31-4411-ba18-a999ae08ee0f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_953fd201-1f25-4852-b8b0-ca4453b0c0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="eols-20211231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_dffb95a3-fa17-4000-b03a-090507748e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f8120061-fa5b-47f6-b5c2-0266717c239b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dffb95a3-fa17-4000-b03a-090507748e69" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f8120061-fa5b-47f6-b5c2-0266717c239b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_00e302fd-0fd3-4469-acbb-6fad19db1390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dffb95a3-fa17-4000-b03a-090507748e69" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_00e302fd-0fd3-4469-acbb-6fad19db1390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_aba715f7-5029-44ff-bfb3-de1f956ca8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dffb95a3-fa17-4000-b03a-090507748e69" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_aba715f7-5029-44ff-bfb3-de1f956ca8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b4209c8b-ed6b-4838-b406-c4673eedf299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dffb95a3-fa17-4000-b03a-090507748e69" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b4209c8b-ed6b-4838-b406-c4673eedf299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_99bef48f-4a1d-4ee5-b352-6b351eb3310f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_99bef48f-4a1d-4ee5-b352-6b351eb3310f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f21c5095-a2eb-4f42-a95b-213d30721060" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:to="loc_srt_RangeAxis_f21c5095-a2eb-4f42-a95b-213d30721060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e2ae3580-fbb1-4b93-9f2c-a80cf661c07e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f21c5095-a2eb-4f42-a95b-213d30721060" xlink:to="loc_srt_RangeMember_e2ae3580-fbb1-4b93-9f2c-a80cf661c07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_96de5240-51dd-4062-a090-79886bd540b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e2ae3580-fbb1-4b93-9f2c-a80cf661c07e" xlink:to="loc_srt_MinimumMember_96de5240-51dd-4062-a090-79886bd540b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_74490c0d-0808-455c-a144-736acf7d1d5a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e2ae3580-fbb1-4b93-9f2c-a80cf661c07e" xlink:to="loc_srt_MaximumMember_74490c0d-0808-455c-a144-736acf7d1d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e96546dc-e86d-4aee-818f-dcdcd6b7f520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:to="loc_us-gaap_AwardTypeAxis_e96546dc-e86d-4aee-818f-dcdcd6b7f520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3900faba-6a45-494e-acc3-e27f08ec826a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e96546dc-e86d-4aee-818f-dcdcd6b7f520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3900faba-6a45-494e-acc3-e27f08ec826a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0ad06cf5-fb02-4f3e-bea6-b198874f123c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3900faba-6a45-494e-acc3-e27f08ec826a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0ad06cf5-fb02-4f3e-bea6-b198874f123c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_0d0c2e13-981a-4716-8c98-16aa338d7da8" xlink:href="eols-20211231.xsd#eols_RestrictedStockUnitsRSUsPerformanceConditionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_0ad06cf5-fb02-4f3e-bea6-b198874f123c" xlink:to="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_0d0c2e13-981a-4716-8c98-16aa338d7da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember_a085f7e3-a1e7-4fec-8250-245c71390797" xlink:href="eols-20211231.xsd#eols_RestrictedStockUnitsRSUsMarketConditionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_0ad06cf5-fb02-4f3e-bea6-b198874f123c" xlink:to="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember_a085f7e3-a1e7-4fec-8250-245c71390797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e9806cb7-552d-42e7-98dd-92a5687561b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3900faba-6a45-494e-acc3-e27f08ec826a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e9806cb7-552d-42e7-98dd-92a5687561b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c8b3456f-d130-432f-9555-fd2415b368ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c8b3456f-d130-432f-9555-fd2415b368ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3bb04ce8-f27f-48a9-b847-2b39e6404eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c8b3456f-d130-432f-9555-fd2415b368ee" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3bb04ce8-f27f-48a9-b847-2b39e6404eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember_8b9b74e2-c6a5-4a12-84b9-d17ef007b458" xlink:href="eols-20211231.xsd#eols_ATMSalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3bb04ce8-f27f-48a9-b847-2b39e6404eff" xlink:to="loc_eols_ATMSalesAgreementMember_8b9b74e2-c6a5-4a12-84b9-d17ef007b458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PublicStockOfferingMember_49c7ba0f-4db5-479d-92b2-8be43e93e0c0" xlink:href="eols-20211231.xsd#eols_PublicStockOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3bb04ce8-f27f-48a9-b847-2b39e6404eff" xlink:to="loc_eols_PublicStockOfferingMember_49c7ba0f-4db5-479d-92b2-8be43e93e0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_6c22ea9e-e524-49e5-8382-f1ec513cc8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3bb04ce8-f27f-48a9-b847-2b39e6404eff" xlink:to="loc_us-gaap_OverAllotmentOptionMember_6c22ea9e-e524-49e5-8382-f1ec513cc8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_51682f0e-e579-412c-8655-f2937f6bb10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:to="loc_us-gaap_DebtInstrumentAxis_51682f0e-e579-412c-8655-f2937f6bb10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8967125c-c5b8-43e9-bbd1-3046466b2e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_51682f0e-e579-412c-8655-f2937f6bb10a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8967125c-c5b8-43e9-bbd1-3046466b2e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember_fd8b5c61-d933-465f-ac1e-accfc0b3f0fe" xlink:href="eols-20211231.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8967125c-c5b8-43e9-bbd1-3046466b2e39" xlink:to="loc_eols_DaewoongConvertibleNoteMember_fd8b5c61-d933-465f-ac1e-accfc0b3f0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_35dda7d5-e005-4f1c-8e49-f1444ddb783d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_35dda7d5-e005-4f1c-8e49-f1444ddb783d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d78b3b76-af72-4c41-bdd8-0c2124eb9edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_35dda7d5-e005-4f1c-8e49-f1444ddb783d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d78b3b76-af72-4c41-bdd8-0c2124eb9edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_bdaa8186-c777-4aac-a909-1b49c97a7df2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d78b3b76-af72-4c41-bdd8-0c2124eb9edb" xlink:to="loc_us-gaap_ConvertibleDebtMember_bdaa8186-c777-4aac-a909-1b49c97a7df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_10b42ce4-63ab-4a55-bcc8-cd8ae29b01e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_10b42ce4-63ab-4a55-bcc8-cd8ae29b01e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_27b093ab-a3b3-4d82-be0b-f65401ab5a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_10b42ce4-63ab-4a55-bcc8-cd8ae29b01e0" xlink:to="loc_us-gaap_EquityComponentDomain_27b093ab-a3b3-4d82-be0b-f65401ab5a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_55eeb76e-547b-432e-915e-f87d1524a19f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_27b093ab-a3b3-4d82-be0b-f65401ab5a43" xlink:to="loc_us-gaap_CommonStockMember_55eeb76e-547b-432e-915e-f87d1524a19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f4cce317-d32e-434f-80d2-cfda84bc1707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_27b093ab-a3b3-4d82-be0b-f65401ab5a43" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f4cce317-d32e-434f-80d2-cfda84bc1707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d49d7bed-f6d3-43a9-bd55-1da2747f4f0d" xlink:to="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e510e327-2e61-41f4-874b-ff19dbe1ecf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e510e327-2e61-41f4-874b-ff19dbe1ecf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0512bbdc-87ad-4d27-9e3a-3eb910c77820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0512bbdc-87ad-4d27-9e3a-3eb910c77820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6edbaacc-0a51-4e56-9098-a8b71a4ab9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6edbaacc-0a51-4e56-9098-a8b71a4ab9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6e03be57-24b3-4318-a86f-124eb7ffa836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6e03be57-24b3-4318-a86f-124eb7ffa836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3a2bb63f-585a-4991-a313-2dd283e46275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3a2bb63f-585a-4991-a313-2dd283e46275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fdaf048c-98f8-4638-af0f-471d17e97b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fdaf048c-98f8-4638-af0f-471d17e97b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_633645d0-6869-427d-af83-cb56c3c4c763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_CommonStockSharesIssued_633645d0-6869-427d-af83-cb56c3c4c763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_8f24179a-527a-4aa2-a895-f69e5c2eed3b" xlink:href="eols-20211231.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_8f24179a-527a-4aa2-a895-f69e5c2eed3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a3855e66-7329-4398-9ea8-9ee23369fe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a3855e66-7329-4398-9ea8-9ee23369fe2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_7b60fc73-a4b0-4865-a90c-6890d777ef9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_7b60fc73-a4b0-4865-a90c-6890d777ef9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e722df93-4ad2-4c38-9427-f3ab3a49f633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e722df93-4ad2-4c38-9427-f3ab3a49f633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_85cf5489-c2c2-42f2-9caf-ab1e8736df8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_85cf5489-c2c2-42f2-9caf-ab1e8736df8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5251dd21-c192-4ca3-9d0d-26522fc38b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5251dd21-c192-4ca3-9d0d-26522fc38b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockMaximumConsiderationReceivable_6f5e3a08-9252-4ca7-9fb3-4ca96f180ae3" xlink:href="eols-20211231.xsd#eols_SaleOfStockMaximumConsiderationReceivable"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_eols_SaleOfStockMaximumConsiderationReceivable_6f5e3a08-9252-4ca7-9fb3-4ca96f180ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_3a269c70-e182-4895-ad01-b50d7ebfec25" xlink:href="eols-20211231.xsd#eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_3a269c70-e182-4895-ad01-b50d7ebfec25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_102d3294-935b-4e36-b068-3a7b38533be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_102d3294-935b-4e36-b068-3a7b38533be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_016c5eb0-4b80-44aa-a035-f991335e4239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_016c5eb0-4b80-44aa-a035-f991335e4239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockCommissionPaid_dd4f7a04-9c52-48c0-82ef-1683cb3f4a2f" xlink:href="eols-20211231.xsd#eols_SaleOfStockCommissionPaid"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_eols_SaleOfStockCommissionPaid_dd4f7a04-9c52-48c0-82ef-1683cb3f4a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a2677a09-57f7-4a65-87c6-ef6806778f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a2677a09-57f7-4a65-87c6-ef6806778f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_feeea32f-a7f0-4670-895f-478eca3c8c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_feeea32f-a7f0-4670-895f-478eca3c8c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_d1429bf9-8ac7-4a8c-809e-a8e5f5be7e02" xlink:href="eols-20211231.xsd#eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_d1429bf9-8ac7-4a8c-809e-a8e5f5be7e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e5b7e9d2-3667-4c17-b563-6caffcfe4634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e5b7e9d2-3667-4c17-b563-6caffcfe4634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0530f183-cd09-4956-ad3b-62232cf2fc36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0530f183-cd09-4956-ad3b-62232cf2fc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4d9f5c1e-4df3-407c-9cd8-e492228182cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4d9f5c1e-4df3-407c-9cd8-e492228182cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5ed9ac03-30fd-466e-9221-119ce411825c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5ed9ac03-30fd-466e-9221-119ce411825c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_f60887c1-5921-4a12-bc2f-f14f0455b935" xlink:href="eols-20211231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_f60887c1-5921-4a12-bc2f-f14f0455b935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3208a3aa-93e3-42c9-8b73-27aa5fd06dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3208a3aa-93e3-42c9-8b73-27aa5fd06dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6ac4f824-2555-4358-af0d-c8fb6d5e7ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6ac4f824-2555-4358-af0d-c8fb6d5e7ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_58e2e6f0-8075-43a2-ad61-2d9952c53380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_58e2e6f0-8075-43a2-ad61-2d9952c53380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_18ded734-d875-4050-a81d-93d1a4097355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_18ded734-d875-4050-a81d-93d1a4097355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3b72f745-f0fe-4bdd-8a0e-abcceaf84e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3b72f745-f0fe-4bdd-8a0e-abcceaf84e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1c7c460b-0a3e-4229-8850-ecd56bcae018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1c7c460b-0a3e-4229-8850-ecd56bcae018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1aaa8ba2-e822-4db8-8231-27a5f449cb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1aaa8ba2-e822-4db8-8231-27a5f449cb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c451c988-aed6-4d32-bfe4-40359373ddb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c451c988-aed6-4d32-bfe4-40359373ddb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized_2d7294ee-2e96-47d8-b546-240d91d1d454" xlink:href="eols-20211231.xsd#eols_AllocatedShareBasedCompensationExpenseCapitalized"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f91c883d-7098-47bd-b038-b18d56d99c27" xlink:to="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized_2d7294ee-2e96-47d8-b546-240d91d1d454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityValuationAssumptionsDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#StockholdersEquityValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_09330a34-3647-4b68-9fc2-926bcef044d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12963f2e-3774-4e2b-a18d-5db3ed02be9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_09330a34-3647-4b68-9fc2-926bcef044d9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12963f2e-3774-4e2b-a18d-5db3ed02be9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bde46ce2-0ff5-4ff4-9105-8ea9446ecb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12963f2e-3774-4e2b-a18d-5db3ed02be9d" xlink:to="loc_us-gaap_AwardTypeAxis_bde46ce2-0ff5-4ff4-9105-8ea9446ecb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb782fd7-007f-4aef-9d37-866db0be0f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bde46ce2-0ff5-4ff4-9105-8ea9446ecb9a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb782fd7-007f-4aef-9d37-866db0be0f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dffdfd75-2d17-48e4-bfa8-5a4e5db6e692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb782fd7-007f-4aef-9d37-866db0be0f27" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dffdfd75-2d17-48e4-bfa8-5a4e5db6e692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f886b6da-d8b1-4dcb-ba1a-3df0f9773f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12963f2e-3774-4e2b-a18d-5db3ed02be9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f886b6da-d8b1-4dcb-ba1a-3df0f9773f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a19a44dd-9f65-4bd3-91cf-238e174d1656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f886b6da-d8b1-4dcb-ba1a-3df0f9773f2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a19a44dd-9f65-4bd3-91cf-238e174d1656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4a3e343b-0e48-486b-88a1-c301797b54c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f886b6da-d8b1-4dcb-ba1a-3df0f9773f2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4a3e343b-0e48-486b-88a1-c301797b54c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_76e56b75-f847-4bd7-9c96-61b153c60687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f886b6da-d8b1-4dcb-ba1a-3df0f9773f2d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_76e56b75-f847-4bd7-9c96-61b153c60687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3eacdd4f-e74c-417f-be6e-78febfb7887f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f886b6da-d8b1-4dcb-ba1a-3df0f9773f2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3eacdd4f-e74c-417f-be6e-78febfb7887f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#StockholdersEquityScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_67f8524c-90fe-4bc7-8be7-ed557f8a4467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01bce980-016b-492c-a07a-bece34e4dd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_67f8524c-90fe-4bc7-8be7-ed557f8a4467" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01bce980-016b-492c-a07a-bece34e4dd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_db9ab32f-2d53-4f0f-8592-64ecf55d3444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01bce980-016b-492c-a07a-bece34e4dd0e" xlink:to="loc_us-gaap_AwardTypeAxis_db9ab32f-2d53-4f0f-8592-64ecf55d3444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c25f3489-a4bb-4f74-84b8-68a99a6d964f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_db9ab32f-2d53-4f0f-8592-64ecf55d3444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c25f3489-a4bb-4f74-84b8-68a99a6d964f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2bfca2f4-db70-44ee-9692-18bf1f087f55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c25f3489-a4bb-4f74-84b8-68a99a6d964f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2bfca2f4-db70-44ee-9692-18bf1f087f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01bce980-016b-492c-a07a-bece34e4dd0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65125793-5f3f-41be-ab78-bca8d93a949e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65125793-5f3f-41be-ab78-bca8d93a949e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1942fc61-eb85-41db-933b-bb3e9e246f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65125793-5f3f-41be-ab78-bca8d93a949e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1942fc61-eb85-41db-933b-bb3e9e246f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8dd3e469-0c70-4d25-b3da-d5cd11ee2558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65125793-5f3f-41be-ab78-bca8d93a949e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8dd3e469-0c70-4d25-b3da-d5cd11ee2558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e4723051-acb3-4354-a66a-773cdf34b5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65125793-5f3f-41be-ab78-bca8d93a949e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e4723051-acb3-4354-a66a-773cdf34b5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0fa29f67-0e8c-460d-86e0-f73c3a13e698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65125793-5f3f-41be-ab78-bca8d93a949e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0fa29f67-0e8c-460d-86e0-f73c3a13e698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_494d7973-8d71-45a6-b3bc-c619a4792ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65125793-5f3f-41be-ab78-bca8d93a949e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_494d7973-8d71-45a6-b3bc-c619a4792ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7eaf1dfe-8b8c-40e9-a012-2fe5f8dfa068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7eaf1dfe-8b8c-40e9-a012-2fe5f8dfa068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1db30061-b5f7-40a6-8b07-d04e8b396f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1db30061-b5f7-40a6-8b07-d04e8b396f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20b2be14-b733-4603-99b8-98c82c6fa8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1db30061-b5f7-40a6-8b07-d04e8b396f42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20b2be14-b733-4603-99b8-98c82c6fa8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ff3bf4de-306d-4a7f-9cb2-2e1fd6b19bde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1db30061-b5f7-40a6-8b07-d04e8b396f42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ff3bf4de-306d-4a7f-9cb2-2e1fd6b19bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_11529fab-5b18-4d19-9f2c-fb4d4b05b464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1db30061-b5f7-40a6-8b07-d04e8b396f42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_11529fab-5b18-4d19-9f2c-fb4d4b05b464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_569270c9-2672-4776-92d7-fcf03210c500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1db30061-b5f7-40a6-8b07-d04e8b396f42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_569270c9-2672-4776-92d7-fcf03210c500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_90cb0d5c-a1a8-405f-9383-a3a051cea354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1db30061-b5f7-40a6-8b07-d04e8b396f42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_90cb0d5c-a1a8-405f-9383-a3a051cea354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3718bdcf-1103-4e13-844d-d7417ca4ac79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3718bdcf-1103-4e13-844d-d7417ca4ac79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3463a838-f33b-4b5a-8b6d-e60bb9a5d24c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3463a838-f33b-4b5a-8b6d-e60bb9a5d24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d7bf1ce9-01a5-4be4-989e-af3d93cd1f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3463a838-f33b-4b5a-8b6d-e60bb9a5d24c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d7bf1ce9-01a5-4be4-989e-af3d93cd1f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0419bd2a-ac06-4514-a6a0-243fcce4b0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0419bd2a-ac06-4514-a6a0-243fcce4b0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_6ab5fee0-30cf-491f-b285-e3b1b7ce629e" xlink:href="eols-20211231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_6ab5fee0-30cf-491f-b285-e3b1b7ce629e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d981a714-ba63-4733-b6a0-f5b64857fee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_6ab5fee0-30cf-491f-b285-e3b1b7ce629e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d981a714-ba63-4733-b6a0-f5b64857fee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2203ef41-034f-4603-8803-d386bc28ee33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_6ab5fee0-30cf-491f-b285-e3b1b7ce629e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2203ef41-034f-4603-8803-d386bc28ee33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8b0a67fa-2e20-4caf-84c7-a9c6e14c7a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8b0a67fa-2e20-4caf-84c7-a9c6e14c7a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7ebfa80f-d667-4fcd-8de0-e292d99a47fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5558d2-86d5-40dc-a9fe-2cef0a5999c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7ebfa80f-d667-4fcd-8de0-e292d99a47fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f4870079-5950-4b0c-9540-947eea1d3762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7ebfa80f-d667-4fcd-8de0-e292d99a47fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f4870079-5950-4b0c-9540-947eea1d3762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_db799175-bc6a-495e-ade5-9c92ec105ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7ebfa80f-d667-4fcd-8de0-e292d99a47fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_db799175-bc6a-495e-ade5-9c92ec105ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0370e8ec-d308-4d2a-8ab2-2ed9260b36cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7ebfa80f-d667-4fcd-8de0-e292d99a47fb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0370e8ec-d308-4d2a-8ab2-2ed9260b36cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_58ea2053-13d9-4213-b279-14b7de91625f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7ebfa80f-d667-4fcd-8de0-e292d99a47fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_58ea2053-13d9-4213-b279-14b7de91625f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a2f7e708-42ba-4206-ad4d-52770aa3c6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8798f325-7e35-4e09-a1dc-53b10c6562f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a2f7e708-42ba-4206-ad4d-52770aa3c6ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8798f325-7e35-4e09-a1dc-53b10c6562f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_882b6870-35f2-49b0-b5e3-7cb94f4f2c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8798f325-7e35-4e09-a1dc-53b10c6562f6" xlink:to="loc_us-gaap_AwardTypeAxis_882b6870-35f2-49b0-b5e3-7cb94f4f2c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c0b95c3-5120-4cd0-9597-a9bb6a561709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_882b6870-35f2-49b0-b5e3-7cb94f4f2c97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c0b95c3-5120-4cd0-9597-a9bb6a561709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_875b607f-fc06-4945-b5e0-71b543766c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c0b95c3-5120-4cd0-9597-a9bb6a561709" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_875b607f-fc06-4945-b5e0-71b543766c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f67f41f8-2768-4383-a37f-4b89bee4270e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8798f325-7e35-4e09-a1dc-53b10c6562f6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f67f41f8-2768-4383-a37f-4b89bee4270e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_78c22fc0-6269-438a-ad0f-dc0c97995a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f67f41f8-2768-4383-a37f-4b89bee4270e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_78c22fc0-6269-438a-ad0f-dc0c97995a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a914a365-1376-4123-8c99-d0f4d4ab3e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_78c22fc0-6269-438a-ad0f-dc0c97995a9a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a914a365-1376-4123-8c99-d0f4d4ab3e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47489192-6794-41a1-a10d-93658d024c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8798f325-7e35-4e09-a1dc-53b10c6562f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47489192-6794-41a1-a10d-93658d024c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6237bcef-9bda-4e6e-886c-d32f7a6e5e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47489192-6794-41a1-a10d-93658d024c3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6237bcef-9bda-4e6e-886c-d32f7a6e5e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_39ece3cd-e4dd-4df8-917f-9d08f76572dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6237bcef-9bda-4e6e-886c-d32f7a6e5e96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_39ece3cd-e4dd-4df8-917f-9d08f76572dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5874ebd6-2ab9-406d-b12a-d4161715aa04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6237bcef-9bda-4e6e-886c-d32f7a6e5e96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5874ebd6-2ab9-406d-b12a-d4161715aa04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_990656d8-e4a1-43ed-889d-834c424c1d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6237bcef-9bda-4e6e-886c-d32f7a6e5e96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_990656d8-e4a1-43ed-889d-834c424c1d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d90bb2e6-bf65-44ea-b87f-758bd4f35a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6237bcef-9bda-4e6e-886c-d32f7a6e5e96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d90bb2e6-bf65-44ea-b87f-758bd4f35a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b4c60bf-b1c2-490c-a82c-749b305eafab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6237bcef-9bda-4e6e-886c-d32f7a6e5e96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b4c60bf-b1c2-490c-a82c-749b305eafab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16785c2f-a270-4744-88d1-b374d4bfd9af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47489192-6794-41a1-a10d-93658d024c3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16785c2f-a270-4744-88d1-b374d4bfd9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5f767225-4ff2-4292-a511-d5db7c5376f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16785c2f-a270-4744-88d1-b374d4bfd9af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5f767225-4ff2-4292-a511-d5db7c5376f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8f4cd9c5-acf2-452c-8883-70258b0d1143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16785c2f-a270-4744-88d1-b374d4bfd9af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8f4cd9c5-acf2-452c-8883-70258b0d1143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6eebd182-6478-4e94-94b7-e442cd1beb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16785c2f-a270-4744-88d1-b374d4bfd9af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6eebd182-6478-4e94-94b7-e442cd1beb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_936288f8-808a-479c-a0b2-e9b28d7e09dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16785c2f-a270-4744-88d1-b374d4bfd9af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_936288f8-808a-479c-a0b2-e9b28d7e09dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5e04763b-d37d-4ce5-8406-d35ff1e394f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16785c2f-a270-4744-88d1-b374d4bfd9af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5e04763b-d37d-4ce5-8406-d35ff1e394f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#StockholdersEquityStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_32115f70-fd7d-4d19-b030-ffdd11668635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_30b2ec8f-a08a-4237-8a24-6cf6b971ce53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_32115f70-fd7d-4d19-b030-ffdd11668635" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_30b2ec8f-a08a-4237-8a24-6cf6b971ce53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d65b438c-7343-42e0-871c-07f6d2f2d7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_30b2ec8f-a08a-4237-8a24-6cf6b971ce53" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d65b438c-7343-42e0-871c-07f6d2f2d7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d44f511b-c0fa-4648-9e39-671caa01c250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d65b438c-7343-42e0-871c-07f6d2f2d7ad" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d44f511b-c0fa-4648-9e39-671caa01c250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_abc65808-2014-4389-a01a-5f6213bfec03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d44f511b-c0fa-4648-9e39-671caa01c250" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_abc65808-2014-4389-a01a-5f6213bfec03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_799e43d6-bc18-41ae-8141-6d4813f0af42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d44f511b-c0fa-4648-9e39-671caa01c250" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_799e43d6-bc18-41ae-8141-6d4813f0af42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f4a6149e-a2f0-45b3-b03a-dfb60f1409a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_30b2ec8f-a08a-4237-8a24-6cf6b971ce53" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f4a6149e-a2f0-45b3-b03a-dfb60f1409a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_44433e7f-a8a4-401a-b695-c3fcd10d0054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f4a6149e-a2f0-45b3-b03a-dfb60f1409a4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_44433e7f-a8a4-401a-b695-c3fcd10d0054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangement" xlink:type="simple" xlink:href="eols-20211231.xsd#MedytoxAllerganSettlementAgreementsandDaewoongArrangement"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2f4aab70-754b-4fd5-8c72-5146e6fc6cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_baee7da4-8f14-4f79-b154-d11dd12d6a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2f4aab70-754b-4fd5-8c72-5146e6fc6cc5" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_baee7da4-8f14-4f79-b154-d11dd12d6a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f55e2f20-d300-4261-83a6-3740a71eedf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f55e2f20-d300-4261-83a6-3740a71eedf0" xlink:to="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_31892936-72c3-482d-9868-bee4c57bbbab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:to="loc_srt_LitigationCaseAxis_31892936-72c3-482d-9868-bee4c57bbbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_92839df2-f829-415d-86bc-23f5430cc344" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_31892936-72c3-482d-9868-bee4c57bbbab" xlink:to="loc_srt_LitigationCaseTypeDomain_92839df2-f829-415d-86bc-23f5430cc344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_b32247d7-08cd-4849-a586-b3473fd3876b" xlink:href="eols-20211231.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_92839df2-f829-415d-86bc-23f5430cc344" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_b32247d7-08cd-4849-a586-b3473fd3876b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a69f8ec4-c7f5-4e90-8a72-1b9480c9d91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:to="loc_us-gaap_DebtInstrumentAxis_a69f8ec4-c7f5-4e90-8a72-1b9480c9d91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42647b16-4560-4100-9135-e23ad05ae0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a69f8ec4-c7f5-4e90-8a72-1b9480c9d91a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_42647b16-4560-4100-9135-e23ad05ae0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongAgreementMember_b4c333f4-2b5d-482b-b4e5-32afed0609f2" xlink:href="eols-20211231.xsd#eols_DaewoongAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42647b16-4560-4100-9135-e23ad05ae0c7" xlink:to="loc_eols_DaewoongAgreementMember_b4c333f4-2b5d-482b-b4e5-32afed0609f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember_1a04083f-4f40-4d2c-82fa-8af89572834e" xlink:href="eols-20211231.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42647b16-4560-4100-9135-e23ad05ae0c7" xlink:to="loc_eols_DaewoongConvertibleNoteMember_1a04083f-4f40-4d2c-82fa-8af89572834e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9c2229e7-e41b-4968-9242-8b7637b0022a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9c2229e7-e41b-4968-9242-8b7637b0022a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e75d0bbf-e9a9-422c-bd65-95baa8ad24de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9c2229e7-e41b-4968-9242-8b7637b0022a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e75d0bbf-e9a9-422c-bd65-95baa8ad24de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_ff840578-c907-421b-9b4f-8ac353b3f274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e75d0bbf-e9a9-422c-bd65-95baa8ad24de" xlink:to="loc_us-gaap_ConvertibleDebtMember_ff840578-c907-421b-9b4f-8ac353b3f274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e1982747-2994-4c97-965b-56653bb1599b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e1982747-2994-4c97-965b-56653bb1599b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6a711db5-4bc2-41b5-9682-13e131a113d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e1982747-2994-4c97-965b-56653bb1599b" xlink:to="loc_us-gaap_EquityComponentDomain_6a711db5-4bc2-41b5-9682-13e131a113d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c0c084b0-f33e-4997-b04d-ffb2b31d8096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6a711db5-4bc2-41b5-9682-13e131a113d3" xlink:to="loc_us-gaap_CommonStockMember_c0c084b0-f33e-4997-b04d-ffb2b31d8096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b197fba1-3e4f-45ee-ac2b-4262559ac59f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:to="loc_srt_RangeAxis_b197fba1-3e4f-45ee-ac2b-4262559ac59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_99bdf1e2-4520-445c-a0b0-cbfc5b1b3887" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b197fba1-3e4f-45ee-ac2b-4262559ac59f" xlink:to="loc_srt_RangeMember_99bdf1e2-4520-445c-a0b0-cbfc5b1b3887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5490631c-517e-44a9-a12b-f076cecac8f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_99bdf1e2-4520-445c-a0b0-cbfc5b1b3887" xlink:to="loc_srt_MaximumMember_5490631c-517e-44a9-a12b-f076cecac8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_523ef8f2-f983-4063-92be-b4e0f8e49992" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:to="loc_srt_StatementScenarioAxis_523ef8f2-f983-4063-92be-b4e0f8e49992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9c6d4928-b592-4fda-a990-88c8fc6eed32" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_523ef8f2-f983-4063-92be-b4e0f8e49992" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9c6d4928-b592-4fda-a990-88c8fc6eed32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_e71b3c44-0d1a-44fb-8d9a-deb74c497fd5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_9c6d4928-b592-4fda-a990-88c8fc6eed32" xlink:to="loc_srt_ScenarioForecastMember_e71b3c44-0d1a-44fb-8d9a-deb74c497fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a8e819b8-5f52-4135-a565-0fdce9a45dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a8e819b8-5f52-4135-a565-0fdce9a45dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c4ad60a9-fbc1-49ac-86ec-fb3995efb833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a8e819b8-5f52-4135-a565-0fdce9a45dfd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c4ad60a9-fbc1-49ac-86ec-fb3995efb833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5f1140e2-ceac-4d69-ae27-a7864080f59a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c4ad60a9-fbc1-49ac-86ec-fb3995efb833" xlink:to="loc_us-gaap_SubsequentEventMember_5f1140e2-ceac-4d69-ae27-a7864080f59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6cd3826-3943-44c1-b483-e48cc5af4713" xlink:to="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_76e9623d-d853-4876-a9d3-41cedf9edc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_76e9623d-d853-4876-a9d3-41cedf9edc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementPaymentTerms_8c926c02-9559-48ba-9159-dcf2afe166de" xlink:href="eols-20211231.xsd#eols_LossContingencySettlementAgreementPaymentTerms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_eols_LossContingencySettlementAgreementPaymentTerms_8c926c02-9559-48ba-9159-dcf2afe166de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_c3a65f56-35b3-4edb-b86f-2c677b57727d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_c3a65f56-35b3-4edb-b86f-2c677b57727d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_1ed6a0a3-1dc2-450f-9508-ce810a44e8cd" xlink:href="eols-20211231.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_1ed6a0a3-1dc2-450f-9508-ce810a44e8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3d4f48fe-0f1b-4c25-be62-57bea8d7c01c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3d4f48fe-0f1b-4c25-be62-57bea8d7c01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear_79ede4f3-527f-4417-b5e0-7fd6deb2f5fa" xlink:href="eols-20211231.xsd#eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear_79ede4f3-527f-4417-b5e0-7fd6deb2f5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_3c3b4cc1-33be-4399-be11-47d5efab8dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_3c3b4cc1-33be-4399-be11-47d5efab8dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestonePaymentInConnectionWithAgreement_e4dd397b-a106-4b5a-aafd-64aaaa0355f8" xlink:href="eols-20211231.xsd#eols_MilestonePaymentInConnectionWithAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_eols_MilestonePaymentInConnectionWithAgreement_e4dd397b-a106-4b5a-aafd-64aaaa0355f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_9312f101-f970-48fa-b782-8ad9c75e73ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_us-gaap_ConvertibleDebt_9312f101-f970-48fa-b782-8ad9c75e73ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_648a9759-87a2-42a7-8903-1238ccd87995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_648a9759-87a2-42a7-8903-1238ccd87995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_e5de47c6-f924-4450-8e36-f0a4232055da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_e5de47c6-f924-4450-8e36-f0a4232055da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned_9321da00-7877-4302-bc69-e37687168fe3" xlink:href="eols-20211231.xsd#eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5814ec9-5584-46cc-bc3a-36ad630ef1a1" xlink:to="loc_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned_9321da00-7877-4302-bc69-e37687168fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="eols-20211231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c4df14f0-18b8-4351-ab39-46d9127df6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_835883b2-67a8-44cd-8184-87ee5959910c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c4df14f0-18b8-4351-ab39-46d9127df6aa" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_835883b2-67a8-44cd-8184-87ee5959910c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9fa8ecad-4e1c-4e1c-a156-f79eb31749c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_e10a42dd-4485-4d07-b462-52009d29a3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9fa8ecad-4e1c-4e1c-a156-f79eb31749c3" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_e10a42dd-4485-4d07-b462-52009d29a3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxes" xlink:type="simple" xlink:href="eols-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0b166244-3bf5-4fc3-917f-beec8873cbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_44548614-50c1-4ea7-926f-a6b109f0d7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0b166244-3bf5-4fc3-917f-beec8873cbdb" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_44548614-50c1-4ea7-926f-a6b109f0d7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="eols-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_18ce7ea9-5e8a-44d1-bb67-a6e80091b95f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_904b46c5-e89e-4383-9755-4d24d92dcda1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18ce7ea9-5e8a-44d1-bb67-a6e80091b95f" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_904b46c5-e89e-4383-9755-4d24d92dcda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6f936825-affd-4494-9f63-660514e5133b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18ce7ea9-5e8a-44d1-bb67-a6e80091b95f" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6f936825-affd-4494-9f63-660514e5133b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2f5dd52c-8de4-420a-bd74-61aa9e36c984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18ce7ea9-5e8a-44d1-bb67-a6e80091b95f" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2f5dd52c-8de4-420a-bd74-61aa9e36c984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_578e9cd4-18cd-415f-9cb2-09217f07eb87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18ce7ea9-5e8a-44d1-bb67-a6e80091b95f" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_578e9cd4-18cd-415f-9cb2-09217f07eb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2ec5a3dc-b7e3-4188-bde4-1cdf402fc096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e527b50c-60c5-47d9-b193-c4db813b0daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ec5a3dc-b7e3-4188-bde4-1cdf402fc096" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e527b50c-60c5-47d9-b193-c4db813b0daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3ad747a3-7aa0-4b1b-bf46-fb12b22479b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e527b50c-60c5-47d9-b193-c4db813b0daa" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3ad747a3-7aa0-4b1b-bf46-fb12b22479b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b707d99b-ec5f-47b4-8b07-60c7a23ec3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e527b50c-60c5-47d9-b193-c4db813b0daa" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b707d99b-ec5f-47b4-8b07-60c7a23ec3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c0dc4b7a-12ef-428c-9a4e-c71d24ac5d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e527b50c-60c5-47d9-b193-c4db813b0daa" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c0dc4b7a-12ef-428c-9a4e-c71d24ac5d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_74ce1d32-a025-4ab3-b12a-ca780b0450c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ec5a3dc-b7e3-4188-bde4-1cdf402fc096" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_74ce1d32-a025-4ab3-b12a-ca780b0450c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_aeecf58e-f9ad-4328-8350-ebb9cdcf139e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_74ce1d32-a025-4ab3-b12a-ca780b0450c1" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_aeecf58e-f9ad-4328-8350-ebb9cdcf139e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a08d538e-1dad-4cb7-8e8e-ba5f24a1b9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_74ce1d32-a025-4ab3-b12a-ca780b0450c1" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a08d538e-1dad-4cb7-8e8e-ba5f24a1b9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bac2cab5-d4a1-407b-bdf5-b496661e825d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_74ce1d32-a025-4ab3-b12a-ca780b0450c1" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bac2cab5-d4a1-407b-bdf5-b496661e825d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3d809903-db90-4f6d-afbc-e73b307f4952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ec5a3dc-b7e3-4188-bde4-1cdf402fc096" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3d809903-db90-4f6d-afbc-e73b307f4952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ebc048b7-37ea-477a-93d8-4c8b8b6ab624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_73031600-3985-4739-b054-0ee3a6c9531b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ebc048b7-37ea-477a-93d8-4c8b8b6ab624" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_73031600-3985-4739-b054-0ee3a6c9531b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f7cf63e2-dbc3-462e-b96c-831ec3bcfe81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_73031600-3985-4739-b054-0ee3a6c9531b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f7cf63e2-dbc3-462e-b96c-831ec3bcfe81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_03be77dc-c37e-476b-977b-6164cc27b605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f7cf63e2-dbc3-462e-b96c-831ec3bcfe81" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_03be77dc-c37e-476b-977b-6164cc27b605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_04097027-a96c-4a79-a7fc-2a7073f3d84f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_03be77dc-c37e-476b-977b-6164cc27b605" xlink:to="loc_us-gaap_DomesticCountryMember_04097027-a96c-4a79-a7fc-2a7073f3d84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_26a52433-adf4-41d2-9a57-476483bec40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_03be77dc-c37e-476b-977b-6164cc27b605" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_26a52433-adf4-41d2-9a57-476483bec40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_64cbce9a-23a9-4ac6-bb5f-f25ac6041252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_73031600-3985-4739-b054-0ee3a6c9531b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_64cbce9a-23a9-4ac6-bb5f-f25ac6041252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_643e050b-6a92-4a69-9a06-96ac78fcfb59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_64cbce9a-23a9-4ac6-bb5f-f25ac6041252" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_643e050b-6a92-4a69-9a06-96ac78fcfb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_eaf4e1cc-bb6c-4054-9075-d7773144581b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_643e050b-6a92-4a69-9a06-96ac78fcfb59" xlink:to="loc_us-gaap_ResearchMember_eaf4e1cc-bb6c-4054-9075-d7773144581b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_8296e435-4a97-4097-820e-8ba9c5ceec15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_73031600-3985-4739-b054-0ee3a6c9531b" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_8296e435-4a97-4097-820e-8ba9c5ceec15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_143ee369-57ba-4887-813f-f10638d6ca02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_8296e435-4a97-4097-820e-8ba9c5ceec15" xlink:to="loc_us-gaap_OperatingLossCarryforwards_143ee369-57ba-4887-813f-f10638d6ca02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_ffc05b14-b88b-4b0a-9de2-aef2880535e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_8296e435-4a97-4097-820e-8ba9c5ceec15" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_ffc05b14-b88b-4b0a-9de2-aef2880535e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_1745e621-1590-4851-baf1-68686181eebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_8296e435-4a97-4097-820e-8ba9c5ceec15" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_1745e621-1590-4851-baf1-68686181eebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_ba2561c4-10f9-4f6f-8e44-a6720e003e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_8296e435-4a97-4097-820e-8ba9c5ceec15" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_ba2561c4-10f9-4f6f-8e44-a6720e003e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_4d9eb5f4-65af-4902-9e3a-1f7889de8609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_8296e435-4a97-4097-820e-8ba9c5ceec15" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_4d9eb5f4-65af-4902-9e3a-1f7889de8609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_404c7468-e34e-4821-8808-89158f1b5f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_4d17d44a-a33d-4ef1-80ee-5f16592055fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_404c7468-e34e-4821-8808-89158f1b5f4c" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_4d17d44a-a33d-4ef1-80ee-5f16592055fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ea17c9b5-b00a-49e9-8b07-732dc1324af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_4d17d44a-a33d-4ef1-80ee-5f16592055fb" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ea17c9b5-b00a-49e9-8b07-732dc1324af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_82e7804f-ca7c-4836-aa59-61ee52b9bec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_4d17d44a-a33d-4ef1-80ee-5f16592055fb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_82e7804f-ca7c-4836-aa59-61ee52b9bec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_dacf8128-48d3-48e8-8ce7-fca8e661bc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_4d17d44a-a33d-4ef1-80ee-5f16592055fb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_dacf8128-48d3-48e8-8ce7-fca8e661bc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_9c55e75b-b828-44c5-a933-4cb17cbfb48f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_4d17d44a-a33d-4ef1-80ee-5f16592055fb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_9c55e75b-b828-44c5-a933-4cb17cbfb48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DeferredTaxAssetsOperatingLeaseLiabilities_412325ad-c497-4d2f-b02f-7d27959c25d3" xlink:href="eols-20211231.xsd#eols_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_4d17d44a-a33d-4ef1-80ee-5f16592055fb" xlink:to="loc_eols_DeferredTaxAssetsOperatingLeaseLiabilities_412325ad-c497-4d2f-b02f-7d27959c25d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_65d4f2f0-f4cf-4283-b2c9-3a181a301d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_4d17d44a-a33d-4ef1-80ee-5f16592055fb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_65d4f2f0-f4cf-4283-b2c9-3a181a301d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_5eb09940-0253-4b30-b596-f0cf61a8da12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_4d17d44a-a33d-4ef1-80ee-5f16592055fb" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_5eb09940-0253-4b30-b596-f0cf61a8da12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6a8586ac-3e47-4d32-bfae-317980ebda68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_4d17d44a-a33d-4ef1-80ee-5f16592055fb" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6a8586ac-3e47-4d32-bfae-317980ebda68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_36510978-9eab-4cef-bfb6-3754d6a32547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_4d17d44a-a33d-4ef1-80ee-5f16592055fb" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_36510978-9eab-4cef-bfb6-3754d6a32547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_71b69382-5855-4b76-87cf-c4f75035b1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_404c7468-e34e-4821-8808-89158f1b5f4c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_71b69382-5855-4b76-87cf-c4f75035b1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ffea1f50-80c5-4abe-92d8-e2f8025ac4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_71b69382-5855-4b76-87cf-c4f75035b1f6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ffea1f50-80c5-4abe-92d8-e2f8025ac4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_e3cb19bf-365b-48c5-bed2-3a63372e8a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_71b69382-5855-4b76-87cf-c4f75035b1f6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_e3cb19bf-365b-48c5-bed2-3a63372e8a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e5ed560b-8c15-45d3-8f0f-87e485b3b13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_71b69382-5855-4b76-87cf-c4f75035b1f6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e5ed560b-8c15-45d3-8f0f-87e485b3b13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_f0d01ee2-7609-4801-b326-15b6c98a49ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_71b69382-5855-4b76-87cf-c4f75035b1f6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_f0d01ee2-7609-4801-b326-15b6c98a49ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_276800aa-dd74-4aa7-a435-a45c6c0760b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_404c7468-e34e-4821-8808-89158f1b5f4c" xlink:to="loc_us-gaap_DeferredTaxLiabilities_276800aa-dd74-4aa7-a435-a45c6c0760b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#IncomeTaxesReconciliationofEffectiveTaxDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3ffb2ec9-2743-447b-9aec-361961f2abb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_d2975c2c-db7a-4ca9-8e14-8fc642864915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ffb2ec9-2743-447b-9aec-361961f2abb6" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_d2975c2c-db7a-4ca9-8e14-8fc642864915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_4bdfb59f-36b3-483b-8c18-a413b5ee9a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ffb2ec9-2743-447b-9aec-361961f2abb6" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_4bdfb59f-36b3-483b-8c18-a413b5ee9a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_ca921cb3-ce48-4b71-8392-e6ab22899180" xlink:href="eols-20211231.xsd#eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ffb2ec9-2743-447b-9aec-361961f2abb6" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_ca921cb3-ce48-4b71-8392-e6ab22899180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_5baabdca-dc40-4c60-8014-b7f89b118d56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ffb2ec9-2743-447b-9aec-361961f2abb6" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_5baabdca-dc40-4c60-8014-b7f89b118d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_17a073b1-e7e9-4d20-994f-a18ced989e59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ffb2ec9-2743-447b-9aec-361961f2abb6" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_17a073b1-e7e9-4d20-994f-a18ced989e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation_43f85a65-477d-424b-8de1-36752fb1d5cc" xlink:href="eols-20211231.xsd#eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ffb2ec9-2743-447b-9aec-361961f2abb6" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation_43f85a65-477d-424b-8de1-36752fb1d5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_7e76b532-a43e-4611-ae59-dbdd8eb93acd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ffb2ec9-2743-447b-9aec-361961f2abb6" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_7e76b532-a43e-4611-ae59-dbdd8eb93acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_a0892a1b-8efc-40a5-8792-07d20fe15a10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ffb2ec9-2743-447b-9aec-361961f2abb6" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_a0892a1b-8efc-40a5-8792-07d20fe15a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_ad83297f-f721-4908-b45e-ebad60e94922" xlink:href="eols-20211231.xsd#eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ffb2ec9-2743-447b-9aec-361961f2abb6" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_ad83297f-f721-4908-b45e-ebad60e94922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_fd03de37-6810-4b1b-9aaa-99b102d9e05e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ffb2ec9-2743-447b-9aec-361961f2abb6" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_fd03de37-6810-4b1b-9aaa-99b102d9e05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c3ae0e84-7009-4062-9857-e64a1eadacc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ffb2ec9-2743-447b-9aec-361961f2abb6" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c3ae0e84-7009-4062-9857-e64a1eadacc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_890a66ee-676c-41cd-88a2-adae818ca68b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ffb2ec9-2743-447b-9aec-361961f2abb6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_890a66ee-676c-41cd-88a2-adae818ca68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#IncomeTaxesUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_13771a39-37a8-463d-8577-2274868fe568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b963d604-87f1-4df1-9522-b6507fcae276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13771a39-37a8-463d-8577-2274868fe568" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b963d604-87f1-4df1-9522-b6507fcae276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3c6c2560-90a5-4a3e-92e9-6619c4642a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b963d604-87f1-4df1-9522-b6507fcae276" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3c6c2560-90a5-4a3e-92e9-6619c4642a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b3e7510f-4b09-4a3a-b235-7239a9ffdb55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b963d604-87f1-4df1-9522-b6507fcae276" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b3e7510f-4b09-4a3a-b235-7239a9ffdb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_223d215c-cb3b-42f6-aa6c-13c3af73d02c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b963d604-87f1-4df1-9522-b6507fcae276" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_223d215c-cb3b-42f6-aa6c-13c3af73d02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="eols-20211231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_a86edf57-5944-497d-936e-5c065661d2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7f295307-9a53-4592-a012-28e9d37d7ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_a86edf57-5944-497d-936e-5c065661d2ad" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7f295307-9a53-4592-a012-28e9d37d7ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="eols-20211231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5d8076bb-6529-4738-ba61-ed5d9fcfa033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5d8076bb-6529-4738-ba61-ed5d9fcfa033" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e4439b72-62bf-447b-9555-ef9a2364629b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e4439b72-62bf-447b-9555-ef9a2364629b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e50c755-b64d-4a64-8460-dff914fc7999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e4439b72-62bf-447b-9555-ef9a2364629b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e50c755-b64d-4a64-8460-dff914fc7999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EvolusIncMember_cccd6ffc-64c1-4e8e-981e-a597dbcc689b" xlink:href="eols-20211231.xsd#eols_EvolusIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e50c755-b64d-4a64-8460-dff914fc7999" xlink:to="loc_eols_EvolusIncMember_cccd6ffc-64c1-4e8e-981e-a597dbcc689b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_eb4a685d-5740-4104-884e-de9a3556c986" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:to="loc_dei_LegalEntityAxis_eb4a685d-5740-4104-884e-de9a3556c986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_75e44c1a-4398-456d-94fd-feadb9810797" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_eb4a685d-5740-4104-884e-de9a3556c986" xlink:to="loc_dei_EntityDomain_75e44c1a-4398-456d-94fd-feadb9810797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SCHAEONLLCMember_892e0b23-89fe-4faa-8e6b-a059702664a1" xlink:href="eols-20211231.xsd#eols_SCHAEONLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_75e44c1a-4398-456d-94fd-feadb9810797" xlink:to="loc_eols_SCHAEONLLCMember_892e0b23-89fe-4faa-8e6b-a059702664a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8f58e92d-b20f-4c0a-bbfe-721e9c780f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8f58e92d-b20f-4c0a-bbfe-721e9c780f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4d37b307-4d25-41dc-b1de-d585bba4425c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8f58e92d-b20f-4c0a-bbfe-721e9c780f98" xlink:to="loc_us-gaap_EquityComponentDomain_4d37b307-4d25-41dc-b1de-d585bba4425c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_311f9640-6ab1-479b-9040-4dabd32e90f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4d37b307-4d25-41dc-b1de-d585bba4425c" xlink:to="loc_us-gaap_CommonStockMember_311f9640-6ab1-479b-9040-4dabd32e90f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_bd3f275f-1b57-4deb-b332-7e89866852b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:to="loc_srt_LitigationCaseAxis_bd3f275f-1b57-4deb-b332-7e89866852b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a578ddf5-25d2-4810-a669-1fcd1388b9f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_bd3f275f-1b57-4deb-b332-7e89866852b5" xlink:to="loc_srt_LitigationCaseTypeDomain_a578ddf5-25d2-4810-a669-1fcd1388b9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_ac809dce-ef6f-41e3-b11e-b24c303dad90" xlink:href="eols-20211231.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a578ddf5-25d2-4810-a669-1fcd1388b9f5" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_ac809dce-ef6f-41e3-b11e-b24c303dad90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5e3eceb5-252a-46d2-9b0f-a0c144d77bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:to="loc_us-gaap_DebtInstrumentAxis_5e3eceb5-252a-46d2-9b0f-a0c144d77bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_502a5552-51d0-4f90-a81f-82063c69a8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5e3eceb5-252a-46d2-9b0f-a0c144d77bcc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_502a5552-51d0-4f90-a81f-82063c69a8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember_f3c54bc0-29ca-4e45-a4a4-7e5366ff308d" xlink:href="eols-20211231.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_502a5552-51d0-4f90-a81f-82063c69a8a0" xlink:to="loc_eols_DaewoongConvertibleNoteMember_f3c54bc0-29ca-4e45-a4a4-7e5366ff308d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1753c019-1142-4942-8b76-d1631d5e23fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1753c019-1142-4942-8b76-d1631d5e23fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8ca24f29-f2d4-4625-bc4c-98c670ea5696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1753c019-1142-4942-8b76-d1631d5e23fa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8ca24f29-f2d4-4625-bc4c-98c670ea5696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_efacc7d8-5d69-47b0-8ff8-ec5dedbc3575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8ca24f29-f2d4-4625-bc4c-98c670ea5696" xlink:to="loc_us-gaap_ConvertibleDebtMember_efacc7d8-5d69-47b0-8ff8-ec5dedbc3575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b99e5aeb-246b-4464-9bad-4b1b3176587a" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_4f7342ef-f447-4c73-8f90-9b025c4401e9" xlink:href="eols-20211231.xsd#eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:to="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_4f7342ef-f447-4c73-8f90-9b025c4401e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_3b44514f-a636-4843-a061-71b7c37fe51a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_3b44514f-a636-4843-a061-71b7c37fe51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_9b126f39-3703-4519-952b-44e9efa2eb76" xlink:href="eols-20211231.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_9b126f39-3703-4519-952b-44e9efa2eb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_75df47b8-0a0b-46a9-99c8-2187ca24190e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_75df47b8-0a0b-46a9-99c8-2187ca24190e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_d315228d-e6ca-4a2a-be69-853dd7787fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:to="loc_us-gaap_ConvertibleDebt_d315228d-e6ca-4a2a-be69-853dd7787fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_db99524e-d1f7-43d6-a6d6-67028aad07fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_db99524e-d1f7-43d6-a6d6-67028aad07fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_f0599b90-948e-4a09-b906-85a5e9f76d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba31943c-22fa-488d-9364-0518ad328890" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_f0599b90-948e-4a09-b906-85a5e9f76d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>eols-20211231_g1.jpg
<TEXT>
begin 644 eols-20211231_g1.jpg
M_]C_X  02D9)1@ ! @$ S #,  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]4HHHH **** "BDS2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,T +1
M0** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUYYLRQ Y$:\C'1FY/Z;?;]:Z[P[8"R@1 ,$J"V1@[F&3G@=.G/. !7">,?\
MC[D_X!_Z M>FF@ KS"Y3^Q+SCA8Y ?E)SM.#CG'\)P<_G7IXKS+QC_Q]R?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0C 8X*DC."#^F>F?0]^E<1X:UXZ.[12 A&/S=<J1QG'Z'OP/3! /2*XGXBS
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M<]8SCH,8QRH_ 5MT4 <[;^!+:(Y;<W'1FX^ORA370)&(P%48 & !P !VIU%
M"8K.U+P]!J/S2+\V#\PX;IC/'7&.,YK2HH YI/ %NI!)<X/0L,'VX4'\JW;#
M3X[!?*B7:N2<>Y[Y/)JQ10 C"LW6O#\>K[?,+#9G&T@=<>H/I6G10!%;6JVJ
MB)!A5& !_G_]=2T44 17%JER-LBAAG.& (SZ\U%#I<,!#I&BL.A5%!_,"K5%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY&)Z<X!V@9[]"?QH KS?#V$@A'<-V+;6'Y #^=<_I]_+X;G,4A)53\RJ<@Y
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBD- "T4E% "T4@I: "BDH% "T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M44 &*,444 %%%% !1110 4@%+10 4444 %%%% !1110 4444 %%%% !1110
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M MD-K&?WCC#<9PI'(]B?Y<\<&NGVUEW/AF"ZE^TNN6('!/RY&,''T&,=,=J
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MD00>:[E\?-L("Y]LJ3_CUP.E8MU:7'@R3S(R'C<8R0=I..A&>".HYZ=#]X4
M>CVT*VZK&HPJ@ #V P.M2XJAH>KKJT2W"<9X(R"01U''YCID$' S6A0 TUP'
MQ*U0.R6BG[OS,..IX7W! SQZ$'GMTGBCQ0FBI@8:5A\J_P#LQ]OY]!W(Y+PC
MX=?5Y?MTX!CW$G</OL<]A@8!Y/;^'!YP =;X-TDZ9;JK9W.=[ ]BP&!@@$8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+-)CY6* 'W4$G_T(5T/B77AHT1DX+GA%/<]SQV'4]/3()%:%A9+8QK GW4
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MEK9;'FA1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ I*6B@ %%%% !24M% "4"EHH ****
M$-%+10 E%+10 @I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&I:1J
M1A^+_P#4'ZC^8KAA7<^+_P#4'ZC^8KAA7%7^(^CR7_=_F_R0ZBBBL&>H@HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ****!%W0_^/A/K7HHKSK0_^/A/K7HHKMPWPGS><_QUZ"TM)2ULMCS0
MHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* "BBB@ HHHH 1AD&O1?#O\ Q[Q?[@KSINE>B^'?^/>+_<% &C1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?Y5Z)7G?AO\ X^8_Q_E7HE=V'^$^;SG_ 'CY(****V/-"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS"_\ ];)_UT;^=>GU
MYA?_ .MD_P"NC?SH AHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&Z5Z+X=_X]XO\ <%>=-TKT
M7P[_ ,>\7^X* -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ?[@H T:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *0TM% #<4ZBB@ HHHH *#110 F*7%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 8_B[_CUD_X!_Z&M<'7>>+O^/63_@'_
M *&M<'7%B?C^1]'DG^[O_$_R04445@>H%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%%# *!10*.@NYH>&_^/F/\
M?Y5Z)7G?AO\ X^8_Q_E7HE=V'^$^;SG_ 'CY(****V/-"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS"_\ ];)_UT;^=>GU
MYA?_ .MD_P"NC?SH AHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&Z5Z+X=_X]XO\ <%>=-TKT
M7P[_ ,>\7^X* -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#'\7?\>LG_ /_ $-:X.N\\7?\>LG_
M  #_ -#6N#KBQ/Q_(^CR3_=W_B?Y(****P/4"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBBA@% HH%'07<T/#?_
M !\Q_C_*O1*\[\-_\?,?X_RKT2N[#_"?-YS_ +Q\D%%%%;'FA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YA?\ ^MD_ZZ-_
M.O3Z\PO_ /6R?]=&_G0!#1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% "-TKT7P[_P >\7^X*\Z;
MI7HOAW_CWB_W!0!HT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 8_B[_CUD_X!_P"AK7!UWGB[_CUD
M_P" ?^AK7!UQ8GX_D?1Y)_N[_P 3_)!1116!Z@4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444, H%% HZ"[FAX;
M_P"/F/\ '^5>B5YWX;_X^8_Q_E7HE=V'^$^;SG_>/D@HHHK8\T**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,+_ /ULG_71
MOYUZ?7F%_P#ZV3_KHW\Z (:*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1NE>B^'?\ CWB_W!7G
M3=*]%\._\>\7^X* -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***,T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% &/XN_X]9/^ ?^AK7!UWGB[_CU
MD_X!_P"AK7!UQ8GX_D?1Y)_N[_Q/\D%%%%8'J!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110P"@44"CH+N:'AO
M_CYC_'^5>B5YWX;_ ./F/\?Y5Z)7=A_A/F\Y_P!X^2"BBBMCS0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\PO_ /6R?]=&
M_G7I]>87_P#K9/\ KHW\Z (:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1NE>B^'?^/>+_ '!7
MG3=*]%\._P#'O%_N"@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9I13781@LQ  &23P !WKA=7\72WLGDVF0N"/E7+MZD<9'MC![GT !WE%>?\
MV34K/][F0[?]L2=>/NY;/Y<=:TO#/C)KEEMI^68G#\#GL".![ CV&.] '745
M%=7 MD:5NB*6..N ,UP>D6!\42/-.Y&S;PH['=@#.< 8]#GZ\T >@T5P-Y&_
MA*97B):*0<AB.<=1QW&<@XXSCGG/=0SB91(O*L 0?8C(ZT 24E9VNZTNE1ER
M?G((0=<GZ<<#O_B17/\ @N:>^D>>1V* $8).TLW. ,8&/;!''8XH [$4M HH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Q_%W_'K)_P#_P!#6N#KO/%W_'K)_P  _P#0UK@Z
MXL3\?R/H\D_W=_XG^2"BBBL#U HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH8!0**!1T%W-#PW_P ?,?X_RKT2
MO._#?_'S'^/\J]$KNP_PGS><_P"\?)!1116QYH4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %>87_ /K9/^NC?SKT^O,+_P#U
MLG_71OYT 0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 C=*]%\._\ 'O%_N"O.FZ5Z+X=_X]XO
M]P4 :-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !2&EHH 2EHI* ,7Q?J@LH&7^*4%0/8CYCU'0?J16/X!TC[
MUXP_V4S_ ./'D?@"#_>!K(\2Z@=8N/+CY4$(@SP23@GKCD]^.,9KT"PLQ91I
M"/X% X&,GN<>YYH PO'UYY4*Q \R-R,=57D\_7;[_K5?X?Z;L5KH]6.U>".!
M@D^^3Q[8^M1?$7_EC_VT_P#9:VO!W_'I'_P/_P!#:@#8+5Y[XXTX6TPE4864
M9[8W#AN!^!/J2:]$%<9\1O\ EC_VT_\ 9: -N2Y^U6)E)R6MV)(QUV'/3W_*
ML/X=_P#+;_MG_P"S5L^$4$EHBL,@AP0>007;BL8^'+K1I-]H=ZMU!VCH> 02
M >.XP>O3N 6/B"Z^5&I^^7)''. /FY^I'U_"MS2YA#;1R-PJPH2?8(":YN'P
MK<:I+]HNR%&1\N<\ @[1M. ,9YSG/..<U'XTUPW3?8(AD!AN(.2S=E 'H>O?
M=V&.0"A<S/XHN0BY"=L\A5'4X'<_S(&<8KT"RM%LT6%/NH !T_/C')ZGWK+\
M/Z2FAQ;Y#AF"ERQ  /9>N.,XSW/X :EM>1W6?+=6QUVL#C/TH GHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH Q_%W_'K)_P  _P#0UK@Z[SQ=_P >LG_ /_0UK@ZXL3\?
MR/H\D_W=_P")_D@HHHK ]0**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ****& 4"B@4=!=S0\-_P#'S'^/\J]$KSOP
MW_Q\Q_C_ "KT2N[#_"?-YS_O'R04445L>:%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7F%__K9/^NC?SKT^O,+_ /ULG_71
MOYT 0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 C=*]%\._P#'O%_N"O.FZ5Z+X=_X]XO]P4 :
M-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_'\CZ/)/]W?^)_D@HHHK ]0**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ****& 4"B@4=!=S0\-_\ 'S'^/\J]$KSO
MPW_Q\Q_C_*O1*[L/\)\WG/\ O'R04445L>:%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7F%_P#ZV3_KHW\Z]/KS"_\ ];)_
MUT;^= $-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 (W2O1?#O_ ![Q?[@KSINE>B^'?^/>+_<%
M &C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4  >P&!3Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,?Q=_P >LG_ /_0UK@Z[SQ=_QZR?
M\ _]#6N#KBQ/Q_(^CR3_ '=_XG^2"BBBL#U HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH8!0**!1T%W-#PW_Q
M\Q_C_*O1*\[\-_\ 'S'^/\J]$KNP_P )\WG/^\?)!1116QYH4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>87_\ K9/^NC?S
MKT^O,+__ %LG_71OYT 0T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 C=*]%\._\>\7^X*\Z;I7
MHOAW_CWB_P!P4 :-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &/XN_P"/63_@'_H:UP==YXN_X]9/
M^ ?^AK7!UQ8GX_D?1Y)_N[_Q/\D%%%%8'J!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110P"@44"CH+N:'AO_CY
MC_'^5>B5YWX;_P"/F/\ '^5>B5W8?X3YO.?]X^2"BBBMCS0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\PO_P#6R?\ 71OY
MUZ?7F%__ *V3_KHW\Z (:*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1NE>B^'?^/>+_<%>=-TK
MT7P[_P >\7^X* -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#'\7?\>LG_ /_0UK@Z[SQ=_QZR?\
M _\ 0UK@ZXL3\?R/H\D_W=_XG^2"BBBL#U HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH8!0**!1T%W-#PW_Q\
MQ_C_ "KT2O._#?\ Q\Q_C_*O1*[L/\)\WG/^\?)!1116QYH4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>87_P#K9/\ KHW\
MZ]/KS"__ -;)_P!=&_G0!#1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% "-TKT7P[_Q[Q?[@KSIN
ME>B^'?\ CWB_W!0!HT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 8_B[_CUD_X!_Z&M<'7>>+O^/63
M_@'_ *&M<'7%B?C^1]'DG^[O_$_R04445@>H%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%# *!10*.@NYH>&_^
M/F/\?Y5Z)7G?AO\ X^8_Q_E7HE=V'^$^;SG_ 'CY(****V/-"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS"_\ ];)_UT;^
M=>GUYA?_ .MD_P"NC?SH AHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&Z5Z+X=_X]XO\ <%>=
M-TKT7P[_ ,>\7^X* -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#/$N3^0;)_"K.A>.)-XCN"&5CC=@*1G '3 P._?OGC%=U7F/C+_C[D_X!_Z
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M !_E7HE=V'^$^;SG_>/D@HHHK8\T**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O,+_\ ULG_ %T;^=>GUYA?_P"MD_ZZ-_.@
M"&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** $;I7HOAW_CWB_W!7G3=*]%\._\ 'O%_N"@#1HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** ,CQ5IIO[=D499?F7KU'7@=21D >IKC?"_BC^R,QN,Q,<\8W X
MZCIG..1^([@^DUGW_A^"_.^5 6]1E2>G4J1GIWZ4 95YX]@B4-&"[$?=QMQT
MX)/],]/QKE-/L9/$,Y=NA;+G/ !/0$Y[<*.?R!KM?^$.M/\ GG_X^_\ \56K
M:VJVJB)!A5& !_G_ /70 74 N4:)LX=2IQUP1BO-XI9?#%P>,XR.1@,A/4=<
M9Q^!X/<5Z;BH[BU2Y&V10PSG# $9]>: .;?XA0 $JCDXX!"@9^NXX_(UA,TW
MBZ8<;40>Y502>>O+'IQC..P!(ZS_ (0VT_YY_P#C[_\ Q5:MO:I;#;&H49SA
M0 ,^O% "65FMFBPI]U  .GY\8Y/4^]8WB[7O[-C\M#^]D&!R00#G+<?ITYYY
MP16_5"]T.&^<32IN90 ,DXP#G&,X/7N* ,+P/H/D+]KD'S./DR#D#GGG^]_+
MOR175YH)H H \_!;PK=%RG[I]P&"3\A(/!/=>,@_U!JQKGB#_A(%%K;(Y)8%
MLX' X&<$\9())P!@?AW-&: *6C:?_9T*09R5'/U)R>PXR>/:KM%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% &/XN_X]9/\ @'_H:UP==YXN_P"/63_@'_H:UP=<6)^/Y'T>
M2?[N_P#$_P D%%%%8'J!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110P"@44"CH+N:'AO\ X^8_Q_E7HE>=^&_^
M/F/\?Y5Z)7=A_A/F\Y_WCY(****V/-"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KS"__P!;)_UT;^=>GUYA?_ZV3_KHW\Z
M(:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 1NE>B^'?^/>+_<%>=-TKT7P[_Q[Q?[@H T:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ,?Q=_P >LG_ /_0UK@Z[SQ=_QZR?\ _]#6N#KBQ/Q_(^CR3_
M '=_XG^2"BBBL#U HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH8!0**!1T%W-#PW_Q\Q_C_*O1*\[\-_\ 'S'^
M/\J]$KNP_P )\WG/^\?)!1116QYH4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %>87_\ K9/^NC?SKT^O,+__ %LG_71OYT 0
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 C=*]%\._\>\7^X*\Z;I7HOAW_CWB_P!P4 :-%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &/XN_P"/63_@'_H:UP==YXN_X]9/^ ?^AK7!UQ8GX_D?1Y)_
MN[_Q/\D%%%%8'J!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110P"@44"CH+N:'AO_CYC_'^5>B5YWX;_P"/F/\
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M!#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% "-TKT7P[_Q[Q?[@KSINE>B^'?\ CWB_W!0!HT44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 8_B[_CUD_X!_Z&M<'7>>+O^/63_@'_ *&M<'7%B?C^1]'D
MG^[O_$_R04445@>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%%# *!10*.@NYH>&_^/F/\?Y5Z)7G?AO\ X^8_
MQ_E7HE=V'^$^;SG_ 'CY(****V/-"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KS"_\ ];)_UT;^=>GUYA?_ .MD_P"NC?SH
M AHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!&Z5Z+X=_X]XO\ <%>=-TKT7P[_ ,>\7^X* -&B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH HZQK":2@ED!(+!?E )R03W(]*QO^%@P?W9/R7_XJCX@_P#'
MNO\ UU'_ *"U5_#'ABWO+=9I%W,Q;^)AT8C'!'I0!8_X6#!_=D_)?_BJW=.U
M./45,D1W*#C.".>#W ]:S_\ A#;7_GG_ .//_P#%5?L--CTY?+B&%)SC)/.
M.Y/I0!;-9VIZ_#IG$K88@D* 23C^6>V<#\C3?$&K_P!E0F;JV0%!S@D_3T&3
MVSC&:XG0-);Q#*[S,< 99AC))X YZ=/3  QQQ0!TT/CVWD(4AU![LHQ_XZ2?
MTK;L=0COU\V)MRYQ^([8/(K)F\%VL@*A2I]59L_^/$C]*X_]YX8N?[VWZ@,I
M_P ^X##OB@#TQW$8+,< #))X  [URY\<F9S'!"T@'0@G)'KM"D@9_P#KXZ5?
M\477F6;RH>&5"",C(9E_F#5/X??ZAO\ KJ?_ $%: +FA^*5U)C"Z^7*"?E)S
MG'7L.1W&/?UQMUP?CBW-E.ETG!8 ^IW(1S@\=,?ET]>\H BNKI;53*YPJC))
M_P __KK/T7Q''JY98PPV@$[AQS[@D?G^'0XY?QCKK7LGV.+)53@@ Y9P<8]2
M >@]?7@UU'AW0QH\>S.78Y8@=_0=\#MGW/&<4 :M%(#FEH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH Q_%W_ !ZR?\ _]#6N#KO/%W_'K)_P#_T-:X.N+$_'\CZ/)/\ =W_B
M?Y(****P/4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBBA@% HH%'07<T/#?_'S'^/\J]$KSOPW_P ?,?X_RKT2
MN[#_  GS><_[Q\D%%%%;'FA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5YA?_P"MD_ZZ-_.O3Z\PO_\ 6R?]=&_G0!#1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% "-TKT7P[_Q[Q?[@KSINE>B^'?^/>+_ '!0!HT444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% ',_$'_CW7_KJ/_06K&T/QH-.C2W:/(4G+!N<%B>F.V?6NZN;5+D;9%##
M.<, 1GUYJG-X?MY@5,28/]U0I_-<&@"G8>-+>[.W)0]O,  /7N"0/QQ[5N-7
M)Z[X(CV&2W!5E&=N2P.,D]<G)[=NV.<U1\#:T4?[&V2K9*^BD D_@?Y]N2:
M+7Q$F(6*/^$EB1[J !_,UI>"+<16RL/XV9C]<[?Y**ROB+_RQ_[:?^RUM>#?
M^/2/_@?_ *&U &P:XKXB0@-%)_$0P)]E((_F:[>N+^(W_+'_ +:?^RT 7$1]
M3TT*H^;9@ 9Y$;=._)"_GZ52\$:W%:HT$C;6+E@6X4@J._0=.^.V,UM^#?\
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M ?\ H:UP==YXN_X]9/\ @'_H:UP=<6)^/Y'T>2?[N_\ $_R04445@>H%%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/!3EO7#*.O3GC:>/I0!Z!FN#^(-YYDJ0C&$7/'7+'D'\ #^-07?C:Y/R?*C
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M_P >LG_ /_0UK@Z[SQ=_QZR?\ _]#6N#KBQ/Q_(^CR3_ '=_XG^2"BBBL#U
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH8!0**!1T%W-#PW_Q\Q_C_*O1*\[\-_\ 'S'^/\J]$KNP_P )\WG/
M^\?)!1116QYH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %>87_\ K9/^NC?SKT^O,+__ %LG_71OYT 0T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 C=*]%\._\>\7^X*\Z;I7HOAW_CWB_P!P4 :-%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2&EHH 2ES11
M0 4E+10 E+110 4444 %5'TF)Y/M!0&3 Y(].AQTR/7KVSBK=% "&@4M% $-
MS91W6/,16QTW*#C/7K26UE':Y\M%7/7:H&<=.E3T4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% &/XN_X]9/^ ?^AK7!UWGB[_CUD_X!_P"AK7!UQ8GX_D?1Y)_N[_Q/
M\D%%%%8'J!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110P"@44"CH+N:'AO_CYC_'^5>B5YWX;_ ./F/\?Y5Z)7
M=A_A/F\Y_P!X^2"BBBMCS0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *\PO_ /6R?]=&_G7I]>87_P#K9/\ KHW\Z (:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH 1NE>B^'?^/>+_ '!7G3=*]%\._P#'O%_N"@#1HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH Q_%W_'K)_P#_P!#6N#KO/%W_'K)_P  _P#0UK@ZXL3\?R/H\D_W
M=_XG^2"BBBL#U HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH8!0**!1T%W-#PW_P ?,?X_RKT2O._#?_'S'^/\
MJ]$KNP_PGS><_P"\?)!1116QYH4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>87_ /K9/^NC?SKT^O,+_P#ULG_71OYT 0T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 C=*]%\._\ 'O%_N"O.FZ5Z+X=_X]XO]P4 :-%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "BBB@ HHHH **** $;I7HOAW_ (]XO]P5YTW2O1?#O_'O%_N"@#1HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% !1110 4444 %%%% !7F%__K9/^NC?SKT^O,+_ /ULG_71OYT
M0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 C=*]%\._P#'O%_N"O.FZ5Z+X=_X]XO]P4 :-%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444, H%%
MHZ"[FAX;_P"/F/\ '^5>B5YWX;_X^8_Q_E7HE=V'^$^;SG_>/D@HHHK8\T**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,+_
M /ULG_71OYUZ?7F%_P#ZV3_KHW\Z (:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1NE>B^'?\
MCWB_W!7G3=*]%\._\>\7^X* -&BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNWGOZ=<\^G(!VU<7\1_^6/\ VT_]EKLS7G?C:\^VW B3+; %P.1N)YP!GGD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O,+__ %LG_71OYUZ?7F%__K9/^NC?SH A
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!&Z5Z+X=_X]XO]P5YTW2O1?#O_'O%_N"@#1HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O,+__ %LG_71OYUZ?7F%__K9/^NC?SH AHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!&Z5Z+X=_X]XO]P5YTW2O1?#O_'O%_N"@#1HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8_B[_
M (]9/^ ?^AK7!UWGB[_CUD_X!_Z&M<'7%B?C^1]'DG^[O_$_R0E+116!Z@44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444, H%% HZ"[FAX;_P"/F/\ '^5>B5YWX;_X^8_Q_E7HE=V'^$^;SG_>
M/D@HHHK8\T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "O,+_ /ULG_71OYUZ?7F%_P#ZV3_KHW\Z (:*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH 1NE>B^'?\ CWB_W!7G3=*]%\._\>\7^X* -&BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% "-TKT7P[_ ,>\7^X*\Z;I7HOAW_CWB_W!0!HT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH R_$6L_V1%YH&6)VJ.V2"<GVX_'I
MQU'+E+_7_F^Y&P(Z[$P0.W+,#^(YXXS7<RP++C< =I!&0#@CH1[^]/H \VN=
M,O- &\$B-6!RC93)QR5_3D8/3TKJ/"7B(ZJK))CS$QTXR,8SC/7/7  Y%7O$
MUXMK;R%OXE*CIDEA@?XGV!KE/AY"3,\G\(CP3[LP(_D: .\-<%K7BN74'\BU
MW!>VP'>V.<\<@<=N<9SZ#I/&%W]EMGP<%\*.,YSU'_?.?_UU@_#VP#L]P1]P
M *<<9.=W;J!CIV/O0 )X>U!EWF4@X/RF5MW';C*\_7ZXJII_B:XT>4Q7!9E!
M^96.6'3D$_IS@CZYKT2N-^(EAQ'<CU*'DY[E>.G'/Y_D =@CB0!E.01D$<@@
M]Z\^\(H-5N6>X&\["WS<C.5'3IP#P.@[=!73>"KS[1;*.28R5.?;D8]@"!7,
M^"W%C=-%*=K%63G^]N'&>G8_7MVH U_'NE!XQ=*OS*PW$8&0>,GN<$ #TR:V
M/#-VUW;1R/RQ!!//.TE<\]SCGWK.\=:DL,/V?J\A'&>0 <[OS&.WMT-6-+F&
MA6:-/Q@$X[Y8E@N#CGGD=N>PS0!%XRU[^SX_)0XDD'4$94=SZ\]!^)SD51\#
MZ#Y0^V2#!880$#H?XO7GH.G&>H-9>C::_B.<W,P_=Y^8CY0<#A1^F>^.IR1G
MT,T "TM(!BEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH Q_%W_'K)_P#_P!#6N#KO/%W_'K)
M_P  _P#0UK@ZXL3\?R/H\D_W=_XG^2"BBBL#U HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH8!0**!1T%W-#PW
M_P ?,?X_RKT2O._#?_'S'^/\J]$KNP_PGS><_P"\?)!1116QYH4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>87_ /K9/^NC
M?SKT^O,+_P#ULG_71OYT 0T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C=*]%\._\ 'O%_N"O.
MFZ5Z+X=_X]XO]P4 :-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^AK7!UWGB[_CUD_X!_Z&M<'7%B?C^1]'DG^[O_$_R04445@>H%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%# *
M!10*.@NYH>&_^/F/\?Y5Z)7G?AO_ (^8_P ?Y5Z)7=A_A/F\Y_WCY(****V/
M-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MS"__ -;)_P!=&_G7I]>87_\ K9/^NC?SH AHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&Z5Z+
MX=_X]XO]P5YTW2O1?#O_ ![Q?[@H T:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,444 %+24
M4 %%%% !1110 4M)10 M%)10 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8_B[_CUD_X
M!_Z&M<'7>>+O^/63_@'_ *&M<'7%B?C^1]'DG^[O_$_R04445@>H%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M# *!10*.@NYH>&_^/F/\?Y5Z)7G?AO\ X^8_Q_E7HE=V'^$^;SG_ 'CY(***
M*V/-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KS"_\ ];)_UT;^=>GUYA?_ .MD_P"NC?SH AHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&Z
M5Z+X=_X]XO\ <%>=-TKT7P[_ ,>\7^X* -&BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\7?\>LG
M_ /_ $-:X.N\\7?\>LG_  #_ -#6N#KBQ/Q_(^CR3_=W_B?Y(****P/4"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBBA@% HH%'07<T/#?_ !\Q_C_*O1*\[\-_\?,?X_RKT2N[#_"?-YS_ +Q\
MD%%%%;'FA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5YA?\ ^MD_ZZ-_.O3Z\PO_ /6R?]=&_G0!#1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"-TKT7P[_P >\7^X*\Z;I7HOAW_CWB_W!0!HT444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% "-TKT7P[_ ,>\7^X*\Z;I7HOAW_CWB_W!0!HT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"/>+_<%>=-TKT7P[_Q[Q?[@H T:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4445@>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%%# *!10*.@NYH>&_\ CYC_ !_E7HE>=^&_^/F/\?Y5Z)7=
MA_A/F\Y_WCY(****V/-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KS"_P#];)_UT;^=>GUYA?\ ^MD_ZZ-_.@"&BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** $;I7HOAW_ (]XO]P5YTW2O1?#O_'O%_N"@#1HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***!
M0 AKG?$_BH::/)CYE(^H4'N??T'XGC -SQ)KXT= <9=\[1VXZD^PS]3^9'"^
M'Y(&E,MVQP.1D%@S9_BQD^^,8/<]B ;'A;PL;P_;+GE2<JK<EB>=QSV_]"ZG
MCKW!K&_X3*T_YZ?^./\ _$T^'Q9;3L(U?+,0 -K]2<#JM %/Q]"9+<,.B2*3
M[#!7^9%5OAY<!HI(NZN&]L, !_Z":Z/4+07L;PG^-2.1G![''L>:\[TK4'\.
M3LC@D [7 R,C/##.,^HSU![9S0!Z8:Y7XA3 0I'_ !&3('LJD'^8J^WC.U4$
M[\D#H%;)]N0!^9KE=3OI/%,RQ1+@*#C/8$\N2!QQCCGVR3R =)X#MS%;;C_&
M[,/IPO\ -370U6TRP&GQ+ O1!U]3U)ZGJ>:9K&J+I<1G;G' &0"2>@_Q]LG%
M &#XU\0_9E^RQD;G!#]R%(Z>F6'X@=N0:L^#=!_L^/SG&))!R"!E1V'KSU/X
M#&16+X2TQM5E-],=P5LYSR7&".!V ^@Z <9%=Y0!Y]IW[[4CO^;$LO7G[H;;
MU],#'I@5U_B2W%Q;2J>R%N/5?F'ZBN2U$?V#??:64F-F+#ISN&&Q]"3Q],]<
MUI^(O%T,T#QPOEW&W[I'!^]]X#MD>O/X@ 3X=W.Z.2+'W6#9_P!X8QCVV_K7
M6UA>#M).GPY<8>0[B",$#H ?Y^V2,9K=H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_%W_'
MK)_P#_T-:X.N\\7?\>LG_ /_ $-:X.N+$_'\CZ/)/]W?^)_D@HHHK ]0****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M****& 4"B@4=!=S0\-_\?,?X_P J]$KSOPW_ ,?,?X_RKT2N[#_"?-YS_O'R
M04445L>:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7F%_\ ZV3_ *Z-_.O3Z\PO_P#6R?\ 71OYT 0T444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 C=*]%\._\>\7^X*\Z;I7HOAW_ (]XO]P4 :-%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M% %#5]&CU
M90D@Z'((X8>N#SU[_P"(%8__  KZW_O2?FO_ ,373T4 <Q_PKZ#^])^:_P#Q
M-2V?@F"T=907)0Y 8C&1TZ '@UT5!H 9574-%AU#'FH&([\@]^,C!QSTZ5<Q
M2T <Q_PKZW_O2?FO_P 36YIVDQ:<"L*[=QR>22?Q))JW10 5F:WX>CU?;YA8
M;,XVD#KC/4'TK3H- $5K;+:J(HQA5& !_G_]=2T"B@"*XM4N1MD4,,YPP!&?
M7FHH=+A@(=(T5AT*HH/Y@5:HH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?Q=_QZR?
M\ _]#6N#KO/%W_'K)_P#_P!#6N#KBQ/Q_(^CR3_=W_B?Y(****P/4"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MBA@% HH%'07<T/#?_'S'^/\ *O1*\[\-_P#'S'^/\J]$KNP_PGS><_[Q\D%%
M%%;'FA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5YA?_ .MD_P"NC?SKT^O,+_\ ULG_ %T;^= $-%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M(W2O1?#O_'O%_N"O.FZ5Z+X=_P"/>+_<% &C1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C^+O^/6
M3_@'_H:UP==YXN_X]9/^ ?\ H:UP=<6)^/Y'T>2?[N_\3_)!1116!Z@4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444, H%% HZ"[FAX;_X^8_Q_E7HE>=^&_P#CYC_'^5>B5W8?X3YO.?\ >/D@
MHHHK8\T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O,+_P#ULG_71OYUZ?7F%_\ ZV3_ *Z-_.@"&BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M$;I7HOAW_CWB_P!P5YTW2O1?#O\ Q[Q?[@H T:*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?Q=_Q
MZR?\ _\ 0UK@Z[SQ=_QZR?\  /\ T-:X.N+$_'\CZ/)/]W?^)_D@HHHK ]0*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ****& 4"B@4=!=S0\-_\ 'S'^/\J]$KSOPW_Q\Q_C_*O1*[L/\)\WG/\
MO'R04445L>:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7F%_P#ZV3_KHW\Z]/KS"_\ ];)_UT;^= $-%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 (W2O1?#O_ ![Q?[@KSINE>B^'?^/>+_<% &C1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]@!Z_P#ZSQ7.^%M<N-6E9G(\M5Y 48!/3!SN[$\Y'4=Q@ ZP44@I: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *"<44C4 S&\7-_HSC_<_P#0UKA:[;Q:3]G9/4K^C UQ&:XL1\=_
M(^CR56P[_P 3?X(6BBBL#U HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH>P!0**3.*.@K&CX;_ ./F/\?Y5Z$*
M\[\//MN(S]?Y5Z&#FN[#OW3YK.E?$7\D.-+29I:V/.L%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% " YKS&__ -;)_P!=&_G7
MIN<<UYA=N))'8=W8_F<T 1T44M "44M% "44M% "44M% "44M% "44M% "44
MM% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M!&* &MTKT3P
M\<6\7^X*\[?@$^U>C:&GEP1H>R#- &A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@7G'). "2>I_P]L#-9'@_P ._8$\^0$2N.AXVC/3'J< G/3I@<YZ.@!:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *1J6D:@$8?B__ %!^H_F*X85W/B__ %!^H_F*X85QU_B/
MH\E_W?YO\D.HHHKG9ZB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH$7=#_X^$^M>BBO.M#_X^$^M>BBN
MW"_"SYO.?XZ]!:6DI:V6QYH4444P"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** &M7ETWWC]37J+5Y=-]X_4T -%+2"EH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!LG2O2M(_U2?2O-9.E>E:1_JD^E %RBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Y]\/O]>W_ %R/_H2UZ#7GWP^_U[?]<C_Z$M>@T <7\1O^6/\
MVT_]EK:\'?\ 'I'_ ,#_ /0VJCX_L?.B6<?\LVYY&,-QG\P/S_)? -YYL+1$
MY,;<#'16Y'/UW>_Z4 =.*XOXC?\ +'_MI_[+7:5P7Q!O/,E2$8PBYXZY8\@_
M@ ?QH Z/P;_QZ1_\#_\ 0VK9-4M"M?LL$<>,80$@YSDC+=?<FK;N(P68X &2
M3P !WH J:MJBZ7$9FYQT&0"2>@_Q]LG%<=X8TAM:E-Y/\R*W.[G<V.!CT''M
MT&,9Q%?3-XHNA$G"+D \D!1U<CU/X=@?6N^LK-;-%A3[J  =/SXQR>I]Z .+
MEU"7Q+<&WB<I" WW<\KTR1E2=QP,=@>G4EE_I,OA4+<Q2[@6 (P5!X)&1D@C
M&?0CMZB/X??Z]O\ KD?_ $):Z;QHX6U<$]2H'N=P./R!- &AI.HC4HEN ,;@
M>#V()!_45;KG? B,MMENA=BO.>.!^'S _P ^]=%0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2-2T
MC4 C#\7_ .H/U'\Q7#"NY\7_ .H/U'\Q7#"N.O\ $?1Y+_N_S?Y(=1117.SU
M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110(NZ'_ ,?"?6O117G6A_\ 'PGUKT45VX7X6?-YS_'7H+2T
ME+6RV/-"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 UJ\NF^\?J:]1:O+IOO'ZF@!HI:04M !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -DZ5Z5I'^J
M3Z5YK)TKTK2/]4GTH N4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=H4G&.5+ @_0\\9/83:%X.FEF%]>,-X;=MSDDC.,D$ 8(! &1CCCI7:FN/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#-U_6AI$?G%=V6"@9QR<GKSV![&N7O?B TZ-&D>
MUF! ;>3C/?@#GTYX-=U10!Y3H&M'2)/."[LJ5(SC@X/7GN!V-=CHGC0:E*(#
M'MW X.[=R!GT'8&NEHH BNK9;I3$XRK#!!_S_P#JKSV32KKP])YT8)5<_,HR
MI4<G<!T'KGTR#QFO1Z* //7\=7-Q^[0*&8@ JI+9ST )(YZ=*N>'?"[W;?:K
MO)YX5\[B1QEL\X'8'K].O;48H 2N4\;ZNT>VRCSND )QW!) 4=^3U_+G)KJ\
M4M &+X6T+^RHOF_UCX+<Y'&<#TX!Y]\\D8K:HHH X^_\/W%C<&[M/FWDD@D#
MJ<E3DC(/;N/J 27VG7VN;8IU2-%.21@^W0,QR 3CH/4]*["B@"&RM%LT6%/N
MH !T_/C')ZGWJ:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "D:EI&H!&'XO_P!0?J/YBN&%=SXO
M_P!0?J/YBN&%<=?XCZ/)?]W^;_)#J***YV>H@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****!%W0_^/A/K
M7HHKSK0_^/A/K7HHKMPOPL^;SG^.O06EI*6MEL>:%%%%, HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K5Y=-]X_4UZBU>73?>/U-
M#12T@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ;)TKTK2/]4GTKS63I7I6D?ZI/I0!<HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !2-2TC4 C#\7_Z@_4?S%<,*[GQ?_J#]1_,5PPKCK_$
M?1Y+_N_S?Y(=1117.SU$%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110(NZ'_Q\)]:]%%>=:'_ ,?"?6O1
M17;A?A9\WG/\=>@M+24M;+8\T****8!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% #6KRZ;[Q^IKU%J\NF^\?J: &BEI!2T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 V3I7I6D?ZI/I7FLG2O2M(_U2?2@"Y1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% "8I:** "BBB@! *7%%% #:7%+10 F*,4M% "8I:** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D
M:EI&H!&'XO\ ]0?J/YBN&%=SXO\ ]0?J/YBN&%<=?XCZ/)?]W^;_ "0ZBBBN
M=GJ(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@1=T/\ X^$^M>BBO.M#_P"/A/K7HHKMPOPL^;SG^.O0
M6EI*6MEL>:%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!K5Y=-]X_4UZBU>73?>/U- #12T@I: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;)TKTK2
M/]4GTKS63I7I6D?ZI/I0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%%% !1110 4444 %%%% !1110 V3I7I6D?ZI/I7FLG2O2M(_U2?2@"Y1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )GM
M0&!XHKG[J1BQY[T =#29KF<GU-'F'WH Z;-&:YGS#[T>8?>@#ILT9KF?,/O1
MYA]Z .FS1FN9\P^]'F'WH Z;-&:YGS#[T>8?>@#ILT9KF?,/O1YA]Z .FS1F
MN9\P^]'F'WH Z;-&:YGS#[T>8?>@#ILT9KF?,/O1YA]Z .FS1FN9\P^]'F'W
MH Z;-&:YGS#[T>8?>@#IMU+7+^:?>DR?4T =317+9/J:,GU- '4T5RV3ZFC)
M]30!U-%<MD^IHR?4T =31FN6R?4UO:4<QKGW_F: +=%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%!XI-U "T4"B@ HI,T9H 6BC-%
M !12$XI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "D-+2,<4!L8?C#_ %!^H_F*X?M7;^,&
M_P!')]P/UKB,=JXJ_P 1]'DO^[O_ !/\D***!16#/304444#"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBC-!-R
M[H?_ !\)]:]%%>=Z NZX0>_\J]#0YKMPWPGSN<_QUZ#J6DI:V1Y@4444P"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &M7ETWWC]37
MJ3#->7W2;'=?[K$?D: (Q2TE+0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% #9.E>E:1_JD^E>:OTKT
M?19-\*..A7- %^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *YN[^^:Z.N=O!AV'H: (<4M)10 M%)10 M%)10 M%)10
M M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 N:2BB@ HHHH ****
M"BBB@ -;VD_ZM?Q_G6":WM)_U:_C_.@"W1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% #9'$8+,< #))X  [UPFK^+I;Z3R;3(7! VKE
MV]2.,CVQ@]SZ#6\?WGE0K$#@R-R,=57D\_7;[_K5?X?:;L5KH]6.U>".!@D^
M^3Q[8Z]: ,W['J5G^]S(=O;>).O'W<MGKZ<=:T?#/C)KIEMI^68G#\#GL".!
M[ CV&.]=A7G?CK31:S"51A91GMC<.&X'X$^I)H [ZZN!;(TK=$4DXZX S7":
M1IY\4R/-.Y&S;PH['=@#.< 8]#GZ\UU,EU]JL6E)R6MV)(QUV'/3WS]*P_AR
M/]=_VS_]FH JWL3^$IE>(EHI!R&(YQU''<9R#CC..><]W%.)U$B\JP!!]CR*
MY;XALHBC4_?+DCCG !W<_4CZ_A6YI<P@MHY&X584)/L$!- #-=UE=*C+D_.0
M0@ZY/TXX'?\ Q(KG_!<\]](\\CL4 (P2=I9N< 8P,>V"..QQ67<S/XJN0BY"
M=L\A5'4D#N?YD#.,5W]E:+9HL*?=0 #I^?&.3U/O0!.*6D%+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !36I310!@>,O^/<_[RUQ5=MXS/\ HY_WEKB<YKBQ/\3Y'TF2W^KOU?Z
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M ****  UO:3_ *L?C_.L&M[2O]6/Q_G0!;HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#B_B/\ \L?^VG_LM;7@W_CTC_X'_P"AM61\
M1825BD_A!8$^[ $?R-:7@>X$MLJC^!F4_7.[^3"@#?KB_B/_ ,L?^VG_ ++7
M:5Q/Q&<$Q+GD!SCO@[<'\<'\J -KP@@DLT5AD$."#R""[<5C_P#".76BR;[,
M[U;J#M'0\ @D \=Q@]>G?;\((4M8P1CACSZ%B0?Q'-;.: .+B\+7&JR_:+PA
M1D?+G/ (.T;3@#&><YSS@YS47C373=-]@B&<,-V#DLW90!Z'J.N[L,<[?BOQ
M#_9:;4(\U^@/8?WL?H,]_7!%97@?P^4/VR08X_=\]B""V/<=/Q..AH V/#VD
M)H4.^0X9@I<L0 #V7KCC.,]S^ &I;7L=UGRW5L==K XSTZ5P-C'_ ,)5=,TI
M*KM) 4YP!@  GIUR>.3G@9XN>(?#PT0+>6Q8%7Y[@ YQSCIVYSG.#[@'<T52
MT;4/[1A2?&"PY^H.#W/&1Q[5=H **** "BBB@ HHHH ;)($ZTS[2*6:$2\&H
MOL H D^TK1]I6HOL H^P"@"7[2M'VE:B^P"C[ * )?M*T?:5J+[ */L H E^
MTK1]I6HOL H^P"@"7[2M'VE:B^P"C[ * )?M*T?:5J+[ */L H E^TK1]I6H
MOL H^P"@"7[2M'VE:B^P"C[ * )?M*T?:5J+[ */L H E^TK1]I6HOL H^P"
M@"7[0M!N%J+[ *7[ * ,OQ3&;N I&,MN'%<I_8L_]S]:[X:>M+]A%93HJ4KG
M;ALPJ4(<B[W. _L.?^Y^M']B3_W#^==_]A%'V$5/U=&_]LUC@/[$G_N'\Z/[
M$G_N'\Z[_P"PBC["*/JZ#^V:QP']B3_W#^=']B3_ -P_G7?_ &$4?811]70?
MVS6. _L2?^X?SH_L2?\ N'\Z[_["*/L(H^KH/[9K' ?V)/\ W#^=']B3_P!P
M_G7?_811]A%'U=!_;-8X#^Q)_P"X?SH_L2?^X?SKO_L(H^PBCZN@_MFL<!_8
MD_\ </YT?V)/_</YUW_V$4?811]70?VS6. _L2?^X?SH_L2?^X?SKO\ ["*/
ML(H^KH/[9K' ?V)/_</YT?V)/_</YUW_ -A%'V$4?5T']LUC@/[$G_N'\Z/[
M$G_N'\Z[_P"PBC["*/JZ#^V:QP']B3_W#^=']B3_ -P_G7?_ &$4?811]70?
MVS6. _L2?^X?SH_L2?\ N'\Z[_["*/L(H^KH/[9K' ?V)/\ W#^=']B3_P!P
M_G7?_811]A%'U=!_;-8X#^Q)_P"X?SI?[$G_ +A_.N^^PBC["*/JZ#^V:QP'
M]B7']P_G2#0[@\;.#UYKT#["*/L(H^KH/[9K=D<;H.DS03H[KA!GG/M7;>>M
M1_8!1]@%:PCRHXL3B98B?,R3[0M'VE:B^P"C[ *HP)?M*T?:5J+[ */L H E
M^TK1]I6HOL H^P"@"7[2M'VE:B^P"C[ * )?M*T?:5J+[ */L H E^TK1]I6
MHOL H^P"@"7[2M'VE:B^P"C[ * )?M*T?:5J+[ */L H E^TK1]I6HOL H^P
M"@"7[2M'VE:B^P"C[ * )?M*T?:5J+[ */L H E^TK1]I6HOL H^P"@"7[2M
M'VE:B^P"C[ * )?M*T?:5J+[ */L H E^TK1]I6HOL H^P"@"7[2M'VE:B^P
M"C[ * )?M*T?:5J+[ */L H E^TK1]I6HOL H^P"@"7[2M'VE:B^P"C[ * )
M?M*T?:5J+[ */L H E^TK1]I6HOL H^P"@"7[2M'VE:B^P"C[ * )?M*T?:5
MJ+[ */L H E^TKZUP5[H5Q+([*F59V(Y]\UW/V 4"P44 < -!N/^>?ZBE_L"
MX_N?J*[[["*/L(H X'^P+C^Y^HH_L"X_N?J*[[["*/L(H X'^P+C^Y^HH_L"
MX_N?J*[[["*/L(H X'^P+C^Y^HH_L"X_N?J*[[["*/L(H X'^P+C^Y^HH_L"
MX_N?J*[[["*/L(H X'^P+C^Y^HH_L"X_N?J*[[["*/L(H X'^P+C^Y^HH_L"
MX_N?J*[[["*/L(H X'^P+C^Y^HH_L"X_N?J*[[["*/L(H X'^P+C^Y^HH_L"
MX_N?J*[[["*/L(H X'^P+C^Y^HH_L"X_N?J*[[["*/L(H X'^P+C^Y^HH_L"
MX_N?J*[[["*/L(H X'^P+C^Y^HH_L"X_N?J*[[["*/L(H X'^P+C^Y^HH_L"
MX_N?J*[[["*/L(H X'^P+C^Y^HH_L"X_N?J*[[["*/L(H X'^P+C^Y^HH_L"
MX_N?J*[[["*/L(H X!] N"#\GZBNUT=OL\*1OPRJ,BK1L :3[ * )?M"T?:5
MJ+[ */L H E^TK1]I6HOL H^P"@"7[2M'VE:B^P"C[ * )?M*T?:5J+[ */L
M H E^TK1]I6HOL H^P"@"7[2M'VE:B^P"C[ * )?M*T?:5J+[ */L H E^TK
M1]I6HOL H^P"@"7[2M'VE:B^P"C[ * )?M*T?:5J+[ */L H E^TK1]I6HOL
M H^P"@"7[2M'VE:B^P"C[ * )?M*T?:5J+[ */L H E^TK1]I6HOL H^P"@"
M7[2M'VE:B^P"C[ * )?M*T?:5J+[ */L H E^TK1]I6HOL H^P"@"7[2M'VE
M:B^P"C[ * )?M*T?:5J+[ */L H E^TK1]I6HOL H^P"@"7[2M'VE:B^P"C[
M * )?M*T?:5J+[ */L H E^TK1]I6HOL H^P"@"7[4M8MY"TCLP&1FM?[".E
M'V%?>@#"^S/Z4?9G]*W?L*^IH^PKZF@#"^S/Z4?9G]*W?L*^IH^PKZF@#"^S
M/Z4?9G]*W?L*^IH^PKZF@#"^S/Z4?9G]*W?L*^IH^PKZF@#"^S/Z4?9G]*W?
ML*^IH^PKZF@#"^S/Z4?9G]*W?L*^IH^PKZF@#"^S/Z4?9G]*W?L*^IH^PKZF
M@#"^S/Z4?9G]*W?L*^IH^PKZF@#"^S/Z4?9G]*W?L*^IH^PKZF@#"^S/Z4?9
MG]*W?L*^IH^PKZF@#"^S/Z4?9G]*W?L*^IH^PKZF@#"^S/Z4?9G]*W?L*^IH
M^PKZF@#"^S/Z4?9G]*W?L*^IH^PKZF@#"^S/Z4?9G]*W?L*^IH^PKZF@#"^S
M/Z4?9G]*W?L*^IH^PKZF@#"%JY[5KZ?*(HP#UY_G4WV%?4TGV!?>@"4W"BD^
MTK47V 4?8!0!+]I6C[2M1?8!1]@% $OVE:/M*U%]@%'V 4 2_:5H^TK47V 4
M?8!0!+]I6C[2M1?8!1]@% $OVE:/M*U%]@%'V 4 2_:5H^TK47V 4?8!0!+]
MI6C[2M1?8!1]@% $OVE:/M*U%]@%'V 4 2_:5H^TK47V 4?8!0!+]I6C[2M1
M?8!1]@% $IN13U</TJ V -310B/I0 ^BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** ,OQ)I7]IPM$/O#YE_WAVZ@<C(YX&<]JX_PMXB_L=F@
MFR$)Y^7E6R 2>AQ@<CD\<#K7HAK(U?PO#JA\QP0_&60X)QV.01^.,\#G% $M
MQXDMK<;FE4\X^4[C^2Y-<-K=V?$%T%BY!PBG!' R2QZG&23TZ=1UK9?X<@DX
MEP,\ IDX^NX9_(5T&D>'X=*_U8^8C!9CEB,YQZ#\ ,X&: +MM;BV18EZ(H49
MZX Q4>H7RV$;3O\ =4=N3Z ?B:LUS'BS1+C5'18R/* .<G #<\D8R<C@=<<]
M,\@&#H]H_B:X,TW*+C=@XP.=J@=<9_3)SD\^AQH(P%48 & !P !VJGI6FKIT
M:PIV')QC)[GOU_3IT%7A0!Y_X"0QW#JPP1&P(/!!#+Q71>-9A':NIZN5 ^NX
M-_(&H-7\*-)+]KM7V2[LG/"].HP#U[@YSD_0P2^&;K4B%NY@8U.<(.<_]\J.
MF<$YQZ<F@"UX$MS%;;C_ !NS#Z<+_-3714R"$0*(UX50 ![ 8%/H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Q1BBB@ H(HHH
M 3;2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/\@#T$M0&S6=HVLIJR>8G!'WE[@_X>A[_7(%NZO$LU\R1@JCN3[9P/4^PYH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH I:SIW]I1-;YV[L<XST(/3(]*X_\
MX0:YV^7O3;G.-SXSC&<;<9QWKO:* ,3PUX:&C@LQW.X&3C@#T'?KU/&<#@8K
M;HHH PM?\*)JQ$@.Q^Y SD>XR.1Z^G'IC!M_!-U;'='(JG&,J[@X].%KNZ*
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M!P,=,CGIWQQTSS7044 <9_PKG_IK_P"0_P#[*K6L^"1,D:6^U2F<ENK9QR6
M)R"/3'/&,8KJ:* *6C:?_9\*09R5'/U)R>PXR>/:KM%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 5]1MS<Q/$O5T8#/3)!%</_PK^?\ O1_FW_Q->@44 >?_ /"OY_[T?YM_
M\35[3_A]M*M,^<'E5!P?0;L@_7CV'K7944 -2,1@*!@ 8 '  ':J^I::FH(8
M9!D'\P>Q!]?_ -1XJU10!QG_  KG_IK_ .0__LJ/^%<_]-?_ "'_ /95V=%
M%+2]'BTQ=D0QG&2>2<#N?Z=.N!5PBEHH Y_7/!R:H_G!BCG&>-P.!CID<].^
M..F>:H:3X$-LZ322<HP.U1QD'(^8_AGCV]ZZ^B@!KQB0%6&01@@\@@]JY.Z^
M'BNQ9)-JD\*5W8]L[AG_ #UZUUU% '&?\*Y_Z:_^0_\ [*MG0_"L>E?/]Z3G
MYCQU]!D@<=^O7G!Q6U10!1URQ>]A>&,X9@!DD@8R,CC/49%97A;PJVDLTLC
ML1M 7.,9!SD@'.1_^O/'1T4 ,G@$ZF-N58$$>Q&#7(6W@N:PG$T+KM5N"V2V
M#P00!@\$CJ,^W;LJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HH%% !1110 4444 %%%% !1156_U.+3QOE8*#TSU/
M3H!R>O;I0!:HKFYO'UO&2H#L!W51@_\ ?1!_2M;3]:AU'/E.&([<@]N<'!QS
MUZ4 7J*3-+0 45AW_C*VM.-V\@](QGJ,YSPI_ _UJ>P\46]\0BOAB!PP*G)Q
MQD\$\] 3[4 :M%%07EZEFOF2,%4=R?;.!ZGCH.: )Z*Q?^$RM/\ GI_XX_\
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M@>^* -ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BC-% !1110 4444 %%%!H ***S=7\0PZ3_K#\Q&0JC+$9QGT'XD9P<4 :
M5%9^CZ[%JP+19RN,AA@C.<>W..Q-:% !14%Y>I9KYDC!5'<GVS@>IXZ#FL*;
MQ];QDJ [ =U48/\ WT0?TH Z2BLW3/$4&I?+&_S8'RMPW3.,'KC'.,UI4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% "4M<7\1_^6/\ VT_]EK-T^ZN]<1;*,X2-<%N5&,8
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ML5MX,LH.>GWF/ P,9XR1[D]. : .D\%WYO+<!NL9*9]0 ".W8''X9JK\0O\
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M<UG> M2,,WV<D[9 <#MN SGVX!''7C/3CN=0O!91O,?X%)P3C)[#/N>*\_\
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M17E=W?M87<DZ?>6:3&1D?>((_$4 >I8I17"V_A^X\1_Z3.^Q6R5!!/7'1<@
M$=\Y.,\YS6;J.DS^&W$BMP3PZ9P<'."/?&<'(/O@T >FT5F^'=3_ +1@24_>
MQAN1U'!Z8QGKCWK-\5^)Y-(9$C4'<"27!QUX ((Y'?ZB@#I**\]_X6%<?W8_
MR;_XJC_A85Q_=C_)O_BJ /0J#7#Z7XVN+R5(=B8=@#M5LXSR?O'H.:[B@""]
MO%LT:9_NH"3T_(9QR>@]Z\U^PS:[YU\< (,MG(!PO1< ] !U/ID\YK9\6WYU
M69=.AYVMR>HW$>P) 4$Y_'(XKH)M,73;.2%.T+Y.,9.PY;OU_3IT% &#\.6Q
MYW_;/_V:NU!S7%_#D9\[_MG_ .S5V@&* /,[DMXCO"H;AV(4\X"J"1P?4#..
M.3VKL4\%VJ@ ID@=2S9/OP0/R%<GJ%D_ARY$Z*?+#94XX(;.4R<\XR.>>]=?
M9>*[>\&X.%(ZB0A3W]3@].Q/O0!R?BKP[_8[+/#D(3Q\W*MDD =#C X/)XY/
M2NT\/Z@;^!)F^\1S[E25)Z#KC/M7&Z_K+^('%M;J2BG(P.2>FX^@Y[XZY/H.
MVTNR%A&L"]$'7U/4GJ>IYH NT4"B@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MELGG@]_7OP:A\/\ A]]=<W=P24)Y)X+D=AZ =./H/;OTC$8"J, #  X  [4
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MM(S^9 KTS% "BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RJZMQ<WC1-T>X*G'7!
M?%>J$5YA_P O_P#V]?\ M2O4* .7^(0_T=?^NH_]!:F?#N<&%X\_,),D>S*
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M@]ZX?P_9_P#"0W+W<N-JD$J><YR$'&!@ <^N.0<FNC\8:?+?PB*$9.\$C('
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!YGY#?VAMP<_:<XP<XW[L_3'.?3FO3,TE% &+XS_X])/^
M ?\ H:UD?#F A99,?*2H!]U!)_F*[&EH **** "BBB@#%\6SRP0,\'7/S$=0
MN#DC].>PR>,9'G>E:HVF2"9 "P!'S#(Y_4?@1Z=,BO7C310!Y_\ \+#N/[L?
MY-_\52IX_N9"%5$))P %8DD]OO5Z#10 4W%.H- ""O//#[_:=0,J<J7E;.#T
M(;!]NHZ^M>AT4 (:<!28S3J $Q7G=^_VG4@4YQ-&. ?X-H;\L'\L]*]$-)0
MA%**!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F?D-_
M:&W!S]ISC!SC?NS],<Y].:],IM #LUB^,O\ CTD_X!_Z&M;'6G"@#C?AS 0L
MLF/E)4 ^Z@D_S%=CBEHH ****  T444 !K.\02B&WE9N 8V'XL-H_4UHTA-
M'%_#J,XE;'!* 'MD;LC]1^==B\0<%2,@C!!Y!![4\"EH \]N_#]SH4OFVVYE
MZ J-QP>S+SG&.N,=#P> D?Q N% !"' ZE3D^_# ?D*]#HH \WE%YXF8'!V'&
M.JQ#!P3SU/)SU/7' Q7<:#I TJ(0CKU8YSEB!G'3CC XZ>]:%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HQ110 8HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "DQ2T4 &**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HQ110 4444 %%%% !1110 4444 %&*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>eols-20211231_g2.jpg
<TEXT>
begin 644 eols-20211231_g2.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @/" \;$10;(QP<%QH@)"8F'" D("4T+R D*"<K*SDK)R@I
M,#(U,C I-SL[.SLW.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .^Q_C1_;EE_SVC_ .^Q_C1</9R[,O451_MRR_Y[1_\ ?8_QH_MRR_Y[1_\
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M+_C1_;MC_P ]XO\ OXO^- %ZBJ/]NV/_ #WB_P"_B_XT?V[8_P#/>+_OXO\
MC0!>HJC_ &[8_P#/>+_OXO\ C1_;MC_SWB_[^+_C0!>HJC_;MC_SWB_[^+_C
M1_;MC_SWB_[^+_C0!>HJC_;MC_SWB_[^+_C1_;MC_P ]XO\ OXO^- %ZBJ/]
MNV/_ #WB_P"_B_XT?V[8_P#/>+_OXO\ C0!>HJC_ &[8_P#/>+_OXO\ C1_;
MMC_SWB_[^+_C0!>HJC_;MC_SWB_[^+_C1_;MC_SWB_[^+_C0!>HJC_;MC_SW
MB_[^+_C1_;MC_P ]XO\ OXO^- %ZBJ/]NV/_ #WB_P"_B_XT?V[8_P#/>+_O
MXO\ C0!>HJC_ &[8_P#/>+_OXO\ C1_;MC_SWB_[^+_C0!>HJC_;MC_SWB_[
M^+_C1_;MC_SWB_[^+_C0!>HJC_;MC_SWB_[^+_C1_;MC_P ]XO\ OXO^- %Z
MBJ/]NV/_ #WB_P"_B_XT?V[8_P#/>+_OXO\ C0!>HJC_ &[8_P#/>+_OXO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5);_ZP?6HZDM_]8/K36Y%3X6>IZ?_ *A/]VO./&W_ !_?
MA7H^G_ZA/]VO./&W_']^%=R/BZGQ,P****8@HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHH&>O:1K,.KQ[D//<5H5XWINIS:7()$/3\J]*T#Q-#K"#G##KFD!MTF:.E%
M!2TE+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIKDCQ2LZL!E=A R.AZJ?44 8-%:?B/1_[$NC",E< J3UP?R[Y%5]*L&U2Y2
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M#F**O7]E']L:"VW.-^U<X))Z=@!U_2NFM? 4-M%YEY-L_P!T@ ?\";/\OSH
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M>IH0PYKS_4](ETV0JPX]>U<U2G8^CP.81K*SW*0HHZT5BD>DF%%%%, HHHH
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MP****9 4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****!![U/8V$N
MH.$C&?7%6-(T:;6)-J#CN:],T708='C 49;N>] REX=\+QZ4H=AE_P"5=!11
M2 *6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM1_PA5][4 8-%;W_  A5][4?\(5?>U &#16]_P (5?>U'_"%7WM0!@T5O?\
M"%7WM1_PA5][4 8-%;W_  A5][4?\(5?>U &#16]_P (5?>U'_"%7WM0!@T5
MO?\ "%7WM1_PA5][4 8-%;W_  A5][4?\(5?>U &#16]_P (5?>U'_"%7WM0
M!@T5O?\ "%7WM1_PA5][4 8-%;W_  A5][4?\(5?>U &#16]_P (5?>U'_"%
M7WM0!@T5O?\ "%7WM1_PA5][4 8-%;W_  A5][4?\(5?>U &#16]_P (5?>U
M'_"%7WM0!@T5O?\ "%7WM1_PA5][4 8-%;W_  A5][4?\(5?>U &#16]_P (
M5?>U'_"%7WM0!@T5O?\ "%7WM1_PA5][4 8-%;W_  A5][4?\(5?>U &#16]
M_P (5?>U'_"%7WM0!@T5O?\ "%7WM1_PA5][4 8-%;W_  A5][4?\(5?>U &
M#16]_P (5?>U'_"%7WM0!@T5O?\ "%7WM1_PA5][4 8-%;W_  A5][4?\(5?
M>U &#16]_P (5?>U'_"%7Q]* ,&MKP]X:EUA@Q&$SUK4T;P+*\@:?[H]*[R"
MW2V4*HP!2 @T[38M-0(@Z=^]7*2B@ HI:* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HI:* $HI:* $HQFE
MHH ;M%&VG44 )M%&!2T4 -VTN*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:*
M$Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B
M@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BE
MHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&VEHH ;BE
MP*6B@!*,4M% ""C%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )B
MC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "
M8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10
M F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T
M4 )BC%+10 E%+10 4E+10 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >5^-1_Q-)O^ ?\ H"UB8K<\:_\ (4F_X!_Z+6L.F 8HQ110(,48
MHHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH
M,48HHH ,48HHH ,48HHH ,48HHH ,48HHH&&*3%+10!L>$1_Q,8Z]6%>4^$?
M^0C'7JU# 6BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'EGC7_D*R_\
M _\ 0%K#K<\:_P#(4F_X!_Z+6L.F 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ;'A'_D
M(QUZM7E/A'_D(QUZM0P%HHHI %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MY9XU_P"0I-_P#_T6M8=;GC7_ )"DW_ /_1:UATP"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#8\(_P#(1CKU:O*?"/\ R$8Z]6H8"T444@"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ$7<1E\D.N\#.W(W8]<=<4
M 34444 %%%0P7<5UGRW5MIP=I!P1V..A]J )J*** "BBB@ HJK<:I:VCB.25
M$9NBLZ@G\"<U:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q?%7B+_A&;=)O+\S?*J8W
M;>H8YSAO2MJN,^*G_'A#_P!?2?\ H#UV= &+I7B/^T[^XL_+V_9B/FW9SGVP
M,?F:VJXOPK_R'=0^J_S-4_#NI:]XFC?9,L:QR,/,:-68],*%P!@>O7F@#T"B
MN4T;7+ZRU#^S+_:SNFZ.1!@,!G((X&>#Z=/<&LS1]4US7YKB&*546*9QYC(K
M$ ' 0   ],DGF@#OJ*Y+3M;U#2-033[\K()@3'*HVY([$# _R.N>$;5M1\1W
MDL%DZPQ6[;6D90[%NX /''^3S0!UU%<MI.M7MEJ/]FWQ5V="T<BC;NQG((Z9
MX/Y=\UE6&J:YKE[=6T,JHD$[C>R*2 &8*H&,'IU.30!WU8N@^(O[;N+F'R]G
MV679G=NW<L,XP,?=]ZUXPP4!CDX&3[UQ_@3_ (_]3_Z^C_Z')0!UEZ\L4+M$
MH9PI*@G )QP,U6T.XN[JU5[J,1RG.Y5.1UX[GJ/<U+JL[6UI+(APR1.0>O(4
MD=:Y:3Q#>KX8^W[_ -]@?-M7O,%Z8V]..E ':45P4U]XACL/[2\V,*$#^5Y8
MY7U+8SG'. 1_2G'4M>U.S;4XI$BC"LRQ; Q*KURQ&<G!Z8_"@#J=?N;VTMB]
MI&)),CY6.!CN>HS^8J2ZU6+2[99[HB,87=U8!B.G YY[USVM>*)VT!=0@/EN
MP3H V#NVL/F!'K6;\2(;R6P$YF'DD1YCV#)8Y^;=U_"@#T#.:6LG0;._M%;[
M5.)\[=N(U3'7/3KGBJOBOQ#+HXB@MU#SW#;4!Z#IEC^?^<4 =!6=K^KKH5E)
M=$;O+ XZ9)(4#\R*YV^/B'0H3=M-'.J#<\?EA>!R<, #P/7\C53QM<SZUH_V
MV&7;;M'&6C* DDR ?>ZC!QT]* .B\.7FJ7H\R[2)4= R>66W<\X.2>Q[5I:C
MJ4&E1&:9MB @$D$]>!TS63X5LM0MHU:XN!*C1+M41JF.!W'7BL?XGVUVUFTJ
MR@0@(#'L!);?][=U'4<>U ';(X<!AT(S3JX?4?[;T/2WN?M0D*>6P B087HP
MZ'/4'U&/>I_&/BR6STZ&6T.)+G!7@,=H7<W!!'<#I0!V-%<AKOBN5-(AN+8X
MENC&J\ X)^]P01V(_&GZKKE^UU'I=H5,WEAI)''"CCG XR>O3'('T .LHKB[
MW5-7\(%)KN1;F!G"L50(ZY[X7 /^1QD5V2L&&1T- #J*** "BBB@ HHHH **
M** /+/&O_(4F_P" ?^BUK#K<\:_\A2;_ (!_Z+6L.F 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ;'A'_D(QUZM7E/A'_D(QUZM0P%HHHI %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7%^%?\ D.ZA]5_F:[2N+\*_\AW4/JO\S0!VE8NH^,=+TF3RII@&'4 ,
MY'UV@X_&K>NW$EI8SRQ_?2)ROU"DY_"L+X?Z7:C3$F"J[S;B[, 23N(QD^E
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/+/&O_(4F_X!_P"BUK#K<\:_\A2;_@'_ *+6L.F 5U>@WL,.C7,;.H9BV%+
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M8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RSQK_R%)O^ ?\
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MVMX([?B8%EP"O49R.?E[4 4[JUDLI#%(-K*<$&HJT+BTO+^]:)QNG9L$$KU
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M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+/&O_(4F_P" ?^BUK#K<\:_\A2;_ (!_Z+6L.F 4444 %%%% !1110 4444
M%=/#=:+J=ND<RF!XQC<@R#^C$^O(S[US%% '76VKZ7X:1FM"TTK# 9P0!^87
MCOP.?6N3=S(Q8G))R?QIM% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!L>$?^0C'7JU>4^$?^0C'7JU# 6BBBD 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TE "UAW_ /Q]
M+_O5MUB:A_Q]K]: -NBBB@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*6BDH **** (+NT2[0JPR#
M7 :]H+Z8Y9>5->C5#<VR72%6&0:F<%)'5A,9/#RTV/)J*V_$'A]M.;>HRIK$
M'%<<X.+/J,/B(UH*284444C8**** "BBB@ HHIT<9E8*.IH2;)E)15Q$0R$*
M.2:[/PYX9$ $LGWO0]JD\.>&1:#S9!\Q[5TP7;733I6/ S#,7-\D=@  I:**
MV/(%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ I*6DH QXN;W\*V:QHO\ C]_"MF@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /+/&O_ "%)O^ ?^BUK#K<\:_\
M(4F_X!_Z+6L.F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 ;'A'_ )",=>K5Y3X1_P"0
MC'7JU# 6BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %)2T4 )TJA<:>9IA)Z&M"B@!**6B@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH 2BEHH
M 2BEHH 2C%+10!#<6ZW"E6&0:X/Q#X=:P;S$'RFO0:CGA6=2K#(-3*"DCIPN
M+E0E=;'DG6CK70^(?#9LR9(QQW%<Z#7).#BSZC#XF%:%TQ:*,4=:DW"BBGP0
M/=-M49H2N3*:BKL2*%IVVJ,Y]*[GP[X;6S422#+5)X>\.K8*'898UT XKII4
M[:GSV89BZKY8[" 8HI:6MCRF)12T4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4 8\2M
M]MSCC%;%)BEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RSQK
M_P A2;_@'_HM:PZW/&O_ "%)O^ ?^BUK#I@%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M&QX1_P"0C'7JU>4^$?\ D(QUZM0P%HHHI %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 E%+24 %%%&* (YH5F7:>E<3XC\-&W)EB''H*[JF21B48-3*
M"DCHPN*G0E=;'D5*>.*ZCQ'X9,),L0_ 5SMG927\FQ!WYKEE3:9]+1QM.K#G
MOZB6MH]XX1!7?:!X?33EW$98T_0]!334!/+5LUO3IVU/%S#,'5?+'8!112UJ
M>8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 >6>-?^0I-_P#_T6M8=;GC7_D*3?\ _]%K6
M'3 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ****!&QX1_P"0C'7JU>4^$?\ D(QUZM0QBT44
M4@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BEHH 2BBB@ HHHH 9)
M&)!@]ZJVFE0VC%E R?:KM%!2G)*P4444$A2TE+0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTT 96C_ZU_K6Q6/I'^M?ZUL4 )2T4E "T4E% &-#_P ?GYUM5BP_\?GYULT
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MUCZ;_P ?3?2MANAK'TW_ (^G^E &S2TE% "T4E% "TR3[II],E^Z: ,?3/\
MCX;ZUM5BZ9_KV^M;1H 6BDHH 6DHHH R-=ZK6I!]Q?H*R]=ZK6I!]Q?H* )*
M*2B@!:2EI* ,>S_X^C^-;-8UE_Q]'\:V* %HI** %HI*#0!BWG_'V/I6T.E8
MMYQ>#Z5M#I0 M%%)0 M)110!6U#_ %1J'1?]0/K4VH?ZHU#HO^H'UH T***2
M@!:*2B@!:PD_X_3]:W*PX_\ C]/UH W*6DHH 6DHI: $JEK'^H-7:I:O_J30
M ND_ZD?2KE4])_U(JY0 M%)10 M-;I2TC=* ,G1_OO\ [QK8K'T?_6/_ +QK
M7H 6BDHH *#2TE &/#_Q_?A6Q6/%Q>_A6S0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% 'EGC7_ )"DO_ /_1:UAUUWBGP]<7VH22H.&V_HBC^E
M97_")7?I^E,#&HK9_P"$2N_3]*/^$2N_3]* ,:BMG_A$KOT_2C_A$KOT_2@#
M&HK9_P"$2N_3]*/^$2N_3]* ,:BMG_A$KOT_2C_A$KOT_2@#&HK9_P"$2N_3
M]*/^$2N_3]* ,:BMG_A$KOT_2C_A$KOT_2@#&HK9_P"$2N_3]*/^$2N_3]*
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MN%("?^WY_04G]OS^@I/[$F]:/[#F]:8"_P!OS^@I?[?G]!3?[#F]:/[#F]:
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M8^C_ .L?_>-:] "T444 )1110!CQ<WOX5LUCQ?\ ']^%:] "T4F:6@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>eols-20211231_g3.jpg
<TEXT>
begin 644 eols-20211231_g3.jpg
M_]C_X  02D9)1@ ! @$ S #,  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]4HHHH ***3- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "
MT4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0
M M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,
MT +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)F
MC- "T4F:,T +129HS0 444F: %HHHH 6BDS1F@!:*3-&: %HI,T9H 6BDS1F
M@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T
M9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3
M-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6B
MDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %I#1FB@ HHHH 6BDS1F@!:*3
M-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6B
MDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %
MHI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@
M!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H **** "BBB@!:*3-&: %HI
M,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:
M*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H
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M?_/9/SH_X3*S_P">R?G7FG]@Q>E']@Q>E'UB'</[&JGI?_"96?\ SV3\Z/\
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M?_/9/SH_X3*S_P">R?G7FG]@Q>E']@Q>E'UB'</[&JGI?_"96?\ SV3\Z/\
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MS3^P(?[M']@0_P!VCZQ$/[&JGI?_  F5G_SV7]:/^$RL_P#GLOZUYI_8$/\
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M>R?G1_PF5G_SV3\Z\T_L&+TH_L&+TH^L0[A_8U4]+_X3*S_Y[)^='_"96?\
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M>R?G1_PF5G_SV3\Z\T_L&+TH_L&+TH^L0[A_8U4]+_X3*S_Y[)^='_"96?\
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M>R?G1_PF5G_SV3\Z\T_L&+TH_L&+TH^L0[A_8U4]+_X3*S_Y[)^='_"96?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4A.!10::6I,MC&TG_CZE_P!W
M^E;-8VD_\?,O^[_2MFKJG)@/A8M)2BD-9G8A:***!A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%%- "]_I6)X;ZR_P"_6VO]*Q/#G67_ 'ZTI_ SAKK]
M_ VZ*#161W!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53UC
M_4O]*N53UC_4O]*NE\1CBOX4O0[SX='_ $"'_=/\S725S?PZ_P"/"'_=/\S7
M25Z*/CWN%%%% A*44E**D#AOBS_Q[I_UT%8%M]T?05O_ !9_X]T_ZZ"L"V^Z
M/H*Y\5T/9R/>8\4M(*6N4]X**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** $%8FJ?\ 'Q']:VQ6)JG_ !\1_6M*?Q,X\=\,?5&\WWC3!3V^\:8*
MA[G7'86BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2@T4&FMR
M9;?(QM)_X^9?]W^E;-8VD_\ 'S+_ +O]*V:TJG)@-F**0THI#61V+J+1110,
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHIKJ +_ $K$\.=9?]^MM?Z5
MB>'.LO\ OUI3^!G%7_CP_KJ;9HH-%9':@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *IZQ_J7^E7*IZQ_J7^E72^(QQ7\*7H=Y\.O^/"'_=/
M\S725S?PZ_X\(?\ =/\ ,UTE>@CX][A1113$)2BDI14@<-\6?^/=/^N@K MO
MNCZ"M_XL_P#'NG_705@6WW1]!7/BNA[.1[S'BEI!2URGO!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 @K$U3_CXC^M;8K$U3_CXC^M:4_B9Q
MX[X8^J-YOO&F"GM]XTP5#W.N.PM%%%(84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 E!HH--;DRV^1C:3_ ,?,O^[_ $K9K&TG_CYE_P!W^E;-:53D
MP&S%%(:44AK([%U%HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
MUU %_I6)X<ZR_P"_6VO]*Q/#G67_ 'ZTI_ SBK_QX?UU-LT4&BLCM04444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %4]8_U+_2KE4]8_U+_2KI
M?$8XK^%+T.\^'7_'A#_NG^9KI*YOX=?\>$/^Z?YFNDKT$?'O<****8A*44E*
M*D#AOBS_ ,>Z?]=!6!;?='T%;_Q9_P"/=/\ KH*P+;[H^@KGQ70]G(]YCQ2T
M@I:Y3W@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 05B:I_Q\
M1_6ML5B:I_Q\1_6M*?Q,X\=\,?5&\WWC3!3V^\:8*A[G7'86BBBD,**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH 2@T4&FMR9;?(QM)_P"/F7_=_I6S
M6-I/_'S+_N_TK9K2J<F V8HI#2BD-9'8NHM%%% PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 4444 %%%% !1113!"4M(.:,'_)H"Z#-+1BB@-PHHHI %%%% !1110 4444
M%%%% !1110 4444 %%)1UH"PN:2@T9IM!N+1112 **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** $H-%!IK<F6WR,;2?^/F7_=_I6S6
M-I/_ !\R_P"[_2MFM*IR8#9BBD-**0UD=BZBT444#"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?7K1G%>B7=A%J:<X([$=:X74M-.GN8V_ ^HK.M1Y5='5@LQCB+QDK,JYSQ0
M7X'-/@M6NV6->I/Y#UKN]+T..P7H"W<D44Z3J>16-S"&&2ZR>R.%%I(?X&_[
MY-1.C0XW@KGU%=U<>+(8&V]<>E2Q7,&MJ5X;U!ZUHL/%=3C_ +4Q$5>4+(X8
M6KMT1C]!Q46""01@CUKTZ"+R5"#H!7G6IX,TN>SFHK4E%(VP&82Q$Y*UDEH0
MI$TGW5)^@S230M#RRD9Z9XZ5TW@D</\ 44WQW_RS_P"!4U17)<IX^2Q?L;:7
M.9(Q3X8'F^ZI./04SIQ75>"#E7_WOZ5G1AS3L=&-KNC1E-:M'+RPM%@LI&?4
M5L6L/]I0"(??@).!@DHYRQ SRP/T&,#J:M^-_O1CU!_2N<1RA#+P0<@CJ*<_
M<FUT(P]26*HQEM)/3^O0Z-]91\6C*[(46-EQA@R'@@;CR3U!]!UZ54O4&EQO
M;9R\I7(..%7D9P2 Q/N?E]":@_X22XV[-YQC'09_/&<^^<UG.Y<EB<D\DGK1
M*HFO,='"R3UT6]D[W:V>RM_PPE%%%9':%%%% !1110 4444 %%%% !5/6/\
M4O\ 2KE4]8_U+_2KI?$8XK^%+T.\^'7_ !X0_P"Z?YFNDKF_AU_QX0_[I_F:
MZ2O01\>]PHHHIB$I124HJ0.&^+/_ ![I_P!=!6!;?='T%;_Q9_X]T_ZZ"L"V
M^Z/H*Y\5T/9R/>8\4M(*6N4]X**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** $%8FJ?\?$?UK;%8FJ?\?$?UK2G\3./'?#'U1O-]XTP4]OO&F"H
M>YUQV%HHHI#"BBB@ HHHH **** "BBB@ HHHH 2GVQ^=?]X4VE@'SK_O"G%Z
MHSJ_!+T9Z?&>!7-W'@I9V:3>1N8G\ZZ*+@ >U<+?^(+B.5T5\!7(Q@>M=U5Q
MY5<^:R^G6J3DJ<K=[F]9>$H[9MS,6] 1Q5[5=573T)SEAT']*XT^(;@\%S@^
MR_X50E;S#N;DGN:R=>,=$=RRNM.:=65UY!*YF9I3U8D_GS7=>$SF ?6N$S7=
M^%/]0/K48=WJ-FF=)1H+U.<\4G]^:N^#+4MOE/X51\6MF<_A6UX*G!B*=U//
MX]*N/\;4SKRDL!&RWT#Q?J!ME$2_Q]:XTIFNF\;Q'<C]JYPU&);Y[=#IRF$(
MT(VW>XZ"4VS"13C%>D64_P!H02#N,UYC("17I&B1F*)%/7 J\,UJKG+G=.*4
M9=3A-<7]_(1_?:NN\)V@BA#$<OUKD=9S]HE_WS7;^'YA- C#THH?$T&:-K#4
MT<[XPOR[_9P<!0/QKG@HZUK^)XC'<,2."!@UDD=JRKR?/KL>AE\(QH1MU18T
MR^.G2"5.@ZC_ .M5[6?$CWX*J,+QQW-91.,>OMWI&RA.[@CKGKS25235EL5/
M#4I5%-I<QT7@RR\QVE8= ,'W[UK^)Y)EC"0*6+'G''%5/!<P9&C[@Y/X]*N^
M(M<;2]I"AMQ(Y..:ZH6]GJ['AXN4Y8QZ7:>B..31;@?\LC^E/MM,N(75UB8$
M$<C&,5J#QTXX\L9^I_PH'CF3^X/S/^%8\E*+YN8]"57'-.+I*W]>9U83S%VL
M.HYS]*\SU&#[/O3T)_G70?\ "<2,<!!^9_PK!O[G[4S.PQNIUJL)I-;D95AJ
MU&<Y25DSTC3/]4G^Z/Y5Q/B?4/MLICYVH<8[9'>NVTP?NE_W1_*O/]2A9)G5
MN[$_A5UF_9HYLKA&6*FWYV*@ -;?A34S;2>43\C]/K6, #5C2K<W$R*O\+ _
ME7/2G+GT/8QD(U*4^;L=QXBM?M$##OBN5\)6@N9LG_EFN<?CBNSU%PD;$_W3
M7(^!V_?2#U3^M=%5+VD3Q<'.7U2LET.DU_4!81%SP6X&/>O/CF3EN3[UVWC&
M)GAR@SAAFN*# ]*C%23]VYV9+"/LY26_<:0%Y'4=^]=_X8U$WL0R<LO&:X(+
M77>"(2B.QZ%N/ZU.'DT^5%YQ"#H7ZIF?XQM1#(KC^,']*P/N\5TOC@[FC7T#
M?K7.=:FNO?\ (WRR3EAHW 4M)2UD=P4444 %%%% !1110 4444 %%%% "4&B
M@TUN3+;Y&-I/_'S+_N_TK9K&TG_CYE_W?Z5LUI5.3 ;,44AI12&LCL746BBB
M@84444 %%%% !1110 4444 %%%% !1110 4444 )BD8=/K2FD?M]:<7=HB:O
M%_,]+LAF-/H*HWGB**V8QMU%7]/_ -6G^Z*X+Q"F)VKMJ5.6"/F<%A8UZ\HO
M0ZN+Q5 YP6P?>KKJFI(5#95NZFO.'4GTQ71>"+@[VB/0+G%12Q'//E.K%Y7&
MA2=2,MC,UG1SI;>JGH:O^#K<32,_78./QK6\9K^XW=PPQ53P1."'C[CG\Z7(
MHUD7+%2JX%R>^Q>\5:@UI%A?O.<9]*X=0!S_ #ZUUWC>(E$;L&Y-<D%I8B;Y
MK&^30BL/=;WU .8_G7J.F.*]%T>\^VQJ_MS]:\[/R_05W'A&U,$//\3$_@:6
M%F^9QZ$9W&+II];G->);(6LQ]'&?2G^$!BX'^XW]*E\9R"290.<)_6H_"7_'
MR/\ <;^E'):L:IMY?KORO]3>\7#]P?J*XA:[GQ?_ *@_A7#@<48O5HC)7:@U
MYF]X/M!+(9#_  BMWQ-?_8H\#[S\"LOP2_+KWJ7QQ 66.7LA.?Q %:1TI:')
M62JYARRT7_#G)8_,]3WH)\OE>H].*?TZTUN/QKCT4D>\E%KEZ=CT+P_?&]B#
MGKT_*N2\468MYB%'##/XUT7@V,QP\_WC6-XTDS,%'4)FNVKK3N>#@?=QLDMM
M3,TG4SIK^9VZ$?C7?,B:C'MZAA7F\8,IV 99C@"O0M#TXZ=$(LYQ_7FIPDG*
M+[&F=0A&2DM)>1/#"FG1[1PJ\\UPFM:J=1?=_"I^4?UKMM9T_P#M&)H<XSTQ
M[<UY[.I@8JXP0>G]:,0VHV1.30A4G*3UEV8P+MI1SS2T5R(]Y:A1110,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBBFNH O\ 2L3PYUE_WZVU_I6)
MX<ZR_P"_6E/X&<5?^/#^NIMFB@T5D=J"BBB@ HHHH **** "BBB@ HHHH *3
M-+2'CF@ HJW;Z/+<C>HR*AN;-[8['&#UJN1[]#)5H.7+=7()>A^E>D:,?W*?
M[HKS1^ <^E>F:+_J4_W16^&^(\S/-*<%YLXSQ.,W#?2MOP=9^6AF/5LUA^+"
M3<,!_=KI_"K![= .V<_G54W>LS'&-K 4Y?(I>+5FFVQ1(S+W(KFO[#G_ .>3
M<#VKI]=\1R:;)Y80$$9!)_\ K51;QU(/X!^9_P **L8-ZL,%/%4J24()I]?Z
M93T>SN;.0,(V ) /3&*['5(A/$ZD?PGC'<"N97QS(>3&,?4TG_";/*"NP8(Z
MY.:I2A&#5S/$4,56JJ3A9JVQST>3M#<$D5ZC/]P_3^E>8EM[*WJW]:]-D^X1
M_L_TJ:#3BR\XNJE-O^M3S%CR1[FEB^\H_P!H?SIKXR?J:FM8?/D1!U+#]#7.
ME>2]3V*C2I-^1Z1<\J?H?ZUY?MW_ *_SKU&X^Z?H?Y5YBO!S6^+EHCRLC>D_
ME^IV/A#4?.3RB>5)JKXSL NVX'7H:P]%O_L$ROV)Y_&N]U"U6\C9#_$./YU<
M/?IVZF6*B\'BU4Z/4\\T^T^W2K%ZD9]@*]%ED6R0L>%0?RKG_!NE&W#32##9
M('TI_C34O+06XZMR?I4TH.G!M[CQL_K>+C2CLCE;B4W+M)U+,?UZ5Z%I5I]D
MB5.O )]:\[C.&7M\R_H:]-B?>H([CBEAO>NR\YO&%.*V.+URUN+^8MY;%%^[
M6:-%G/6)OTK;E\82PNT;1C@G^(_X4S_A.)/[@Q]3_A3J1I\VLM2J%3&1@N6"
MLTK%CPC%-;%HI$8)U!-3^-+?=&LF.58<_6L\^/''5!574_%37\9C9  ??_ZU
M)U(^SLG<S6&Q,L0JKBEY(T_!5MD/.1SG ^E6/&&H- HB7^/K2^"Y T13NI%4
M?&R89&_S^=6F_9$->TS%\W1G.8[4MG<&T82*<$')QW]C35&.337(QZUR0:4M
MSW:D8N$H[GIUG<?:$63U&:\[U+_72GU<UWVCILA3Z"N"U/\ UTG^^:Z,2[Q1
MXV4*U>HNAT/@D</_ +W]*9X[',?_  *G>"3]_P#WOZ4>.O\ EF>WS5<?X0IO
M_A27J<NQQ75^"/N/_O?TKDV4M^==;X(0JCG_ &_Z5AA5[^YVYM9867J5_&_W
MX_HW]*YNNC\<</']&_I7."C$.\R\J5L-$6BBBL3O"BBB@ HHHH **** "BBB
M@ HHHH *IZQ_J7^E7*IZQ_J7^E72^(QQ7\*7H=Y\.O\ CPA_W3_,UTE<W\.O
M^/"'_=/\S725Z"/CWN%%%%,0E**2E%2!PWQ9_P"/=/\ KH*P+;[H^@K?^+/_
M ![I_P!=!6!;?='T%<^*Z'LY'O,>*6D%+7*>\%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% ""L35/^/B/ZUMBL35/^/B/ZUI3^)G'COACZHWF
M^\:8*>WWC3!4/<ZX["T444AA1110 4444 %%%% !1110 4444 %+;',B_P"\
M*;3HVV,&/0'M51W(J?"_0].BX KS;4/]:^>\A_G72KXU0#&QN/I7+S2>8[2_
MWF)P:Z,1-2BCQ\IP]2E4FY1M<BZTM HKFZGL[6L)CO7=^%#F ?6N$''%=!H_
MB9=.C$;*2<]L5MAY)39Y^;49U*7NJ[N5O%0VSD>N*;X;U4:?)@GY9.OU[5!J
M]^-0E,BC ]ZHA/\ Z]*53EJ7-*>&Y\,J<]['HVI:<NHH4/<<&N+N_#LUL2-N
M0.A!I^E^(I;#Y3\R>AZ_G6O_ ,)PAZQM^E;N=*IN>;3HXO"2M%714T7PJSL)
M9N ""!]*[#&WGTKD;SQHT@Q&I!/<U-;>-%50K(Q8 9/')[FBG.G%NQEBL/BL
M0U.2OY+H86K\W$O?#G^9K8\(:N(LVS<<_+6'>3_:)'E'&]B<'ZU7!*G(X([U
MSPJJ,VSV)X15L/R/>VAWGB#0AJ2YSAQT]ZY)] G0[=O-7-/\5O;81P&4?G^=
M:'_"=)_SS;]*V;C4/.I+'89<D5=":'X7:)A--C(Z#%/\6B&-?F \T],=:JW7
MC-Y!B-<?7K7/2RM.2SG)/>E*I%0Y$:4,)B:M95:CM;H7_#FIBQDYX63 -=KJ
M>GIJ<>P_4'T]Z\Y";>:T]*\0RV V#E?]KFII5%!<KU-,?E\YS]K3W"Z\-S6Q
MQC<.Q%3:=X7EN6_>#:O!SU_2M)/&R]#&?PQBDD\;<?*AS_M=*IPI)\US%UL?
M*/(XV?<N:QHT/EY(V[1U'&:X>0;@3[U<U#4Y+\[I#QZ#@55?YQBLZM6,WHCN
MP&&J4:;YG=GI.EMF)/\ ='\JR/$7ATWY\U#\X'3UJI:^,DMT5-C$@ <8JK;^
M+)8F8GYD9B0#U /05T2E&44CR*.%Q4*LIP5M]RB= GSMV\_I73>'O#_]G?O'
M^^WZ567QNO\ SS;/X53O_&#S K$NW/=N:E<D'<WK/'8CW&K)ESQ?JP1?LHZM
MU-<WIUV;&191VX.*@9S(=S')/>D(SCVK&I7O),]"A@84J/L^^YZ1%,M_'VPP
MY_&N1U'PG);']V R_E5#3]4DT\Y0_GS6_%XW"CYT)^F*T]I3JK7<\]X;$X.;
M=/6/8R[+PQ+<MM8;5[GO79Q1)I\80<*HK!;QNISM0Y]\5A:AK$E^?F. .PJE
M.%):"EAL3C))ST0W6-0-_(9!]WICTQ57--P!2US.?.V>Y3IJ$5%= I:0"EJ"
MPHHHH **** "BBB@ HHHH **** $H-%!IK<F6WR,;2?^/F7_ '?Z5LUC:3_Q
M\R_[O]*V:TJG)@-F**0THI#61V+J+1110,**** "BBB@ HHHH **** "BBB@
M HHHH **** "FM_6EQ2.OIV-5%V=R)I\K/3-/_U:_P"Z*X_6]'EFF:15R#5Z
M#QDD"A"C$@=L8I__  G*?\\V_2NR4H2BKL^=HT\30J.48MF%_P (_/(<!.OO
M73^&]!.F@L_+L/TSZU47QRG_ #S;]*IWWB]YQB,;?KUJ(JFO>3U-JGU[$KD:
MLBQXRU '; #GG)QVK'T/4/[.E#G[K=?QJ@[ER6/WCU-)BL956YIGI4,"H4/9
MOK>YZ1=6J:E&4/*L*XR\\,S6IP!N'J/\*CTW6Y+#@'*^AK;B\;K_ !(<^QK=
MRC-H\V%'%X-OD5T9VE>%9)V#2C:H[=<_RQ76W$ZZ<FX]%&,5@S>-\_=0_C7/
MWVIR7QRY^@'04G5C232&\-B<9-.II%="*[NC>.9O4]_2M'PM*$N%)]"/SK)
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M\127WR_=7T[U2G&FM#.5#%XR45-62*>I7'VB1I/4\5K>$M4%LWDL<!^1GI6
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M4M% ";: *6B@ I,4M% !28I:* "@T44 %%%%%P"BBB@ HHHH **** "BBB@
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MZQ_J7^E7*IZQ_J7^E72^(QQ7\*7H=Y\.O^/"'_=/\S725S?PZ_X\(?\ =/\
M,UTE>@CX][A1113$)2BDHJ0.'^+/_'NG_705@6WW1]!6_P#%G_CW3_KH*P+;
M[H^@K#$[(]G(]YD@HI,TN:Y#W@HHS1FBX!11FC-%P"BC-&:+@%%&:,T7 **,
MT9HN 449HS1< HHS1FBX!11FC-%P"BC-&:+@%%&:,T7 **,T9HN 449HS1<
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MS44>QB']I5^_Y'C/VJ[_ .>!_*C[5=_\\#^5>S44>QB']I5^_P"1XS]JN_\
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M_P CQG[5=_\ / _E1]JN_P#G@?RKV:BCV,0_M*OW_(\9^U7?_/ _E1]JN_\
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MJN_^>!_*O9J*/8Q#^TJ_?\CQG[5=_P#/ _E1]JN_^>!_*O9J*/8Q#^TJ_?\
M(\9^U7?_ #P/Y4?:KO\ YX'\J]FHH]C$/[2K]_R/&?M5W_SP/Y4?:KO_ )X'
M\J]FHH]C$/[2K]_R/&?M5W_SP/Y4?:KO_G@?RKV:BCV,0_M*OW_(\9^U7?\
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M=_\ / _E7LU%'L8A_:5?O^1XS]JN_P#G@?RH^U7?_/ _E7LU%'L8A_:5?O\
MD>,_:KO_ )X'\J/M5W_SP/Y5[-11[&(?VE7[_D>,BZN_^>)_*J^HW%P\966,
MHK<9([XKVZN.^*/_ ![)_P!=E_\ 0'H5&"=["EF%>2M?\B[\/#_H42_W=P^N
M"1FNDKG?A\<V4?U?_P!#:NBK0Y HHHH **** .%^+'_'O'_UU'_H+5TOA7_C
MT@_ZY)_Z"*YKXL?\>\?_ %U'_H+5TOA7_CT@_P"N2?\ H(H U:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*\N^)G_'RO\ UR7_ -":
MO4:\N^)G_'RO_7)?_0FH ]17H*6D7H*6@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /*] _P"0L?\ KM/_ ">O5*\KT#_D+'_KM/\
MR>O5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S_$
M7_'K/_UQD_\ 0#7&?";_ );_ /;+_P!GKL_$7_'K/_UQD_\ 0#7&?";_ );_
M /;+_P!GH ]#HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 E>7?$S_CY7_KDO\ Z$U>HUY=\3/^
M/E?^N2_^A-0!ZBO04M(O04M !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 >5Z!_R%C_ -=I_P"3UZI7E>@?\A8_]=I_Y/7JE !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9_B+_CUG_ZXR?\
MH!KC/A-_RW_[9?\ L]=GXB_X]9_^N,G_ * :XSX3?\M_^V7_ +/0!Z'1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=\4?^/9/^NR_^
M@/78UQWQ1_X]D_Z[+_Z ] %[X??\>4?U?_T,UT=<Y\/O^/*/ZO\ ^AFNCH *
M*** "BBB@#A?BQ_Q[Q_]=1_Z"U=+X5_X](/^N2?^@BN:^+'_ ![Q_P#74?\
MH+5TOA7_ (](/^N2?^@B@#5HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** $KR[XF?\?*_]<E_]":O4:\N^)G_ !\K_P!<E_\ 0FH ]17H
M*6D7H*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M*] _Y"Q_Z[3_ ,GKU2O*] _Y"Q_Z[3_R>O5* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH S_$7_'K/_P!<9/\ T UQGPF_Y;_]LO\
MV>NS\1?\>L__ %QD_P#0#7&?";_EO_VR_P#9Z /0Z*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KCOBC_P >R?\ 79?_ $!Z[&N.^*/_
M ![)_P!=E_\ 0'H O?#[_CRC^K_^AFNCKG/A]_QY1_5__0S71T %%%% !111
M0!POQ8_X]X_^NH_]!:NE\*_\>D'_ %R3_P!!%<U\6/\ CWC_ .NH_P#06KI?
M"O\ QZ0?]<D_]!% &K1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 )7EWQ,_X^5_ZY+_Z$U>HUY=\3/\ CY7_ *Y+_P"A-0!ZBO04M(O0
M4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >5Z!_R
M%C_UVG_D]>J5Y7H'_(6/_7:?^3UZI0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &?XB_X]9_\ KC)_Z :XSX3?\M_^V7_L]=GXB_X]
M9_\ KC)_Z :XSX3?\M_^V7_L] 'H=%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5QWQ1_P"/9/\ KLO_ * ]=C7'?%'_ (]D_P"NR_\
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M9_Q\K_UR7_T)J]1KR[XF?\?*_P#7)?\ T)J /45Z"EI%Z"EH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RO0/^0L?^NT_\GKU2O*]
M _Y"Q_Z[3_R>O5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH S_$7_ !ZS_P#7&3_T UQGPF_Y;_\ ;+_V>NS\1?\ 'K/_ -<9/_0#
M7&?";_EO_P!LO_9Z /0Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KCOBC_ ,>R?]=E_P#0'KL:X[XH_P#'LG_79?\ T!Z +WP^_P"/
M*/ZO_P"AFNCKG/A]_P >4?U?_P!#-='0 4444 %%%% '"_%C_CWC_P"NH_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 2O+OB9_Q\K_UR7_T)J]1KR[XF?\?*_P#7)?\ T)J /45Z"EI%
MZ"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RO0/
M^0L?^NT_\GKU2O*] _Y"Q_Z[3_R>O5* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH S_$7_ !ZS_P#7&3_T UQGPF_Y;_\ ;+_V>NS\
M1?\ 'K/_ -<9/_0#7&?";_EO_P!LO_9Z /0Z*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFWP?T0W$[7K#Y(5*J3D?.W''8X7.0>FX''< &)X7U)_"5Z//!3!V2@]E;'/
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M@"]FC-8/CK4I-+LY;B$[9$V8. >KJ#P01T-<;X;^*H@MY#>,7G5LH H4,"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E
M>@?\A8_]=I_Y/7JE>5Z!_P A8_\ 7:?^3UZI0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% &?XB_P"/6?\ ZXR?^@&N,^$W_+?_ +9?
M^SUV?B+_ (]9_P#KC)_Z :XSX3?\M_\ ME_[/0!Z'1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#RO0/\ D+'_ *[3_P GKU2O*] _Y"Q_Z[3_
M ,GKU2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,_
MQ%_QZS_]<9/_ $ UQGPF_P"6_P#VR_\ 9Z[/Q%_QZS_]<9/_ $ UQGPF_P"6
M_P#VR_\ 9Z /0Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP%& ,GGI6=K7A2UULJ]Q&&91@'+*<=<94C(],].<=30 [PM_QYV__7"+_P!
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MR7_T)J]1KR[XF?\ 'RO_ %R7_P!":@#U =!3A2+T%+0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'E>@?\A8_]=I_Y/7JE>5Z!_P A
M8_\ 7:?^3UZI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &?XB_P"/6?\ ZXR?^@&N,^$W_+?_ +9?^SUV?B+_ (]9_P#KC)_Z :XS
MX3?\M_\ ME_[/0!Z'1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %<=\4?^/9/^NR_P#H#UV-<=\4?^/9/^NR_P#H#T 7OA]_QY1_5_\
MT,UT=<Y\/O\ CRC^K_\ H9KHZ "BBB@ HHHH X7XL?\ 'O'_ -=1_P"@M72^
M%?\ CT@_ZY)_Z"*YKXL?\>\?_74?^@M72^%?^/2#_KDG_H(H U:*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*\N^)G_ !\K_P!<E_\
M0FKU&O+OB9_Q\K_UR7_T)J /45Z"EI%Z"EH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#RO0/^0L?^NT_\GKU2O*] _P"0L?\ KM/_
M ">O5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S_
M !%_QZS_ /7&3_T UQGPF_Y;_P#;+_V>NS\1?\>L_P#UQD_] -<9\)O^6_\
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M:,U4U344TV)[F0X2-23TR<= ,D#)/ &>20*\AU_X@W>OR>1:;T3<2BQ;O-;
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MC_UVG_D]>J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 445SWC;Q8/#</F@!I'.U%)[XY8C.=J]\=R!D9R #H:,UY-\*-
M:GOKITFED=1"QP[LPSO09P2>>:]5E<HI8 L0"<#&3[#) R?<@>IH DS17CNL
MV.ML9+R0R(H!9A'.JHJJ,G"K)T 'N3WR:M?"?6I[ZZ=)I9'40,<.[,,[T&<$
MGGF@#UBB@44 %&:9-*(5+L0%4$DDX  Y))/0"O+M?^+,ER3;6"')<!9#\S-]
M(RO4G@9R<=@3P >J49KQB+0-<E <--A@#S<;3SZ@R @^Q&1WIVD?$*\\.R_9
M+T%U1L,'YE7J<A\_-UR,D@@ *0#F@#V7-&:IZ7J2:G$ES&<I(H(Z9&>H."1D
M'@C/!!%>?^//B7)82M96F 4X:0X8[N#A1R..C9!.<C (R0#TRC->-?V)KEU^
M]S,-_P V//"=>?N;QM^F!CI@5J>!?B'*LHTZ^R6+!%9A\ZM]W8PQDY/<\@_>
MR#E0#U'-&:2L'QEXI7P[ 9N#*W$:L3R>,GCG"@Y/3L,@D4 ;]%>4_#C[9KT[
M7<TTAAB;)7>X5F.2% !"X7J1TQ@;<'CU6@!:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#/\1?\ 'K/_ -<9/_0#7&?";_EO
M_P!LO_9Z[/Q%_P >L_\ UQD_] -<9\)O^6__ &R_]GH ]#HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,T9I#10 M%>;>,?BFUB[V
MEHHW(2K2/V89#!5]0<<GC(/RD8)PH])UN^'G@S#>2<&;R^YS\A==H]!@#'3C
M% 'LU%>*1>+=1\+2B"Y+, 0S)*0^X$8XD^8X],$@,#D'D5ZQX?UQ-;A6YC(^
M8#< <[6Q\RG@<CZ#(P1P10!IT5YKXPT75;FZDDM3((3MV[9P@X10?EWC'.>W
MO6-_PCFN?WIO_ D?_'* /8Z*\<_X1S7/[TW_ ($C_P".5@VOB"_,RPI/(TGF
M!5'G%E+;L 9+%""?JI'M0!] T444 %&:#6;X@UQ-$A:YD(^4':"<;FQ\JC@\
MGZ' R3P#0!I9HS7BFBWFH^+K@[)I$4G+E'98T'8!01SQ@#J>I/WF'LMK!]G1
M8\EMB@;G.6.!C)/<GN?6@";-%>:>._B7)82M96F 4X:0X8[N#A1R..C9!.<C
M QDX_P#8NN77[W,PW_-CSPG7G[F\;?I@8Z8% 'L>:,UY?X%^(4JRC3K[)8L$
M5F'SJWW=C#&3D]SR#][(.5].- #J*P?&/BE?#T!FX,K<1JQ/)XR>.<*#D].P
MR"17$?#G[9KL[7<TTAAB;)7>X5F.2% !"X7J1TQ@;<'@ ]5HI!2T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'?%'_CV3_KLO
M_H#UV-<=\4?^/9/^NR_^@/0!>^'W_'E']7_]#-='7.?#[_CRC^K_ /H9KHZ
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M1W%8/Q,_Y!\W_;/_ -&)7E'@Z_NE=K&S8*UT I)P,;<G<&Z@A=W3G!.!NVX
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M8Y/4FO;[6U6T184&$10JCDX"C &3STKF/!/AU/"EL9;@A)),&5F<;1R0BY.
M,9YZY8GDC%/?XGZ>I $I.3@D1R<<$Y.5''&.,G)'&,D '4XHQ69HWB>VUK/V
M>0.1G(Y5N,<[6 ..1SC&>,YK4H \O^+_ /H4UK>1\2C=ANO^K963@Y'!8]N<
M\YKTBPO!?1I<+D+(BL >N& (SC//-<7\9/\ CS3_ *[K_P"@/6O\-Y3+I\!8
MDG#CDYX61@!]   /0<4 =+1110 4444 %%%% !1110 4444 %%%% "5Y=\3/
M^/E?^N2_^A-7J->7?$S_ (^5_P"N2_\ H34 >HKT%+31T%.% !1110 4444
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M%=>3BES0 9KRCXS6"1/#.J@/('#$=]FS;GW&2,]<8'0#'J<LHA!=B J@DDG
M ')))Z 5XQXNUL^,[N.VM@=BG8F1U+'YI#@;@N .N<*N< DB@#U#P3J9U*SA
MG;.XIM))W$E"4+$GNVW/X]^M;=0:?9"QC2W7)6-%49ZX4 #.,<\5/0 4444
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MB<8(.#5WP_X[M-=(BB8B1@3L<;6X]^5)QS@$G'/8X .AHHHH **** "BBB@
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M_77A']V-6S_P)QC/^YR1]#UKJ/B9_P @^;_MG_Z-2LOX-_\ 'F__ %W;_P!
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M1110 E>7?$S_ (^5_P"N2_\ H35ZC7EWQ,_X^5_ZY+_Z$U 'J*]!2TB]!2T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %+25B>-M-.I6
M<T"YW%-P &XDH0X4 =VVX_'H>E &U17B_P ,?%BZ/*UO,VV&;&"<X5QP"><
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M-P6.,^I^]M4#(KT;P7X*3PXF3AIW'SO_ .RK_LC\V/)[ ;]A8)8(L$2A408
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M,8&Y25;')XR#CG.,9YK4%<S\.(FBL(0P(.'.",<,[$'Z$$$>HYKIQ0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >5Z!_P A8_\
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M /;+_P!GH ]#HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2]6%U(#LWP2#&"2J!0<#/7*D<X_+FO8XI1, ZD%6 ((.00>001U!H \F\?>
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MNL2@<.^W'3?)RY'S9PJMC!!!W=<BO4C0 44"B@ HHHH **** "BBB@ HHHH
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MUZ UYQHMOJ>B%GMXID+C!_<L0<=.&4C(['&1D^IKW@4M 'CG_"1ZY_=F_P#
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M /;+_P!GH ]#HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M% !1110 4444 %%%% !1110!7OK".^&R9%=0<X=0PSTS@@\\U)%$(0$4 *H
M  P !P  .@%248H !1110 4444 %%%%  :BN;5+M3%(H=#C*L P.#D<'CK4M
M% $%A8)IZ+!$H5$& !_GDGJ2>2>3S4]%% !1110 4444 %%%% !1110 4444
M %%%% "5Y=\3/^/E?^N2_P#H35ZC7EWQ,_X^5_ZY+_Z$U 'J*]!2TB]!2T %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y7H'_(6/\
MUVG_ )/7JE>5Z!_R%C_UVG_D]>J4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!G^(O^/6?_KC)_P"@&N,^$W_+?_ME_P"SUV?B+_CU
MG_ZXR?\ H!KC/A-_RW_[9?\ L] 'H=%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2O+OB9_Q\K_U
MR7_T)J]1KR[XF?\ 'RO_ %R7_P!":@#U%>@I:1>@I: "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH \KT#_D+'_KM/\ R>O5*\KT#_D+
M'_KM/_)Z]4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#/\1?\>L__ %QD_P#0#7&?";_EO_VR_P#9Z[/Q%_QZS_\ 7&3_ - -<9\)
MO^6__;+_ -GH ]#HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N.^*/_ ![)_P!=E_\ 0'KL:X[XH_\ 'LG_ %V7_P! >@"]\/O^/*/Z
MO_Z&:Z.N<^'W_'E']7_]#-='0 4444 %%%% '"_%C_CWC_ZZC_T%JZ7PK_QZ
M0?\ 7)/_ $$5S7Q8_P"/>/\ ZZC_ -!:NE\*_P#'I!_UR3_T$4 :M%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E>7?$S_CY7_KDO_H3
M5ZC7EWQ,_P"/E?\ KDO_ *$U 'J*]!2TB]!2T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!Y7H'_(6/_7:?^3UZI7E>@?\A8_]=I_Y
M/7JE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9_B+
M_CUG_P"N,G_H!KC/A-_RW_[9?^SUV?B+_CUG_P"N,G_H!KC/A-_RW_[9?^ST
M >AT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'?%'_
M (]D_P"NR_\ H#UV-<=\4?\ CV3_ *[+_P"@/0!>^'W_ !Y1_5__ $,UT=<Y
M\/O^/*/ZO_Z&:Z.@ HHHH **** .%^+'_'O'_P!=1_Z"U=+X5_X](/\ KDG_
M *"*YKXL?\>\?_74?^@M72^%?^/2#_KDG_H(H U:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!*\N^)G_'RO_7)?_0FKU&O+OB9_Q\K_
M -<E_P#0FH ]17H*6D7H*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /*] _Y"Q_Z[3_R>O5*\KT#_D+'_KM/_)Z]4H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 E>7?$S_CY7_KDO_H35ZC7EWQ,_X^5_ZY+_ .A-
M0!ZBO04M(O04M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >5Z!_R%C_UVG_D]>J5Y7H'_ "%C_P!=I_Y/7JE !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 9_B+_ (]9_P#KC)_Z :XSX3?\
MM_\ ME_[/79^(O\ CUG_ .N,G_H!KC/A-_RW_P"V7_L] 'H=%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD7H*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >5Z!_P A8_\
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M_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\
M%T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N
M1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;
MG^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >
MHT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\
M?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%
M_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y
M=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__
M !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\
MO_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM
M&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='
M_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\
M%T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N
M1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;
MG^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >
MHT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\
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M /%T?\+1N?[D7_?+_P#Q= 'J-%>7?\+1N?[D7_?+_P#Q='_"T;G^Y%_WR_\
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M'_"T;G^Y%_WR_P#\70!ZC17EW_"T;G^Y%_WR_P#\71_PM&Y_N1?]\O\ _%T
M>HT5Y=_PM&Y_N1?]\O\ _%T?\+1N?[D7_?+_ /Q= 'J-%>7?\+1N?[D7_?+_
M /Q='_"T;G^Y%_WR_P#\70!ZC17EW_"T;G^Y%_WR_P#\71_PM&Y_N1?]\O\
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MC17EW_"T;G^Y%_WR_P#\71_PM&Y_N1?]\O\ _%T >HT5Y=_PM&Y_N1?]\O\
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M'_"T;G^Y%_WR_P#\70!ZC17EW_"T;G^Y%_WR_P#\71_PM&Y_N1?]\O\ _%T
M>HT5Y=_PM&Y_N1?]\O\ _%T?\+1N?[D7_?+_ /Q= 'J-%>7?\+1N?[D7_?+_
M /Q='_"T;G^Y%_WR_P#\70!ZC17EW_"T;G^Y%_WR_P#\71_PM&Y_N1?]\O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 E>7_$S_CY7_KDO_H35ZA7EWQ,_P"/E?\ KDO_ *$U 'J
MZ"G"FCH*<* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH \KT#_D+'_KM/\ R>O5*\KT#_D+'_KM/_)Z]4H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 E>7?$S_CY7_KDO_H35ZC7EWQ,_P"/E?\ KDO_ *$U 'J*]!2T
MB]!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y7H
M'_(6/_7:?^3UZI7E>@?\A8_]=I_Y/7JE !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 9_B+_CUG_P"N,G_H!KC/A-_RW_[9?^SUV?B+
M_CUG_P"N,G_H!KC/A-_RW_[9?^ST >AT444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7'?%'_ (]D_P"NR_\ H#UV-<=\4?\ CV3_ *[+
M_P"@/0!>^'W_ !Y1_5__ $,UT=<Y\/O^/*/ZO_Z&:Z.@ HHHH **** .%^+'
M_'O'_P!=1_Z"U=+X5_X](/\ KDG_ *"*YKXL?\>\?_74?^@M72^%?^/2#_KD
MG_H(H U:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*\
MN^)G_'RO_7)?_0FKU&O+OB9_Q\K_ -<E_P#0FH ]17H*6D7H*6@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*] _Y"Q_Z[3_R>O5*
M\KT#_D+'_KM/_)Z]4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!=I_Y/7JE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 9_B+_ (]9_P#KC)_Z :XSX3?\M_\ ME_[/79^(O\ CUG_ .N,G_H!KC/A
M-_RW_P"V7_L] 'H=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5QWQ1_X]D_Z[+_ .@/78UQWQ1_X]D_Z[+_ .@/0!>^'W_'E']7_P#0
MS71USGP^_P"/*/ZO_P"AFNCH **** "BBB@#A?BQ_P >\?\ UU'_ *"U=+X5
M_P"/2#_KDG_H(KFOBQ_Q[Q_]=1_Z"U=+X5_X](/^N2?^@B@#5HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** $KR[XF?\ 'RO_ %R7_P!"
M:O4:\N^)G_'RO_7)?_0FH ]17H*6D7H*6@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /*] _Y"Q_Z[3_R>O5*\KT#_ )"Q_P"NT_\
M)Z]4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G^(O^/6?_KC)
M_P"@&N,^$W_+?_ME_P"SUV?B+_CUG_ZXR?\ H!KC/A-_RW_[9?\ L] 'H=%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^3UZI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'N_2N-^(_C"7P\L0@ W2L22W( 0J2N/]K."<\#..2".RKS#XV?\ +M_VV_\
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MX^5_ZY+_ .A-0!Z@.@IPIHZ"G"@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /*] _Y"Q_Z[3_R>O5*\KT#_D+'_KM/_)Z]4H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/\1?\ 'K/_ -<9
M/_0#7&?";_EO_P!LO_9Z[/Q%_P >L_\ UQD_] -<9\)O^6__ &R_]GH ]#HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQX(=QO?((.YP.""3@J,+VZ9P"3708I:*  4444 %%%% !1110 4444 %%%%
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M$(-=C2WD!58C\OE[5(&,;1E3A>G ]!Z5JVMLMJBPH,(BA5&2<!1@#)YZ5-2
M8H *Y#4OA997IWJK1G))\IL Y]F#  =@H _3'848H Y32?AG9:<=Q0R,"2#*
M=W48QM "D?4$Y[],6/$W@2W\1.LTI=75=N48#(SD A@PX)/3'7G/&.CQ10 R
M.(0@(H 50  !@ #@  = *4G%.Q534]233(GN9#A(U)/3)QT R0,D\ 9Y) H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#RO0/^0L?^NT_\GKU2O*] _Y"Q_Z[3_R>O5* "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S_$7_ !ZS_P#7&3_T
M UQGPF_Y;_\ ;+_V>NS\1?\ 'K/_ -<9/_0#7&?";_EO_P!LO_9Z /0Z***
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MF<$'GFBRL([$;(45%)SA%"C/3. !SQ5FC%  ***6@!,T9I** %HHHH ****
M"BBB@ HHHH **IWFM06)V32QHQ&<.ZJ<=,X)''%6S0 M%%% !1110 4444 %
M0W5HEVICD4,IQE6 8'!R.#QUJ:B@"G9:5%89\F-$W8SL55SCIG &<9JYFBC%
M !1110 4444 %%%% !15.SUJ"^.R&6-V SA'5CCIG )XYJY0 4444 %%%% !
M1110 E>7?$S_ (^5_P"N2_\ H35ZC7EWQ,_X^5_ZY+_Z$U 'J*]!2TB]!2T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !10*6@!**0TF: '9HS244 +FBD%+0 4444 %&:*2@!:*04M !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'E>@?\ (6/_ %VG_D]>J5Y7H'_(6/\ UVG_ )/7JE !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 9HS332T *#FBD6EH *,T4AH
M 7-%-)Q2@T +1110 4444 %%-S2@T +10:;F@!V:*2DS0 ZBFYHS0 ZB@4&@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,
M_P 1?\>L_P#UQD_] -<9\)O^6_\ VR_]GKL_$7_'K/\ ]<9/_0#7&?";_EO_
M -LO_9Z /0Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ S1FFGK2F@!:*04M !112&@!:*04M !103BD!H 6BBB@ HIH-*30
M M%-S1F@!V:*2@4 +113<T .HI!2T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7'?%'_CV3_KLO_H#UV-<=\4?^/9/^NR_^@/0
M!>^'W_'E']7_ /0S71USGP^_X\H_J_\ Z&:Z.@ HHHH **** .%^+'_'O'_U
MU'_H+5TOA7_CT@_ZY)_Z"*YKXL?\>\?_ %U'_H+5TOA7_CT@_P"N2?\ H(H
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MJQ!EL3G! D7@8&,*_/7)RN.W!Z=_42<4 +124=* %HI,TM 'CGQD_P"/Q/\
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M. [;$X *QJ2V2,\D#+'GDY XP*]NTS3DTR)+:,82-0!TR<=2< #)/)..22:
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M]AUY.%]2^&?_ "#X?^VG_HQZ .H%%%% !129ILLPA!=B J@DDG  ')))Z 4
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MP00A(((Z$5Q?P9U)YHIK9CE(F4KUR-^[(ZXQE<X ZDGO78^*?^/.X_ZX2_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E>@?\A8_P#7:?\
MD]>J5Y7H'_(6/_7:?^3UZI0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'C?P<_X^W_ .N#?^AI7L8KQSX-_P#'X_\ UP;_
M -#2O6-8U9-(A>ZESLC&3@9)R<  >I) ]/4@<T 9_B[Q.GAZ$RL1YC B->NY
ML<<9'RCC<<CCW(!X3P%X3/B-VU:^)<%SA6'WV&.3QC8.@ XR,' 7!QM+N(_%
ME\T]_($B + .X4;0PVQ!CMP.>2!DX)X)R/6HO$EE" BSPA5   EC  '   /
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M 4444 %%%% !1110 4444 %%%% "&C%+10 E>*Z+_P A3_MH?YU[77BFB_\
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M=#@Y7')SQQD^+_ TGAH1NS!UD&"54@*PY*Y/4'^$\$X/RC% 'LOA;_CSM_\
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M_KDO_H34 >H#H*<*:.@IPH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ_Z[3_R>O5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+6+.R,8&3DG)R23ZDDGT] !Q5R@ HHHH **** "BBB@ HHHH **** "BBB@
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M$7&K3"_OLA0<A6Y+?_6KU8+MX[4 +1110 4444 %%%% !1110 4444 %%%%
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MBBB@!#24ZB@ HI* * %HHQ10 AI,T[%&V@!!1FEQ1B@ S2&@T"@!,TM+BC%
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M9IV*,4 -S2BEQ1B@ -)2XHH 3-&:7%% !2&EHH 2BEQ1B@!**7%&* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,_
MQ%_QZS_]<9/_ $ UQGPF_P"6_P#VR_\ 9Z[/Q%_QZS_]<9/_ $ UQGPF_P"6
M_P#VR_\ 9Z /0Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@!M*:7%% !0:** $I.E.Q1B@ I,4N*,4 )BEHHH 3%(!GK3J*
M"BBC% #:,4[%&* $QWH%+BC% !24M%  .**** "BBB@ HHHH **** "BBB@
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MKR[XF?\ 'RO_ %R7_P!":O4:\N^)G_'RO_7)?_0FH ]17H*6D7H*6@ HHHH
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MS<Q@,#@IP6Z\,&/!XXVD9Y(KD)$/@_4< DK!*#D89C&P!(Y &XHV#TYZ'H:
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M<NBD[' 8MCG V@$'&<#!R<#CK5KX2^*&NU.G298Q+N1B00$!5=GKP3QUX..
M!GT*200@NQ 50223@ #DDD] *\;\%!;C5_,@'[H23L-JD (5<*<8&T<@#..H
M% 'LDLHA!=B J@DDG  ')))Z 5XCXFU>3QG>K##]S=LB'S8QGF0C&1D<MQPH
M .=N:Z_XK>+1:I_9T1&^0?O""<JO!"\=W[@G[O488&I?A1X7%E#]OD!$DP(7
M.1B/(QQ@<L1G//R[<8R<@'8Z/I":1$EK%G9&,#)R3DY))]223Z>@ XJY2T4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y7H'_(
M6/\ UVG_ )/7JE>5Z!_R%C_UVG_D]>J4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!G^(O^/6?_KC)_P"@&N,^$W_+?_ME_P"SUV?B
M+_CUG_ZXR?\ H!KC/A-_RW_[9?\ L] 'H=%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5QWQ1_X]D_Z[+_Z ]=C7'?%'_CV3_KLO_H#T
M 7OA]_QY1_5__0S71USGP^_X\H_J_P#Z&:Z.@ HHHH **** .%^+'_'O'_UU
M'_H+5TOA7_CT@_ZY)_Z"*YKXL?\ 'O'_ -=1_P"@M72^%?\ CT@_ZY)_Z"*
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M[/P[X3M] 7;"OS'.7;!D.2#C< ..!P,#C.,Y- &U7E'A0G5]9EN=X(B,K*0
M0RC]TH!'&-K YYSCWS7H?B;6?[%MI+O&2B\#&1N8A5SR.,D9YSC..:Y#X-:8
M889;HYQ*ZJ 1CB,'Y@>X)8CV*G\ #T.BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!*\N^)G_'RO\ UR7_ -":O4:\N^)G_'RO_7)?
M_0FH ]17H*6FCH*<* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \KT#_D+'_KM/_)Z]4KRO0/^0L?^NT_\GKU2@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHKT%+2+T%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'E>@?\A8_]=I_Y/7JE>5Z!_P A8_\ 7:?^3UZI0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &?XB_P"/6?\ ZXR?^@&N,^$W_+?_
M +9?^SUV?B+_ (]9_P#KC)_Z :XSX3?\M_\ ME_[/0!Z'1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %<=\4?^/9/^NR_P#H#UV-<=\4
M?^/9/^NR_P#H#T 7OA]_QY1_5_\ T,UT=<Y\/O\ CRC^K_\ H9KHZ "BBB@
MHHHH X7XL?\ 'O'_ -=1_P"@M72^%?\ CT@_ZY)_Z"*YKXL?\>\?_74?^@M7
M2^%?^/2#_KDG_H(H U:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@!*\N^)G_ !\K_P!<E_\ 0FKU&O+OB9_Q\K_UR7_T)J /45Z"EI%Z
M"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RO0/^
M0L?^NT_\GKU2O*] _P"0L?\ KM/_ ">O5* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH S_ !%_QZS_ /7&3_T UQGPF_Y;_P#;+_V>
MNS\1?\>L_P#UQD_] -<9\)O^6_\ VR_]GH ]#HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "N.^*/_'LG_79?_0'KL:X[XH_\>R?]=E_
M] >@"]\/O^/*/ZO_ .AFNCKG/A]_QY1_5_\ T,UT= !1110 4444 <+\6/\
MCWC_ .NH_P#06KI?"O\ QZ0?]<D_]!%<U\6/^/>/_KJ/_06KI?"O_'I!_P!<
MD_\ 010!JT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "
M5Y=\3/\ CY7_ *Y+_P"A-7J->7?$S_CY7_KDO_H34 >HKT%+2+T%+0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E>@?\ (6/_ %VG
M_D]>J5Y7H'_(6/\ UVG_ )/7JE !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 9_B+_CUG_ZXR?^@&N,^$W_ "W_ .V7_L]=GXB_X]9_
M^N,G_H!KC/A-_P M_P#ME_[/0!Z'1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<=\4?^/9/^NR_^@/78UQWQ1_X]D_Z[+_Z ] %[X??
M\>4?U?\ ]#-='7.?#[_CRC^K_P#H9KHZ "BBB@ HHHH X7XL?\>\?_74?^@M
M72^%?^/2#_KDG_H(KFOBQ_Q[Q_\ 74?^@M72^%?^/2#_ *Y)_P"@B@#5HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $KR[XF?\?*_P#7
M)?\ T)J]1KR[XF?\?*_]<E_]":@#U%>@I:1>@I: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH \KT#_ )"Q_P"NT_\ )Z]4KRO0/^0L
M?^NT_P#)Z]4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#/\1?\>L__7&3_P! -<9\)O\ EO\ ]LO_ &>NS\1?\>L__7&3_P! -<9\
M)O\ EO\ ]LO_ &>@#T.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *X[XH_\>R?]=E_] >NQKCOBC_Q[)_UV7_T!Z +WP^_X\H_J_P#Z
M&:Z.N<^'W_'E']7_ /0S71T %%%% !1110!POQ8_X]X_^NH_]!:NE\*_\>D'
M_7)/_017-?%C_CWC_P"NH_\ 06KI?"O_ !Z0?]<D_P#010!JT444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% "5Y=\3/^/E?^N2_P#H35ZC
M7EWQ,_X^5_ZY+_Z$U 'J*]!2TB]!2T %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!Y7H'_(6/\ UVG_ )/7JE>5Z!_R%C_UVG_D]>J4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G^(O^/6?
M_KC)_P"@&N,^$W_+?_ME_P"SUV?B+_CUG_ZXR?\ H!KC/A-_RW_[9?\ L] '
MH=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 2O+OB9_Q\K_UR7_T)J]1KR[XF?\ 'RO_ %R7_P!"
M:@#U%>@I:1>@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH \KT#_D+'_KM/\ R>O5*\KT#_D+'_KM/_)Z]4H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#/\1?\>L__ %QD_P#0#7&?";_E
MO_VR_P#9Z[/Q%_QZS_\ 7&3_ - -<9\)O^6__;+_ -GH ]#HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_"W;7^Y+_WRG_Q= '<T5PW_  MVU_N2_P#?*?\ Q='_  MVU_N2_P#?*?\
MQ= '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW_  MVU_N2_P#?
M*?\ Q='_  MVU_N2_P#?*?\ Q= '<T5PW_"W;7^Y+_WRG_Q='_"WK7^Y+_WR
MG_Q= '<T5PW_  MVU_N2_P#?*?\ Q='_  MVU_N2_P#?*?\ Q= '<T5PW_"W
M;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW_  MVU_N2_P#?*?\ Q='_  MV
MU_N2_P#?*?\ Q= '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW_
M  MVU_N2_P#?*?\ Q='_  MVU_N2_P#?*?\ Q= '<T5PW_"W;7^Y+_WRG_Q=
M'_"W;7^Y+_WRG_Q= '<T5PW_  MVU_N2_P#?*?\ Q='_  MVU_N2_P#?*?\
MQ= '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW_  MVU_N2_P#?
M*?\ Q='_  MVU_N2_P#?*?\ Q= '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WR
MG_Q= '<T5PW_  MVU_N2_P#?*?\ Q='_  MVU_N2_P#?*?\ Q= '<T5PW_"W
M;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW_  MVU_N2_P#?*?\ Q='_  MV
MU_N2_P#?*?\ Q= '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW_
M  MVU_N2_P#?*?\ Q='_  MVU_N2_P#?*?\ Q= '<T5PW_"W;7^Y+_WRG_Q=
M'_"W;7^Y+_WRG_Q= '<T5PW_  MVU_N2_P#?*?\ Q='_  MVU_N2_P#?*?\
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MO_?*?_%T?\+=M?[DO_?*?_%T =S17#?\+=M?[DO_ 'RG_P 71_PMVU_N2_\
M?*?_ != '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW_"W;7^Y+
M_P!\I_\ %T?\+=M?[DO_ 'RG_P 70!W-%<-_PMVU_N2_]\I_\71_PMVU_N2_
M]\I_\70!W-%<-_PMVU_N2_\ ?*?_ !='_"W;7^Y+_P!\I_\ %T =S17#?\+=
MM?[DO_?*?_%T?\+=M?[DO_?*?_%T =S17#?\+=M?[DO_ 'RG_P 71_PMVU_N
M2_\ ?*?_ != '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW_"W;
M7^Y+_P!\I_\ %T?\+=M?[DO_ 'RG_P 70!W-%<-_PMVU_N2_]\I_\71_PMVU
M_N2_]\I_\70!W-%<-_PMVU_N2_\ ?*?_ !='_"W;7^Y+_P!\I_\ %T =S17#
M?\+=M?[DO_?*?_%T?\+=M?[DO_?*?_%T =S17#?\+=M?[DO_ 'RG_P 71_PM
MVU_N2_\ ?*?_ != '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW
M_"W;7^Y+_P!\I_\ %T?\+=M?[DO_ 'RG_P 70!W-%<-_PMVU_N2_]\I_\71_
MPMVU_N2_]\I_\70!W-%<-_PMVU_N2_\ ?*?_ !='_"W;7^Y+_P!\I_\ %T =
MS17#?\+=M?[DO_?*?_%T?\+=M?[DO_?*?_%T =S17#?\+=M?[DO_ 'RG_P 7
M1_PMVU_N2_\ ?*?_ != '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<
MT5PW_"W;7^Y+_P!\I_\ %T?\+=M?[DO_ 'RG_P 70!W-%<-_PMVU_N2_]\I_
M\71_PMVU_N2_]\I_\70!W-%<-_PMVU_N2_\ ?*?_ !='_"W;7^Y+_P!\I_\
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M\71_PMVU_N2_]\I_\70!W-%<-_PMVU_N2_\ ?*?_ !='_"W;7^Y+_P!\I_\
M%T =S17#?\+=M?[DO_?*?_%T?\+=M?[DO_?*?_%T =S17#?\+=M?[DO_ 'RG
M_P 71_PMVU_N2_\ ?*?_ != '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q
M= '<T5PW_"W;7^Y+_P!\I_\ %T?\+=M?[DO_ 'RG_P 70!W-%<-_PMVU_N2_
M]\I_\71_PMVU_N2_]\I_\70!W-%<-_PMVU_N2_\ ?*?_ !='_"W;7^Y+_P!\
MI_\ %T =S17#?\+=M?[DO_?*?_%T?\+=M?[DO_?*?_%T =S17#?\+=M?[DO_
M 'RG_P 71_PMVU_N2_\ ?*?_ != '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_W
MRG_Q= '<T5PW_"W;7^Y+_P!\I_\ %T?\+=M?[DO_ 'RG_P 70!W-%<-_PMVU
M_N2_]\I_\71_PMVU_N2_]\I_\70!W-%<-_PMVU_N2_\ ?*?_ !='_"W;7^Y+
M_P!\I_\ %T =S17#?\+=M?[DO_?*?_%T?\+=M?[DO_?*?_%T =S17#?\+=M?
M[DO_ 'RG_P 71_PMVU_N2_\ ?*?_ != '<T5PW_"W;7^Y+_WRG_Q='_"W;7^
MY+_WRG_Q= '<T5PW_"W;7^Y+_P!\I_\ %T?\+=M?[DO_ 'RG_P 70!W-%<-_
MPMVU_N2_]\I_\71_PMVU_N2_]\I_\70!W-%<-_PMVU_N2_\ ?*?_ !='_"W;
M7^Y+_P!\I_\ %T =S17#?\+=M?[DO_?*?_%T?\+=M?[DO_?*?_%T =S17#?\
M+=M?[DO_ 'RG_P 71_PMVU_N2_\ ?*?_ != '<T5PW_"W;7^Y+_WRG_Q='_"
MW;7^Y+_WRG_Q= '<UQWQ1_X]D_Z[+_Z ]5_^%NVO]R7_ +Y3_P"+K!\9>/H-
M;A6&-7!$@;Y@H& K#LQ]: .T^'W_ !Y1_5__ $,UT=<S\.G#V49'J_\ Z&:Z
M:@ HHHH *0\<TM% %&^TF+4!B90P!SA@",^O-4QX/L_^>*?]\+_A6SBEH Q?
M^$0L_P#GBG_?"_X4?\(A9_\ /%/^^%_PK:HH Q?^$0L_^>*?]\+_ (4?\(A9
M_P#/%/\ OA?\*VJ* ,7_ (1"S_YXI_WPO^%'_"(6?_/%/^^%_P *VJ* ,7_A
M$+/_ )XI_P!\+_A1_P (A9_\\4_[X7_"MJB@#%_X1"S_ .>*?]\+_A1_PB%G
M_P \4_[X7_"MJB@#%_X1"S_YXI_WPO\ A1_PB%G_ ,\4_P"^%_PK:HH Q?\
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MBG_?"_X4?\(A9_\ /%/^^%_PK:HH Q?^$0L_^>*?]\+_ (4?\(A9_P#/%/\
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M\(A9_P#/%/\ OA?\*VJ* ,7_ (1"S_YXI_WPO^%'_"(6?_/%/^^%_P *VJ*
M,7_A$+/_ )XI_P!\+_A1_P (A9_\\4_[X7_"MJB@#%_X1"S_ .>*?]\+_A1_
MPB%G_P \4_[X7_"MJB@#%_X1"S_YXI_WPO\ A1_PB%G_ ,\4_P"^%_PK:HH
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M_P \4_[X7_"MJB@#%_X1"S_YXI_WPO\ A1_PB%G_ ,\4_P"^%_PK:HH Q?\
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MBG_?"_X4?\(A9_\ /%/^^%_PK:HH Q?^$0L_^>*?]\+_ (4?\(A9_P#/%/\
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M_P"%'_"(6?\ SQ3_ +X7_"MJB@#%_P"$0L_^>*?]\+_A1_PB%G_SQ3_OA?\
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M+/\ YXI_WPO^%'_"(6?_ #Q3_OA?\*VJ* ,7_A$+/_GBG_?"_P"%'_"(6?\
MSQ3_ +X7_"MJB@#%_P"$0L_^>*?]\+_A1_PB%G_SQ3_OA?\ "MJB@#%_X1"S
M_P">*?\ ?"_X4?\ "(6?_/%/^^%_PK:HH Q?^$0L_P#GBG_?"_X4?\(A9_\
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<4 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>eols-20211231_g4.jpg
<TEXT>
begin 644 eols-20211231_g4.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=I;&)E<G0@
M2&5R;F%N9&5Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,R
M,   DI(  @    ,R,   ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?_BZ/)\4_P#0]:Y_X%R__%T?6Z/</["S#^3\5_F?4E%?+?D^*?\ H>M<_P#
MN7_XNCR?%/\ T/6N?^!<O_Q='UNCW#^PLP_D_%?YGU)17RWY/BG_ *'K7/\
MP+E_^+H\GQ3_ -#UKG_@7+_\71];H]P_L+,/Y/Q7^9]245\M^3XI_P"AZUS_
M ,"Y?_BZ/)\4_P#0]:Y_X%R__%T?6Z/</["S#^3\5_F?4E%?+?D^*?\ H>M<
M_P# N7_XNCR?%/\ T/6N?^!<O_Q='UNCW#^PLP_D_%?YGU)17RWY/BG_ *'K
M7/\ P+E_^+H\GQ3_ -#UKG_@7+_\71];H]P_L+,/Y/Q7^9]245\M^3XI_P"A
MZUS_ ,"Y?_BZ/)\4_P#0]:Y_X%R__%T?6Z/</["S#^3\5_F?4E%?+?D^*?\
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M3LF95<GQM&'/.%EIU75V[]SZWHKY;\GQ3_T/6N?^!<O_ ,71Y/BG_H>M<_\
M N7_ .+J?K='N:_V%F'\GXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='D^*?^AZU
MS_P+E_\ BZ/K='N']A9A_)^*_P SZDHKY;\GQ3_T/6N?^!<O_P 71Y/BG_H>
MM<_\"Y?_ (NCZW1[A_868?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\ %T>3XI_Z
M'K7/_ N7_P"+H^MT>X?V%F'\GXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='D^*?
M^AZUS_P+E_\ BZ/K='N']A9A_)^*_P SZDHKY;\GQ3_T/6N?^!<O_P 71Y/B
MG_H>M<_\"Y?_ (NCZW1[A_868?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\ %T>3
MXI_Z'K7/_ N7_P"+H^MT>X?V%F'\GXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='
MD^*?^AZUS_P+E_\ BZ/K='N']A9A_)^*_P SZDHKY;\GQ3_T/6N?^!<O_P 7
M1Y/BG_H>M<_\"Y?_ (NCZW1[A_868?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\
M%T>3XI_Z'K7/_ N7_P"+H^MT>X?V%F'\GXK_ #/J2BODC2-0\5:G->H?&>MQ
M?9IC'D7LIW=>?O\ M6GY/BG_ *'K7/\ P+E_^+JI8FE%V;,J63XVM!3A"Z?F
MO\SZDHKY;\GQ3_T/6N?^!<O_ ,71Y/BG_H>M<_\  N7_ .+J?K='N:_V%F'\
MGXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='D^*?^AZUS_P+E_\ BZ/K='N']A9A
M_)^*_P SZDHKY;\GQ3_T/6N?^!<O_P 71Y/BG_H>M<_\"Y?_ (NCZW1[A_86
M8?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\ %T>3XI_Z'K7/_ N7_P"+H^MT>X?V
M%F'\GXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='D^*?^AZUS_P+E_\ BZ/K='N'
M]A9A_)^*_P SZDHKY;\GQ3_T/6N?^!<O_P 71Y/BG_H>M<_\"Y?_ (NCZW1[
MA_868?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\ %T>3XI_Z'K7/_ N7_P"+H^MT
M>X?V%F'\GXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='D^*?^AZUS_P+E_\ BZ/K
M='N']A9A_)^*_P SZDHKY;\GQ3_T/6N?^!<O_P 71Y/BG_H>M<_\"Y?_ (NC
MZW1[A_868?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\ %T>3XI_Z'K7/_ N7_P"+
MH^MT>X?V%F'\GXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='D^*?^AZUS_P+E_\
MBZ/K='N']A9A_)^*_P SZDHKY;\GQ3_T/6N?^!<O_P 71Y/BG_H>M<_\"Y?_
M (NCZW1[A_868?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\ %T>3XI_Z'K7/_ N7
M_P"+H^MT>X?V%F'\GXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='D^*?^AZUS_P+
ME_\ BZ/K='N']A9A_)^*_P SZDHKY;\GQ3_T/6N?^!<O_P 71Y/BG_H>M<_\
M"Y?_ (NCZW1[A_868?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\ %T>3XI_Z'K7/
M_ N7_P"+H^MT>X?V%F'\GXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='D^*?^AZU
MS_P+E_\ BZ/K='N']A9A_)^*_P SZDHKY;\GQ3_T/6N?^!<O_P 71Y/BG_H>
MM<_\"Y?_ (NCZW1[A_868?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\ %UF:#J'B
MO6;&2X;QGKD.R4Q[1>RG. #G[_O5+$TFF[[&4LGQL:D:;AJ[VU73?KYGUO17
MRWY/BG_H>M<_\"Y?_BZ/)\4_]#UKG_@7+_\ %U/UNCW-?["S#^3\5_F?4E%?
M+?D^*?\ H>M<_P# N7_XNCR?%/\ T/6N?^!<O_Q='UNCW#^PLP_D_%?YGU)1
M7RWY/BG_ *'K7/\ P+E_^+H\GQ3_ -#UKG_@7+_\71];H]P_L+,/Y/Q7^9]2
M45\M^3XI_P"AZUS_ ,"Y?_BZ/)\4_P#0]:Y_X%R__%T?6Z/</["S#^3\5_F?
M4E%?+?D^*?\ H>M<_P# N7_XNCR?%/\ T/6N?^!<O_Q='UNCW#^PLP_D_%?Y
MGU)17RWY/BG_ *'K7/\ P+E_^+H\GQ3_ -#UKG_@7+_\71];H]P_L+,/Y/Q7
M^9]245\M^3XI_P"AZUS_ ,"Y?_BZ/)\4_P#0]:Y_X%R__%T?6Z/</["S#^3\
M5_F?4E%?+?D^*?\ H>M<_P# N7_XNCR?%/\ T/6N?^!<O_Q='UNCW#^PLP_D
M_%?YGU)17RWY/BG_ *'K7/\ P+E_^+H\GQ3_ -#UKG_@7+_\71];H]P_L+,/
MY/Q7^9]245\M^3XI_P"AZUS_ ,"Y?_BZ/)\4_P#0]:Y_X%R__%T?6Z/</["S
M#^3\5_F?4E%?+?D^*?\ H>M<_P# N7_XNCR?%/\ T/6N?^!<O_Q='UNCW#^P
MLP_D_%?YGU)17RWY/BG_ *'K7/\ P+E_^+H\GQ3_ -#UKG_@7+_\71];H]P_
ML+,/Y/Q7^9]245\M^3XI_P"AZUS_ ,"Y?_BZ/)\4_P#0]:Y_X%R__%T?6Z/<
M/["S#^3\5_F?4E%?+?D^*?\ H>M<_P# N7_XNCR?%/\ T/6N?^!<O_Q='UNC
MW#^PLP_D_%?YGU)17RWY/BG_ *'K7/\ P+E_^+H\GQ3_ -#UKG_@7+_\71];
MH]P_L+,/Y/Q7^9]245\M^3XI_P"AZUS_ ,"Y?_BZ/)\4_P#0]:Y_X%R__%T?
M6Z/</["S#^3\5_F?4E%?+?D^*?\ H>M<_P# N7_XNCR?%/\ T/6N?^!<O_Q=
M'UNCW#^PLP_D_%?YGU)17RWY/BG_ *'K7/\ P+E_^+H\GQ3_ -#UKG_@7+_\
M71];H]P_L+,/Y/Q7^9]245\LO'XI2-F_X3G7#M!/_'W+_P#%UGZ%?>*M7TP7
M1\::Y#\Y7:+V4]/^!U7UFDUS7,GD^-C45-PU=VM5TWZ^9];45\M^3XI_Z'K7
M/_ N7_XNCR?%/_0]:Y_X%R__ !=3];H]S7^PLP_D_%?YGU)17RWY/BG_ *'K
M7/\ P+E_^+H\GQ3_ -#UKG_@7+_\71];H]P_L+,/Y/Q7^9]245\M^3XI_P"A
MZUS_ ,"Y?_BZ/)\4_P#0]:Y_X%R__%T?6Z/</["S#^3\5_F?4E%?+?D^*?\
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M% '-^$_^/S6/^OL_S-=)7-^$_P#C\UC_ *^S_,UTE;U_XC_KH>;E?^Z1^?\
MZ4PHHHK ](**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KFO W_($G_Z^F_]!6NE
MKFO W_($G_Z^F_\ 05K>'\*7R_4\VO\ [[1])_\ MITM%%%8'I!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ,F_X]Y/]T_RK!\$_P#(NC_KJW]*WIO^/>3_ '3_
M "K!\$_\BZ/^NK?TK>/\*7JOU/-J_P"_4O\ #+_VTZ&BBBL#T@HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7'WJA-0N%4!5$K  #@#-:.#4%+N<E/$J>(G02UC;\2"BBBLSK"BBB@ HHHH
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M]>2>*X^L*[BY:=M?4];*Z=2G1:FFE=\J>ZCT04445SGJ!1110 4444 %%%%
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MH84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAYN5_P"Z1^?_ *4PHHHK ](**** "BBB@ HHHH **** "BBB@ HHHH ****
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M2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M _Z^#_-*WH?Q/O\ R/-S3_=7ZQ_]*1TE%%%8'I!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '-^$_^/S6/^OL_S-=)7-^$_P#C\UC_ *^S
M_,UTE;U_XC_KH>;E?^Z1^?\ Z4PHHHK ](**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KFO W_($G_Z^F_]!6NEKFO W_($G_Z^F_\ 05K>'\*7R_4\VO\ [[1]
M)_\ MITM%%%8'I!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,F_X]Y/]T_RK!\$
M_P#(NC_KJW]*WIO^/>3_ '3_ "K!\$_\BZ/^NK?TK>/\*7JOU/-J_P"_4O\
M#+_VTZ&BBBL#T@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,/QC_P BQ<?[R?\
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M^!_Y^HWZ*P/^$K3_ *!.I?\ ?C_Z]'_"5I_T"=2_[\?_ %Z/J]7^4/[7P/\
MS]1OT5@?\)6G_0)U+_OQ_P#7H_X2M/\ H$ZE_P!^/_KT?5ZO\H?VO@?^?J-^
MBL#_ (2M/^@3J7_?C_Z]'_"5I_T"=2_[\?\ UZ/J]7^4/[7P/_/U&_16!_PE
M:?\ 0)U+_OQ_]>C_ (2M/^@3J7_?C_Z]'U>K_*']KX'_ )^HWZ*P/^$K3_H$
MZE_WX_\ KT?\)6G_ $"=2_[\?_7H^KU?Y0_M? _\_4;]%8'_  E:?] G4O\
MOQ_]>C_A*T_Z!.I?]^/_ *]'U>K_ "A_:^!_Y^HWZ*P/^$K3_H$ZE_WX_P#K
MT?\ "5I_T"=2_P"_'_UZ/J]7^4/[7P/_ #]1OT5@?\)6G_0)U+_OQ_\ 7H_X
M2M/^@3J7_?C_ .O1]7J_RA_:^!_Y^HWZ*P/^$K3_ *!.I?\ ?C_Z]'_"5I_T
M"=2_[\?_ %Z/J]7^4/[7P/\ S]1OT5@?\)6G_0)U+_OQ_P#7H_X2M/\ H$ZE
M_P!^/_KT?5ZO\H?VO@?^?J-^BL#_ (2M/^@3J7_?C_Z]'_"5I_T"=2_[\?\
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MO^_'_P!>CZO5_E#^U\#_ ,_4;]%8'_"5I_T"=2_[\?\ UZ/^$K3_ *!.I?\
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MU+_OQ_\ 7H_X2M/^@3J7_?C_ .O1]7J_RA_:^!_Y^HWZ*P/^$K3_ *!.I?\
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M_OQ_]>C_ (2M/^@3J7_?C_Z]'U>K_*']KX'_ )^HWZ*P/^$K3_H$ZE_WX_\
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M +\?_7H_X2M/^@3J7_?C_P"O1]7J_P H?VO@?^?J-^BL#_A*T_Z!.I?]^/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5Y/\6?\ DI?PU_[";_\ H<%>L5Y/\6?^2E_#7_L)O_Z'!0!ZQ1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y/\%?^0YXZ_P"PR_\
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M* "BBB@ HHHH **** "BBB@#SOX[?\DAU/\ ZZP?^C5KL?#7_(IZ1_UXP_\
MH KCOCM_R2'4_P#KK!_Z-6NQ\-?\BGI'_7C#_P"@"@#3HHHH J:K_P @>]_Z
M]W_]!->>_L__ /)*8/\ K[F_F*]"U7_D#WO_ %[O_P"@FO/?V?\ _DE,'_7W
M-_,4 >FT444 %%9?B+Q#9^&-).I:DEPUJCJLC01&0Q@_Q$#G:.YJ71]=TOQ!
M9"[T2_@OH#U>%PVT^A'4'V- %^BL/Q7<^)+;2U_X0ZPL[N_9P#]MD*QQKW)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >=_';_DD.I_\ 76#_ -&K78^&O^13TC_KQA_] %<=\=O^20ZG
M_P!=8/\ T:M=CX:_Y%/2/^O&'_T 4 :=%%% %35?^0/>_P#7N_\ Z":\]_9_
M_P"24P?]?<W\Q7H6J_\ ('O?^O=__037GO[/_P#R2F#_ *^YOYB@#TVBBB@
MKQ?QK_PAW]NR?\(0;_\ X2_!P/#.>O\ TVQ^[VY^]W]:[WXC64^H>$7M[;2;
MK6"TR%[*UO/LK2KGD%\'Y?4=ZY31_$'BGP_9"TT3X/?88!U2'5(EW'U)V9)]
MS0!V7@/_ (2G_A%8?^$Y\G^U=YSY6W.S QNV_+NZ]..E<9^SI_R3.?\ ["4O
M_H$==_X8U75=8TDW.NZ&^AW(E*"U>X$Q*@##;@!UR>/:N+^ NE:CH_P\FMM7
ML+JPG.H2.(KJ%HF*E$P<, <<'GVH Z3XE_\ ),/$7_8/E_\ 0:X"XO[S3/V4
M(+S3;N>SN8[:#9/;R&-US<J#AAR,@D?C7HGQ!M;B]^'6O6UG!)<3RV,BQQ1(
M69R5X  Y)K@=3T359/V6TTF/3+QM2^SP#[&MNQFR+E21LQNX STZ4 4#X>\:
MR_#$>,;GQOJL.I6^GB]BM(Y,0>4B;@'7^-BHR2<Y)YS5GP[I7C/XE>%1XEO/
M%U]H\LR$6%IIS&*+*?+N< @MN92<=OTKMKJQNV^!\U@MK,;P^'&A%N(SYAD^
MS8V;>N[/&.N:/A-8W>F_"S1;34;6:TN8XY \,\91TS*YY4\C@@T 8?@CQCJ/
MBCX(:CJE],PU&TMKF%KB/Y&9DC+*XQT."O([C-<[\._#OB_QOX(M+_6O&VL6
M%KEUM5M)B)I0';+R2$[FYR /115OX9Z5J.C_  '\16VKV%U83D7CB*ZA:)BI
M@7!PP!QP>?:LSX6^,O$?AOX>6,<_A34=;TMS*UE<:8OFNG[Q@R.G4?,&(/H1
MZ4 =1X.US7_#WQ&G\">*]1.JK);?:M-OY%Q)(G=6]?NMR<G*GD@C'*^'K7Q?
MXU^('C'3(?%NI:;I-CJ<H9XIF:1?WL@2.,D_(H .0,=![8ZKP?H6O^(?B-/X
M[\5:>=*6*W^RZ=82-ND1.<LWI]YO3ECQQ3_A9I6HZ?XR\?3W]A=6L5WJ[26\
MD\+(LR^9*=R$CYA@CD>HH K>(M6\0ZAXPTWX=>%]6DM9+:Q2;4]6<;YBH '&
M3]X_*2>N7'/7-/Q-I7BWX8:8/$ND>*]1UVSMG7[=8:M)YH=&(7*L>5Y(Z?7D
M BM3QEH&OZ%\0[?QWX3L/[4)MOLNHZ>K;9)4[,OJ>%]_E'!!.,OQ-JOBSXG:
M8/#6D^%-1T*RNI%^W7VJQ^5L12&PJGD\@=.O3N30!/XS\27N@>)/"OCFRU"[
M;PUJ2)#>VIE8Q*LBY639G .TD\=T]ZT_B]XDO[32],\/>&;EXM8UZY6*"6!R
MK1Q@C<P8<C)*C/IN]*Z/7/!EEJ_P\D\*+A(%LUM[=V'^K9 -C?@5!_.O./A%
MX7\17OB@Z[XWM+F"31;---T^.YB*$@ @L-W7 R-PZ[CZ4 3_ !%\;W'A2[T7
MP7;:])INZU5[_6YT>XE5.1P/F8LQ4G/7D<CK7)ZAXXLO#,2ZGX0^)VJZY=QN
MOF:;JT,[QW"9Y"ED 4_EQT.<5Z1\0?#>O6WB_2O'/A"V2^OM/B-O<V!;:;B$
MY^Z?7YF]^F,XQ4%UX^\:Z[Y-CX5\$ZCIEV\J^==ZQ"4AB7/S8Z;O3(YQT&<4
M 8WQ0\3ZY=W'P]N?!^H7%C)K1:1(TE(1R_D%!(HX8#>>"".M5?&\/BWX5V^F
M^(+/Q=J&M&XN1;75I?L7B=V5F&Q<_*/E;IR..:Z3XD:5JE_X^^'=Q;6-Q=)9
MWSO=S6\#-'"-T/+$9VC@]3V/I3OCKI6HZOX-TR#2;"ZOI4U>*1X[:%I&51'(
M"Q"@X&2.?<4 <]XMT;QIX+\(CQB_C74;K4[5XGN[.5O]%(=PI58^G!8#ITSC
M%='\1_B5/X=\!:3J.E>7!>ZVJ&&25=ZVRL@9G(P=V-PXP>O3L=3XPV%YJ?PG
MUBSTVTGO+F3R-D%O&9';$\9.%')P 3^%9'B;P3JGB'X8>&3I/^C:[HL-M<VT
M<PV9=8UW(<_=.0.O=<''4 'G]SXFTFWL7O=.^,>M2ZTB[U2:VN#:R/\ W?+*
M8 /3O]*W_%'C_4]>_9[@\0V=U-IVI?:D@GDLY6B.Y6(."#G!&#CWQ6[+\2O&
M$NF&SMOAWJ\>N%-@=X_]%5^F[>>".^,_CWJ/XI:7XEU7X*P6M]:?;]<,L+7$
M6FP,X)!.<*,G@8R>F<]!0!0N_"/C4>"'\43>.M4BUF&T-Y]D1]ML J[O+V="
M<<9(Z]?6KMT]W\2?@M:Z_-J]_I4\-C<O<16$IC2Y9 RD..ZDH>/]HUW.JV\T
MGP[O;:.&1YVTJ2-8E4EBWE$;0.N<\8KE_AKH-_\ \*+BT6_MIK"\GM[N$QW4
M31M&7>0 E2,C@@_2@#!^"'A.=O"NB^(1XBU=8@T^=+%P?LA^=T^Y_P"/?[W-
M=_\ $:[N++X:Z_<61*S)8R;67JN1@D?0$FN+^$NI:YX>T^P\%ZSX3U6W>WEF
M#:CY6;8*2S@E^G4[1C/8UZI=6T-[:36MU&LL$\;1R1MT92,$'Z@T <;\'K"S
ML?A3HOV%5_?PF:5AU:1F.[/T/'X5A^(_'/Q&\/0ZA?3^"[+^R[-F/VDWR$F,
M-@-M#YY&.,5GZ;9>-OA)/-I^E:1)XI\,O(TD"0-BXMLGD8P2?I@@GG*Y-'B7
MQ7XO\=Z!=>'M(^'^IV(OE\J6ZU+,*QKGDX*C/US^!H ;\5=9D\1?L^66KS1+
M#)>O;S-&AR%)SP*]:TK_ ) ]E_U[I_Z"*\M^(/A35;7X!Z?X?M+6;4;ZT^SH
M\=G$TA.WJ0 ,X]ZLV?Q5UFVL8(&^&WBAC%&J$BT?G Q_=H Z'XD^!Y_&>E6;
MZ7>BQU;3+@7-E.P^4,,<'N.0#GGD#BN83XG^*/!T\-O\3O#9AM7<1C5]/.^/
M/J5&?KU!X.%K9U_7?'-YX:TC7_".D&%A(SWVCWT6VX= 2 /FQCIG  /*XSR*
MY?Q7XD\6_$+PY+X8L/ &I:=)>,BSW-^I6*$!@Q*L5 /(Z^G:@#V:":.YMXY[
M=UDBE4.CJ<AE(R"/PI]4-!TS^Q?#NG:7YAE^Q6L=OYA_BV*%S^E7Z "O)_BS
M_P E+^&O_83?_P!#@KUBO)_BS_R4OX:_]A-__0X* /6**** "BBB@ HHK"\3
M^-- \'1V\GB2_P#L:W)98CY,DFXKC/W%..HZT ;M%<9IWQ=\":I="WM?$=NL
MAZ?:(Y(%/_ I% _6NR!#*"I!!&01WH 6BBB@ HHHH ***Y76_B9X.\.Z@UCJ
M^NV\-RAVO$BO*4/HVP':?K0!U5%4]*U?3]<T]+[1[R&\M9/NRPON&>X]C[5<
MH **** "BBB@#R?X*_\ (<\=?]AE_P#T)Z]8KR?X*_\ (<\=?]AE_P#T)Z]8
MH **** "BBB@ HHHH **** "BBB@ HHI"0JDL0 !DD]J %HKE='^)GA'7]>&
MBZ/K"W5^Q<+&D$H#;02V'*[2, \YY[5H^(?%V@>%84D\0:I!9"3[BN27?W"C
M)/Y4 ;-%87ASQKX=\6A_^$>U6&\:,;GC *.H]2C -CWQ6[0 45SWB+QYX8\*
M2K%K^L06DS#<(<,\F/7:H) _"KF@>)]%\4V;7.@:C#?1(0'\L_,A/3<IP1^(
MH U:*Q/$7C+P]X31&\0ZK!9&0;DC;+.P]0B@L1[XI?#WB_0/%<3OX?U6"]\L
M9=$)#H/4H<,!]10!M45A>)/&OAWP@D3>(M4BLC-_JT*L[L/4*H)Q[XJUH'B3
M2/%&G?;M OXKVWW;2R9!4]<,IP5//0@4 :=%9$_BG1K?Q/!X=DO,ZK/'YJ6R
M1.YV<\D@$+T/4BM>@ HHHH **** "BBB@ HHHH **** "BBB@ KR?]G;_DG^
MH_\ 87E_]%Q5ZQ7D_P"SM_R3_4?^PO+_ .BXJ /6**** "BBB@ HHHH ****
M "BBB@ HHHH **Y;Q#\2_"7A75/[.U[5A:W>P2>7]GEDPIZ'*J1VIV@_$?PK
MXF-V-#U7[4;.$SS_ .CRIL0=_F49^@YH Z>BN!_X7?\ #S_H8/\ R2N/_C=;
M/AKXA^%_%]]+9^'=4^V7$,?FNGV>6/"Y SEU ZD4 =+117(ZA\5/!.EZD;"\
M\0VRW"MM8(KR*I]"R@J/Q- '745!97MKJ-E%=Z?<17-M,NZ.:%PRN/4$=:P_
M$/Q \+>%;@6^O:S!:SD ^2 TC@'H2J D?C0!T=%9NA^(M(\2V1N]"U""^A!P
MS1-DH?1AU4^QK-\1_$+PKX2NDM=?UB*UN&&X0A'D<#L2$!('UH Z2BJ>E:M8
M:WIL6H:1=Q7=I,,I+$V0>Q'L0>U5+7Q3HU[XENM M+SSM2M$#W$*1.1&#CJ^
M-N>1QG- &O1110 4444 %%%% !1110 4444 %%%% %>__P"0;<_]<7_D:\W_
M &?/^26)_P!?LW]*](O_ /D&W/\ UQ?^1KS?]GS_ ))8G_7[-_2@#U"BBB@
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M44 %>3_%G_DI?PU_[";_ /H<%>L5Y/\ %G_DI?PU_P"PF_\ Z'!0!ZQ1110
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MV\BAF*;-OS A5(;(^]TXK/\ @7K6DVG@8Z'<30V6K6%S,MW;S,$D)WDAL'J
M"%]MM9SZYI.M_M1:0VC2Q7'V:PE@N)XB"KR!)3C(X. 0,_AVH [KP=X[_P"$
MGUK6]'O=._LS4M'G\N2'S_-$B9(#J=J\9'IT(/>C7?'?]E^/='\*:?IW]H7N
MH*9)F\[RQ:Q#^,_*<\*QQQT'K7)?$0'P)\2]%\?0JPL;K_B7ZMM&?E(^5L?0
M9^L:CO4OPCM)_$FN:Y\0M3C*R:G,T%BK?P0*<?\ LJCZJ: /4+N.:6RGCM9!
M%,\;+'(1G8Q'!Q[&N.\#_#G3/!GAV:'4Q:ZC>3.\MW?3Q#]X"2>=V< #KSZF
MNUEE2&%Y96"1HI9F/0 =37BB7^H?&G4+D2:G_8O@VVF,7E)(%FOB.?FST&".
M.@SW/( +WP6$)\5^-9-!7;X<:]46@7_5E@6SL]L8_#;7K]9F@V&D:/I<.EZ"
ML$5K;KA8H7#8]SW)/J>M:= !1110 4444 >3_!7_ )#GCK_L,O\ ^A/7K%>3
M_!7_ )#GCK_L,O\ ^A/7K% !1110 4444 %%%% !1110 4444 %(Z+(C(ZAE
M88*D9!'I2T4 >1:G9VUE^U#X=CL[>*W0Z.[%8D"@G_2.<#Z5TUO\.HYOB9J'
MBS79H=2\V-8[*VDBR+4  =R03U[=6/K7/ZY_R=-X<_[ K_\ MQ4OCCQIJ^J>
M,/\ A!/!=S%878C#ZAJDK "V0@'"?[6&'(YR0!CD@ S-=BL%_:-\.Q^%8HH[
MV.)VU7[,,*$P?OXXW8SU]5]J]EKD/ _A#P]X+M9(M-NDN[^Z;-S>S2AI9VS]
M>!GL/U-7XO'/AZ?QD_A:+45;5T4DP;&QD#<5#8P2!SC/\C0!C^%?AQ#H_B36
MM>UR6#5M1U*X,D<TD/\ J$)SL&<^PR.P KD_#*67_#2&J_\ ")I&FG1V&W4?
ML_$/G<= .,YQ^(;WJ77O$^K?$'QA?>$O#.I)HVCZ>WEZGJ6\"24Y(*1\^H(X
MZX.3C@][X.\.^'_".DII7AXPX)W2/Y@:29L<LQ[_ ,AVH X'X:V%IXJ^(?C'
MQ%K4"7=W:Z@;6U$RAQ!&I8#:#WP%&?8^II?']A:^%/BOX*US0X$L[C4;TV=X
ML*A5G1F1<D#@G#G\E]*3X:W]IX5^(GC'P[K=PEG=W6H&ZM#.P03QL6(VD]3A
ME./KZ&E^(%_:>*_BKX+T30YTO+C3KTWEXT+!U@161N2.^$/'N/6@"&XN]*\/
M_M :M>>.O+BAN[2/^R;NZ3,* * R@GA3G//U_O<T="\2Z-HOC[QEXPT--GA>
M&R2-S$NR.ZN\KM$8Z9)W#I_$3WKVC4=*T[5[<0:M86M]"#D1W,*R*#]&!KRF
M6TMOB+\1XM#TVWBA\(^%I-]Q'#&%BN+GD!0!@8'(_!O[PH N_#N*TT2*Y\7^
M.]3LK+7?$3>:JWEPD1B@_@10Q'8#\ !VKU))$EC62)E=& 964Y!!Z$&O$O!.
ME^'/$OB?Q?<?$!;:XUF&_DB$%])M$%L/NE 2, <C(Z #UYW?@C,1;>)+'3IY
M+C0+/4V32Y78L-ASD*3V^Z?^!$]Z /4J*** "BBB@ HHHH **** "BBB@ HH
MHH *\G_9V_Y)_J/_ &%Y?_1<5>L5Y/\ L[?\D_U'_L+R_P#HN*@#UBBBB@ H
MHHH **** "BBB@ HHHH **** / [?QIIEA\=/%NH:EIU[JDBJMC;6UC:B=\(
M5#G!( P4YY[UZEX,\8^&O&$-PV@J(;B#Y+FUF@$4T?LR]Q]"165X)\8^%]3U
MS68(],M_#^MQ3E;R"8)')/C/SY&-W.<]^A[BN<TR[M-8_::EO?"[++:P::8M
M3G@YC>3D=1P>?+'U4^E 'HGB>_T?PMX9OM9O[2W\JTC+;1&H+MT51[DD#\:Y
M/X,^&Y[31+KQ/K$875=?E-P_RX\N(G*J!V!ZX],>E9OCIY/B#\3M-\#6C9TS
M32+[5V'0D?=C/X$#'J_M7J=U=6FDZ9+=7<B6UG:Q%W<\+&BCG\@* .7^+.JW
M.B_"O7+RR<QS"%8E=3@KYDBQD@^N&-1^ /!N@V/PYTNW&EVLPO+..:Y::%7,
MS.@8[LCGKP.PK*\9:OI_Q*^"^O/X2N#>[54E1&RN&C=)"NTC.2J\>N:U/A_X
MRT"^^'.EW U2UA%G910W2S3*AA9$"MN!/ R.#W&#0!S'PLE_X1[Q=XY\.6I9
MM-TVX^T6L3-_JP=V5'X!1^%'P-TBRU?P]?>*=6MX[S5]1OI?-N)D#%1Q\JYZ
M#)/\NU'PLB_X2'Q=XY\1VN]=,U*X%O:RLN/,QNRP]L%3^-'P-U>RTCP_?^%=
M6N(K/5].OI?-MYG"%EX^9<]1D']/44 (]G;^$?VD=+M]#B6TM->T]S=V\0VH
M742,&"C@<QK^;>IJCX5U+0/#7Q"\91_$!K>VU2XO&F@N+Z/*RVQ)VA"1C&,<
M=^!SCB])>6WB[]I#2[C0Y5N[70K!Q=W$1W1AV$@"AAP?OC\CZ5Z=JFC:/JJ*
M^M:;8WBPC<&NX$D">_S XH \2\+^*X?!^@^,M?T:W9-*U+41%H%J5*B68[@6
M5?[OW3]% Z\5W/P^L-)\":.(/$>LV,7B35I/M-]]IND65Y&Y"X)R<9[=22>]
M8.@Q2?$3QK=>*;>V7^PO#R/;Z%;%-J33@?ZS''&<'_OGT-97P\T3P1K_ ( U
M'5/&TMO<:Q)-,=3N+V;;- =QP1DY7C!XZG([8H ]WHKSSX'WE_>?#"V.H/)(
MD4\D5I)+G<T /R_@#D#V ':O0Z "BBB@ HHHH **** "BBB@ HHHH KW_P#R
M#;G_ *XO_(UYO^SY_P DL3_K]F_I7I%__P @VY_ZXO\ R->;_L^?\DL3_K]F
M_I0!ZA1110 4444 %%%% !1110 4444 %%%% 'AOC#Q3I]A^T3!-JEM<7L6E
M:;Y45K:P>=))*ZEL!?7;)[=!7?\ @_Q[X8\4ZE+9:=;2:=JD +/9WML(9@.Y
M &0>O0'-5=-\7^&F^)^J:7?Z5!I&NPKLCO+A41KV/MM?@G@*0#V^AKF/%U[9
M:Q\?/"$?AF2.XU&R+G4)K<[@D/'RL1W"[_\ OH>M '3?$+QK>6%S!X6\(*MS
MXFU$80#!6S0]97]..F?KZ \-X%\+IX/^/_\ 92W,EW*-(:6>XD/,LK$%F_.M
M?2OA1XUT35[W5-.\=0)?7[9N+B334E=_;+YP/88[>E<S'H?C,_'>6Q'BZ(:V
M--WG4O[/CVF/CY/+QM_&@#Z&KA].^',2_$75?%6NS0ZG)<A5LHI(LBT4<8&2
M03@#G QSZUKW_CGP_I/B:R\.ZCJ*QZK>!1'%L8@ECA06 P"3T!_J*XKQEXQU
M?Q!XRE\"^#;N/3FA3=J6JR, 85.,JGO\PY'.3@8P30!1O8K%?VF-(3PI'%'-
M%:2?VO\ 9@ @&UN' XW?=_';46@:CH7AOXL^,?\ A/3!;7UU/YMC<WJ91[8D
MX5&(P.-H]\8[5WO@CPGX=\%V+6VD3QW%W<'-Q=22AI9V]_;V%;VIZ-I.KQJ-
M9TVRODCY7[7 D@7W&X'% 'B7ACQ79^$H/&_B?1H"F@WEVD6CVQ0JMQ<?,#L7
MLO.3CL,=1BNS^'EEIO@G2C-XKUFQA\2ZV_VJ\^U7*)(6;D( 3SC/;N3[5CZ+
M /B1\0I-8MX$'AGPR3#I< 7;%<7'4OCT! /_ 'S[UD?#C1_!_B/POK.I>.VM
MKC6WNI?[2>^EVR6X'3&2"H]QW&.V* /6?&6F6VK>%;E;H7[+ OVB,:;*R3LZ
M@D!".I_2O&_ 7@?7H/%EG)XL&N&TUA#?HT%V^(YT;*_:< $MC!SQR?KCNO@7
M=7=S\.V2XDEFM+>]EAL)9<[FMQC;U[ [A[8QVKTB@ HHHH **** "BBB@ HH
MHH **** "BBB@#SOX[?\DAU/_KK!_P"C5KL?#7_(IZ1_UXP_^@"N.^.W_)(=
M3_ZZP?\ HU:['PU_R*>D?]>,/_H H TZ*** *FJ_\@>]_P"O=_\ T$UY[^S_
M /\ )*8/^ON;^8KT+5?^0/>_]>[_ /H)KSW]G_\ Y)3!_P!?<W\Q0!Z;1110
M 51UK6+/0-$N]5U)S':VD1DD(&3@=@.Y)X'N:O5R'Q4T&\\2_#35M.TT.]TR
M++'&G_+4HX?;COD+P/7% '-Z;XR^)?B.R&M:#X8TF+29/G@AO)V%Q<)V*D$*
M,^X_.D\(_$CQ1XRU#Q-8V>E6-E>:;&GV2WN@^5D+$,LK!N0"#R M6O"'Q:\)
M?\(79C4]3ATR[L;=8+FSG!5T=%VD*N/F''&,^G6L/X0ZQ'X@^*GC758('@BN
MA$\:.NUMN2%)'J0 ?QH Y_P=-\0%^)WBUM'MM!;5BZ?;TN#+Y*G)QY>#G\S7
MT'"9#;QF<*)=HWA>@;'./QKQGP[KVF>$OCAXU'B2\CTT7GER0/<?*LB]>#TZ
M$?KZ5[/'(LL:R1L&1P&4CN#0!\_^+_"+^,_COXAL+:=K>^@TJ.ZLI5;;MF01
M;<GL#DC/;.>U:?\ PNJ_7P.=):SE_P"$X6;^SOLWE\^9T\['3/M_>[8K7TG_
M ).FUS_L#+_[1KMSX(T0^.!XK^R+_:8@\K=CC/3?C^]CY<^E 'COA3PA)X,^
M/'AFRNYVN+^YTN6[O9&;=NF<3AL'OC:!GOC/>O2/&?C^]TGQ%:>&/"FEKJNO
MW2>;LD?;%!'_ 'G/X'C(X^H!P]<_Y.F\.?\ 8%?_ -N*K:U?Q_#_ ./4WB+7
MED71M<L5MTO-A9;>10@VG X_U?\ X_GL: $\5_$;XB>!]#:X\0^'](9Y65;>
M\M'=X$;/*2(6W E=V#G&1WKH?%_C3Q%X;\.Z/XDM-/M+[2GCB?5(E1_.B# '
M<AW8QSCD'''//')_&CXC>'=5\!7&BZ'>1:I<73QL[VX+K;HKJVXMT!) 7'^U
M73>*O&5OX7^&VEVD=NFH:KJEE%;6>GLN[SBT84EE[J,\COG'>@!NN_%"2\U?
M1M$^':VFJZCJ2K/)+,&:*V@(SEPI!#=\9&,<C)%7M?\ &>J:-\2O#'AM(K.2
MWU6-C<RF-MX8 _<^; ''<&O.?!MA>?!+Q-:'Q9#;MINO0I&VH1K_ ,>4PY\M
MCZ<\]CU'W2*Z?QP0WQ]\"%2"#'*01WX:@";Q1\2_$FE?%$^$]"T>TU(S6R-;
MJQ9&$C#)9VW8V  GIGWJG=_%7Q;X7UIM#\7>'+2XU2ZB5M-_LN1A'.[-M"G<
M21SG)]NG.:FB /[5$V1G&C@CVX%'CL _'[P+D9^20\_\"H LQ>/_ !?X>\6:
M3IOQ TC3;>RUF7R;:YT]V/E2$@!7W$@\LH/0<DC.,5L^)/&FHZ/\3_#?ARVA
MM7L]55S.\B,9%QG&TA@!T[@USWQP_P"/SP9_V&4_FM1?%6<>'_B;X,\3WZ.-
M+MG>&>9%+"(GH3CV8GWVF@#I_BIXSU'P/X;L=0TF&UFEN-0CM76Y1F4*R.Q(
MVL.<J/UJC\4?B)J?@34_#L6F6$%]'J4LJS1.&\QMIC 6,@X!.\C)![<5PWQO
M\>:'XATK2=)T&\CU I?I<S309*1X5E52W3)W,<?[-=+\65#?$OX:A@"/[2DX
M(_VX* (]4^)?C3P7/97OCOP_I\>D7K; =/D8RP-C(5LL03CT Z'GM2:E\1_'
MV@Z7;^)=<\,:?%X?E=-\$<S&ZA1C\I8D[?3MU(SBI?VAP#X$TH$9!UF'(/\
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M!B>(O!OA[Q8B+XATJ"],8VI(V5=1Z!U(8#VS2^'O!_A_PI&Z>']+@LO,&'=
M6=AZ%F))_.MJB@!DL2SPO$^[;(I5MK%3@C'!'(/N*SO#WAK2/"NF?V?H%FMI
M;;S(4#LY9CU)9B2?Q-:E% ',^(?AUX3\57RWNO:-%<W*@#S@[QLP'3<4(W?C
MFMS3=,LM'T^*QTNUCM;6$82*)<*M6J* "BBB@ HHHH **** "BBB@ HHHH *
M*** "O)_V=O^2?ZC_P!A>7_T7%7K%>3_ +.W_)/]1_["\O\ Z+BH ]8HHHH
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MHNG3W8.1<26B-(#Z[B,U8MM)TZRO9[RST^UM[JYQY\\4*J\N.FY@,M^-6Z*
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MKYH7^[OQG'/3-6Z*  C(P>165#X7T"VOC>V^AZ;%=DY,\=I&LF?7<!FM6B@
MJI8Z5I^E^=_9EA:V?GN9)?L\*Q^8W]YL 9/N:MT4 5+?2M.M+^>^M;"UAN[G
M'GW$<*K)+CIN8#+?C1<Z5IUY>V]Y>6%K<75J2;>>6%6>$_[+$97\*MT4 5=0
MTRPU:T-KJME;WUN2&,-S$LB$CH<,"*LHBQHJ(H55& H& !Z4M% !1110 5Y/
M\6?^2E_#7_L)O_Z'!7K%>3_%G_DI?PU_[";_ /H<% 'K%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'D_P5_Y#GCK_L,O_P"A/7K%
M>3_!7_D.>.O^PR__ *$]>L4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HHHH \[^.W_ "2'4_\ KK!_Z-6NQ\-?\BGI'_7C#_Z *X[X[?\
M)(=3_P"NL'_HU:['PU_R*>D?]>,/_H H TZ*** *FJ_\@>]_Z]W_ /037GO[
M/_\ R2F#_K[F_F*] UF01:%?R/\ =2VD8_0*:\#^%GQ@\.>#/ \>D:O#?O<K
M/)(3!"K+ACQR6% 'T317E'_#1?@S_GWU;_P'3_XNC_AHOP9_S[ZM_P" Z?\
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M7X,_Y]]6_P# =/\ XNC_ (:+\&?\^^K?^ Z?_%T >KUY/\6?^2E_#7_L)O\
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MH_X:+\&?\^^K?^ Z?_%T?\-%^#/^??5O_ =/_BZ /5Z*\H_X:+\&?\^^K?\
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M^??5O_ =/_BZ /5Z*\H_X:+\&?\ /OJW_@.G_P 71_PT7X,_Y]]6_P# =/\
MXN@#U>BO*/\ AHOP9_S[ZM_X#I_\71_PT7X,_P"??5O_  '3_P"+H ]7HKRC
M_AHOP9_S[ZM_X#I_\71_PT7X,_Y]]6_\!T_^+H ]7HKRC_AHOP9_S[ZM_P"
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MOJW_ (#I_P#%T >KT5Y1_P -%^#/^??5O_ =/_BZ/^&B_!G_ #[ZM_X#I_\
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M ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@
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M7AK_ )%/2/\ KQA_] %<=\=O^20ZG_UU@_\ 1JUV/AK_ )%/2/\ KQA_] %
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MIKM)I-H[L69H$)8G))VCF@"S17G?Q=\4ZMH-CH^FZ#<+976M7HM?MS@$6ZY
M)YX!^8<^@-43\.O'.D207N@_$*^O+L2+YT&J%I('7/S84DX[\ 9]"* /4J*:
MF\1KYA4O@;BHP"?:G4 %>3_%G_DI?PU_[";_ /H<%>L5Y/\ %G_DI?PU_P"P
MF_\ Z'!0!ZQ1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!Y/\ !7_D.>.O^PR__H3UZQ7D_P %?^0YXZ_[#+_^A/7K% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#\A4] !7D_Q9_P"2E_#7_L)O_P"AP5ZQ7D_Q9_Y*7\-?^PF__H<% 'K%%%%
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M-'QY";0QC]B3SC_=[$UH^*/#?@+X:Z7<>*8?#]J+^,@6D;.[!YS]T*A8@>O
MX )KB]1T?5_#?AO1HM1OY+'5O&FJ+_;&I X>",D8B#?P_>R?H1TH ]ZT^PMM
M+TZWL;")8;:WC$<4:CA5 P*L5XGXF\-VGPFUCP[J?@V\NXI+[4$M+JPEG,BW
MB-]YB#W' SV++C%>V4 %%%% !1110 4444 %%%% !1110 4444 %>3_L[?\
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M5Z1?_P#(-N?^N+_R->;_ +/G_)+$_P"OV;^E 'J%%%% !1110 4444 %%%%
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MOC /S#C/<>M1^+-%\0>%_B4/'7A;3&U>&[MA:ZG81-B5@, .OK]U.@)^7T/
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M2\16.F:IX;:,:WH=T+JT60X63D$ID\<E5//!Q@]<UD7?Q$\9:AIDFG:7\/\
M5[3694,?GSKBVA8\;Q(0 V.HZ4 87B#QOK'B'X0:1XWT>YGLKW2;Y1J%O;3,
MD4N& (90?F4G8<-G 8CZVOC%XTU*;2]"L?!5W=17-_ VJM):R%'^SI&6&<'H
M1DX[[,<UUGA/X=0Z+\*Y/"FH,DLEY#)]K=!QYD@P2/\ =X /^R*XKX*^#M;@
MUJ_O_%]E/$=/M!I=FMU$RAHRQ+;<@97L#W#&@#1\>>.;S5?AIX:7PY=RVNJ>
M)IH8XY+=RCQX(\S#*<C#[5..Q-5_BE=^)-+\6>"M'\,:S=V]Q<*T!9IV996R
MBAY 3A\9)^;-9GP[\ :S8_%=H-7M;D:+X=-PVFRS1,(Y"[?+M8C#'#%CR<$5
MU?C_ $K4;SXM^!KRSL+JXM;660W$\4+,D(ROWF POXT 8'C&P\5?"ZPM/%%I
MXQU+642X2.]L]0D+12!L_=&<+TQQR,YSQ7M,$RW%O'-'G9(@=<^A&:\^^..F
M7^K?#66UTJRN+ZX-U$PAMHFD<@$Y.%!-=WIJ-'I-HCJ598$!4C!!VCB@"S11
M10 5Y/\ %G_DI?PU_P"PF_\ Z'!7K%>3_%G_ )*7\-?^PF__ *'!0!ZQ1110
M 54U?38=9T6^TNZ9T@O;>2WD:,@,%=2I()!&<'T-6Z* /+H?@%X>AA$"ZYXB
M-N./(^VH$([C C%=IX7\&:%X.LFMM L5MP_^LD)+22?[S'D_3I6[10!SGB[P
M)H?C6WA36K=_.MSF"Y@?9+%]&]/8Y%<Q/\"_#-Y92PZC?ZS?3R *MY=78DEB
M4$'"Y7:,XQTSC->E44 9EW=6?A7PO)<7,C+9Z;:Y+.?F*HN!^)Q^9KS;X"^&
M5MM'O_%4UJEM+K$S&WB7I% &. /8MG\%%>JWUA9ZG9O::E:P7=M)C?#<1B1&
MP<C*G@\T^WMX;2VCM[2&."")0D<42A511T  X H DKGO%W@O3O&=O8Q:I-=1
M+8W*W,9MG526 Q@[E/'/M70T4 8GBGPAHOC+2Q8Z_:">-6W1NIVO$WJK#D?R
M/>N=TOX.^&M/U2#4+R74M8FMCFW&IW7G+#CIA< 8'OGI7>T4 9GB#PYI7BG2
M7TW7;1+JV<YVDD%6'1E(Y!]Q7'VGP3\+P74$EY-JFIPVQ!@M+Z[\R&+'0!0!
MQ[&O0Z* $50JA5 "@8  Z4M%% !1110!Y/\ !7_D.>.O^PR__H3UZQ7D_P %
M?^0YXZ_[#+_^A/7K% !1110 4444 %%%% !1110 4444 %%%% %'6=%T_P 0
M:3-INL6J75I.,/&_Z$$<@CU'-<+'\#?# 9(Y[W6;JRC;<EA-?9@7V"@ _K7I
M%% '-^)_ >B>*O"T/A^]BDMK&W='@%HP0Q%00-N01T)'(/6EG\!^'KOP?;^&
M;RQ%QIMJ@6%9&.]"/X@PY#<GD>M='10!YS!\$/"Z30_;+K5]0MK=@8K*[O2\
M*8[!0 <>V:[F^T;3M3T>32K^SBFL)(Q&UNR_+M'0#TQ@8QTQ5VB@#S=/@9X5
M#+')<ZO+8(VY=.DOB;=3G/ QG]:]#M+2"QLXK6SA2"WA0)''&,*BC@ "I:*
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M[?\ )/\ 4?\ L+R_^BXJ /6**** "BBB@ HHHH **** "BBB@ HHHH ****
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M !5'_"D[W_HH'B#_ +^M_P#%4 >L45Y/_P *3O?^B@>(/^_K?_%4?\*3O?\
MHH'B#_OZW_Q5 'K%%>3_ /"D[W_HH'B#_OZW_P 51_PI.]_Z*!X@_P"_K?\
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M_HH'B#_OZW_Q5'_"D[W_ **!X@_[^M_\50!ZQ17D_P#PI.]_Z*!X@_[^M_\
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M)WO_ $4#Q!_W];_XJ@#UBBO)_P#A2=[_ -% \0?]_6_^*H_X4G>_]% \0?\
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M!X@_[^M_\50!ZQ17D_\ PI.]_P"B@>(/^_K?_%4?\*3O?^B@>(/^_K?_ !5
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M#_OZW_Q5'_"D[W_HH'B#_OZW_P 50!ZQ17D__"D[W_HH'B#_ +^M_P#%4?\
M"D[W_HH'B#_OZW_Q5 'J%_\ \@VY_P"N+_R->;_L^?\ )+$_Z_9OZ52NO@M>
MQ6<TA\?:^VV-FVF4X.!T^]7(_"KX;7/BGP2NHP^*]6TI3<21_9[20A.,<]1R
M: /HNBO)_P#A2=[_ -% \0?]_6_^*H_X4G>_]% \0?\ ?UO_ (J@#UBBO)_^
M%)WO_10/$'_?UO\ XJC_ (4G>_\ 10/$'_?UO_BJ /6**\G_ .%)WO\ T4#Q
M!_W];_XJC_A2=[_T4#Q!_P!_6_\ BJ /6**\G_X4G>_]% \0?]_6_P#BJ/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\G^+/\ R4OX:_\
M83?_ -#@KUBO)_BS_P E+^&O_83?_P!#@H ]8HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH \G^"O_ "'/'7_89?\ ]">O6*\G^"O_
M "'/'7_89?\ ]">O6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O)_V
M=O\ DG^H_P#87E_]%Q5ZQ7D_[.W_ "3_ %'_ +"\O_HN*@#UBBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** *]__ ,@VY_ZXO_(UYO\ L^?\DL3_ *_9OZ5Z
M1?\ _(-N?^N+_P C7F_[/G_)+$_Z_9OZ4 >H4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!YW\=O^20ZG_UU@_]&K78^&O^13TC_KQA_P#0!7'?';_DD.I_
M]=8/_1JUV/AK_D4](_Z\8?\ T 4 :=%%% %35?\ D#WO_7N__H)KSW]G_P#Y
M)3!_U]S?S%>A:K_R![W_ *]W_P#037GO[/\ _P DI@_Z^YOYB@#TVBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KR?XL_\E+^&O\ V$W_ /0X*]8K
MR?XL_P#)2_AK_P!A-_\ T."@#UBBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#R?X*_P#(<\=?]AE__0GKUBO)_@K_ ,ASQU_V&7_]
M">O6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O)_V=O^2?ZC_V%Y?_
M $7%7K%>3_L[?\D_U'_L+R_^BXJ /6**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH KW_P#R#;G_ *XO_(UYO^SY_P DL3_K]F_I7I%__P @VY_ZXO\ R->;
M_L^?\DL3_K]F_I0!ZA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G?QV_Y
M)#J?_76#_P!&K78^&O\ D4](_P"O&'_T 5QWQV_Y)#J?_76#_P!&K78^&O\
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MU#3M1D\WS%Q\P6)B"GID9]<T =%\4_%VK^'8-%TWPX88M2UJ]%K%<3+N6$9
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MNM\#:Q?W/Q>\<VM]J-S+9VC)Y,,T[-'",G.U2<+^% 'IU%>.Z WB7XNW%]K
M\1WWA_P_%.T%E;Z:_ERR[?XV?KW'X\#'>]HVK^(? WQ(L?"7B35I-:TO5XV-
MA>W _?1NO\#'JW3'/=E/'(H ]4HKP['BSQ-\;_$F@:;XFO\ 3=,B"/,8Y2QB
M0*F%B!.$)8]1CO\ 0ZFEW6O^ ?BUIOAG4->O-=TC6H6:)[]R\T#@-_$>>J@>
MF&Z<4 >NT444 %>3_%G_ )*7\-?^PF__ *'!7K%>3_%G_DI?PU_[";_^AP4
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M7K%>3_!7_D.>.O\ L,O_ .A/7K% !1110 4444 %%%% !1110 4444 %%%%
M!117F?B/QGK6O^-H_"'P]N%@FMFWZIJAB61+90<% &!!;^O Z' !Z913(4:.
M!$DE:9E4 R. "Q]3@ ?D*XWXE>-KSPE8:?:Z):)=ZQJ]Q]FLXY/N \98\C."
MR_G[4 =K17D6O7WQ0\#:.?$FJ:SIFM6<!0WFGBV$7EJ6"_(X )Z]3TZX-=1X
MM^(L&@?#ZR\0V%L;J?5%B&GVS\%WD7<N['/ ZX^G>@#M:*\LN+?XO:?I#ZVV
ML:3<S11F:31_L@"[1R5#C#%L=L_C6A<?%BU'P?\ ^$TMK7=,P$0M&;A9]VW:
M3W4'GU(]": /0Z*\?U34_B?X/T&/Q7K6J:?J=G&4>]TE;98_)1B!\L@&21D#
MDG'O72>/O'S:1X1L)/#@,VL:\$32XBH+#> ?,(/' (Z\9([9H [RBL_0K;4;
M30[2'6[XW^H+&/M%QY:H&?O@*  !T%:% !1110 4444 %%%% !1110 4444
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M!@[F!Z/GBH]1M_BSXSM6TN[L].\*V$PV7,R7 EE=#U"E6/;Z?6@#G?AMK_\
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M;:8;&,87&W?L^4_Q#CL1W%)'?_&"TTW^RSH>E7=TB>6NK_:U"GMO,9();OT
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M HHHH **** "BBB@ HHHH \[^.W_ "2'4_\ KK!_Z-6NQ\-?\BGI'_7C#_Z
M*X[X[?\ )(=3_P"NL'_HU:['PU_R*>D?]>,/_H H TZ*** *FJ_\@>]_Z]W_
M /037GO[/_\ R2F#_K[F_F*]"U7_ ) ][_U[O_Z":\]_9_\ ^24P?]?<W\Q0
M!Z;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y/\6?\ DI?PU_["
M;_\ H<%>L5Y/\6?^2E_#7_L)O_Z'!0!ZQ1110 4444 %%%% !1110 5R&H^
MSJ_Q*L/%.HZEYMOIL6VTT_R,!'_OE]W)R<_=[+Z5U]% !1110 4444 %%%%
M!1110 4444 >3_!7_D.>.O\ L,O_ .A/7K%>3_!7_D.>.O\ L,O_ .A/7K%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7D_[.W_ "3_ %'_ +"\O_HN
M*O6*\G_9V_Y)_J/_ &%Y?_1<5 'K%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 5[__ )!MS_UQ?^1KS?\ 9\_Y)8G_ %^S?TKTB_\ ^0;<_P#7%_Y&O-_V
M?/\ DEB?]?LW]* /4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA]_T'6_\ I__ (B@#T"BO/\ _A>/P^_Z#K?^ 4__ ,11_P +Q^'W_0=;_P
MI_\ XB@#T"BO/_\ A>/P^_Z#K?\ @%/_ /$4?\+Q^'W_ $'6_P# *?\ ^(H
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MA]_T'6_\ I__ (B@#T"BO/\ _A>/P^_Z#K?^ 4__ ,11_P +Q^'W_0=;_P
MI_\ XB@#T"BO/_\ A>/P^_Z#K?\ @%/_ /$4?\+Q^'W_ $'6_P# *?\ ^(H
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MO^@ZW_@%/_\ $4?\+Q^'W_0=;_P"G_\ B* /0**\_P#^%X_#[_H.M_X!3_\
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M%>?_ /"\?A]_T'6_\ I__B*/^%X_#[_H.M_X!3__ !% '<7_ /R#;G_KB_\
M(UYO^SY_R2Q/^OV;^E6KOXW> );*>--<8L\;*H^QS\DC_<KBO@]\3?"?A3P"
MNFZ]JAMKL7,DAC%M*_RG&#E5([4 >]T5Y_\ \+Q^'W_0=;_P"G_^(H_X7C\/
MO^@ZW_@%/_\ $4 >@45Y_P#\+Q^'W_0=;_P"G_\ B*/^%X_#[_H.M_X!3_\
MQ% 'H%%>?_\ "\?A]_T'6_\  *?_ .(H_P"%X_#[_H.M_P" 4_\ \10!Z!17
MG_\ PO'X??\ 0=;_ , I_P#XBC_A>/P^_P"@ZW_@%/\ _$4 >@45Y_\ \+Q^
M'W_0=;_P"G_^(H_X7C\/O^@ZW_@%/_\ $4 >@45Y_P#\+Q^'W_0=;_P"G_\
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MO^@ZW_@%/_\ $4 >@45Y_P#\+Q^'W_0=;_P"G_\ B*/^%X_#[_H.M_X!3_\
MQ% 'H%%>?_\ "\?A]_T'6_\  *?_ .(H_P"%X_#[_H.M_P" 4_\ \10!Z!17
MG_\ PO'X??\ 0=;_ , I_P#XBC_A>/P^_P"@ZW_@%/\ _$4 >@45Y_\ \+Q^
M'W_0=;_P"G_^(H_X7C\/O^@ZW_@%/_\ $4 >@45Y_P#\+Q^'W_0=;_P"G_\
MB*/^%X_#[_H.M_X!3_\ Q% $?QV_Y)#J?_76#_T:M=CX:_Y%/2/^O&'_ - %
M>/\ Q8^*7A#Q/\.;[2]$U4W-Y*\12,VTJ9"R*3RR@= :]>\+.LO@_1G0Y5K"
M @^H,:T :M%%% ",H92K $$8((ZUCIX.\,1KMC\.:2J^BV,0_P#9:V:* ,?_
M (1'PW_T+^E?^ 4?_P 31_PB/AO_ *%_2O\ P"C_ /B:V** ,?\ X1'PW_T+
M^E?^ 4?_ ,31_P (CX;_ .A?TK_P"C_^)K8HH Q_^$1\-_\ 0OZ5_P" 4?\
M\31_PB/AO_H7]*_\ H__ (FMBB@#'_X1'PW_ -"_I7_@%'_\31_PB/AO_H7]
M*_\  */_ .)K8HH Q_\ A$?#?_0OZ5_X!1__ !-'_"(^&_\ H7]*_P# */\
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MPB/AO_H7]*_\ H__ (FMBB@#'_X1'PW_ -"_I7_@%'_\31_PB/AO_H7]*_\
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M'_\ $T?\(CX;_P"A?TK_ , H_P#XFMBB@#'_ .$1\-_]"_I7_@%'_P#$T?\
M"(^&_P#H7]*_\ H__B:V** ,?_A$?#?_ $+^E?\ @%'_ /$T?\(CX;_Z%_2O
M_ */_P")K8HH Q_^$1\-_P#0OZ5_X!1__$T?\(CX;_Z%_2O_  "C_P#B:V**
M ,?_ (1'PW_T+^E?^ 4?_P 31_PB/AO_ *%_2O\ P"C_ /B:V** ,?\ X1'P
MW_T+^E?^ 4?_ ,31_P (CX;_ .A?TK_P"C_^)K8HH Q_^$1\-_\ 0OZ5_P"
M4?\ \31_PB/AO_H7]*_\ H__ (FMBB@#'_X1'PW_ -"_I7_@%'_\31_PB/AO
M_H7]*_\  */_ .)K8HH Q_\ A$?#?_0OZ5_X!1__ !-'_"(^&_\ H7]*_P#
M*/\ ^)K8HH Q_P#A$?#?_0OZ5_X!1_\ Q-'_  B/AO\ Z%_2O_ */_XFMBB@
M#'_X1'PW_P!"_I7_ (!1_P#Q-'_"(^&_^A?TK_P"C_\ B:V** ,?_A$?#?\
MT+^E?^ 4?_Q-'_"(^&_^A?TK_P  H_\ XFMBB@#'_P"$1\-_]"_I7_@%'_\
M$TU/!OAB-<1^'-)09SA;&(?^RUM44 8__"(^&_\ H7]*_P# */\ ^)H_X1'P
MW_T+^E?^ 4?_ ,36Q10!C_\ "(^&_P#H7]*_\ H__B:/^$1\-_\ 0OZ5_P"
M4?\ \36Q10!C_P#"(^&_^A?TK_P"C_\ B:/^$1\-_P#0OZ5_X!1__$UL44 8
M_P#PB/AO_H7]*_\  */_ .)H_P"$1\-_]"_I7_@%'_\ $UL44 8__"(^&_\
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MW_T+^E?^ 4?_ ,36Q10!C_\ "(^&_P#H7]*_\ H__B:/^$1\-_\ 0OZ5_P"
M4?\ \36Q10!C_P#"(^&_^A?TK_P"C_\ B:/^$1\-_P#0OZ5_X!1__$UL44 8
M_P#PB/AO_H7]*_\  */_ .)H_P"$1\-_]"_I7_@%'_\ $UL44 8__"(^&_\
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M H__ (FMBB@#'_X1'PW_ -"_I7_@%'_\31_PB/AO_H7]*_\  */_ .)K8HH
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1(,!0.  .PIU% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059659002408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EVOLUS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-1385614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">520 Newport Center Dr., Suite 1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newport Beach<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">284-4555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.00001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EOLS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Smaller Reporting Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 423.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,694,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant's Proxy Statement for the 2022 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December&#160;31, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity CIK</a></td>
<td class="text">0001570562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059663963448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Irvine, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059660134328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 146,256<span></span>
</td>
<td class="nump">$ 102,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">14,657<span></span>
</td>
<td class="nump">9,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,762<span></span>
</td>
<td class="nump">3,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">5,082<span></span>
</td>
<td class="nump">4,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">11,042<span></span>
</td>
<td class="nump">2,188<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">178,799<span></span>
</td>
<td class="nump">127,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,371<span></span>
</td>
<td class="nump">1,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,722<span></span>
</td>
<td class="nump">3,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">50,625<span></span>
</td>
<td class="nump">55,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">21,208<span></span>
</td>
<td class="nump">21,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,758<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">257,483<span></span>
</td>
<td class="nump">209,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,091<span></span>
</td>
<td class="nump">9,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">29,993<span></span>
</td>
<td class="nump">9,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation settlement</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">63,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">1,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">5,314<span></span>
</td>
<td class="nump">3,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Promissory note payable to Evolus Founders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebtCurrent', window );">Term loan, net of discount and issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">74,384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">57,663<span></span>
</td>
<td class="nump">180,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveNoncurrent', window );">Accrued litigation settlement</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">2,256<span></span>
</td>
<td class="nump">3,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">39,426<span></span>
</td>
<td class="nump">38,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Term loan, net of discount and issuance costs</a></td>
<td class="nump">71,222<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">175,607<span></span>
</td>
<td class="nump">282,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December&#160;31, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.00001 par value; 100,000,000 shares authorized; 55,576,988 and 33,749,228 shares issued and outstanding at December&#160;31, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">504,757<span></span>
</td>
<td class="nump">303,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(422,882)<span></span>
</td>
<td class="num">(376,072)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">81,876<span></span>
</td>
<td class="num">(72,958)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 257,483<span></span>
</td>
<td class="nump">$ 209,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Obligation Payable to Related Party, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059658810744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">55,576,988<span></span>
</td>
<td class="nump">33,749,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">55,576,988<span></span>
</td>
<td class="nump">33,749,228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059660233880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 99,673<span></span>
</td>
<td class="nump">$ 56,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Product cost of sales (excludes amortization of intangible assets)</a></td>
<td class="nump">43,534<span></span>
</td>
<td class="nump">18,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement payment from daewoong</a></td>
<td class="num">(25,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">112,068<span></span>
</td>
<td class="nump">98,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,064<span></span>
</td>
<td class="nump">1,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Revaluation of contingent royalty obligation to Evolus Founders</a></td>
<td class="nump">6,290<span></span>
</td>
<td class="num">(2,007)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,622<span></span>
</td>
<td class="nump">7,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">83,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,956<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">144,078<span></span>
</td>
<td class="nump">209,608<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(44,405)<span></span>
</td>
<td class="num">(153,068)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest expense</a></td>
<td class="num">(1,396)<span></span>
</td>
<td class="num">(10,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from extinguishment of debts, net</a></td>
<td class="num">(968)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(46,768)<span></span>
</td>
<td class="num">(162,936)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(46,810)<span></span>
</td>
<td class="num">(163,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive gain:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (46,810)<span></span>
</td>
<td class="num">$ (163,019)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="num">$ (4.83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="num">$ (4.83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding used to compute basic net loss per share (in shares)</a></td>
<td class="nump">49,773,101<span></span>
</td>
<td class="nump">33,737,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding used to compute diluted net loss per share (in shares)</a></td>
<td class="nump">49,773,101<span></span>
</td>
<td class="nump">33,737,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList', window );">Cost, Product and Service [Extensible Enumeration]</a></td>
<td class="text">Product revenue, net<span></span>
</td>
<td class="text">Product revenue, net<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 98,971<span></span>
</td>
<td class="nump">$ 55,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 702<span></span>
</td>
<td class="nump">$ 738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of cost from product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123410239&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfCostGoodOrServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059657291592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Follow-on Offering</div></th>
<th class="th"><div>A T M Sales Agreement</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series A Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Follow-on Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>A T M Sales Agreement</div>
</th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th">
<div>Additional Paid In Capital </div>
<div>Follow-on Offering</div>
</th>
<th class="th">
<div>Additional Paid In Capital </div>
<div>A T M Sales Agreement</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,562,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 79,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 292,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (213,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">10,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(163,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163,013)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,749,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="num">(72,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(376,072)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodValuesLitigationSettlement', window );">Issuance of common stock in connection with litigation settlement</a></td>
<td class="nump">48,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for conversion of convertible note (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,136,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for conversion of convertible note</a></td>
<td class="nump">39,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643,872<span></span>
</td>
<td class="nump">10,350,000<span></span>
</td>
<td class="nump">934,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">$ 92,212<span></span>
</td>
<td class="nump">$ 10,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">655<span></span>
</td>
<td class="nump">$ 92,212<span></span>
</td>
<td class="nump">$ 10,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">9,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(46,810)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,810)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">55,576,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 81,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 504,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (422,882)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodValuesLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Values, Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodValuesLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059653447560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (46,810)<span></span>
</td>
<td class="num">$ (163,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,622<span></span>
</td>
<td class="nump">7,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,576<span></span>
</td>
<td class="nump">10,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">2,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount on short-term investments</a></td>
<td class="nump">272<span></span>
</td>
<td class="num">(427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_OperatingLeaseRightofUseAssetAmortization', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">941<span></span>
</td>
<td class="nump">2,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid-in-kind interest on convertible note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Revaluation of contingent royalty obligation to Evolus Founders</a></td>
<td class="nump">6,290<span></span>
</td>
<td class="num">(2,007)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from extinguishment of debts, net</a></td>
<td class="nump">968<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses', window );">Non-cash portion of accrued settlement expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(2,979)<span></span>
</td>
<td class="nump">4,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(5,566)<span></span>
</td>
<td class="num">(1,085)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(7,264)<span></span>
</td>
<td class="num">(1,690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(787)<span></span>
</td>
<td class="nump">2,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">20,891<span></span>
</td>
<td class="num">(4,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_IncreaseDecreaseInAccruedLitigationSettlement', window );">Accrued litigation settlement</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(838)<span></span>
</td>
<td class="num">(734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(33,388)<span></span>
</td>
<td class="num">(57,871)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(393)<span></span>
</td>
<td class="num">(815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForSoftware', window );">Additions to capitalized software</a></td>
<td class="num">(577)<span></span>
</td>
<td class="num">(2,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(74,668)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Maturities of short-term investments</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">12,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="num">(76,323)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of promissory note payable to Evolus Founders</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_PaymentsOfContingentRoyaltyObligation', window );">Payment of contingent royalty obligation to Evolus Founders</a></td>
<td class="num">(3,097)<span></span>
</td>
<td class="num">(1,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Proceeds from issuance of long-term debt, net of discounts</a></td>
<td class="nump">71,958<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments for debt issuance costs</a></td>
<td class="num">(3,263)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payment for debt obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(523)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for offering costs</a></td>
<td class="num">(214)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan', window );">Issuance of common stock in connection with incentive equity plan</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">73,052<span></span>
</td>
<td class="nump">38,347<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash and cash equivalents</a></td>
<td class="nump">43,694<span></span>
</td>
<td class="num">(7,330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">102,562<span></span>
</td>
<td class="nump">109,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">146,256<span></span>
</td>
<td class="nump">102,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">7,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible note to equity</a></td>
<td class="nump">39,808<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedForAccruedLitigationSettlementExpense', window );">Issuance of common stock in exchange for litigation settlement expense</a></td>
<td class="nump">48,421<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capitalized software recorded in accounts payable and accrued expenses</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember', window );">Follow-on Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from follow-on offering, net of underwriting fees</a></td>
<td class="nump">92,426<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember', window );">A T M Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from follow-on offering, net of underwriting fees</a></td>
<td class="nump">$ 10,910<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments Of Non Cash Portion Of Accrued Settlement Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_IncreaseDecreaseInAccruedLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_IncreaseDecreaseInAccruedLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_OperatingLeaseRightofUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-of-Use Asset, Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_OperatingLeaseRightofUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_PaymentsOfContingentRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Contingent Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_PaymentsOfContingentRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments For) Issuance Of Common Stock In Connection With Equity Incentive Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedForAccruedLitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Accrued Litigation Settlement Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedForAccruedLitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059662131912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business <div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolus, Inc., (&#8220;Evolus&#8221; or the &#8220;Company&#8221;) is a performance beauty company focused on delivering products in the self-pay aesthetic market. The Company received the approval of its first product Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in February 2019. The product was also approved by Health Canada in August 2018 and the European Commission (&#8220;EC&#8221;) in September 2019. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States in May 2019 and in Canada through a distribution partner in October 2019. The Company currently generates all of its net revenues from Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is headquartered in Newport Beach, California.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared on a basis that assumes that the Company will continue as a going concern, and do not include any adjustments that may result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company&#8217;s assets and the satisfaction of the Company&#8217;s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has incurred recurring net operating losses and negative cash flows from operating activities and management expects operating losses and negative cash flows to continue for at least the next 12 months. As of December&#160;31, 2021, the Company had $146,256 in cash and cash equivalents and an accumulated deficit of $422,882. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company entered into a $125,000 Term Loan agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and Biopharma Credit PLC (collectively, &#8220;Pharmakon&#8221;). The first tranche of $75,000 was funded on December 29, 2021. The second tranche of $50,000 may be drawn at the Company&#8217;s election no later than December 31, 2022, subject to the terms and conditions of the loan agreement. As of December&#160;31, 2021, the Company has not drawn the second tranche. The Company received net proceeds of approximately $68,695 from Pharmakon, after issuance costs and debt discounts. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6. Term Loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company and Oxford Finance LLC (&#8220;Oxford&#8221;) entered into an agreement, pursuant to which the Company paid Oxford $76,447 to pay off the Oxford Term Loan. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6. Term Loans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company, Medytox, Inc. (&#8220;Medytox&#8221;), Allergan, Inc. and Allergan Limited (together, &#8220;Allergan&#8221;) entered into settlement agreements in connection with the International Trade Commission (&#8220;ITC&#8221;) action, for which the Company agreed to pay $15,000 in 2021, $15,000 in 2022 and $5,000 in 2023 with additional terms including specified royalty payments as described below and in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company and Daewoong entered into certain agreements, pursuant to which Daewoong (1) paid the Company $25,500 in April 2021 and (2) agreed to reimburse the Company certain amounts with respect to the royalties payable to Medytox and Allergan, among other terms. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information. In addition, in March 2021 the outstanding Daewoong Convertible Note (as such term is defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Daewoong Convertible Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), including accrued interest, in the amount of $40,779 was converted into 3,136,869 shares of the Company&#8217;s common stock. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Daewoong Convertible Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company completed a follow-on public offering and issued 10,350,000 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,350,000 shares of common stock, at a price to the public of $9.50 per share. The Company received net proceeds of approximately $92,426 from the offering, after deducting underwriting discounts and commissions, excluding other offering expenses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June, July and August 2021, the Company sold 934,367 common shares at the prevailing market prices for total net proceeds of $10,910 under the existing &#8220;at-the-market&#8221; sales agreement. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10. Stockholders&#8217; Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional details. </span></div>The Company believes that its current capital resources, which consist of cash and cash equivalents, will be sufficient to fund operations through at least the next twelve months based on its expected cash needs. The Company may be required to raise additional capital to fund future operations through entering into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its controllable and variable expenditures and current rate of spending through reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059662072072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies <div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain comparative amounts for prior year have been reclassified to conform to current year presentations. Such reclassifications did not affect net income or retained earnings.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make certain estimates and assumptions in order to prepare financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company&#8217;s most significant estimates relate to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations, stock-based compensation and royalty obligations, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#8217;s actual results could differ materially from those estimates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the full impact of&#160;the COVID-19&#160;outbreak is unknown and cannot be reasonably estimated. However, where possible, management has made appropriate accounting estimates with respect to certain accounting matters, which include the fair value of royalty obligations, allowance for doubtful accounts, inventory valuation and impairment assessments of goodwill and other long-lived assets, based on the facts and circumstances available as of the reporting date. The Company&#8217;s future assessment of the magnitude and duration of&#160;the COVID-19 outbreak, as well as other factors, could result in material impacts to the Company&#8217;s financial statements in future reporting periods.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, Evolus and Daewoong Pharmaceutical Co. Ltd. (&#8220;Daewoong&#8221;) entered into an agreement (the &#8220;Daewoong Agreement&#8221;), pursuant to which the Company received an exclusive distribution license to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, Russia, certain members of the Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the United States in May 2019 and in Canada through its distribution partner in October 2019 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&#8217;s business and its financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company&#8217;s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by physicians and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak and restrictions intended to slow the spread of COVID-19, including quarantines, government-mandated actions, stay-at-home orders and other restrictions,&#160;have adversely affected the Company&#8217;s business in a number of ways, which have resulted, and may continue to result, in a period of business disruption and in reduced sales and operations. In addition, any disruption and volatility in the global capital markets may increase the Company&#8217;s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. The Company has determined that it operates in a single operating and reportable segment. The Company&#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company&#8217;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#8217;s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#8217; ability to pay.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company&#8217;s statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the statements of operations and comprehensive loss using the specific-identification method. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of finished goods held for sale and distribution. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost is determined based on the estimated amount payable to the Company&#8217;s supplier after accounting for any reimbursement receivable pursuant to the Daewoong Settlement Agreement (as such term is defined, and such agreement is discussed, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), usin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g the first-in, first-out method with prioritization of the items with the earliest expiration dates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Inventory valuation reserves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for the periods presented. Adverse changes in assumptions utilized in the Company&#8217;s inventory reserve calculations could result in an increase to its inventory valuation reserves.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product cost of sales, excluding amortization of intangible assets, consisted of the inventory cost, and, for periods on or after December 16, 2020, included certain royalties on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> payable to Medytox and Allergan pursuant to the Medytox/Allergan Settlement Agreements (as such term is defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), as partially offset by reimbursement receivable from Daewoong pursuant to the Daewoong Settlement Agreement with respect to such royalties.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</span></div><div style="margin-bottom:9pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of approximately five years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the term of the related lease. </span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has one reporting unit. There was no impairment of goodwill for any of the periods presented.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon FDA approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in February 2019, the in process research and development (&#8220;IPR&amp;D&#8221;) related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;was evaluated as completed and reclassified to a definite-lived distribution right intangible asset, which is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&#160;20 years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&#160;two years&#160;upon being placed in service.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was no material impairment of long-lived assets for any periods presented.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;), at the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#8220;ROU&#8221;) asset which represents the Company&#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancelable period of the lease and may include options to extend or terminate the lease </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when it is reasonably certain that the Company will exercise such options. The Company&#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of&#160;December&#160;31, 2021.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Royalty Obligation Payable to the Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable are determined at each reporting period end and recorded in operating expenses in the accompanying statements of operations and comprehensive loss and as a liability in the accompanying balance sheets. </span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Promissory Note Payable to the Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2018, the Company recognized a promissory note payable at present value using a discount rate for similar rated debt securities. Discount amortization related to the promissory note is recorded in interest expense in the accompanying statements of operations and comprehensive loss with a corresponding increase to the liabilities in the accompanying balance sheets.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Debt</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt represents the debt balance with Pharmakon as of December&#160;31, 2021 and Oxford as of December&#160;31, 2020 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6. Term Loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, net of debt issuance costs. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are amortized into interest expense over the term of the debt.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates product revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and service revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through a distribution partner in Canada.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Canada as it does not control the product before control is transferred to a customer. The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the amount of consideration expected to be received. For the years ended December 31, 2021 and 2020, the Company recognized $702 and $738, respectively, of revenues related to international sales. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross-to-Net Revenue Adjustments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides customers with discounts, such as trade and volume discounts and prompt pay discounts, that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, primarily for the volume based rebates, coupons, consumer loyalty programs and co-branded marketing programs. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Volume-based Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Coupons</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company issued customers coupons redeemable into gift cards funded by the Company for the benefit of patients. The coupons were accounted for as variable consideration. The Company estimated coupon redemption rates based on historical data and future expectations. The coupons were accrued based on estimated redemption rates and the volume of products purchased and were recorded as a reduction to revenues on product delivery. All issued coupons expired on June 30, 2020.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Consumer Loyalty Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; In May 2020, the Company launched a consumer loyalty program, which allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and redeem the rewards for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward (&#8220;Reward&#8221;) that the customer might redeem in the future. The standalone selling price of the Reward is measured based on historical sales data, estimated average selling price of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time of redemption, expected customer and consumer participation rates in the loyalty program, and estimated number of qualifying treatments to be performed by customers. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue. Subsequently, when customers redeem the Reward and the related product is delivered, the deferred revenue is recognized in net revenues at that time.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Co-Branded Marketing Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company offers eligible customers with a certain level of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> purchases to receive advertising co-branded with the Company. The co-branded advertising represents a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the advertisement. The standalone selling price of the advertisement is measured based on the estimated market value of similar advertisement adjusted for the customer&#8217;s portion of the advertisement. The portion of invoice price allocated to the advertisement is initially recorded as deferred revenue. Subsequently, when the advertisement airs, the deferred revenue is recognized in net revenues at that time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract balances</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration becomes unconditional. The Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of&#160;December&#160;31, 2021 and 2020, all amounts included in accounts receivable, net on the accompanying balance sheets are related to contracts with customers.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any contract assets nor unbilled receivables as of&#160;December&#160;31, 2021 or 2020. Sales commissions are included in selling, general and administrative expenses when incurred.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients primarily under the rebate and coupon programs and deferred revenue associated with Rewards under the consumer loyalty program and co-</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">branded marketing programs. The Company&#8217;s contract liabilities are included in accounts payable and accrued expenses in the accompanying balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the accrued revenue contract liabilities, primarily related to volume-based rebates, consumer loyalty program, and co-branded media programs, were $7,934 and $3,081, respectively, which were recorded in accrued expenses in the accompanying balance sheets. For the years ended December 31, 2021 and 2020, provisions for rebate, coupon, consumer loyalty programs, and co-branded media programs were $16,139 and $16,896, respectively, which were offset by related payments, redemptions and adjustments of $11,286 and $15,524, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the&#160;years ended December 31, 2021 and 2020, the Company recognized $2,802 and $0, respectively, of revenue related to amounts included in contract liabilities at the beginning of the period and did not recognize any revenue related to changes in transaction prices regarding its contracts with customers from previous periods.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collectability</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.&#160;The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of December 31, 2021 and 2020, allowance for doubtful accounts was $2,385 and $2,118, respectively. For the years ended December 31, 2021 and 2020, provision for bad debts was $589 and $2,066, respectively, and the write-off amount was $322 and $335, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Practical Expedients</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.</span></div><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.</span></div><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Settlement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, upon entering into certain agreements to settle intellectual property disputes relating to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company agreed to pay to Allergan and Medytox </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$35,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in multiple payments over two years, of which $15,000 was paid in the third quarter of 2021 and $15,000 was paid in the first quarter of 2022, and issued 6,762,652 shares of its common stock to Medytox. In addition, for the period from December 16, 2020 to September 16, 2022, the Company agreed to pay to Allergan and Medytox a royalty on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on a certain dollar amount per vial sold in the United States and a low-double digit royalty on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sold in other Evolus territories. For the period from September 17, 2022 to September 16, 2032, the Company agreed to pay to Medytox a mid-single digit royalty percentage on all net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The royalty payments are made quarterly and recorded as product cost of sales on the accompanying statements of operations and comprehensive loss in the periods the royalties are incurred.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The settlement agreements resulted in an $83,421 charge for the year ended December&#160;31, 2020, which consisted of $35,000 in deferred cash payments and $48,421 from the issuance of 6,762,652 shares of the Company&#8217;s common stock in February </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021. In the year ended December 31, 2021, the Company made cash payments of $15,000 to Medytox and Allergan. As of December&#160;31, 2021, a current liability of $15,000 and non-current liability of $5,000 were recorded in the accompanying balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in March 2021, Daewoong and the Company entered into certain agreements, pursuant to which Daewoong agreed to pay the Company an amount equal to $25,500, which was recorded as a settlement payment from Daewoong and included as part of cost of sales on the accompanying statements of operations and comprehensive loss for the year ended December 31, 2021. For the period from December 16, 2020 to September 16, 2022, Daewoong also agreed to reimburse the Company certain amounts with respect to the royalties payable to Medytox and Allergan. This reimbursement is received quarterly and recorded as an offset to the related royalties to Medytox and Allergan in the product cost of sales on the accompanying statements of operations and comprehensive loss.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the details of all litigation settlement agreements.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate, and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) is based on the fair value on the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the balance sheets and in the selling, general and administrative or research and development expenses in the statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred and primarily include costs related to social media ads and co-branded marketing programs. Advertising costs are included in selling, general and administrative expenses. For the years ended December 31, 2021 and 2020, the Company incurred advertising costs of $16,391 and $4,979, respectively.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. </span></div><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its statement of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&#160;50%&#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. The Company does not expect that changes to state tax laws through December&#160;31, 2021 to materially impact its financial statements.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. The dilutive effect of stock options and restricted stock units is computed under the treasury stock method. The dilutive effect of the Daewoong Convertible Note is computed under the if-converted method. Potentially dilutive securities are excluded from the computations of diluted net loss per share if their effect would be antidilutive.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and 2020, excluded from the dilutive net loss per share computation were stock options of 3,922,286 and 4,407,498, respectively, non-vested RSUs of 1,926,467 and 1,173,741, respectively, and 0 shares and 3,076,923, shares issuable upon conversion of the Daewoong Convertible Note, respectively, because their inclusion would have been anti-dilutive. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Pronouncements</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provisions remove certain exceptions including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020 and interim periods therein. The Company has adopted the guidance on the effective date of January 1, 2021. There are no material impacts to the financial statements as a result of this adoption.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements&#160;Issued But Not&#160;Adopted&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other (Topic 350):&#160;Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January&#160;1, 2023. The standard requires prospective application. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact on its financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU No. 2016-13, the FASB issued ASU 2018-19,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 326, Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU does not change the core principle of the guidance in ASU No. 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&#160;The FASB also subsequently issued ASU No. 2019-04 which did not change the core principle of the guidance in ASU No. 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January 1, 2023. The Company is in the process of determining the effects the adoption will have on its financial statements and reviewing credit loss models to assess the impact of the adoption of the standard on the financial statements. Based on initial assessments, the Company believes that while adoption will modify the way it analyzes financial instruments, it does not expect adoption of this guidance will have a material impact to its financial statements.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and in January 2021, the FASB issued ASU No. 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope (&#8220;ASU 2021-01&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Both ASU No. 2020-04 and ASU No. 2021-01 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or another reference rate expected to be discontinued because of reference rate reform. ASU No. 2020-04 and ASU No. 2021-01 are effective upon issuance for contract modifications and hedging relationships, and the Company is allowed to elect to apply the amendments prospectively through December 31, 2022. The Company does not expect adoption of this guidance will have a material impact on its financial statements.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This update will increase transparency of government assistance received by most business entities by requiring the disclosure of: (1) the types of transactions; (2) the accounting for the transactions; and, (3) the effect of the transactions on a business entity&#8217;s financial statements. ASU No. 2021-10 is effective for financial statements issued for annual periods beginning after December 15, 2021, with early application permitted. The Company does not expect adoption of this guidance will have a material impact on its financial statements.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059662126248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Short-Term Investments</a></td>
<td class="text">Fair Value Measurements and Short-Term Investments <div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-Term Investments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company did not hold any short-term investments. As of December&#160;31, 2020, all of the Company&#8217;s investments had remaining maturities of less than 12 months. The following is a summary of the Company&#8217;s short-term investments, considered available-for-sale, as of December&#160;31, 2020:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:52.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:52.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:52.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the&#160;year ended December 31, 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the contingent royalty obligation payable to the Evolus Founders based on Level 3 inputs using a discounted cash flows method. The significant unobservable input assumptions that can significantly change the fair value include (i) projected amount and timing of net revenues during the payment period, which terminates in the quarter following the 10-year anniversary of the first commercial sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States, (ii) the discount rate and (iii) the timing of payments. During the years ended December 31, 2021 and 2020, the Company utilized discount rates between 13.0% and 20.0%, reflecting changes in the Company&#8217;s risk profile. Net revenue projections are also updated to reflect changes in the timing of expected sales. Significant increases (decreases) in the discount rate would result in a significantly lower (higher) fair value measurement, which could materially impact the fair value reported on the balance sheet.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:58.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,097)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recorded in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,007)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,546&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Assets and Liabilities</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, short-term available-for-sale debt securities, accounts receivable, accounts payable, accrued expenses, lease liabilities, and long-term debt. The carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of the promissory note payable to the Evolus Founders, long-term debt and operating lease liabilities using the discounted cash flow analysis based on the interest rates for similar rated debt securities (Level 2). As of December 31, 2021, the fair value of the long-term debt was $75,448. As of December&#160;31, 2020, the fair value of the contingent promissory note and long-term debt was estimated to be $19,284 and $76,368, respectively. The fair value of operating lease liabilities&#160;as of December&#160;31, 2021 and 2020 approximated their carrying value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059662195512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:30.643%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.849%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution right</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,390&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,625&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:30.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.837%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.896%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution right</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,810)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,757&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,460)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,965&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,460)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,505&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Intangible assets with indefinite lives have an indeterminable average life.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;December&#160;31, 2021 that are subject to amortization:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.142%"><tr><td style="width:1.0%"/><td style="width:55.931%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.869%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution right represents the license and associated distribution right to develop Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the initial term of which expires in September 2023 and is automatically extended for unlimited additional three-year terms provided that the Company meets certain performance requirements. Additionally, upon FDA approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;on February 1, 2019, the IPR&amp;D project was completed and reclassified as a definite-lived distribution right intangible asset, which is amortized on a straight-line basis over the estimated useful life of 20 years. The Company paid Daewoong a $2,000 milestone payment, pursuant to the Daewoong Agreement, which increased the cost basis of the distribution. In connection with EU approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company paid a $1,000 milestone payment to Daewoong in the fourth quarter of fiscal year 2019, which increased the cost basis of the distribution right. Under the Daewoong Arrangement (as defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), there is no additional cash consideration due to Daewoong. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div>For the years ended December 31, 2021 and 2020, the Company capitalized $633 and $2,266, respectively, related to costs of computer software developed for internal use. The software is amortized over a two-year period using the straight-line method. For the years ended December 31, 2021 and 2020, total intangible assets amortization expense of $5,305 and $3,635, respectively, was recorded within depreciation and amortization on the accompanying statements of operations and comprehensive loss.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059662120488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses <div style="margin-bottom:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:58.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties under the Medytox/Allergan Settlement Agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued revenue contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059662155608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loans</a></td>
<td class="text">Term Loans<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmakon Term Loans</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2021, the Company entered into a loan agreement with Pharmakon. Pursuant to the terms of the agreement, Pharmakon agreed to make term loans to the Company in two tranches (&#8220;Pharmakon Term Loans&#8221;). The first tranche of $75,000 was funded on December 29, 2021. The second tranche of $50,000 may be drawn at the Company&#8217;s election no later than December 31, 2022. As of December&#160;31, 2021, the Company has not drawn the second tranche. The Pharmakon Term Loans will mature on the sixth year anniversary of the closing date of the first tranche (&#8220;Maturity Date&#8221;). </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Term Loans accrue interest at a per annum rate equal to the 3-month U.S. Dollar LIBOR rate (subject to a LIBOR rate floor of 1.0%) plus 8.5% per annum; provided that, upon a public statement or publication of information in certain circumstances that LIBOR has ceased or will cease to be provided or be representative or the occurrence of an early opt-in determination by the collateral agent, the Pharmakon Term Loans will be amended to provide for an alternative to the 3-month U.S. Dollar LIBOR rate established by the lenders holding a majority of the outstanding Pharmakon Term Loans, giving due consideration to the selection or recommendation of a replacement rate or mechanism for determining such rate by any applicable governmental authority or the then-prevailing market conventions. The Company agreed to make 12 equal quarterly payments of principal on the outstanding Pharmakon Term Loans commencing on or immediately following the 39th-month anniversary of the funding date of the first tranche continuing through the Maturity Date.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may elect to prepay all amounts, not less than $20,000, owed prior to the Maturity Date. Prepayments of the first tranche prior to the second anniversary of the closing date of the first tranche and prepayments of the second tranche prior to the second anniversary of the date on which the second tranche is drawn by the Company will be accompanied by a make whole amount equal to the sum of all interest that would have accrued through such second anniversary. Prepayments of the Pharmakon Term Loans will also be accompanied by a prepayment premium equal to the principal amount so prepaid multiplied by 3.0% if made prior to the third anniversary of the closing date of the first tranche, 2.0% if made on or after the third anniversary of the closing date of the first tranche but prior to the fourth anniversary of the closing date of the first tranche, and 1.0% if made on or after the fourth anniversary of the closing date of the first tranche but prior to the Maturity Date. If the Pharmakon Term Loans are accelerated following the occurrence of an event of default, including a material adverse change, the Company is required to immediately pay Pharmakon an amount equal to the sum of all outstanding principal, unpaid interest, and applicable make whole and prepayment premiums.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Term Loans are secured by substantially all of the Company&#8217;s assets. The Pharmakon Term Loans contain customary affirmative and restrictive covenants and representations and warranties. The affirmative covenants include, </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">among others, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. The restrictive covenants include, among others, incurring certain additional indebtedness, consummating certain change in control transactions, or incurring any non- permitted lien or other encumbrance on the Company&#8217;s assets, without Pharmakon&#8217;s prior written consent. The Pharmakon Term Loans do not contain covenants requiring the Company to maintain a minimum cash threshold or minimum revenues or earnings. As of December&#160;31, 2021, the Company was in compliance with its debt covenants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing date of the first tranche, the Company incurred $3,042 and $3,263 in debt discounts and issuance costs related to the Pharmakon Term Loans, respectively. Debt discounts and issuance costs related to the entire Pharmakon Term Loans have been allocated pro rata between the funded and unfunded portions. Debt discounts and issuance costs allocated to the first tranche of $75,000 have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. As of December&#160;31, 2021, the borrowings outstanding under the Pharmakon Term Loans were classified as long-term debt in the accompanying balance sheets. Debt discounts and issuance costs associated with the unfunded tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. The overall effective interest rate was approximately 10.89% as of December&#160;31, 2021.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.476%"><tr><td style="width:1.0%"/><td style="width:68.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.582%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discounts and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,778)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net of discounts and issuance costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,222&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oxford Term Loans</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2019, the Company entered into a Loan and Security Agreement with Oxford (the &#8220;Loan Agreement&#8221;), providing for a credit facility of up to $100,000. Pursuant to the terms of the credit facility, the lender extended term loans (the &#8220;Oxford Term Loan&#8221;), available in two advances, to the Company. The first tranche of $75,000 was funded on the closing date. The second tranche of $25,000 was not drawn. The credit facility bore an annual interest rate equal to the greater of 9.5%, or the 30-day U.S. Dollar LIBOR rate plus 7.0%. The Company agreed to pay interest-only for the first 36 months until May 2022, followed by a 23 months amortization period.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing date, the Company incurred $1,094 and $2,205 in debt discounts and issuance costs related to the Oxford Term Loan, respectively. Debt&#160;discounts and issuance costs related to the entire Oxford Term Loan have been allocated pro rata between the funded and unfunded portions. Debt&#160;discounts and issuance costs related to the Oxford Term Loan have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. The overall effective interest rate was approximately 11.6% as of December&#160;31, 2020. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the earliest to occur of the maturity date, the acceleration of the Oxford Term Loan, or the prepayment of the Oxford Term Loan, the Company was required to pay to Oxford a final payment of 5.5% of the full principal amount of the Oxford Term Loan funded (&#8220;Final Payment&#8221;). The Company could elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee was also paid, which would be equal to 2.0% of the amount prepaid if the prepayment occurred after March 15, 2020 and on or prior to March 15, 2021, or 1.0% of the amount prepaid if the prepayment occurred thereafter (&#8220;Prepayment Fee&#8221;).</span></div>On January 4, 2021, the Company and Oxford entered into an agreement (&#8220;Payoff Letter&#8221;), pursuant to which (i) the Company paid Oxford $76,447 to discharge in full all outstanding obligations, including accrued interest by and between Oxford, in its capacity as collateral agent and lender, and the Company, and (ii) effective upon such repayment, the Loan Agreement, and all unfunded commitments thereunder, guarantees and other security interests granted to Oxford in connection with the Loan Agreement and all other obligations of and restrictions on the Company under the Loan Agreement, terminated. As a condition to entering into the Payoff Letter, Oxford agreed to waive a total of $4,300 of fees comprised of (i) $2,800 of the Final Payment and (ii) the Prepayment Fee of $1,500. As a result, the Company recorded a loss of $1,939 in extinguishment of debts, net on the accompanying statements of operations and comprehensive loss. Daewoong Convertible Note<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2020, the Company entered into a Convertible Promissory Note Purchase Agreement with Daewoong for the principal amount of $40,000 (the &#8220;Daewoong Convertible Note&#8221;), which was funded on July 30, 2020. Additionally, on July 6, 2020, the Company, Daewoong and Oxford entered into a Subordination Agreement pursuant to which the Daewoong Convertible Note was subordinated to the Company&#8217;s obligations under the Loan Agreement.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Convertible Note bore interest at a rate of 3.0% payable semi-annually in arrears on June 30th and December 31st of each year and was to mature on July 30, 2025, subject to earlier conversion as provided below. Interest was initially paid in kind by adding the accrued amount thereof to the outstanding principal amount on a semi-annual basis on June 30th and December 31st of each calendar year for so long as any principal amount under the Oxford Term Loan remained outstanding and the Subordination Agreement was not terminated. Interest became payable in cash after the Oxford Term Loan was repaid in full, and the Subordination Agreement was terminated on January 4, 2021. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;23, 2021, the outstanding principal balance including all accrued and unpaid interest thereon, of $40,779 was converted into 3,136,869 shares of the Company&#8217;s common stock under the Conversion Agreement at the conversion price of $13.00 per share. The conversion was accounted for as an extinguishment of debt resulting in a gain of $971, which is recorded in loss from extinguishment of debts, net on the accompanying statements of operations and comprehensive loss. The Daewoong Convertible Note was not registered, and the shares of the Company&#8217;s common stock issued upon conversion of the Daewoong Convertible Note have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the details of the Conversion Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059662187784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Daewoong Convertible Note<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Daewoong Convertible Note</a></td>
<td class="text">Term Loans<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmakon Term Loans</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2021, the Company entered into a loan agreement with Pharmakon. Pursuant to the terms of the agreement, Pharmakon agreed to make term loans to the Company in two tranches (&#8220;Pharmakon Term Loans&#8221;). The first tranche of $75,000 was funded on December 29, 2021. The second tranche of $50,000 may be drawn at the Company&#8217;s election no later than December 31, 2022. As of December&#160;31, 2021, the Company has not drawn the second tranche. The Pharmakon Term Loans will mature on the sixth year anniversary of the closing date of the first tranche (&#8220;Maturity Date&#8221;). </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Term Loans accrue interest at a per annum rate equal to the 3-month U.S. Dollar LIBOR rate (subject to a LIBOR rate floor of 1.0%) plus 8.5% per annum; provided that, upon a public statement or publication of information in certain circumstances that LIBOR has ceased or will cease to be provided or be representative or the occurrence of an early opt-in determination by the collateral agent, the Pharmakon Term Loans will be amended to provide for an alternative to the 3-month U.S. Dollar LIBOR rate established by the lenders holding a majority of the outstanding Pharmakon Term Loans, giving due consideration to the selection or recommendation of a replacement rate or mechanism for determining such rate by any applicable governmental authority or the then-prevailing market conventions. The Company agreed to make 12 equal quarterly payments of principal on the outstanding Pharmakon Term Loans commencing on or immediately following the 39th-month anniversary of the funding date of the first tranche continuing through the Maturity Date.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may elect to prepay all amounts, not less than $20,000, owed prior to the Maturity Date. Prepayments of the first tranche prior to the second anniversary of the closing date of the first tranche and prepayments of the second tranche prior to the second anniversary of the date on which the second tranche is drawn by the Company will be accompanied by a make whole amount equal to the sum of all interest that would have accrued through such second anniversary. Prepayments of the Pharmakon Term Loans will also be accompanied by a prepayment premium equal to the principal amount so prepaid multiplied by 3.0% if made prior to the third anniversary of the closing date of the first tranche, 2.0% if made on or after the third anniversary of the closing date of the first tranche but prior to the fourth anniversary of the closing date of the first tranche, and 1.0% if made on or after the fourth anniversary of the closing date of the first tranche but prior to the Maturity Date. If the Pharmakon Term Loans are accelerated following the occurrence of an event of default, including a material adverse change, the Company is required to immediately pay Pharmakon an amount equal to the sum of all outstanding principal, unpaid interest, and applicable make whole and prepayment premiums.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Term Loans are secured by substantially all of the Company&#8217;s assets. The Pharmakon Term Loans contain customary affirmative and restrictive covenants and representations and warranties. The affirmative covenants include, </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">among others, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. The restrictive covenants include, among others, incurring certain additional indebtedness, consummating certain change in control transactions, or incurring any non- permitted lien or other encumbrance on the Company&#8217;s assets, without Pharmakon&#8217;s prior written consent. The Pharmakon Term Loans do not contain covenants requiring the Company to maintain a minimum cash threshold or minimum revenues or earnings. As of December&#160;31, 2021, the Company was in compliance with its debt covenants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing date of the first tranche, the Company incurred $3,042 and $3,263 in debt discounts and issuance costs related to the Pharmakon Term Loans, respectively. Debt discounts and issuance costs related to the entire Pharmakon Term Loans have been allocated pro rata between the funded and unfunded portions. Debt discounts and issuance costs allocated to the first tranche of $75,000 have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. As of December&#160;31, 2021, the borrowings outstanding under the Pharmakon Term Loans were classified as long-term debt in the accompanying balance sheets. Debt discounts and issuance costs associated with the unfunded tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. The overall effective interest rate was approximately 10.89% as of December&#160;31, 2021.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.476%"><tr><td style="width:1.0%"/><td style="width:68.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.582%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discounts and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,778)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net of discounts and issuance costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,222&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oxford Term Loans</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2019, the Company entered into a Loan and Security Agreement with Oxford (the &#8220;Loan Agreement&#8221;), providing for a credit facility of up to $100,000. Pursuant to the terms of the credit facility, the lender extended term loans (the &#8220;Oxford Term Loan&#8221;), available in two advances, to the Company. The first tranche of $75,000 was funded on the closing date. The second tranche of $25,000 was not drawn. The credit facility bore an annual interest rate equal to the greater of 9.5%, or the 30-day U.S. Dollar LIBOR rate plus 7.0%. The Company agreed to pay interest-only for the first 36 months until May 2022, followed by a 23 months amortization period.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing date, the Company incurred $1,094 and $2,205 in debt discounts and issuance costs related to the Oxford Term Loan, respectively. Debt&#160;discounts and issuance costs related to the entire Oxford Term Loan have been allocated pro rata between the funded and unfunded portions. Debt&#160;discounts and issuance costs related to the Oxford Term Loan have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. The overall effective interest rate was approximately 11.6% as of December&#160;31, 2020. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the earliest to occur of the maturity date, the acceleration of the Oxford Term Loan, or the prepayment of the Oxford Term Loan, the Company was required to pay to Oxford a final payment of 5.5% of the full principal amount of the Oxford Term Loan funded (&#8220;Final Payment&#8221;). The Company could elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee was also paid, which would be equal to 2.0% of the amount prepaid if the prepayment occurred after March 15, 2020 and on or prior to March 15, 2021, or 1.0% of the amount prepaid if the prepayment occurred thereafter (&#8220;Prepayment Fee&#8221;).</span></div>On January 4, 2021, the Company and Oxford entered into an agreement (&#8220;Payoff Letter&#8221;), pursuant to which (i) the Company paid Oxford $76,447 to discharge in full all outstanding obligations, including accrued interest by and between Oxford, in its capacity as collateral agent and lender, and the Company, and (ii) effective upon such repayment, the Loan Agreement, and all unfunded commitments thereunder, guarantees and other security interests granted to Oxford in connection with the Loan Agreement and all other obligations of and restrictions on the Company under the Loan Agreement, terminated. As a condition to entering into the Payoff Letter, Oxford agreed to waive a total of $4,300 of fees comprised of (i) $2,800 of the Final Payment and (ii) the Prepayment Fee of $1,500. As a result, the Company recorded a loss of $1,939 in extinguishment of debts, net on the accompanying statements of operations and comprehensive loss. Daewoong Convertible Note<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2020, the Company entered into a Convertible Promissory Note Purchase Agreement with Daewoong for the principal amount of $40,000 (the &#8220;Daewoong Convertible Note&#8221;), which was funded on July 30, 2020. Additionally, on July 6, 2020, the Company, Daewoong and Oxford entered into a Subordination Agreement pursuant to which the Daewoong Convertible Note was subordinated to the Company&#8217;s obligations under the Loan Agreement.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Convertible Note bore interest at a rate of 3.0% payable semi-annually in arrears on June 30th and December 31st of each year and was to mature on July 30, 2025, subject to earlier conversion as provided below. Interest was initially paid in kind by adding the accrued amount thereof to the outstanding principal amount on a semi-annual basis on June 30th and December 31st of each calendar year for so long as any principal amount under the Oxford Term Loan remained outstanding and the Subordination Agreement was not terminated. Interest became payable in cash after the Oxford Term Loan was repaid in full, and the Subordination Agreement was terminated on January 4, 2021. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;23, 2021, the outstanding principal balance including all accrued and unpaid interest thereon, of $40,779 was converted into 3,136,869 shares of the Company&#8217;s common stock under the Conversion Agreement at the conversion price of $13.00 per share. The conversion was accounted for as an extinguishment of debt resulting in a gain of $971, which is recorded in loss from extinguishment of debts, net on the accompanying statements of operations and comprehensive loss. The Daewoong Convertible Note was not registered, and the shares of the Company&#8217;s common stock issued upon conversion of the Daewoong Convertible Note have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the details of the Conversion Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059663179576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">Operating Leases<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s corporate headquarters in Newport Beach, California is leased under a five-year non-cancelable operating lease, which expires on January 31, 2025. Lease payments increase each year on February 1 based on an annual rent escalation clause. The Company may, under certain circumstances, terminate the lease on the 36-month anniversary of the lease commencement date by providing a written notice 12 months prior to such anniversary and paying a termination fee&#160;equal to six months basic rent plus certain other expenses. The Company has an option to extend the term of the lease for an additional 60 months, which is not recognized as part of its ROU assets and lease liabilities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease agreement does not contain any residual value guarantees or material restrictive covenants. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU assets if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial implications of a decision to extend or not to extend a lease&#160;in&#160;determining&#160;if the renewal option is reasonably certain to be exercised.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.154%"><tr><td style="width:1.0%"/><td style="width:62.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term and discount rate are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.154%"><tr><td style="width:1.0%"/><td style="width:62.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4%</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease&#160;expenses were included in the selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss. Operating lease right-of-use assets and related current and noncurrent operating lease liabilities are presented in the accompanying balance sheets. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the future minimum payments under the operating lease agreements with non-cancelable terms as of December&#160;31, 2021:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.327%"><tr><td style="width:1.0%"/><td style="width:76.348%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059660131032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:10pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately $2,012. Certain minimum purchase commitments related to the purchase of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are described below.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Supply Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Agreement includes certain minimum annual purchases that the Company is required to make in order to maintain the exclusivity of the license. The Company may, however, meet these minimum purchase obligations by achieving certain market share in its covered territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. No amounts were accrued as of December&#160;31, 2021 and 2020.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16 and 28, 2020, two putative securities class action complaints were filed in the U.S. District Court for the Southern District of New York by Evolus shareholders Armin Malakouti and Clinton Cox, respectively, naming the Company and certain of its officers as defendants. The complaints assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, claiming that the defendants made false and materially misleading statements and failed to disclose material adverse facts related to the Company&#8217;s acquisition of the right to sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the complaint against the Company filed by Allergan and Medytox in the U.S. International Trade Commission related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;ITC Action&#8221;), and risks related to the ITC Action. The complaints assert a putative class period of February 1, 2019 to July 6, 2020. The court consolidated the actions on November 13, 2020, under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-08647 (PGG). On September 17, 2021, the court appointed a lead plaintiff and lead counsel. On November 17, 2021, the lead plaintiff filed an amended class action complaint against the Company, three of its officers, and Alphaeon Corporation, the Company&#8217;s former majority shareholder. On January 18, 2022, the Company and the officer defendants served their motion to dismiss the amended complaint, which is scheduled to be fully briefed on June 16, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2020 and December 2, 2020, two putative Evolus shareholders filed substantially similar shareholder derivative actions in the U.S. District Court for the Southern District of New York against certain of the Company&#8217;s officers and directors as defendants. The complaints alleged substantially similar facts as those in the Securities Class Action and assert claims for, among other things, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of Section 14(a) of the Exchange Act and for contribution under Sections 10(b) and 21(D) of the Exchange Act. On December 29, 2020, the plaintiffs filed a joint stipulation to consolidate their actions and on February 5, 2021, the court consolidated the action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus, Inc. Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-09986-PPG, and adjourned defendants&#8217; time to move, answer or otherwise respond to the complaints. On September 20, 2021, the court so-ordered the parties&#8217; stipulated stay of the consolidated derivative suit pending the court&#8217;s decision on the defendants&#8217; motion to dismiss the Securities Class Action.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional suits will be filed, or additional allegations will be made by stockholders, with respect to these same or similar or other matters and also naming the Company and/or its officers and directors as defendants. The Company believes that the complaints are without merit and intends to vigorously defend against it. However, the outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss and accordingly has not accrued any liability associated with this action.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Books and Records Demand</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, the Company received a letter from a putative stockholder demanding inspection of specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law. The Company was subsequently informed that the stockholder sold his shares of the Company&#8217;s common stock. On October 13, 2021, the Company received a substantially similar demand to inspect specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law from another putative stockholder. The subject of the demand is substantially similar to the allegations in the putative securities class action and derivative complaints described above. The Company responded to that demand on December 17, 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Legal Matters</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is, from time to time, involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of </span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&#8217;s financial results for that period.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. No amounts were accrued as of December&#160;31, 2021.</span></div> Medytox/Allergan Settlement Agreements and Daewoong Arrangement<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medytox/Allergan Settlement Agreements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Settlement Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company, Allergan and Medytox entered into a Settlement and License Agreement (the &#8220;U.S. Settlement Agreement&#8221;), pursuant to which, among other things: (i) Allergan and Medytox agreed to file a petition requesting the remedial orders related to the ITC Action be rescinded with respect to the Company; (ii) Medytox agreed to dismiss substantially similar litigation in California against the Company; (iii) the Company, on the one hand, and Medytox and Allergan, on the other hand, agreed to mutually release certain claims they may have against one another and their respective affiliates, (iv) Allergan and Medytox granted to the Company and its agents a license to manufacture and commercialize certain products identified in the U.S. Settlement Agreement, including Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Licensed Products&#8221;), in the United States during the 21 month period that, pursuant to the ITC Action, the Company was restricted from, among other things, selling, marketing, or promoting such imported Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States (the &#8220;Restricted Period&#8221;); (v) the Company agreed to pay to Allergan and Medytox $35,000 in multiple payments over two years, of which the Company paid the first cash payment of $15,000 in the third quarter of 2021 and the second payment of $15,000 in the first quarter of 2022; and (vi) during the Restricted Period, the Company agreed to pay to Allergan and Medytox certain confidential royalties on the sale of Licensed Products, calculated on dollar amount per vial sold of Licensed Products by or on behalf of the Company in the United States.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ROW Settlement Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company and Medytox entered into a Settlement and License Agreement (the &#8220;ROW Settlement Agreement&#8221; and, together with the U.S. Settlement Agreement, the &#8220;Medytox/Allergan Settlement Agreements&#8221;), pursuant to which, among other things: (i) the Company and Medytox agreed to mutually release certain claims they may have against one another and their respective affiliates; (ii) Medytox granted to the Company and its agents a license to manufacture and commercialize the Licensed Products, in Canada, the European Union, Switzerland, member countries and cooperating countries of the European Economic Area, Russia, certain members of the Commonwealth of Independent States, South Africa, Australia and Japan (the &#8220;ROW Territories&#8221;) during the Restricted Period; (iii) Medytox granted to the Company and its agents a fully paid up license to manufacture and commercialize the Licensed Products in the ROW Territories and the United States from the end of the Restricted Period (the &#8220;Medytox License Period&#8221;); (iv) the Company and Medytox agreed to enter into the Share Issuance Agreement (as defined below) pursuant to which the Company issued 6,762,652 shares (the &#8220;Settlement Shares&#8221;) of the Company&#8217;s common stock, par value $0.00001 per share, to Medytox; (v) the Company and Medytox agreed to enter into the Registration Rights Agreement (as defined below), pursuant to which the Company granted certain registration rights to Medytox with respect to the Settlement Shares; (vi) during the Restricted Period, the Company agreed to pay Medytox a confidential low-double digit royalty on net sales of the Licensed Products sold by or on behalf of the Company in the ROW Territories; and (vii) during the Medytox License Period, the Company </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreed to pay Medytox a confidential mid-single digit royalty percentage on net sales of the Licensed Products sold by or on behalf of the Company in the United States and the ROW Territories.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share Issuance Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the ROW Settlement Agreement, the Company and Medytox entered into a Share Issuance Agreement effective February 18, 2021 (the &#8220;Share Issuance Agreement&#8221;). Pursuant to the Share Issuance Agreement and subject to the terms and conditions set forth therein, among other things, the Company issued to Medytox the Settlement Shares to enter into the ROW Settlement Agreement and in consideration for Medytox&#8217;s representations, warranties, and other agreements set forth in the Share Issuance Agreement. The Settlement Shares are subject to contractual restrictions on transfer that, subject to certain limited exceptions such as transfers to affiliates, prevented Medytox from transferring any shares of common stock prior to February 16, 2022 and, thereafter, prohibit Medytox from transferring more than 25% of the shares it holds prior to September 16, 2023, more than 50% of the shares it holds prior to September 16, 2024 and more than 75% of the shares it holds prior to September 16, 2025, with such contractual restrictions terminating on September 16, 2025.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registration Rights Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the ROW Settlement Agreement, the Company and Medytox also entered into a Registration Rights Agreement effective February 18, 2021 (the &#8220;Registration Rights Agreement&#8221;). Pursuant to the Registration Rights Agreement, among other things, the Company agreed, after March 31, 2022, (i) to comply with certain requests by Medytox to register for sale, under the Securities Act, the Settlement Shares, and (ii) to include the Settlement Shares in certain registrations by the Company of its securities for sale under the Securities Act, to the extent requested by Medytox, in each case subject to certain customary conditions, exceptions and limitations as set forth in the Registration Rights Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Medytox&#8217;s registration rights under the Registration Rights Agreement will terminate at such time that Medytox is able to sell all of the Settlement Shares over a three-month period, or less, pursuant to an exemption to registration under the Securities Act.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daewoong Arrangement</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Daewoong Arrangement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, the Company and Daewoong entered into a Confidential Settlement and Release Agreement (the &#8220;Daewoong Arrangement&#8221;), pursuant to which, among other things: (i) Daewoong agreed to (a) pay to the Company an amount equal to $25,500, which the Company received in April 2021, (b) pay certain legal fees incurred by the Company&#8217;s litigation counsel in connection with its defense of the ITC Action (including any appeal of the resulting remedial orders), (c) cancel all remaining milestone payments, totaling $10,500 in aggregate, and (d) reimburse the Company certain amounts (calculated on a dollar amount per vials sold basis in the United States) for sales of certain products with respect to which the Company is required to pay Medytox and Allergan royalties pursuant to the U.S. Settlement Agreement; and (ii) the Company agreed to (a) release, on behalf of itself and certain of its affiliates and representatives, certain claims they may have against Daewoong related to the allegations made in or the subject matter of the Medytox/Allergan Actions, or any orders, remedies and losses resulting from the Medytox/Allergan Actions, and (b) coordinate with Daewoong on certain matters related to the Medytox/Allergan Actions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conversion Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Daewoong Arrangement, the Company and Daewoong also entered into a Convertible Promissory Note Conversion Agreement (the &#8220;Conversion Agreement&#8221;), pursuant to which, among other things, (i) the principal balance under the Daewoong Convertible Note, together with all accrued and unpaid interest thereon, in the amount of $40,779 was converted into 3,136,869 shares of Common Stock at the conversion price of $13.00 per share (the &#8220;Conversion Shares&#8221;); and (ii) the Daewoong Convertible Note was deemed cancelled and satisfied in full in connection with such conversion.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the conversion, shares owned by Daewoong, together with its affiliates and attribution parties, did not exceed 9.99% of the Company&#8217;s then outstanding common shares immediately following such issuance, as required under the terms of the Daewoong Convertible Note. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Daewoong Agreement Amendment</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Daewoong Arrangement, on March 23, 2021, the Company and Daewoong also entered into the Third Amendment to the Supply Agreement (the &#8220;Daewoong Agreement Amendment&#8221;). Pursuant to the Daewoong Agreement Amendment, the parties amended the Daewoong Agreement to (i) expand the territory within which the Company may distribute Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to certain countries in Europe, (ii) reduce the period of time with respect to which the Company is required to deliver binding forecasts to Daewoong; (iii) introduce certain limitations on Daewoong&#8217;s ability to convert the Company&#8217;s exclusive license for certain territories to a non-exclusive license in the event the Company fails to meet certain minimum purchase requirements for such territory; (iv) adjust the minimum purchase requirements and reduce the transfer price per vial of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> applicable to various territories, (v) require that any Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> supplied by Daewoong match certain shelf-life thresholds, and (vi) prohibit the Company from sharing certain confidential information of Daewoong with Medytox or its affiliates or representatives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059662181384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has 10,000,000 authorized shares of preferred stock with a par value of $0.00001 per share. As of December&#160;31, 2021, no shares of its preferred stock were issued and outstanding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has 100,000,000 authorized shares of common stock with a par value of $0.00001 per share. As of December&#160;31, 2021, 55,576,988 shares of its common stock were issued and outstanding.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2021, the Company issued 6,762,652 shares of its common stock to Medytox pursuant to the Share Issuance Agreement. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, the Company issued 3,136,869 shares of its common stock to Daewoong in connection with the conversion of Daewoong Convertible Note. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Daewoong Convertible Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company completed a follow-on public offering and issued 10,350,000 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,350,000 shares of common stock, at a price to the public of $9.50 per share. The Company received net proceeds of approximately $92,426 from the offering, after deducting underwriting discounts and commissions, excluding other offering expenses.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8220;At-the-market&#8221; Offerings of Common Stock</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2021, the Company entered into an &#8220;at-the-market&#8221; sales agreement with SVB Leerink LLC (the &#8220;Sales Agent&#8221;) pursuant to which shares of the Company&#8217;s common stock may be sold from time to time for aggregate gross proceeds of up to $75,000 (the &#8220;ATM Program&#8221;). The Sales Agent is entitled to compensation, at a commission rate equal to 3.0% of the gross proceeds from sales of the Company&#8217;s common shares under the ATM Program.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, the Company sold a total of 934,367 shares of its common stock pursuant to the ATM Program at the prevailing market prices for total net proceeds of $10,910 and paid total commissions of $337 to the Sales Agent.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Omnibus Incentive Plan and Stock-based Compensation Allocation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2017 Omnibus Incentive Plan (the &#8220;Plan&#8221;) provides for the grant of incentive options to employees of the Company, and for the grant of non-statutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&#8217;s officers, directors, consultants and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is 4,361,291 shares, plus an annual increase on each anniversary of November 21, 2017 equal to 4.0% of the total issued and outstanding shares of the Company&#8217;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&#8217;s board of directors). On November 21, 2021 and 2020, an additional 2,223,080 shares and 1,349,969 shares, respectively, were reserved under the evergreen provision of the Plan. As of December&#160;31, 2021, the Company had an aggregate of 3,361,247 shares of its common stock available for future issuance under the Plan.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Award Activity and Balances</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options are granted at exercise prices based on the Company&#8217;s common stock price on the date of grant. The options and RSU grants generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE3MzI_fb117ad8-2568-44c6-bb64-c540497d2484">one</span>-to four-year period. There have been no awards granted with performance conditions or market conditions for the periods presented. The options have a contractual term of ten years. The fair value of options is estimated using the Black&#8209;Scholes option pricing model, which has various inputs, including the grant date common share price, exercise price, risk&#8209;free interest rate, volatility, expected life and dividend yield. The change of any of these inputs could significantly impact the determination of the fair value of the Company&#8217;s options as well as significantly impact its results of operations. The fair value of RSU grants is determined at the grant date based on the common share price. The Company records stock-based compensation expense net of actual forfeitures when they occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant assumptions used in the Black-Scholes option-pricing are as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company has limited data regarding company&#8209;specific historical or implied volatility of its share price. Consequently, the Company estimates its volatility based on the average historical volatility of the stock price from a set of peer companies and its own stock performance, since our shares do not have sufficient trading history. Management considers factors such as stage of life cycle, competitors, size, market capitalization and financial leverage in the selection of similar entities.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The expected term represents the period of time in which the options granted are expected to be outstanding. The Company estimates the expected term of options with consideration of vesting date, contractual term, and historical experience. The expected term of &#8220;plain vanilla&#8221; options is estimated based on the midpoint between the vesting date and the end of the contractual term under the simplified method permitted by the SEC implementation guidance. The weighted&#8209;average expected term of the Company&#8217;s options is approximately six years.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk&#8209;Free Rate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The risk&#8209;free interest rate is selected based upon the implied yields in effect at the time of the option grant on U.S. Treasury zero&#8209;coupon issues with a term approximately equal to the expected life of the option being valued.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dividends.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company does not anticipate paying cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield rate of zero.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-averages for assumptions used in determining the fair value of stock options granted were as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:58.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.2%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.14</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the Plan for the year ended December 31, 2021 and 2020, is presented below:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:41.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.784%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Terms (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(892,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,407,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(742,902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,922,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316,637&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.44&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,922,286&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of outstanding and exercisable options represents the excess of the fair market value of our common stock over the exercise price of underlying options as of&#160;December&#160;31, 2021 and 2020. The total intrinsic value of options exercised during the year ended December&#160;31, 2021 was $200. There were no options exercised during the year ended December&#160;31, 2020. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, the Company recorded expenses related to stock options of $5,302 and $7,968, respectively. As of&#160;December&#160;31, 2021, there was $6,358 of total unrecognized compensation cost, net of actual forfeitures, related to stock option-based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&#160;1.68 years. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity under the Plan for the year ended December 31, 2021 and 2020, is presented below:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:58.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,870&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.89&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173,741&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566,788)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(530,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,926,467&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.06&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, the Company recorded expenses related to restricted stock units of $4,274 and $2,615, respectively. Total fair value of RSUs vested during the years ended December 31, 2021 and 2020 was </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5,892 and $1,980, respectively. As of&#160;December&#160;31, 2021, there was $11,768 of total unrecognized compensation cost, net of actual forfeitures, related to RSU-based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&#160;2.87 years. </span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense arising from the above Plan:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:58.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during the years ended December 31, 2021 and 2020, the Company capitalized $63 and $21, respectively, of stock-based compensation expense in capitalized software. Capitalized software is a component of intangible assets and is presented in the accompanying balance sheets. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets</span> for capitalized software information.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059662181384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medytox/Allergan Settlement Agreements and Daewoong Arrangement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Medytox/Allergan Settlement Agreements and Daewoong Arrangement</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:10pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately $2,012. Certain minimum purchase commitments related to the purchase of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are described below.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Supply Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Agreement includes certain minimum annual purchases that the Company is required to make in order to maintain the exclusivity of the license. The Company may, however, meet these minimum purchase obligations by achieving certain market share in its covered territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. No amounts were accrued as of December&#160;31, 2021 and 2020.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16 and 28, 2020, two putative securities class action complaints were filed in the U.S. District Court for the Southern District of New York by Evolus shareholders Armin Malakouti and Clinton Cox, respectively, naming the Company and certain of its officers as defendants. The complaints assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, claiming that the defendants made false and materially misleading statements and failed to disclose material adverse facts related to the Company&#8217;s acquisition of the right to sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the complaint against the Company filed by Allergan and Medytox in the U.S. International Trade Commission related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;ITC Action&#8221;), and risks related to the ITC Action. The complaints assert a putative class period of February 1, 2019 to July 6, 2020. The court consolidated the actions on November 13, 2020, under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-08647 (PGG). On September 17, 2021, the court appointed a lead plaintiff and lead counsel. On November 17, 2021, the lead plaintiff filed an amended class action complaint against the Company, three of its officers, and Alphaeon Corporation, the Company&#8217;s former majority shareholder. On January 18, 2022, the Company and the officer defendants served their motion to dismiss the amended complaint, which is scheduled to be fully briefed on June 16, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2020 and December 2, 2020, two putative Evolus shareholders filed substantially similar shareholder derivative actions in the U.S. District Court for the Southern District of New York against certain of the Company&#8217;s officers and directors as defendants. The complaints alleged substantially similar facts as those in the Securities Class Action and assert claims for, among other things, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of Section 14(a) of the Exchange Act and for contribution under Sections 10(b) and 21(D) of the Exchange Act. On December 29, 2020, the plaintiffs filed a joint stipulation to consolidate their actions and on February 5, 2021, the court consolidated the action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus, Inc. Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-09986-PPG, and adjourned defendants&#8217; time to move, answer or otherwise respond to the complaints. On September 20, 2021, the court so-ordered the parties&#8217; stipulated stay of the consolidated derivative suit pending the court&#8217;s decision on the defendants&#8217; motion to dismiss the Securities Class Action.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional suits will be filed, or additional allegations will be made by stockholders, with respect to these same or similar or other matters and also naming the Company and/or its officers and directors as defendants. The Company believes that the complaints are without merit and intends to vigorously defend against it. However, the outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss and accordingly has not accrued any liability associated with this action.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Books and Records Demand</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, the Company received a letter from a putative stockholder demanding inspection of specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law. The Company was subsequently informed that the stockholder sold his shares of the Company&#8217;s common stock. On October 13, 2021, the Company received a substantially similar demand to inspect specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law from another putative stockholder. The subject of the demand is substantially similar to the allegations in the putative securities class action and derivative complaints described above. The Company responded to that demand on December 17, 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Legal Matters</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is, from time to time, involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of </span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&#8217;s financial results for that period.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. No amounts were accrued as of December&#160;31, 2021.</span></div> Medytox/Allergan Settlement Agreements and Daewoong Arrangement<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medytox/Allergan Settlement Agreements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Settlement Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company, Allergan and Medytox entered into a Settlement and License Agreement (the &#8220;U.S. Settlement Agreement&#8221;), pursuant to which, among other things: (i) Allergan and Medytox agreed to file a petition requesting the remedial orders related to the ITC Action be rescinded with respect to the Company; (ii) Medytox agreed to dismiss substantially similar litigation in California against the Company; (iii) the Company, on the one hand, and Medytox and Allergan, on the other hand, agreed to mutually release certain claims they may have against one another and their respective affiliates, (iv) Allergan and Medytox granted to the Company and its agents a license to manufacture and commercialize certain products identified in the U.S. Settlement Agreement, including Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Licensed Products&#8221;), in the United States during the 21 month period that, pursuant to the ITC Action, the Company was restricted from, among other things, selling, marketing, or promoting such imported Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States (the &#8220;Restricted Period&#8221;); (v) the Company agreed to pay to Allergan and Medytox $35,000 in multiple payments over two years, of which the Company paid the first cash payment of $15,000 in the third quarter of 2021 and the second payment of $15,000 in the first quarter of 2022; and (vi) during the Restricted Period, the Company agreed to pay to Allergan and Medytox certain confidential royalties on the sale of Licensed Products, calculated on dollar amount per vial sold of Licensed Products by or on behalf of the Company in the United States.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ROW Settlement Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company and Medytox entered into a Settlement and License Agreement (the &#8220;ROW Settlement Agreement&#8221; and, together with the U.S. Settlement Agreement, the &#8220;Medytox/Allergan Settlement Agreements&#8221;), pursuant to which, among other things: (i) the Company and Medytox agreed to mutually release certain claims they may have against one another and their respective affiliates; (ii) Medytox granted to the Company and its agents a license to manufacture and commercialize the Licensed Products, in Canada, the European Union, Switzerland, member countries and cooperating countries of the European Economic Area, Russia, certain members of the Commonwealth of Independent States, South Africa, Australia and Japan (the &#8220;ROW Territories&#8221;) during the Restricted Period; (iii) Medytox granted to the Company and its agents a fully paid up license to manufacture and commercialize the Licensed Products in the ROW Territories and the United States from the end of the Restricted Period (the &#8220;Medytox License Period&#8221;); (iv) the Company and Medytox agreed to enter into the Share Issuance Agreement (as defined below) pursuant to which the Company issued 6,762,652 shares (the &#8220;Settlement Shares&#8221;) of the Company&#8217;s common stock, par value $0.00001 per share, to Medytox; (v) the Company and Medytox agreed to enter into the Registration Rights Agreement (as defined below), pursuant to which the Company granted certain registration rights to Medytox with respect to the Settlement Shares; (vi) during the Restricted Period, the Company agreed to pay Medytox a confidential low-double digit royalty on net sales of the Licensed Products sold by or on behalf of the Company in the ROW Territories; and (vii) during the Medytox License Period, the Company </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreed to pay Medytox a confidential mid-single digit royalty percentage on net sales of the Licensed Products sold by or on behalf of the Company in the United States and the ROW Territories.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share Issuance Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the ROW Settlement Agreement, the Company and Medytox entered into a Share Issuance Agreement effective February 18, 2021 (the &#8220;Share Issuance Agreement&#8221;). Pursuant to the Share Issuance Agreement and subject to the terms and conditions set forth therein, among other things, the Company issued to Medytox the Settlement Shares to enter into the ROW Settlement Agreement and in consideration for Medytox&#8217;s representations, warranties, and other agreements set forth in the Share Issuance Agreement. The Settlement Shares are subject to contractual restrictions on transfer that, subject to certain limited exceptions such as transfers to affiliates, prevented Medytox from transferring any shares of common stock prior to February 16, 2022 and, thereafter, prohibit Medytox from transferring more than 25% of the shares it holds prior to September 16, 2023, more than 50% of the shares it holds prior to September 16, 2024 and more than 75% of the shares it holds prior to September 16, 2025, with such contractual restrictions terminating on September 16, 2025.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registration Rights Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the ROW Settlement Agreement, the Company and Medytox also entered into a Registration Rights Agreement effective February 18, 2021 (the &#8220;Registration Rights Agreement&#8221;). Pursuant to the Registration Rights Agreement, among other things, the Company agreed, after March 31, 2022, (i) to comply with certain requests by Medytox to register for sale, under the Securities Act, the Settlement Shares, and (ii) to include the Settlement Shares in certain registrations by the Company of its securities for sale under the Securities Act, to the extent requested by Medytox, in each case subject to certain customary conditions, exceptions and limitations as set forth in the Registration Rights Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Medytox&#8217;s registration rights under the Registration Rights Agreement will terminate at such time that Medytox is able to sell all of the Settlement Shares over a three-month period, or less, pursuant to an exemption to registration under the Securities Act.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daewoong Arrangement</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Daewoong Arrangement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, the Company and Daewoong entered into a Confidential Settlement and Release Agreement (the &#8220;Daewoong Arrangement&#8221;), pursuant to which, among other things: (i) Daewoong agreed to (a) pay to the Company an amount equal to $25,500, which the Company received in April 2021, (b) pay certain legal fees incurred by the Company&#8217;s litigation counsel in connection with its defense of the ITC Action (including any appeal of the resulting remedial orders), (c) cancel all remaining milestone payments, totaling $10,500 in aggregate, and (d) reimburse the Company certain amounts (calculated on a dollar amount per vials sold basis in the United States) for sales of certain products with respect to which the Company is required to pay Medytox and Allergan royalties pursuant to the U.S. Settlement Agreement; and (ii) the Company agreed to (a) release, on behalf of itself and certain of its affiliates and representatives, certain claims they may have against Daewoong related to the allegations made in or the subject matter of the Medytox/Allergan Actions, or any orders, remedies and losses resulting from the Medytox/Allergan Actions, and (b) coordinate with Daewoong on certain matters related to the Medytox/Allergan Actions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conversion Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Daewoong Arrangement, the Company and Daewoong also entered into a Convertible Promissory Note Conversion Agreement (the &#8220;Conversion Agreement&#8221;), pursuant to which, among other things, (i) the principal balance under the Daewoong Convertible Note, together with all accrued and unpaid interest thereon, in the amount of $40,779 was converted into 3,136,869 shares of Common Stock at the conversion price of $13.00 per share (the &#8220;Conversion Shares&#8221;); and (ii) the Daewoong Convertible Note was deemed cancelled and satisfied in full in connection with such conversion.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the conversion, shares owned by Daewoong, together with its affiliates and attribution parties, did not exceed 9.99% of the Company&#8217;s then outstanding common shares immediately following such issuance, as required under the terms of the Daewoong Convertible Note. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Daewoong Agreement Amendment</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Daewoong Arrangement, on March 23, 2021, the Company and Daewoong also entered into the Third Amendment to the Supply Agreement (the &#8220;Daewoong Agreement Amendment&#8221;). Pursuant to the Daewoong Agreement Amendment, the parties amended the Daewoong Agreement to (i) expand the territory within which the Company may distribute Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to certain countries in Europe, (ii) reduce the period of time with respect to which the Company is required to deliver binding forecasts to Daewoong; (iii) introduce certain limitations on Daewoong&#8217;s ability to convert the Company&#8217;s exclusive license for certain territories to a non-exclusive license in the event the Company fails to meet certain minimum purchase requirements for such territory; (iv) adjust the minimum purchase requirements and reduce the transfer price per vial of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> applicable to various territories, (v) require that any Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> supplied by Daewoong match certain shelf-life thresholds, and (vi) prohibit the Company from sharing certain confidential information of Daewoong with Medytox or its affiliates or representatives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059663150280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit PlanThe Company maintains a defined contribution&#160;401(k) plan covering substantially all employees. Matching contributions totaled $481 and $524&#160;for the years ended December 31, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059663185464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loss before income taxes was entirely generated from its U.S. operations. The current and deferred expense is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:58.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred (benefit) provision:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred provision (benefit) </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision (benefit) for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has federal net operating loss (&#8220;NOL&#8221;) carryforwards of $273,776, of which $72,579 will begin to expire in 2034. The federal NOLs generated in 2018 and in the subsequent years in the amount of $201,197 have an indefinite carryforward period. As of December&#160;31, 2021,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company has state NOL carryforwards of $169,332, which will begin to expire in 2038. As of December&#160;31, 2021, the Company has federal research and development (&#8220;R&amp;D&#8221;) credit carryforwards of $2,929, which will begin to expire in 2034. The Company also has California R&amp;D credit carryforwards of $2,918, which has an indefinite carryforward period. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOL and the R&amp;D credit carryforwards generated by the Company in tax years ended February 11, 2018 and prior have been included in the consolidated and unitary income tax returns of Alphaeon Corporation (&#8220;Alphaeon&#8221;). After the Company left Alphaeon consolidated and unitary income tax group on February 11, 2018, the Company files its own standalone income tax returns. Deferred tax assets in the accompanying financial statements reflect the Company's standalone tax attributes that are reportable on its own income tax returns.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, if a company experiences a greater than 50 percentage point aggregate change in ownership of certain significant stockholders over a three-year period, utilization of its pre-change NOL carryforwards and R&amp;D credit carryforwards is subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state laws. The annual limitation generally is determined by multiplying the value of the Company&#8217;s stock at the time of such ownership change, subject to certain adjustments, by the applicable long-term tax-exempt rate. The annual limitations may </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result in the expiration of NOL and R&amp;D credit carryforwards before utilization and may be material. The Company has started but has not completed an analysis to determine whether its NOL and R&amp;D credits generated through December&#160;31, 2021 are likely to be limited by Section&#160;382 and 383. The Company anticipates that an ownership change as defined under Section&#160;382 may have occurred and that the resulting limitation would significantly reduce the Company&#8217;s ability to utilize its NOL and R&amp;D credit carryforwards before they expire. Additionally, future ownership changes under Section&#160;382 and 383 may also limit the Company's ability to fully utilize any remaining tax benefits. The Company&#8217;s net deferred income tax assets have been offset by a valuation allowance. Therefore, any resulting reduction to the Company&#8217;s NOL and R&amp;D credit carryforwards once the analysis is complete will be offset by a corresponding reduction of the valuation allowance and there would be no impact on the Company&#8217;s balance sheet, statement of operations, or cash flows.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred tax assets and liabilities were as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"/><td style="width:57.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other deferred assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,370&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,337&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(873)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,362)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income taxes</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"/><td style="width:57.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,832)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,217)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of Federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meals and entertainment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers' compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory note - debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"/><td style="width:57.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has considered the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above. The Company&#8217;s effective income tax rate would not be impacted if the unrecognized tax benefits are recognized. Additional amounts in the summary rollforward could impact the Company&#8217;s effective tax rate if it did not maintain a full valuation allowance on its net deferred tax assets. The Company does not expect its unrecognized tax benefits to change significantly over the next 12&#160;months.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There were no accrued interest and penalties associated with uncertain tax positions as of December&#160;31, 2021 and 2020. The Company&#8217;s tax returns for all years since inception are open for audit. </span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;). The Cares Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions which are expected to impact the Company&#8217;s financial statements include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. There was no material impact on its financial position, results of operations, or cash flows related to the CARES Act.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2020, the United States enacted the Consolidated Appropriations Act, which extended many of the benefits of the CARES Act that were scheduled to expire. The Company noted no material impacts due to the Consolidated Appropriations Act on its financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059662180552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payment Obligations Related to the Acquisition by Alphaeon</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was acquired by Strathspey Crown Holdings Group, LLC (&#8220;SCH&#8221;) in 2013 and subsequently by its subsidiary, Alphaeon Corporation (&#8220;Alphaeon&#8221;), by means of a stock purchase agreement (&#8220;Stock Purchase Agreement&#8221;) pursuant to which Alphaeon assumed certain payment obligations related to the acquisition. On December 14, 2017, the Stock Purchase Agreement was amended (&#8220;Amended Stock Purchase Agreement&#8221;), and, as a result, effective upon the closing of the Company&#8217;s IPO, the Company assumed all of Alphaeon&#8217;s payment obligations under the Amended Stock Purchase Agreement. </span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended Stock Purchase Agreement, the payment obligations to the Evolus founders consists of: quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The obligations terminate in the quarter following the&#160;10-year anniversary of the first commercial sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the United States. In November 2021, we paid $20,000&#160;to satisfy in full a promissory note that matured in November 2021. Under the Amended Stock Purchase Agreement, the Company recorded the fair value of all revised payment obligations owed to the Evolus Founders. See&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Fair Value Measurements and Short-Term Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for more information about the Company&#8217;s accounting thereof.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Related Party Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2021, the Company and Medytox entered into a Settlement and License Agreement (the &#8220;ROW Settlement Agreement&#8221; and, together with the U.S. Settlement Agreement, the &#8220;Medytox/Allergan Settlement Agreements&#8221;), pursuant to which, among other things, the Company issued 6,762,652 shares (the &#8220;Settlement Shares&#8221;) of the Company&#8217;s common stock, par value $0.00001 per share, to Medytox. See&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for more information about the Company&#8217;s accounting thereof.</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, the Company and Daewoong entered into a Confidential Settlement and Release Agreement (the &#8220;Daewoong Settlement Agreement&#8221;) and a Convertible Promissory Note Conversion Agreement (the &#8220;Conversion Agreement&#8221;). Pursuant to the Conversion Agreement, among other things, (i) the principal balance under the Daewoong Convertible Note, together with all accrued and unpaid interest thereon, in the amount of $40,779 was converted, at the conversion price of $13.00 per share, into 3,136,869 shares of Common Stock (the &#8220;Conversion Shares&#8221;); and (ii) the Daewoong Convertible Note was deemed cancelled and satisfied in full in connection with such conversion. See&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for more information about the Company&#8217;s accounting thereof.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059658803672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain comparative amounts for prior year have been reclassified to conform to current year presentations. Such reclassifications did not affect net income or retained earnings.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make certain estimates and assumptions in order to prepare financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company&#8217;s most significant estimates relate to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations, stock-based compensation and royalty obligations, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#8217;s actual results could differ materially from those estimates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the full impact of&#160;the COVID-19&#160;outbreak is unknown and cannot be reasonably estimated. However, where possible, management has made appropriate accounting estimates with respect to certain accounting matters, which include the fair value of royalty obligations, allowance for doubtful accounts, inventory valuation and impairment assessments of goodwill and other long-lived assets, based on the facts and circumstances available as of the reporting date. The Company&#8217;s future assessment of the magnitude and duration of&#160;the COVID-19 outbreak, as well as other factors, could result in material impacts to the Company&#8217;s financial statements in future reporting periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties and Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, Evolus and Daewoong Pharmaceutical Co. Ltd. (&#8220;Daewoong&#8221;) entered into an agreement (the &#8220;Daewoong Agreement&#8221;), pursuant to which the Company received an exclusive distribution license to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, Russia, certain members of the Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the United States in May 2019 and in Canada through its distribution partner in October 2019 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&#8217;s business and its financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company&#8217;s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by physicians and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak and restrictions intended to slow the spread of COVID-19, including quarantines, government-mandated actions, stay-at-home orders and other restrictions,&#160;have adversely affected the Company&#8217;s business in a number of ways, which have resulted, and may continue to result, in a period of business disruption and in reduced sales and operations. In addition, any disruption and volatility in the global capital markets may increase the Company&#8217;s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company&#8217;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#8217;s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#8217; ability to pay.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. The Company has determined that it operates in a single operating and reportable segment. The Company&#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company&#8217;s statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the statements of operations and comprehensive loss using the specific-identification method. </span></div>The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of finished goods held for sale and distribution. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost is determined based on the estimated amount payable to the Company&#8217;s supplier after accounting for any reimbursement receivable pursuant to the Daewoong Settlement Agreement (as such term is defined, and such agreement is discussed, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), usin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g the first-in, first-out method with prioritization of the items with the earliest expiration dates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Inventory valuation reserves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for the periods presented. Adverse changes in assumptions utilized in the Company&#8217;s inventory reserve calculations could result in an increase to its inventory valuation reserves.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product cost of sales, excluding amortization of intangible assets, consisted of the inventory cost, and, for periods on or after December 16, 2020, included certain royalties on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> payable to Medytox and Allergan pursuant to the Medytox/Allergan Settlement Agreements (as such term is defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), as partially offset by reimbursement receivable from Daewoong pursuant to the Daewoong Settlement Agreement with respect to such royalties.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</span></div><div style="margin-bottom:9pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentProperty and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of approximately five years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the term of the related lease.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">GoodwillGoodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has one reporting unit.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon FDA approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in February 2019, the in process research and development (&#8220;IPR&amp;D&#8221;) related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;was evaluated as completed and reclassified to a definite-lived distribution right intangible asset, which is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&#160;20 years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&#160;two years&#160;upon being placed in service.</span></div>The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was no material impairment of long-lived assets for any periods presented<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;), at the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#8220;ROU&#8221;) asset which represents the Company&#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancelable period of the lease and may include options to extend or terminate the lease </span></div>when it is reasonably certain that the Company will exercise such options. The Company&#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of&#160;December&#160;31, 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingent Royalty Obligation Payable and Promissory Note Payable to the Evolus Founders</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Royalty Obligation Payable to the Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable are determined at each reporting period end and recorded in operating expenses in the accompanying statements of operations and comprehensive loss and as a liability in the accompanying balance sheets. </span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Promissory Note Payable to the Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2018, the Company recognized a promissory note payable at present value using a discount rate for similar rated debt securities. Discount amortization related to the promissory note is recorded in interest expense in the accompanying statements of operations and comprehensive loss with a corresponding increase to the liabilities in the accompanying balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Debt</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt represents the debt balance with Pharmakon as of December&#160;31, 2021 and Oxford as of December&#160;31, 2020 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6. Term Loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, net of debt issuance costs. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are amortized into interest expense over the term of the debt.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates product revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and service revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through a distribution partner in Canada.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Canada as it does not control the product before control is transferred to a customer. The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the amount of consideration expected to be received. For the years ended December 31, 2021 and 2020, the Company recognized $702 and $738, respectively, of revenues related to international sales. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross-to-Net Revenue Adjustments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides customers with discounts, such as trade and volume discounts and prompt pay discounts, that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, primarily for the volume based rebates, coupons, consumer loyalty programs and co-branded marketing programs. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Volume-based Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Coupons</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company issued customers coupons redeemable into gift cards funded by the Company for the benefit of patients. The coupons were accounted for as variable consideration. The Company estimated coupon redemption rates based on historical data and future expectations. The coupons were accrued based on estimated redemption rates and the volume of products purchased and were recorded as a reduction to revenues on product delivery. All issued coupons expired on June 30, 2020.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Consumer Loyalty Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; In May 2020, the Company launched a consumer loyalty program, which allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and redeem the rewards for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward (&#8220;Reward&#8221;) that the customer might redeem in the future. The standalone selling price of the Reward is measured based on historical sales data, estimated average selling price of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time of redemption, expected customer and consumer participation rates in the loyalty program, and estimated number of qualifying treatments to be performed by customers. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue. Subsequently, when customers redeem the Reward and the related product is delivered, the deferred revenue is recognized in net revenues at that time.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Co-Branded Marketing Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company offers eligible customers with a certain level of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> purchases to receive advertising co-branded with the Company. The co-branded advertising represents a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the advertisement. The standalone selling price of the advertisement is measured based on the estimated market value of similar advertisement adjusted for the customer&#8217;s portion of the advertisement. The portion of invoice price allocated to the advertisement is initially recorded as deferred revenue. Subsequently, when the advertisement airs, the deferred revenue is recognized in net revenues at that time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract balances</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration becomes unconditional. The Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of&#160;December&#160;31, 2021 and 2020, all amounts included in accounts receivable, net on the accompanying balance sheets are related to contracts with customers.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any contract assets nor unbilled receivables as of&#160;December&#160;31, 2021 or 2020. Sales commissions are included in selling, general and administrative expenses when incurred.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients primarily under the rebate and coupon programs and deferred revenue associated with Rewards under the consumer loyalty program and co-</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">branded marketing programs. The Company&#8217;s contract liabilities are included in accounts payable and accrued expenses in the accompanying balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the accrued revenue contract liabilities, primarily related to volume-based rebates, consumer loyalty program, and co-branded media programs, were $7,934 and $3,081, respectively, which were recorded in accrued expenses in the accompanying balance sheets. For the years ended December 31, 2021 and 2020, provisions for rebate, coupon, consumer loyalty programs, and co-branded media programs were $16,139 and $16,896, respectively, which were offset by related payments, redemptions and adjustments of $11,286 and $15,524, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the&#160;years ended December 31, 2021 and 2020, the Company recognized $2,802 and $0, respectively, of revenue related to amounts included in contract liabilities at the beginning of the period and did not recognize any revenue related to changes in transaction prices regarding its contracts with customers from previous periods.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collectability</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.&#160;The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of December 31, 2021 and 2020, allowance for doubtful accounts was $2,385 and $2,118, respectively. For the years ended December 31, 2021 and 2020, provision for bad debts was $589 and $2,066, respectively, and the write-off amount was $322 and $335, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Practical Expedients</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate, and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) is based on the fair value on the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the balance sheets and in the selling, general and administrative or research and development expenses in the statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text">Advertising CostsAdvertising costs are expensed as incurred and primarily include costs related to social media ads and co-branded marketing programs. Advertising costs are included in selling, general and administrative expenses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. </span></div><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its statement of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&#160;50%&#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. The Company does not expect that changes to state tax laws through December&#160;31, 2021 to materially impact its financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. The dilutive effect of stock options and restricted stock units is computed under the treasury stock method. The dilutive effect of the Daewoong Convertible Note is computed under the if-converted method. Potentially dilutive securities are excluded from the computations of diluted net loss per share if their effect would be antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Pronouncements</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provisions remove certain exceptions including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020 and interim periods therein. The Company has adopted the guidance on the effective date of January 1, 2021. There are no material impacts to the financial statements as a result of this adoption.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements&#160;Issued But Not&#160;Adopted&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other (Topic 350):&#160;Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January&#160;1, 2023. The standard requires prospective application. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact on its financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU No. 2016-13, the FASB issued ASU 2018-19,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 326, Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU does not change the core principle of the guidance in ASU No. 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&#160;The FASB also subsequently issued ASU No. 2019-04 which did not change the core principle of the guidance in ASU No. 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January 1, 2023. The Company is in the process of determining the effects the adoption will have on its financial statements and reviewing credit loss models to assess the impact of the adoption of the standard on the financial statements. Based on initial assessments, the Company believes that while adoption will modify the way it analyzes financial instruments, it does not expect adoption of this guidance will have a material impact to its financial statements.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and in January 2021, the FASB issued ASU No. 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope (&#8220;ASU 2021-01&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Both ASU No. 2020-04 and ASU No. 2021-01 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or another reference rate expected to be discontinued because of reference rate reform. ASU No. 2020-04 and ASU No. 2021-01 are effective upon issuance for contract modifications and hedging relationships, and the Company is allowed to elect to apply the amendments prospectively through December 31, 2022. The Company does not expect adoption of this guidance will have a material impact on its financial statements.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This update will increase transparency of government assistance received by most business entities by requiring the disclosure of: (1) the types of transactions; (2) the accounting for the transactions; and, (3) the effect of the transactions on a business entity&#8217;s financial statements. ASU No. 2021-10 is effective for financial statements issued for annual periods beginning after December 15, 2021, with early application permitted. The Company does not expect adoption of this guidance will have a material impact on its financial statements.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059660236824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Short-term Investments Available-for-sale</a></td>
<td class="text">As of December&#160;31, 2020, all of the Company&#8217;s investments had remaining maturities of less than 12 months. The following is a summary of the Company&#8217;s short-term investments, considered available-for-sale, as of December&#160;31, 2020:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:52.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:52.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:52.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Fair Value Measurement for Contingent Royalty Obligation Payable</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:58.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,097)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recorded in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,007)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,546&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059662304552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:30.643%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.849%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution right</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,390&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,625&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:30.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.837%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.896%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution right</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,810)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,757&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,460)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,965&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,460)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,505&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Intangible assets with indefinite lives have an indeterminable average life.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense of Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;December&#160;31, 2021 that are subject to amortization:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.142%"><tr><td style="width:1.0%"/><td style="width:55.931%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.869%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059662144296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:58.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties under the Medytox/Allergan Settlement Agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued revenue contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059662288776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.476%"><tr><td style="width:1.0%"/><td style="width:68.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.582%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discounts and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,778)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net of discounts and issuance costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,222&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059662427288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Composition of Lease Expense and Other Quantitative Information</a></td>
<td class="text">he components of operating lease expense are as follows:<div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.154%"><tr><td style="width:1.0%"/><td style="width:62.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term and discount rate are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.154%"><tr><td style="width:1.0%"/><td style="width:62.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the future minimum payments under the operating lease agreements with non-cancelable terms as of December&#160;31, 2021:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.327%"><tr><td style="width:1.0%"/><td style="width:76.348%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059663844232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Key Assumptions Used to Determine Fair Value of Options Granted</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-averages for assumptions used in determining the fair value of stock options granted were as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:58.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.2%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.14</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the Plan for the year ended December 31, 2021 and 2020, is presented below:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:41.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.784%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Terms (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(892,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,407,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(742,902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,922,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316,637&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.44&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,922,286&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of RSUs Activity</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity under the Plan for the year ended December 31, 2021 and 2020, is presented below:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:58.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,870&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.89&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173,741&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566,788)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(530,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,926,467&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.06&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense arising from the above Plan:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:58.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059658781000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Current and Deferred Income Tax Expense</a></td>
<td class="text">The current and deferred expense is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:58.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred (benefit) provision:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred provision (benefit) </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision (benefit) for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred tax assets and liabilities were as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"/><td style="width:57.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other deferred assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,370&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,337&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(873)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,362)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income taxes</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax</a></td>
<td class="text">A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"/><td style="width:57.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,832)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,217)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of Federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meals and entertainment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers' compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory note - debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"/><td style="width:57.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059653000776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 04, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 23, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 06, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,256,000<span></span>
</td>
<td class="nump">$ 102,562,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">422,882,000<span></span>
</td>
<td class="nump">376,072,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Settlement payment from daewoong</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eols_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,426,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember', window );">A T M Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">934,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember', window );">Intellectual Property Disputes, Jeuveau</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember', window );">Intellectual Property Disputes, Jeuveau | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember', window );">Pharmakon Term Loans | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember', window );">Tranche A Loan | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from issuance of secured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansTwoMember', window );">Tranche B Loan | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_OxfordTermLoanFacilityMember', window );">Oxford Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of long-term lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,447,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,447,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember', window );">Daewoong Convertible Note | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,779,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember', window );">Daewoong Convertible Note | Convertible Debt | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Conversion of common shares (in shares) | shares</a></td>
<td class="nump">3,136,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,136,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eols_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eols_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_OxfordTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_OxfordTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059652887784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 18, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 01, 2019</div></th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>reporting_unit </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Settlement payment from daewoong</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,673,000<span></span>
</td>
<td class="nump">56,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Accrued revenue contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,934,000<span></span>
</td>
<td class="nump">3,081,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RebatesAndCouponsCreditsAndPayments', window );">Rebates and coupons, credits and payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,139,000<span></span>
</td>
<td class="nump">16,896,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability', window );">Payments for provisions for accrued volume-based rebate and coupon liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,286,000<span></span>
</td>
<td class="nump">15,524,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer, liability, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,802,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">83,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">63,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveNoncurrent', window );">Accrued litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,391,000<span></span>
</td>
<td class="nump">4,979,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,385,000<span></span>
</td>
<td class="nump">2,118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589,000<span></span>
</td>
<td class="nump">2,066,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Allowance for credit loss, writeoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322,000<span></span>
</td>
<td class="nump">$ 335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement', window );">Issuance of common stock in connection with litigation settlement (in shares) | shares</a></td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from the computation of diluted net loss per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,922,286<span></span>
</td>
<td class="nump">4,407,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from the computation of diluted net loss per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,926,467<span></span>
</td>
<td class="nump">1,173,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from the computation of diluted net loss per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,076,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember', window );">Intellectual Property Disputes, Jeuveau</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LossContingencySettlementAgreementPaymentTerms', window );">Settlement agreement, payment terms (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss contingency accrual, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember', window );">Intellectual Property Disputes, Jeuveau | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss contingency accrual, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">702,000<span></span>
</td>
<td class="nump">738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 702,000<span></span>
</td>
<td class="nump">$ 738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember', window );">Software development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LossContingencySettlementAgreementPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Settlement Agreement, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LossContingencySettlementAgreementPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Provisions For Accrued Volume-Based Rebate, Coupon And Consumer Loyalty Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RebatesAndCouponsCreditsAndPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rebates And Coupons, Credits And Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RebatesAndCouponsCreditsAndPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares, Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodSharesLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059653246760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Short-term Investments Available for Sale (Details) - U.S treasury securities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract', window );"><strong>Gross Unrealized</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059657344392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="nump">$ 75,448<span></span>
</td>
<td class="nump">$ 76,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Contingent promissory note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember', window );">Contingent Royalty Obligation | Measurement Input, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Measurement input | year</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember', window );">Contingent Royalty Obligation | Measurement Input, Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.130<span></span>
</td>
<td class="nump">0.130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember', window );">Contingent Royalty Obligation | Measurement Input, Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.200<span></span>
</td>
<td class="nump">0.200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059659006472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 44,740<span></span>
</td>
<td class="nump">$ 41,546<span></span>
</td>
<td class="nump">$ 44,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">44,740<span></span>
</td>
<td class="nump">41,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Contingent royalty obligation payable to Evolus Founders | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Contingent royalty obligation payable to Evolus Founders | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Contingent royalty obligation payable to Evolus Founders | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 44,740<span></span>
</td>
<td class="nump">41,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S treasury securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S treasury securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S treasury securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059659119272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Reconciliation of Fair Value Measurement of Contingent Royalty Obligation Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of period</a></td>
<td class="nump">$ 41,546<span></span>
</td>
<td class="nump">$ 44,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(3,097)<span></span>
</td>
<td class="num">(1,130)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value recorded in operating expenses</a></td>
<td class="nump">6,290<span></span>
</td>
<td class="num">(2,007)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of period</a></td>
<td class="nump">$ 44,740<span></span>
</td>
<td class="nump">$ 41,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059657267560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Original Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,390<span></span>
</td>
<td class="nump">$ 65,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,765)<span></span>
</td>
<td class="num">(10,460)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,625<span></span>
</td>
<td class="nump">55,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,208<span></span>
</td>
<td class="nump">21,208<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_IntangibleAssetsGrossIncludingGoodwill', window );">Intangible assets, gross (including goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,598<span></span>
</td>
<td class="nump">86,965<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Total net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,833<span></span>
</td>
<td class="nump">$ 76,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Life (Years)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Original Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,076<span></span>
</td>
<td class="nump">$ 59,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,589)<span></span>
</td>
<td class="num">(5,650)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,487<span></span>
</td>
<td class="nump">$ 53,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Capitalized software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Life (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Original Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,314<span></span>
</td>
<td class="nump">$ 6,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,176)<span></span>
</td>
<td class="num">(4,810)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 1,871<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_IntangibleAssetsGrossIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Gross (Including Goodwill)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_IntangibleAssetsGrossIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059659063032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangibles (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 3,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">3,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">2,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">2,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">2,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">35,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">$ 50,625<span></span>
</td>
<td class="nump">$ 55,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059652991880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAdditions', window );">Capitalized computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
<td class="nump">$ 2,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,305<span></span>
</td>
<td class="nump">$ 3,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Capitalized software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember', window );">SCH | Evolus, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements', window );">Extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentsForIntangibleAssets', window );">Milestone payment for intangible assets</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquired Finite-lived Intangible Asset, Period Of Extension Of Terms Based On Certain Performance Requirements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment In Connection With License And Supply Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentsForIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments For Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentsForIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions made to capitalized computer software costs during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_SCHAEONLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059659992968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties under the Medytox/Allergan Settlement Agreements</a></td>
<td class="nump">$ 12,447<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related benefits</a></td>
<td class="nump">6,856<span></span>
</td>
<td class="nump">4,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Accrued revenue contract liabilities</a></td>
<td class="nump">7,934<span></span>
</td>
<td class="nump">3,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">595<span></span>
</td>
<td class="nump">895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">2,161<span></span>
</td>
<td class="nump">1,050<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 29,993<span></span>
</td>
<td class="nump">$ 9,102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059653452392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term Loans - Pharmakon Term Loans (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 14, 2021 </div>
<div>USD ($) </div>
<div>payment </div>
<div>tranche</div>
</th>
<th class="th"><div>Mar. 15, 2019</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentAmountThreshold', window );">Debt instrument, prepayment amount threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember', window );">Pharmakon Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember', window );">Pharmakon Term Loans | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal', window );">Number of periodic payments | payment</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="nump">$ 3,042,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="nump">$ 3,263,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.89%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember', window );">Pharmakon Term Loans | Term Loan | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember', window );">Tranche A Loan | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod', window );">Anniversary period</a></td>
<td class="text">39 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember', window );">Tranche A Loan | Term Loan | Prior to the 3rd anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount', window );">Debt instrument, percentage of principal amount, prepaid multiplied</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember', window );">Tranche A Loan | Term Loan | After the 3rd anniversary but prior to the 4th anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount', window );">Debt instrument, percentage of principal amount, prepaid multiplied</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember', window );">Tranche A Loan | Term Loan | After the 4th anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount', window );">Debt instrument, percentage of principal amount, prepaid multiplied</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansTwoMember', window );">Tranche B Loan | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Periodic Payments, Principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Payment Commencement Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentAmountThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Amount Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentAmountThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Terms, Prepayment Multiple On Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentTermsAxis=eols_TermOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentTermsAxis=eols_TermOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentTermsAxis=eols_TermTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentTermsAxis=eols_TermTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentTermsAxis=eols_TermThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentTermsAxis=eols_TermThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059658927192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term Loans - Schedule of Long Term Debt Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2026</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discounts and issuance costs</a></td>
<td class="num">(3,778)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt, net of discounts and issuance costs</a></td>
<td class="nump">$ 71,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059653173720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loans - Oxford Term Loans (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 04, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 15, 2019 </div>
<div>USD ($) </div>
<div>advance</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from extinguishment of debts, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 968,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityMember', window );">Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment', window );">Percentage of final payment of full principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentFeePercentageYearTwo', window );">Prepayment fee percentage, year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentFeePercentageThereafter', window );">Prepayment fee percentage, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_OxfordTermLoansMember', window );">Oxford Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,094,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_OxfordTermLoanFacilityMember', window );">Oxford Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of long-term lines of credit</a></td>
<td class="nump">$ 76,447,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,447,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentFeeAmountWaived', window );">Debt instrument fee amount comprised</a></td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentOfFinalPaymentAmountWaived', window );">Debt instrument of principal amount payment</a></td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentFeeAmountWaived', window );">Debt instrument prepayment fee amount</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from extinguishment of debts, net</a></td>
<td class="nump">$ 1,939,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Contingent promissory note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LineofCreditFacilityNumberofAdvances', window );">Number of advances | advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPeriodOfInterestOnlyPayments', window );">Period of interest only payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentAmortizationPeriod', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | First tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Contingent promissory note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | Term Loan Facility, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Contingent promissory note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Amortization Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentFeeAmountWaived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Fee Amount Waived</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentFeeAmountWaived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentOfFinalPaymentAmountWaived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Of Final Payment Amount Waived</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentOfFinalPaymentAmountWaived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Percentage Of Principal Amount, Balloon Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPeriodOfInterestOnlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Period Of Interest Only Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPeriodOfInterestOnlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentFeeAmountWaived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Prepayment Fee Amount, Waived</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentFeeAmountWaived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentFeePercentageThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee Percentage, Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentFeePercentageThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentFeePercentageYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee Percentage, Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentFeePercentageYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LineofCreditFacilityNumberofAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Number of Advances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LineofCreditFacilityNumberofAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_OxfordTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_OxfordTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059657331160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Daewoong Convertible Note (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 23, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 06, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from extinguishment of debts, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (968,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember', window );">Daewoong Convertible Note | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,779,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from extinguishment of debts, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 971,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember', window );">Daewoong Convertible Note | Convertible Debt | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Conversion of common shares (in shares) | shares</a></td>
<td class="nump">3,136,869<span></span>
</td>
<td class="nump">3,136,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059657247464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LesseeOperatingLeaseTerminationPeriod', window );">Operating lease, termination period</a></td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate', window );">Operating lease, period to provide written notice to terminate contract</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent', window );">Operating lease, equivalent rent termination period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">60 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Period Of Written Notice Prior To Lease Terminate Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Fee, Period Of Rent Equivalent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LesseeOperatingLeaseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LesseeOperatingLeaseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059653409912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Components of Lease Expense and Other Quantitative Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed operating lease expense</a></td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="nump">$ 1,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable operating lease expense</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term operating lease expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, cost</a></td>
<td class="nump">$ 1,129<span></span>
</td>
<td class="nump">$ 1,288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059743496920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="nump">9.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059659092424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Maturity of Operating Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">1,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">4,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 3,521<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059659063032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 02, 2020 </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Oct. 28, 2020 </div>
<div>complaint</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitment, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss contingency, new claims filed, number | complaint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss contingency, number of plaintiffs | plaintiff</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059650914584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 21, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 21, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 21, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,576,988<span></span>
</td>
<td class="nump">33,749,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,576,988<span></span>
</td>
<td class="nump">33,749,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 655<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares authorized under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,361,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase percentage of maximum shares outstanding (equal to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance', window );">Additional shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,223,080<span></span>
</td>
<td class="nump">1,349,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,361,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,576<span></span>
</td>
<td class="nump">10,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AllocatedShareBasedCompensationExpenseCapitalized', window );">Capitalized share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement', window );">Issuance of common stock in connection with litigation settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643,872<span></span>
</td>
<td class="nump">186,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 655<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember', window );">Daewoong Convertible Note | Convertible Debt | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Conversion of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,136,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,136,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember', window );">A T M Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">934,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from stock offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SaleOfStockMaximumConsiderationReceivable', window );">Maximum consideration receivable | $</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage', window );">Sale of stock, commission payment upon gross proceeds</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SaleOfStockCommissionPaid', window );">Aggregate net proceeds from stock offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember', window );">A T M Sales Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">934,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember', window );">A T M Sales Agreement | Additional Paid In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eols_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from stock offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850,243<span></span>
</td>
<td class="nump">1,301,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,274<span></span>
</td>
<td class="nump">$ 2,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for unrecognized costs to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of awards vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,892<span></span>
</td>
<td class="nump">$ 1,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized costs other than options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsPerformanceConditionsMember', window );">RSUs Performance Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsMarketConditionsMember', window );">RSUs Market Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm', window );">Weighted average expected term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield rate of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(99,435)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,302<span></span>
</td>
<td class="nump">$ 7,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock option costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for unrecognized costs to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AllocatedShareBasedCompensationExpenseCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allocated Share-Based Compensation Expense Capitalized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AllocatedShareBasedCompensationExpenseCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SaleOfStockCommissionPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Commission Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SaleOfStockCommissionPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Commission Payment Upon Gross Proceeds, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SaleOfStockMaximumConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Consideration Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SaleOfStockMaximumConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares, Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodSharesLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eols_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eols_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsPerformanceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsPerformanceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsMarketConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsMarketConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059657222888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Valuation Assumptions (Details) - Common stock options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">78.90%<span></span>
</td>
<td class="nump">61.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 1 month 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059650876712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Stock Option Activity (Details) - Common stock options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">4,407,498<span></span>
</td>
<td class="nump">3,977,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">357,125<span></span>
</td>
<td class="nump">1,322,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">99,435<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares)</a></td>
<td class="num">(742,902)<span></span>
</td>
<td class="num">(892,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">3,922,286<span></span>
</td>
<td class="nump">4,407,498<span></span>
</td>
<td class="nump">3,977,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Exercisable (in shares)</a></td>
<td class="nump">2,316,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 12.20<span></span>
</td>
<td class="nump">$ 14.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">9.18<span></span>
</td>
<td class="nump">8.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">9.81<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited (in dollars per share)</a></td>
<td class="nump">16.21<span></span>
</td>
<td class="nump">15.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">11.23<span></span>
</td>
<td class="nump">$ 12.20<span></span>
</td>
<td class="nump">$ 14.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable (in dollars per share)</a></td>
<td class="nump">$ 11.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">7 years 7 months 28 days<span></span>
</td>
<td class="text">8 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term , Exercisable (Years)</a></td>
<td class="text">6 years 8 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Beginning balance</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 7,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending balance</a></td>
<td class="nump">455<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 7,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Vested and expected to vest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Outstanding (in shares)</a></td>
<td class="nump">3,922,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 11.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Average remaining contractual term (Years)</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059658877672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details) - RSUs - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">1,173,741<span></span>
</td>
<td class="nump">229,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,850,243<span></span>
</td>
<td class="nump">1,301,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(566,788)<span></span>
</td>
<td class="num">(186,870)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(530,729)<span></span>
</td>
<td class="num">(170,698)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">1,926,467<span></span>
</td>
<td class="nump">1,173,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 6.42<span></span>
</td>
<td class="nump">$ 15.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">7.94<span></span>
</td>
<td class="nump">5.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">5.08<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">7.22<span></span>
</td>
<td class="nump">7.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 8.06<span></span>
</td>
<td class="nump">$ 6.42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059663989592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,576<span></span>
</td>
<td class="nump">$ 10,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">9,372<span></span>
</td>
<td class="nump">10,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059656056456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medytox/Allergan Settlement Agreements and Daewoong Arrangement (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 23, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 18, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Sep. 15, 2025</div></th>
<th class="th"><div>Sep. 15, 2024</div></th>
<th class="th"><div>Sep. 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear', window );">Share issuance agreement, percentage of share dispose per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement', window );">Issuance of common stock in connection with litigation settlement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_DaewoongAgreementMember', window );">Daewoong Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term purchase commitment, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentInConnectionWithAgreement', window );">Contingent milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember', window );">Daewoong Convertible Note | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,779,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember', window );">Daewoong Convertible Note | Convertible Debt | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned', window );">Common stock shares beneficially own percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember', window );">Daewoong Convertible Note | Convertible Debt | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Conversion of common shares (in shares) | shares</a></td>
<td class="nump">3,136,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,136,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember', window );">Intellectual Property Disputes, Jeuveau</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LossContingencySettlementAgreementPaymentTerms', window );">Settlement agreement, payment terms (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember', window );">Intellectual Property Disputes, Jeuveau | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember', window );">Intellectual Property Disputes, Jeuveau | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Percentage of Shares Beneficially Owned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LossContingencySettlementAgreementPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Settlement Agreement, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LossContingencySettlementAgreementPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentInConnectionWithAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment In Connection With Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentInConnectionWithAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Issuance Agreement, Percentage of Share Dispose Per Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares, Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodSharesLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_DaewoongAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_DaewoongAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059662086536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contributions to 401(k) plan</a></td>
<td class="nump">$ 481<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059652751816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Current and Deferred Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred (benefit) provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred provision (benefit)</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision (benefit) for income taxes</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059657342360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to income tax matters</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">273,776,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards, subject to expiration</a></td>
<td class="nump">72,579,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">201,197,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">2,929,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">169,332,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 2,918,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059653162488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 67,039<span></span>
</td>
<td class="nump">$ 60,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">2,839<span></span>
</td>
<td class="nump">3,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Other deferred assets</a></td>
<td class="nump">2,617<span></span>
</td>
<td class="nump">2,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued compensation</a></td>
<td class="nump">4,017<span></span>
</td>
<td class="nump">2,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">893<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements', window );">Accrued legal settlement</a></td>
<td class="nump">20,276<span></span>
</td>
<td class="nump">21,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(85,527)<span></span>
</td>
<td class="num">(78,313)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred income tax assets</a></td>
<td class="nump">12,370<span></span>
</td>
<td class="nump">13,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible amortization</a></td>
<td class="num">(11,528)<span></span>
</td>
<td class="num">(12,240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(690)<span></span>
</td>
<td class="num">(873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed asset depreciation</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="num">(12,410)<span></span>
</td>
<td class="num">(13,362)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred income taxes</a></td>
<td class="num">$ (40)<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the estimated loss from legal settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059652754824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax at statutory rate</a></td>
<td class="num">$ (9,832)<span></span>
</td>
<td class="num">$ (34,217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of Federal benefit</a></td>
<td class="num">(1,872)<span></span>
</td>
<td class="num">(7,232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation', window );">Revaluation of contingent royalty obligation</a></td>
<td class="nump">1,595<span></span>
</td>
<td class="num">(513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals and entertainment</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in state tax rate</a></td>
<td class="nump">129<span></span>
</td>
<td class="num">(242)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation', window );">Officers' compensation</a></td>
<td class="nump">2,076<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount', window );">Promissory note - debt discount</a></td>
<td class="nump">120<span></span>
</td>
<td class="num">(145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingenciesOther', window );">Other, net</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">7,214<span></span>
</td>
<td class="nump">41,341<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision (benefit) for income taxes</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Officers' Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Promissory Note, Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Revaluation Of Contingent Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingenciesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in other income tax contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingenciesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059663262216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 2,924<span></span>
</td>
<td class="nump">$ 2,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases to current year tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 2,924<span></span>
</td>
<td class="nump">$ 2,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140059652784536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 14, 2017</div></th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 23, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 18, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember', window );">Daewoong Convertible Note | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember', window );">Intellectual Property Disputes, Jeuveau</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement', window );">Issuance of common stock in connection with litigation settlement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Daewoong Convertible Note | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Conversion of common shares (in shares) | shares</a></td>
<td class="nump">3,136,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,136,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember', window );">Evolus, Inc. | SCH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale', window );">Period of termination of first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount in period | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Period Of Termination Of First Commercial Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares, Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodSharesLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_SCHAEONLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>eols-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:eols="http://www.evolus.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="eols-20211231.xsd" xlink:type="simple"/>
    <context id="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4fa2f71f5a7041d1ace4d871fe10e977_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaa72dc4cee564575a0f6a6004820d124_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e4bb2c0e721463db9317bbec67a63bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8935b4319e2d40ef96ac74a02189f082_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib874ac63dd264f8fabd518dd19e7db7a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic4cecda8a60147e1a6dbe55bc70c5855_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iff1ebb6d09924e6db55a5c3231e23615_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7a339248c57c4c3fbb0a8c12261031e6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9c58ee31658f47ddb1bed8a3b81a0f35_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8472362221cf41d88c702018e38d71e8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idebc0775b4d14420bd4c6971f6b63b0b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9be00354c46b4b8b96a26749f9c3e28d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idb18fef826e14bf1b6a11208896433a1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic454c127b7694ec7929df6e51728c3f3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9496baa43c834ff9b11ec53efd6d7f91_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i618370635dad4cc09cde0158985bd9fc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff982f9041634290a7428662c88e90ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if065d88090344c76906d42f9e58f3946_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idac57e11cdc94016861bd9248bcdb528_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7dae31c8b50a4ed9834cf14ad981a07f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b072e47c4674802bf86129ee1b3d043_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib5bcb363afdf4b8db455485e8e2ad3fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic40c99d6b0a04616bf00bfc233eced25_D20210228-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-28</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i55331949261b40a1b1fb09e4158cee28_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib797f956941d4495ae3f6f4926ca7cd1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iae9c7ae95d9f43cbb4015233b65597a5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ida8a057d5f3b4f8999abff6725b2469f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9bdbef71f2046fc80639fa5cacb44eb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i19668eba2a9a432cbae4ec0e6254aa0e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b39b85b47cc450fbde4206b76345039_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i191b278dcfec47f3972561e051202c15_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ide759804fa684555b30ad8d92e40dd8f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4e49ab226c6f4296b8a462ca4e5b73d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7f853492f874d82b33dd9c2cb1fff79_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba22e2b749b44db0bac4acb2ea8a9073_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0eed27f558fa49d5b84d4d3ba1bfef2d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i861bdd7e206b435b912b799375902ac9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7a53a744c7f48d4bb28c1d16000d70f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb4365e9adeb459aa371d09c5f6def3f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia43c0d4587004db0b6f491872654d03a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic59095e4226448ca90c7c028c530b46b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf213e710f77493dadadc321fcf59639_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1a49dbd0cdc4fa299c6fc4b349cd1c9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9c22c52daf7d4250a52799a0d558499a_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i6b22c9a255f64ef69528be6cf90f2d57_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie3dc0d8eadaf4cf7918bae649c0b4261_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8655593ec8584a3a81c2026e2ac5d7f4_D20230101-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="ibdb8c8bf46044c1d94ceba9d58481dda_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ib67b7815bf86448c836c0674ab2cd400_I20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-23</instant>
        </period>
    </context>
    <context id="i67974a995ff142e8bcd737a314d25651_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i87285d3792f541dfb0b8bd76edc9ed8b_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i369b3df3ec04419fa040ca2ec1d798db_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i581d900790a24282bf837c0e06b7b5f4_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i3f2ebd8bfca6432bb520e3b56fadc096_D20210601-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="icdebbf3fdf644e34be10eab249d933bc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic3bdecfb61f64eacb1bec28f7caef51c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia035180a7f3e4b968ed0e22107620141_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if89a2df2b8e54c8d8ee79434f9442e05_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia1af8740f4504d02a822562858322d3f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic88608af4b8d44f29f8f6a890a3e0859_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="ia307b0175e9a4f089eff6272a567b599_D20210218-20210218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-18</startDate>
            <endDate>2021-02-18</endDate>
        </period>
    </context>
    <context id="i7e4a414b331e4768a456b40889b5bf16_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iec7e63cb81e2460c81caf30e8a3ecb3e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3a7d2bddc6cf450cb25bddf49c81a86d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id34ebca0dbac4892b9e26b1d887fc863_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i41ae1e1c1bad4e168f9a39b7db9fc6ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1fc31951483143dfaeb4fa1205ce3584_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6de2de54a6f5422793e33fa044c6ac61_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b5f19e8647e4e1294248e74152897f8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if36312ac79504238b5690df729b1f37c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc1dd5e647ea4c61b81e841d2fa58ac8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaaadf7ebcb2440558c596d02aa4fe18d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i188292fb611741ec93ece11f8e4d57aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2126481ac7a74980a92e9285369775dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21f2ba8ba1854a108007d265c9b25d60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie9646e12d03f4e54b9e9276d5b1d0f3a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id68d8821d04841b29a08745afac4b24a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c80b688d1614017ad7563e60cbf9695_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93faa46c660e429db8bd1d5c2859380e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81b74edf017e427b8f5b7fafd4bc3d1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i17c0c8daaf4141d78d576fc09db214fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief25c158c2d14085a69e4a3d492bdfd3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i95e8f96583894a6cb3bc3881f9f0ed7d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44f0543f775c46f490919b75592c1ee5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4297d135149943959e21307f69d5bb57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3723caf0d1864617b4ad156f12392622_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i239343ea90f94848ab298a3e8b49d754_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9aa9cf7ce6924d97b753fab0a35caffd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a3026926537414c9e558b2f48c5ac00_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i57c030fa26f84d46a809534c6d533f06_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iecd7c427bcea41a68a2333c4ab2e58f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i135354304f194b65a202352820714058_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5bcc0e46ed1c4cd4b910b9542aaeca6e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3ef09bce4de74ec69fa66b0204b03c06_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3bbaa2f404694cf09f8b1dd48adb8b5a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26cd83bcd422412f813d386ddac29197_D20190201-20190201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-01</endDate>
        </period>
    </context>
    <context id="i88606d7b76234da8a815ea40351a89f6_D20190201-20190201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-01</endDate>
        </period>
    </context>
    <context id="i58135f80c4e74590a70a971e21d37e1f_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i925e16da5e194d4986f670bfe115cfd7_I20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-14</instant>
        </period>
    </context>
    <context id="i96e618230e7d48238d27ef49600d13df_I20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-14</instant>
        </period>
    </context>
    <context id="ia0b2c7ebaf23495d8d1cc10fab315eb7_D20211214-20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-14</startDate>
            <endDate>2021-12-14</endDate>
        </period>
    </context>
    <context id="if4f1ae42ca284ea69054431a374441c1_D20211214-20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-14</startDate>
            <endDate>2021-12-14</endDate>
        </period>
    </context>
    <context id="i4ec3d79630cc4ba09ef1b19959bd91f0_D20211214-20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-14</startDate>
            <endDate>2021-12-14</endDate>
        </period>
    </context>
    <context id="i559b9a0d8aa547d0b36e58c3d536751e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id698b63e55694d648621289908e0dcbe_I20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-14</instant>
        </period>
    </context>
    <context id="i3e5503a1fc4a4988a8da895468afd601_I20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-14</instant>
        </period>
    </context>
    <context id="i0449988c955c422a849943b6ec89fe73_I20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-14</instant>
        </period>
    </context>
    <context id="i709c7ab6d38744cca0fbeb034841964d_I20190315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-15</instant>
        </period>
    </context>
    <context id="ie909f3b79bd4486daae42675b5641c62_I20190315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-15</instant>
        </period>
    </context>
    <context id="ifbb534318d9f4bd5bc4b81a523ac249b_I20190315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-15</instant>
        </period>
    </context>
    <context id="i458308c7266b440eb668d7481bd1e4b3_D20190315-20190315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-15</startDate>
            <endDate>2019-03-15</endDate>
        </period>
    </context>
    <context id="i69e7efe2c2b144989db5533678b61c21_D20190315-20190315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-15</startDate>
            <endDate>2019-03-15</endDate>
        </period>
    </context>
    <context id="idf71c87e895a46f09a7abf6657f2b04d_I20190315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-15</instant>
        </period>
    </context>
    <context id="i97c0f553670c4c3495114a22bf868a2f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b43edc16c22483086f802b6b9cf884c_I20190315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-15</instant>
        </period>
    </context>
    <context id="i4cac7bab107947c89fb60b9a19aa1ed2_D20210104-20210104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-04</endDate>
        </period>
    </context>
    <context id="iaae348537d9a4136a16f6e54e4e524a6_I20200706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-06</instant>
        </period>
    </context>
    <context id="i99d0525d0e434079b1d9eb140af4688c_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i639ff7637d4f4af7b61468f913b844be_D20201016-20201028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2020-10-16</startDate>
            <endDate>2020-10-28</endDate>
        </period>
    </context>
    <context id="id67d131284974c959850a72560bf6292_D20201127-20201202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2020-11-27</startDate>
            <endDate>2020-12-02</endDate>
        </period>
    </context>
    <context id="ibb11d4e5afdb4c27ae1e67ee48ded284_D20210325-20210325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="i63f4e91998714dab927a5acf4a92ddb8_D20210326-20210326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="i75496e7d4351422aa519e8a590bc554b_I20210326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="ic142d9a5a6964798b2bc095cf05edeb8_I20171121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2017-11-21</instant>
        </period>
    </context>
    <context id="i0caf9e9143e34777b8ae279b103a9da1_D20171121-20171121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2017-11-21</startDate>
            <endDate>2017-11-21</endDate>
        </period>
    </context>
    <context id="i517a2340d6ac4cfb8363af7585980dcf_I20211121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2021-11-21</instant>
        </period>
    </context>
    <context id="i7869351f7bde4260a08aa49ce4ef2470_I20201121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2020-11-21</instant>
        </period>
    </context>
    <context id="i68cb09998d774788979c19e4685aad8f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id708d9ed50e54617af7629252e0fa1c6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iecdda6aa05b04bfcab114de1346b4b98_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:RestrictedStockUnitsRSUsPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifd29a6c578714db49b385b4f9e60b606_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:RestrictedStockUnitsRSUsPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ef5563a248f47b9b87ca621a1f1eed8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:RestrictedStockUnitsRSUsMarketConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1da74bb1ddc84684bf5d405096cdedeb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:RestrictedStockUnitsRSUsMarketConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie061e2ccf1e04536b767f55687880f70_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia803156cd5cc4477b4ba2e43f8f8880d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1328d543a76b4257a15411d3fc978c8d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35d707ed76cb4921a043c6af35bf1696_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i42f7ff0b06244a60a0750a47b3a469a0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic78866655f1e4fb7a2d18ed23eaca432_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88950351bb5049948706e070a4d2f1ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb1c0ae2c17f459f9a60df92e9ad83ba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if4b758b9624b4b0996306bc2eeaddce7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i422b9466ee0c476e8729e37ee5d9e9d1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i68cbcb58dbd347d186d56f67bdc0d88b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i258260be7e354c3dabf4d4df2ee981e1_I20210218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-18</instant>
        </period>
    </context>
    <context id="i58d3338bb29342a7bea51d1b86c744ea_I20230915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-15</instant>
        </period>
    </context>
    <context id="i9886998085bb48b9b58c8a53127543d0_I20240915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-15</instant>
        </period>
    </context>
    <context id="ib98c7c392d2f4eaf8e8ab779dee845dd_I20250915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-15</instant>
        </period>
    </context>
    <context id="i002a56e0c1ec4c04b5999635912fcdc8_D20210323-20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-23</startDate>
            <endDate>2021-03-23</endDate>
        </period>
    </context>
    <context id="i75469af343584e09847fb0027c3e78c7_D20210323-20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-23</startDate>
            <endDate>2021-03-23</endDate>
        </period>
    </context>
    <context id="if65ecdee742e445f89295c829f75efac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff738c7de2844195a714ca1b57f846c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa6947c0461b47158a26475a99eabf01_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4b16f01a5f7415687373739c3bf5523_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a37e00a5294439283de4636c2dc8b56_D20171214-20171214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-14</startDate>
            <endDate>2017-12-14</endDate>
        </period>
    </context>
    <context id="ib72da45d6b9e4dfd9eaea3fd7a90255c_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="reporting_unit">
        <measure>eols:reporting_unit</measure>
    </unit>
    <unit id="year">
        <measure>eols:year</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="tranche">
        <measure>eols:tranche</measure>
    </unit>
    <unit id="payment">
        <measure>eols:payment</measure>
    </unit>
    <unit id="advance">
        <measure>eols:advance</measure>
    </unit>
    <unit id="complaint">
        <measure>eols:complaint</measure>
    </unit>
    <unit id="plaintiff">
        <measure>eols:plaintiff</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl80L2ZyYWc6YTc2Y2EwNmJmZGExNDgwMDg0NjBmMWNjYjExNTYzMmYvdGFibGU6M2QwMTI5NGUwY2ZlNGNmNmEwOGI5OGJjMGQ2Y2EwMGYvdGFibGVyYW5nZTozZDAxMjk0ZTBjZmU0Y2Y2YTA4Yjk4YmMwZDZjYTAwZl8yLTEtMS0xLTI0Njk3_74df87d4-d24a-4062-9daf-7364c28aad83">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl80L2ZyYWc6YTc2Y2EwNmJmZGExNDgwMDg0NjBmMWNjYjExNTYzMmYvdGFibGU6M2QwMTI5NGUwY2ZlNGNmNmEwOGI5OGJjMGQ2Y2EwMGYvdGFibGVyYW5nZTozZDAxMjk0ZTBjZmU0Y2Y2YTA4Yjk4YmMwZDZjYTAwZl80LTEtMS0xLTI0Njk3_e8344e00-c296-477d-a1a1-bc689559faf6">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl80L2ZyYWc6YTc2Y2EwNmJmZGExNDgwMDg0NjBmMWNjYjExNTYzMmYvdGFibGU6M2QwMTI5NGUwY2ZlNGNmNmEwOGI5OGJjMGQ2Y2EwMGYvdGFibGVyYW5nZTozZDAxMjk0ZTBjZmU0Y2Y2YTA4Yjk4YmMwZDZjYTAwZl81LTEtMS0xLTI0Njk3_5099efe3-41fe-4d4a-a40a-ca2369847dce">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl80L2ZyYWc6YTc2Y2EwNmJmZGExNDgwMDg0NjBmMWNjYjExNTYzMmYvdGFibGU6M2QwMTI5NGUwY2ZlNGNmNmEwOGI5OGJjMGQ2Y2EwMGYvdGFibGVyYW5nZTozZDAxMjk0ZTBjZmU0Y2Y2YTA4Yjk4YmMwZDZjYTAwZl84LTEtMS0xLTI0Njk3_f21de7f7-160c-4a69-bd79-fb58af3b4f35">0001570562</dei:EntityCentralIndexKey>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfOS0wLTEtMS0yNDY5Nw_88e79aa4-bc34-4d38-bbd8-aeec1c06ccdf">http://fasb.org/us-gaap/2021-01-31#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfOS0wLTEtMS0yNDY5Nw_bbfa6ccc-bec5-4fce-81ec-f28ff59e01f1">http://fasb.org/us-gaap/2021-01-31#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i68cb09998d774788979c19e4685aad8f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE3MzI_fb117ad8-2568-44c6-bb64-c540497d2484">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNDk4_d9286a33-6ae7-438f-a11e-f1defd658898">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNDk1_8aa7e4eb-9f5f-4e93-bcbc-4eac1840e2fd">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zMjk4NTM0ODg2OTI4_6d3ac15a-b300-400c-8d1e-f7dc8c2c5c9b">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zMjk4NTM0ODg2OTI4_3b045ff2-414d-43e0-b828-5b1172095d0c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNTA3_04bd61ad-1d1a-4cc7-8018-88f9824949f1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNTAz_53ca8415-9bc3-4fb1-a9d5-1ba613010af4">001-38381</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNDk5_bb927288-6cc7-4112-ad32-878c411ebf2e">EVOLUS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YTQ2NjQ3NjNlMDIzNDk4ZGEwODhhNjRlM2FlNThjNWIvdGFibGVyYW5nZTphNDY2NDc2M2UwMjM0OThkYTA4OGE2NGUzYWU1OGM1Yl8wLTAtMS0xLTI0Njk3_abb789d5-6e78-4496-84c2-e9ea914391ce">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YTQ2NjQ3NjNlMDIzNDk4ZGEwODhhNjRlM2FlNThjNWIvdGFibGVyYW5nZTphNDY2NDc2M2UwMjM0OThkYTA4OGE2NGUzYWU1OGM1Yl8wLTItMS0xLTI0Njk3_5e39c71a-c0fa-49b3-9be4-ee23250693e3">46-1385614</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YTQ2NjQ3NjNlMDIzNDk4ZGEwODhhNjRlM2FlNThjNWIvdGFibGVyYW5nZTphNDY2NDc2M2UwMjM0OThkYTA4OGE2NGUzYWU1OGM1Yl8yLTEtMS0xLTI0Njk3L3RleHRyZWdpb246YTEyZWJiMTAxYmZhNDZjNzlkZTU4MDg0OTdlY2EzMzFfNA_b4f380c2-8808-445a-a505-2204882db4b1">520 Newport Center Dr., Suite 1200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YTQ2NjQ3NjNlMDIzNDk4ZGEwODhhNjRlM2FlNThjNWIvdGFibGVyYW5nZTphNDY2NDc2M2UwMjM0OThkYTA4OGE2NGUzYWU1OGM1Yl8yLTEtMS0xLTI0Njk3L3RleHRyZWdpb246YTEyZWJiMTAxYmZhNDZjNzlkZTU4MDg0OTdlY2EzMzFfNw_8f646d3a-2efe-4e50-8420-e76703de28bb">Newport Beach</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YTQ2NjQ3NjNlMDIzNDk4ZGEwODhhNjRlM2FlNThjNWIvdGFibGVyYW5nZTphNDY2NDc2M2UwMjM0OThkYTA4OGE2NGUzYWU1OGM1Yl8yLTEtMS0xLTI0Njk3L3RleHRyZWdpb246YTEyZWJiMTAxYmZhNDZjNzlkZTU4MDg0OTdlY2EzMzFfMTE_5cc76cef-182d-4aa1-8f95-26e9da3fccfa">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YTQ2NjQ3NjNlMDIzNDk4ZGEwODhhNjRlM2FlNThjNWIvdGFibGVyYW5nZTphNDY2NDc2M2UwMjM0OThkYTA4OGE2NGUzYWU1OGM1Yl8yLTEtMS0xLTI0Njk3L3RleHRyZWdpb246YTEyZWJiMTAxYmZhNDZjNzlkZTU4MDg0OTdlY2EzMzFfMTQ_ea5dc133-298c-4eca-a799-58ea1257fd87">92660</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YTQ2NjQ3NjNlMDIzNDk4ZGEwODhhNjRlM2FlNThjNWIvdGFibGVyYW5nZTphNDY2NDc2M2UwMjM0OThkYTA4OGE2NGUzYWU1OGM1Yl8yLTEtMS0xLTI0Njk3L3RleHRyZWdpb246YTEyZWJiMTAxYmZhNDZjNzlkZTU4MDg0OTdlY2EzMzFfMTg_39dc62b6-7a7e-41f1-a8be-ef5e39860ea6">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YTQ2NjQ3NjNlMDIzNDk4ZGEwODhhNjRlM2FlNThjNWIvdGFibGVyYW5nZTphNDY2NDc2M2UwMjM0OThkYTA4OGE2NGUzYWU1OGM1Yl8yLTEtMS0xLTI0Njk3L3RleHRyZWdpb246YTEyZWJiMTAxYmZhNDZjNzlkZTU4MDg0OTdlY2EzMzFfMjI_8cfcbf75-de9c-48aa-930f-792698cdc192">284-4555</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6Y2E1NzQxZTRmODU3NGZkMmI5ZTlmMGQ1NmI4NGQ2YzEvdGFibGVyYW5nZTpjYTU3NDFlNGY4NTc0ZmQyYjllOWYwZDU2Yjg0ZDZjMV8yLTAtMS0xLTI0Njk3_7b0d2378-723c-493c-902c-785a1ee81a52">Common Stock, $0.00001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6Y2E1NzQxZTRmODU3NGZkMmI5ZTlmMGQ1NmI4NGQ2YzEvdGFibGVyYW5nZTpjYTU3NDFlNGY4NTc0ZmQyYjllOWYwZDU2Yjg0ZDZjMV8yLTEtMS0xLTI0Njk3_533ff849-5c19-4f30-ac3d-db7f8f6386cd">EOLS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6Y2E1NzQxZTRmODU3NGZkMmI5ZTlmMGQ1NmI4NGQ2YzEvdGFibGVyYW5nZTpjYTU3NDFlNGY4NTc0ZmQyYjllOWYwZDU2Yjg0ZDZjMV8yLTItMS0xLTI0Njk3_5428be29-5d88-499b-b540-1c6622b635c8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNTA1_72744ac7-e12a-48ba-89c2-c25c0adbfeb4">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNTA0_e3d67385-967a-456b-be6c-5c6734515af3">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNDk3_e84c041d-553a-477f-83b9-8df5e227f275">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNTAw_867c4a2d-9f08-41f9-97c1-59bd722489e0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YzdjMzhkZThlZmI5NDk1YmEzZjRkMjljNjFmOTM5MDEvdGFibGVyYW5nZTpjN2MzOGRlOGVmYjk0OTViYTNmNGQyOWM2MWY5MzkwMV8yLTAtMS0xLTI0Njk3_1536bf97-e22c-440c-9631-7f32c294ce23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YzdjMzhkZThlZmI5NDk1YmEzZjRkMjljNjFmOTM5MDEvdGFibGVyYW5nZTpjN2MzOGRlOGVmYjk0OTViYTNmNGQyOWM2MWY5MzkwMV8yLTMtMS0xLTI0Njk3_14aef32c-223f-40dd-8e7a-f1a3a8c4fe4e">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGFibGU6YzdjMzhkZThlZmI5NDk1YmEzZjRkMjljNjFmOTM5MDEvdGFibGVyYW5nZTpjN2MzOGRlOGVmYjk0OTViYTNmNGQyOWM2MWY5MzkwMV8zLTMtMS0xLTI0Njk3_a58136e4-718f-4003-b9c9-c01b5919236e">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNDk2_e577062b-ac89-451e-8408-05a9a96ff4e5">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNTAx_8276c257-33d9-401f-bb64-680440762b74">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zMjk4NTM0ODg2OTQ2_ca85489e-9ef6-45a6-b157-a53078b6e8c8">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i4fa2f71f5a7041d1ace4d871fe10e977_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8yODkw_63546625-21df-4bf2-8c51-408ebb78f88e"
      unitRef="usd">423200000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="iaa72dc4cee564575a0f6a6004820d124_I20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8xMDk5NTExNjMxMzI2_ac19b21a-a6d5-4f9d-9974-e96535e33189"
      unitRef="shares">55694452</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xL2ZyYWc6ZjFmYThhNzhiZWMxNDg0MjhlNDhjOWUzMWNhNWY2OTAvdGV4dHJlZ2lvbjpmMWZhOGE3OGJlYzE0ODQyOGU0OGM5ZTMxY2E1ZjY5MF8zNTAy_83e7ed89-93dc-43f0-9d25-fd0f7d6e537e">Portions of the registrant's Proxy Statement for the 2022 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December&#160;31, 2021.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83MC9mcmFnOjQ4NmMwZjUwODBkZTQ4OGM5N2Y4MzhmZTY2OGI3YmQ5L3RhYmxlOjRiNmViMjViMDNiMjQwODc5NjIzYmQ3ZWY3OTM5NzkxL3RhYmxlcmFuZ2U6NGI2ZWIyNWIwM2IyNDA4Nzk2MjNiZDdlZjc5Mzk3OTFfMS0wLTEtMS0zOTIxOC90ZXh0cmVnaW9uOjcwMTc3NzMyZjExNjRhZjJhMTU3ZjVhOTYxMmNmNDk3XzMyOTg1MzQ4ODM0MTA_9ff647d4-2077-488a-a759-cfa2f14a8707">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83My9mcmFnOmMyOGUxNDNiMDBkMTQyOTQ5ZGVhYThiNzMxNTE4N2Q5L3RhYmxlOjhjYzZhYjU0MzliZjRjNzY4YmY5ZmE2NWYzNzVhNDY1L3RhYmxlcmFuZ2U6OGNjNmFiNTQzOWJmNGM3NjhiZjlmYTY1ZjM3NWE0NjVfMC0xLTEtMS0zOTIyMi90ZXh0cmVnaW9uOjVkY2MwOTZlZjAzMDQzM2M4MTA1MTVlMjE2Mjg5N2E1XzMyOTg1MzQ4ODMzNzA_ea406d11-2b3d-41a7-9110-1712883cfdd5">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83My9mcmFnOmMyOGUxNDNiMDBkMTQyOTQ5ZGVhYThiNzMxNTE4N2Q5L3RleHRyZWdpb246YzI4ZTE0M2IwMGQxNDI5NDlkZWFhOGI3MzE1MTg3ZDlfMzI5ODUzNDg4Njc1NQ_20539ded-907d-4afa-ba7e-af5fb67cc74d">Irvine, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNC0xLTEtMS0yNDY5Nw_8d8d466f-d942-480a-8042-7a8187b1f693"
      unitRef="usd">146256000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNC0zLTEtMS0yNDY5Nw_75410dad-5ab0-4bdb-94c4-2439e8eed353"
      unitRef="usd">102562000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNS0xLTEtMS0yNDY5Nw_c72884e1-ea77-4738-8e65-af3faa19139a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNS0zLTEtMS0yNDY5Nw_b73c1ec3-0241-4688-8545-0218a03f607f"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNi0xLTEtMS0yNDY5Nw_f6d88153-a4bc-47a7-841e-33a8d8de9ea9"
      unitRef="usd">14657000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNi0zLTEtMS0yNDY5Nw_de1db430-5a9e-426b-999d-a77e2b0aae0e"
      unitRef="usd">9680000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNy0xLTEtMS0yNDY5Nw_d4fc6836-66da-48ef-904b-09b88d8f4a24"
      unitRef="usd">1762000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNy0zLTEtMS0yNDY5Nw_147cd452-7f86-49ed-9bd9-223681c3ac5d"
      unitRef="usd">3354000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfOC0xLTEtMS0yNDY5Nw_d2872fc1-a55c-4d58-8698-ca3db7716301"
      unitRef="usd">5082000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfOC0zLTEtMS0yNDY5Nw_ccfad016-6437-4159-b3dc-e4d8e7b16ac1"
      unitRef="usd">4828000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfOS0xLTEtMS0zMDM3Nw_c0fa29da-be43-40cd-8242-f7af7bc4c634"
      unitRef="usd">11042000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfOS0zLTEtMS0yNzk0Ng_2e932be6-a0ec-44be-ac4c-eb9436e3787a"
      unitRef="usd">2188000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfOS0xLTEtMS0yNDY5Nw_956aa0cf-7b7a-4fd4-975c-3528454c828c"
      unitRef="usd">178799000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfOS0zLTEtMS0yNDY5Nw_0961f8e7-f244-4f6a-8a71-1cfde362ac6c"
      unitRef="usd">127612000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTAtMS0xLTEtMjQ2OTc_485778f8-5fa2-4948-af72-930072a64986"
      unitRef="usd">1371000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTAtMy0xLTEtMjQ2OTc_58c616ca-936b-44c5-81a9-0296daf699a1"
      unitRef="usd">1297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTItMS0xLTEtMjQ2OTc_2481c940-0a9b-46be-a3f8-495d2a6e5a25"
      unitRef="usd">2722000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTItMy0xLTEtMjQ2OTc_6128b558-796f-43c8-b416-a3de8c3c14f6"
      unitRef="usd">3414000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTMtMS0xLTEtMjQ2OTc_50c28993-f1df-48e5-b018-d2ce7743d30b"
      unitRef="usd">50625000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTMtMy0xLTEtMjQ2OTc_d6a761d4-6ef1-4553-b6e2-9bc96f9eb827"
      unitRef="usd">55297000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTQtMS0xLTEtMjQ2OTc_d03f1f77-9daa-48ec-ad25-7ebf675195dc"
      unitRef="usd">21208000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTQtMy0xLTEtMjQ2OTc_9ec99555-e907-48ed-b5bd-6f765fa2e342"
      unitRef="usd">21208000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTUtMS0xLTEtMjQ2OTc_888a0625-7353-4c05-9655-78c3feb337a4"
      unitRef="usd">2758000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTUtMy0xLTEtMjQ2OTc_4c2d3b07-320c-4e15-8edb-a6fa2f070973"
      unitRef="usd">240000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTYtMS0xLTEtMjQ2OTc_81e79c82-8508-4593-9b65-7fe2aa291879"
      unitRef="usd">257483000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTYtMy0xLTEtMjQ2OTc_dff6e78e-d689-4f82-af85-1a16cfdd4bc7"
      unitRef="usd">209068000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTktMS0xLTEtMjQ2OTc_cd574ec4-a524-4448-a90f-d25623dec31b"
      unitRef="usd">6091000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMTktMy0xLTEtMjQ2OTc_2f5822f5-3728-46cc-a512-3c1345f25a1c"
      unitRef="usd">9615000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjItMS0xLTEtMjQ2OTc_25400266-9e3d-47e1-8c7f-d409d1fff152"
      unitRef="usd">29993000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjItMy0xLTEtMjQ2OTc_2847f1fa-22f3-474f-9828-8073200994cf"
      unitRef="usd">9102000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjMtMS0xLTEtMjQ2OTc_86b9e62c-1705-4bd8-8770-1b1eb8af7436"
      unitRef="usd">15000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjMtMy0xLTEtMjQ2OTc_25d84597-d20e-47b5-9d16-617fd0c19505"
      unitRef="usd">63421000</us-gaap:LitigationReserveCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjQtMS0xLTEtMjQ2OTc_03440f0b-fbcd-4ab5-a13a-95d7349c9443"
      unitRef="usd">1265000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjQtMy0xLTEtMjQ2OTc_140338db-20eb-4c62-b530-a5dae3028715"
      unitRef="usd">1212000</us-gaap:OperatingLeaseLiabilityCurrent>
    <eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjUtMS0xLTEtMjQ2OTc_10821f8c-6823-44dd-980e-08c38343d7ec"
      unitRef="usd">5314000</eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent>
    <eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjUtMy0xLTEtMjQ2OTc_82e103aa-11ba-4172-9ae4-fe1d5b76e41b"
      unitRef="usd">3446000</eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjYtMS0xLTEtMjQ2OTc_55ada439-39e8-4481-87dc-8c2af7469ae9"
      unitRef="usd">0</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjYtMy0xLTEtMjQ2OTc_bc39979d-5b0c-4bb7-a75d-d0ad6cc00574"
      unitRef="usd">19068000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:SecuredDebtCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjctMS0xLTEtMjQ2OTc_a4d5b46a-99dd-4132-bb54-4eff9c2cd528"
      unitRef="usd">0</us-gaap:SecuredDebtCurrent>
    <us-gaap:SecuredDebtCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjctMy0xLTEtMjQ2OTc_37be1a17-1cea-4e54-bd11-de2581837057"
      unitRef="usd">74384000</us-gaap:SecuredDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjgtMS0xLTEtMjQ2OTc_d9e2ad6d-863c-4c02-ba23-310671b0316f"
      unitRef="usd">57663000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjgtMy0xLTEtMjQ2OTc_33a1e85f-0915-4d26-9d1a-864701081d04"
      unitRef="usd">180248000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LitigationReserveNoncurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjktMS0xLTEtMjQ2OTc_7a042829-d316-47dc-a28d-6163ba515657"
      unitRef="usd">5000000</us-gaap:LitigationReserveNoncurrent>
    <us-gaap:LitigationReserveNoncurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMjktMy0xLTEtMjQ2OTc_9acb5a4f-51c4-406d-891d-9068089b4cea"
      unitRef="usd">20000000</us-gaap:LitigationReserveNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzAtMS0xLTEtMjQ2OTc_5a25241f-3189-4ae5-aca5-6f58dec88f5a"
      unitRef="usd">2256000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzAtMy0xLTEtMjQ2OTc_a73d22a6-c5d2-48fe-ac27-7b812b237613"
      unitRef="usd">3147000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractualObligation
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzEtMS0xLTEtMjQ2OTc_46f6041f-385c-4c9a-ab29-8e317ad12461"
      unitRef="usd">39426000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzEtMy0xLTEtMjQ2OTc_90990c2c-ee44-46e6-a201-451d2d5eca46"
      unitRef="usd">38100000</us-gaap:ContractualObligation>
    <us-gaap:SecuredLongTermDebt
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzMtMS0xLTEtMzc1OTI_7874359c-ca3c-4e5b-9b37-dcd97e75797f"
      unitRef="usd">71222000</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzMtMy0xLTEtMzc1OTI_650f8d3a-9456-42e1-9afa-19e10127bbeb"
      unitRef="usd">0</us-gaap:SecuredLongTermDebt>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzQtMS0xLTEtMjQ2OTc_a36059e1-0101-406d-b716-d9c7dab1c239"
      unitRef="usd">0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzQtMy0xLTEtMjQ2OTc_b705426c-edee-403e-845d-d556da40174a"
      unitRef="usd">40506000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzUtMS0xLTEtMjQ2OTc_74a6dc48-874a-4c45-90be-31856674d7df"
      unitRef="usd">40000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzUtMy0xLTEtMjQ2OTc_d5ffe047-e3ce-47c3-988f-4deece566790"
      unitRef="usd">25000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzYtMS0xLTEtMjQ2OTc_aa887844-a6f5-4de9-a86d-59dfc323ee69"
      unitRef="usd">175607000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzYtMy0xLTEtMjQ2OTc_227d0d2b-af48-4f40-87ca-5c652ba9bf07"
      unitRef="usd">282026000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzctMS0xLTEtMjQ2OTc_2738e5ec-5176-4313-a7f2-9a37b7812eff"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfMzctMy0xLTEtMjQ2OTc_7993e775-a787-4361-b3ea-2f8d5b542512"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjpmYTJiNzUxMTI5NzU0MzRhOGVmNzQyYmNhOTIxNDJiN18yMQ_893bc3a2-78bd-40cf-b0e8-692ccde811b8"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjpmYTJiNzUxMTI5NzU0MzRhOGVmNzQyYmNhOTIxNDJiN18yMQ_df503efc-cfca-44f5-9eae-fb64da60ffc3"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjpmYTJiNzUxMTI5NzU0MzRhOGVmNzQyYmNhOTIxNDJiN18zNQ_139dc042-42d4-40cc-848f-2316e8d4e8ba"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjpmYTJiNzUxMTI5NzU0MzRhOGVmNzQyYmNhOTIxNDJiN18zNQ_4814a95c-e7d2-4608-a225-f7def44a78da"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjpmYTJiNzUxMTI5NzU0MzRhOGVmNzQyYmNhOTIxNDJiN181Nw_1116df36-1b41-4fcd-81f2-784318712a93"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjpmYTJiNzUxMTI5NzU0MzRhOGVmNzQyYmNhOTIxNDJiN181Nw_32984a35-ee88-440a-be6f-8b95946942c7"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjpmYTJiNzUxMTI5NzU0MzRhOGVmNzQyYmNhOTIxNDJiN181Nw_b9f65947-b46e-4911-98c1-8fa7cc378b73"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjpmYTJiNzUxMTI5NzU0MzRhOGVmNzQyYmNhOTIxNDJiN181Nw_c1d30c2f-bf3b-4e1d-b529-8472c9b416f4"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMS0xLTEtMjQ2OTc_519d7c46-901a-48c9-b474-470bbff315f8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDAtMy0xLTEtMjQ2OTc_030d0ce3-f3be-46a7-b419-f533411b615c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjozNjMxMzJiMzBmMGE0YmEwYjg2NTQ2NzE0ZDExNDliYV8xOA_28ff7473-ec30-492d-a495-290dc565d76a"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjozNjMxMzJiMzBmMGE0YmEwYjg2NTQ2NzE0ZDExNDliYV8xOA_3c288fea-c326-4f33-bb0c-5c15a0c74b1e"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjozNjMxMzJiMzBmMGE0YmEwYjg2NTQ2NzE0ZDExNDliYV8zMg_54c3811a-6a51-4143-9748-72382377ec17"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjozNjMxMzJiMzBmMGE0YmEwYjg2NTQ2NzE0ZDExNDliYV8zMg_af3ac09c-c2b7-45e2-a71b-24ff2bd96dfa"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjozNjMxMzJiMzBmMGE0YmEwYjg2NTQ2NzE0ZDExNDliYV8xNjQ5MjY3NDQxODU1_806dcf99-f8a9-46c7-9438-e079f7ae4bd8"
      unitRef="shares">55576988</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjozNjMxMzJiMzBmMGE0YmEwYjg2NTQ2NzE0ZDExNDliYV8xNjQ5MjY3NDQxODU1_bba46a71-0684-417f-9da1-de05dac3f583"
      unitRef="shares">55576988</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjozNjMxMzJiMzBmMGE0YmEwYjg2NTQ2NzE0ZDExNDliYV8xNjQ5MjY3NDQxODU5_227f836f-dc57-4573-99cb-9525600e6bf2"
      unitRef="shares">33749228</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMC0xLTEtMjQ2OTcvdGV4dHJlZ2lvbjozNjMxMzJiMzBmMGE0YmEwYjg2NTQ2NzE0ZDExNDliYV8xNjQ5MjY3NDQxODU5_44b1464a-f022-49c5-83da-0df241bced77"
      unitRef="shares">33749228</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMS0xLTEtMjQ2OTc_f8e5dd36-c6d6-44e8-b6a4-3caec159d9f2"
      unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDEtMy0xLTEtMjQ2OTc_5adc8181-465f-4d4b-8e28-3431a37d77ce"
      unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDItMS0xLTEtMjQ2OTc_30746a3c-230b-4d98-a27f-e446139db3b8"
      unitRef="usd">504757000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDItMy0xLTEtMjQ2OTc_575a1a1d-674e-435c-9fb4-44ce7c8a3d6a"
      unitRef="usd">303113000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDQtMS0xLTEtMjQ2OTc_d69e93e6-74ac-493c-b6d2-08cc2d3f0310"
      unitRef="usd">-422882000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDQtMy0xLTEtMjQ2OTc_1c70a4bc-02ee-4e40-98e7-7de3b8ccfac3"
      unitRef="usd">-376072000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDUtMS0xLTEtMjQ2OTc_4f135843-f85e-4631-8123-18eb7132e6ab"
      unitRef="usd">81876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDUtMy0xLTEtMjQ2OTc_c8cf20e5-bdff-4d67-a2a1-a6fdb2e0fde5"
      unitRef="usd">-72958000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDYtMS0xLTEtMjQ2OTc_308040b4-8d50-47c8-b6b1-02a60263df0b"
      unitRef="usd">257483000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl83Ni9mcmFnOjIwNWJlMTM5YTRhODQ5NzY5YjYyMTE1MzdmZjE4NzdmL3RhYmxlOmEyYTUxMWQyMzA3YTQ0YjhhNzZmZWRmODM5MWIwYzIyL3RhYmxlcmFuZ2U6YTJhNTExZDIzMDdhNDRiOGE3NmZlZGY4MzkxYjBjMjJfNDYtMy0xLTEtMjQ2OTc_6a538440-bfae-4698-8d8c-08b3fc751028"
      unitRef="usd">209068000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8935b4319e2d40ef96ac74a02189f082_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfNC0xLTEtMS0yNDY5Nw_33719b85-9ce4-4259-a7ae-f76f09f12152"
      unitRef="usd">98971000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib874ac63dd264f8fabd518dd19e7db7a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfNC0zLTEtMS0yNDY5Nw_fc10a82f-41bd-478f-9aef-8600d2a6672e"
      unitRef="usd">55802000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4cecda8a60147e1a6dbe55bc70c5855_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfNS0xLTEtMS0yNDY5Nw_62332eca-1cb7-43a0-8331-106f69378ae9"
      unitRef="usd">702000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff1ebb6d09924e6db55a5c3231e23615_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfNS0zLTEtMS0yNDY5Nw_a17dac92-ed62-4f3f-acf1-f3b5743b9c45"
      unitRef="usd">738000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfNi0xLTEtMS0yNDY5Nw_a5fcc44a-9b26-4799-8736-b8115657252d"
      unitRef="usd">99673000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfNi0zLTEtMS0yNDY5Nw_a6ece64b-8935-483b-98d2-7fa67fe7345a"
      unitRef="usd">56540000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfOS0xLTEtMS0yNDY5Nw_e3f31cc5-3434-4c4e-8bcb-f823e56288e4"
      unitRef="usd">43534000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfOS0zLTEtMS0yNDY5Nw_ad2459ab-517c-451c-bbd6-2d588984b45d"
      unitRef="usd">18299000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTAtMS0xLTEtMzQ4Mzk_bb846b4a-0789-4f87-af8b-219983bb0b48"
      unitRef="usd">25500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTAtMy0xLTEtMzQ4Mzk_f8fb2171-22c2-42aa-ac48-83727688e5fb"
      unitRef="usd">0</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTAtMS0xLTEtMjQ2OTc_a92481fb-2f3f-4c80-bdf6-d89939c75508"
      unitRef="usd">112068000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTAtMy0xLTEtMjQ2OTc_342f645e-e86d-47b0-9b9d-ff4857586670"
      unitRef="usd">98190000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTEtMS0xLTEtMjQ2OTc_b0cf94d9-6581-4e7f-b126-245378ad6abc"
      unitRef="usd">2064000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTEtMy0xLTEtMjQ2OTc_5728ffcd-eda9-479d-9960-ae8ce4ad0b80"
      unitRef="usd">1722000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTItMS0xLTEtMjQ2OTc_29ba470d-48b0-4f9e-816d-b27a393ecef0"
      unitRef="usd">-6290000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTItMy0xLTEtMjQ2OTc_6ceaa7d1-6626-4e21-a1fc-14c13f404094"
      unitRef="usd">2007000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTMtMS0xLTEtMjQ2OTc_43c83079-ab82-4627-a7ce-ff3ad05502d9"
      unitRef="usd">5622000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTMtMy0xLTEtMjQ2OTc_8cd03709-dbaf-4726-9dc0-370ba53bd45f"
      unitRef="usd">7027000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:LitigationSettlementExpense
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTQtMS0xLTEtMjQ2OTc_a771b460-d925-4313-b9dc-3fe2fced1271"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTQtMy0xLTEtMjQ2OTc_2a0511ba-f098-4b45-8035-45a63178bc81"
      unitRef="usd">83421000</us-gaap:LitigationSettlementExpense>
    <us-gaap:RestructuringCharges
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTUtMS0xLTEtMjQ2OTc_ac5bf79c-4e96-43c4-a644-c5c5ca8d7ee5"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTUtMy0xLTEtMjQ2OTc_81e0245a-e9f6-42e1-b282-de672a921f25"
      unitRef="usd">2956000</us-gaap:RestructuringCharges>
    <us-gaap:CostsAndExpenses
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTYtMS0xLTEtMjQ2OTc_f600d468-4343-450a-ab5c-4c57366f5323"
      unitRef="usd">144078000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTYtMy0xLTEtMjQ2OTc_d1d238e2-13ed-4d22-89d2-14ab303a2a0c"
      unitRef="usd">209608000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTctMS0xLTEtMjQ2OTc_fb84da04-c7ee-4775-92cb-03041d371707"
      unitRef="usd">-44405000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTctMy0xLTEtMjQ2OTc_55a108e2-0937-4884-aa68-fa84a84fec56"
      unitRef="usd">-153068000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTktMS0xLTEtMjQ2OTc_0a983321-90b4-4b2c-82c4-5973c4788e89"
      unitRef="usd">1000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMTktMy0xLTEtMjQ2OTc_b31497bc-212d-4cdd-8015-276956e36149"
      unitRef="usd">635000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjAtMS0xLTEtMjQ2OTc_8f3575a2-3a32-4849-95ec-3ec2b57de2c5"
      unitRef="usd">-1396000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjAtMy0xLTEtMjQ2OTc_ba52fc41-5c4a-4db0-901d-078ae79176ef"
      unitRef="usd">-10503000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjEtMS0xLTEtMjg3ODk_f0f9be40-4b85-4243-a339-42fcb91e3712"
      unitRef="usd">-968000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjEtMy0xLTEtMjg3OTY_100569a5-0ce6-489b-986c-ac009467cc16"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjItMS0xLTEtMjQ2OTc_bf4165f7-94ae-4215-b444-40c96225819f"
      unitRef="usd">-46768000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjItMy0xLTEtMjQ2OTc_3528ebd0-6e26-410b-9b34-3fbbce70eec8"
      unitRef="usd">-162936000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjMtMS0xLTEtMjQ2OTc_c63770f3-92ea-425c-8432-c7f6422f7479"
      unitRef="usd">42000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjMtMy0xLTEtMjQ2OTc_4c5ee0dc-6c67-4fa4-a1f6-d7a1eb3699b8"
      unitRef="usd">77000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjQtMS0xLTEtMjQ2OTc_cb1d55ba-ccd7-4fc6-9b1b-77b3ab9891a8"
      unitRef="usd">-46810000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjQtMy0xLTEtMjQ2OTc_e18d7bcf-f85b-42e4-9051-c07f43981587"
      unitRef="usd">-163013000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjYtMS0xLTEtMjQ2OTc_9751c160-8a39-4933-a7bf-e228d6db753f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjYtMy0xLTEtMjQ2OTc_c0787e46-87cc-4436-b519-32b6e20594e3"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjctMS0xLTEtMjQ2OTc_1ad9c99a-0ac3-4ad0-9835-66408b10e72e"
      unitRef="usd">-46810000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjctMy0xLTEtMjQ2OTc_a652c052-9c27-4e3b-b249-a392dcfc6908"
      unitRef="usd">-163019000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjgtMS0xLTEtMjQ2OTc_33e11ff9-220d-4ca2-964c-19fdbfa92a24"
      unitRef="usdPerShare">-0.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjgtMS0xLTEtMjQ2OTc_8c4979f8-f2c9-4157-b559-b9628085fac7"
      unitRef="usdPerShare">-0.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjgtMy0xLTEtMjQ2OTc_15522681-abac-4412-a309-4b0483c7c7e3"
      unitRef="usdPerShare">-4.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjgtMy0xLTEtMjQ2OTc_5e44196f-bbb6-4226-98ca-00ca3692237c"
      unitRef="usdPerShare">-4.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjktMS0xLTEtMjQ2OTc_0b505e87-7bc8-4db3-9d90-b236e6b3e75d"
      unitRef="shares">49773101</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjktMS0xLTEtMjQ2OTc_83b334dc-924c-4a80-abfe-910c8a977fc1"
      unitRef="shares">49773101</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjktMy0xLTEtMjQ2OTc_72fdaa4d-c268-4212-a635-a7684fbd2511"
      unitRef="shares">33737838</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84Mi9mcmFnOjc2MWFhY2E2OGQ0OTQyOTY4ZDcxZjc4NWFmNjZmNDAyL3RhYmxlOjcwZTBlNzgyZTQ0YzQxZWNhYjk1YTIzNzEzMTcxNDI5L3RhYmxlcmFuZ2U6NzBlMGU3ODJlNDRjNDFlY2FiOTVhMjM3MTMxNzE0MjlfMjktMy0xLTEtMjQ2OTc_733a1629-7f95-429e-803b-be760f8429b1"
      unitRef="shares">33737838</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="i7a339248c57c4c3fbb0a8c12261031e6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOC0xLTEtMS0yNDY5Nw_2d9dd743-0bd5-4a00-a466-5d67913131a7"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i7a339248c57c4c3fbb0a8c12261031e6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOC0zLTEtMS0yNDY5Nw_12a6c83a-9b5e-4d7a-b2fb-25be693b21c1"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i9c58ee31658f47ddb1bed8a3b81a0f35_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOC01LTEtMS0yNDY5Nw_1b615c64-863c-4cfd-a7b7-231cd15139e2"
      unitRef="shares">33562665</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i9c58ee31658f47ddb1bed8a3b81a0f35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOC03LTEtMS0yNDY5Nw_04646d39-8bf3-449f-b25b-59be84ce5c5e"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8472362221cf41d88c702018e38d71e8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOC05LTEtMS0yNDY5Nw_5d13bc1f-4a9e-4517-b674-57cbc5c79447"
      unitRef="usd">292509000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idebc0775b4d14420bd4c6971f6b63b0b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOC0xMS0xLTEtMjQ2OTc_1dfd270e-fa41-42ed-9948-76d879fe8744"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9be00354c46b4b8b96a26749f9c3e28d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOC0xMy0xLTEtMjQ2OTc_060d5136-a5fe-4c59-9fd4-677de26366e2"
      unitRef="usd">-213059000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idb18fef826e14bf1b6a11208896433a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOC0xNS0xLTEtMjQ2OTc_06c4f7db-e22e-4185-9ec8-8614d41618d5"
      unitRef="usd">79457000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic454c127b7694ec7929df6e51728c3f3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOS01LTEtMS0yNDY5Nw_96bad6ec-d31a-4d6e-8630-7fd6a4536b7d"
      unitRef="shares">186563</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9496baa43c834ff9b11ec53efd6d7f91_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOS05LTEtMS0yNDY5Nw_dfa89c5b-fafd-48e7-9d0e-f331aaf12c0c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfOS0xNS0xLTEtMjQ2OTc_9e84f5ea-7ff4-4729-8bc2-29485c40571c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9496baa43c834ff9b11ec53efd6d7f91_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTAtOS0xLTEtMjQ2OTc_b8c50d46-f1ba-49df-ac8a-1225bab2bfb4"
      unitRef="usd">10604000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTAtMTUtMS0xLTI0Njk3_51ec4631-39c4-4894-b31c-23dd22d32f1a"
      unitRef="usd">10604000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i618370635dad4cc09cde0158985bd9fc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTEtMTMtMS0xLTI0Njk3_92f5be58-1db2-4b18-b166-5baf8d96de3b"
      unitRef="usd">-163013000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTEtMTUtMS0xLTI0Njk3_749b252a-0e08-4943-a60a-3e93d7506bed"
      unitRef="usd">-163013000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iff982f9041634290a7428662c88e90ce_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTItMTEtMS0xLTI0Njk3_064ddb2b-c7da-4a40-b4d0-e779bcd8908e"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTItMTUtMS0xLTI0Njk3_810b8ef2-1057-4500-8fb2-6b3c66d9e37f"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="if065d88090344c76906d42f9e58f3946_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTMtMS0xLTEtMjQ2OTc_0b051c83-c29d-4906-aa51-52f90ee8be0d"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="if065d88090344c76906d42f9e58f3946_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTMtMy0xLTEtMjQ2OTc_5202f5a9-c097-4be4-bb3c-ab4a5082dcaa"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="idac57e11cdc94016861bd9248bcdb528_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTMtNS0xLTEtMjQ2OTc_e63dd452-c00d-4ae5-9ef5-42a39737cd0e"
      unitRef="shares">33749228</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="idac57e11cdc94016861bd9248bcdb528_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTMtNy0xLTEtMjQ2OTc_11df84c0-ba8d-4466-88e9-0a7f0e8346e3"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7dae31c8b50a4ed9834cf14ad981a07f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTMtOS0xLTEtMjQ2OTc_ef66c670-c34f-49c7-975b-e0697ea0bcc6"
      unitRef="usd">303113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7b072e47c4674802bf86129ee1b3d043_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTMtMTEtMS0xLTI0Njk3_ccc1938c-6ea7-4d00-9e79-19e9a0c729f1"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib5bcb363afdf4b8db455485e8e2ad3fa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTMtMTMtMS0xLTI0Njk3_db2a653e-8905-495b-bd02-3cc530159798"
      unitRef="usd">-376072000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTMtMTUtMS0xLTI0Njk3_effbd372-3cd9-4ac4-994e-a497c5daace6"
      unitRef="usd">-72958000</us-gaap:StockholdersEquity>
    <eols:StockIssuedDuringPeriodSharesLitigationSettlement
      contextRef="ic40c99d6b0a04616bf00bfc233eced25_D20210228-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTQtNS0xLTEtMjg1MDM_98e09eb6-f2a5-4627-ba49-75ac75801968"
      unitRef="shares">6762652</eols:StockIssuedDuringPeriodSharesLitigationSettlement>
    <eols:StockIssuedDuringPeriodValuesLitigationSettlement
      contextRef="i55331949261b40a1b1fb09e4158cee28_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTQtOS0xLTEtMjg1MDM_1adab10a-f5d5-44ab-ad13-9dff66b52f5f"
      unitRef="usd">48421000</eols:StockIssuedDuringPeriodValuesLitigationSettlement>
    <eols:StockIssuedDuringPeriodValuesLitigationSettlement
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTQtMTUtMS0xLTI4NTAz_f248486d-cf5e-475f-a6b0-db6afa5a5e5a"
      unitRef="usd">48421000</eols:StockIssuedDuringPeriodValuesLitigationSettlement>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ib797f956941d4495ae3f6f4926ca7cd1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTUtNS0xLTEtMjg1MDM_4061fd94-7cc8-44d6-b50c-22f2ca1459cf"
      unitRef="shares">3136869</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i55331949261b40a1b1fb09e4158cee28_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTUtOS0xLTEtMjg1MDM_6ece05e9-35b4-49a5-9a89-88e7d711fc0e"
      unitRef="usd">39808000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTUtMTUtMS0xLTI4NTAz_50bed79b-64c0-4470-9b60-1f59c361373c"
      unitRef="usd">39808000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iae9c7ae95d9f43cbb4015233b65597a5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTYtNS0xLTEtMjg1MDM_1b5ca9b8-2925-4daa-8956-88cd1638afa3"
      unitRef="shares">10350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ida8a057d5f3b4f8999abff6725b2469f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTYtOS0xLTEtMjg1MDM_d6e6bc4c-2597-4b17-86c0-532fac778285"
      unitRef="usd">92212000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if9bdbef71f2046fc80639fa5cacb44eb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTYtMTUtMS0xLTI4NTAz_1e9bba52-f851-4c04-b2b2-75d4f9f6eeb6"
      unitRef="usd">92212000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i19668eba2a9a432cbae4ec0e6254aa0e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTctNS0xLTEtMjg1MDM_e079cc17-af93-4f78-8118-b0b1cd869fbc"
      unitRef="shares">934367</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8b39b85b47cc450fbde4206b76345039_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTctOS0xLTEtMjg1MDM_33c67f7a-5a82-4d1d-8307-187e07a7790b"
      unitRef="usd">10910000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i191b278dcfec47f3972561e051202c15_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTctMTUtMS0xLTI4NTAz_6971fbb9-49be-4065-a476-da47db783925"
      unitRef="usd">10910000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib797f956941d4495ae3f6f4926ca7cd1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTQtNS0xLTEtMjgyOTQ_08a1eea7-0bb2-47b5-be14-6f5b0786b866"
      unitRef="shares">643872</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i55331949261b40a1b1fb09e4158cee28_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTQtOS0xLTEtMjgzMzY_c7a9199c-31e4-40ba-883d-0fb2ded755e7"
      unitRef="usd">655000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTgtMTUtMS0xLTMwMzg2_b3d888e7-4ab2-4f8d-b837-313c3e02f265"
      unitRef="usd">655000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i55331949261b40a1b1fb09e4158cee28_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTUtOS0xLTEtMjgzNTI_e2f833ec-3779-41da-82ad-d9db1907dbbb"
      unitRef="usd">9638000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTktMTUtMS0xLTMwMzg2_d2ccea12-7c8d-45c3-a18e-6fdbd0cc5ce5"
      unitRef="usd">9638000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ide759804fa684555b30ad8d92e40dd8f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMTYtMTMtMS0xLTI4MzY3_8549450d-0c11-4f7d-8608-1a82ec52e8b1"
      unitRef="usd">-46810000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjAtMTUtMS0xLTMwMzg2_06c3707d-b262-4b5c-b9c1-fc05d71fc0be"
      unitRef="usd">-46810000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i4e49ab226c6f4296b8a462ca4e5b73d2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjItMS0xLTEtMzAzOTM_171d74fb-f424-4577-9b35-9055ca26d423"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i4e49ab226c6f4296b8a462ca4e5b73d2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjItMy0xLTEtMzAzOTM_339a3e1c-5ea0-484a-b7c0-e7c6c794739b"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ic7f853492f874d82b33dd9c2cb1fff79_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjItNS0xLTEtMzAzOTM_08823764-9219-4c9a-b4d1-917c1bbde309"
      unitRef="shares">55576988</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ic7f853492f874d82b33dd9c2cb1fff79_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjItNy0xLTEtMzAzOTM_3aec663d-d132-4b5b-aee4-433465f8921d"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iba22e2b749b44db0bac4acb2ea8a9073_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjItOS0xLTEtMzAzOTM_88d7faf9-d0bb-4f6e-a15c-a1775bee261c"
      unitRef="usd">504757000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0eed27f558fa49d5b84d4d3ba1bfef2d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjItMTEtMS0xLTMwMzkz_d3356777-81b0-41f6-adcd-70a63ae85d96"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i861bdd7e206b435b912b799375902ac9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjItMTMtMS0xLTMwMzkz_0b5cab24-c2d0-4057-9922-1905e7410da8"
      unitRef="usd">-422882000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84NS9mcmFnOmFiOGMyZTY3NzAwYjRiODZhMjBjMzdlMTZkMDRmZDA0L3RhYmxlOjM5NWY2YmYwMWNmMjRhOWY4NmIzZWY5NzZiZDhiMTcxL3RhYmxlcmFuZ2U6Mzk1ZjZiZjAxY2YyNGE5Zjg2YjNlZjk3NmJkOGIxNzFfMjItMTUtMS0xLTMwMzkz_2ae63d5d-d1ec-4bb7-b202-66c20b84f15a"
      unitRef="usd">81876000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMy0xLTEtMS0yNDY5Nw_0b7510aa-b117-4476-8c58-d2c897befad9"
      unitRef="usd">-46810000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMy0zLTEtMS0yNDY5Nw_4edf637f-29a2-4f12-9483-d814fb570f51"
      unitRef="usd">-163013000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNS0xLTEtMS0yNDY5Nw_788476a3-673c-4ea3-b2c7-f6d9621380f3"
      unitRef="usd">5622000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNS0zLTEtMS0yNDY5Nw_572e3ac0-e871-423c-9d99-927a0683a3cf"
      unitRef="usd">7027000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNi0xLTEtMS0yNDY5Nw_828c941c-61d7-4fe0-a0ec-8fcd132b636b"
      unitRef="usd">9576000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNi0zLTEtMS0yNDY5Nw_3bf62583-3529-44f7-b79f-7b590b23f1cb"
      unitRef="usd">10584000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNy0xLTEtMS0yNDY5Nw_af1f29f6-a0fe-45f9-9c5d-1ab233822743"
      unitRef="usd">589000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNy0zLTEtMS0yNDY5Nw_72515e65-f86b-4853-ae70-b94022a1582b"
      unitRef="usd">2066000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfOC0xLTEtMS0yNDY5Nw_83c2970e-cf57-4e1e-b4a1-cba463eec2b0"
      unitRef="usd">-272000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfOC0zLTEtMS0yNDY5Nw_c1b9172f-311c-4ffb-9567-657e0714c610"
      unitRef="usd">427000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <eols:OperatingLeaseRightofUseAssetAmortization
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfOS0xLTEtMS0yNDY5Nw_c7fcbf36-f707-4db6-b799-1f7b0e2a99b5"
      unitRef="usd">692000</eols:OperatingLeaseRightofUseAssetAmortization>
    <eols:OperatingLeaseRightofUseAssetAmortization
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfOS0zLTEtMS0yNDY5Nw_b66476fd-e77c-4c8f-b5ee-e98ae454f765"
      unitRef="usd">654000</eols:OperatingLeaseRightofUseAssetAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTAtMS0xLTEtMjQ2OTc_c3971061-55db-4ed4-bb67-ff810f80bef1"
      unitRef="usd">941000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTAtMy0xLTEtMjQ2OTc_7230a9f2-c623-4a0b-802c-2f2f1e77dccc"
      unitRef="usd">2691000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:PaidInKindInterest
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTEtMS0xLTEtMjQ2OTc_ec1511f5-856c-4fb7-9c39-03d567b4b670"
      unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTEtMy0xLTEtMjQ2OTc_06be0994-9a61-46c3-a796-e6cca4a02b3f"
      unitRef="usd">506000</us-gaap:PaidInKindInterest>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTItMS0xLTEtMjQ2OTc_0a9d99fc-411a-483d-b036-4dad41e2b2b0"
      unitRef="usd">15000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTItMy0xLTEtMjQ2OTc_2e4fe1f8-bca2-4017-bdfc-e2c62ccc1004"
      unitRef="usd">25000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTMtMS0xLTEtMjQ2OTc_f8c3fa8d-97da-44bf-8615-b187c0b6db1b"
      unitRef="usd">6290000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTMtMy0xLTEtMjQ2OTc_a798ed79-7961-4de7-84f1-dc15d592ce2b"
      unitRef="usd">-2007000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTQtMS0xLTEtMzQxMjY_d18fd243-a18f-4f0c-8d2c-00377c9d968a"
      unitRef="usd">-968000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTQtMy0xLTEtMzQxMjY_ce56270c-04ce-42c5-9f0a-73840e5948c4"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <eols:AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTQtMS0xLTEtMjQ2OTc_d688ea9b-a7bb-49d4-8d1b-584fc1cc5b3c"
      unitRef="usd">0</eols:AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses>
    <eols:AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTQtMy0xLTEtMjQ2OTc_d80e2a68-be5f-45d6-b61f-935848c00c56"
      unitRef="usd">48421000</eols:AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTYtMS0xLTEtMjQ2OTc_61a9ed37-7cc2-47d8-9ff2-5f688e79f1bc"
      unitRef="usd">2979000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTYtMy0xLTEtMjQ2OTc_c0e9a1a3-8c04-48c7-807d-903b16e8298c"
      unitRef="usd">-4542000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTctMS0xLTEtMjQ2OTc_e5d9e321-b5d9-443c-b6a8-3f5709778eb6"
      unitRef="usd">5566000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTctMy0xLTEtMjQ2OTc_8bb282e5-a8dc-411e-b144-6edae642df4f"
      unitRef="usd">1085000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTgtMS0xLTEtMjQ2OTc_6f1d7da4-6c96-47d0-916f-91b70a61f94a"
      unitRef="usd">7264000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTgtMy0xLTEtMjQ2OTc_52562fb9-90c6-4aa0-9ee2-46030477ed23"
      unitRef="usd">1690000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTktMS0xLTEtMjQ2OTc_cba0ed2a-6451-4ca3-9a84-72523695d7ec"
      unitRef="usd">-787000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMTktMy0xLTEtMjQ2OTc_c59eee1c-7c3d-4b5d-956a-8b0f16b9c532"
      unitRef="usd">2320000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjAtMS0xLTEtMjQ2OTc_4bb55979-e5fe-4140-9ca8-0ef4ff9c7875"
      unitRef="usd">20891000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjAtMy0xLTEtMjQ2OTc_c5a3748a-076f-4062-918e-c63da44eb7f3"
      unitRef="usd">-4248000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <eols:IncreaseDecreaseInAccruedLitigationSettlement
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjEtMS0xLTEtMjQ2OTc_83b626ad-797a-4d31-8cfe-afb8f8695503"
      unitRef="usd">-15000000</eols:IncreaseDecreaseInAccruedLitigationSettlement>
    <eols:IncreaseDecreaseInAccruedLitigationSettlement
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjEtMy0xLTEtMjQ2OTc_d8f0b5d0-6909-4820-9708-ba3e86f9b0b5"
      unitRef="usd">35000000</eols:IncreaseDecreaseInAccruedLitigationSettlement>
    <eols:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjItMS0xLTEtMjQ2OTc_9908326a-8740-4a40-b0d8-a9aaee0f9b53"
      unitRef="usd">-838000</eols:IncreaseDecreaseInOperatingLeaseLiabilities>
    <eols:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjItMy0xLTEtMjQ2OTc_04ec1c36-ba8e-4812-a51c-937fafea21da"
      unitRef="usd">-734000</eols:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjMtMS0xLTEtMjQ2OTc_508acecb-943a-4d23-a714-e41f7327b013"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjMtMy0xLTEtMjQ2OTc_0208d526-d102-478f-a018-28e023fab7c2"
      unitRef="usd">-1497000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjQtMS0xLTEtMjQ2OTc_c4b6f351-d9c2-496a-9848-3da41bd2ac43"
      unitRef="usd">-33388000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjQtMy0xLTEtMjQ2OTc_5566de41-9306-47e8-abc1-43a237532240"
      unitRef="usd">-57871000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjYtMS0xLTEtMjQ2OTc_fb8fb32a-4a50-49c9-8998-9481679a5990"
      unitRef="usd">393000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjYtMy0xLTEtMjQ2OTc_3f259f82-ede2-407e-8561-219761ebb04f"
      unitRef="usd">815000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForSoftware
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjctMS0xLTEtMjQ2OTc_5e1649da-2fbf-48c8-a318-5393c148c9be"
      unitRef="usd">577000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjctMy0xLTEtMjQ2OTc_e9ca6759-1ea3-4ffd-b149-33aaca9858c7"
      unitRef="usd">2323000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjgtMS0xLTEtMjQ2OTc_206e4fa4-b8b2-4c18-86c4-8a3bb057231a"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjgtMy0xLTEtMjQ2OTc_46ffb0b6-13b4-4d1e-8fe4-b0cdf6f71e23"
      unitRef="usd">74668000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjktMS0xLTEtMjQ2OTc_a1175e4e-00fd-41b5-bd9b-d33391c1ee9b"
      unitRef="usd">5000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMjktMy0xLTEtMjQ2OTc_96eb8ff6-130e-4189-942e-b80f0517600e"
      unitRef="usd">90000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzAtMS0xLTEtMjQ2OTc_32f62352-c7ac-45a2-bd21-40f6c0e54783"
      unitRef="usd">4030000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzAtMy0xLTEtMjQ2OTc_46124ba9-8aad-410f-8439-2c9dad58cd89"
      unitRef="usd">12194000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfDebt
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzItMS0xLTEtMzQwNjg_69a241db-cb59-4fa4-be7a-d3c4ad3eba95"
      unitRef="usd">76323000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzItMy0xLTEtMzQwNjg_570b772f-21d5-458a-a017-9f6e502ffa50"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzQtMS0xLTEtNDA5OTM_f80ddebe-ea6f-4b3e-b536-45833aa842b2"
      unitRef="usd">20000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzQtMy0xLTEtNDA5OTM_3520650d-e8fb-4479-9c65-225d82c2c456"
      unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
    <eols:PaymentsOfContingentRoyaltyObligation
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzItMS0xLTEtMjQ2OTc_34a97664-7e3f-452c-91c5-9e095b93d8b4"
      unitRef="usd">3097000</eols:PaymentsOfContingentRoyaltyObligation>
    <eols:PaymentsOfContingentRoyaltyObligation
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzItMy0xLTEtMjQ2OTc_0822e66a-8bea-4493-8cae-87074fc22f4a"
      unitRef="usd">1130000</eols:PaymentsOfContingentRoyaltyObligation>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzMtMS0xLTEtMjQ2OTc_ae89578d-62b4-4ea0-b80a-9f891d2cd6d6"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzMtMy0xLTEtMjQ2OTc_914d45a4-16fd-4b96-bf4e-9808c24d312d"
      unitRef="usd">40000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzUtMS0xLTEtMjQ2OTc_4b6c2b7e-16dc-4102-836a-f2a66c6b2112"
      unitRef="usd">71958000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzUtMy0xLTEtMjQ2OTc_1015a4d0-9513-4d44-926d-c69b0a2ed4dd"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzYtMS0xLTEtMjQ2OTc_0f3fb7da-0df1-4826-98f1-e7dc047bca6d"
      unitRef="usd">3263000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzYtMy0xLTEtMjQ2OTc_37c041d9-4794-4490-a973-d1cd65198e66"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzctMS0xLTEtMjQ2OTc_3a9c3bff-9b53-472e-95dd-f2c9d295f5b9"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzctMy0xLTEtMjQ2OTc_9364cefd-796b-496c-b89a-0f614b35454e"
      unitRef="usd">523000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if9bdbef71f2046fc80639fa5cacb44eb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzgtMS0xLTEtMjQ2OTc_de6f7b17-8bfc-4f50-8af1-810277f30c66"
      unitRef="usd">92426000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib7a53a744c7f48d4bb28c1d16000d70f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzgtMy0xLTEtMjQ2OTc_a3017c93-ed9d-4e2e-b5c6-020181765171"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzktMS0xLTEtMjQ2OTc_c83b08ca-efbc-4244-8ad6-0bb85f3a44dd"
      unitRef="usd">214000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfMzktMy0xLTEtMjQ2OTc_0aeea0f1-3955-4320-b3f2-a308d47a7bfd"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDAtMS0xLTEtMjQ2OTc_9367de95-7cc1-49ee-95d4-bb61958db75f"
      unitRef="usd">655000</eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan>
    <eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDAtMy0xLTEtMjQ2OTc_872c86e5-c608-425b-be1a-440c6967223b"
      unitRef="usd">0</eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i191b278dcfec47f3972561e051202c15_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDItMS0xLTEtMzQwODk_5ece6db1-90e3-428a-8f49-3954716abab0"
      unitRef="usd">10910000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="idb4365e9adeb459aa371d09c5f6def3f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDItMy0xLTEtMzQxMTY_135427ff-bc85-4080-bdb6-dcd2f99e95dd"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDEtMS0xLTEtMjQ2OTc_d445ac5a-ef10-4940-9767-8fb4238fb920"
      unitRef="usd">73052000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDEtMy0xLTEtMjQ2OTc_76cb8ede-acbc-491c-9cb1-abe985b61d59"
      unitRef="usd">38347000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDMtMS0xLTEtMjQ2OTc_3451f208-7852-4b9b-a1dd-a38057550e0b"
      unitRef="usd">43694000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDMtMy0xLTEtMjQ2OTc_b37d3e14-da88-420c-b12d-86d42b21350d"
      unitRef="usd">-7330000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDQtMS0xLTEtMjQ2OTc_76fdbca1-ab44-4598-bf4b-90fb60cc2b17"
      unitRef="usd">102562000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idb18fef826e14bf1b6a11208896433a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDQtMy0xLTEtMjQ2OTc_e99e2b84-b9ed-4c04-91b9-ed53f0f72fc3"
      unitRef="usd">109892000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDUtMS0xLTEtMjQ2OTc_cdc11b78-4844-410a-9e68-c11e40b9da7e"
      unitRef="usd">146256000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjZmZTRkYTY0NWQ0ZDQzMmNiYTI4MTE2NjY5Y2VkOGVjL3RhYmxlcmFuZ2U6NmZlNGRhNjQ1ZDRkNDMyY2JhMjgxMTY2NjljZWQ4ZWNfNDUtMy0xLTEtMjQ2OTc_f525bf99-6ae6-4d29-b315-ea1f1901b4dc"
      unitRef="usd">102562000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfMy0xLTEtMS0yNDY5Nw_936916b6-6c9f-44e0-a5fa-7ad73d3bcb47"
      unitRef="usd">138000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfMy0zLTEtMS0yNDY5Nw_dbe97218-5f6c-4c99-a3e7-aecd617dc489"
      unitRef="usd">7244000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfNC0xLTEtMS0yNDY5Nw_c942fcee-c39b-4a8b-9e50-a01608e39506"
      unitRef="usd">14000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfNC0zLTEtMS0yNDY5Nw_a966c462-4244-4b2c-bc06-c705f60fca58"
      unitRef="usd">65000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfNi0xLTEtMS0yNDY5Nw_da4c0375-7851-4184-9094-9d3d5ac69b1a"
      unitRef="usd">39808000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfNi0zLTEtMS0yNDY5Nw_a3f8aede-1571-448d-87bf-ce7f05da9170"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <eols:StockIssuedForAccruedLitigationSettlementExpense
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfNy0xLTEtMS0yNDY5Nw_fc893de9-105c-4836-9da8-5876d8e98b7b"
      unitRef="usd">48421000</eols:StockIssuedForAccruedLitigationSettlementExpense>
    <eols:StockIssuedForAccruedLitigationSettlementExpense
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfNy0zLTEtMS0yNDY5Nw_2462140c-e9eb-405a-92e3-488f5dc92cf1"
      unitRef="usd">0</eols:StockIssuedForAccruedLitigationSettlementExpense>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfOC0xLTEtMS0yNDY5Nw_285d6609-a915-4fac-9e91-3f94db80310d"
      unitRef="usd">10000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl84OC9mcmFnOjk5NjRhODMyNDM1NzQ2OWM5Zjk4ZDZjZTI5ZWUwODE5L3RhYmxlOjA0MmZiNGM2ZWNiMTQ0Y2NhNTM1OGQwOTA0Zjg0M2Q4L3RhYmxlcmFuZ2U6MDQyZmI0YzZlY2IxNDRjY2E1MzU4ZDA5MDRmODQzZDhfOC0zLTEtMS0yNDY5Nw_f0deb605-d977-4efb-9571-d10278d26c16"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfNjY4Mw_288af611-4ae7-4a3c-86ca-e5de0c1956e0">Description of Business &lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evolus, Inc., (&#x201c;Evolus&#x201d; or the &#x201c;Company&#x201d;) is a performance beauty company focused on delivering products in the self-pay aesthetic market. The Company received the approval of its first product Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) in February 2019. The product was also approved by Health Canada in August 2018 and the European Commission (&#x201c;EC&#x201d;) in September 2019. Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#x201c;frown lines,&#x201d; in adults. The Company commercially launched Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States in May 2019 and in Canada through a distribution partner in October 2019. The Company currently generates all of its net revenues from Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company is headquartered in Newport Beach, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Financial Condition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared on a basis that assumes that the Company will continue as a going concern, and do not include any adjustments that may result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company&#x2019;s assets and the satisfaction of the Company&#x2019;s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception, the Company has incurred recurring net operating losses and negative cash flows from operating activities and management expects operating losses and negative cash flows to continue for at least the next 12 months. As of December&#160;31, 2021, the Company had $146,256 in cash and cash equivalents and an accumulated deficit of $422,882. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company entered into a $125,000 Term Loan agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and Biopharma Credit PLC (collectively, &#x201c;Pharmakon&#x201d;). The first tranche of $75,000 was funded on December 29, 2021. The second tranche of $50,000 may be drawn at the Company&#x2019;s election no later than December 31, 2022, subject to the terms and conditions of the loan agreement. As of December&#160;31, 2021, the Company has not drawn the second tranche. The Company received net proceeds of approximately $68,695 from Pharmakon, after issuance costs and debt discounts. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6. Term Loans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company and Oxford Finance LLC (&#x201c;Oxford&#x201d;) entered into an agreement, pursuant to which the Company paid Oxford $76,447 to pay off the Oxford Term Loan. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6. Term Loans &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company, Medytox, Inc. (&#x201c;Medytox&#x201d;), Allergan, Inc. and Allergan Limited (together, &#x201c;Allergan&#x201d;) entered into settlement agreements in connection with the International Trade Commission (&#x201c;ITC&#x201d;) action, for which the Company agreed to pay $15,000 in 2021, $15,000 in 2022 and $5,000 in 2023 with additional terms including specified royalty payments as described below and in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company and Daewoong entered into certain agreements, pursuant to which Daewoong (1) paid the Company $25,500 in April 2021 and (2) agreed to reimburse the Company certain amounts with respect to the royalties payable to Medytox and Allergan, among other terms. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information. In addition, in March 2021 the outstanding Daewoong Convertible Note (as such term is defined in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7. Daewoong Convertible Note&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), including accrued interest, in the amount of $40,779 was converted into 3,136,869 shares of the Company&#x2019;s common stock. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7. Daewoong Convertible Note&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company completed a follow-on public offering and issued 10,350,000 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,350,000 shares of common stock, at a price to the public of $9.50 per share. The Company received net proceeds of approximately $92,426 from the offering, after deducting underwriting discounts and commissions, excluding other offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June, July and August 2021, the Company sold 934,367 common shares at the prevailing market prices for total net proceeds of $10,910 under the existing &#x201c;at-the-market&#x201d; sales agreement. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 10. Stockholders&#x2019; Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional details. &lt;/span&gt;&lt;/div&gt;The Company believes that its current capital resources, which consist of cash and cash equivalents, will be sufficient to fund operations through at least the next twelve months based on its expected cash needs. The Company may be required to raise additional capital to fund future operations through entering into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its controllable and variable expenditures and current rate of spending through reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMjg1Nw_8d8d466f-d942-480a-8042-7a8187b1f693"
      unitRef="usd">146256000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMjk1Mw_d69e93e6-74ac-493c-b6d2-08cc2d3f0310"
      unitRef="usd">-422882000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia43c0d4587004db0b6f491872654d03a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTA5OTUxMTY2MDU3Mg_9303f5ff-01cf-403a-b34d-fbaa96b56b87"
      unitRef="usd">125000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic59095e4226448ca90c7c028c530b46b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTA5OTUxMTY2MDc0Ng_f3f0a4d2-3a5f-4348-9705-358a14ef15f4"
      unitRef="usd">75000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iaf213e710f77493dadadc321fcf59639_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTA5OTUxMTY2MDgwNQ_e4fc726f-bb7f-4342-944b-4f17e48c9f5b"
      unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="ia1a49dbd0cdc4fa299c6fc4b349cd1c9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTA5OTUxMTY2MTA0OA_4aa28b57-2a58-4f5f-95d4-528e934ca146"
      unitRef="usd">68695000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i9c22c52daf7d4250a52799a0d558499a_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTY0OTI2NzQ1NjQzOA_63e4d6cf-5c48-430e-b1a7-149a5851cf2d"
      unitRef="usd">76447000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i6b22c9a255f64ef69528be6cf90f2d57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTY0OTI2NzQ1Njc3OQ_ac30d780-4777-49e5-abed-6e079218d311"
      unitRef="usd">15000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="ie3dc0d8eadaf4cf7918bae649c0b4261_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTY0OTI2NzQ1Njc5Mg_3143eaf7-cd30-490b-a9bb-d35fa77f0a38"
      unitRef="usd">15000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i8655593ec8584a3a81c2026e2ac5d7f4_D20230101-20231231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTY0OTI2NzQ1NjgwOA_01b4e8bc-a988-4543-bdfc-8c97097267b0"
      unitRef="usd">5000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ibdb8c8bf46044c1d94ceba9d58481dda_D20210401-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMTY0OTI2NzQ1Nzc4NQ_ea8018bf-44c3-43df-8edf-08ac1b0b5b09"
      unitRef="usd">25500000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:ConvertibleDebt
      contextRef="ib67b7815bf86448c836c0674ab2cd400_I20210323"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMzg0ODI5MDcxNTcwOA_8c83e1d8-b357-405a-8bbb-b86865f13dd4"
      unitRef="usd">40779000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="i67974a995ff142e8bcd737a314d25651_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMzg0ODI5MDcxNTcyNg_c3cd713f-2461-4c6e-b548-bdbf8ad75cd4"
      unitRef="shares">3136869</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i87285d3792f541dfb0b8bd76edc9ed8b_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMzg0ODI5MDcwNzAzMw_38327937-d86b-4f0c-aba4-ee5aca0a863b"
      unitRef="shares">10350000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i369b3df3ec04419fa040ca2ec1d798db_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMzg0ODI5MDcxNTc0Ng_db73e69f-fbeb-4895-89d8-0ab7c70c5e47"
      unitRef="shares">1350000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i581d900790a24282bf837c0e06b7b5f4_I20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMzg0ODI5MDcxNTc1Nw_5406e129-051f-4b8e-8c9e-044ca62e0436"
      unitRef="usdPerShare">9.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i87285d3792f541dfb0b8bd76edc9ed8b_D20210401-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMzg0ODI5MDcxNTczNw_f1ca0685-34f6-4ff9-993c-fd502308c55c"
      unitRef="usd">92426000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3f2ebd8bfca6432bb520e3b56fadc096_D20210601-20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMzg0ODI5MDcxNTc2NA_05e96378-4da1-463a-8e40-6796bb00e1e1"
      unitRef="shares">934367</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i3f2ebd8bfca6432bb520e3b56fadc096_D20210601-20210831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85NC9mcmFnOjMzNzZjOTFmMWRjYTQzZjA4YzJkZjE2NjRhYTcwNmZlL3RleHRyZWdpb246MzM3NmM5MWYxZGNhNDNmMDhjMmRmMTY2NGFhNzA2ZmVfMzg0ODI5MDcxNTcxNw_17349bc1-c217-4fb3-87fe-be81568549e2"
      unitRef="usd">10910000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NzU_1c2f8f3e-e6bc-4f44-81a5-503ff7682b64">Basis of Presentation and Summary of Significant Accounting Policies &lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain comparative amounts for prior year have been reclassified to conform to current year presentations. Such reclassifications did not affect net income or retained earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management is required to make certain estimates and assumptions in order to prepare financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company&#x2019;s most significant estimates relate to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations, stock-based compensation and royalty obligations, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#x2019;s actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the full impact of&#160;the COVID-19&#160;outbreak is unknown and cannot be reasonably estimated. However, where possible, management has made appropriate accounting estimates with respect to certain accounting matters, which include the fair value of royalty obligations, allowance for doubtful accounts, inventory valuation and impairment assessments of goodwill and other long-lived assets, based on the facts and circumstances available as of the reporting date. The Company&#x2019;s future assessment of the magnitude and duration of&#160;the COVID-19 outbreak, as well as other factors, could result in material impacts to the Company&#x2019;s financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2013, Evolus and Daewoong Pharmaceutical Co. Ltd. (&#x201c;Daewoong&#x201d;) entered into an agreement (the &#x201c;Daewoong Agreement&#x201d;), pursuant to which the Company received an exclusive distribution license to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, Russia, certain members of the Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#x2019;s commercialization of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company commercially launched Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in the United States in May 2019 and in Canada through its distribution partner in October 2019 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&#x2019;s business and its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company&#x2019;s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by physicians and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 outbreak and restrictions intended to slow the spread of COVID-19, including quarantines, government-mandated actions, stay-at-home orders and other restrictions,&#160;have adversely affected the Company&#x2019;s business in a number of ways, which have resulted, and may continue to result, in a period of business disruption and in reduced sales and operations. In addition, any disruption and volatility in the global capital markets may increase the Company&#x2019;s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. The Company has determined that it operates in a single operating and reportable segment. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company&#x2019;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#x2019;s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#x2019; ability to pay.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments consist of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company&#x2019;s statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the statements of operations and comprehensive loss using the specific-identification method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of finished goods held for sale and distribution. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost is determined based on the estimated amount payable to the Company&#x2019;s supplier after accounting for any reimbursement receivable pursuant to the Daewoong Settlement Agreement (as such term is defined, and such agreement is discussed, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), usin&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;g the first-in, first-out method with prioritization of the items with the earliest expiration dates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Inventory valuation reserves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for the periods presented. Adverse changes in assumptions utilized in the Company&#x2019;s inventory reserve calculations could result in an increase to its inventory valuation reserves.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product cost of sales, excluding amortization of intangible assets, consisted of the inventory cost, and, for periods on or after December 16, 2020, included certain royalties on the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; payable to Medytox and Allergan pursuant to the Medytox/Allergan Settlement Agreements (as such term is defined in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), as partially offset by reimbursement receivable from Daewoong pursuant to the Daewoong Settlement Agreement with respect to such royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&#x2014;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&#x2014;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of approximately five years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the term of the related lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#x2019;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has one reporting unit. There was no impairment of goodwill for any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon FDA approval of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in February 2019, the in process research and development (&#x201c;IPR&amp;amp;D&#x201d;) related to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;was evaluated as completed and reclassified to a definite-lived distribution right intangible asset, which is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#x2019;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&#160;20 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&#160;two years&#160;upon being placed in service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was no material impairment of long-lived assets for any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Codification 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 842&#x201d;), at the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#x2019;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#x201c;ROU&#x201d;) asset which represents the Company&#x2019;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#x2019;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancelable period of the lease and may include options to extend or terminate the lease &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;when it is reasonably certain that the Company will exercise such options. The Company&#x2019;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of&#160;December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Royalty Obligation Payable to the Evolus Founders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable are determined at each reporting period end and recorded in operating expenses in the accompanying statements of operations and comprehensive loss and as a liability in the accompanying balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Promissory Note Payable to the Evolus Founders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 12, 2018, the Company recognized a promissory note payable at present value using a discount rate for similar rated debt securities. Discount amortization related to the promissory note is recorded in interest expense in the accompanying statements of operations and comprehensive loss with a corresponding increase to the liabilities in the accompanying balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt represents the debt balance with Pharmakon as of December&#160;31, 2021 and Oxford as of December&#160;31, 2020 (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6. Term Loans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, net of debt issuance costs. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are amortized into interest expense over the term of the debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates product revenue from the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States and service revenue from the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; through a distribution partner in Canada.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#x2019; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in Canada as it does not control the product before control is transferred to a customer. The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the amount of consideration expected to be received. For the years ended December 31, 2021 and 2020, the Company recognized $702 and $738, respectively, of revenues related to international sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s disaggregation of revenue is consistent with its operating segment as disclosed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gross-to-Net Revenue Adjustments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides customers with discounts, such as trade and volume discounts and prompt pay discounts, that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, primarily for the volume based rebates, coupons, consumer loyalty programs and co-branded marketing programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Volume-based Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Coupons&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company issued customers coupons redeemable into gift cards funded by the Company for the benefit of patients. The coupons were accounted for as variable consideration. The Company estimated coupon redemption rates based on historical data and future expectations. The coupons were accrued based on estimated redemption rates and the volume of products purchased and were recorded as a reduction to revenues on product delivery. All issued coupons expired on June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Consumer Loyalty Program&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; In May 2020, the Company launched a consumer loyalty program, which allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and redeem the rewards for Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward (&#x201c;Reward&#x201d;) that the customer might redeem in the future. The standalone selling price of the Reward is measured based on historical sales data, estimated average selling price of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; at the time of redemption, expected customer and consumer participation rates in the loyalty program, and estimated number of qualifying treatments to be performed by customers. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue. Subsequently, when customers redeem the Reward and the related product is delivered, the deferred revenue is recognized in net revenues at that time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Co-Branded Marketing Programs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company offers eligible customers with a certain level of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; purchases to receive advertising co-branded with the Company. The co-branded advertising represents a performance obligation. At the time Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product is sold to customers, the invoice price is allocated between the product sold and the advertisement. The standalone selling price of the advertisement is measured based on the estimated market value of similar advertisement adjusted for the customer&#x2019;s portion of the advertisement. The portion of invoice price allocated to the advertisement is initially recorded as deferred revenue. Subsequently, when the advertisement airs, the deferred revenue is recognized in net revenues at that time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration becomes unconditional. The Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of&#160;December&#160;31, 2021 and 2020, all amounts included in accounts receivable, net on the accompanying balance sheets are related to contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any contract assets nor unbilled receivables as of&#160;December&#160;31, 2021 or 2020. Sales commissions are included in selling, general and administrative expenses when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients primarily under the rebate and coupon programs and deferred revenue associated with Rewards under the consumer loyalty program and co-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;branded marketing programs. The Company&#x2019;s contract liabilities are included in accounts payable and accrued expenses in the accompanying balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the accrued revenue contract liabilities, primarily related to volume-based rebates, consumer loyalty program, and co-branded media programs, were $7,934 and $3,081, respectively, which were recorded in accrued expenses in the accompanying balance sheets. For the years ended December 31, 2021 and 2020, provisions for rebate, coupon, consumer loyalty programs, and co-branded media programs were $16,139 and $16,896, respectively, which were offset by related payments, redemptions and adjustments of $11,286 and $15,524, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the&#160;years ended December 31, 2021 and 2020, the Company recognized $2,802 and $0, respectively, of revenue related to amounts included in contract liabilities at the beginning of the period and did not recognize any revenue related to changes in transaction prices regarding its contracts with customers from previous periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collectability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#x2019;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#x2019;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.&#160;The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of December 31, 2021 and 2020, allowance for doubtful accounts was $2,385 and $2,118, respectively. For the years ended December 31, 2021 and 2020, provision for bad debts was $589 and $2,066, respectively, and the write-off amount was $322 and $335, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Practical Expedients&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#x2019;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation Settlement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, upon entering into certain agreements to settle intellectual property disputes relating to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company agreed to pay to Allergan and Medytox &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$35,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in multiple payments over two years, of which $15,000 was paid in the third quarter of 2021 and $15,000 was paid in the first quarter of 2022, and issued 6,762,652 shares of its common stock to Medytox. In addition, for the period from December 16, 2020 to September 16, 2022, the Company agreed to pay to Allergan and Medytox a royalty on the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, based on a certain dollar amount per vial sold in the United States and a low-double digit royalty on net sales of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sold in other Evolus territories. For the period from September 17, 2022 to September 16, 2032, the Company agreed to pay to Medytox a mid-single digit royalty percentage on all net sales of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The royalty payments are made quarterly and recorded as product cost of sales on the accompanying statements of operations and comprehensive loss in the periods the royalties are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The settlement agreements resulted in an $83,421 charge for the year ended December&#160;31, 2020, which consisted of $35,000 in deferred cash payments and $48,421 from the issuance of 6,762,652 shares of the Company&#x2019;s common stock in February &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021. In the year ended December 31, 2021, the Company made cash payments of $15,000 to Medytox and Allergan. As of December&#160;31, 2021, a current liability of $15,000 and non-current liability of $5,000 were recorded in the accompanying balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separately, in March 2021, Daewoong and the Company entered into certain agreements, pursuant to which Daewoong agreed to pay the Company an amount equal to $25,500, which was recorded as a settlement payment from Daewoong and included as part of cost of sales on the accompanying statements of operations and comprehensive loss for the year ended December 31, 2021. For the period from December 16, 2020 to September 16, 2022, Daewoong also agreed to reimburse the Company certain amounts with respect to the royalties payable to Medytox and Allergan. This reimbursement is received quarterly and recorded as an offset to the related royalties to Medytox and Allergan in the product cost of sales on the accompanying statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the details of all litigation settlement agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#x2019;s common stock, expected risk-free interest rate, and the option&#x2019;s expected life. The fair value of the Company&#x2019;s restricted stock units (&#x201c;RSUs&#x201d;) is based on the fair value on the grant date of the Company&#x2019;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the balance sheets and in the selling, general and administrative or research and development expenses in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as incurred and primarily include costs related to social media ads and co-branded marketing programs. Advertising costs are included in selling, general and administrative expenses. For the years ended December 31, 2021 and 2020, the Company incurred advertising costs of $16,391 and $4,979, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#x2019;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&#160;50%&#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. The Company does not expect that changes to state tax laws through December&#160;31, 2021 to materially impact its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. The dilutive effect of stock options and restricted stock units is computed under the treasury stock method. The dilutive effect of the Daewoong Convertible Note is computed under the if-converted method. Potentially dilutive securities are excluded from the computations of diluted net loss per share if their effect would be antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2021 and 2020, excluded from the dilutive net loss per share computation were stock options of 3,922,286 and 4,407,498, respectively, non-vested RSUs of 1,926,467 and 1,173,741, respectively, and 0 shares and 3,076,923, shares issuable upon conversion of the Daewoong Convertible Note, respectively, because their inclusion would have been anti-dilutive. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. FASB issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provisions remove certain exceptions including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020 and interim periods therein. The Company has adopted the guidance on the effective date of January 1, 2021. There are no material impacts to the financial statements as a result of this adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&#160;Issued But Not&#160;Adopted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU No. 2017-04,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles&#x2014;Goodwill and Other (Topic 350):&#160;Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#x2019;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January&#160;1, 2023. The standard requires prospective application. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU No. 2016-13, the FASB issued ASU 2018-19,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Topic 326, Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU does not change the core principle of the guidance in ASU No. 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&#160;The FASB also subsequently issued ASU No. 2019-04 which did not change the core principle of the guidance in ASU No. 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January 1, 2023. The Company is in the process of determining the effects the adoption will have on its financial statements and reviewing credit loss models to assess the impact of the adoption of the standard on the financial statements. Based on initial assessments, the Company believes that while adoption will modify the way it analyzes financial instruments, it does not expect adoption of this guidance will have a material impact to its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and in January 2021, the FASB issued ASU No. 2021-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Scope (&#x201c;ASU 2021-01&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Both ASU No. 2020-04 and ASU No. 2021-01 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (&#x201c;LIBOR&#x201d;) or another reference rate expected to be discontinued because of reference rate reform. ASU No. 2020-04 and ASU No. 2021-01 are effective upon issuance for contract modifications and hedging relationships, and the Company is allowed to elect to apply the amendments prospectively through December 31, 2022. The Company does not expect adoption of this guidance will have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the FASB issued ASU No. 2021-10,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This update will increase transparency of government assistance received by most business entities by requiring the disclosure of: (1) the types of transactions; (2) the accounting for the transactions; and, (3) the effect of the transactions on a business entity&#x2019;s financial statements. ASU No. 2021-10 is effective for financial statements issued for annual periods beginning after December 15, 2021, with early application permitted. The Company does not expect adoption of this guidance will have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#x2019;s present or future financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NzA_21c8b528-fbb5-4383-8aaf-6c8531c02b3c">Basis of PresentationThe accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNTQ5NzU1ODE4MzQ0Ng_68858edf-d438-4e74-9451-a17d4110d2c6">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain comparative amounts for prior year have been reclassified to conform to current year presentations. Such reclassifications did not affect net income or retained earnings.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NzY_f627393a-25f0-4176-9441-eb42a0355317">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management is required to make certain estimates and assumptions in order to prepare financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company&#x2019;s most significant estimates relate to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations, stock-based compensation and royalty obligations, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#x2019;s actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the full impact of&#160;the COVID-19&#160;outbreak is unknown and cannot be reasonably estimated. However, where possible, management has made appropriate accounting estimates with respect to certain accounting matters, which include the fair value of royalty obligations, allowance for doubtful accounts, inventory valuation and impairment assessments of goodwill and other long-lived assets, based on the facts and circumstances available as of the reporting date. The Company&#x2019;s future assessment of the magnitude and duration of&#160;the COVID-19 outbreak, as well as other factors, could result in material impacts to the Company&#x2019;s financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NTE_67956f29-418d-485b-8118-f2de06641b36">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2013, Evolus and Daewoong Pharmaceutical Co. Ltd. (&#x201c;Daewoong&#x201d;) entered into an agreement (the &#x201c;Daewoong Agreement&#x201d;), pursuant to which the Company received an exclusive distribution license to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, Russia, certain members of the Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#x2019;s commercialization of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company commercially launched Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in the United States in May 2019 and in Canada through its distribution partner in October 2019 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&#x2019;s business and its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company&#x2019;s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by physicians and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 outbreak and restrictions intended to slow the spread of COVID-19, including quarantines, government-mandated actions, stay-at-home orders and other restrictions,&#160;have adversely affected the Company&#x2019;s business in a number of ways, which have resulted, and may continue to result, in a period of business disruption and in reduced sales and operations. In addition, any disruption and volatility in the global capital markets may increase the Company&#x2019;s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company&#x2019;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#x2019;s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#x2019; ability to pay.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NTI_80ae1dcb-f106-4bf0-a8f6-4a24d86a05cc">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. The Company has determined that it operates in a single operating and reportable segment. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NDY_c0cb6f7e-9a4d-4312-a446-801faed32734">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NDM_e5c9ee5b-005f-41c7-a885-e95c8a953a8a">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments consist of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company&#x2019;s statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the statements of operations and comprehensive loss using the specific-identification method. &lt;/span&gt;&lt;/div&gt;The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4MzY_0613a1ad-4592-4979-a5cb-5bcf8a144d23">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of finished goods held for sale and distribution. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost is determined based on the estimated amount payable to the Company&#x2019;s supplier after accounting for any reimbursement receivable pursuant to the Daewoong Settlement Agreement (as such term is defined, and such agreement is discussed, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), usin&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;g the first-in, first-out method with prioritization of the items with the earliest expiration dates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Inventory valuation reserves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for the periods presented. Adverse changes in assumptions utilized in the Company&#x2019;s inventory reserve calculations could result in an increase to its inventory valuation reserves.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product cost of sales, excluding amortization of intangible assets, consisted of the inventory cost, and, for periods on or after December 16, 2020, included certain royalties on the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; payable to Medytox and Allergan pursuant to the Medytox/Allergan Settlement Agreements (as such term is defined in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), as partially offset by reimbursement receivable from Daewoong pursuant to the Daewoong Settlement Agreement with respect to such royalties.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NDc_b8ad9840-84af-41d7-b054-d389abf64c82">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&#x2014;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&#x2014;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4Njc_f9421c44-29ac-43e0-abc0-9ea612688b9e">Property and EquipmentProperty and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of approximately five years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the term of the related lease.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzI5ODUzNDk3Mzg2Nw_adf48651-a74c-4ef0-a7e5-d48234ce4631">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4MzM_d2f96f50-3741-4e43-8d1b-e589aae2cb7b">GoodwillGoodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#x2019;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has one reporting unit.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTI1MzY_ed830b77-7a10-45db-9b37-03aeb4a7eae6"
      unitRef="reporting_unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="icdebbf3fdf644e34be10eab249d933bc_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTI1NjU_2ff4e77e-6514-4b11-a064-6218b766d466"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTI1NjU_8d694f23-b51b-4a2d-8fb1-25cf0ba1eed2"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTI1NjU_bf860f36-322f-44bd-a4b0-2da32811785b"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NTg_7859c22e-31a8-4820-b349-0082b7eb66ad">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon FDA approval of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in February 2019, the in process research and development (&#x201c;IPR&amp;amp;D&#x201d;) related to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;was evaluated as completed and reclassified to a definite-lived distribution right intangible asset, which is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#x2019;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&#160;20 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&#160;two years&#160;upon being placed in service.&lt;/span&gt;&lt;/div&gt;The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was no material impairment of long-lived assets for any periods presented</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic3bdecfb61f64eacb1bec28f7caef51c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTMyNDk_d254ef37-4422-4003-8862-530c3f585d54">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia035180a7f3e4b968ed0e22107620141_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTM3MDc_ad38901e-7a29-466e-8d60-c7b4e239ec67">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTQ2NTY_06e82ab4-6099-4f6d-9c14-a278023ef0f5"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTQ2NTY_1b6dbd09-8518-408e-bf14-52f7ccaee1ad"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="icdebbf3fdf644e34be10eab249d933bc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTQ2NTY_5c7180a3-4551-44ee-a6a7-eebd2ff76a9e"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4Mzc_acd4edb7-a5c8-4090-8a0c-508bffd0e31f">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Codification 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 842&#x201d;), at the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#x2019;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#x201c;ROU&#x201d;) asset which represents the Company&#x2019;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#x2019;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancelable period of the lease and may include options to extend or terminate the lease &lt;/span&gt;&lt;/div&gt;when it is reasonably certain that the Company will exercise such options. The Company&#x2019;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of&#160;December&#160;31, 2021.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NDQ_0690ed2a-b1df-4c47-9999-ea11e2c4efb6">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Royalty Obligation Payable to the Evolus Founders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable are determined at each reporting period end and recorded in operating expenses in the accompanying statements of operations and comprehensive loss and as a liability in the accompanying balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Promissory Note Payable to the Evolus Founders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 12, 2018, the Company recognized a promissory note payable at present value using a discount rate for similar rated debt securities. Discount amortization related to the promissory note is recorded in interest expense in the accompanying statements of operations and comprehensive loss with a corresponding increase to the liabilities in the accompanying balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NjM_e80ddf27-e49b-4af7-a974-6c7a3f3d0201">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt represents the debt balance with Pharmakon as of December&#160;31, 2021 and Oxford as of December&#160;31, 2020 (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6. Term Loans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, net of debt issuance costs. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are amortized into interest expense over the term of the debt.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4Nzg_f5e15e50-275b-4147-9e50-b92e4eb604ea">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates product revenue from the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States and service revenue from the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; through a distribution partner in Canada.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#x2019; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in Canada as it does not control the product before control is transferred to a customer. The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the amount of consideration expected to be received. For the years ended December 31, 2021 and 2020, the Company recognized $702 and $738, respectively, of revenues related to international sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s disaggregation of revenue is consistent with its operating segment as disclosed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gross-to-Net Revenue Adjustments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides customers with discounts, such as trade and volume discounts and prompt pay discounts, that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, primarily for the volume based rebates, coupons, consumer loyalty programs and co-branded marketing programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Volume-based Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Coupons&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company issued customers coupons redeemable into gift cards funded by the Company for the benefit of patients. The coupons were accounted for as variable consideration. The Company estimated coupon redemption rates based on historical data and future expectations. The coupons were accrued based on estimated redemption rates and the volume of products purchased and were recorded as a reduction to revenues on product delivery. All issued coupons expired on June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Consumer Loyalty Program&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; In May 2020, the Company launched a consumer loyalty program, which allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and redeem the rewards for Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward (&#x201c;Reward&#x201d;) that the customer might redeem in the future. The standalone selling price of the Reward is measured based on historical sales data, estimated average selling price of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; at the time of redemption, expected customer and consumer participation rates in the loyalty program, and estimated number of qualifying treatments to be performed by customers. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue. Subsequently, when customers redeem the Reward and the related product is delivered, the deferred revenue is recognized in net revenues at that time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Co-Branded Marketing Programs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company offers eligible customers with a certain level of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; purchases to receive advertising co-branded with the Company. The co-branded advertising represents a performance obligation. At the time Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product is sold to customers, the invoice price is allocated between the product sold and the advertisement. The standalone selling price of the advertisement is measured based on the estimated market value of similar advertisement adjusted for the customer&#x2019;s portion of the advertisement. The portion of invoice price allocated to the advertisement is initially recorded as deferred revenue. Subsequently, when the advertisement airs, the deferred revenue is recognized in net revenues at that time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration becomes unconditional. The Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of&#160;December&#160;31, 2021 and 2020, all amounts included in accounts receivable, net on the accompanying balance sheets are related to contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any contract assets nor unbilled receivables as of&#160;December&#160;31, 2021 or 2020. Sales commissions are included in selling, general and administrative expenses when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients primarily under the rebate and coupon programs and deferred revenue associated with Rewards under the consumer loyalty program and co-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;branded marketing programs. The Company&#x2019;s contract liabilities are included in accounts payable and accrued expenses in the accompanying balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the accrued revenue contract liabilities, primarily related to volume-based rebates, consumer loyalty program, and co-branded media programs, were $7,934 and $3,081, respectively, which were recorded in accrued expenses in the accompanying balance sheets. For the years ended December 31, 2021 and 2020, provisions for rebate, coupon, consumer loyalty programs, and co-branded media programs were $16,139 and $16,896, respectively, which were offset by related payments, redemptions and adjustments of $11,286 and $15,524, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the&#160;years ended December 31, 2021 and 2020, the Company recognized $2,802 and $0, respectively, of revenue related to amounts included in contract liabilities at the beginning of the period and did not recognize any revenue related to changes in transaction prices regarding its contracts with customers from previous periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collectability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#x2019;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#x2019;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.&#160;The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of December 31, 2021 and 2020, allowance for doubtful accounts was $2,385 and $2,118, respectively. For the years ended December 31, 2021 and 2020, provision for bad debts was $589 and $2,066, respectively, and the write-off amount was $322 and $335, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Practical Expedients&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if89a2df2b8e54c8d8ee79434f9442e05_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMjA5NjE_8ca5ad8f-9f76-474b-8e24-d5e97607d03a"
      unitRef="usd">702000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1af8740f4504d02a822562858322d3f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTcxODMzOA_f70fc496-c955-4608-aeab-bade7c435c5f"
      unitRef="usd">738000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5ODE4NA_745516b1-faaf-45fc-8587-805ceac5a12a"
      unitRef="usd">7934000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5ODE5Mg_1df0ef73-81ce-4a07-9cd7-8f9b8e433167"
      unitRef="usd">3081000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <eols:RebatesAndCouponsCreditsAndPayments
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5ODQwNQ_1cabb32b-ed1f-4cb5-9613-46c4bcb4f9dc"
      unitRef="usd">16139000</eols:RebatesAndCouponsCreditsAndPayments>
    <eols:RebatesAndCouponsCreditsAndPayments
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5ODQxMw_1b3fe53e-082a-48cc-bbbc-669d28a09a4f"
      unitRef="usd">16896000</eols:RebatesAndCouponsCreditsAndPayments>
    <eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5ODUwMg_5e50799e-1a6b-4dc6-b4bd-42d87b5a161a"
      unitRef="usd">11286000</eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability>
    <eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5ODUxMA_0469a9e2-f585-4b96-a0e9-1f067b5109ff"
      unitRef="usd">15524000</eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzg0ODI5MDc0OTM5MQ_2cde9984-81ee-49a1-8bc4-5dfbad393ea3"
      unitRef="usd">2802000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzg0ODI5MDc0OTM5OQ_cc922ef4-7e50-46ef-8ac1-90952d9a37a6"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTcxODA2Ng_540ac6e0-a115-47fa-afe4-6d6d8db5c013"
      unitRef="usd">2385000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTcxODA3NA_2575a921-0442-4c69-b2e6-b5508c118b67"
      unitRef="usd">2118000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTcxODE1NA_af1f29f6-a0fe-45f9-9c5d-1ab233822743"
      unitRef="usd">589000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTcxODE2Ng_72515e65-f86b-4853-ae70-b94022a1582b"
      unitRef="usd">2066000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTcxODE4NA_9956ea6d-4110-4fd4-8521-95578f95f52b"
      unitRef="usd">322000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTcxODE3OA_9882bf83-1e63-4a0a-932d-9b62aa26218c"
      unitRef="usd">335000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NDU_9575e4fb-eda2-47e1-9fb1-0b8257fed385">&lt;div style="margin-bottom:10pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#x2019;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ic88608af4b8d44f29f8f6a890a3e0859_I20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5ODg0NA_e4632a7c-76ea-4795-8b7a-beb2ede47ca2"
      unitRef="usd">35000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <eols:LossContingencySettlementAgreementPaymentTerms
      contextRef="ia307b0175e9a4f089eff6272a567b599_D20210218-20210218"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5ODg1Nw_6d5ab27c-6fbc-4f63-955b-e1a8d93251f4">P2Y</eols:LossContingencySettlementAgreementPaymentTerms>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="i7e4a414b331e4768a456b40889b5bf16_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzg0ODI5MDc2NjI5OA_ad1c59d2-ab76-4248-9566-5a8a609571d2"
      unitRef="usd">15000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="iec7e63cb81e2460c81caf30e8a3ecb3e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzg0ODI5MDc2NjMwNw_adaa4cb7-045c-4f7d-8411-d1830786ec56"
      unitRef="usd">15000</us-gaap:LossContingencyAccrualPayments>
    <eols:StockIssuedDuringPeriodSharesLitigationSettlement
      contextRef="ic40c99d6b0a04616bf00bfc233eced25_D20210228-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5NjcwNA_98e09eb6-f2a5-4627-ba49-75ac75801968"
      unitRef="shares">6762652</eols:StockIssuedDuringPeriodSharesLitigationSettlement>
    <us-gaap:LitigationSettlementExpense
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY3OTIxMg_2a0511ba-f098-4b45-8035-45a63178bc81"
      unitRef="usd">83421000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i3a7d2bddc6cf450cb25bddf49c81a86d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMjg3NTk_8d118999-93df-48d9-a083-fe8fb00adcdf"
      unitRef="usd">35000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMjg3ODM_cc25f872-6a7b-4a15-ab91-3a74a023c7ae"
      unitRef="usd">48421000</us-gaap:PaymentsForLegalSettlements>
    <eols:StockIssuedDuringPeriodSharesLitigationSettlement
      contextRef="ic40c99d6b0a04616bf00bfc233eced25_D20210228-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY5NjcwOA_98e09eb6-f2a5-4627-ba49-75ac75801968"
      unitRef="shares">6762652</eols:StockIssuedDuringPeriodSharesLitigationSettlement>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i6b22c9a255f64ef69528be6cf90f2d57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzg0ODI5MDc0OTQyMQ_55b5550e-8184-4f30-a9fa-09ebb20e72c6"
      unitRef="usd">15000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LitigationReserveCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMjkwMTc_fb7ea66a-609f-4034-8507-fa7ec73ec9c0"
      unitRef="usd">15000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveNoncurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMjkwNDk_7a042829-d316-47dc-a28d-6163ba515657"
      unitRef="usd">5000000</us-gaap:LitigationReserveNoncurrent>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzg0ODI5MDc0OTQwMw_f45258b2-48a8-4a79-863f-3eb7fbfb173b"
      unitRef="usd">25500000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4Mzk_74d363bf-098c-4b4e-a0be-68f9e95a4456">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#x2019;s common stock, expected risk-free interest rate, and the option&#x2019;s expected life. The fair value of the Company&#x2019;s restricted stock units (&#x201c;RSUs&#x201d;) is based on the fair value on the grant date of the Company&#x2019;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the balance sheets and in the selling, general and administrative or research and development expenses in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzg0ODI5MDc1ODI5Nw_d1261128-0701-4975-b3f3-267b3e1ff8c1">Advertising CostsAdvertising costs are expensed as incurred and primarily include costs related to social media ads and co-branded marketing programs. Advertising costs are included in selling, general and administrative expenses.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY4ODc2Ng_23766db8-1e6e-40f9-802e-57d598e3d6db"
      unitRef="usd">16391000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY4ODc3NA_f4e2597d-12fb-4d84-beff-4915dea1a11e"
      unitRef="usd">4979000</us-gaap:AdvertisingExpense>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NjA_7971fe35-d41b-4262-b12f-12372a0ac6da">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#x2019;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&#160;50%&#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. The Company does not expect that changes to state tax laws through December&#160;31, 2021 to materially impact its financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NTY_7303416f-1a93-4cf5-b3ce-e6ebf4d4f566">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. The dilutive effect of stock options and restricted stock units is computed under the treasury stock method. The dilutive effect of the Daewoong Convertible Note is computed under the if-converted method. Potentially dilutive securities are excluded from the computations of diluted net loss per share if their effect would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id34ebca0dbac4892b9e26b1d887fc863_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTY0OTI2NzUwMzg0OA_0a6d196c-2ddc-4cb9-b304-35039821fa0d"
      unitRef="shares">3922286</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i41ae1e1c1bad4e168f9a39b7db9fc6ce_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTY0OTI2NzUwMzg1NA_05939937-3bd6-4e44-a03d-b7fb6a149f2b"
      unitRef="shares">4407498</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1fc31951483143dfaeb4fa1205ce3584_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY4MjMzOA_bac9ec71-af08-4e5b-a75a-13b42c630d2f"
      unitRef="shares">1926467</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6de2de54a6f5422793e33fa044c6ac61_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY4MjM0MQ_0813652c-6951-4dde-a20f-2cad4c501e62"
      unitRef="shares">1173741</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3b5f19e8647e4e1294248e74152897f8_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMTA5OTUxMTY4MzUwNA_1fce593a-fdfe-4d33-971a-6b7dc59423e6"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if36312ac79504238b5690df729b1f37c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfMzUzMjM_5ef9f47e-ebf4-4efd-8409-1c9e05987b81"
      unitRef="shares">3076923</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl85Ny9mcmFnOjk1ZWMwM2FiOTY4MzQ2NmU4ZGVmYzcxMjMzNDNhYjJkL3RleHRyZWdpb246OTVlYzAzYWI5NjgzNDY2ZThkZWZjNzEyMzM0M2FiMmRfNDE4NjE_ecdf43b7-b4ab-4fa5-9591-0abc45c60efc">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. FASB issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provisions remove certain exceptions including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020 and interim periods therein. The Company has adopted the guidance on the effective date of January 1, 2021. There are no material impacts to the financial statements as a result of this adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&#160;Issued But Not&#160;Adopted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU No. 2017-04,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles&#x2014;Goodwill and Other (Topic 350):&#160;Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#x2019;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January&#160;1, 2023. The standard requires prospective application. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU No. 2016-13, the FASB issued ASU 2018-19,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Topic 326, Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU does not change the core principle of the guidance in ASU No. 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&#160;The FASB also subsequently issued ASU No. 2019-04 which did not change the core principle of the guidance in ASU No. 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January 1, 2023. The Company is in the process of determining the effects the adoption will have on its financial statements and reviewing credit loss models to assess the impact of the adoption of the standard on the financial statements. Based on initial assessments, the Company believes that while adoption will modify the way it analyzes financial instruments, it does not expect adoption of this guidance will have a material impact to its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and in January 2021, the FASB issued ASU No. 2021-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Scope (&#x201c;ASU 2021-01&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Both ASU No. 2020-04 and ASU No. 2021-01 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (&#x201c;LIBOR&#x201d;) or another reference rate expected to be discontinued because of reference rate reform. ASU No. 2020-04 and ASU No. 2021-01 are effective upon issuance for contract modifications and hedging relationships, and the Company is allowed to elect to apply the amendments prospectively through December 31, 2022. The Company does not expect adoption of this guidance will have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the FASB issued ASU No. 2021-10,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This update will increase transparency of government assistance received by most business entities by requiring the disclosure of: (1) the types of transactions; (2) the accounting for the transactions; and, (3) the effect of the transactions on a business entity&#x2019;s financial statements. ASU No. 2021-10 is effective for financial statements issued for annual periods beginning after December 15, 2021, with early application permitted. The Company does not expect adoption of this guidance will have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#x2019;s present or future financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzMwMjI_f6ad7183-4063-402b-8339-e9fdcdc46b69">Fair Value Measurements and Short-Term Investments &lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company did not hold any short-term investments. As of December&#160;31, 2020, all of the Company&#x2019;s investments had remaining maturities of less than 12 months. The following is a summary of the Company&#x2019;s short-term investments, considered available-for-sale, as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the&#160;year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of the contingent royalty obligation payable to the Evolus Founders based on Level 3 inputs using a discounted cash flows method. The significant unobservable input assumptions that can significantly change the fair value include (i) projected amount and timing of net revenues during the payment period, which terminates in the quarter following the 10-year anniversary of the first commercial sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States, (ii) the discount rate and (iii) the timing of payments. During the years ended December 31, 2021 and 2020, the Company utilized discount rates between 13.0% and 20.0%, reflecting changes in the Company&#x2019;s risk profile. Net revenue projections are also updated to reflect changes in the timing of expected sales. Significant increases (decreases) in the discount rate would result in a significantly lower (higher) fair value measurement, which could materially impact the fair value reported on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,097)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value recorded in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Financial Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist primarily of cash and cash equivalents, short-term available-for-sale debt securities, accounts receivable, accounts payable, accrued expenses, lease liabilities, and long-term debt. The carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of the promissory note payable to the Evolus Founders, long-term debt and operating lease liabilities using the discounted cash flow analysis based on the interest rates for similar rated debt securities (Level 2). As of December 31, 2021, the fair value of the long-term debt was $75,448. As of December&#160;31, 2020, the fair value of the contingent promissory note and long-term debt was estimated to be $19,284 and $76,368, respectively. The fair value of operating lease liabilities&#160;as of December&#160;31, 2021 and 2020 approximated their carrying value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzMwMTg_974d9664-b11c-487e-afdf-79789a51cf76">As of December&#160;31, 2020, all of the Company&#x2019;s investments had remaining maturities of less than 12 months. The following is a summary of the Company&#x2019;s short-term investments, considered available-for-sale, as of December&#160;31, 2020:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifc1dd5e647ea4c61b81e841d2fa58ac8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZToxZDA3YWYyNTUzMzY0MTgyOTczMTE1ZmQzNmFhZWZhNi90YWJsZXJhbmdlOjFkMDdhZjI1NTMzNjQxODI5NzMxMTVmZDM2YWFlZmE2XzQtMS0xLTEtMjQ2OTc_e07c135f-6dd9-4130-8a48-50a0f4550d01"
      unitRef="usd">5000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifc1dd5e647ea4c61b81e841d2fa58ac8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZToxZDA3YWYyNTUzMzY0MTgyOTczMTE1ZmQzNmFhZWZhNi90YWJsZXJhbmdlOjFkMDdhZjI1NTMzNjQxODI5NzMxMTVmZDM2YWFlZmE2XzQtMy0xLTEtMjQ2OTc_47772e67-5b84-4186-ba0a-dd9364ba9bbb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifc1dd5e647ea4c61b81e841d2fa58ac8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZToxZDA3YWYyNTUzMzY0MTgyOTczMTE1ZmQzNmFhZWZhNi90YWJsZXJhbmdlOjFkMDdhZjI1NTMzNjQxODI5NzMxMTVmZDM2YWFlZmE2XzQtNS0xLTEtMjQ2OTc_315c7d3f-50aa-47c7-860d-32280ae9cbbf"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifc1dd5e647ea4c61b81e841d2fa58ac8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZToxZDA3YWYyNTUzMzY0MTgyOTczMTE1ZmQzNmFhZWZhNi90YWJsZXJhbmdlOjFkMDdhZjI1NTMzNjQxODI5NzMxMTVmZDM2YWFlZmE2XzQtNy0xLTEtMjQ2OTc_e64af5af-a35e-4499-a728-97e6de7273f6"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzMwMTQ_f0ba9a7e-157e-43f8-804b-c495c9d396b3">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iaaadf7ebcb2440558c596d02aa4fe18d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpkZmNhZmU2YzRmN2U0NTc1OWY1ZTM1MDU5ZjYyMjc2Zi90YWJsZXJhbmdlOmRmY2FmZTZjNGY3ZTQ1NzU5ZjVlMzUwNTlmNjIyNzZmXzUtMS0xLTEtMjQ2OTc_16b66496-ec1c-4c29-8510-389311104b27"
      unitRef="usd">44740000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i188292fb611741ec93ece11f8e4d57aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpkZmNhZmU2YzRmN2U0NTc1OWY1ZTM1MDU5ZjYyMjc2Zi90YWJsZXJhbmdlOmRmY2FmZTZjNGY3ZTQ1NzU5ZjVlMzUwNTlmNjIyNzZmXzUtMy0xLTEtMjQ2OTc_1374bd8a-baa4-47fc-b38a-45867a99062b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i2126481ac7a74980a92e9285369775dc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpkZmNhZmU2YzRmN2U0NTc1OWY1ZTM1MDU5ZjYyMjc2Zi90YWJsZXJhbmdlOmRmY2FmZTZjNGY3ZTQ1NzU5ZjVlMzUwNTlmNjIyNzZmXzUtNS0xLTEtMjQ2OTc_a2c54b17-fe2f-4269-85f8-d0b95c6b84c9"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i21f2ba8ba1854a108007d265c9b25d60_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpkZmNhZmU2YzRmN2U0NTc1OWY1ZTM1MDU5ZjYyMjc2Zi90YWJsZXJhbmdlOmRmY2FmZTZjNGY3ZTQ1NzU5ZjVlMzUwNTlmNjIyNzZmXzUtNy0xLTEtMjQ2OTc_2361f4d0-177f-444f-bd54-7b048367e577"
      unitRef="usd">44740000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ifc1dd5e647ea4c61b81e841d2fa58ac8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpiMmQ4OTA5YTY0YjQ0ZTNmYmIyMjIzZmE5NDExMmIxOC90YWJsZXJhbmdlOmIyZDg5MDlhNjRiNDRlM2ZiYjIyMjNmYTk0MTEyYjE4XzMtMS0xLTEtMjQ2OTc_b5925fab-71f9-419c-b78a-a960887c54f4"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ie9646e12d03f4e54b9e9276d5b1d0f3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpiMmQ4OTA5YTY0YjQ0ZTNmYmIyMjIzZmE5NDExMmIxOC90YWJsZXJhbmdlOmIyZDg5MDlhNjRiNDRlM2ZiYjIyMjNmYTk0MTEyYjE4XzMtMy0xLTEtMjQ2OTc_7dce9da0-e5c4-4f09-ab5a-d94526ca394e"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="id68d8821d04841b29a08745afac4b24a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpiMmQ4OTA5YTY0YjQ0ZTNmYmIyMjIzZmE5NDExMmIxOC90YWJsZXJhbmdlOmIyZDg5MDlhNjRiNDRlM2ZiYjIyMjNmYTk0MTEyYjE4XzMtNS0xLTEtMjQ2OTc_caf129d6-d503-4837-a321-0a1603106fa2"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i2c80b688d1614017ad7563e60cbf9695_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpiMmQ4OTA5YTY0YjQ0ZTNmYmIyMjIzZmE5NDExMmIxOC90YWJsZXJhbmdlOmIyZDg5MDlhNjRiNDRlM2ZiYjIyMjNmYTk0MTEyYjE4XzMtNy0xLTEtMjQ2OTc_b7547b16-64b9-4860-9fa1-5b4fdf2cc214"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i93faa46c660e429db8bd1d5c2859380e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpiMmQ4OTA5YTY0YjQ0ZTNmYmIyMjIzZmE5NDExMmIxOC90YWJsZXJhbmdlOmIyZDg5MDlhNjRiNDRlM2ZiYjIyMjNmYTk0MTEyYjE4XzUtMS0xLTEtMjQ2OTc_2000b058-8cfa-4fd7-8703-c2d8a8ec3ba5"
      unitRef="usd">41546000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i81b74edf017e427b8f5b7fafd4bc3d1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpiMmQ4OTA5YTY0YjQ0ZTNmYmIyMjIzZmE5NDExMmIxOC90YWJsZXJhbmdlOmIyZDg5MDlhNjRiNDRlM2ZiYjIyMjNmYTk0MTEyYjE4XzUtMy0xLTEtMjQ2OTc_d492fb01-710b-4b3d-b4ea-587d470388d6"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i17c0c8daaf4141d78d576fc09db214fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpiMmQ4OTA5YTY0YjQ0ZTNmYmIyMjIzZmE5NDExMmIxOC90YWJsZXJhbmdlOmIyZDg5MDlhNjRiNDRlM2ZiYjIyMjNmYTk0MTEyYjE4XzUtNS0xLTEtMjQ2OTc_1a9888e3-b80e-4e68-a744-2e80d752e577"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ief25c158c2d14085a69e4a3d492bdfd3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTpiMmQ4OTA5YTY0YjQ0ZTNmYmIyMjIzZmE5NDExMmIxOC90YWJsZXJhbmdlOmIyZDg5MDlhNjRiNDRlM2ZiYjIyMjNmYTk0MTEyYjE4XzUtNy0xLTEtMjQ2OTc_a232eae6-a543-4f10-a857-5a362c3072a6"
      unitRef="usd">41546000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i95e8f96583894a6cb3bc3881f9f0ed7d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzEyNDI_03fa3d3f-375a-42e3-9203-f3e8fd0d80c9"
      unitRef="year">10</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i44f0543f775c46f490919b75592c1ee5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzE0NDg_96786f26-7959-40dc-891d-d5cad26a650e"
      unitRef="number">0.130</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i4297d135149943959e21307f69d5bb57_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzE0NDg_b45242c8-32db-4396-941a-8bf67071f2e9"
      unitRef="number">0.130</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i3723caf0d1864617b4ad156f12392622_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzE0NTU_3018d156-47c0-49d2-9f1f-a8fbeda32091"
      unitRef="number">0.200</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i239343ea90f94848ab298a3e8b49d754_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzE0NTU_d8c2befd-1178-4c25-bef7-87aada76cfb0"
      unitRef="number">0.200</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzMwMjU_51e8d44f-f86c-470f-b83c-d1c1888069b9">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,097)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value recorded in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTphZjI5MDlhMDE4MDM0MTEyODQ3NDllYTFkNGFiNmMxNy90YWJsZXJhbmdlOmFmMjkwOWEwMTgwMzQxMTI4NDc0OWVhMWQ0YWI2YzE3XzItMS0xLTEtMjQ2OTc_f0a35048-ba4b-4835-8c35-8ee1a6628370"
      unitRef="usd">41546000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="idb18fef826e14bf1b6a11208896433a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTphZjI5MDlhMDE4MDM0MTEyODQ3NDllYTFkNGFiNmMxNy90YWJsZXJhbmdlOmFmMjkwOWEwMTgwMzQxMTI4NDc0OWVhMWQ0YWI2YzE3XzItMy0xLTEtMjQ2OTc_1fdadd4e-fd32-4c83-86db-22a4e4e03c10"
      unitRef="usd">44683000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTphZjI5MDlhMDE4MDM0MTEyODQ3NDllYTFkNGFiNmMxNy90YWJsZXJhbmdlOmFmMjkwOWEwMTgwMzQxMTI4NDc0OWVhMWQ0YWI2YzE3XzMtMS0xLTEtMjQ2OTc_5e59c741-d734-4135-b8fa-a23cce2f0dcd"
      unitRef="usd">3097000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTphZjI5MDlhMDE4MDM0MTEyODQ3NDllYTFkNGFiNmMxNy90YWJsZXJhbmdlOmFmMjkwOWEwMTgwMzQxMTI4NDc0OWVhMWQ0YWI2YzE3XzMtMy0xLTEtMjQ2OTc_b2750db9-1f64-43bd-bdc2-912281c77b0a"
      unitRef="usd">1130000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTphZjI5MDlhMDE4MDM0MTEyODQ3NDllYTFkNGFiNmMxNy90YWJsZXJhbmdlOmFmMjkwOWEwMTgwMzQxMTI4NDc0OWVhMWQ0YWI2YzE3XzQtMS0xLTEtMjQ2OTc_ff4c010d-dac1-4abe-9e8a-7257712cdfd4"
      unitRef="usd">-6290000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTphZjI5MDlhMDE4MDM0MTEyODQ3NDllYTFkNGFiNmMxNy90YWJsZXJhbmdlOmFmMjkwOWEwMTgwMzQxMTI4NDc0OWVhMWQ0YWI2YzE3XzQtMy0xLTEtMjQ2OTc_2aff2ca7-8881-45de-a90c-d7cbdf9ffdec"
      unitRef="usd">2007000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTphZjI5MDlhMDE4MDM0MTEyODQ3NDllYTFkNGFiNmMxNy90YWJsZXJhbmdlOmFmMjkwOWEwMTgwMzQxMTI4NDc0OWVhMWQ0YWI2YzE3XzUtMS0xLTEtMjQ2OTc_3f03405d-6eb9-4e8e-ab7c-7daae503657e"
      unitRef="usd">44740000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90YWJsZTphZjI5MDlhMDE4MDM0MTEyODQ3NDllYTFkNGFiNmMxNy90YWJsZXJhbmdlOmFmMjkwOWEwMTgwMzQxMTI4NDc0OWVhMWQ0YWI2YzE3XzUtMy0xLTEtMjQ2OTc_df1b5c1b-af80-46ac-9e4c-2ab437dfd1b6"
      unitRef="usd">41546000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzE2NDkyNjc0NDUxOTU_d750404b-814a-431f-b0a0-dd3850aee394"
      unitRef="usd">75448000</us-gaap:LongTermDebtFairValue>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzI4OTI_51b12262-f9fe-4d4c-b4f2-d75a9cae440c"
      unitRef="usd">19284000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:LongTermDebtFairValue
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDAvZnJhZzpkZTdmN2E4Yjg0ZmI0NjVhYTllNzcyMjdkZWZlODYzMS90ZXh0cmVnaW9uOmRlN2Y3YThiODRmYjQ2NWFhOWU3NzIyN2RlZmU4NjMxXzI4OTk_80a78a7c-1cef-413e-93c2-faa5273c7fd2"
      unitRef="usd">76368000</us-gaap:LongTermDebtFairValue>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE4ODY_57590ba4-bac6-4270-b6c8-871c2b217cbe">Goodwill and Intangible Assets &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Original Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Book Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution right&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Original Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Book Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution right&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Intangible assets with indefinite lives have an indeterminable average life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;December&#160;31, 2021 that are subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.142%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distribution right represents the license and associated distribution right to develop Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the initial term of which expires in September 2023 and is automatically extended for unlimited additional three-year terms provided that the Company meets certain performance requirements. Additionally, upon FDA approval of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;on February 1, 2019, the IPR&amp;amp;D project was completed and reclassified as a definite-lived distribution right intangible asset, which is amortized on a straight-line basis over the estimated useful life of 20 years. The Company paid Daewoong a $2,000 milestone payment, pursuant to the Daewoong Agreement, which increased the cost basis of the distribution. In connection with EU approval of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company paid a $1,000 milestone payment to Daewoong in the fourth quarter of fiscal year 2019, which increased the cost basis of the distribution right. Under the Daewoong Arrangement (as defined in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), there is no additional cash consideration due to Daewoong. See&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional information.&lt;/span&gt;&lt;/div&gt;For the years ended December 31, 2021 and 2020, the Company capitalized $633 and $2,266, respectively, related to costs of computer software developed for internal use. The software is amortized over a two-year period using the straight-line method. For the years ended December 31, 2021 and 2020, total intangible assets amortization expense of $5,305 and $3,635, respectively, was recorded within depreciation and amortization on the accompanying statements of operations and comprehensive loss.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE4ODA_661176ab-8481-4fc6-9976-59de5653f73c">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Original Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Book Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution right&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Original Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Book Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution right&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Intangible assets with indefinite lives have an indeterminable average life.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic3bdecfb61f64eacb1bec28f7caef51c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzMtMS0xLTEtMjQ2OTc_66ea53cd-913f-4541-9b5f-4d5b64841350">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9aa9cf7ce6924d97b753fab0a35caffd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzMtMy0xLTEtMjQ2OTc_fb3f06e2-4bd5-4211-b75a-6f45197d70dc"
      unitRef="usd">59076000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9aa9cf7ce6924d97b753fab0a35caffd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzMtNS0xLTEtMjQ2OTc_523a3665-1521-4a77-a8dd-05e787e22033"
      unitRef="usd">8589000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9aa9cf7ce6924d97b753fab0a35caffd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzMtNy0xLTEtMjQ2OTc_6f3a6214-8bfd-4e2a-9627-cd20ce6f2b86"
      unitRef="usd">50487000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2a3026926537414c9e558b2f48c5ac00_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzQtMS0xLTEtMjQ2OTc_1bf41e4c-79f9-4f05-96cf-b68dba82bea0">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i57c030fa26f84d46a809534c6d533f06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzQtMy0xLTEtMjQ2OTc_257d9961-2c38-4114-ad66-0801eae34718"
      unitRef="usd">7314000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i57c030fa26f84d46a809534c6d533f06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzQtNS0xLTEtMjQ2OTc_e5476c58-7345-4a34-b264-7f2689d23ae4"
      unitRef="usd">7176000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i57c030fa26f84d46a809534c6d533f06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzQtNy0xLTEtMjQ2OTc_8f170da9-fead-4dca-82dc-1cfc9285108b"
      unitRef="usd">138000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzUtMy0xLTEtMjQ2OTc_4a94cf4a-ced0-4cd5-9c65-9a746d71d7b6"
      unitRef="usd">66390000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzUtNS0xLTEtMjQ2OTc_d5c03b33-90ab-40d4-9df7-3f567eb09cfd"
      unitRef="usd">15765000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzUtNy0xLTEtMjQ2OTc_5fdaabf5-5222-40ad-9255-baaa99b847cf"
      unitRef="usd">50625000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzctMy0xLTEtMjQ2OTc_cd17a90e-e6ae-4851-a4d6-f59068fd9ec9"
      unitRef="usd">21208000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzctNy0xLTEtMjQ2OTc_6d78cf7a-250f-4102-8328-e92822d405a7"
      unitRef="usd">21208000</us-gaap:Goodwill>
    <eols:IntangibleAssetsGrossIncludingGoodwill
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzgtMy0xLTEtMjQ2OTc_6acd0a46-e1ee-4b2a-8e4c-5e64746bd826"
      unitRef="usd">87598000</eols:IntangibleAssetsGrossIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzgtNS0xLTEtMjQ2OTc_5a45e39e-0a5e-4f49-864c-996ad61ad861"
      unitRef="usd">15765000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZToyMzM4ZDg2ODRlZjE0MmQ0OWVjNTc3YzQyM2Y0YTNkYy90YWJsZXJhbmdlOjIzMzhkODY4NGVmMTQyZDQ5ZWM1NzdjNDIzZjRhM2RjXzgtNy0xLTEtMjQ2OTc_3d1a83a3-67c8-4cfc-8add-742e0f959066"
      unitRef="usd">71833000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iecd7c427bcea41a68a2333c4ab2e58f4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzMtMS0xLTEtMjQ2OTc_6a6cfa48-6891-49ed-92a9-a8052cf5a11b">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i135354304f194b65a202352820714058_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzMtMy0xLTEtMjQ2OTc_664c291f-316b-4bf3-a4a2-5a0acc592bad"
      unitRef="usd">59076000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i135354304f194b65a202352820714058_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzMtNS0xLTEtMjQ2OTc_ffac1cb6-fa31-4b31-a1d6-76cc94131003"
      unitRef="usd">5650000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i135354304f194b65a202352820714058_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzMtNy0xLTEtMjQ2OTc_27f8f939-c6a7-47e2-aff0-f0a6c02ef51a"
      unitRef="usd">53426000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i5bcc0e46ed1c4cd4b910b9542aaeca6e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzQtMS0xLTEtMjQ2OTc_7e98d9de-00fa-4c74-a055-7e287480fa37">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3ef09bce4de74ec69fa66b0204b03c06_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzQtMy0xLTEtMjQ2OTc_b3d73ecd-4710-4ca4-a4f1-a6dc006bee3a"
      unitRef="usd">6681000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3ef09bce4de74ec69fa66b0204b03c06_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzQtNS0xLTEtMjQ2OTc_ee236dd7-6b68-47b4-b037-64e0bac0ae5e"
      unitRef="usd">4810000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3ef09bce4de74ec69fa66b0204b03c06_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzQtNy0xLTEtMjQ2OTc_f0a62185-4955-46b8-8e0d-236344394099"
      unitRef="usd">1871000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzUtMy0xLTEtMjQ2OTc_03a84a44-8b5e-47ad-a383-f4b7e6a60ef8"
      unitRef="usd">65757000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzUtNS0xLTEtMjQ2OTc_3b59655f-9038-4407-a5ac-5da688b5e871"
      unitRef="usd">10460000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzUtNy0xLTEtMjQ2OTc_c72be905-b088-49d6-8f8a-5777748eb9e2"
      unitRef="usd">55297000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzctMy0xLTEtMjQ2OTc_3141a7bf-aff7-413c-b9d7-77ad498d6b1d"
      unitRef="usd">21208000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzctNy0xLTEtMjQ2OTc_7adf1286-99ef-47c1-b74d-6997618e1d54"
      unitRef="usd">21208000</us-gaap:Goodwill>
    <eols:IntangibleAssetsGrossIncludingGoodwill
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzgtMy0xLTEtMjQ2OTc_0fc82f61-7270-475e-86e3-da17b61de950"
      unitRef="usd">86965000</eols:IntangibleAssetsGrossIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzgtNS0xLTEtMjQ2OTc_0dd30b9c-f3fb-4572-a590-6690ea2b164b"
      unitRef="usd">10460000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3NjQxNTJkZjA5NzM0OTlkYmViMWM5MmI5MTQ0NDU5ZS90YWJsZXJhbmdlOjc2NDE1MmRmMDk3MzQ5OWRiZWIxYzkyYjkxNDQ0NTllXzgtNy0xLTEtMjQ2OTc_e68f42e9-7cd2-4fb0-a511-11087855d872"
      unitRef="usd">76505000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE4Nzg_e57352f5-dc9f-4b8c-93f1-f73c9980c787">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;December&#160;31, 2021 that are subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.142%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3ZjI2OTc1YThjNzM0ODY0OGJkMTk2YTg4YjZlOTYwZC90YWJsZXJhbmdlOjdmMjY5NzVhOGM3MzQ4NjQ4YmQxOTZhODhiNmU5NjBkXzItMS0xLTEtMjQ2OTc_0ad1357a-7603-40bf-a5b3-2c0ef165786e"
      unitRef="usd">3016000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3ZjI2OTc1YThjNzM0ODY0OGJkMTk2YTg4YjZlOTYwZC90YWJsZXJhbmdlOjdmMjY5NzVhOGM3MzQ4NjQ4YmQxOTZhODhiNmU5NjBkXzMtMS0xLTEtMjQ2OTc_9deb1f23-ae8a-4b8c-b9da-2800a312a80d"
      unitRef="usd">3034000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3ZjI2OTc1YThjNzM0ODY0OGJkMTk2YTg4YjZlOTYwZC90YWJsZXJhbmdlOjdmMjY5NzVhOGM3MzQ4NjQ4YmQxOTZhODhiNmU5NjBkXzQtMS0xLTEtMjQ2OTc_249f2489-f7be-4057-81a5-fb9d02fc277f"
      unitRef="usd">2955000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3ZjI2OTc1YThjNzM0ODY0OGJkMTk2YTg4YjZlOTYwZC90YWJsZXJhbmdlOjdmMjY5NzVhOGM3MzQ4NjQ4YmQxOTZhODhiNmU5NjBkXzUtMS0xLTEtMjQ2OTc_c7d38ee0-d31f-4350-8a16-94d4c9aa0295"
      unitRef="usd">2955000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3ZjI2OTc1YThjNzM0ODY0OGJkMTk2YTg4YjZlOTYwZC90YWJsZXJhbmdlOjdmMjY5NzVhOGM3MzQ4NjQ4YmQxOTZhODhiNmU5NjBkXzUtMS0xLTEtMzA0NTk_717c2948-8959-4671-a492-7b39f90599c7"
      unitRef="usd">2955000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3ZjI2OTc1YThjNzM0ODY0OGJkMTk2YTg4YjZlOTYwZC90YWJsZXJhbmdlOjdmMjY5NzVhOGM3MzQ4NjQ4YmQxOTZhODhiNmU5NjBkXzYtMS0xLTEtMjQ2OTc_71152e05-820e-442c-86f8-34851af1151b"
      unitRef="usd">35710000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90YWJsZTo3ZjI2OTc1YThjNzM0ODY0OGJkMTk2YTg4YjZlOTYwZC90YWJsZXJhbmdlOjdmMjY5NzVhOGM3MzQ4NjQ4YmQxOTZhODhiNmU5NjBkXzctMS0xLTEtMjQ2OTc_ad5bfcf1-2e32-45b1-8597-721b8de2d8a2"
      unitRef="usd">50625000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <eols:AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements
      contextRef="i3bbaa2f404694cf09f8b1dd48adb8b5a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE4ODQ_88907c01-f858-4d03-8101-31a86f78a67d">P3Y</eols:AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i26cd83bcd422412f813d386ddac29197_D20190201-20190201"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzk2MA_5886100f-8b9b-43dd-9093-c42f4366abd6">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <eols:MilestonePaymentsForIntangibleAssets
      contextRef="i88606d7b76234da8a815ea40351a89f6_D20190201-20190201"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzk5Mg_594c519a-64ae-42b2-9f73-3d673a73849e"
      unitRef="usd">2000000</eols:MilestonePaymentsForIntangibleAssets>
    <eols:MilestonePaymentInConnectionWithLicenseAndSupplyAgreement
      contextRef="i58135f80c4e74590a70a971e21d37e1f_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzExNjg_71e2cfa2-a3e0-48a2-9c36-8b166e46f9ac"
      unitRef="usd">1000000</eols:MilestonePaymentInConnectionWithLicenseAndSupplyAgreement>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE0OTg_912a6d1d-7cfd-4bc1-a777-78615cd5a3d9"
      unitRef="usd">633000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE1MDU_a48c0e9d-eb0a-49b6-9872-97f1fa97488d"
      unitRef="usd">2266000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i2a3026926537414c9e558b2f48c5ac00_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE4Nzk_ec9a77dc-6d2d-433d-9707-2d6677ee2a44">P2Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE3MzY_5a6aea43-8064-433d-a856-083bb6131470"
      unitRef="usd">5305000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDMvZnJhZzo4YWQ1MmYxOGI2MmU0ODQ1YjZkYWMwN2MyMzRjYjA0MS90ZXh0cmVnaW9uOjhhZDUyZjE4YjYyZTQ4NDViNmRhYzA3YzIzNGNiMDQxXzE3NDM_02fa01e7-ce5d-473d-bedb-ef8e37b0da09"
      unitRef="usd">3635000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90ZXh0cmVnaW9uOjE5YTdjNWIwMjdkODRhOGJiMWJjMjZkYjJiNzE4NjRiXzc5_47da6775-20e4-4e65-8cb6-50dddcf21559">Accrued Expenses &lt;div style="margin-bottom:9pt;padding-right:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties under the Medytox/Allergan Settlement Agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued revenue contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90ZXh0cmVnaW9uOjE5YTdjNWIwMjdkODRhOGJiMWJjMjZkYjJiNzE4NjRiXzc3_5d3e799a-b1e6-47f3-b634-d8cd53131e76">&lt;div style="margin-bottom:9pt;padding-right:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties under the Medytox/Allergan Settlement Agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued revenue contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzItMS0xLTEtMzA0Njc_553d8011-defc-49cf-b3f5-423983fb7041"
      unitRef="usd">12447000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzItMy0xLTEtMzA0Njc_8f01036a-3aeb-410b-91e1-96477e4dd873"
      unitRef="usd">0</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzItMS0xLTEtMjQ2OTc_b04b690b-48d1-49b2-aafb-441085627fa4"
      unitRef="usd">6856000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzItMy0xLTEtMjQ2OTc_5b46f3e9-3c5f-498b-a163-6544d2108b9f"
      unitRef="usd">4076000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzMtMS0xLTEtMjQ2OTc_745516b1-faaf-45fc-8587-805ceac5a12a"
      unitRef="usd">7934000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzMtMy0xLTEtMjQ2OTc_1df0ef73-81ce-4a07-9cd7-8f9b8e433167"
      unitRef="usd">3081000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzQtMS0xLTEtMjQ2OTc_081630a2-cd67-474d-ab39-f238ae824784"
      unitRef="usd">595000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzQtMy0xLTEtMjQ2OTc_2fd70cff-8387-48d0-bce0-26904ed08912"
      unitRef="usd">895000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzUtMS0xLTEtMjQ2OTc_bea16e4c-dc1f-479e-8ffe-3d1e79e1ba63"
      unitRef="usd">2161000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzUtMy0xLTEtMjQ2OTc_d22745c1-5606-44fd-83a1-2fdfdf13c90f"
      unitRef="usd">1050000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzYtMS0xLTEtMjQ2OTc_67a63f46-cd7b-4f9e-b523-e72f96e9282d"
      unitRef="usd">29993000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMDYvZnJhZzoxOWE3YzViMDI3ZDg0YThiYjFiYzI2ZGIyYjcxODY0Yi90YWJsZTo4YWQ1M2JhNDZkMmU0MDFhYjZkMjZmMzJmZWYzNGIyYS90YWJsZXJhbmdlOjhhZDUzYmE0NmQyZTQwMWFiNmQyNmYzMmZlZjM0YjJhXzYtMy0xLTEtMjQ2OTc_4f55957f-65d5-4b10-8db5-eb7da0c60f94"
      unitRef="usd">9102000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV84MjQ2MzM3MjMwMDk0_be7ccbc1-50fe-4f0c-bea7-1be4afbfe813">Term Loans&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pharmakon Term Loans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 14, 2021, the Company entered into a loan agreement with Pharmakon. Pursuant to the terms of the agreement, Pharmakon agreed to make term loans to the Company in two tranches (&#x201c;Pharmakon Term Loans&#x201d;). The first tranche of $75,000 was funded on December 29, 2021. The second tranche of $50,000 may be drawn at the Company&#x2019;s election no later than December 31, 2022. As of December&#160;31, 2021, the Company has not drawn the second tranche. The Pharmakon Term Loans will mature on the sixth year anniversary of the closing date of the first tranche (&#x201c;Maturity Date&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmakon Term Loans accrue interest at a per annum rate equal to the 3-month U.S. Dollar LIBOR rate (subject to a LIBOR rate floor of 1.0%) plus 8.5% per annum; provided that, upon a public statement or publication of information in certain circumstances that LIBOR has ceased or will cease to be provided or be representative or the occurrence of an early opt-in determination by the collateral agent, the Pharmakon Term Loans will be amended to provide for an alternative to the 3-month U.S. Dollar LIBOR rate established by the lenders holding a majority of the outstanding Pharmakon Term Loans, giving due consideration to the selection or recommendation of a replacement rate or mechanism for determining such rate by any applicable governmental authority or the then-prevailing market conventions. The Company agreed to make 12 equal quarterly payments of principal on the outstanding Pharmakon Term Loans commencing on or immediately following the 39th-month anniversary of the funding date of the first tranche continuing through the Maturity Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may elect to prepay all amounts, not less than $20,000, owed prior to the Maturity Date. Prepayments of the first tranche prior to the second anniversary of the closing date of the first tranche and prepayments of the second tranche prior to the second anniversary of the date on which the second tranche is drawn by the Company will be accompanied by a make whole amount equal to the sum of all interest that would have accrued through such second anniversary. Prepayments of the Pharmakon Term Loans will also be accompanied by a prepayment premium equal to the principal amount so prepaid multiplied by 3.0% if made prior to the third anniversary of the closing date of the first tranche, 2.0% if made on or after the third anniversary of the closing date of the first tranche but prior to the fourth anniversary of the closing date of the first tranche, and 1.0% if made on or after the fourth anniversary of the closing date of the first tranche but prior to the Maturity Date. If the Pharmakon Term Loans are accelerated following the occurrence of an event of default, including a material adverse change, the Company is required to immediately pay Pharmakon an amount equal to the sum of all outstanding principal, unpaid interest, and applicable make whole and prepayment premiums.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmakon Term Loans are secured by substantially all of the Company&#x2019;s assets. The Pharmakon Term Loans contain customary affirmative and restrictive covenants and representations and warranties. The affirmative covenants include, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;among others, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. The restrictive covenants include, among others, incurring certain additional indebtedness, consummating certain change in control transactions, or incurring any non- permitted lien or other encumbrance on the Company&#x2019;s assets, without Pharmakon&#x2019;s prior written consent. The Pharmakon Term Loans do not contain covenants requiring the Company to maintain a minimum cash threshold or minimum revenues or earnings. As of December&#160;31, 2021, the Company was in compliance with its debt covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing date of the first tranche, the Company incurred $3,042 and $3,263 in debt discounts and issuance costs related to the Pharmakon Term Loans, respectively. Debt discounts and issuance costs related to the entire Pharmakon Term Loans have been allocated pro rata between the funded and unfunded portions. Debt discounts and issuance costs allocated to the first tranche of $75,000 have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. As of December&#160;31, 2021, the borrowings outstanding under the Pharmakon Term Loans were classified as long-term debt in the accompanying balance sheets. Debt discounts and issuance costs associated with the unfunded tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. The overall effective interest rate was approximately 10.89% as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.476%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,778)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long term debt, net of discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Oxford Term Loans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 15, 2019, the Company entered into a Loan and Security Agreement with Oxford (the &#x201c;Loan Agreement&#x201d;), providing for a credit facility of up to $100,000. Pursuant to the terms of the credit facility, the lender extended term loans (the &#x201c;Oxford Term Loan&#x201d;), available in two advances, to the Company. The first tranche of $75,000 was funded on the closing date. The second tranche of $25,000 was not drawn. The credit facility bore an annual interest rate equal to the greater of 9.5%, or the 30-day U.S. Dollar LIBOR rate plus 7.0%. The Company agreed to pay interest-only for the first 36 months until May 2022, followed by a 23 months amortization period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing date, the Company incurred $1,094 and $2,205 in debt discounts and issuance costs related to the Oxford Term Loan, respectively. Debt&#160;discounts and issuance costs related to the entire Oxford Term Loan have been allocated pro rata between the funded and unfunded portions. Debt&#160;discounts and issuance costs related to the Oxford Term Loan have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. The overall effective interest rate was approximately 11.6% as of December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the earliest to occur of the maturity date, the acceleration of the Oxford Term Loan, or the prepayment of the Oxford Term Loan, the Company was required to pay to Oxford a final payment of 5.5% of the full principal amount of the Oxford Term Loan funded (&#x201c;Final Payment&#x201d;). The Company could elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee was also paid, which would be equal to 2.0% of the amount prepaid if the prepayment occurred after March 15, 2020 and on or prior to March 15, 2021, or 1.0% of the amount prepaid if the prepayment occurred thereafter (&#x201c;Prepayment Fee&#x201d;).&lt;/span&gt;&lt;/div&gt;On January 4, 2021, the Company and Oxford entered into an agreement (&#x201c;Payoff Letter&#x201d;), pursuant to which (i) the Company paid Oxford $76,447 to discharge in full all outstanding obligations, including accrued interest by and between Oxford, in its capacity as collateral agent and lender, and the Company, and (ii) effective upon such repayment, the Loan Agreement, and all unfunded commitments thereunder, guarantees and other security interests granted to Oxford in connection with the Loan Agreement and all other obligations of and restrictions on the Company under the Loan Agreement, terminated. As a condition to entering into the Payoff Letter, Oxford agreed to waive a total of $4,300 of fees comprised of (i) $2,800 of the Final Payment and (ii) the Prepayment Fee of $1,500. As a result, the Company recorded a loss of $1,939 in extinguishment of debts, net on the accompanying statements of operations and comprehensive loss. Daewoong Convertible Note&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 6, 2020, the Company entered into a Convertible Promissory Note Purchase Agreement with Daewoong for the principal amount of $40,000 (the &#x201c;Daewoong Convertible Note&#x201d;), which was funded on July 30, 2020. Additionally, on July 6, 2020, the Company, Daewoong and Oxford entered into a Subordination Agreement pursuant to which the Daewoong Convertible Note was subordinated to the Company&#x2019;s obligations under the Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Daewoong Convertible Note bore interest at a rate of 3.0% payable semi-annually in arrears on June 30th and December 31st of each year and was to mature on July 30, 2025, subject to earlier conversion as provided below. Interest was initially paid in kind by adding the accrued amount thereof to the outstanding principal amount on a semi-annual basis on June 30th and December 31st of each calendar year for so long as any principal amount under the Oxford Term Loan remained outstanding and the Subordination Agreement was not terminated. Interest became payable in cash after the Oxford Term Loan was repaid in full, and the Subordination Agreement was terminated on January 4, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;23, 2021, the outstanding principal balance including all accrued and unpaid interest thereon, of $40,779 was converted into 3,136,869 shares of the Company&#x2019;s common stock under the Conversion Agreement at the conversion price of $13.00 per share. The conversion was accounted for as an extinguishment of debt resulting in a gain of $971, which is recorded in loss from extinguishment of debts, net on the accompanying statements of operations and comprehensive loss. The Daewoong Convertible Note was not registered, and the shares of the Company&#x2019;s common stock issued upon conversion of the Daewoong Convertible Note have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the details of the Conversion Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <eols:DebtInstrumentNumberOfTranches
      contextRef="i925e16da5e194d4986f670bfe115cfd7_I20211214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjQ1ODUz_9d3cb6a8-c3e4-47c4-a658-59b91863b500"
      unitRef="tranche">2</eols:DebtInstrumentNumberOfTranches>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic59095e4226448ca90c7c028c530b46b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjQyNTA5_f3f0a4d2-3a5f-4348-9705-358a14ef15f4"
      unitRef="usd">75000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iaf213e710f77493dadadc321fcf59639_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjQyNTI5_e4fc726f-bb7f-4342-944b-4f17e48c9f5b"
      unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i96e618230e7d48238d27ef49600d13df_I20211214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjY2NTk2_46ca1116-f1ea-473b-a7cc-6332cff2acf0"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia0b2c7ebaf23495d8d1cc10fab315eb7_D20211214-20211214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjQyNTQ1_6101e7cf-631b-4c69-ad12-1198585d55cf"
      unitRef="number">0.085</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <eols:DebtInstrumentNumberOfPeriodicPaymentsPrincipal
      contextRef="if4f1ae42ca284ea69054431a374441c1_D20211214-20211214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8zMjk4NTM0OTA1MTA3_2f92eb0e-132f-433e-a531-0ccf202d7746"
      unitRef="payment">12</eols:DebtInstrumentNumberOfPeriodicPaymentsPrincipal>
    <eols:DebtInstrumentPeriodicPaymentPaymentCommencementPeriod
      contextRef="i4ec3d79630cc4ba09ef1b19959bd91f0_D20211214-20211214"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjQ2MDc2_919a6916-5b86-404d-a93b-a28c24ef161f">P39M</eols:DebtInstrumentPeriodicPaymentPaymentCommencementPeriod>
    <eols:DebtInstrumentPrepaymentAmountThreshold
      contextRef="i559b9a0d8aa547d0b36e58c3d536751e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV82MDQ3MzEzOTgzNjg0_adfba3b4-232b-4385-8ed3-eab5df6d6d60"
      unitRef="usd">20000</eols:DebtInstrumentPrepaymentAmountThreshold>
    <eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount
      contextRef="id698b63e55694d648621289908e0dcbe_I20211214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjQ5MjA3_dcd282cf-a998-4187-9748-b137c9c1208f"
      unitRef="number">0.030</eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount>
    <eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount
      contextRef="i3e5503a1fc4a4988a8da895468afd601_I20211214"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjQ5MjE1_f7cfa451-13c6-4dd6-a206-9ba9ce6de340"
      unitRef="number">0.020</eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount>
    <eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount
      contextRef="i0449988c955c422a849943b6ec89fe73_I20211214"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjQ5MjIz_222682fe-6ec1-49ef-9906-1b082de8a797"
      unitRef="number">0.010</eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i96e618230e7d48238d27ef49600d13df_I20211214"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjUxNTA1_76d481aa-94f8-49c0-8dee-95063209080b"
      unitRef="usd">3042000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i96e618230e7d48238d27ef49600d13df_I20211214"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjUxNTEz_1cef67b1-119d-48af-b630-01f0bcfe99a1"
      unitRef="usd">3263000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic59095e4226448ca90c7c028c530b46b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjUxMjQy_f3f0a4d2-3a5f-4348-9705-358a14ef15f4"
      unitRef="usd">75000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ia43c0d4587004db0b6f491872654d03a_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjUxNDc4_eaf692c0-28c2-49ef-b74a-4dea8964d10a"
      unitRef="number">0.1089</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8zODQ4MjkwNzIxNjQ1_e02c47f1-f381-4f05-aa76-f4ce389f5132">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.476%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,778)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long term debt, net of discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF8xLTEtMS0xLTM5MDQ2_8089ff7b-cfcd-441f-a1fe-3fbd7383529e"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF8yLTEtMS0xLTM5MDQ2_21f9af8e-72ae-4b2e-8cab-5186c51057db"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF8zLTEtMS0xLTM5MDQ2_9b734015-8ddc-48e9-9741-fd0a1caacb44"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF80LTEtMS0xLTM5MDQ2_9cebb421-4a8f-43b0-b756-8bf5cc28f981"
      unitRef="usd">25000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF81LTEtMS0xLTM5MDQ2_06ee7995-3930-45b8-a746-eaaad29b533f"
      unitRef="usd">25000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF82LTEtMS0xLTM5MDQ2_fbb89175-5be9-4076-a672-a4ed34d58446"
      unitRef="usd">25000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF83LTEtMS0xLTM5MDQ2_ae8320d5-4d24-4da6-bb04-3dbf2df03546"
      unitRef="usd">75000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF84LTEtMS0xLTM5MDQ2_12d13705-ef15-48d9-92ad-7b35e5e55777"
      unitRef="usd">3778000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGFibGU6NTQ4NDU5YWU3ZDUyNDc4MGJlMjY4MGM4OWExMWQzYjgvdGFibGVyYW5nZTo1NDg0NTlhZTdkNTI0NzgwYmUyNjgwYzg5YTExZDNiOF85LTEtMS0xLTM5MDQ4_6a7a6992-48c9-4ea0-96a2-362527546e00"
      unitRef="usd">71222000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i709c7ab6d38744cca0fbeb034841964d_I20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3MTk1Mw_e8790f97-73b6-4b70-a2f2-8a8f03317199"
      unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <eols:LineofCreditFacilityNumberofAdvances
      contextRef="i709c7ab6d38744cca0fbeb034841964d_I20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3MjA3NA_d7c40baa-7b0a-4237-a603-a4a1e7430cd6"
      unitRef="advance">2</eols:LineofCreditFacilityNumberofAdvances>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ie909f3b79bd4486daae42675b5641c62_I20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3MjEyNQ_8ddbba87-ec0b-4368-87be-7b6a2ed8100d"
      unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ifbb534318d9f4bd5bc4b81a523ac249b_I20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3MjE4Mw_b76d8188-dde3-493a-beec-ddb861745643"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i709c7ab6d38744cca0fbeb034841964d_I20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3MjI3NQ_db1e4a20-4fab-4b31-985c-36d611f24749"
      unitRef="number">0.095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i458308c7266b440eb668d7481bd1e4b3_D20190315-20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3MjMyMg_5f675b7e-45da-4c34-93d5-0bd405d1c045"
      unitRef="number">0.070</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <eols:DebtInstrumentPeriodOfInterestOnlyPayments
      contextRef="i69e7efe2c2b144989db5533678b61c21_D20190315-20190315"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV82MDQ3MzEzOTgzNzAw_f0978877-b941-4aa6-8746-533a35afe77a">P36M</eols:DebtInstrumentPeriodOfInterestOnlyPayments>
    <eols:DebtInstrumentAmortizationPeriod
      contextRef="i69e7efe2c2b144989db5533678b61c21_D20190315-20190315"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV82MDQ3MzEzOTgzNjQy_85a842b4-8de5-4e52-90d7-d9d01106b911">P23M</eols:DebtInstrumentAmortizationPeriod>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="idf71c87e895a46f09a7abf6657f2b04d_I20190315"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjU5MzIw_ddfeddc0-9fcf-4fcb-9194-6b4c0232be2b"
      unitRef="usd">1094000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="idf71c87e895a46f09a7abf6657f2b04d_I20190315"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjU5MzI4_c6c90353-2f30-400a-8af4-ede313c66d1d"
      unitRef="usd">2205000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i97c0f553670c4c3495114a22bf868a2f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMDk5NTExNjU5ODEy_6777cd5b-93e0-4a23-b4bd-8235715ef5f1"
      unitRef="number">0.116</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <eols:DebtInstrumentPercentageOfPrincipalAmountBalloonPayment
      contextRef="i9b43edc16c22483086f802b6b9cf884c_I20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3MjY0OQ_e38e4f48-2347-4997-96ca-29cc0dc1802a"
      unitRef="number">0.055</eols:DebtInstrumentPercentageOfPrincipalAmountBalloonPayment>
    <eols:DebtInstrumentPrepaymentFeePercentageYearTwo
      contextRef="i9b43edc16c22483086f802b6b9cf884c_I20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3Mjg4MQ_81a89e4e-0300-4739-9ef2-211648ec7ccf"
      unitRef="number">0.020</eols:DebtInstrumentPrepaymentFeePercentageYearTwo>
    <eols:DebtInstrumentPrepaymentFeePercentageThereafter
      contextRef="i9b43edc16c22483086f802b6b9cf884c_I20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3Mjk5Mw_b1cfeeb8-4453-44c8-a126-37fe85d07cf1"
      unitRef="number">0.010</eols:DebtInstrumentPrepaymentFeePercentageThereafter>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i4cac7bab107947c89fb60b9a19aa1ed2_D20210104-20210104"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3Mzc2MQ_2cdbbad6-e8cc-4477-9a71-6878efc82e4c"
      unitRef="usd">76447000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <eols:DebtInstrumentFeeAmountWaived
      contextRef="i4cac7bab107947c89fb60b9a19aa1ed2_D20210104-20210104"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3NDMxMQ_799a189e-a568-4f29-948c-2343f158eacd"
      unitRef="usd">4300000</eols:DebtInstrumentFeeAmountWaived>
    <eols:DebtInstrumentOfFinalPaymentAmountWaived
      contextRef="i4cac7bab107947c89fb60b9a19aa1ed2_D20210104-20210104"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3NDM0MA_59277322-8889-4ee1-b1dc-76b8b1306933"
      unitRef="usd">2800000</eols:DebtInstrumentOfFinalPaymentAmountWaived>
    <eols:DebtInstrumentPrepaymentFeeAmountWaived
      contextRef="i4cac7bab107947c89fb60b9a19aa1ed2_D20210104-20210104"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV8xMzc0Mzg5NTM3NDM5Ng_ae92d07e-5158-49ff-8fbb-9a35ebd57d20"
      unitRef="usd">1500000</eols:DebtInstrumentPrepaymentFeeAmountWaived>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4cac7bab107947c89fb60b9a19aa1ed2_D20210104-20210104"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDM3L2ZyYWc6ZTZkYjhhOWJiMjQ4NDA1MjgwZTI2MGNmMjhjNDNiNDkvdGV4dHJlZ2lvbjplNmRiOGE5YmIyNDg0MDUyODBlMjYwY2YyOGM0M2I0OV82MDQ3MzEzOTgzNjkz_3e935901-ce77-44c6-839d-0ff9d96e1db9"
      unitRef="usd">-1939000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iaae348537d9a4136a16f6e54e4e524a6_I20200706"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTIvZnJhZzo0OWRhZGUyYjA4YmE0MTI5YTc0MTU4YWMzYjYwZmM2Yy90ZXh0cmVnaW9uOjQ5ZGFkZTJiMDhiYTQxMjlhNzQxNThhYzNiNjBmYzZjXzIwMg_975826bd-2491-471d-900f-1259e3991238"
      unitRef="usd">40000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaae348537d9a4136a16f6e54e4e524a6_I20200706"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTIvZnJhZzo0OWRhZGUyYjA4YmE0MTI5YTc0MTU4YWMzYjYwZmM2Yy90ZXh0cmVnaW9uOjQ5ZGFkZTJiMDhiYTQxMjlhNzQxNThhYzNiNjBmYzZjXzY1Nw_f59d05dc-0c33-4a59-9934-41dbe9133dff"
      unitRef="number">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebt
      contextRef="ib67b7815bf86448c836c0674ab2cd400_I20210323"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTIvZnJhZzo0OWRhZGUyYjA4YmE0MTI5YTc0MTU4YWMzYjYwZmM2Yy90ZXh0cmVnaW9uOjQ5ZGFkZTJiMDhiYTQxMjlhNzQxNThhYzNiNjBmYzZjXzEwOTk1MTE2MzYwMTk_8c83e1d8-b357-405a-8bbb-b86865f13dd4"
      unitRef="usd">40779000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="i67974a995ff142e8bcd737a314d25651_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTIvZnJhZzo0OWRhZGUyYjA4YmE0MTI5YTc0MTU4YWMzYjYwZmM2Yy90ZXh0cmVnaW9uOjQ5ZGFkZTJiMDhiYTQxMjlhNzQxNThhYzNiNjBmYzZjXzEwOTk1MTE2MzYwMTU_c3cd713f-2461-4c6e-b548-bdbf8ad75cd4"
      unitRef="shares">3136869</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ib67b7815bf86448c836c0674ab2cd400_I20210323"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTIvZnJhZzo0OWRhZGUyYjA4YmE0MTI5YTc0MTU4YWMzYjYwZmM2Yy90ZXh0cmVnaW9uOjQ5ZGFkZTJiMDhiYTQxMjlhNzQxNThhYzNiNjBmYzZjXzEwOTk1MTE2MzYxMDQ_1aae903e-25cd-4d08-aa75-03e90f96b824"
      unitRef="usdPerShare">13.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i99d0525d0e434079b1d9eb140af4688c_D20210301-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTIvZnJhZzo0OWRhZGUyYjA4YmE0MTI5YTc0MTU4YWMzYjYwZmM2Yy90ZXh0cmVnaW9uOjQ5ZGFkZTJiMDhiYTQxMjlhNzQxNThhYzNiNjBmYzZjXzYwNDczMTM5NjEwMTQ_d6bd1789-ec46-4f46-804a-eb3d43897c1e"
      unitRef="usd">971000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90ZXh0cmVnaW9uOjIwNjM0MTFhYzMwODRkYjI5ZWM3NGY3YjI5NzVmOTNiXzI5Mzk_414f6ff0-30ed-4736-b335-a9454b401ba1">Operating Leases&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s corporate headquarters in Newport Beach, California is leased under a five-year non-cancelable operating lease, which expires on January 31, 2025. Lease payments increase each year on February 1 based on an annual rent escalation clause. The Company may, under certain circumstances, terminate the lease on the 36-month anniversary of the lease commencement date by providing a written notice 12 months prior to such anniversary and paying a termination fee&#160;equal to six months basic rent plus certain other expenses. The Company has an option to extend the term of the lease for an additional 60 months, which is not recognized as part of its ROU assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease agreement does not contain any residual value guarantees or material restrictive covenants. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU assets if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial implications of a decision to extend or not to extend a lease&#160;in&#160;determining&#160;if the renewal option is reasonably certain to be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of operating lease expense are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.154%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease term and discount rate are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.154%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease&#160;expenses were included in the selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss. Operating lease right-of-use assets and related current and noncurrent operating lease liabilities are presented in the accompanying balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the future minimum payments under the operating lease agreements with non-cancelable terms as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.348%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90ZXh0cmVnaW9uOjIwNjM0MTFhYzMwODRkYjI5ZWM3NGY3YjI5NzVmOTNiXzMyOTg1MzQ4ODY5NjE_6362e68a-4fb0-4fc1-a45f-67f17c980ed8">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <eols:LesseeOperatingLeaseTerminationPeriod
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90ZXh0cmVnaW9uOjIwNjM0MTFhYzMwODRkYjI5ZWM3NGY3YjI5NzVmOTNiXzYzNA_c987593e-73e6-40bb-97d3-6bf673764297">P36M</eols:LesseeOperatingLeaseTerminationPeriod>
    <eols:LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90ZXh0cmVnaW9uOjIwNjM0MTFhYzMwODRkYjI5ZWM3NGY3YjI5NzVmOTNiXzcxNg_055c1fb4-81d2-403c-ae76-6cb3464dd11f">P12M</eols:LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate>
    <eols:LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90ZXh0cmVnaW9uOjIwNjM0MTFhYzMwODRkYjI5ZWM3NGY3YjI5NzVmOTNiXzc4Mw_805db418-69ba-4d4d-8a25-1dae3e37f77a">P6M</eols:LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90ZXh0cmVnaW9uOjIwNjM0MTFhYzMwODRkYjI5ZWM3NGY3YjI5NzVmOTNiXzkwMg_da8545ed-76e8-43d7-93c7-7101c47d37ee">P60M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90ZXh0cmVnaW9uOjIwNjM0MTFhYzMwODRkYjI5ZWM3NGY3YjI5NzVmOTNiXzI5NDA_cffc4ca2-4305-42ba-84ac-f805d7cb1f7a">he components of operating lease expense are as follows:&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.154%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease term and discount rate are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.154%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTo3YTY4MzEyNTYyODA0ZDc3YmUzZGJmYzExYzZiNzY4Ni90YWJsZXJhbmdlOjdhNjgzMTI1NjI4MDRkNzdiZTNkYmZjMTFjNmI3Njg2XzItMS0xLTEtMjQ2OTc_2b9af4a6-b0d7-4fb8-94f0-6afec3c4fdc2"
      unitRef="usd">1065000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTo3YTY4MzEyNTYyODA0ZDc3YmUzZGJmYzExYzZiNzY4Ni90YWJsZXJhbmdlOjdhNjgzMTI1NjI4MDRkNzdiZTNkYmZjMTFjNmI3Njg2XzItMy0xLTEtMjQ2OTc_95445bf1-59f3-4057-b574-effa204667e1"
      unitRef="usd">1080000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTo3YTY4MzEyNTYyODA0ZDc3YmUzZGJmYzExYzZiNzY4Ni90YWJsZXJhbmdlOjdhNjgzMTI1NjI4MDRkNzdiZTNkYmZjMTFjNmI3Njg2XzMtMS0xLTEtMjQ2OTc_912cdef7-6482-42ed-9f22-a99f443b6c3d"
      unitRef="usd">64000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTo3YTY4MzEyNTYyODA0ZDc3YmUzZGJmYzExYzZiNzY4Ni90YWJsZXJhbmdlOjdhNjgzMTI1NjI4MDRkNzdiZTNkYmZjMTFjNmI3Njg2XzMtMy0xLTEtMjQ2OTc_cfe998cb-687c-4e32-804d-65593976d62b"
      unitRef="usd">40000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTo3YTY4MzEyNTYyODA0ZDc3YmUzZGJmYzExYzZiNzY4Ni90YWJsZXJhbmdlOjdhNjgzMTI1NjI4MDRkNzdiZTNkYmZjMTFjNmI3Njg2XzQtMS0xLTEtMjQ2OTc_7e1ff44c-56db-4c75-a4d4-a60a3cd26a9b"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTo3YTY4MzEyNTYyODA0ZDc3YmUzZGJmYzExYzZiNzY4Ni90YWJsZXJhbmdlOjdhNjgzMTI1NjI4MDRkNzdiZTNkYmZjMTFjNmI3Njg2XzQtMy0xLTEtMjQ2OTc_6bfcf153-6b77-4060-8824-5f5dca67c2c8"
      unitRef="usd">168000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTo3YTY4MzEyNTYyODA0ZDc3YmUzZGJmYzExYzZiNzY4Ni90YWJsZXJhbmdlOjdhNjgzMTI1NjI4MDRkNzdiZTNkYmZjMTFjNmI3Njg2XzUtMS0xLTEtMjQ2OTc_aa59fbcc-5dab-4161-b004-697b40d5f824"
      unitRef="usd">1129000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTo3YTY4MzEyNTYyODA0ZDc3YmUzZGJmYzExYzZiNzY4Ni90YWJsZXJhbmdlOjdhNjgzMTI1NjI4MDRkNzdiZTNkYmZjMTFjNmI3Njg2XzUtMy0xLTEtMjQ2OTc_0a459fc2-ed24-48b2-a1b4-dbcb2dd7f320"
      unitRef="usd">1288000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTozYTJjNDRjNzQ4NjQ0MWRlYWUyNmVhOWQwMmE0N2NlZi90YWJsZXJhbmdlOjNhMmM0NGM3NDg2NDQxZGVhZTI2ZWE5ZDAyYTQ3Y2VmXzItMS0xLTEtMzk2ODQ_5e6a5510-7f6a-4e6b-907e-8227dba41d0d">P3Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTozYTJjNDRjNzQ4NjQ0MWRlYWUyNmVhOWQwMmE0N2NlZi90YWJsZXJhbmdlOjNhMmM0NGM3NDg2NDQxZGVhZTI2ZWE5ZDAyYTQ3Y2VmXzItMy0xLTEtMzk2ODQ_51cfe10b-88da-4dc6-a35e-3c74b5ad94e4">P4Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTozYTJjNDRjNzQ4NjQ0MWRlYWUyNmVhOWQwMmE0N2NlZi90YWJsZXJhbmdlOjNhMmM0NGM3NDg2NDQxZGVhZTI2ZWE5ZDAyYTQ3Y2VmXzMtMS0xLTEtMzk2ODQ_9eba11d8-5202-4c99-bbe7-a2585fd1b9a1"
      unitRef="number">0.094</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTozYTJjNDRjNzQ4NjQ0MWRlYWUyNmVhOWQwMmE0N2NlZi90YWJsZXJhbmdlOjNhMmM0NGM3NDg2NDQxZGVhZTI2ZWE5ZDAyYTQ3Y2VmXzMtMy0xLTEtMzk2ODQ_d0f97f0e-225e-4133-af84-b2b4675fb562"
      unitRef="number">0.094</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90ZXh0cmVnaW9uOjIwNjM0MTFhYzMwODRkYjI5ZWM3NGY3YjI5NzVmOTNiXzI5NDE_aaef9730-9049-41b0-98f0-8f2b273eeec8">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the future minimum payments under the operating lease agreements with non-cancelable terms as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.348%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTowM2FkMmNlOTQ0ZDk0ZjY5YjBkMGNiMzhlMWZiNmRlZC90YWJsZXJhbmdlOjAzYWQyY2U5NDRkOTRmNjliMGQwY2IzOGUxZmI2ZGVkXzItMS0xLTEtMjQ2OTc_51ad2912-0d13-4d00-94ab-2d9308a8564e"
      unitRef="usd">1265000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTowM2FkMmNlOTQ0ZDk0ZjY5YjBkMGNiMzhlMWZiNmRlZC90YWJsZXJhbmdlOjAzYWQyY2U5NDRkOTRmNjliMGQwY2IzOGUxZmI2ZGVkXzMtMS0xLTEtMjQ2OTc_88b794e6-33cc-46ca-b54d-f11fac8a4280"
      unitRef="usd">1320000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTowM2FkMmNlOTQ0ZDk0ZjY5YjBkMGNiMzhlMWZiNmRlZC90YWJsZXJhbmdlOjAzYWQyY2U5NDRkOTRmNjliMGQwY2IzOGUxZmI2ZGVkXzQtMS0xLTEtMjQ2OTc_d16244eb-a3c6-4ffd-b8b5-1966bf8a75cf"
      unitRef="usd">1377000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTowM2FkMmNlOTQ0ZDk0ZjY5YjBkMGNiMzhlMWZiNmRlZC90YWJsZXJhbmdlOjAzYWQyY2U5NDRkOTRmNjliMGQwY2IzOGUxZmI2ZGVkXzUtMS0xLTEtMjQ2OTc_8eb0f090-56bc-4e2d-bb13-3bda7568b947"
      unitRef="usd">115000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTowM2FkMmNlOTQ0ZDk0ZjY5YjBkMGNiMzhlMWZiNmRlZC90YWJsZXJhbmdlOjAzYWQyY2U5NDRkOTRmNjliMGQwY2IzOGUxZmI2ZGVkXzYtMS0xLTEtMjQ2OTc_d9e79110-d58a-4284-82ad-ec017c028cbc"
      unitRef="usd">4077000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTowM2FkMmNlOTQ0ZDk0ZjY5YjBkMGNiMzhlMWZiNmRlZC90YWJsZXJhbmdlOjAzYWQyY2U5NDRkOTRmNjliMGQwY2IzOGUxZmI2ZGVkXzctMS0xLTEtMjQ2OTc_865c5d95-3848-4be7-9114-e3f141aa987d"
      unitRef="usd">556000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTUvZnJhZzoyMDYzNDExYWMzMDg0ZGIyOWVjNzRmN2IyOTc1ZjkzYi90YWJsZTowM2FkMmNlOTQ0ZDk0ZjY5YjBkMGNiMzhlMWZiNmRlZC90YWJsZXJhbmdlOjAzYWQyY2U5NDRkOTRmNjliMGQwY2IzOGUxZmI2ZGVkXzgtMS0xLTEtMjQ2OTc_18a2124e-334b-470e-9f74-320766e0fe11"
      unitRef="usd">3521000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTgvZnJhZzplMTJjODc2MjJiNjA0NmFkYTQwNGUyMDhiMjZiMDRhNC90ZXh0cmVnaW9uOmUxMmM4NzYyMmI2MDQ2YWRhNDA0ZTIwOGIyNmIwNGE0XzIwNzUy_e172672c-31e6-4b82-b627-417b652b3388">Commitments and Contingencies &lt;div style="margin-bottom:10pt;padding-right:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately $2,012. Certain minimum purchase commitments related to the purchase of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License and Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Daewoong Agreement includes certain minimum annual purchases that the Company is required to make in order to maintain the exclusivity of the license. The Company may, however, meet these minimum purchase obligations by achieving certain market share in its covered territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#x2019;s future market share in various jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. No amounts were accrued as of December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Class Action Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 16 and 28, 2020, two putative securities class action complaints were filed in the U.S. District Court for the Southern District of New York by Evolus shareholders Armin Malakouti and Clinton Cox, respectively, naming the Company and certain of its officers as defendants. The complaints assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, claiming that the defendants made false and materially misleading statements and failed to disclose material adverse facts related to the Company&#x2019;s acquisition of the right to sell Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the complaint against the Company filed by Allergan and Medytox in the U.S. International Trade Commission related to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;ITC Action&#x201d;), and risks related to the ITC Action. The complaints assert a putative class period of February 1, 2019 to July 6, 2020. The court consolidated the actions on November 13, 2020, under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Evolus Inc. Securities Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 1:20-cv-08647 (PGG). On September 17, 2021, the court appointed a lead plaintiff and lead counsel. On November 17, 2021, the lead plaintiff filed an amended class action complaint against the Company, three of its officers, and Alphaeon Corporation, the Company&#x2019;s former majority shareholder. On January 18, 2022, the Company and the officer defendants served their motion to dismiss the amended complaint, which is scheduled to be fully briefed on June 16, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shareholder Derivative Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2020 and December 2, 2020, two putative Evolus shareholders filed substantially similar shareholder derivative actions in the U.S. District Court for the Southern District of New York against certain of the Company&#x2019;s officers and directors as defendants. The complaints alleged substantially similar facts as those in the Securities Class Action and assert claims for, among other things, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of Section 14(a) of the Exchange Act and for contribution under Sections 10(b) and 21(D) of the Exchange Act. On December 29, 2020, the plaintiffs filed a joint stipulation to consolidate their actions and on February 5, 2021, the court consolidated the action under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Evolus, Inc. Derivative Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 1:20-cv-09986-PPG, and adjourned defendants&#x2019; time to move, answer or otherwise respond to the complaints. On September 20, 2021, the court so-ordered the parties&#x2019; stipulated stay of the consolidated derivative suit pending the court&#x2019;s decision on the defendants&#x2019; motion to dismiss the Securities Class Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is possible that additional suits will be filed, or additional allegations will be made by stockholders, with respect to these same or similar or other matters and also naming the Company and/or its officers and directors as defendants. The Company believes that the complaints are without merit and intends to vigorously defend against it. However, the outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss and accordingly has not accrued any liability associated with this action.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Books and Records Demand&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 5, 2021, the Company received a letter from a putative stockholder demanding inspection of specified categories of the Company&#x2019;s books and records under Section 220 of the Delaware General Corporations Law. The Company was subsequently informed that the stockholder sold his shares of the Company&#x2019;s common stock. On October 13, 2021, the Company received a substantially similar demand to inspect specified categories of the Company&#x2019;s books and records under Section 220 of the Delaware General Corporations Law from another putative stockholder. The subject of the demand is substantially similar to the allegations in the putative securities class action and derivative complaints described above. The Company responded to that demand on December 17, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is, from time to time, involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&#x2019;s financial results for that period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#x2019;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. No amounts were accrued as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt; Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medytox/Allergan Settlement Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;U.S. Settlement Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective February 18, 2021, the Company, Allergan and Medytox entered into a Settlement and License Agreement (the &#x201c;U.S. Settlement Agreement&#x201d;), pursuant to which, among other things: (i) Allergan and Medytox agreed to file a petition requesting the remedial orders related to the ITC Action be rescinded with respect to the Company; (ii) Medytox agreed to dismiss substantially similar litigation in California against the Company; (iii) the Company, on the one hand, and Medytox and Allergan, on the other hand, agreed to mutually release certain claims they may have against one another and their respective affiliates, (iv) Allergan and Medytox granted to the Company and its agents a license to manufacture and commercialize certain products identified in the U.S. Settlement Agreement, including Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;Licensed Products&#x201d;), in the United States during the 21 month period that, pursuant to the ITC Action, the Company was restricted from, among other things, selling, marketing, or promoting such imported Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States (the &#x201c;Restricted Period&#x201d;); (v) the Company agreed to pay to Allergan and Medytox $35,000 in multiple payments over two years, of which the Company paid the first cash payment of $15,000 in the third quarter of 2021 and the second payment of $15,000 in the first quarter of 2022; and (vi) during the Restricted Period, the Company agreed to pay to Allergan and Medytox certain confidential royalties on the sale of Licensed Products, calculated on dollar amount per vial sold of Licensed Products by or on behalf of the Company in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ROW Settlement Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective February 18, 2021, the Company and Medytox entered into a Settlement and License Agreement (the &#x201c;ROW Settlement Agreement&#x201d; and, together with the U.S. Settlement Agreement, the &#x201c;Medytox/Allergan Settlement Agreements&#x201d;), pursuant to which, among other things: (i) the Company and Medytox agreed to mutually release certain claims they may have against one another and their respective affiliates; (ii) Medytox granted to the Company and its agents a license to manufacture and commercialize the Licensed Products, in Canada, the European Union, Switzerland, member countries and cooperating countries of the European Economic Area, Russia, certain members of the Commonwealth of Independent States, South Africa, Australia and Japan (the &#x201c;ROW Territories&#x201d;) during the Restricted Period; (iii) Medytox granted to the Company and its agents a fully paid up license to manufacture and commercialize the Licensed Products in the ROW Territories and the United States from the end of the Restricted Period (the &#x201c;Medytox License Period&#x201d;); (iv) the Company and Medytox agreed to enter into the Share Issuance Agreement (as defined below) pursuant to which the Company issued 6,762,652 shares (the &#x201c;Settlement Shares&#x201d;) of the Company&#x2019;s common stock, par value $0.00001 per share, to Medytox; (v) the Company and Medytox agreed to enter into the Registration Rights Agreement (as defined below), pursuant to which the Company granted certain registration rights to Medytox with respect to the Settlement Shares; (vi) during the Restricted Period, the Company agreed to pay Medytox a confidential low-double digit royalty on net sales of the Licensed Products sold by or on behalf of the Company in the ROW Territories; and (vii) during the Medytox License Period, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;agreed to pay Medytox a confidential mid-single digit royalty percentage on net sales of the Licensed Products sold by or on behalf of the Company in the United States and the ROW Territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Share Issuance Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the ROW Settlement Agreement, the Company and Medytox entered into a Share Issuance Agreement effective February 18, 2021 (the &#x201c;Share Issuance Agreement&#x201d;). Pursuant to the Share Issuance Agreement and subject to the terms and conditions set forth therein, among other things, the Company issued to Medytox the Settlement Shares to enter into the ROW Settlement Agreement and in consideration for Medytox&#x2019;s representations, warranties, and other agreements set forth in the Share Issuance Agreement. The Settlement Shares are subject to contractual restrictions on transfer that, subject to certain limited exceptions such as transfers to affiliates, prevented Medytox from transferring any shares of common stock prior to February 16, 2022 and, thereafter, prohibit Medytox from transferring more than 25% of the shares it holds prior to September 16, 2023, more than 50% of the shares it holds prior to September 16, 2024 and more than 75% of the shares it holds prior to September 16, 2025, with such contractual restrictions terminating on September 16, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Registration Rights Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the ROW Settlement Agreement, the Company and Medytox also entered into a Registration Rights Agreement effective February 18, 2021 (the &#x201c;Registration Rights Agreement&#x201d;). Pursuant to the Registration Rights Agreement, among other things, the Company agreed, after March 31, 2022, (i) to comply with certain requests by Medytox to register for sale, under the Securities Act, the Settlement Shares, and (ii) to include the Settlement Shares in certain registrations by the Company of its securities for sale under the Securities Act, to the extent requested by Medytox, in each case subject to certain customary conditions, exceptions and limitations as set forth in the Registration Rights Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, Medytox&#x2019;s registration rights under the Registration Rights Agreement will terminate at such time that Medytox is able to sell all of the Settlement Shares over a three-month period, or less, pursuant to an exemption to registration under the Securities Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Daewoong Arrangement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Daewoong Arrangement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 23, 2021, the Company and Daewoong entered into a Confidential Settlement and Release Agreement (the &#x201c;Daewoong Arrangement&#x201d;), pursuant to which, among other things: (i) Daewoong agreed to (a) pay to the Company an amount equal to $25,500, which the Company received in April 2021, (b) pay certain legal fees incurred by the Company&#x2019;s litigation counsel in connection with its defense of the ITC Action (including any appeal of the resulting remedial orders), (c) cancel all remaining milestone payments, totaling $10,500 in aggregate, and (d) reimburse the Company certain amounts (calculated on a dollar amount per vials sold basis in the United States) for sales of certain products with respect to which the Company is required to pay Medytox and Allergan royalties pursuant to the U.S. Settlement Agreement; and (ii) the Company agreed to (a) release, on behalf of itself and certain of its affiliates and representatives, certain claims they may have against Daewoong related to the allegations made in or the subject matter of the Medytox/Allergan Actions, or any orders, remedies and losses resulting from the Medytox/Allergan Actions, and (b) coordinate with Daewoong on certain matters related to the Medytox/Allergan Actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Conversion Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the Daewoong Arrangement, the Company and Daewoong also entered into a Convertible Promissory Note Conversion Agreement (the &#x201c;Conversion Agreement&#x201d;), pursuant to which, among other things, (i) the principal balance under the Daewoong Convertible Note, together with all accrued and unpaid interest thereon, in the amount of $40,779 was converted into 3,136,869 shares of Common Stock at the conversion price of $13.00 per share (the &#x201c;Conversion Shares&#x201d;); and (ii) the Daewoong Convertible Note was deemed cancelled and satisfied in full in connection with such conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After the conversion, shares owned by Daewoong, together with its affiliates and attribution parties, did not exceed 9.99% of the Company&#x2019;s then outstanding common shares immediately following such issuance, as required under the terms of the Daewoong Convertible Note. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Daewoong Agreement Amendment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the Daewoong Arrangement, on March 23, 2021, the Company and Daewoong also entered into the Third Amendment to the Supply Agreement (the &#x201c;Daewoong Agreement Amendment&#x201d;). Pursuant to the Daewoong Agreement Amendment, the parties amended the Daewoong Agreement to (i) expand the territory within which the Company may distribute Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to certain countries in Europe, (ii) reduce the period of time with respect to which the Company is required to deliver binding forecasts to Daewoong; (iii) introduce certain limitations on Daewoong&#x2019;s ability to convert the Company&#x2019;s exclusive license for certain territories to a non-exclusive license in the event the Company fails to meet certain minimum purchase requirements for such territory; (iv) adjust the minimum purchase requirements and reduce the transfer price per vial of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; applicable to various territories, (v) require that any Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; supplied by Daewoong match certain shelf-life thresholds, and (vi) prohibit the Company from sharing certain confidential information of Daewoong with Medytox or its affiliates or representatives.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTgvZnJhZzplMTJjODc2MjJiNjA0NmFkYTQwNGUyMDhiMjZiMDRhNC90ZXh0cmVnaW9uOmUxMmM4NzYyMmI2MDQ2YWRhNDA0ZTIwOGIyNmIwNGE0XzE5MQ_e204d948-8b60-40eb-b709-7b09dad2a389"
      unitRef="usd">2012000</us-gaap:PurchaseObligation>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTgvZnJhZzplMTJjODc2MjJiNjA0NmFkYTQwNGUyMDhiMjZiMDRhNC90ZXh0cmVnaW9uOmUxMmM4NzYyMmI2MDQ2YWRhNDA0ZTIwOGIyNmIwNGE0XzE3Mjk_69ced800-0313-4728-abf8-370178059516"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTgvZnJhZzplMTJjODc2MjJiNjA0NmFkYTQwNGUyMDhiMjZiMDRhNC90ZXh0cmVnaW9uOmUxMmM4NzYyMmI2MDQ2YWRhNDA0ZTIwOGIyNmIwNGE0XzE3Mjk_7b05bafd-d509-4bd8-bc4d-bb10841ef0eb"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i639ff7637d4f4af7b61468f913b844be_D20201016-20201028"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTgvZnJhZzplMTJjODc2MjJiNjA0NmFkYTQwNGUyMDhiMjZiMDRhNC90ZXh0cmVnaW9uOmUxMmM4NzYyMmI2MDQ2YWRhNDA0ZTIwOGIyNmIwNGE0XzE2ODE3_9d5f8def-6639-46f1-a450-5e4abfdb45d3"
      unitRef="complaint">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="id67d131284974c959850a72560bf6292_D20201127-20201202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTgvZnJhZzplMTJjODc2MjJiNjA0NmFkYTQwNGUyMDhiMjZiMDRhNC90ZXh0cmVnaW9uOmUxMmM4NzYyMmI2MDQ2YWRhNDA0ZTIwOGIyNmIwNGE0XzE4MDc2_3c4f59e3-02e2-40c7-9dc2-05e264e7f395"
      unitRef="plaintiff">2</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMTgvZnJhZzplMTJjODc2MjJiNjA0NmFkYTQwNGUyMDhiMjZiMDRhNC90ZXh0cmVnaW9uOmUxMmM4NzYyMmI2MDQ2YWRhNDA0ZTIwOGIyNmIwNGE0XzYwNDczMTM5OTE2MDI_05028225-8ff0-41b0-972f-1afe1a0b727e"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU4NTU_aa6b2c3f-185d-4584-ae78-6ca85df3e9e8">Stockholders&#x2019; Equity &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has 10,000,000 authorized shares of preferred stock with a par value of $0.00001 per share. As of December&#160;31, 2021, no shares of its preferred stock were issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has 100,000,000 authorized shares of common stock with a par value of $0.00001 per share. As of December&#160;31, 2021, 55,576,988 shares of its common stock were issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 28, 2021, the Company issued 6,762,652 shares of its common stock to Medytox pursuant to the Share Issuance Agreement. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 25, 2021, the Company issued 3,136,869 shares of its common stock to Daewoong in connection with the conversion of Daewoong Convertible Note. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7. Daewoong Convertible Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company completed a follow-on public offering and issued 10,350,000 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,350,000 shares of common stock, at a price to the public of $9.50 per share. The Company received net proceeds of approximately $92,426 from the offering, after deducting underwriting discounts and commissions, excluding other offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x201c;At-the-market&#x201d; Offerings of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 26, 2021, the Company entered into an &#x201c;at-the-market&#x201d; sales agreement with SVB Leerink LLC (the &#x201c;Sales Agent&#x201d;) pursuant to which shares of the Company&#x2019;s common stock may be sold from time to time for aggregate gross proceeds of up to $75,000 (the &#x201c;ATM Program&#x201d;). The Sales Agent is entitled to compensation, at a commission rate equal to 3.0% of the gross proceeds from sales of the Company&#x2019;s common shares under the ATM Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2021, the Company sold a total of 934,367 shares of its common stock pursuant to the ATM Program at the prevailing market prices for total net proceeds of $10,910 and paid total commissions of $337 to the Sales Agent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Omnibus Incentive Plan and Stock-based Compensation Allocation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2017 Omnibus Incentive Plan (the &#x201c;Plan&#x201d;) provides for the grant of incentive options to employees of the Company, and for the grant of non-statutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&#x2019;s officers, directors, consultants and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is 4,361,291 shares, plus an annual increase on each anniversary of November 21, 2017 equal to 4.0% of the total issued and outstanding shares of the Company&#x2019;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&#x2019;s board of directors). On November 21, 2021 and 2020, an additional 2,223,080 shares and 1,349,969 shares, respectively, were reserved under the evergreen provision of the Plan. As of December&#160;31, 2021, the Company had an aggregate of 3,361,247 shares of its common stock available for future issuance under the Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Award Activity and Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options are granted at exercise prices based on the Company&#x2019;s common stock price on the date of grant. The options and RSU grants generally vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE3MzI_fb117ad8-2568-44c6-bb64-c540497d2484"&gt;one&lt;/span&gt;-to four-year period. There have been no awards granted with performance conditions or market conditions for the periods presented. The options have a contractual term of ten years. The fair value of options is estimated using the Black&#x2011;Scholes option pricing model, which has various inputs, including the grant date common share price, exercise price, risk&#x2011;free interest rate, volatility, expected life and dividend yield. The change of any of these inputs could significantly impact the determination of the fair value of the Company&#x2019;s options as well as significantly impact its results of operations. The fair value of RSU grants is determined at the grant date based on the common share price. The Company records stock-based compensation expense net of actual forfeitures when they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant assumptions used in the Black-Scholes option-pricing are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Volatility.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The Company has limited data regarding company&#x2011;specific historical or implied volatility of its share price. Consequently, the Company estimates its volatility based on the average historical volatility of the stock price from a set of peer companies and its own stock performance, since our shares do not have sufficient trading history. Management considers factors such as stage of life cycle, competitors, size, market capitalization and financial leverage in the selection of similar entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The expected term represents the period of time in which the options granted are expected to be outstanding. The Company estimates the expected term of options with consideration of vesting date, contractual term, and historical experience. The expected term of &#x201c;plain vanilla&#x201d; options is estimated based on the midpoint between the vesting date and the end of the contractual term under the simplified method permitted by the SEC implementation guidance. The weighted&#x2011;average expected term of the Company&#x2019;s options is approximately six years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Risk&#x2011;Free Rate.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The risk&#x2011;free interest rate is selected based upon the implied yields in effect at the time of the option grant on U.S. Treasury zero&#x2011;coupon issues with a term approximately equal to the expected life of the option being valued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Dividends.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The Company does not anticipate paying cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield rate of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-averages for assumptions used in determining the fair value of stock options granted were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity under the Plan for the year ended December 31, 2021 and 2020, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Terms (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,977,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(892,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,407,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(742,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,922,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,922,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of outstanding and exercisable options represents the excess of the fair market value of our common stock over the exercise price of underlying options as of&#160;December&#160;31, 2021 and 2020. The total intrinsic value of options exercised during the year ended December&#160;31, 2021 was $200. There were no options exercised during the year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2021 and 2020, the Company recorded expenses related to stock options of $5,302 and $7,968, respectively. As of&#160;December&#160;31, 2021, there was $6,358 of total unrecognized compensation cost, net of actual forfeitures, related to stock option-based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&#160;1.68 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity under the Plan for the year ended December 31, 2021 and 2020, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(186,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,850,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(566,788)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(530,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,926,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2021 and 2020, the Company recorded expenses related to restricted stock units of $4,274 and $2,615, respectively. Total fair value of RSUs vested during the years ended December 31, 2021 and 2020 was &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5,892 and $1,980, respectively. As of&#160;December&#160;31, 2021, there was $11,768 of total unrecognized compensation cost, net of actual forfeitures, related to RSU-based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&#160;2.87 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expense arising from the above Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, during the years ended December 31, 2021 and 2020, the Company capitalized $63 and $21, respectively, of stock-based compensation expense in capitalized software. Capitalized software is a component of intangible assets and is presented in the accompanying balance sheets. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt; for capitalized software information.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzY4_b8c9f883-e19e-431a-b2f9-bd9375cb436e"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEyOA_967958f4-55d6-410f-bf6b-a851cf556fab"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE1Mg_10e03a40-ddca-46d8-b476-49d6c02606cd"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE1Mg_87c0c877-5f32-406a-9b00-2e162f07e8eb"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzIxMw_3f51e8db-b0ae-4fc5-b520-2fd1677fc5c6"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzI3MA_0fbf0733-bf07-4ce0-9166-79a2e61ee3bb"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2NDA4OTE_806dcf99-f8a9-46c7-9438-e079f7ae4bd8"
      unitRef="shares">55576988</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2NDA4OTE_bba46a71-0684-417f-9da1-de05dac3f583"
      unitRef="shares">55576988</us-gaap:CommonStockSharesIssued>
    <eols:StockIssuedDuringPeriodSharesLitigationSettlement
      contextRef="ic40c99d6b0a04616bf00bfc233eced25_D20210228-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2NDE2MDQ_98e09eb6-f2a5-4627-ba49-75ac75801968"
      unitRef="shares">6762652</eols:StockIssuedDuringPeriodSharesLitigationSettlement>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="ibb11d4e5afdb4c27ae1e67ee48ded284_D20210325-20210325"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2MzM5MDE_ff4708ce-89d3-4eed-ac5d-5646cc2975d8"
      unitRef="shares">3136869</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i87285d3792f541dfb0b8bd76edc9ed8b_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2MzQxMjQ_ccb1b13e-aad9-4ff9-b24e-3a5ccd3de6fb"
      unitRef="shares">10350000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i369b3df3ec04419fa040ca2ec1d798db_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2MzQyNTQ_fe771b96-89b8-4c61-b639-ca1088a1fee2"
      unitRef="shares">1350000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i581d900790a24282bf837c0e06b7b5f4_I20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2MzQzMTA_7cfdb2f3-7f32-4acf-9d6d-08c5e316b8f3"
      unitRef="usdPerShare">9.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i87285d3792f541dfb0b8bd76edc9ed8b_D20210401-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2MzQzNzY_52ae306a-8a73-424d-8326-b85ea46cdd15"
      unitRef="usd">92426000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <eols:SaleOfStockMaximumConsiderationReceivable
      contextRef="i63f4e91998714dab927a5acf4a92ddb8_D20210326-20210326"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzgyNDYzMzcyMjE0MTY_c008a1ce-163b-4fa2-b597-28c52c1dacd1"
      unitRef="usd">75000</eols:SaleOfStockMaximumConsiderationReceivable>
    <eols:SaleOfStockCommissionPaymentUponGrossProceedsPercentage
      contextRef="i75496e7d4351422aa519e8a590bc554b_I20210326"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzgyNDYzMzcyMjE0MjU_c4416aed-3f87-4cc0-af6f-e05ac95b0ba6"
      unitRef="number">0.030</eols:SaleOfStockCommissionPaymentUponGrossProceedsPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i19668eba2a9a432cbae4ec0e6254aa0e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2NDA0OTg_e079cc17-af93-4f78-8118-b0b1cd869fbc"
      unitRef="shares">934367</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8b39b85b47cc450fbde4206b76345039_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2NDA1MDI_33c67f7a-5a82-4d1d-8307-187e07a7790b"
      unitRef="usd">10910000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <eols:SaleOfStockCommissionPaid
      contextRef="i191b278dcfec47f3972561e051202c15_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzM4NDgyOTA3MTAzMDM_dde0d6e5-f141-421e-aa5e-f4e870267612"
      unitRef="usd">337000</eols:SaleOfStockCommissionPaid>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ic142d9a5a6964798b2bc095cf05edeb8_I20171121"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwMDk_bf2ace62-a168-496b-8677-0bac18c673d5"
      unitRef="shares">4361291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i0caf9e9143e34777b8ae279b103a9da1_D20171121-20171121"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTQ_72553e1e-d3d0-418c-bdd8-c8c1ab8f2d1b"
      unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="i517a2340d6ac4cfb8363af7585980dcf_I20211121"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEzMzA_4731c7d4-b071-498e-8203-5e1b1b9af747"
      unitRef="shares">2223080</eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="i7869351f7bde4260a08aa49ce4ef2470_I20201121"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEzNDQ_7db6fe88-849e-4b53-816f-a981edc8c5a5"
      unitRef="shares">1349969</eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE0Nzg_3035e4d2-461f-4aec-b20c-32e0cffcde6c"
      unitRef="shares">3361247</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id708d9ed50e54617af7629252e0fa1c6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU4NjQ_e4c7bd23-78d4-4c7c-ae8b-ee1b206d4ae1">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iecdda6aa05b04bfcab114de1346b4b98_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE3NzA_067f6e3a-a3c4-4939-a5fb-4c6e1de311c3"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ifd29a6c578714db49b385b4f9e60b606_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE3NzA_1dccebcf-f089-4ec9-b00a-2f093df771bd"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8ef5563a248f47b9b87ca621a1f1eed8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE3NzA_dd8e157b-a378-4f53-bed4-819eb7ba47f0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1da74bb1ddc84684bf5d405096cdedeb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE3NzA_e2a529f5-5619-44b4-bbb1-f5e6744acb8e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzE5MDM_bf95c68a-4d11-4a0b-a0d8-3ea5cb1900be">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <eols:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzM2NDQ_b1349f70-b1e8-4918-bd7a-db196f4625c9">P6Y</eols:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzQwNTE_7fe7c5e5-8f63-4542-aed9-9219d0c0bdee"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU4NTc_feedcadd-a3b9-48ae-a640-a2e39f4c8de4">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-averages for assumptions used in determining the fair value of stock options granted were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo1N2ZiNjY3ZjM4OTM0YzhkYTMzOTBmMjA3ZGY4MjRhYS90YWJsZXJhbmdlOjU3ZmI2NjdmMzg5MzRjOGRhMzM5MGYyMDdkZjgyNGFhXzItMS0xLTEtMjQ2OTc_0785c25e-8581-47cb-933d-53474c3ab710"
      unitRef="number">0.789</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo1N2ZiNjY3ZjM4OTM0YzhkYTMzOTBmMjA3ZGY4MjRhYS90YWJsZXJhbmdlOjU3ZmI2NjdmMzg5MzRjOGRhMzM5MGYyMDdkZjgyNGFhXzItMy0xLTEtMjQ2OTc_63fc07c2-8a67-42d7-bba4-f5e411ae2649"
      unitRef="number">0.612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo1N2ZiNjY3ZjM4OTM0YzhkYTMzOTBmMjA3ZGY4MjRhYS90YWJsZXJhbmdlOjU3ZmI2NjdmMzg5MzRjOGRhMzM5MGYyMDdkZjgyNGFhXzMtMS0xLTEtMjQ2OTc_fb8f2bd7-816d-4fe4-b874-da3942dd2daa"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo1N2ZiNjY3ZjM4OTM0YzhkYTMzOTBmMjA3ZGY4MjRhYS90YWJsZXJhbmdlOjU3ZmI2NjdmMzg5MzRjOGRhMzM5MGYyMDdkZjgyNGFhXzMtMy0xLTEtMjQ2OTc_799aa29d-625a-4aa2-a4d8-6c938d49f0fb"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo1N2ZiNjY3ZjM4OTM0YzhkYTMzOTBmMjA3ZGY4MjRhYS90YWJsZXJhbmdlOjU3ZmI2NjdmMzg5MzRjOGRhMzM5MGYyMDdkZjgyNGFhXzQtMS0xLTEtMjQ2OTc_48ef3528-0633-4379-ba80-ec370d84e600">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo1N2ZiNjY3ZjM4OTM0YzhkYTMzOTBmMjA3ZGY4MjRhYS90YWJsZXJhbmdlOjU3ZmI2NjdmMzg5MzRjOGRhMzM5MGYyMDdkZjgyNGFhXzQtMy0xLTEtMjQ2OTc_ff504856-d5ea-4140-ba91-3ceb1b847d0c">P6Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo1N2ZiNjY3ZjM4OTM0YzhkYTMzOTBmMjA3ZGY4MjRhYS90YWJsZXJhbmdlOjU3ZmI2NjdmMzg5MzRjOGRhMzM5MGYyMDdkZjgyNGFhXzUtMS0xLTEtMjQ2OTc_6634a732-1a15-4755-b3f3-dbb94074357a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo1N2ZiNjY3ZjM4OTM0YzhkYTMzOTBmMjA3ZGY4MjRhYS90YWJsZXJhbmdlOjU3ZmI2NjdmMzg5MzRjOGRhMzM5MGYyMDdkZjgyNGFhXzUtMy0xLTEtMjQ2OTc_c96677ac-9543-4fe0-9447-c6aa8f40a2d0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU4NTg_b362b1c8-6b56-4cc3-9707-1bbb6473dbb5">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity under the Plan for the year ended December 31, 2021 and 2020, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Terms (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,977,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(892,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,407,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(742,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,922,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,922,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie061e2ccf1e04536b767f55687880f70_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzktMS0xLTEtMjQ2OTc_685f1c9d-2aa1-4a4c-aacd-f2ba29b956c9"
      unitRef="shares">3977401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie061e2ccf1e04536b767f55687880f70_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzktMy0xLTEtMjQ2OTc_8d8cac20-3875-4f95-a2a5-25a5e43ffb0f"
      unitRef="usdPerShare">14.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia803156cd5cc4477b4ba2e43f8f8880d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzktNS0xLTEtMjQ2OTc_74d73774-15a0-46fa-bed0-0eb80d62d946">P8Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ie061e2ccf1e04536b767f55687880f70_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzktNy0xLTEtMjQ2OTc_9614ca21-195c-4484-af93-2510c0d6fb0a"
      unitRef="usd">7198000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzEwLTEtMS0xLTI0Njk3_aff63884-49f4-436f-99ab-e8f6977b22ef"
      unitRef="shares">1322119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzEwLTMtMS0xLTI0Njk3_5ca80612-81b0-4e72-ba17-5b97fb04721b"
      unitRef="usdPerShare">8.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzExLTEtMS0xLTI0Njk3_c5a7c468-4e6f-49c5-8b9a-bb9e89af39d7"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzExLTMtMS0xLTI0Njk3_cffa8957-a8da-4825-b67a-e0c240239147"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzEyLTEtMS0xLTI0Njk3_74f8c4c3-b7c6-4db4-8496-eca1eb4a5758"
      unitRef="shares">892022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzEyLTMtMS0xLTI0Njk3_c781689c-6211-482d-8590-9c6cc64fd2d3"
      unitRef="usdPerShare">15.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1328d543a76b4257a15411d3fc978c8d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzEzLTEtMS0xLTI0Njk3_a5837f47-b59d-4f8b-beb9-dc3c73eb0cd0"
      unitRef="shares">4407498</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1328d543a76b4257a15411d3fc978c8d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzEzLTMtMS0xLTI0Njk3_f9b09dc4-2e1b-4bb9-938a-2bbe0a69d6d5"
      unitRef="usdPerShare">12.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzEzLTUtMS0xLTI0Njk3_0a220dbc-02dd-4d7f-af5e-beef0e7543e4">P7Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i1328d543a76b4257a15411d3fc978c8d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzEzLTctMS0xLTI0Njk3_81e84da3-82ef-4821-8106-b8c9a94fa1a2"
      unitRef="usd">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE0LTEtMS0xLTMyMjA5_090dd20c-2c6f-4b55-b6cd-307aa4a386e4"
      unitRef="shares">357125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE0LTMtMS0xLTM0MzU4_f648b7ed-9518-4664-94eb-8b12722119ab"
      unitRef="usdPerShare">9.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE1LTEtMS0xLTMyMjA5_c390393d-a2be-4152-8c41-8f2a1dd158fe"
      unitRef="shares">99435</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE1LTMtMS0xLTM0MzY2_8d4ec85e-eaaa-4a2e-b380-a5d561a24514"
      unitRef="usdPerShare">9.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE2LTEtMS0xLTMyMjA5_95277614-54a6-4b87-a69b-4ca352f83b36"
      unitRef="shares">742902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE2LTMtMS0xLTM0MzY2_38342790-49e1-4651-aaa1-91b51d9a4014"
      unitRef="usdPerShare">16.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE3LTEtMS0xLTMyMjEx_d6871710-5e01-41e2-bf4a-f0526894b26f"
      unitRef="shares">3922286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE3LTMtMS0xLTMyMjE2_7ef3484a-0242-4950-9779-6743784ccae0"
      unitRef="usdPerShare">11.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE3LTUtMS0xLTMyMjE4_d87cd6e6-f007-4981-9616-7c58a47a5c11">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE3LTctMS0xLTMyMjIw_a1e05aef-2277-4431-aef0-4038aaeff4bc"
      unitRef="usd">455000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE0LTEtMS0xLTI0Njk3_2aab1567-c47e-462a-af1a-30d727611b79"
      unitRef="shares">2316637</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE0LTMtMS0xLTI0Njk3_6d0797fe-9931-4a44-b70c-eba953b4d10f"
      unitRef="usdPerShare">11.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE0LTUtMS0xLTI0Njk3_10833fd8-58dd-4193-9801-f2885b99d95b">P6Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE0LTctMS0xLTI0Njk3_cd977c43-1bc0-4a0c-b9e1-163af47a044a"
      unitRef="usd">98000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE1LTEtMS0xLTI0Njk3_73579d32-747f-4255-b64d-28740d45878b"
      unitRef="shares">3922286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE1LTMtMS0xLTI0Njk3_c1deee7b-9618-497b-80c2-370ea92cc225"
      unitRef="usdPerShare">11.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE1LTUtMS0xLTI0Njk3_1674a06f-4b92-4904-8c27-8621a9ec13c0">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo0NjVmZDNkYmMyZDU0MTBjYTU5MThjMTVkYzk1ZjAxZS90YWJsZXJhbmdlOjQ2NWZkM2RiYzJkNTQxMGNhNTkxOGMxNWRjOTVmMDFlXzE1LTctMS0xLTI0Njk3_67cade09-ffd6-4151-bd2c-8bcecb1cf71e"
      unitRef="usd">455000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzEwOTk1MTE2NDE1MDI_53ae9a07-0278-4531-bdbe-cb62a928a886"
      unitRef="usd">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzYwNDczMTM5NjY2MDk_69f1fdf3-2d94-4fb2-a276-1ea94836aa6b"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzQ2NTU_f1b8ca53-d308-4b44-b8db-3c6472a846f2"
      unitRef="usd">5302000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i88b38b15d2f74919915230e85c1722dc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzQ2NjI_031c2416-01bc-4485-9a5e-8aadd54331a0"
      unitRef="usd">7968000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i35d707ed76cb4921a043c6af35bf1696_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzQ3MDA_ed2950e2-97ef-4b57-92cb-6d95462bb53e"
      unitRef="usd">6358000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzQ5MjM_6b3fa762-dc29-42ac-9c90-c6bb0dd92710">P1Y8M4D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU4NjA_68f85bc4-bcc1-4e4f-8f8c-e62f7105661c">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity under the Plan for the year ended December 31, 2021 and 2020, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(186,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,850,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(566,788)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(530,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,926,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i42f7ff0b06244a60a0750a47b3a469a0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzgtMS0xLTEtMjQ2OTc_c5e9a8a6-c28e-4a4e-83ec-1cc87dc95605"
      unitRef="shares">229870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i42f7ff0b06244a60a0750a47b3a469a0_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzgtMy0xLTEtMjQ2OTc_b86b01df-c44e-4cf6-b4e8-ba2e0a443490"
      unitRef="usdPerShare">15.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzktMS0xLTEtMjQ2OTc_dfff72a9-586d-426c-84aa-79f5ad856f96"
      unitRef="shares">1301439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzktMy0xLTEtMjQ2OTc_3fbac9bf-c1c0-4628-99f1-f8794a7194ae"
      unitRef="usdPerShare">5.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzEwLTEtMS0xLTI0Njk3_5bdbfa77-5ab4-4c0d-b7eb-e124d6963822"
      unitRef="shares">186870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzEwLTMtMS0xLTI0Njk3_2490cb8f-93cd-4065-8433-639cabfe3af4"
      unitRef="usdPerShare">13.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzExLTEtMS0xLTI0Njk3_7ea18fb6-e61f-4d69-84f1-d7d9ff1cdff0"
      unitRef="shares">170698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzExLTMtMS0xLTI0Njk3_45da0f30-592b-4414-be51-15041b64bfd4"
      unitRef="usdPerShare">7.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic78866655f1e4fb7a2d18ed23eaca432_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzEyLTEtMS0xLTI0Njk3_e0ec1200-66e8-44e8-b2e4-9cafcacd9af6"
      unitRef="shares">1173741</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic78866655f1e4fb7a2d18ed23eaca432_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzEyLTMtMS0xLTI0Njk3_5142bd82-a045-490c-b0a3-ccc7ae808e0d"
      unitRef="usdPerShare">6.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzEzLTEtMS0xLTMyMjAw_98aec670-b86d-4eb1-8009-8023be8ca45c"
      unitRef="shares">1850243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzEzLTMtMS0xLTMyMjA0_5160b265-b74b-4e43-a6c8-6e953d4d3c80"
      unitRef="usdPerShare">7.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzE0LTEtMS0xLTMyMjAw_3e32f1af-2f19-4a58-94b4-f59eb0e1a1e8"
      unitRef="shares">566788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzE0LTMtMS0xLTMyMjA0_1d9b9126-4a68-4062-aaf3-6274227ce8fa"
      unitRef="usdPerShare">5.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzE1LTEtMS0xLTMyMjAw_82356123-e7b6-43f4-8970-1a52611d254e"
      unitRef="shares">530729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzE1LTMtMS0xLTMyMjA0_f6cb12c8-ff90-40f4-9640-5ba59932b027"
      unitRef="usdPerShare">7.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i88950351bb5049948706e070a4d2f1ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzE2LTEtMS0xLTMyMTk4_d62a51e2-61bd-421e-9593-05be5087c0f7"
      unitRef="shares">1926467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i88950351bb5049948706e070a4d2f1ba_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTo4OWQxYzhiZTI1N2Y0YWI2OTAyYzM1OGI1Y2M2YTU2NC90YWJsZXJhbmdlOjg5ZDFjOGJlMjU3ZjRhYjY5MDJjMzU4YjVjYzZhNTY0XzE2LTMtMS0xLTMyMTk4_7c80661a-8c05-4988-a504-549f918a2811"
      unitRef="usdPerShare">8.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzUwOTk_d29014d6-8f25-4d2c-b83b-a21b15b7bad6"
      unitRef="usd">4274000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzUxMDY_ce2bad86-4861-4a91-8660-5154824a77dc"
      unitRef="usd">2615000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzUxODE_97aec235-fb69-45e3-a109-cd1581a50a7e"
      unitRef="usd">5892000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i8ca327f5daf34725b1e5b80570e0af49_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzUxODg_aaaddcd1-9cac-4967-8cdf-d4215b28ac77"
      unitRef="usd">1980000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i88950351bb5049948706e070a4d2f1ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzUyMjY_de22436a-1c85-4a3a-9408-aedad5de05b2"
      unitRef="usd">11768000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="idd67b6f34e3040f58a3931c6b786528d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU0NDA_d722d8c2-be90-4916-9f56-ac88bc3675aa">P2Y10M13D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU4Njc_26e1dc0f-785a-47a1-ba93-33202329d687">&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expense arising from the above Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifb1c0ae2c17f459f9a60df92e9ad83ba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTpkMjU5OTY3MjAwMjA0ZGExOGI2NWZiYjQzZjk5ZGMyYS90YWJsZXJhbmdlOmQyNTk5NjcyMDAyMDRkYTE4YjY1ZmJiNDNmOTlkYzJhXzItMS0xLTEtMjQ2OTc_44c281ac-cf26-4dda-abfc-97b4d0c80d2b"
      unitRef="usd">9372000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if4b758b9624b4b0996306bc2eeaddce7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTpkMjU5OTY3MjAwMjA0ZGExOGI2NWZiYjQzZjk5ZGMyYS90YWJsZXJhbmdlOmQyNTk5NjcyMDAyMDRkYTE4YjY1ZmJiNDNmOTlkYzJhXzItMy0xLTEtMjQ2OTc_6b4356bf-9ae5-43c4-ad3d-71180dbc0592"
      unitRef="usd">10408000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i422b9466ee0c476e8729e37ee5d9e9d1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTpkMjU5OTY3MjAwMjA0ZGExOGI2NWZiYjQzZjk5ZGMyYS90YWJsZXJhbmdlOmQyNTk5NjcyMDAyMDRkYTE4YjY1ZmJiNDNmOTlkYzJhXzMtMS0xLTEtMjQ2OTc_0a6b357f-7bb3-4be9-bf65-f9fb69a6d90a"
      unitRef="usd">204000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i68cbcb58dbd347d186d56f67bdc0d88b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTpkMjU5OTY3MjAwMjA0ZGExOGI2NWZiYjQzZjk5ZGMyYS90YWJsZXJhbmdlOmQyNTk5NjcyMDAyMDRkYTE4YjY1ZmJiNDNmOTlkYzJhXzMtMy0xLTEtMjQ2OTc_47044bab-a7e5-4424-ac24-dac218ca518c"
      unitRef="usd">176000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTpkMjU5OTY3MjAwMjA0ZGExOGI2NWZiYjQzZjk5ZGMyYS90YWJsZXJhbmdlOmQyNTk5NjcyMDAyMDRkYTE4YjY1ZmJiNDNmOTlkYzJhXzQtMS0xLTEtMjQ2OTc_f0bc4dd9-6f09-4790-9afc-05a833331118"
      unitRef="usd">9576000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90YWJsZTpkMjU5OTY3MjAwMjA0ZGExOGI2NWZiYjQzZjk5ZGMyYS90YWJsZXJhbmdlOmQyNTk5NjcyMDAyMDRkYTE4YjY1ZmJiNDNmOTlkYzJhXzQtMy0xLTEtMjQ2OTc_e90fb2db-e851-49ad-864d-37ef7c51c790"
      unitRef="usd">10584000</us-gaap:AllocatedShareBasedCompensationExpense>
    <eols:AllocatedShareBasedCompensationExpenseCapitalized
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU2MDA_c3f9684d-501b-4394-851e-2681d274da6e"
      unitRef="usd">63000</eols:AllocatedShareBasedCompensationExpenseCapitalized>
    <eols:AllocatedShareBasedCompensationExpenseCapitalized
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjEvZnJhZzo1ODg4YzFjZmIwMmU0YWM0YWI1MzEwOWUzN2FjMjZhYS90ZXh0cmVnaW9uOjU4ODhjMWNmYjAyZTRhYzRhYjUzMTA5ZTM3YWMyNmFhXzU2MDg_7e5a93f6-de25-40ae-bdf7-1fa1ae4c9993"
      unitRef="usd">21000</eols:AllocatedShareBasedCompensationExpenseCapitalized>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i258260be7e354c3dabf4d4df2ee981e1_I20210218"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjI5MDk0_49e645b8-8d84-4ec5-bdd4-b3dbc549f458"
      unitRef="usd">35000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <eols:LossContingencySettlementAgreementPaymentTerms
      contextRef="ia307b0175e9a4f089eff6272a567b599_D20210218-20210218"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjI5MTI0_6d5ab27c-6fbc-4f63-955b-e1a8d93251f4">P2Y</eols:LossContingencySettlementAgreementPaymentTerms>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i7e4a414b331e4768a456b40889b5bf16_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjI5MTgx_5f19366a-3a61-489a-bb51-a026c46dfb09"
      unitRef="usd">15000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="iec7e63cb81e2460c81caf30e8a3ecb3e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8zODQ4MjkwNzA3MTM4_b83f8346-042b-4256-91ee-3c2029c8cfab"
      unitRef="usd">15000</us-gaap:PaymentsForLegalSettlements>
    <eols:StockIssuedDuringPeriodSharesLitigationSettlement
      contextRef="ic40c99d6b0a04616bf00bfc233eced25_D20210228-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjM3NjI4_98e09eb6-f2a5-4627-ba49-75ac75801968"
      unitRef="shares">6762652</eols:StockIssuedDuringPeriodSharesLitigationSettlement>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i258260be7e354c3dabf4d4df2ee981e1_I20210218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjMwNzY0_9947b5a8-0ab6-4c0c-a23a-0a10380a632e"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear
      contextRef="i58d3338bb29342a7bea51d1b86c744ea_I20230915"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjMyMzI4_ef714d71-05e2-4b3c-ab55-43a6f1b3179e"
      unitRef="number">0.25</eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear>
    <eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear
      contextRef="i9886998085bb48b9b58c8a53127543d0_I20240915"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjMyMzk0_feb505de-5fe2-40e1-a59b-c16b5282dd05"
      unitRef="number">0.50</eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear>
    <eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear
      contextRef="ib98c7c392d2f4eaf8e8ab779dee845dd_I20250915"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjMyNDYz_be4317e6-d006-4d9a-a122-2f9211537461"
      unitRef="number">0.75</eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="i002a56e0c1ec4c04b5999635912fcdc8_D20210323-20210323"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjM0NTI1_c3e66004-7e9c-4813-ac28-f1c0786042cf"
      unitRef="usd">25500000</us-gaap:LongTermPurchaseCommitmentAmount>
    <eols:MilestonePaymentInConnectionWithAgreement
      contextRef="i002a56e0c1ec4c04b5999635912fcdc8_D20210323-20210323"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjM0ODAz_fa63c3cf-0d15-41aa-b36b-c884b1befff9"
      unitRef="usd">10500000</eols:MilestonePaymentInConnectionWithAgreement>
    <us-gaap:ConvertibleDebt
      contextRef="ib67b7815bf86448c836c0674ab2cd400_I20210323"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjM1OTAz_6ee35dac-3819-433a-b8c5-f9f4afc7b09f"
      unitRef="usd">40779000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="ibb11d4e5afdb4c27ae1e67ee48ded284_D20210325-20210325"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjM1OTY5_ff4708ce-89d3-4eed-ac5d-5646cc2975d8"
      unitRef="shares">3136869</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ib67b7815bf86448c836c0674ab2cd400_I20210323"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjM3ODc1_dbce3a2c-e214-4651-922f-8d8de9d859dc"
      unitRef="usdPerShare">13.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <eols:DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned
      contextRef="i75469af343584e09847fb0027c3e78c7_D20210323-20210323"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xNDc0L2ZyYWc6NTAxMWQ4MWEwZTZkNDEwOWEyZTYyYjk3YmNjZjkxMDUvdGV4dHJlZ2lvbjo1MDExZDgxYTBlNmQ0MTA5YTJlNjJiOTdiY2NmOTEwNV8xMDk5NTExNjM2MjU4_018d6157-51af-41ef-8082-39921928854d"
      unitRef="number">0.0999</eols:DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjQvZnJhZzoyOGJmMWMyNGU2NDI0YTFmOTQ1YmVmYzJiZGVlNzZlNi90ZXh0cmVnaW9uOjI4YmYxYzI0ZTY0MjRhMWY5NDViZWZjMmJkZWU3NmU2XzE4OQ_8a23a722-c3c5-4d79-921a-4c417f5a2eaf">Employee Benefit PlanThe Company maintains a defined contribution&#160;401(k) plan covering substantially all employees. Matching contributions totaled $481 and $524&#160;for the years ended December 31, 2021 and 2020, respectively.</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjQvZnJhZzoyOGJmMWMyNGU2NDI0YTFmOTQ1YmVmYzJiZGVlNzZlNi90ZXh0cmVnaW9uOjI4YmYxYzI0ZTY0MjRhMWY5NDViZWZjMmJkZWU3NmU2XzE2Mg_ae0b96b8-ff76-4b88-b88c-d53521ab61e6"
      unitRef="usd">481000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjQvZnJhZzoyOGJmMWMyNGU2NDI0YTFmOTQ1YmVmYzJiZGVlNzZlNi90ZXh0cmVnaW9uOjI4YmYxYzI0ZTY0MjRhMWY5NDViZWZjMmJkZWU3NmU2XzE2OQ_788fbbab-0ba9-4f04-a609-642b3ddf4b88"
      unitRef="usd">524000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzYxMTQ_a75f91b9-ab26-47d6-8577-10919d9adb7f">Income Taxes &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s loss before income taxes was entirely generated from its U.S. operations. The current and deferred expense is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred (benefit) provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred provision (benefit) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision (benefit) for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company has federal net operating loss (&#x201c;NOL&#x201d;) carryforwards of $273,776, of which $72,579 will begin to expire in 2034. The federal NOLs generated in 2018 and in the subsequent years in the amount of $201,197 have an indefinite carryforward period. As of December&#160;31, 2021,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company has state NOL carryforwards of $169,332, which will begin to expire in 2038. As of December&#160;31, 2021, the Company has federal research and development (&#x201c;R&amp;amp;D&#x201d;) credit carryforwards of $2,929, which will begin to expire in 2034. The Company also has California R&amp;amp;D credit carryforwards of $2,918, which has an indefinite carryforward period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The NOL and the R&amp;amp;D credit carryforwards generated by the Company in tax years ended February 11, 2018 and prior have been included in the consolidated and unitary income tax returns of Alphaeon Corporation (&#x201c;Alphaeon&#x201d;). After the Company left Alphaeon consolidated and unitary income tax group on February 11, 2018, the Company files its own standalone income tax returns. Deferred tax assets in the accompanying financial statements reflect the Company's standalone tax attributes that are reportable on its own income tax returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In general, if a company experiences a greater than 50 percentage point aggregate change in ownership of certain significant stockholders over a three-year period, utilization of its pre-change NOL carryforwards and R&amp;amp;D credit carryforwards is subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state laws. The annual limitation generally is determined by multiplying the value of the Company&#x2019;s stock at the time of such ownership change, subject to certain adjustments, by the applicable long-term tax-exempt rate. The annual limitations may &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;result in the expiration of NOL and R&amp;amp;D credit carryforwards before utilization and may be material. The Company has started but has not completed an analysis to determine whether its NOL and R&amp;amp;D credits generated through December&#160;31, 2021 are likely to be limited by Section&#160;382 and 383. The Company anticipates that an ownership change as defined under Section&#160;382 may have occurred and that the resulting limitation would significantly reduce the Company&#x2019;s ability to utilize its NOL and R&amp;amp;D credit carryforwards before they expire. Additionally, future ownership changes under Section&#160;382 and 383 may also limit the Company's ability to fully utilize any remaining tax benefits. The Company&#x2019;s net deferred income tax assets have been offset by a valuation allowance. Therefore, any resulting reduction to the Company&#x2019;s NOL and R&amp;amp;D credit carryforwards once the analysis is complete will be offset by a corresponding reduction of the valuation allowance and there would be no impact on the Company&#x2019;s balance sheet, statement of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of deferred tax assets and liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other deferred assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed asset depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of Federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revaluation of contingent royalty obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Meals and entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in state tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers' compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promissory note - debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax provision (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has considered the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above. The Company&#x2019;s effective income tax rate would not be impacted if the unrecognized tax benefits are recognized. Additional amounts in the summary rollforward could impact the Company&#x2019;s effective tax rate if it did not maintain a full valuation allowance on its net deferred tax assets. The Company does not expect its unrecognized tax benefits to change significantly over the next 12&#160;months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There were no accrued interest and penalties associated with uncertain tax positions as of December&#160;31, 2021 and 2020. The Company&#x2019;s tax returns for all years since inception are open for audit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (&#x201c;CARES Act&#x201d;). The Cares Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions which are expected to impact the Company&#x2019;s financial statements include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. There was no material impact on its financial position, results of operations, or cash flows related to the CARES Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 27, 2020, the United States enacted the Consolidated Appropriations Act, which extended many of the benefits of the CARES Act that were scheduled to expire. The Company noted no material impacts due to the Consolidated Appropriations Act on its financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzYxMDc_42d8268b-ccef-408e-b3d0-d2a106be7181">The current and deferred expense is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred (benefit) provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred provision (benefit) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision (benefit) for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzMtMS0xLTEtMjQ2OTc_f6dc0a8c-85db-4a38-b6be-ed841cd84dd1"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzMtMy0xLTEtMjQ2OTc_5397415a-2c76-4215-8127-76bacf5eb246"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzQtMS0xLTEtMjQ2OTc_3e9e3b21-bf9b-4a8f-a276-9686c4327b97"
      unitRef="usd">27000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzQtMy0xLTEtMjQ2OTc_e37e3485-2d8a-483b-a444-c409934ca91a"
      unitRef="usd">52000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzYtMS0xLTEtMjQ2OTc_d86df0fc-a2e3-4e5b-aeff-6655eef11487"
      unitRef="usd">27000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzYtMy0xLTEtMjQ2OTc_6b300b04-444b-4228-8c5d-8421ec08288c"
      unitRef="usd">52000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzgtMS0xLTEtMjQ2OTc_6a7e541b-ac35-4ccb-98bd-d74abff8bce3"
      unitRef="usd">20000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzgtMy0xLTEtMjQ2OTc_c82039a0-be21-484a-bce9-4cbe6e5a8c66"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzktMS0xLTEtMjQ2OTc_5ab380a0-9d4e-4038-aca3-7ea0fda9aabd"
      unitRef="usd">-5000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzktMy0xLTEtMjQ2OTc_dedcceb0-fb96-4cb8-9748-20a1e5cab3f2"
      unitRef="usd">25000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzExLTEtMS0xLTI0Njk3_01d802b9-e6df-45c2-960a-3928c4ec152d"
      unitRef="usd">15000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzExLTMtMS0xLTI0Njk3_42d01d76-a1a1-4f11-a3ea-63f196afb092"
      unitRef="usd">25000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzEyLTEtMS0xLTI0Njk3_d0b9318b-f971-4d1f-91bb-97cb7162d1e0"
      unitRef="usd">42000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo5YWJiY2E2MGE1YTg0ZjIzOThiOWIyMjk0ZWRkNjVkMy90YWJsZXJhbmdlOjlhYmJjYTYwYTVhODRmMjM5OGI5YjIyOTRlZGQ2NWQzXzEyLTMtMS0xLTI0Njk3_bf647c7f-0058-4d36-9698-222548554420"
      unitRef="usd">77000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="if65ecdee742e445f89295c829f75efac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzI0NA_8b816ad7-54e6-4575-8620-c09ba12472f2"
      unitRef="usd">273776000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="if65ecdee742e445f89295c829f75efac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzI1Nw_8fc0abe9-da84-43b1-b0d4-9438e67d2b93"
      unitRef="usd">72579000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="if65ecdee742e445f89295c829f75efac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzM3MA_c2fc38bf-be0f-4871-8952-e94fac175d9e"
      unitRef="usd">201197000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="iff738c7de2844195a714ca1b57f846c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzQ2Ng_329818dc-6e9d-4431-bd4b-83ffec0acfa8"
      unitRef="usd">169332000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="iaa6947c0461b47158a26475a99eabf01_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzU5Nw_c7420ffa-2d4d-448b-8c9a-a3740b9667f1"
      unitRef="usd">2929000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="id4b16f01a5f7415687373739c3bf5523_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzY5Nw_e748c618-5ea5-41b4-a29b-3b03aeb9aafc"
      unitRef="usd">2918000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzYxMTc_8ba3c80e-15cb-47b8-b186-0ffe08b39a17">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of deferred tax assets and liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other deferred assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed asset depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzMtMS0xLTEtMjQ2OTc_2bd8cadc-c448-4fef-85e0-6049163a3b2f"
      unitRef="usd">67039000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzMtMy0xLTEtMjQ2OTc_1c1c41fa-95ac-444e-99a7-b88fcbc57573"
      unitRef="usd">60083000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzQtMS0xLTEtMjQ2OTc_c555e9c1-39a2-4e27-993f-fcb9ec8f3fe5"
      unitRef="usd">2839000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzQtMy0xLTEtMjQ2OTc_bf0d0f83-e6f8-4529-9747-7ddaa7b660aa"
      unitRef="usd">3938000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzUtMS0xLTEtMjQ2OTc_7848fb99-4e55-471b-aa2e-553a6b9c7c38"
      unitRef="usd">2617000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzUtMy0xLTEtMjQ2OTc_67a7d11c-d32f-450d-b200-1ee647dfa8ef"
      unitRef="usd">2617000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzYtMS0xLTEtMjQ2OTc_96a250fd-799f-4baf-a10f-588053506630"
      unitRef="usd">4017000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzYtMy0xLTEtMjQ2OTc_220e781a-eda9-4c54-955d-2f5a6a19fcfb"
      unitRef="usd">2559000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <eols:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzctMS0xLTEtMjQ2OTc_b17a5e89-91d7-4bf2-a133-ebfeac8cc000"
      unitRef="usd">893000</eols:DeferredTaxAssetsOperatingLeaseLiabilities>
    <eols:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzctMy0xLTEtMjQ2OTc_7a0e312f-df3a-4b7c-b178-96371db7fa09"
      unitRef="usd">1114000</eols:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzgtMS0xLTEtMjQ2OTc_00c6ad5f-2442-408f-bbc9-c744d5e450bb"
      unitRef="usd">20276000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzgtMy0xLTEtMjQ2OTc_b1f5b34e-2a56-4ae9-bb01-c3c680fe5dd4"
      unitRef="usd">21318000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzEwLTEtMS0xLTI0Njk3_c084ea87-8dd2-4949-b8a1-d91c9fa6748f"
      unitRef="usd">216000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzEwLTMtMS0xLTI0Njk3_01231ded-44d0-429d-926b-b096b8f9ec40"
      unitRef="usd">21000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzExLTEtMS0xLTI0Njk3_883c1c76-d1f1-4a90-bdba-cb3a9c80052c"
      unitRef="usd">85527000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzExLTMtMS0xLTI0Njk3_da7f7144-3c34-4b2d-a42f-b075351d931e"
      unitRef="usd">78313000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzEyLTEtMS0xLTI0Njk3_409a40cd-c6a9-4e80-9395-3a9486417b70"
      unitRef="usd">12370000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzEyLTMtMS0xLTI0Njk3_fd7d459b-d48f-4280-af4b-2e32cbdcf9a3"
      unitRef="usd">13337000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE0LTEtMS0xLTI0Njk3_4d579acf-bf73-4248-8270-a99b2c8ba5b3"
      unitRef="usd">11528000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE0LTMtMS0xLTI0Njk3_30abe92d-d566-4223-8348-69b033bacab9"
      unitRef="usd">12240000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE1LTEtMS0xLTI0Njk3_b1ba59ae-0190-4229-9771-08c3fee60487"
      unitRef="usd">690000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE1LTMtMS0xLTI0Njk3_98f1a9f4-f8b6-4d74-9b51-595653622039"
      unitRef="usd">873000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE2LTEtMS0xLTI0Njk3_780b5d65-2628-4411-9a93-ea1b4a78e94d"
      unitRef="usd">192000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE2LTMtMS0xLTI0Njk3_4a01a411-ee63-4c00-8eb4-1b458f6abc24"
      unitRef="usd">249000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE3LTEtMS0xLTI0Njk3_25c57e01-d2b8-4d71-8529-9bc7ba434cc3"
      unitRef="usd">12410000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE3LTMtMS0xLTI0Njk3_d0f91215-7ac8-4285-a155-c43962f9aab8"
      unitRef="usd">13362000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE4LTEtMS0xLTI0Njk3_baaee1db-e832-4dc6-9280-a0c4d5dd3c29"
      unitRef="usd">40000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTo2ZTk3NjUyZWZlYmE0NmE0OWExZTdmNzA2OTgwNGEyZS90YWJsZXJhbmdlOjZlOTc2NTJlZmViYTQ2YTQ5YTFlN2Y3MDY5ODA0YTJlXzE4LTMtMS0xLTI0Njk3_3cbcf38c-2e02-450f-abe9-5acdda79a1ef"
      unitRef="usd">25000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzYxMTA_166f4c7e-017b-4db5-a6ca-1edc469725bc">A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of Federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revaluation of contingent royalty obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Meals and entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in state tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers' compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promissory note - debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax provision (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzItMS0xLTEtMjQ2OTc_34d1473f-af86-460f-aaa3-930710596cb9"
      unitRef="usd">-9832000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzItMy0xLTEtMjQ2OTc_cf9efdc5-8cb2-431d-9b88-fb4bb1d3269a"
      unitRef="usd">-34217000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzMtMS0xLTEtMjQ2OTc_480b49e6-c596-4e83-aa3d-ad5b1d68e97e"
      unitRef="usd">-1872000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzMtMy0xLTEtMjQ2OTc_ca3e12c8-256e-4745-88be-74ad7a1ccfa0"
      unitRef="usd">-7232000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzUtMS0xLTEtMjQ2OTc_a62d871a-94c6-4f8c-a73b-e31cfdfe05f1"
      unitRef="usd">1595000</eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation>
    <eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzUtMy0xLTEtMjQ2OTc_503c13f6-b33e-4e7d-bf9f-5a087db271b2"
      unitRef="usd">-513000</eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzYtMS0xLTEtMjQ2OTc_f574edf4-ecc9-453a-9663-e9b570f56734"
      unitRef="usd">230000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzYtMy0xLTEtMjQ2OTc_4a67ef9a-6e45-44fa-9672-aa5ed430ddef"
      unitRef="usd">366000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzctMS0xLTEtMjQ2OTc_487f8b39-3f7f-413f-9ac2-aabb47f315c7"
      unitRef="usd">129000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzctMy0xLTEtMjQ2OTc_b950759b-9a31-4d7c-bdbf-e83e2cf6e336"
      unitRef="usd">-242000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <eols:EffectiveIncomeTaxRateReconciliationOfficersCompensation
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzgtMS0xLTEtMjQ2OTc_ea703a6c-b3f4-44b7-a710-f8273573f181"
      unitRef="usd">2076000</eols:EffectiveIncomeTaxRateReconciliationOfficersCompensation>
    <eols:EffectiveIncomeTaxRateReconciliationOfficersCompensation
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzgtMy0xLTEtMjQ2OTc_0a076daf-addf-4122-af92-0417f197a32a"
      unitRef="usd">133000</eols:EffectiveIncomeTaxRateReconciliationOfficersCompensation>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzktMS0xLTEtMjQ2OTc_dd825bba-84da-4f2f-be17-e66d87718b5c"
      unitRef="usd">-17000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzktMy0xLTEtMjQ2OTc_4a38ed41-223e-4dd0-a1be-345590752874"
      unitRef="usd">616000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzEwLTEtMS0xLTI0Njk3_5720a47f-4a0e-4745-ace1-aa41385dd84f"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzEwLTMtMS0xLTI0Njk3_a17dc206-7b35-443f-84c7-36e2398facbc"
      unitRef="usd">147000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <eols:EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzExLTEtMS0xLTI0Njk3_2539da7c-fe29-4ab4-81a7-c42fd2557a94"
      unitRef="usd">120000</eols:EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount>
    <eols:EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzExLTMtMS0xLTI0Njk3_57feaabd-6e63-4b44-a819-67b19b2b7a18"
      unitRef="usd">-145000</eols:EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesOther
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzEyLTEtMS0xLTI0Njk3_e295e9aa-9fe7-445f-a902-ceea6a6062a7"
      unitRef="usd">399000</us-gaap:IncomeTaxReconciliationTaxContingenciesOther>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesOther
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzEyLTMtMS0xLTI0Njk3_21422a96-fc6e-444b-a8b2-864a81826c61"
      unitRef="usd">117000</us-gaap:IncomeTaxReconciliationTaxContingenciesOther>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzEzLTEtMS0xLTI0Njk3_5507a4b0-60c4-4cb8-869a-a1875e695dcb"
      unitRef="usd">7214000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzEzLTMtMS0xLTI0Njk3_3da1248c-1595-4e36-8470-348f45d6f137"
      unitRef="usd">41341000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzE0LTEtMS0xLTI0Njk3_b156f9f0-9431-439b-9146-6471de172fd2"
      unitRef="usd">42000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTowM2I5Y2Q5YTBjZjU0OTI5ODA2YTJmMWI4YWQ1NWM5MS90YWJsZXJhbmdlOjAzYjljZDlhMGNmNTQ5Mjk4MDZhMmYxYjhhZDU1YzkxXzE0LTMtMS0xLTI0Njk3_5f84bb76-6eb6-4d04-b2f0-fc0613068e17"
      unitRef="usd">77000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzYxMTE_49feedae-1607-4e01-be33-8b6cc31dc945">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTphNmUwNjc2MjM2NWE0NmY2OWQ2YWQyZGY0YzI0NGQyNy90YWJsZXJhbmdlOmE2ZTA2NzYyMzY1YTQ2ZjY5ZDZhZDJkZjRjMjQ0ZDI3XzItMS0xLTEtMjQ2OTc_db8d48da-f6fb-4bd7-beba-bf684fb98c8b"
      unitRef="usd">2924000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="idb18fef826e14bf1b6a11208896433a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTphNmUwNjc2MjM2NWE0NmY2OWQ2YWQyZGY0YzI0NGQyNy90YWJsZXJhbmdlOmE2ZTA2NzYyMzY1YTQ2ZjY5ZDZhZDJkZjRjMjQ0ZDI3XzItMy0xLTEtMjQ2OTc_84bdc2d9-6e31-40b1-89c4-8651925e72ae"
      unitRef="usd">2761000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTphNmUwNjc2MjM2NWE0NmY2OWQ2YWQyZGY0YzI0NGQyNy90YWJsZXJhbmdlOmE2ZTA2NzYyMzY1YTQ2ZjY5ZDZhZDJkZjRjMjQ0ZDI3XzQtMS0xLTEtMjQ2OTc_ff23f6fd-4c98-4714-8211-14fddbb3d991"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ib2505e28518945fb9d1b8842d7a49f94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTphNmUwNjc2MjM2NWE0NmY2OWQ2YWQyZGY0YzI0NGQyNy90YWJsZXJhbmdlOmE2ZTA2NzYyMzY1YTQ2ZjY5ZDZhZDJkZjRjMjQ0ZDI3XzQtMy0xLTEtMjQ2OTc_3ea2d93b-9b81-4c97-91ff-65876259cabd"
      unitRef="usd">163000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTphNmUwNjc2MjM2NWE0NmY2OWQ2YWQyZGY0YzI0NGQyNy90YWJsZXJhbmdlOmE2ZTA2NzYyMzY1YTQ2ZjY5ZDZhZDJkZjRjMjQ0ZDI3XzctMS0xLTEtMjQ2OTc_023ef668-13b6-44b9-ba68-9134ad7ebdb0"
      unitRef="usd">2924000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90YWJsZTphNmUwNjc2MjM2NWE0NmY2OWQ2YWQyZGY0YzI0NGQyNy90YWJsZXJhbmdlOmE2ZTA2NzYyMzY1YTQ2ZjY5ZDZhZDJkZjRjMjQ0ZDI3XzctMy0xLTEtMjQ2OTc_9d4c08e7-e171-4980-8440-c9a12022d294"
      unitRef="usd">2924000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="i9e4bb2c0e721463db9317bbec67a63bb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzQ3MDQ_b3e44634-5efb-4562-882d-853de0c373a2"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="ia04e516f2c6b4521bfa9ce8683f471d3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMjcvZnJhZzo2MTVjNzVkZDE0NDY0NzU1OWY0ZGU2NTI3MTliNDEzNy90ZXh0cmVnaW9uOjYxNWM3NWRkMTQ0NjQ3NTU5ZjRkZTY1MjcxOWI0MTM3XzQ3MDQ_e26246fd-411e-4f1b-adb1-6c3b66b17263"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMzAvZnJhZzpiZDliZWY3MmZlZWQ0ODkxYjYxNmUwY2Q5ZjNkYjdkMS90ZXh0cmVnaW9uOmJkOWJlZjcyZmVlZDQ4OTFiNjE2ZTBjZDlmM2RiN2QxXzc5MDg_40c7c2fa-986f-4971-b940-a76f1574f182">Related Party Transactions &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Payment Obligations Related to the Acquisition by Alphaeon&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was acquired by Strathspey Crown Holdings Group, LLC (&#x201c;SCH&#x201d;) in 2013 and subsequently by its subsidiary, Alphaeon Corporation (&#x201c;Alphaeon&#x201d;), by means of a stock purchase agreement (&#x201c;Stock Purchase Agreement&#x201d;) pursuant to which Alphaeon assumed certain payment obligations related to the acquisition. On December 14, 2017, the Stock Purchase Agreement was amended (&#x201c;Amended Stock Purchase Agreement&#x201d;), and, as a result, effective upon the closing of the Company&#x2019;s IPO, the Company assumed all of Alphaeon&#x2019;s payment obligations under the Amended Stock Purchase Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Amended Stock Purchase Agreement, the payment obligations to the Evolus founders consists of: quarterly royalty payments of a low single digit percentage of net sales of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The obligations terminate in the quarter following the&#160;10-year anniversary of the first commercial sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in the United States. In November 2021, we paid $20,000&#160;to satisfy in full a promissory note that matured in November 2021. Under the Amended Stock Purchase Agreement, the Company recorded the fair value of all revised payment obligations owed to the Evolus Founders. See&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Fair Value Measurements and Short-Term Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;for more information about the Company&#x2019;s accounting thereof.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Related Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 18, 2021, the Company and Medytox entered into a Settlement and License Agreement (the &#x201c;ROW Settlement Agreement&#x201d; and, together with the U.S. Settlement Agreement, the &#x201c;Medytox/Allergan Settlement Agreements&#x201d;), pursuant to which, among other things, the Company issued 6,762,652 shares (the &#x201c;Settlement Shares&#x201d;) of the Company&#x2019;s common stock, par value $0.00001 per share, to Medytox. See&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;for more information about the Company&#x2019;s accounting thereof.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 23, 2021, the Company and Daewoong entered into a Confidential Settlement and Release Agreement (the &#x201c;Daewoong Settlement Agreement&#x201d;) and a Convertible Promissory Note Conversion Agreement (the &#x201c;Conversion Agreement&#x201d;). Pursuant to the Conversion Agreement, among other things, (i) the principal balance under the Daewoong Convertible Note, together with all accrued and unpaid interest thereon, in the amount of $40,779 was converted, at the conversion price of $13.00 per share, into 3,136,869 shares of Common Stock (the &#x201c;Conversion Shares&#x201d;); and (ii) the Daewoong Convertible Note was deemed cancelled and satisfied in full in connection with such conversion. See&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Daewoong Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;for more information about the Company&#x2019;s accounting thereof.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <eols:RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale
      contextRef="i9a37e00a5294439283de4636c2dc8b56_D20171214-20171214"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMzAvZnJhZzpiZDliZWY3MmZlZWQ0ODkxYjYxNmUwY2Q5ZjNkYjdkMS90ZXh0cmVnaW9uOmJkOWJlZjcyZmVlZDQ4OTFiNjE2ZTBjZDlmM2RiN2QxXzEwOTk1MTE2NDYwNDM_204f8b17-5fd5-4b99-b594-2d4ec03659ce">P10Y</eols:RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="ib72da45d6b9e4dfd9eaea3fd7a90255c_D20211101-20211130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMzAvZnJhZzpiZDliZWY3MmZlZWQ0ODkxYjYxNmUwY2Q5ZjNkYjdkMS90ZXh0cmVnaW9uOmJkOWJlZjcyZmVlZDQ4OTFiNjE2ZTBjZDlmM2RiN2QxXzIwOTU_21f68e42-c4d7-4bac-b3a6-32c4c2839770"
      unitRef="usd">20000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <eols:StockIssuedDuringPeriodSharesLitigationSettlement
      contextRef="ic40c99d6b0a04616bf00bfc233eced25_D20210228-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMzAvZnJhZzpiZDliZWY3MmZlZWQ0ODkxYjYxNmUwY2Q5ZjNkYjdkMS90ZXh0cmVnaW9uOmJkOWJlZjcyZmVlZDQ4OTFiNjE2ZTBjZDlmM2RiN2QxXzE2NDkyNjc0NTc5Mjg_98e09eb6-f2a5-4627-ba49-75ac75801968"
      unitRef="shares">6762652</eols:StockIssuedDuringPeriodSharesLitigationSettlement>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i258260be7e354c3dabf4d4df2ee981e1_I20210218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMzAvZnJhZzpiZDliZWY3MmZlZWQ0ODkxYjYxNmUwY2Q5ZjNkYjdkMS90ZXh0cmVnaW9uOmJkOWJlZjcyZmVlZDQ4OTFiNjE2ZTBjZDlmM2RiN2QxXzE2NDkyNjc0NTgwMDY_9947b5a8-0ab6-4c0c-a23a-0a10380a632e"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ConvertibleDebt
      contextRef="ib67b7815bf86448c836c0674ab2cd400_I20210323"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMzAvZnJhZzpiZDliZWY3MmZlZWQ0ODkxYjYxNmUwY2Q5ZjNkYjdkMS90ZXh0cmVnaW9uOmJkOWJlZjcyZmVlZDQ4OTFiNjE2ZTBjZDlmM2RiN2QxXzE2NDkyNjc0NTcyNzM_6ee35dac-3819-433a-b8c5-f9f4afc7b09f"
      unitRef="usd">40779000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ib67b7815bf86448c836c0674ab2cd400_I20210323"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMzAvZnJhZzpiZDliZWY3MmZlZWQ0ODkxYjYxNmUwY2Q5ZjNkYjdkMS90ZXh0cmVnaW9uOmJkOWJlZjcyZmVlZDQ4OTFiNjE2ZTBjZDlmM2RiN2QxXzE2NDkyNjc0NTczMTk_dbce3a2c-e214-4651-922f-8d8de9d859dc"
      unitRef="usdPerShare">13.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="ibb11d4e5afdb4c27ae1e67ee48ded284_D20210325-20210325"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDM4MzYxZWM0NDQ3YjhiZTIyNjM5ZmVjM2M2OTFiL3NlYzo3NzAzODM2MWVjNDQ0N2I4YmUyMjYzOWZlYzNjNjkxYl8xMzAvZnJhZzpiZDliZWY3MmZlZWQ0ODkxYjYxNmUwY2Q5ZjNkYjdkMS90ZXh0cmVnaW9uOmJkOWJlZjcyZmVlZDQ4OTFiNjE2ZTBjZDlmM2RiN2QxXzE2NDkyNjc0NTczMzk_ff4708ce-89d3-4eed-ac5d-5646cc2975d8"
      unitRef="shares">3136869</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M.HAC5+4^5K^4!@  O1H  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R-
MF5USXC84AJ^WOT)#=]K=F0"V#(1LD\RPD+1T\T%#=G>VG5X(6V!-;(M*<@C_
MOD<VV"1CCIV+8(//Z\?Z>(]T?+Z1ZDF'G!OR$D>)OFB%QJP_=;O:#WG,=$>N
M>0*_+*6*F8%3M>KJM>(LR(+BJ$L=9]"-F4A:E^?9=S-U>2Y3$XF$SQ31:1PS
MM?W,([FY:+FM_1</8A4:^T7W\GS-5GS.S=?U3,%9MU )1,P3+61"%%]>M$;N
MIXDWM '9%=\$W^B#8V(?92'EDSV9!A<MQQ+QB/O&2C#X>.9C'D56"3C^VXFV
MBGO:P,/CO?IU]O#P, NF^5A&WT5@PHO6L$4"OF1I9![DY@^^>Z"^U?-EI+/_
M9)-?V^NUB)]J(^-=,!#$(LD_V<NN(0X"ALZ1 +H+H&\"W&-W\'8!7M. WBZ@
ME[5,_BA9.TR889?G2FZ(LE>#FCW(&C.+AL<7B>WWN5'PJX X<SF6SUR1-ODZ
MGY /[S^2]T0DY%9$$72*/N\:N(6]L.OOY#[G<O2(G$O)K4Q,J,E5$O#@M4 7
MV I N@?\3%'%"?<[Q'-/"'6H6P$TQL.O^:)#Z# +IQ7A$SS\SS2!NSM5=W_U
M-%[1W%ZFYZ'-_<]HH8V"(?\O(MDK)'N99.]8 TD_A8EHR.-VS:MZ# ]WG?87
MA*)?4/2;48R2)&41>>!KJ4P5#JYC5,H1G$&!,VB&,^-*R,".1@+SH[)]:I1V
MX^^G=^]JQL!IP7:**HY3I2S:M= ^M-0/SA3*AZNUVRYM>QC7L. :-AQ(BH&O
M9[9\O!MQK26+--:/9P73&:ISE1AAMM!4$2=W:;S@JHH%UW <M^T-O2'61JY3
M^J73A.B!KX2=P]!<=RRN[+<ZH6_W-U_G)V1Z-^Y@9 =.[C8AFR:^5-!KS';@
M"9D;&%9$*C*6:6+4%CZ#:EQ<?7*%0=(2DC:!?&0O9!K 8!-+X6>D2/?62/8&
M;=<;]@=N#R,L'=KUFA".@D!QK4_V!^0&KB/W277;X9)]ZI [OK%3B8SAH2$%
M3%0'^B85T#<NK-$P\C(1N+B5OR4?VS/H^4>Y22JI<;D]\6?._! #+'.$BYO[
M6\!B;,Z4?!:)7]VVN.9XA*&5^<+%;?XMVDQJ ^;\MU@?GS"XXAD=#-!^+?.%
M6Y,P,C)8U1]'P07.>F<82)D@7-S5;Z1-6+-0)I@;UXC08:_=Z_?[&%&9'ES<
MVQ^%@<P@ES")/BP^DCGW4P6M58F%*XUE'(,+S8WTGT[(>Z?CP)]+UI"<GUF4
M<K*&6:M#IK"T1LLT0G'WAQP;B&1%YMMX(:,JWAJ!J_N;.492I@V*&_N^S<C5
MBQ^R9,6/)K0:H;O1?#+Z"V,JLP1ME"6^PW:P_92 ?4'/,@W#+B!3K=/J<5>C
M>2<QM#(]T$;IX9N,()W"3CE;FZC*K5*-$@Y4NCYMY/K[566^8LN&%KAK6@V&
M*_[@&B,K[9XVLONI37CY_MZN<=D>M9(,5ZPA*]V>-G+[K.O(&)+02JI*TZC1
MN9-)F_D^!QD0"7)!C+#T?(I;]HYP'K/(,I:]"CZU9DDU+"Y9L[6B91J@N(/O
MV*YBKE86Z7=0,"%*A@O6D97I@#;:+AQL8/+]7R43+E7#Y)5.[^%&/1U?/Y!1
M&@@#"YV1,1P6%AG:=<1656 U>G5;*Z]T?J_1AF$>@LUBO5<C4PM4VK[7R/9G
MZ2(2/K2/9%4F,=FI]#,56]A\ONQ1KT//N\]5MS^HS32R]M<K@;E-^9K<IP;Z
M+;$YNZH(M5,>'"#U^X.S7J]_C*KT=Z]9?4<?[.S :A9V#[KD8*35R^8:U9FU
M$YEHNW8R(2>JV,_^JNUR_&6;K\ZS@L 21JZ]R-;0]@6>6\XS/X+XK*5"&060
M!PFT%A&'H"$PBL3RJCVOK3'.&&PMIM-I#B#TZ\(1L?-#JIC8\A0Q,KL]?S&6
MQLZ?0K<#FR@_).N,6!?$&P%#>L')$@PY@#.P)ZNP6^L(Z%#HRW+%8[M<Z*R6
M;:\%/-B4D8!MJ]MGF5=NMK9RPVV=DTRXS^UZ^)>?W8'SV[Y<B>WKO3*->GC2
M&\$3!=E3'74,7*!V@I9YTVM85CNL75W#EY7+C!JQNI)JF2L]/+&]I=K5_(YS
MX7+7/S"J,DMZC;+D>/JED@$/MGN/_JG3'] JENY!O=\FX>R]B2:^K?#DI?_B
MV^+=S"A[(]$M+\]?[-PRF\,UB?@20IW.*0PEE;\KR4^,7&=O#Q;2&!EGAR%G
M,-7M!?#[4DJS/[$W*-Y87?X/4$L#!!0    ( #J(8U2"CQDL'@(  &T%   8
M    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULC93+;MLP$$5_A="BJ\"RY$?;
M5!;@1X(:2 HC05L411>T-):(\*&2HRC]^Y*4K+J +7AC<<BYAW=(#Y-&Z1=3
M B!Y$UR:15 B5K=A:+(2!#4C58&T*P>E!44;ZB(TE0::>Y'@83P>ST-!F0S2
MQ,_M=)JH&CF3L-/$U$)0_6<%7#6+( J.$T^L*-%-A&E2T0*> ;]6.VVCL*?D
M3( T3$FBX; (EM'M:N[R?<(W!HTY&1-7R5ZI%Q=L\T4P=H: 0X:.0.WG%=;
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M_2N$5Q0MX-0BJ6?S -IDW0IL6-"TVV=&IF.ADNA2E-/LU^]24BQ;?#C9"BQ
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M_?LH>(%2RG:<ERL;W,@ ,L5!X'D#O*;9R) N.JR+%[#F\&AU@E:LA,'-ZXI
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M%$!^OV*R6Q0WZD5D^:^&Z3]02P,$%     @ .HAC5(7C!'(L"0  ."D  !@
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MGE"DTN5B@?ZTB;W-ZM T;IR'JH9.-60V>JPBK#\KN6\:)TV@4Y!TT6F:'KU
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M>U.&G_PH0)87X/O"P+AFP =T#_T7_P502P,$%     @ .HAC5.)!L!J,*
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M^<X]7LYIOO,#\TUL,_NOBX7K6J"C_SZRP&._P&-:X/'_,>+_]U?-IB?Y96.
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M;.QA!:!W4(H.MM%7)1 V''N;(2BM)?9=M0UPR:8!"O9 SK.+LK0( SZ2$Y'
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M-LUJA1IV<40(IU4(7R>2ASXZLXCB>9Z]13WWJ^JY$ %[%X4CW@9=&"%%4O!
M0D3R; RS.<%IVX4ZHL(YWIK@S^:S[630KK"E!!!JAT55F&%4OY+)G5(%@*[8
M9UD8,.;):2<?BW"*\0RI;"E"@$,?:31]Y6OBHFJ>2.5O0%L68"SO9;<8HB1?
M8P980\LE\%AXE%Q\T&@5AY5(L$^5X0WK L0&AV$AH1]B3P"S]^O9W4&S;<TV
M1H&6(\88W/=<*?/T1?83YJ*R4Q(M9R\^UD7Y6T]<>X?3$@QL3@LP[W>3"*.]
MLDD%<BHG3X<S-[[4BOQMZ_-0+P;PG0E\[^I=W[G8'A/X SB@L4"*%53-9BP]
M.%V0D8N)X09;)5,+%&E5M-/ C9'Q8HRM$9JHJI5&O0AA$\O[^3/ H[G.80E0
M-VVS:%JR\1;[:!(E9#B$@O>5!(!]=2%),-6/RG2>IUX0T:4'<BX'\H$WW+01
MC7=FN:GM[[T6MJA6'6ZVKR-(_;=H?K*ONZ"$;E=18*5N=#.$1&1U3F[JL"@-
M+:(N-<K]WH;'R>RL;!)T6C&(>K-\B_/:4VQM-4S7[T1\H'D$:K0BO)&N!#3X
MDI_C<$><1%J9\M6T<8R4[0B@Y&OCOR:D=&SWLR:?@U8%&P0CX3Z&$^MQ'(%I
M98M*-O)G08AB4<Z,HM=#KSUX%[TS&*W$ DK.O6".^C/]B-6NR"Y8" [X_@DM
MD4U347TF+&A"*"7X:GX%\J38P#R^(!D9\81-""R$6&=%8RL$89[]7:M _8?6
MB)GF]95429 E%T(B%.]3$,>4AB9P,(DH]SNPD+0@@$O_0\YXV6P78A</J[(X
M/. K5TFJ1@6N==W[JJ<_Z=Q/^O5^P2_QZR5_QO%L@D@R/]).D$2MT1+ULPM3
M81@2C!"L$9!3-P6(:2Q<J,M"V@^ 4[R[FUDN(HIVFFP/+ <T-U78(UR)]8T+
M!^Q71%QD=*B'KY#1AJNH_J8T6S)B(RLF#9187Y/64&KCDR&I"R @&KD68(*
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M<GJQDU FE9Z0LG+^.$JIQ4@:E+DH!1\4_]:+*;Y&@?1=:3 =V>[GV"/C#TI
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M8&1X_-7+'5BOH-K7>.=%958P]&3^[,D]SCKK'UVSPRGQ,HFNV=)']$M-BP_
M[ZL&!*7\@0O<-NTG N_5_P!02P,$%     @ .HAC5#]'7Q'X!@  ;1,  !D
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M3!H:=B=6M%U160<Z+Z4T9\4F&/;UZA=02P,$%     @ .HAC5+/U#IL9#0
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M6$U3B)3VX-&QQF:14R,3>-D".EI@WEGX)ETFC 4D6&I)HBFJW.BH1R^8"O1
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MBI&*R1\V<W2R[N5[5URF+ZPB)-PY[%X>C'U]1P5LUHIF\MLZ5+;F41TQTX<
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MFVO9M11[D )VS;R6B;D:;FFW["@KXJ4B*V!/]IJ=+L7/$C7_[2]/YK/'SYI
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MTTV>#<,U)_=E32I'T9:LX!'+ZCGGR -&&W<JR#[XVHF,GN$<Y*! ",2ZL=3
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MS(!O".K@[SDL-*\)\OA[T\@@>0D+:2O@\?Z%F6)6FWZ-O@9)M/AR@ (P(U(
MP>QE15WMT@)@7<V+?*5O )$ IZ@ G#6 +#A^'*0)P .#K',8'WE#D;BO6^ 2
M#J&"0^,,P1FUZ[0%A/%CN2('>,)&:SRUM*G*=%ZX\2,"?MW!#$!S(+,;V$97
M9$!<<.QU@DNI<^)CR[H"2EU7@,&VR,/D+,MR7 ,^,B,D@;,J"+B -(#J^-7Y
MIW]=O#LX?IV  C2'Y7Q!7._*+V5URY "S$!*G@>+W=DLV6'RG]4M;*>>);<
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M8O#A<&+UHJU2]$(5A]FD>"3W'"T9-,O-0-BQA&,NOTC!/,R;IB/; 6C<BPN
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M4>LIB:9"T6AI6R3A2AGYUHW)5.P_0+-%_"/6'7Q@DL>B17)E2L*:MP$J:%I
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MM*'G1_];-PB+XF94^X7.O]=Y$=U4ZN^:E-Y^Y!L%(PV/21HJ^XL2^NR"14A
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M656M_H$3W%;U%UK>S_\/4$L#!!0    ( #J(8U0>YTWD5@0  , +   9
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MCQKUYCX^'X%R!V%3C,U_8^U^]OY?3@@[_=Y@GQ.JS0,),F@29'!T&:8$D,1
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M9YEJ,(?;'8U9HX;WW]A*H/XP"0S!6Z<@.T M6JCX#%04PYVLS$;#;95C_C]
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M6ZNW @  X04  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL?53;;MI
M$/V5D1M5B41C8R @"DB0-$JE1(IR:1^J/BSV&*^R%W=W'9)^?6?78*@4>+%W
M;F?/&7MFLM;FQ9:(#MZD4'8:E<Y5XSBV68F2V7-=H:)(H8UDCDRSBFUED.6A
M2(HX39*+6#*NHMDD^.[-;*)K)[C">P.VEI*9]P4*O9Y&W6CK>."KTGE'/)M4
M;(6/Z)ZK>T-6W*+D7**R7"LP6$RC>7>\Z/O\D/"#X]KNG<$K66K]XHWO^31*
M/"$4F#F/P.CUBI<HA <B&G\VF%%[I2_</V_1KX-VTK)D%B^U^,ES5TZC400Y
M%JP6[D&O;W"C9^#Q,BUL>,*ZR>W3C5EMG9:;8K(E5\V;O6WZL%<P2@X4I)N"
M-/!N+@HLKYACLXG1:S ^F]#\(4@-U42.*_]1'IVA**<Z-WM"(^%6,V7A](DM
M!=JS2>P(V(?C; .R:$#2 R#=%.ZT<J6%;RK'_'^ F!BUM-(MK45Z%/$*LW/H
M=3N0)FGW"%ZOE=D+>+V#>$L'5]QF0MO:(/R:+ZTS]$O\/@+>;\'[ ;Q_ /R1
M)B6O!8(NX(ZYVG#'T7KK5JO5%^=;[ E\U-BCR'XBQ[9B&4XC&CF+YA6CV3Q
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M7D#O)VUK-P-VT']/G?T-4$L#!!0    ( #J(8U3L1AM&?04  !T.   9
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M4[WF*9[UJ"<UJGOLS>Y62-396\QV%K$V T(#UY#+@EI23^%OY*JN&SF78KE
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M]6&D?C%R[0X "VGH..$>5W1^0V4%Z'\NB;W-BS70G@AG_P%02P,$%     @
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MDA>O0(L+R=+\!=&,2<GB_..*DCGE>H#Z?L%4]LH+_<ZI>A%]_C]02P,$%
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M'Z;<L-&X#1Q?:DWO$]=$ZK^ _F]02P,$%     @ .HAC5!**BQPB P  K H
M !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULS59;3]LP&/TK5K0'D*"Y
M]09J*T$[-"1@J 7V,.W!3;ZV%HZ=V4XOTG[\;">D@:4MDS:)E\:7[SL^/L?^
MZMZ*BV>Y %!HG5 F^\Y"J?3<=66T@ 3+!D^!Z9D9%PE6NBOFKDP%X-@F)=0-
M/*_M)I@P9]"S8_=BT..9HH3!O4 R2Q(L-I= ^:KO^,[+P)C,%\H,N(->BN<P
M ?68W@O=<TN4F"3 ).$,"9CUG0O_?.B')L%&/!%8R4H;F:U,.7\VG>NX[WB&
M$5"(E(' ^K.$(5!JD#2/GP6H4ZYI$JOM%_0KNWF]F2F6,.3T&XG5HN]T'13#
M#&=4C?GJ"Q0;:AF\B%-I?]&JB/4<%&52\:1(U@P2PO(O7A="5!*"UHZ$H$@(
MWB;X.Q+"(L$JY^;,[+9&6.%!3_ 5$B9:HYF&U<9FZ]T09FR<**%GB<Y3@RM,
M!'K"- -T"UAF K1'2B+,8C19<*%.'T DZ)HM0:I\ZA3=82&PD1\=C4!A0N4Q
M^H0(0P\+GDF=*GNNTN3,$FY4$+G,B00[B(P@:J#0/T&!%_B/DQ$Z^G2\ 2QJ
MD(;O1_(*I-<HKA:I5"HHE0HL;'A0J1-T(244(MT0/"64* +R1<$8Z?,YAB@3
M@K"YC;KC3)0#EU@2B;[?Z 70M8)$_MA#+RSIA99><P>]&\[FI\IX%<-4G:"9
MH;LT=.N\R+$Z%LO<].6@TVHVNSUW6=6Y)JH=MK=1KX@V2Z+-O42'G"FM@CY*
M*!4\(5)RL4&,*T IWN IK2,\;/Y!Q3\+NLUZ*JV22NN]5,9\@ZG:H*]32N;8
M5IA?U1NA;T"::5D_KU-=@+3%YEKLL:U=4FA_Q%/5*>EU]BI458 8!;0J.V[E
M98[4KEKDU?O3+5?O_FM_1D1&/#,)6!\H'4(82;)]3IV59,X^HE.^MZWDWM]Y
M55N$<PSS*6WR&G[XYN8?#'O-L?)OX_]W1_'Z@*/^MJ3['[*F^]NB[N^OZN_S
M-*PS*WAKZ8&HG*%;>4J8=]PM%G/")*(PTUE>HZ,KJLB?1GE'\=2^+J9<Z;>*
M;2[T<Q*$"=#S,ZXK>]$Q#Y;R@3KX#5!+ P04    "  ZB&-4) ,L :@#  "8
M$P  &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6S-F%UOVDH0AO_*R.I%
M*S6Q=VT^4@%2$AHU4GH4A:;GXJ@7"QY@U;67[JZA2/WQ9]<X-B3@6)6"N %_
MS,S.S&/F-=M;2?53SQ$-_$Y$JOO>W)C%)]_7DSDF3)_+!:;VSE2JA!E[JF:^
M7BAD<>Z4")\&0=M/&$^]02^_=J\&/9D9P5.\5Z"S)&%J?85"KOH>\9XN//#9
MW+@+_J"W8#,<H7E<W"M[YI=18IY@JKE,0>&T[UV23T/:<0ZYQ7>.*[UU#*Z4
ML90_W<EMW/<"EQ$*G!@7@MFO)5ZC$"Z2S>-7$=0KUW2.V\=/T6_RXFTQ8Z;Q
M6HI_>6SF?:_K08Q3E@GS(%=?L"BHY>)-I-#Y)ZP*V\"#2::-3 IGFT'"T\TW
M^UTT8LN!1 <<:.% FSJ$A4/8U"$J'**\,YM2\CX,F6&#GI(K4,[:1G,'>3-S
M;UL^3QWWD5'V+K=^9G##N(+O3&0(7Y'I3*&%:C2P-(;17"IS]@U5 K?I$K79
MW#J#2ZVQL+GC;,P%-QSU4X 8'$]XP$FF%$]G<,4TU_!^B(9QH3_8 (^C(;Q_
M]P'> 4_AVUQFVL;2/=_8BEQ>_J3(_FJ3/3V0_1 GYQ"2CT #2O:X7S=W#_:X
M#QN[DXM==]]B*%G0D@7-XX6OLOC8I,55@YW5/S)5SSK^WYU= &X-)OI'37IA
MF5Z8IQ<=2.]:IL8&M\\ *+EFPJQ!C@6?L?P'O&!K-A8(1L+GI129AAN9I3&J
MO5@W*W7RE=QH6@ZBJ!-9!LMM>GNL2"MJ[UH-]\5J=\/2:J?8J"PV.D*Q.TNW
MRJ5;I_@8M,OTVD=[##8KM5]Y#/98[3P&.V5TRC(Z;U(&_($[7*( 4M/+;IE$
M]Q117Y3I71P-]<4+B,\QUUGLI$^"2MR"MX5,:[I(MC26G")F4@D/H4<#72Q5
M1[K69+>$2IS(VZA3B3JLZV0E&R0Z2=25N)#6\5"W&LEX8=9P@)-*B$B]$CV>
MC\"HO)MKT*YQ>8/KVE2I ^F<),=*.4BWMOC+I7V9=JS.[)^_,\TLM!C'YF ?
M"A3=%RA:07#HQU?I!*D7B@,D&FDEK:8Y#4Z1":WF/"5OP*0(VHP)W?HS43_3
M7V-2)VVT&KLT/$DFU4"F]2_R?\DD:JI0M)J\M'[RO@:D3H!H-11I^R2!5).5
MUK]X_R60S@NI>0[$W]H%<7M67YF:\52#P*GU"<X[%H_:; -M3HQ<Y!LC8VF,
M3/+#.3(K=L[ WI]*:9Y.W%Y+N1DW^!]02P,$%     @ .HAC5/ XM!$5 P
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M28(S2>XAOT&A_Q$%7N /T.>7T[VW=%?;[3P'G>? Q@O/Q%O@ UY2[56[0;8
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M[R;5VT4T5TDS47QCN_&2*]W;[;#4MR\( ]#?5YRKUXEI\-U]/OT'4$L#!!0
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MS?23!M(8Z/6Y$+@>F W:1S+^"U!+ P04    "  ZB&-40W\7!$$"  #&!0
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6R55.]KVS 0_5<.PZ"#-7;L
MM-M*$F@3Q@8K*^FV?AC[H-B76%0_/.G2-/_]3HIC4DA"^\722??>W7N6-%Q;
M]^AK1()GK8P?)351<Y6FOJQ1"]^S#1K>65BG!7'HEJEO'(HJ@K1*\RR[3+60
M)AD/X]J=&P_MBI0T>.? K[06;G.#RJY'23_9+<SDLJ:PD(Z'C5CB/=*OYLYQ
ME'8LE=1HO+0&'"Y&R77_:C((^3'AM\2UWYM#4#*W]C$$WZI1DH6&4&%)@4'P
M\(035"H0<1O_6LZD*QF ^_,=^Y>HG;7,A<>)50^RHGJ4?$J@PH58*9K9]5=L
M]5P$OM(J'[^P;G.S!,J5)ZM;,'>@I=F.XKGU80^0%T< >0O(7PLH6D 1A6X[
MB[*F@L1XZ.P:7,AFMC")WD0TJY$F_,5[<KPK&4?C'PTZ0=(LX3NR&Q[.X2%*
MQ^K\^HGWE@@S#,>ARX&?Z#0(4\%4^M*N#,%,$,+9%$E(Y=\/4^+. G]:MEW<
M;+O(CW0QQ;('1?\#Y%G>/P"?O!Z>O82G[$=G2MZ9DD>^X@C?Q&HMB<\J^:AS
M8DVP"$TIV:&@6EF_<@A_KN>>'!_%OR>J%EW5(E8='*G:^2Y:WUWGNXJ^4_#]
M;(/"'?;X-'T!$0E]T"RGADNHQ,8?,OLTS^ 5/"_T#SK]@[?IKW;'BT\H'A)\
MFN]S;Y"].Z3OS;"MG'3OEH47[E:XI32>?\Z"B;+>QXL$W/;5V 9DFWCQYI;X
M&L=IS0\MNI# ^PMK:1>$N]P]W>/_4$L#!!0    ( #J(8U0*^<P7@ (  +(&
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;(6576^;,!2&_XJ%>M%*
M:_D*D%0$J6TT;5*K1?W8+J9=..$D6#68V8>D_?>U#6590](;\-=YG_<8^Y!N
MA7Q6!0"2EY)7:NH4B/6EZZIE 255%Z*&2L^LA"PIZJY<NZJ60',;5'(W\+S8
M+2FKG"RU8W.9I:)!SBJ82Z*:LJ3R]1JXV$X=WWD?N&?K LV FZ4U7<,#X%,]
ME[KG]BHY*Z%23%1$PFKJ7/F7UQ.SWB[XR6"K=MK$9+(0XMETON=3QS.&@,,2
MC0+5KPW< .=&2-OXVVDZ/=($[K;?U;_:W'4N"ZK@1O!?+,=BZHP=DL.*-ASO
MQ?8;=/E$1F\IN+)/LNW6>@Y9-@I%V05K!R6KVC=]Z?9A)R#P#P0$74!@?;<@
MZW)&D6:I%%LBS6JM9AHV51NMS;'*?)0'E'J6Z3C,?M0@*;)J36Y!)Z?(.;FC
MV$B&KT2LR(=I<LOH@G&&3*\\G0%2QM49.2&L(H^%:!2M<I6ZJ(T9>7?9F;AN
M300'3,Q@>4%"_PL)O,!_>IB1TY.S_U5<G5:?6]#G%EC9\(!LE]'OJX5"J3__
MGR.:8:\96LW1 4WM,!A*L(U*;)2Y")O,#^(H=3<#K%'/&GW&"H=8;52\RPH#
M;Y@5]:SH,]9HB!4-L))DF!7WK/@S5C3$BO=9_H$M3'I4<A3U*)!R(OI3S.TI
MKNFKKBLX>%*3/1,C[U#"X][%^*B+6U#JDK"R;A!R?5<0)"@<HH_WZ.=1% _3
M)SU]<I0^US"=+=E0WH"YU!^W@_^[U$.>)GM'.XP"_X,G=Z<$F6I^1^6:54H3
M5CK,NTCT09)MA6P[*&I;E18"=8VSS4+_5$":!7I^)02^=TRAZW]3V1M02P,$
M%     @ .HAC5%!Y6LN) @  ( <  !D   !X;"]W;W)K<VAE971S+W-H965T
M-#@N>&ULE57?;],P$/Y7K(B'(4U-FK3=-*61MG8()!#5IL$#XL%U+HTU.PZV
MLS*)/YZSDX8":=>])/YQWW??W=GG=*OTHRD!+/DI167F06EM?16&AI4@J1FI
M&BK<*926U.)4;T)3:Z"Y!TD1QE$T"R7E59"E?FVELU0U5O *5IJ81DJJGV]
MJ.T\& >[A3N^*:U;"+.TIANX!_M0KS3.PIXEYQ(JPU5%-!3SX'I\=3MS]M[@
M"X>MV1L3%\E:J4<W^9#/@\@) @',.@:*OR=8@!"."&7\Z#B#WJ4#[H]W[.]\
M[!C+FAI8*/&5Y[:<!Y<!R:&@C;!W:OL>NGBFCH\I8?R7;%O;Z30@K#%6R0Z,
M"B2OVC_]V>5A#Q G!P!Q!XA/!20=(/D7,#X F'2 R:F :0?PH8=M[#YQ2VII
MEFJU)=I9(YL;^.Q[-.:+5^Z<W%N-NQQQ-ELH*;G%PEM"JYPL5&5YM8&*<3#D
M; F6<F'>IJ%%7PX1LH[WIN6-#_ N@8U(%)^3.(JC6N"!M;PH!G@6QWD^,SLB
M\67+PY1LJ09XEB?H2<:>9_QPOR1G;X:BNCV=)1ID"3'_?1'BO@BQITU>+((9
MJ,*2&R:4:320;]=K8S5>KN]'O":]U\1[G1SPNFHT*_&.$=:[/R=4JF8XORW9
MA2=SW><IBZ,QMJ,H#9\&5$QZ%9.C*CXJ8U#!+N!G;!U,-U0,29C\)^&/\[9\
MQRS^DC?MY4U?)>^<5-C\&)Y":4C!!>2XTL@U:/*+'#N?B];/;#]_P])FO;39
M:Z6U0E1!^AMG4-:QZW<S>U%6N-==W-OQB>H-KPP14" F&EU@9+KMQ^W$JMHW
MG+6RV+[\L,0G#+0SP/U"*;N;N![6/XK9;U!+ P04    "  ZB&-40-NHR94)
M   7,P  &0   'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6RU6VUOVS@2_BN$
ML8MM@3862;TND@!ITEQSVW:#IMG]<+@/C,W80B71I6@[.>R//Y*23=D2*<6M
M"Z3Q"SE\9CCSS'"HG*X9_U;.*17@*<^*\FPT%V+Q^WA<3N8T)^4)6]!"?O/(
M>$Z$?,MGXW+!*9GJ27DV1IX7CG.2%J/S4_W9+3\_94N1I06]Y:!<YCGAS^]H
MQM9G(SC:?/ EG<V%^F!\?KH@,WI'Q?WBELMWXZV4:9K3HDQ9 3A]/!M=P-\_
M1K&:H$?\E=)UV7@-E"H/C'U3;VZF9R-/(:(9G0@E@LA?*WI)LTQ)DCB^UT)'
MVS75Q.;KC?1KK;Q4YH&4]))E?Z=3,3\;Q2,PI8]DF8DO;/V!U@H%2MZ$9:7^
M'ZRKL5$R I-E*5A>3Y8(\K2H?I.GVA"-"0A:)J!Z MJ?X%DFX'H"'CK!KR?X
M0R<$]81@;P*.+!/">D(X=(6HGA#M3["M$-<3XJ&0DGI",G0"]#8[YPW5 FXW
MN[7;UBF;[89ZO\>58VFOO"*"G)]RM@9<C9?RU OMVGJ^=,:T4%%X)[C\-I7S
MQ/F=8)-O<Y9-*2]_ ^^_+U/Q#-Z"SX1SHN(#O+JB@J19^1K\ L:@G!-.2Y 6
MX+Y(1?E&?BA??YVS94F*:7DZ%A*3DCR>U.N_J]9'EO4_$7X"4/@&( _!^[LK
M\.J7UQU2+H=("2HI%<8.(5=N(=?T00J)>X2\=POYS%92"%1"8&05<NT6<K&0
MZF!OQRC&^E:I_QI@) Q[]/O0 VTY,T)J:%99-VY95W32DC5 S7\/E^H-E_K'
MX'UU&._C<"%>EY"QC-YM"*-M"",M%5ND7F:D+ %[!#J6P7\^RN_!C:!Y^5^'
M=+R5CK5TWR+]5F9%RCF=@E*)?[.A +(4<\;3_\DO7DD*J#[M"MV;2GZHY:NB
M8'4.O>K?Z7C5W-<! W=4\+<J^"]384$X6)%L237T*<LRPDNPH+Q2XS7XIT%V
M72I5Z\5-I/2M%^SITS=J1YE@JTQPT'ZD9;GLWXN@9>+]37"-V $<;@&'!P&6
M)6$I9-)(BUD?ZK 7M6O$#NIHBSIRHKYD>2Z+Q$-]/K*Z\C[R(2-W-(BW&L0O
MT."'73X>Y/)]HW8T2;::)"_>BS<#'3YIF3<(@BA,XG@/>7L@QI&?(!1W@X>>
MJ;"\ ^"_P/UK^0.4Z!C9HT6C3H1.+6ZDN4DQH2K13!H:*<?I!%V)BQI0PF#?
M73H&6;P>FFP(D1/H)_*4YLL<%,O\0;JWA-N.WF4AZUT@YA0L,E+TV/]]O6#3
MJCX.(4J@!:O)K="=7"^*8DDR64)/Y FZI"H>)[00\OBK<.>U)EV$2;^KB8)U
M W:OZI]XWJ^.T@":Q K=F?5B.DW585I"J4'*'\I7TL2/C.L0U3[C-O ?]2I-
M R.$L!?OD>7'CH$0^TD2)I:=,%D5NM/JW>'P;V [9V+E'WYD0652)W3GSIM"
M\+0HTPGX2W.W+=;"5A@A6_J )@-"=PK4Y>1;U>*8JHA?T*(DNG-"G]1K.YIV
M2DLD6^V'?E?B"V+?@MID/=B3]L@B%2338:[W[! -XC9WX7W\[3'(Q@<FT<%!
MF4Y;WG4R,+D'>4<X&R"3%="!64%&S(051=UK6Z=B#C))%;/*_B45(J.YI+J>
MV+JJUV^Z21B%* Q0MZU1X]3DSA-6Z#W1CMK9(/1Q'*$]!^D8!^,P:#C2+G"3
M-%!/TC"D>TO2*;@I0.WTKBTUG([\8[B,85KD9MJ7%A*U.'<AT3'(PG_(D"]R
MD^\5H6O&9+*]9,6*<I$^9!1\9D+11O.C*_H@]$?#8M?P+XJ.L1&&*5'? 4'I
MH-OIC:VH\J [!BYKR3L9#^(P;N3AJB,U8. N>D.5R$V5%^ K^ 3N2";17LPX
MU6SBZG<8SL3'X$QL.!.[.?/S?F%:GV2DR04G,D55G.G>@@^X38P)EF6II>;
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MHPW"&.CW:\[586 ^T+;NB]]02P,$%     @ .HAC5#,DNFCK @  O@@  !D
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M<6OG;D300#*C.=,T97\A:I%))M88_?L'4I)K#9GZTR"H4PGJ6$&=(X+N!&Y
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MQ6,Q4Z9@)/CW*-2+@=6U2 @SMN3Z0:P^0U%0V_ %@JOLEZSRV YF#)9*B[@
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M89E0CW]*TEXETP*;XU?VV]QX-&;)-$RE^).OS/:J-^R1%:Q9)LR#W-]!:=#
M\D52Z/POV9=[W1Z),FUD7()1@Y@GQ2_[7CJB ?". ;P2X'4%^"7 ?P>@_2.
M?@GHOY= CP &)6#05:6@! 3O <=4"DM ^ [@'U-I6 *&726,2L"H*X"ZKY'+
MCZ13A#P_+S-FV&2LY)XHNQ_Y[" _=#D>CPE/;'X\&H5?.>+,Y $$,[ B"Z;,
M"_FF6*)9?G(U.9N!85SH<_*).$1OF0)->$*>$F[T!2[B^-M69IHE*SUV#&IC
M.9VHE'Q=2/:.2/Z=J4OB#2Z(YWJT8#] ,FTGN84ED@P_()FUD\P@NB2T;TEH
M> !^TP[_*G>7Q'<+'9X>9^3LT_D!EML.[O#I!Y9\Z6#)*TD=M0-$=UV"X[^Q
MJ95OWB%.=-A!L?ON%KK'B!Q,@BH3O"H3O)S9_]E,('_]AEO)W$"L_VX1Y%>"
M_%Q0_XB@J8QC9,7DCIXO2,H4V3&1 3G#?%I)(9C2) 556';H)'TI^(<YO[T
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MOCL)3N,98Q_GV(1N.#Y$!*P1YUZ&F$FJ>.\6$R/3_&6SE 9?2OEP"VP%RF[
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M8FF<JT)7P.[X2^>92S!#),2&N U!/_;Z=-2]LCOC!SO>3,XZA)@=$F([H/G
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M.HAC5 M8N/SM    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ .HAC5)E<G",0!@  G"<  !,
M ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  ZB&-4M3Y6
MOY0&  "]&@  &               @($,"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ .HAC5(*/&2P> @  ;04  !@
M ("!U@X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( #J(
M8U3HX6?QX@8  !\>   8              " @2H1  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    "  ZB&-4E*>'?LH"  "R"0  &
M        @(%"&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ .HAC5)EJ48I>!@  >1D  !@              ("!0AL  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( #J(8U2M*FR%D@4  '88   8
M              " @=8A  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    "  ZB&-4A>,$<BP)   X*0  &               @(&>)P  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ .HAC5).4Z)_$"0
M]!<  !@              ("! #$  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( #J(8U3B0; :C"@  +6&   8              " @?HZ
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  ZB&-4/T=?
M$?@&  !M$P  &0              @(&\8P  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( #J(8U2JKU_UN@4  -\-   9
M  " @>MJ  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M.HAC5'.O"^2N @  NP4  !D              ("!W'   'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    "  ZB&-4L_4.FQD-  !2*   &0
M            @('!<P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( #J(8U3 LMN?'PT  ' H   9              " @1&!  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ .HAC5#[91"'$!0
M; T  !D              ("!9XX  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    "  ZB&-4? QC_?H4  #^0P  &0              @(%B
ME   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( #J(8U0#
M]U_8; T  ,4E   9              " @9.I  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ .HAC5-J0!2P %0  0D0  !D
M     ("!-K<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #J(8U0>YTWD5@0  , +   9              "
M@0D4 0!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ .HAC
M5"+<TVD;!   -@H  !D              ("!EA@! 'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    "  ZB&-4_(B\P[\"  "_!0  &0
M        @('H' $ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( #J(8U2"0UNKMP(  .$%   9              " @=X? 0!X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ .HAC5)_W'=IW P  * @
M !D              ("!S"(! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    "  ZB&-4?QH$@D %  !;#0  &0              @(%Z)@$
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( #J(8U3L1AM&
M?04  !T.   9              " @?$K 0!X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ .HAC5'Z9"+I-!@  E!X  !D
M ("!I3$! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  Z
MB&-4XWA.[N$'  #_)@  &0              @($I. $ >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( #J(8U3):'A1A0(   X&   9
M          " @4%  0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#
M%     @ .HAC5!**BQPB P  K H  !D              ("!_4(! 'AL+W=O
M<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  ZB&-4) ,L :@#  "8
M$P  &0              @(%61@$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM
M;%!+ 0(4 Q0    ( #J(8U3P.+01%0,  -X'   9              " @35*
M 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ .HAC5+*;
MT446!   $Q   !D              ("!@4T! 'AL+W=O<FMS:&5E=',O<VAE
M970S-BYX;6Q02P$"% ,4    "  ZB&-4]+,1()("  !(!P  &0
M    @('.40$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M #J(8U0,U7C330,  %0,   9              " @9=4 0!X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ .HAC5-]HNEO3 @  VP<  !D
M             ("!&U@! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    "  ZB&-4 Q#,48P$  #2%0  &0              @($E6P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( #J(8U2#N%#RJ (
M *L'   9              " @>A? 0!X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ .HAC5$OD;PG^!   ,18  !D              ("!
MQV(! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  ZB&-4
MMH5M.% #  "2"P  &0              @('\9P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    ( #J(8U19NCFD; (  !('   9
M      " @8-K 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ .HAC5._]3I2M @  , <  !D              ("!)FX! 'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  ZB&-40W\7!$$"  #&!0
M&0              @($*<0$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    ( #J(8U0*^<P7@ (  +(&   9              " @8)S 0!X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ .HAC5%!Y6LN)
M @  ( <  !D              ("!.78! 'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    "  ZB&-40-NHR94)   7,P  &0
M@('Y> $ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( #J(
M8U0_]O,GQ@(  -P'   9              " @<6" 0!X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @ .HAC5$]TJ2Q(!0  K14  !D
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M=#4U+GAM;%!+ 0(4 Q0    ( #J(8U1VFD$OY (  "<)   9
M  " @::: 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @
M.HAC5)S9/"T* P  L H  !D              ("!P9T! 'AL+W=O<FMS:&5E
M=',O<VAE970U-RYX;6Q02P$"% ,4    "  ZB&-4S<6FC,(#  !S#0  &0
M            @($"H0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4
M Q0    ( #J(8U1L_#'S\P,  (,,   9              " @?ND 0!X;"]W
M;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ .HAC5/[-S[VN @
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M96QS+RYR96QS4$L! A0#%     @ .HAC5#ZS$.H4!0  =2@   \
M     ( !U+0! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #J(8U3U29+,
M 0(  %XD   :              "  16Z 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( #J(8U363,"2X $  .,C   3
M  "  4Z\ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !% $4 VA(  %^^
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>163</ContextCount>
  <ElementCount>490</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Statements of Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StatementsofStockholdersEquityDeficit</Role>
      <ShortName>Statements of Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StatementsofCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Fair Value Measurements and Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestments</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Term Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/TermLoans</Role>
      <ShortName>Term Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - Daewoong Convertible Note</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/DaewoongConvertibleNote</Role>
      <ShortName>Daewoong Convertible Note</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135110 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2142111 - Disclosure - Medytox/Allergan Settlement Agreements and Daewoong Arrangement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangement</Role>
      <ShortName>Medytox/Allergan Settlement Agreements and Daewoong Arrangement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2144112 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2146113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2153114 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Fair Value Measurements and Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/AccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Term Loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/TermLoansTables</Role>
      <ShortName>Term Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/TermLoans</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/OperatingLeases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2336306 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/StockholdersEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2347307 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/DescriptionofBusiness</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Fair Value Measurements and Short-Term Investments - Short-term Investments Available for Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Short-term Investments Available for Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Fair Value Measurements and Short-Term Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Fair Value Measurements and Short-Term Investments - Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Fair Value Measurements and Short-Term Investments - Reconciliation of Fair Value Measurement of Contingent Royalty Obligation Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Reconciliation of Fair Value Measurement of Contingent Royalty Obligation Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/AccruedExpensesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Term Loans - Pharmakon Term Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails</Role>
      <ShortName>Term Loans - Pharmakon Term Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Term Loans - Schedule of Long Term Debt Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails</Role>
      <ShortName>Term Loans - Schedule of Long Term Debt Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Term Loans - Oxford Term Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/TermLoansOxfordTermLoansDetails</Role>
      <ShortName>Term Loans - Oxford Term Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Daewoong Convertible Note (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/DaewoongConvertibleNoteDetails</Role>
      <ShortName>Daewoong Convertible Note (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/DaewoongConvertibleNote</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Operating Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeasesNarrativeDetails</Role>
      <ShortName>Operating Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Operating Leases - Components of Lease Expense and Other Quantitative Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails</Role>
      <ShortName>Operating Leases - Components of Lease Expense and Other Quantitative Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Operating Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails</Role>
      <ShortName>Operating Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - Operating Leases - Maturity of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Operating Leases - Maturity of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Commitment and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentandContingenciesDetails</Role>
      <ShortName>Commitment and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Stockholders' Equity - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityValuationAssumptionsDetails</Role>
      <ShortName>Stockholders' Equity - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2441424 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2443425 - Disclosure - Medytox/Allergan Settlement Agreements and Daewoong Arrangement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails</Role>
      <ShortName>Medytox/Allergan Settlement Agreements and Daewoong Arrangement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangement</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Income Taxes - Components of Current and Deferred Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Components of Current and Deferred Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Income Taxes - Reconciliation of Effective Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2452431 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="eols-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2454432 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/RelatedPartyTransactions</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="eols-20211231.htm">eols-20211231.htm</File>
    <File>eols-20211231.xsd</File>
    <File>eols-20211231_cal.xml</File>
    <File>eols-20211231_def.xml</File>
    <File>eols-20211231_lab.xml</File>
    <File>eols-20211231_pre.xml</File>
    <File>exhibit102012312110k.htm</File>
    <File>exhibit21112312110k.htm</File>
    <File>exhibit23112312110k.htm</File>
    <File>exhibit31112312110k.htm</File>
    <File>exhibit31212312110k.htm</File>
    <File>exhibit32112312110k.htm</File>
    <File>exhibit4312312110k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>eols-20211231_g1.jpg</File>
    <File>eols-20211231_g2.jpg</File>
    <File>eols-20211231_g3.jpg</File>
    <File>eols-20211231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="709">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "eols-20211231.htm": {
   "axisCustom": 1,
   "axisStandard": 23,
   "contextCount": 163,
   "dts": {
    "calculationLink": {
     "local": [
      "eols-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "eols-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "eols-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "eols-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eols-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "eols-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 590,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 3,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 7
   },
   "keyCustom": 48,
   "keyStandard": 442,
   "memberCustom": 22,
   "memberStandard": 35,
   "nsprefix": "eols",
   "nsuri": "http://www.evolus.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.evolus.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Fair Value Measurements and Short-Term Investments",
     "role": "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestments",
     "shortName": "Fair Value Measurements and Short-Term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.evolus.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Accrued Expenses",
     "role": "http://www.evolus.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Term Loans",
     "role": "http://www.evolus.com/role/TermLoans",
     "shortName": "Term Loans",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - Daewoong Convertible Note",
     "role": "http://www.evolus.com/role/DaewoongConvertibleNote",
     "shortName": "Daewoong Convertible Note",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Operating Leases",
     "role": "http://www.evolus.com/role/OperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - Commitments and Contingencies",
     "role": "http://www.evolus.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135110 - Disclosure - Stockholders' Equity",
     "role": "http://www.evolus.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142111 - Disclosure - Medytox/Allergan Settlement Agreements and Daewoong Arrangement",
     "role": "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangement",
     "shortName": "Medytox/Allergan Settlement Agreements and Daewoong Arrangement",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144112 - Disclosure - Employee Benefit Plan",
     "role": "http://www.evolus.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.evolus.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146113 - Disclosure - Income Taxes",
     "role": "http://www.evolus.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153114 - Disclosure - Related Party Transactions",
     "role": "http://www.evolus.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Fair Value Measurements and Short-Term Investments (Tables)",
     "role": "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables",
     "shortName": "Fair Value Measurements and Short-Term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.evolus.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.evolus.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Term Loans (Tables)",
     "role": "http://www.evolus.com/role/TermLoansTables",
     "shortName": "Term Loans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - Operating Leases (Tables)",
     "role": "http://www.evolus.com/role/OperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336306 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.evolus.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347307 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.evolus.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Balance Sheets",
     "role": "http://www.evolus.com/role/BalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business (Details)",
     "role": "http://www.evolus.com/role/DescriptionofBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia1a49dbd0cdc4fa299c6fc4b349cd1c9_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfSecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ifc1dd5e647ea4c61b81e841d2fa58ac8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Fair Value Measurements and Short-Term Investments - Short-term Investments Available for Sale (Details)",
     "role": "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails",
     "shortName": "Fair Value Measurements and Short-Term Investments - Short-term Investments Available for Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ifc1dd5e647ea4c61b81e841d2fa58ac8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Fair Value Measurements and Short-Term Investments - Narrative (Details)",
     "role": "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails",
     "shortName": "Fair Value Measurements and Short-Term Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Fair Value Measurements and Short-Term Investments - Assets and Liabilities Measured on a Recurring Basis (Details)",
     "role": "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements and Short-Term Investments - Assets and Liabilities Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "iaaadf7ebcb2440558c596d02aa4fe18d_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i9e4bb2c0e721463db9317bbec67a63bb_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Fair Value Measurements and Short-Term Investments - Reconciliation of Fair Value Measurement of Contingent Royalty Obligation Payable (Details)",
     "role": "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails",
     "shortName": "Fair Value Measurements and Short-Term Investments - Reconciliation of Fair Value Measurement of Contingent Royalty Obligation Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)",
     "role": "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangibles (Details)",
     "role": "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails",
     "shortName": "Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangibles (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedComputerSoftwareAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "role": "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedComputerSoftwareAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Accrued Expenses (Details)",
     "role": "http://www.evolus.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://www.evolus.com/role/BalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i709c7ab6d38744cca0fbeb034841964d_I20190315",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Term Loans - Pharmakon Term Loans (Details)",
     "role": "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails",
     "shortName": "Term Loans - Pharmakon Term Loans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i559b9a0d8aa547d0b36e58c3d536751e_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "eols:DebtInstrumentPrepaymentAmountThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Term Loans - Schedule of Long Term Debt Maturities (Details)",
     "role": "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails",
     "shortName": "Term Loans - Schedule of Long Term Debt Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Term Loans - Oxford Term Loans (Details)",
     "role": "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
     "shortName": "Term Loans - Oxford Term Loans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i9b43edc16c22483086f802b6b9cf884c_I20190315",
      "decimals": "INF",
      "lang": "en-US",
      "name": "eols:DebtInstrumentPercentageOfPrincipalAmountBalloonPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Daewoong Convertible Note (Details)",
     "role": "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
     "shortName": "Daewoong Convertible Note (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "iaae348537d9a4136a16f6e54e4e524a6_I20200706",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Operating Leases - Narrative (Details)",
     "role": "http://www.evolus.com/role/OperatingLeasesNarrativeDetails",
     "shortName": "Operating Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Operating Leases - Components of Lease Expense and Other Quantitative Information (Details)",
     "role": "http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails",
     "shortName": "Operating Leases - Components of Lease Expense and Other Quantitative Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Operating Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)",
     "role": "http://www.evolus.com/role/OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails",
     "shortName": "Operating Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - Operating Leases - Maturity of Operating Lease Liabilities (Details)",
     "role": "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails",
     "shortName": "Operating Leases - Maturity of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Commitment and Contingencies (Details)",
     "role": "http://www.evolus.com/role/CommitmentandContingenciesDetails",
     "shortName": "Commitment and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ic142d9a5a6964798b2bc095cf05edeb8_I20171121",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Statements of Operations and Comprehensive Loss",
     "role": "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Stockholders' Equity - Valuation Assumptions (Details)",
     "role": "http://www.evolus.com/role/StockholdersEquityValuationAssumptionsDetails",
     "shortName": "Stockholders' Equity - Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i1328d543a76b4257a15411d3fc978c8d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity (Details)",
     "role": "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
     "shortName": "Stockholders' Equity - Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6e3df3c365874895bd381f7f65e69d93_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ic78866655f1e4fb7a2d18ed23eaca432_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)",
     "role": "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails",
     "shortName": "Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i42f7ff0b06244a60a0750a47b3a469a0_I20191231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441424 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)",
     "role": "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ifb1c0ae2c17f459f9a60df92e9ad83ba_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443425 - Disclosure - Medytox/Allergan Settlement Agreements and Daewoong Arrangement (Details)",
     "role": "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
     "shortName": "Medytox/Allergan Settlement Agreements and Daewoong Arrangement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ib98c7c392d2f4eaf8e8ab779dee845dd_I20250915",
      "decimals": "2",
      "lang": "en-US",
      "name": "eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Employee Benefit Plan (Details)",
     "role": "http://www.evolus.com/role/EmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Income Taxes - Components of Current and Deferred Tax Expense (Details)",
     "role": "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails",
     "shortName": "Income Taxes - Components of Current and Deferred Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.evolus.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Income Taxes - Reconciliation of Effective Tax (Details)",
     "role": "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails",
     "shortName": "Income Taxes - Reconciliation of Effective Tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i7a339248c57c4c3fbb0a8c12261031e6_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Statements of Stockholders\u2019 Equity (Deficit)",
     "role": "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit",
     "shortName": "Statements of Stockholders\u2019 Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i7a339248c57c4c3fbb0a8c12261031e6_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i9e4bb2c0e721463db9317bbec67a63bb_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452431 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)",
     "role": "http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "idb18fef826e14bf1b6a11208896433a1_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "ia04e516f2c6b4521bfa9ce8683f471d3_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454432 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.evolus.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i9a37e00a5294439283de4636c2dc8b56_D20171214-20171214",
      "decimals": null,
      "lang": "en-US",
      "name": "eols:RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Statements of Cash Flows",
     "role": "http://www.evolus.com/role/StatementsofCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://www.evolus.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20211231.htm",
      "contextRef": "i6bbe07a81ec2478d9ec9c19042628567_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 59,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "CANADA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity CIK"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Smaller Reporting Company"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "eols_ATMSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A T M Sales Agreement",
        "label": "A T M Sales Agreement [Member]",
        "terseLabel": "A T M Sales Agreement"
       }
      }
     },
     "localname": "ATMSalesAgreementMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/StatementsofCashFlows",
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Finite-lived Intangible Asset, Period Of Extension Of Terms Based On Certain Performance Requirements",
        "label": "Acquired Finite-lived Intangible Asset, Period Of Extension Of Terms Based On Certain Performance Requirements",
        "terseLabel": "Extension period"
       }
      }
     },
     "localname": "AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments Of Non Cash Portion Of Accrued Settlement Expenses",
        "label": "Adjustments Of Non Cash Portion Of Accrued Settlement Expenses",
        "terseLabel": "Non-cash portion of accrued settlement expenses"
       }
      }
     },
     "localname": "AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_AllocatedShareBasedCompensationExpenseCapitalized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocated Share-Based Compensation Expense Capitalized",
        "label": "Allocated Share-Based Compensation Expense Capitalized",
        "terseLabel": "Capitalized share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseCapitalized",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.evolus.com/20211231",
     "xbrltype": "stringItemType"
    },
    "eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "terseLabel": "Additional shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockAdditionalCapitalSharesReservedforFutureIssuance",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eols_ContingentRoyaltyObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Royalty Obligation [Member]",
        "label": "Contingent Royalty Obligation [Member]",
        "terseLabel": "Contingent Royalty Obligation"
       }
      }
     },
     "localname": "ContingentRoyaltyObligationMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Royalty Obligation Payable to Related Party, Current",
        "label": "Contingent Royalty Obligation Payable to Related Party, Current",
        "terseLabel": "Contingent royalty obligation payable to Evolus Founders"
       }
      }
     },
     "localname": "ContingentRoyaltyObligationPayabletoRelatedPartyCurrent",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_DaewoongAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Daewoong Agreement",
        "label": "Daewoong Agreement [Member]",
        "terseLabel": "Daewoong Agreement"
       }
      }
     },
     "localname": "DaewoongAgreementMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_DaewoongConvertibleNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Daewoong Convertible Note",
        "label": "Daewoong Convertible Note [Member]",
        "terseLabel": "Daewoong Convertible Note"
       }
      }
     },
     "localname": "DaewoongConvertibleNoteMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_DebtInstrumentAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Amortization Period",
        "label": "Debt Instrument, Amortization Period",
        "terseLabel": "Amortization period"
       }
      }
     },
     "localname": "DebtInstrumentAmortizationPeriod",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Percentage of Shares Beneficially Owned",
        "label": "Debt Instrument, Convertible, Percentage of Shares Beneficially Owned",
        "terseLabel": "Common stock shares beneficially own percentage"
       }
      }
     },
     "localname": "DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "eols_DebtInstrumentFeeAmountWaived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Fee Amount Waived",
        "label": "Debt Instrument Fee Amount Waived",
        "terseLabel": "Debt instrument fee amount comprised"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmountWaived",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number of Periodic Payments, Principal",
        "label": "Debt Instrument, Number of Periodic Payments, Principal",
        "terseLabel": "Number of periodic payments"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfPeriodicPaymentsPrincipal",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "eols_DebtInstrumentNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number of Tranches",
        "label": "Debt Instrument, Number of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfTranches",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "eols_DebtInstrumentOfFinalPaymentAmountWaived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Of Final Payment Amount Waived",
        "label": "Debt Instrument Of Final Payment Amount Waived",
        "terseLabel": "Debt instrument of principal amount payment"
       }
      }
     },
     "localname": "DebtInstrumentOfFinalPaymentAmountWaived",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Percentage Of Principal Amount, Balloon Payment",
        "label": "Debt Instrument, Percentage Of Principal Amount, Balloon Payment",
        "terseLabel": "Percentage of final payment of full principal amount"
       }
      }
     },
     "localname": "DebtInstrumentPercentageOfPrincipalAmountBalloonPayment",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eols_DebtInstrumentPeriodOfInterestOnlyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Period Of Interest Only Payments",
        "label": "Debt Instrument, Period Of Interest Only Payments",
        "terseLabel": "Period of interest only payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodOfInterestOnlyPayments",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Payment Commencement Period",
        "label": "Debt Instrument, Periodic Payment, Payment Commencement Period",
        "terseLabel": "Anniversary period"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPaymentCommencementPeriod",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_DebtInstrumentPrepaymentAmountThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Amount Threshold",
        "label": "Debt Instrument, Prepayment Amount Threshold",
        "terseLabel": "Debt instrument, prepayment amount threshold"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentAmountThreshold",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_DebtInstrumentPrepaymentFeeAmountWaived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Prepayment Fee Amount, Waived",
        "label": "Debt Instrument Prepayment Fee Amount, Waived",
        "terseLabel": "Debt instrument prepayment fee amount"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeeAmountWaived",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_DebtInstrumentPrepaymentFeePercentageThereafter": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Fee Percentage, Thereafter",
        "label": "Debt Instrument, Prepayment Fee Percentage, Thereafter",
        "terseLabel": "Prepayment fee percentage, thereafter"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentageThereafter",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eols_DebtInstrumentPrepaymentFeePercentageYearTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Fee Percentage, Year Two",
        "label": "Debt Instrument, Prepayment Fee Percentage, Year Two",
        "terseLabel": "Prepayment fee percentage, year two"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentageYearTwo",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eols_DebtInstrumentPrepaymentTermsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Terms",
        "label": "Debt Instrument, Prepayment Terms [Axis]",
        "terseLabel": "Debt Instrument, Prepayment Terms [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentTermsAxis",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "eols_DebtInstrumentPrepaymentTermsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Terms [Domain]",
        "label": "Debt Instrument, Prepayment Terms [Domain]",
        "terseLabel": "Debt Instrument, Prepayment Terms [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentTermsDomain",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Terms, Prepayment Multiple On Principal Amount",
        "label": "Debt Instrument, Prepayment Terms, Prepayment Multiple On Principal Amount",
        "terseLabel": "Debt instrument, percentage of principal amount, prepaid multiplied"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eols_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Operating Lease Liabilities",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Officers' Compensation",
        "label": "Effective Income Tax Rate Reconciliation, Officers' Compensation",
        "terseLabel": "Officers' compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOfficersCompensation",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Promissory Note, Debt Discount",
        "label": "Effective Income Tax Rate Reconciliation, Promissory Note, Debt Discount",
        "terseLabel": "Promissory note - debt discount"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Revaluation Of Contingent Royalty Obligation",
        "label": "Effective Income Tax Rate Reconciliation, Revaluation Of Contingent Royalty Obligation",
        "terseLabel": "Revaluation of contingent royalty obligation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_EvolusIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evolus, Inc [Member]",
        "label": "Evolus, Inc [Member]",
        "terseLabel": "Evolus, Inc."
       }
      }
     },
     "localname": "EvolusIncMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_FollowOnOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-On Offering [Member]",
        "label": "Follow-On Offering [Member]",
        "terseLabel": "Follow-on Offering"
       }
      }
     },
     "localname": "FollowOnOfferingMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows",
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_IncreaseDecreaseInAccruedLitigationSettlement": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Litigation Settlement",
        "label": "Increase (Decrease) In Accrued Litigation Settlement",
        "verboseLabel": "Accrued litigation settlement"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLitigationSettlement",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_IntangibleAssetsGrossIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets, Gross (Including Goodwill)",
        "label": "Intangible Assets, Gross (Including Goodwill)",
        "totalLabel": "Intangible assets, gross (including goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsGrossIncludingGoodwill",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_IntellectualPropertyDisputesJeuveauMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intellectual Property Disputes, Jeuveau",
        "label": "Intellectual Property Disputes, Jeuveau [Member]",
        "terseLabel": "Intellectual Property Disputes, Jeuveau"
       }
      }
     },
     "localname": "IntellectualPropertyDisputesJeuveauMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Period Of Written Notice Prior To Lease Terminate Date",
        "label": "Lessee, Operating Lease, Period Of Written Notice Prior To Lease Terminate Date",
        "terseLabel": "Operating lease, period to provide written notice to terminate contract"
       }
      }
     },
     "localname": "LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Termination Fee, Period Of Rent Equivalent",
        "label": "Lessee, Operating Lease, Termination Fee, Period Of Rent Equivalent",
        "terseLabel": "Operating lease, equivalent rent termination period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_LesseeOperatingLeaseTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Termination Period",
        "label": "Lessee, Operating Lease, Termination Period",
        "terseLabel": "Operating lease, termination period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationPeriod",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_LineofCreditFacilityNumberofAdvances": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Number of Advances",
        "label": "Line of Credit Facility, Number of Advances",
        "terseLabel": "Number of advances"
       }
      }
     },
     "localname": "LineofCreditFacilityNumberofAdvances",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "eols_LossContingencySettlementAgreementPaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Settlement Agreement, Payment Terms",
        "label": "Loss Contingency, Settlement Agreement, Payment Terms",
        "terseLabel": "Settlement agreement, payment terms (in years)"
       }
      }
     },
     "localname": "LossContingencySettlementAgreementPaymentTerms",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_MilestonePaymentInConnectionWithAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment In Connection With Agreement",
        "label": "Milestone Payment In Connection With Agreement",
        "terseLabel": "Contingent milestone payment"
       }
      }
     },
     "localname": "MilestonePaymentInConnectionWithAgreement",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment In Connection With License And Supply Agreement",
        "label": "Milestone Payment In Connection With License And Supply Agreement",
        "verboseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePaymentInConnectionWithLicenseAndSupplyAgreement",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_MilestonePaymentsForIntangibleAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments For Intangible Assets",
        "label": "Milestone Payments For Intangible Assets",
        "verboseLabel": "Milestone payment for intangible assets"
       }
      }
     },
     "localname": "MilestonePaymentsForIntangibleAssets",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_OperatingLeaseRightofUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Right-of-Use Asset, Amortization",
        "label": "Operating Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightofUseAssetAmortization",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_OxfordTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Term Loan Facility Member",
        "label": "Oxford Term Loan Facility [Member]",
        "terseLabel": "Oxford Term Loan Facility"
       }
      }
     },
     "localname": "OxfordTermLoanFacilityMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_OxfordTermLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Term Loans [Member]",
        "label": "Oxford Term Loans [Member]",
        "terseLabel": "Oxford Term Loans"
       }
      }
     },
     "localname": "OxfordTermLoansMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Provisions For Accrued Volume-Based Rebate, Coupon And Consumer Loyalty Liability",
        "label": "Payments For Provisions For Accrued Volume-Based Rebate And Coupon Liability",
        "terseLabel": "Payments for provisions for accrued volume-based rebate and coupon liability"
       }
      }
     },
     "localname": "PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_PaymentsOfContingentRoyaltyObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Contingent Royalty Obligation",
        "label": "Payments Of Contingent Royalty Obligation",
        "negatedTerseLabel": "Payment of contingent royalty obligation to Evolus Founders"
       }
      }
     },
     "localname": "PaymentsOfContingentRoyaltyObligation",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_PharmakonTermLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmakon Term Loans",
        "label": "Pharmakon Term Loans [Member]",
        "terseLabel": "Pharmakon Term Loans"
       }
      }
     },
     "localname": "PharmakonTermLoansMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_PharmakonTermLoansOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmakon Term Loans One",
        "label": "Pharmakon Term Loans One [Member]",
        "terseLabel": "Tranche A Loan"
       }
      }
     },
     "localname": "PharmakonTermLoansOneMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_PharmakonTermLoansTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmakon Term Loans Two",
        "label": "Pharmakon Term Loans Two [Member]",
        "terseLabel": "Tranche B Loan"
       }
      }
     },
     "localname": "PharmakonTermLoansTwoMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From (Payments For) Issuance Of Common Stock In Connection With Equity Incentive Plan",
        "label": "Proceeds From (Payments For) Issuance Of Common Stock In Connection With Equity Incentive Plan",
        "terseLabel": "Issuance of common stock in connection with incentive equity plan"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Public Stock Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_RebatesAndCouponsCreditsAndPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rebates And Coupons, Credits And Payments",
        "label": "Rebates And Coupons, Credits And Payments",
        "terseLabel": "Rebates and coupons, credits and payments"
       }
      }
     },
     "localname": "RebatesAndCouponsCreditsAndPayments",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Period Of Termination Of First Commercial Sale",
        "label": "Related Party Transaction, Period Of Termination Of First Commercial Sale",
        "terseLabel": "Period of termination of first commercial sale"
       }
      }
     },
     "localname": "RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_RestrictedStockUnitsRSUsMarketConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units (RSUs), Market Conditions",
        "label": "Restricted Stock Units (RSUs), Market Conditions [Member]",
        "terseLabel": "RSUs Market Conditions"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUsMarketConditionsMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_RestrictedStockUnitsRSUsPerformanceConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units (RSUs), Performance Conditions",
        "label": "Restricted Stock Units (RSUs), Performance Conditions [Member]",
        "terseLabel": "RSUs Performance Conditions"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUsPerformanceConditionsMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_SCHAEONLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SCH-AEON, LLC [Member]",
        "label": "SCH-AEON, LLC [Member]",
        "terseLabel": "SCH"
       }
      }
     },
     "localname": "SCHAEONLLCMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_SaleOfStockCommissionPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Commission Paid",
        "label": "Sale Of Stock, Commission Paid",
        "terseLabel": "Aggregate net proceeds from stock offering"
       }
      }
     },
     "localname": "SaleOfStockCommissionPaid",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Commission Payment Upon Gross Proceeds, Percentage",
        "label": "Sale of Stock, Commission Payment Upon Gross Proceeds, Percentage",
        "terseLabel": "Sale of stock, commission payment upon gross proceeds"
       }
      }
     },
     "localname": "SaleOfStockCommissionPaymentUponGrossProceedsPercentage",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eols_SaleOfStockMaximumConsiderationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Consideration Receivable",
        "label": "Sale Of Stock, Maximum Consideration Receivable",
        "verboseLabel": "Maximum consideration receivable"
       }
      }
     },
     "localname": "SaleOfStockMaximumConsiderationReceivable",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Issuance Agreement, Percentage of Share Dispose Per Year",
        "label": "Share Issuance Agreement, Percentage of Share Dispose Per Year",
        "terseLabel": "Share issuance agreement, percentage of share dispose per year"
       }
      }
     },
     "localname": "ShareIssuanceAgreementPercentageOfShareDisposePerYear",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Term",
        "verboseLabel": "Weighted average expected term of options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "eols_StockIssuedDuringPeriodSharesLitigationSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares, Litigation Settlement",
        "label": "Stock Issued During Period Shares Litigation Settlement",
        "terseLabel": "Issuance of common stock in connection with litigation settlement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesLitigationSettlement",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails",
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eols_StockIssuedDuringPeriodValuesLitigationSettlement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Values, Litigation Settlement",
        "label": "Stock Issued During Period Values Litigation Settlement",
        "terseLabel": "Issuance of common stock in connection with litigation settlement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuesLitigationSettlement",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_StockIssuedForAccruedLitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued For Accrued Litigation Settlement Expense",
        "label": "Stock Issued For Accrued Litigation Settlement Expense",
        "terseLabel": "Issuance of common stock in exchange for litigation settlement expense"
       }
      }
     },
     "localname": "StockIssuedForAccruedLitigationSettlementExpense",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facility [Member]",
        "label": "Term Loan Facility [Member]",
        "terseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_TermLoanFacilityTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facility, Tranche One [Member]",
        "label": "Term Loan Facility, Tranche One [Member]",
        "terseLabel": "First tranche"
       }
      }
     },
     "localname": "TermLoanFacilityTrancheOneMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_TermLoanFacilityTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facility, Tranche Two [Member]",
        "label": "Term Loan Facility, Tranche Two [Member]",
        "terseLabel": "Term Loan Facility, Tranche Two"
       }
      }
     },
     "localname": "TermLoanFacilityTrancheTwoMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_TermOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term One",
        "label": "Term One [Member]",
        "terseLabel": "Prior to the 3rd anniversary"
       }
      }
     },
     "localname": "TermOneMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_TermThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Three",
        "label": "Term Three [Member]",
        "terseLabel": "After the 4th anniversary"
       }
      }
     },
     "localname": "TermThreeMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_TermTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Two",
        "label": "Term Two [Member]",
        "terseLabel": "After the 3rd anniversary but prior to the 4th anniversary"
       }
      }
     },
     "localname": "TermTwoMember",
     "nsuri": "http://www.evolus.com/20211231",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r284",
      "r326",
      "r380",
      "r383",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r570",
      "r610",
      "r613",
      "r633",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r284",
      "r326",
      "r380",
      "r383",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r570",
      "r610",
      "r613",
      "r633",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r183",
      "r361",
      "r364",
      "r573",
      "r609",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r183",
      "r361",
      "r364",
      "r573",
      "r609",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r284",
      "r326",
      "r369",
      "r380",
      "r383",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r570",
      "r610",
      "r613",
      "r633",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r284",
      "r326",
      "r369",
      "r380",
      "r383",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r570",
      "r610",
      "r613",
      "r633",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r130",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r130",
      "r135",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r361",
      "r365",
      "r612",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r361",
      "r365",
      "r612",
      "r619",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r130",
      "r135",
      "r255",
      "r381",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.evolus.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r37",
      "r537"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r6",
      "r26",
      "r187",
      "r188"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of discount on short-term investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r44"
     ],
     "calculation": {
      "http://www.evolus.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r44"
     ],
     "calculation": {
      "http://www.evolus.com/role/AccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties under the Medytox/Allergan Settlement Agreements"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r59",
      "r61",
      "r69",
      "r70",
      "r71",
      "r122",
      "r123",
      "r124",
      "r480",
      "r614",
      "r615",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r27",
      "r421",
      "r537"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r418",
      "r419",
      "r420",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r385",
      "r387",
      "r424",
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising costs"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r387",
      "r415",
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r189",
      "r206",
      "r208",
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Allowance for credit loss, writeoff"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r98",
      "r304",
      "r316",
      "r317",
      "r511"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r98",
      "r233",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Securities excluded from the computation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r114",
      "r166",
      "r175",
      "r181",
      "r204",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r477",
      "r481",
      "r500",
      "r535",
      "r537",
      "r578",
      "r596"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r57",
      "r114",
      "r204",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r477",
      "r481",
      "r500",
      "r535",
      "r537"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r193",
      "r216"
     ],
     "calculation": {
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain (Loss), before Tax [Abstract]",
        "terseLabel": "Gross Unrealized"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r191",
      "r194",
      "r216",
      "r583"
     ],
     "calculation": {
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r192",
      "r216"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r388",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r379",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r379",
      "r382",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r97",
      "r474"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "verboseLabel": "Revaluation of contingent royalty obligation to Evolus Founders"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r103",
      "r104",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capitalized software recorded in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAdditions": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions made to capitalized computer software costs during the period.",
        "label": "Capitalized Computer Software, Additions",
        "terseLabel": "Capitalized computer software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAdditions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r32",
      "r100"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets",
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r15",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r93",
      "r100",
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r93",
      "r501"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing information"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r111",
      "r114",
      "r138",
      "r139",
      "r140",
      "r142",
      "r144",
      "r151",
      "r152",
      "r153",
      "r204",
      "r269",
      "r273",
      "r274",
      "r275",
      "r278",
      "r279",
      "r324",
      "r325",
      "r329",
      "r333",
      "r500",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r49",
      "r254",
      "r584",
      "r602"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r263",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Medytox/Allergan Settlement Agreements and Daewoong Arrangement",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/CommitmentsandContingencies",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r266",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingent Royalty Obligation Payable and Promissory Note Payable to the Evolus Founders"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails",
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheetsParenthetical",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets",
      "http://www.evolus.com/role/BalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r25",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r25",
      "r537"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock, $0.00001 par value; 100,000,000 shares authorized; 55,576,988 and 33,749,228 shares issued and outstanding at December\u00a031, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r367",
      "r368",
      "r384",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r64",
      "r66",
      "r67",
      "r74",
      "r587",
      "r604"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r234",
      "r238",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Capitalized software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r156",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties and Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r350",
      "r351",
      "r362"
     ],
     "calculation": {
      "http://www.evolus.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Accrued revenue contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesDetails",
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Contract with customer, liability, revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contingent royalty obligation payable to Evolus Founders"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r20",
      "r581",
      "r598"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r284",
      "r294",
      "r295",
      "r296",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r314",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible Debt Securities"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible note"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r324",
      "r325",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r79",
      "r573"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Product cost of sales (excludes amortization of intangible assets)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r455",
      "r463"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r455",
      "r463",
      "r465"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current provision:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r455",
      "r463"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r103",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of convertible note to equity"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r110",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r298",
      "r305",
      "r306",
      "r308",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "netLabel": "Term Loans",
        "verboseLabel": "Daewoong Convertible Note"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNote",
      "http://www.evolus.com/role/TermLoans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r113",
      "r120",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r314",
      "r315",
      "r316",
      "r317",
      "r512",
      "r579",
      "r581",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r20",
      "r309",
      "r581",
      "r595"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "totalLabel": "Long-term Debt, Gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r283",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": {
     "auth_ref": [
      "r47",
      "r283",
      "r341",
      "r344",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.",
        "label": "Debt Instrument, Convertible, Number of Equity Instruments",
        "terseLabel": "Conversion of common shares (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r281",
      "r314",
      "r315",
      "r510",
      "r512",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r46",
      "r313",
      "r510",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Interest rate, effective percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r46",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate on debt"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r48",
      "r113",
      "r120",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r314",
      "r315",
      "r316",
      "r317",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r48",
      "r113",
      "r120",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r314",
      "r315",
      "r316",
      "r317",
      "r341",
      "r345",
      "r346",
      "r347",
      "r509",
      "r510",
      "r512",
      "r513",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r294",
      "r509",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r294",
      "r310",
      "r314",
      "r315",
      "r511"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized debt discounts and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of Short-term Investments Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r456",
      "r463"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r115",
      "r456",
      "r463",
      "r464",
      "r465"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      },
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes",
        "totalLabel": "Total deferred provision (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails",
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred (benefit) provision:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r21",
      "r22",
      "r446",
      "r580",
      "r594"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r434",
      "r435"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r456",
      "r463"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Operating loss carryforwards, not subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Operating loss carryforwards, subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
        "terseLabel": "Other deferred assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the estimated loss from legal settlements.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal Settlements",
        "terseLabel": "Accrued legal settlement"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r435",
      "r448"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred income taxes"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred income tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Intangible amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Fixed asset depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contributions to 401(k) plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r98",
      "r164"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows",
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DistributionRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels.",
        "label": "Distribution Rights [Member]",
        "terseLabel": "Distribution right"
       }
      }
     },
     "localname": "DistributionRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r75",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r136",
      "r138",
      "r142",
      "r143",
      "r144",
      "r147",
      "r148",
      "r486",
      "r487",
      "r588",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r75",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r138",
      "r142",
      "r143",
      "r144",
      "r147",
      "r148",
      "r486",
      "r487",
      "r588",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r145",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.evolus.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and related benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period for unrecognized costs to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized costs other than options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock option costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r69",
      "r70",
      "r71",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r150",
      "r205",
      "r340",
      "r348",
      "r418",
      "r419",
      "r420",
      "r459",
      "r460",
      "r485",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r614",
      "r615",
      "r616",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails",
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r488",
      "r489",
      "r490",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r296",
      "r314",
      "r315",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r489",
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Short-Term Investments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r296",
      "r370",
      "r371",
      "r376",
      "r377",
      "r489",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r296",
      "r314",
      "r315",
      "r370",
      "r371",
      "r376",
      "r377",
      "r489",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r296",
      "r314",
      "r315",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r489",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r493",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule of Reconciliation of Fair Value Measurement for Contingent Royalty Obligation Payable"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "terseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r494"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Change in fair value recorded in operating expenses",
        "negatedTerseLabel": "Revaluation of contingent royalty obligation to Evolus Founders"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails",
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period",
        "terseLabel": "Contingent royalty obligation payable to Evolus Founders"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r296",
      "r314",
      "r315",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r207",
      "r212",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r307",
      "r338",
      "r484",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Weighted-Average Life (Years)",
        "verboseLabel": "Useful lives of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r234",
      "r235",
      "r239",
      "r242",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r239",
      "r575"
     ],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Original Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r234",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r239",
      "r574"
     ],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Book Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Definite-lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "verboseLabel": "Amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "terseLabel": "Settlement payment from daewoong"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r98",
      "r318",
      "r319"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss from extinguishment of debts, net",
        "terseLabel": "Loss from extinguishment of debts, net"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/StatementsofCashFlows",
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r226",
      "r228",
      "r537",
      "r577"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r98",
      "r227",
      "r229",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r98",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r72",
      "r166",
      "r174",
      "r177",
      "r180",
      "r182",
      "r576",
      "r585",
      "r589",
      "r607"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r246",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r116",
      "r438",
      "r444",
      "r450",
      "r461",
      "r466",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties related to income tax matters"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r117",
      "r133",
      "r134",
      "r165",
      "r436",
      "r462",
      "r467",
      "r608"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "totalLabel": "Total provision (benefit) for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesComponentsofCurrentandDeferredTaxExpenseDetails",
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails",
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r68",
      "r432",
      "r433",
      "r444",
      "r445",
      "r449",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r431",
      "r437"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Change in state tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount",
        "terseLabel": "Meals and entertainment"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income taxes, net of Federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingenciesOther": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in other income tax contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Other, Amount",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingenciesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedTerseLabel": "Research and development tax credit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesReconciliationofEffectiveTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r232",
      "r237"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "totalLabel": "Total net book value"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r92",
      "r94",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r54",
      "r537"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r55",
      "r108",
      "r149",
      "r221",
      "r222",
      "r223",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r81",
      "r82"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r203",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r523",
      "r525"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Lease, cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Composition of Lease Expense and Other Quantitative Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43",
      "r114",
      "r176",
      "r204",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r478",
      "r481",
      "r482",
      "r500",
      "r535",
      "r536"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r114",
      "r204",
      "r500",
      "r537",
      "r582",
      "r600"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r45",
      "r114",
      "r204",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r478",
      "r481",
      "r482",
      "r500",
      "r535",
      "r536",
      "r537"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Contingent promissory note payable"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r49",
      "r254",
      "r262"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Accrued litigation settlement"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets",
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveNoncurrent": {
     "auth_ref": [
      "r49",
      "r254"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.",
        "label": "Estimated Litigation Liability, Noncurrent",
        "terseLabel": "Accrued litigation settlement"
       }
      }
     },
     "localname": "LitigationReserveNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets",
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "negatedTerseLabel": "Settlement payment from daewoong"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation settlement expenses"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r20",
      "r295",
      "r311",
      "r314",
      "r315",
      "r581",
      "r598"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Long term debt, net of discounts and issuance costs"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Long-term debt, fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r120",
      "r267",
      "r300"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r120",
      "r267",
      "r300"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r120",
      "r267",
      "r300"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r120",
      "r267",
      "r300"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r120",
      "r267",
      "r300"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r120",
      "r267",
      "r300"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.",
        "label": "Long-term Purchase Commitment, Amount",
        "terseLabel": "Long-term purchase commitment, amount"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r48",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "terseLabel": "Loss contingency accrual, payments"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Loss contingency, new claims filed, number"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Loss contingency, number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement Input, Expected Term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r93",
      "r96",
      "r99"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r62",
      "r65",
      "r71",
      "r73",
      "r99",
      "r114",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r133",
      "r134",
      "r141",
      "r166",
      "r174",
      "r177",
      "r180",
      "r182",
      "r204",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r487",
      "r500",
      "r586",
      "r603"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows",
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "terseLabel": "Contingent promissory note payable"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Contingent royalty obligation payable to Evolus Founders"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": {
     "auth_ref": [
      "r36",
      "r118",
      "r531"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Notes Payable, Related Parties, Current",
        "terseLabel": "Promissory note payable to Evolus Founders"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r166",
      "r174",
      "r177",
      "r180",
      "r182"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r518",
      "r525"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Fixed operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r522",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r521",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "NOL carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r44"
     ],
     "calculation": {
      "http://www.evolus.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r56",
      "r537"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive gain:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r63",
      "r66",
      "r475",
      "r476",
      "r479"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r58",
      "r60"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on available-for-sale securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Paid-in-kind interest on convertible note"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForSoftware": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments for Software",
        "negatedTerseLabel": "Additions to capitalized software"
       }
      }
     },
     "localname": "PaymentsForSoftware",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payments for debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payments for offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r24",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r24",
      "r537"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December\u00a031, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r224",
      "r225"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible note"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from follow-on offering, net of underwriting fees"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.",
        "label": "Proceeds from Issuance of Other Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt, net of discounts"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from issuance of secured debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "auth_ref": [
      "r84",
      "r86"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-term Investments",
        "terseLabel": "Maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r245",
      "r537",
      "r591",
      "r601"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r245",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r77",
      "r209"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for bad debts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase commitment, amount"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r529",
      "r532"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Related party transaction amount in period"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r527",
      "r528",
      "r530",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayments of Debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Payment for debt obligation"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-term Lines of Credit",
        "terseLabel": "Repayments of long-term lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Repayment of promissory note payable to Evolus Founders"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r429",
      "r572",
      "r635"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "R&amp;D"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units",
        "verboseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r98",
      "r247",
      "r249",
      "r250"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r28",
      "r348",
      "r421",
      "r537",
      "r599",
      "r617",
      "r618"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets",
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r205",
      "r418",
      "r419",
      "r420",
      "r459",
      "r460",
      "r485",
      "r614",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r162",
      "r163",
      "r173",
      "r178",
      "r179",
      "r183",
      "r184",
      "r186",
      "r360",
      "r361",
      "r573"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total net revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r109",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate net proceeds from stock offering",
        "verboseLabel": "Aggregate net proceeds from stock offering"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/StatementsofCashFlows",
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)",
        "verboseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price per share (in dollar per share)",
        "verboseLabel": "Offering price per share (in dollar per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Current and Deferred Income Tax Expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r387",
      "r414",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r387",
      "r414",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r234",
      "r238",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r34",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r388",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "verboseLabel": "Schedule of RSUs Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r394",
      "r404",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Key Assumptions Used to Determine Fair Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r50",
      "r111",
      "r151",
      "r152",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r333",
      "r338",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r443",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Estimated Future Amortization Expense of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtCurrent": {
     "auth_ref": [
      "r18",
      "r579",
      "r597"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.",
        "label": "Secured Debt, Current",
        "terseLabel": "Term loan, net of discount and issuance costs"
       }
      }
     },
     "localname": "SecuredDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecuredLongTermDebt": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.",
        "label": "Secured Long-term Debt, Noncurrent",
        "terseLabel": "Term loan, net of discount and issuance costs"
       }
      }
     },
     "localname": "SecuredLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service revenue"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.evolus.com/role/StatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Restricted stock units granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock Unit"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of awards vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield rate",
        "verboseLabel": "Expected dividend yield rate of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum number of shares authorized under the plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Stock Options, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Cancelled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r396",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Annual increase percentage of maximum shares outstanding (equal to)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r386",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled/forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r388",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "verboseLabel": "Contractual term of options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r409",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term , Exercisable (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Average remaining contractual term (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]",
        "terseLabel": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r519",
      "r525"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term operating lease expense"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r107",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Software development"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r111",
      "r114",
      "r138",
      "r139",
      "r140",
      "r142",
      "r144",
      "r151",
      "r152",
      "r153",
      "r204",
      "r269",
      "r273",
      "r274",
      "r275",
      "r278",
      "r279",
      "r324",
      "r325",
      "r329",
      "r333",
      "r340",
      "r500",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r53",
      "r69",
      "r70",
      "r71",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r150",
      "r205",
      "r340",
      "r348",
      "r418",
      "r419",
      "r420",
      "r459",
      "r460",
      "r485",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r614",
      "r615",
      "r616",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/RelatedPartyTransactionsDetails",
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows",
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r150",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows",
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r52",
      "r299",
      "r340",
      "r341",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for conversion of convertible note (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r340",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r25",
      "r340",
      "r348",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Stock options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r53",
      "r340",
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for conversion of convertible note"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r340",
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r25",
      "r29",
      "r30",
      "r114",
      "r190",
      "r204",
      "r500",
      "r537"
     ],
     "calculation": {
      "http://www.evolus.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets",
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r112",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r508",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r508",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r508",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/StatementsofCashFlows",
      "http://www.evolus.com/role/StatementsofStockholdersEquityDeficit",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r307",
      "r338",
      "r484",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfCostGoodOrServiceExtensibleList": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of cost from product sold and service rendered.",
        "label": "Cost, Product and Service [Extensible Enumeration]",
        "terseLabel": "Cost, Product and Service [Extensible Enumeration]"
       }
      }
     },
     "localname": "TypeOfCostGoodOrServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r119",
      "r370",
      "r377",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsShorttermInvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r430",
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r520",
      "r525"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable operating lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r137",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding used to compute diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r136",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding used to compute basic net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolus.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r636": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r637": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r638": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r639": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r640": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r641": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r642": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r643": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r644": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r645": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r646": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r647": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r648": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r649": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r650": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r651": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r652": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r653": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001570562-22-000067-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001570562-22-000067-xbrl.zip
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MD$EDP*RF\,<E[$%X=K'G1F#NGKNB-"TDWTB=Y;#N68)FZ/MZ#]!,%$!32,)
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M0:P@G,6)2%-F]!S@RSU B]P;ZBPZ?R'8$26YDIB#Z8<11R@U)&%:*,),@N8
M7Q:"O\1S@B]6)#0!$]"@V%'+J!+ 7M+$,(4-<O$<'(WT$ K= HFB>XQ,)-R
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ML_SBY7_O W%5T8X]BSX47=G[[]5*]JI.!:CIZH%5]M6^Q'[+P\^S^@M3F"?
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M'1[OOMV,=]_^"7-OHMV-ORYVWWY$NV]A??O;YP=D$Q^>'+#M-_SKSL87^MF
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MX-ODWEG,2JG@G+49]Q@IH&1B600!CUG_$B(V'Y @FU*8C(Q;:G!1#&VT1K(
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MZDH%X]A7?/S#0>!](X5.A9;X!!)':W,Z4^B4"\#.;&AYQZ$P=2.>'QH5ER8
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MI 'Z^+#2F/M_Z9KS.GJJ:55]#-([C\MZ>^U#:AZ&V8?^82_44CR9-TR'6N+
ML@F9B,\H3?9NC@-O(:LZY+O!]T0K#/J] C>=SKK;K!/TK/1MPO\5,CFIK%1(
M2PQQ+ Q?*'OT/*(\@000&NZ'S5N!>QR]Z4*-Z7&^GIZ%RQS<#)N(BD3H9I59
MT=;^:?9OX^E$DBR9-A\R> 1M&;0'-Q=6A0#[%@?A(!2731G)W<B\T@^K8ND9
MB=ZB+1,#)^>F+7:-W'T6Q #8)-0@45@D<CN'[W ]F\S57<I(O"](;XC$VP4Y
M-0KP^%=/3DSG=CUE%KOQ-%?6GI)2W846%@ZA1X6DXFW!K")9S#/"G1;#>H%L
M1.;98-26[3Z!=B5:#8>P0=X1?/E+^K**AYL0KW>+>"W:N(<>&*>;N)3*A,>M
MMU=Y%5,0=2S8';Q+7$Y[O]PTJ1]E4D/W)71P(K6/J&%AC(+#3)(9K929*$J&
MD,=0T8KY#-#*-Z)>G]!5MW8O=_/;HV9D72_E!&.Z"^[]VF% 0@Y!-*L9 Y-W
M8:),LW=X,*I9@=>@7(UNFM!;9A6,*ST"KR82:NR@[&FP,7_KF-:$\7(PE=+W
M;LFAQ/=UO9P]:7KI''YLS-IGB\X3<X3HCXLK'_?D^(^=U3%4<DJNOD-#'?B]
M(JZ_$4" 'OY&5+;C!$A]8[<\UOK3)>)A,:KK/O#4MG''<DYNQU;!!'0H[>IN
M#1&[E1MYP<QSO\_N!9;X+X2'3,Y,+9MNRES(@'=/TN%[(KDQ4@14GHR13@U+
MP)OD%C+%Z3#@DIY2<<$T*+EGP(UTR]*DWM0:>RMXCA#+B*2:!\F,-*;&HQZM
M#(.!)I_=<:.%W-$2H@;MF1R2#Z ; LX9=C&8AY-#G%UB '-J?6A];<OHK&X^
MHF#/?_0<?8X9BM]P&$J/$/;MLCAGQ5%/AR2)ZH3SUDAY$WZH2&E<^%#0!NB\
MUKPF@81YKX>);[>0_S:)-<Y2(55*9^,<,,[%:VC3',* OBT6$^JVLLBK;O\H
MQD4E?.(I.+O:V0NKRI]M-E[#!<H=;2JV2J/+T'UZ:'#(]U4'^M/EA%:]78L5
M6/:*ZC*HG+CJ',SZ@3W0F/B#(@V3%2<<F/F*%G&#.O4&9,%5)T158Z2*>[88
M>4?A/%[UU2+5RQ5VF$YE7M';)PPG)OGK:12CIX3@)FHCHH."/'"BD<*+QYC=
M0(<EW,,Y%[\X-.&;^IM<3R%W+7U<-LYWM"^]_!DD8!#-B_EJI?Y?;FU?CTQN
M#+A9TEBS*D4RC_8)&1P74&ZB9!LH,,%N4RUS$)F%K#\J!K2$ERA(@^*9^ZPY
M^RY5\I[UD&3]29P[=\Q6!8[<@4XY>XC7+E+/SL2:U!%NOZ/AV CQKPH\7+@U
MDS07*V$T4FQ'R5VH[>Q??;%XC>)!JW /U \H%%*L.#YJPM/Q:81EU#F_.Z2<
MDL7;P<ZG*)D"G/ED*F]#?^D% QD[Z268@S251;NJ'JXQ9N2.TN'.X']EQF**
M "9>)[-0PJG-S_?OHM&>TF$!:M<K"?8EVASL,7>);+4LNWKOVK>"5.O)!I)L
M-/-J,=<F-[I[(1-A&UQP0+UJ\K9K #3@>-A[ Y7KKNKF-41C\H5M=/&2O,1Y
M-N0[:&GQM*NM4AZX)38N$Q6KL+M+ #!66(RO$)/EMO2$D@_W/ K[GESW=[U>
MURA:3NU[U[;O/9K:]Z;VO8-P682ES!B%EQK[MW'!?M2:^@/>T/B1B^F]Y!&#
M&>, E(08GXR+_)XP\[.EPW3MINCD0"N0I%V+[R\H]M8M>NY96-/;(\*5Q)B2
M1Y;#0%C+S]U%;90<1;/T@C5>:^5*PG4A%+SL2V1X LTW#EZ^/<U)OD8DPR(5
M_E:710.A3^ 5RROFDJ]RLNI0^2A:,O+"*>V:IFZ*%G(\0%9UP/<&40&3+@?H
MM^$3PD+X;+;8SC%_'47OTIN)?^.5Z;;&%0)>1"3.D>EM&479<M+@PCN.W/NE
M[C7K<\SRGL9%-*PE,!&_LI+*&#,-H26P6A7G?>@CB*XC%3A \QB9%R:'=D2Q
M5'R*9B3".&81PHS9_,0'NLE;1@V'?O0UJ9'!7W+06PLZ-*K/APLM&J:M1.4:
M&?M0,@J;-X_=EXR7% VKN@YMO;G@#GP_#NJ:.Z:1XX<6R1-[7A6NIY=3J /Y
M(Q;E^9LBFL7*D)%IC9DPBN<6>:\" X*RKC3P'1(:1H%CO&2M$5@(?NL=V:58
MA\9 ML;PU$K+IDA$K46?R'G/RD\V?8WV"K;:O(>2J]\.]+&U[ KR2NL>M,*K
M[DJU"B(-4;N0;3S$%]B>/JR*>'<4TGY1E$S#**-I5L(M=^V#-IUV9GK)OXH6
MJDP9N["2B0^VUAL0?,O2[?#3ELM& S%AJ.27C^/1P.IHUB?YY'#F^LH"-3%C
MMA@R#3?) " F#1:PN2P6+M9;@D:6Y/HVCM:X5T25PBR?"(.(U$=S"<Q7O</;
M+DKN8W_;RM2+QE*ONPFBH<J1,LZ.I/EH,7#"$#X(#R0_[5Q+?%&"19:#(O@X
M6P-T*=G=S85*1/&H716>X!\S&]ZF-1E-G_WI^/3S9Z^.=./(//&K'7ZZ->"X
M\^@ W3'F@K 0[MWD.*F#MZ'Y@[Z*#I<@31D"QVC3V6DEYAAWHKW.QV^\,^^]
M>/;LBRRDVN*_U;*M$[T>6@4%<*!@+&AH;'+)_LGG@FX<F_CBTJ4/).O8EBWR
M2G+N#R8VE2N3K3 R;K* 1(&.3 1;,JO[C8JF99ZI+Y]IV?"R6/:0/N*N"X71
M7>8-F]6$.9O.045.L&WE#DP675ML4VM;YE<[31D_*'[["8SD"[&:>-"77K5F
M=N^')R]>?O$M?_Q'5I^A4="NGMD+,I)Q9NU,LNKVJ[,%Q^\GCQX]%!T7=&T$
M?+>_7)C97X,]1J7SL75^ZT?U@J?W[S]2G"&6H!T'C+KM2V<)6:^\DVA&Q8H\
MD(+JR_,\ IT;#N77)E\Z\-^33]2:NR;#JP669&HQND/EFH&LH*OHI*S%@,LR
M$.6D:!TFYY3-(BZ-I$3(C7#B<ZV"W3'25Z1MR5J"5)LK3E%VIA7TE:2= <-Q
M2[GV8+2"-D<4P<1+*CU2?5LJKI$W?FTQ9PAP_V6-@]D(ZFV)T0/1#A_8>T;]
MD_M 0U(5$(W3&NL+O3NC@,;4Y.'C"6?*DLL[80OY)V]@ -5I6X- L8U\03JJ
M58V1HX3 WV:=T/*PSP9EN)'='YT_QJ9.QSWS-9K2I/K/D0*D=#.P8",]L<]6
MI[BJR#Q=F[)[YTH!X-4A0^Y[]E(7Q[.1FI0>4L62HN.<&%I^(- ,\M*V,_+_
MJ.G0CY1LGYU )S@P]J6=L3V,2N9$S'Q(B.9QHGK?#Y*"S)F_T<,TN#G-U#$U
MQ3L02&WKNC+2A=#5?1@$X6]OZV9;59%Y-I M?O&=EP-]P?+OL<0+]N"SJJ+1
MX7\FQZV"=K][\?B9VN&6 WN[[@OZ#FX3N1'L$K!:'[MWCQ$*RE?I;_,Y5+]X
MH].87@"T9\#@&$A#\V,"F;7F?:1)350W]678SBL6\"J<!1+9QK>*SF.[JY<"
MH-$OZ0@K+5'2A2>"A@%K]ET6  ]4!GET\?-YH=48W!J-5Q4#0 1S&7\]6KM6
MZ#1(IODF]!0@;"IG'7DS=/.MRU$T7)D> 3WT><&B V3!ET%9D,?$7TT4\?)H
M)?RDPK!GN\*P,H3D)S"SD%*1\"$*]1I!4XD?0P^Q:9R5K.(@/3S^X+Q'!&8"
MCCC"$=>R6JPJ/[^PA:G5=>6*ZOQH8*!4)3$::U5F/@IKGUZD'4"\X#H"JKIF
MSA)N/<R&"4C!)^3LJ#&3:S__77D2>CHA&T#^NNWQ[#?.3Q2=5'?U#U+;-9PJ
M0B(GOGNEXI7^9NG#:P501"+,40M#*#6\P647-T04A%IOW.)F J6ME],8V5>?
M@<T;T.%,E>KWKU2W%[RB_M7#&P]V4.S.$>S.C$7[ED(!2$%E2PXW]D+,3=.(
M8*NXO+IQBS;^?)3T(Y-+>P-5E5XU2:MS9-X$2ZWQ?)ROT3,I,@=22ZX[1F=R
MACR"KX_))[-_#INPHF>%SVL?TB;032HLG@4OO52M%PMW8C&EZ,O7>A%10WT7
MJ6+6!F$;.1U@,Q<N%JHV0&L_%V%UU>_B%P_0]ITW; -6GH<0YEQOA3@%BG^*
M8N?<.3E(_@YV>E4U;?J1 Y@NA3G80ANNQ$KA%&[$JSX@T!64\Z;,M6L\.J.5
M3"(2D>KD.B8"O]\J3:7S/_SM]/Y4.I]*YP<:&(<NBI74S&I?WFF0MA U8$BU
MXY!9'7&#Q$Q*38*'BRALUT5K,+>8O63W=W8AC_&?.V;&C5P[^O!%,2]\-@BV
M&1 M 1EZ!M7D5($B?*A:(<_BN"RKY1GPW0@>51[>CIF0=I&$28#=%9R %G-H
M">A84;>HEGW;-5MMD0H6- $G?A:=N+_JZ1UG@$(KKN;(9]+?66[MCRY28 L*
M\E@O<FS%\I.BGKDT5<D-AH;&JN^2@RL06TV>XVVZHU)*F=PO]BB?Z#>V-NZU
M5O=(F*=R*:",QL&AI*->2[QF-'[GNBB2D*O2ZJTQ=;YG]?/79\L KV+V(I@6
MV5#]U#A\.]Z6RF@L)4_46JFX4M>XTQH'//>V\Q1P(1]D\V,)IW=L'T]]]U '
M&^U&'Y*BR6?&&ECC;L#T'/-KG*W*\ 33TT=;:($1XBQ#Z3K@AQ1,4BW5M;>C
M29[+58P5%OXL.562! %^>-KC$*6)9FH^)GL[@RG=\OGS]/E9=KV]S?3NP\,Q
M/N5V"A57PT+%CIRSI).L9!E!&I#^*9%>PRPW=/0M*#Z4HJ9A>>14#24&7Z3A
M>*<LW;E;>N\AG 5:JJ>PL_J]YK9=7B *'M,K8+BY;45R6=%T^>O83.N8\)K!
MD_*",5Q$45TB3W7N"]7(K;B%!$USJ355@][.X<GE*VJ\2L3\<&;:3%WD2]Q\
MW)/:-6T[FF@,?#""'>\.KGZI!T&^ H!A2QF>!$\2ZDJIXR,)5*$'B2$]M-^
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M9&=LD)#;G3V7-"8**X(Y;(S\K$*@)=SI8R/>^"#1#ADUR16@$1=<FY?5#JO
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MI").VZCSXEJ06Z$FTQ;D5&]<.HR<KB18J*:Q1PZ>SU')SF+IA[O_3S3HOT*
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MA,:)6U*NRB6:#871G6S*!UU;[!E<MG7AB".0$]<I%9NA!9/S&D+UL[XBUQ_
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MLHS<4T[N)E(-1;LFA&5FF2YG=Y(=1U^61TXE_])U1\=8UVOYL\9Q3X#6;?F
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MM$]S^9'F,E]#?XR)!\+4D I 9CJ&&9*U $N K&JB@T5*3F$:JUU-O/2G*?N
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M>"A0I+B/J*T& ?84>4P6.5W"B*D76!PI"DM-J+CWTR8P'WIH-G!NI&@9<9&
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M <I/H(S_ ^&QN,OKFB);Q.KA'VDJX+98G9C7ZN0WFCWHM]3EVCD?V(D>4/I
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MM4 DW9 BV]=^IU Q1>TK>*0:IFAM/V;4MICN"24C)PQ2#L%;XL>S@E=(8J*
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M4Y-<*MO,-5'P?&/O%MUCVFE"37IY;W9)WUD<%[PS764949=SOM\YHQGB9 1
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M#+3%2SCO2R 1N)JG0!4: AK D\$H&>/YP_'A0_S74KB.B!+2J"*+Z3P'05?
MD$#+_%E2&LK?%/TV2+@--;6W LSS"VY6J^??3!<2E'0[ZUCIEKLO,E_ 6'UX
M$=[3.+XKRK%K 5Y[E=+%O9]"5P-F%$)68L<F*5RSLRR_*MDJJJ,V]K4#4%K
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M7KUUW@93I%D-[E*X7<)VE&RN);T]TM(;,["XK786"(.  !7P+PQ6?!&,R3A
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MB5BE A!06YFXAZ=3SB-S(N%VH:(>S-A$&_2U]R4BP1<%2@&.[\L<ID__1@3
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M%^>@30'6W?D2?DW^W9;VT/'OKOEW48T(PSB(#!.T?\?V=<=TA_K(CD*=.=&
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M 'L\&,0N"J6>Y=XY+ZU+\6@M,^^X(*9CYATQ\X*&$?AV9%F!IX=N9.G.(&;
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MG=_8S)QDZ<.=XD!IKDJO(.:QJ/1#J?1,*[\<\> #@F!-CH .R!B)D07M@=N
MG4Y4A+05+=FCC=+7]_#==D\N0D^R@J8GR\<\@_ZI[8Y.6WW7G;@E<^7,<2W
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MS$Y7@TA4#@.UQCBQL2E-B=5XNJI;&]$HJKM*U9TF%DY*KF0,")1*Q,+KB)P
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M7;>7=WI^D%,UMV'\[T[OBAS*[E/?[O-QAF=*8@T$II#RGB*N@DX&<Z1(Q$Q
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M=JH1Q+[,>D0B"2K8A%K>R.P1P<@0&=,/I["5)&U--G<9HW*VK%7QB#P%-7\
M9E+4_,'5?(JK""HD3;)%!ONDYM8F-0>@B$O,,%<* F69J\@;,A9*+/)#>4>.
M[6EQC3Q.[/'MYM3;L5 *!"T$0=]F:],YBQ/,6"2Y((A[RY"QFB-%!672B*#
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MG&&D#A;VK :_:6^-Y?>E#,WIUC,T!X_%T/RND[%]RWGUII[B*6RWAG?YVO8
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M] M?W*W^E$Q^RG&:8@$S,IKPM$?$+.0% 91Z2=-AS45E.R?51#CS45(<&H:
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MUZG].U('U@4F,:48KR@]46<^'>1HA 7F8"_-9%DMVA&:J9:*'5,WM:"4J-8
M[N)Z+DT]F0'TV2]@,[?YHB<"BV4S:TVZ7&VC:3X^K% SS*>"73"30< UJQ:J
MRY8L2U5F9AZ^IHY. [A:&J_:_G801&57RJ]%I#ZQ4)ZAYSG3.#:VA,U5$5FE
MWXR$]IO].._.J_F<PKPP<9 +,>U<Y['+7"\7!<;$[8*4#9T6T_A.)U)4N2#V
M_2JKZ5115JKG8=)AA+W$ D/BDE17XE1]2"#J#S/!M$3?,O/Q?2B=T?TT5#H=
MU0DM1@>E[G$+W*AX-4W-"E<GX[3II&THIZ77>_"T[_]R?.A0X(V[V]L$9)SM
M=$T?:&[.EP9XFC_==$TH_:$+K.N&#H/R+7'[KRV.I.V>9G@CFNH",T<J(])6
M.AU(0:P-_M2DUS2^J=J/9J!&,_>=DM&@31=4T*7D],R0JH'!H]MS \XECVZ/
MRC(:#(5@+\)UL'=KK^'%-3+H"$J"<44"D.PY;_N&7M^;[V7&M+3WR'QZ<^C8
M?G< U:\#J/H[@.H.H+IUB,@=0'6KYO-0 -5; :>CV'Z2A'$<>7GBA7$4B8AY
MOD@"D<1E*K)<Y)O H+?G!(;OX7'$D[*(_"CA$2NR7.;2"Y,2W@\'+MQ2(*R)
M0W?4)$-GM,^!UVMMW_'+$Y$/XI[@,R9YZPSRNYC W8AE^:][U."76<X"409%
M)F&M,Y%)F>91&)5Y% 72B^_-M7!+/LV6X>]K!^V$7=F*^_ '2Z\=?MB'S[P\
MS3B+F<A*-R_3Q(W2J' S&42NB&6>)EXJO)!A#4NP6E"/PG"?_68^*[,T\LHH
M]B+A!2P+@AB3I5D8!"(L[\VALMOO^S L[,?')^^O#D_X%8SQ\_'^:9EZ)8_R
MQ.5Y'+M1XF4NDPQ)[H1,>13&/"YAZ\-L9>LGY)H85IX)JAEMY@_"(9H^#K\"
MMQ\Z!O<"+&Y-/N-%U;*SLT:>V0[16O*V82YWS7#8H@2Q,AOCHE6MNBW:A0U=
M8"ZU [RV\DP5,])3^)08IU@!CNE6!''NFZ9JZK9U%[5[!%ZI<4?WB7CJ/D;:
M5NRNB:3V,M\:5&.@,UWO)U"40MEL:&%?2&<(K\'0.(98V77_RZLLE3KDW;GI
MV%0(?7,=+7AK- )^R^)(-;*(E(%K= 7K%AUI?65#3;NZ.M^)#HE@V:ZQ</38
M%9R\D05FDB;(ICNG< BACC!F/=4H<)C66<,N3!027%E&1@X\]J-4F&_]B3OK
M*-HF@PZ9RG+Q<Y@8B[V:8?;]9]?/'DT\J,X_>>C,T[T.W7"U?(VE^9VV4I.K
MOE5;^:CY,M*5P2_.8&!:QAS6=+ %U6JN+DO3X,N4CME3J** YKOS#M:N^KE9
M8,"P(&%0BV^34BBYNB,<O-6VX5,G82>V?[?8/E>Z9BLDM7\5(#ZRQU+<&J6(
MK?:DO" !))CD654ND,U28&J(E*%.")HG&5VKLWC$/ Z6 .II31:LGTPU?ROY
MID^@L>EM Q]TF%?K:('5LVB0%XJD1N$Q[%DX!\.D;C"-0"$&.@Z:DD*YM:Q7
MBCD>6;/L'ZONK2NOPZ?V[A<B6Z?8?VM/G-!\T/U[C2D:=OR@QI%9BY@@42I]
M("0RC377>\X^M0A4&Z6'"I.@QH#P^7\O9]()/866OJMMM3O7W^I<:]/AM38=
MWBC#8"L.^L',.637:X(P4[:<\7.I:(#6VSZF90("ZBY;2D-5O)HKV[Y3%W0Y
M-7@2+Y5N@--,W4M+2N\N&LF4K:;A;55CM8+SM-H#T\\,H/U)5RQ]Y_G)1]UY
M57^(FEM3WG:[LEO6KT:BZ0L$G)M9[: VT-$*Q$>HFV1TB/JU,EVR5_, *#?)
M^F*L(YU4!%K4*)?UTZ@*8[H)F:KH!Y":;+?77['7YOJ%Q6[KJ3+4.X#XBN]*
MFV)!QX5<7$HY&\  Z"G&4NB,B=%NJZ/:4:_1CY9]K6-<-S)TH;]%9WT@GTH2
M6^)"G-8S:4 ZI@6W@F"I%PQHS-<93^1[DPDUZ8V=(7W[V9HG[P3O*W1W[P!3
MH,T8FY,N$S, A]NKNW<Y6]-4B\3*K4[<8G8C9]13%U^W\=(NY*A7\M!;[3'M
M#<_% (D_E+@AI9PQB874(!-M#.\Y[Y9%*_^SA)&@]E/03&MY]*XY_61SQDRD
MJ'>2M2UMVF"/7[4*)<'0DS7*F09N$NWCSL#^FPUL]U<=?3NTT3=M9&^?.TW1
M'?#.0+M0 XY1@)79F(_MSK73F%]Q56L?>X"19H*&W"H@K W=6G#EH$5;[P/]
M[PW,MIW!]3T;7&9;-6#Z+J;1X"OK+:2Q*8>*J>.6,?P:PP?9-B4F4F9F:;-M
MO;MTP]#O?MNN3.(K+MW5Y['*[,W?<)5N4Q[08 <,X\'V)_[V-U9^*O!]:VO=
M;1=+-/HG&F%L8+W@HO*FTO8H&(M8V'JM<X#Z[*AR2WT(;?P3%*4N?F#C&"CG
MIBH"53=%?\=EF:NDTD.,4@'/P\5:SCCRP2B'?$,!R3G[I*M'5MCFU&5Q,0>=
M,%/][U9*9UKG#)2J/OH6&87*W^J@7EG-H&[(!H6-4M)TP+UN4*928SB[08LK
MU%>(N*(VGC=3XO6P5W#B;?5)OW)CS>)K*H=;.7/T1EKH1K=")&"=@[#U9V,@
M)I482DF72E/4SC-0V\M944VGI.W,JMV!H1 !]12<=]Z1.XUDSU7;JCJ7KZFH
M4924BK]\W*)]"Y?;*L\^1Y.&!O2C"UI<5R@U*\MZKP0/80=]:P'7V4:7.Q2
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M%?G9')Y>U<M6#V,[HISWQM!,,>.KS\(V3.#F,.T:F,H0RK+HH]1,_EISD9*
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M(#12!*;!&%@Z[CJ3Y^#HU>#*>;>H^<<#&HB".K^AJ-X[>G7GJ717T4Z,;KN
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M7IZ6H.SBK C<*&.9&[$T=[,D+-U0%FE9@!F;AECA'$_B->?.\H2R=MCZJI^
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M%1U$Z#6 N*AAY:;51]#E&$J8$7TEQ11:%+LYQ@]4.Q',$>!&KGFE:MZA^I3
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M&"17K,N5TCA-(*#O%5DK1IT ;<8H/BH"4:RWCN"GCY+<OKY774C]>\7NL;+
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M3!91R4"=QER&<1;M],\6B5.'%<5G@OZ!2P.\M-1W6>EE($YQX;(T9JX?%E'
MD] 30?GDF0_Z)YE$2?HM]$\B9"!D'+&DC*,@2/-0AB'HN2CB">.)O],_VRHP
MWN%OIU[FATD<<#>!,^]&0DB7!5[I!AQN$QY[ODRPH\_$3\-)&JTBR\?ZY_[R
M$Q9QZ><R2Z)4POT5Y-A62,*[XB#+TS)[)(6S$Q%XQWOLP (W@H1;BKFE*"6(
M2!BZ>>HS-P$;@\>P7:%,GCQ;0T*D';W[BT09)J$?,)[FL0>/SXHXR3U1ID%>
M^&68\IU*V1YY^?S^,SSK-)9E7L()=C&"!1=/B=V>O-SUX3X"&R=+"Z2>#R=>
MFL#E$Z[1(^.P *44E"_<]A)9&QWJL28J)&=+Q313-2IX0<]1ONTY W>N0%0T
MNKBN]7&=_2FB$L[.=5JZYV63=S?XM,E7M+91Q$05S'+C/]M/5C,#5M6?_%MK
M,<"=WE<P=22^;NI9C5DWBAZKB.PN+GOTX>6IY**,PB)UBX@5+IB]L9O'N>]Z
MK.!1S!-/EGP%/U)&L<\CR9(\B9)$L$CD7N(7H+&2.!3Y/R>.^U9R(LRQ@N0,
M)6D;<OKW9 A24YI>._NBGJ//]*4S^D7_!AONQ-L4MCZ8=76C<%/F*F_:8<AZ
MN_D.X\S$4J"(20R-Q*O]=[_V:"2HV=[:K[TGV(C]WOZ[]_9K1_4>O=[U@\EV
MD40Y_6HDY^E)/0?]FT;>3\Z["OO%E]<FYMZ;,^K]=55,C],]"3?(; S5$2G\
M3I]%#D/:>CX&NG& 6 A5H(&8J@M,)4L,)3.*&OQK?_^-#I!3<0I1FAG ]%1>
M80G3)27Y^SWLX<(ME].9Q6C@W[HD-4*Z+O M!O&A4'\:HC4D8-%_,$D!4T>M
M0N*PM&?7M L6ZD+HJ5X&W(">,(MZ8?(E5$K#*!P,1]6E5:)X+KY/ZCY/>,7S
M:D[HBQ7"O#5H&[AI9T)![5LM,OUT,>O$Q@!H:(U-.D1_5"5AR@;.Y3FEW7$6
M$T=.*P56T NC,7&V)SS6D2 LA4IRX!(7-&S#_CI._W<<(#.[!UA\PE19%C6[
MZ[U!@Y:H.SWN=R-+[#L_R  AH$(7A)ETMX;R4*(;@3>F1DPM+L(A])=)]G05
MV2"0KC\\VCV%3AEDH?#--%*<MR(MG"^+*9E0F)@G])S.]Y.6PK1+]W+<V;)"
MTUVG" H)6IPDF4#I/<;#6#,>JDQ8?UPTE$96L]4B!::O%9+@)6P.Y<9FO?7#
M41C*G7^S&36VL!R,)^=D<L+_SSI @(8#6&3#^HJ^EG82V:>4X5SIP6 AR?=Q
MK7W15;[9.E'I'M4 QOEUN4"?0?U.W_WJAUWMQ]?5?L2[VH]=[<?6%1OL:C^V
M:CX/5?OQI;4<M_KP6PE1!T/46 S@6J7:L^OY N" &<<+N[!/AC?<=ES;!^ Z
MS,XPB$=4A7[PR[_J6A!@&B7AF!#OVBL+8^^GG]4DQK[9"8*8T9JSWSX *ZEJ
M'IN^5YF$VA_3WD'555;T_<DS,_+*CAQA8^0QJ3)U.4<DO F$KOL\J(F%*6:Q
MU3/,.;^>8^D ]?]%N!48ZABR;*BN0#D05&"\O_:A!KW>*X@IKO5+T,@DU@'T
M_<"A[*@B#8>!^D8?YV[>,;%>%R%;+6NB6K/> '1C4C,.](ATB<NP1L<.WCA%
M^C-L,1HE]5 AMTUA]GH')7=]3:>E-DUT=ON*Y]!'H"N2]PN&#-.]MW$+?C=^
MA3ZR2HR5I1]J\+YQ4>S.@>-L(MK]JHL]YZ7"NFN#'D<V1[SZ8B'%S;!D^Q7C
M%-C9T<)15)R-70T#O[\#^'A+U>1R)G%SDQMU9.+ZX5;JR.[6/P!?O5DJ%\]U
MGH-77REL;1>Z"H/DIY^=0U7V86K>AY^$[5S[R,=4E$9K*:Y8K2$O>K,P9/VF
MA >!LFI64S4K/)$7&*3JQ+1'8V.B':J$JNHFK<[+#&:Q>OY(#2@@*CP=&5S=
M:5T31XHMM.L-0A$/]_"T<,"P=SUJ7?Q\4RD6%!.=P<J#2A<@JNFQMI[9N@U=
M%$,_P^LE9ZVISNB5*,(&84RFU^5'A8GPJU)8]:M7EUV;J !&WT"+5+*Y>5D[
M:&I_C;I5LPJ$*( 'V]=3X7IEJ([1U%:Y\).+'1(<(8O% ,\Z4R64YJH2JWM*
MY6EZI%2M4VE7!V[9&3=9/\TOK)3FNV71PL[*#FG<ARN/%<%:30%_S%P_WTHM
M\;S'LHS6#X9S;9C0ZH;)^J,_UB:/;3/!S83K;:\O%5K4 M^0[0)SF$\M575W
M2\]6MQ*/NV1"IVI[\5I%V[E0A@#V")JR!L.W%.33$7'B"^E.ERU6Q!4U86OX
M-@JD#EL.#Y ],DIH3HQ8T7EIK4QJV/[P2LK!;-='5U3BJU?"*98+/<=*ZGAJ
MQU@.6N 3ZBC% *9[L<RQ\@L\-1C>98,&!O5(H04:U1KW_]R>FP1XGQ1U,61
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M-MV&=7<M(EP]K'M:LR<G4\%/CXQY[VVK^T=O,-BNRDW"=O>M[><@;PV!2X3
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MX0LZ3F^<R5=?2/D4#<3FM_(=>/[>>6Q_C4T8S/$KJ?XY.-G.5CG9WSL^*5[
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ML@:-?ZC[=/T(H'RAS<U#H;4$4S\A[8Q#G(6 ##8,>0[; I/2NB 7-5XO&;@
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MR[I6&XS'.-AJ#3RLR;"_0JQJ^V.U^K;[^2VHP-\@_MOL8.L([^\=M_9/WK5
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M).-Q-TTR6[:[._#XO?/8_AJ;.<][L/*]61]NE[QKN?>?Y,Y>ONZ3V/_\B1V
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M&)3GV%D+KABVB%.FD)68(<LMB8HS[(.\H;/@:)D'ZS/=)I?01# :;!)SRKC
MN9;!YF8:4@DG)"=>TAJ\GE%NWE[L?#C4(3AGM4+1XTS<+C72RD40([#F8M
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MA>%=#=7)/-#[S<-"I'[1B+5T^VR\%%. 56/2/3"I.6>!&4)]B$DAR35%G,:
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M>-A5ULM@W)B]VC*F"XJX,]X5,1K?#&?0.C5V_^^HW2_VT+DYBTDTC42SBU\
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M9KUY=VF"ZLL6[.'P=3KL;5I'P':- P8EU8BA[ 6$1ANCZU/ P]?V<:_?&PU
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M)LYQ8J+O>S&4)L#H(A$O,M-FFC#EX[U3:=IF25WF>TGUT@R>-/).[W(PYUJ
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M\\I@)6,7LTB=Q@HM_J/J03VHD@O+:H-%+DK95:8(Y!]SKQ3V/ CS;6!>:U.
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M/!)>:PEX<@DX?7>$,P(<B0B$B76(,<61-CP@98#5<Y9E8'QN;,FF%HOA#DT
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M\'/W(7='5 3B'<Z15-P@)@T!R-$9RC)8@8QJ+Y1<J0]Y=2*!^H43Y<4LEHB
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M:9:SN>#.7+3!;D@AL:L$@S\9Q0N@7^\)/6\F8WWU0/.(X$4*P'+DLEP+!<C
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M  &P[\J<VN&)&<XBQ>R.G?5,Q/3TJ6)T,1=M&:8T&X,J&0"@^BP,TX] VT"
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M@N20ZAIOBJG>'?5[%P'F%C9O-+,_PAI=PSY("W=>Q FX"!/]"#3%4^ +<<_
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MOLX"$P2;&SJZ9[NN3@R?^"&HS<"=PA<^%\+F7A@:(*$(!];@3 2N9=F1'=+
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M'%%@ 1 ;Y"P(1-UQ;!LD(R'46PE$6HHM-NQO4GR^.5BE^'Q%?#Z!IYS ,HS
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M6-(3]8 FNUG(U07R+5M;8N=1N%#VRQQN3+F&C='EJ#>J;*(I&:512ZV13H[
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MT(5%>!1&PK C@FC+]J?3%U4SU^UF_\U"KC4( L7KR_'Z!-ZR#8L3*W+TP+(
M;PDWU(/(CW2;&9X;!J9+ O/%6WM?&Y9L@D7/!+"/3#J2\>R"Q9T'=YK?7=MP
M$SCE'HOP/.V$(NS!>()$5,YON5E8,V5TJY146DHJ?9E"()'M4A%&5!><^SJU
M+< BCF/IP@]LUXA@3RTLFV*MJO.(<OEL(5NO 'XHMMXL6T^ #<H<5T0^TQU!
M;9W2"-G:-77&;!%2RPA#/!1E.=O4(GD?W"5'+:P5JL4=F:PU/(BB7".;AASE
MSIQV3CHP)GE*LXRE*T&TA"#B,^));N0%EJ];D1OI% P@W6<<!5$04#>RB,U=
M+%\T799-^3>VFX>W.J2DN'DUW#P!*P+?-ESL5N8SBV Q,HY=E".L42%,'CG"
MLAPLLKB"1$'EPUBPJT,4Q5QD^?^&&;814>]C;>:M#K74.W0TLC\JK+(Z,74]
M!3H$<PV+.2"<K(B"]1.X.G.)H4>>Z5JV:T7$(R"F&H:[3?:/<FMLJUOCD:RN
MN'DY;IX '08#/@U9I .QH@EA@O40^:9N4.)&Q'>993(L@#@=.%&^C/6FU:;\
MYO&H8S\LH"=/GYWE:[W$8_7O6"["40%UE.;*X;J<D+J9@AQAZ)EV$##=HR'3
M:61&>B"(JPO'"3W7)5Y@<Q!2*S@2H#P<SQEJ**[>*%=/A5$L3X04-LW$G(TP
M-'1& J%;U+9]P[5-SZ4OWCKDT6:$<GHLF76:"Y;QELS=",4/D:2RC8J,I_!,
MA'MWE&<+(RKPP9'<BKS>KG&O1X1]Q?1?(DN5G%I*3IW<3E4+MEW38!0C+,RH
MDOD9%T1GC!++LP&=T.@%""7/).:;+;*3E,]C"T,M#^9NQ<5+<O%$*5M&W)";
MAJ.[@859&U8$Y@1W=<L1IN5[$>,!&A'T,5:$<G(LQ7H?L[0=YSD6U>FDA=!T
MX)6@T,(XYS"SAZ&,O;"(GC[.,MPJ+)EX#-MT7.V2DDS+2::?,[I067[(7*Y'
MPO0!9 14]PAS=4[-*#1MVV4^Q32.1Z>)*B?'\\86#SVFHIA[A<Q]-FD\1(*Q
M(-0=V3HSH%0'N>WKCAL0/S #EQ'L,$4?4T)?.3B6R^HH6B*354J4'V,;_!CU
MN3@>BUSNC9(ZRTF=_A2D "!A"Y\QW8^$"\:.'>G,-TP=! 5SF&,X)A9%MOQ'
M9X8J=\7V\O!3>BL4#S^>AR>0@TFH:3+?T2..-40H#0 Y!*;N.13DLF<ZW,'S
MZS/"GBHU8YT<^.>@)@?#SB:LP]4)DXWCB#HG?:01V&&>BR(?[-9AO5DJ/72%
M8NO7=+3$AOVF@:$[!J<ZY8$'$LMG.M@YKBT<WPYY($L?$:K\&<^7\9\*?"C&
MWQCC3_8*#!DQJ<=U8ONV3H7EZ!YU#=VB7D3MT(F(!38')0V+DBWB_!5Y/$H&
M]K<<NXST-)C1 6Z#+4V?62'OU2_0LU$,ZT.$XX6\E4!?3J ;TUVRB>U$?F3H
M/L4#B18>3234T1WL82Z(B]$I$.C3YQ$?9G]NO@.L:I6MQ.:VBLWUX6DE-A\I
M-B<C?I%'@\ %.2D"1Z>A0?7 !"D:<<,AEN%X(#K! %Z5VV[S8G.\<?94(]]!
M6\DG:4K]1P?[(%]W@ O1%JRH.O^<)LG[-+ME6:A:4E^=? .9(43(A XDYX*Q
M!FL;",O2O<#AW"(A!R$SV6+ZSA:?&VJ+/*_M=2!@>!V@[*H"82A_;6-. U[2
M&Z$2:0U5)E ^U;2Z8L:[6\"NML6I:E6J6I6J5J6++LMS;;BI6I6J5J6+VA'O
M!MHN8,FL@.1]D]U;B_.9==Q;PJ#T!5@I)C>$:Q+J6&'@6\0%),X=ESE6$'P[
M7<R.G .X]R'8TFV=M_^X/?_.S3,8Q?E?<%_[BWGQUR<3C,O^U]^^&%]^@5'X
MVZ?^X)[:R&R?F%^O#LWS7U_Z,#?RY>J3^?7[%_LK&)E?CW^_ >C^_>S[)^/K
M\:DUJZUH&'@A]4*F1TX4Z#0(78#O =.#R/%H%/@>]P(LPN.;JPJR;HWS3?46
M59)N.4D7!L2+1.29CB TB$C@,# P#,_S'6I9C*"D([Z2=-LAZ2:J!'@@W+@9
M^KHC, AA!$3W?$YUS[&);]J@O9A 2><ZJPHJ;[HMZ#/HM;6#AP)..SP3+(<'
M%JG&>UF&%0_Z@F5EL#S-8R2I7)T8>+*X[AQQ.]BHSR+O)9AU_#Y+VT?ECGV$
M::9X]<=ZPYYY682G$LR?IIM;1*8%Z#/4*?<]G;H$9#)LJTYH%(9!8(6^3U15
MA#U@_)5')E?%^(K!EV/P">1E"0:XRPJP!3M!+G=UGT21[MB>ZYBVSUD0OGA+
MG!TJ#;EST&KG!OPLW*DG9;CP<;[4!P3D]\C_\.C5>3;JDQE4V,2)3.X$U#9)
M$#&?"\_QK CS["SIAWTX7%;>B=7IR.D.+(9IB<AQ/)U8F.M# U\/&/SI$PL[
M?8L@#(RU^&$?RS^[X:55,E3)4!7+>FXR=,+.\$/*#4^XNB NV!F^9^@>I8;.
M?49@V\S0Q/)'STB&CN=+RLRR@['TR'LRS<;SR#:7>W?5$AI616:=OM9B.;)D
M'L.Z84H=?%5FVY4M@+M9&K @3L T%WF=HY?V"DQ!SN$/5F@<)A (#4S\1&;E
M];K(\V#GM[&77RZ*(A&R#.UM7+3D_>B89;VBE6;E8\MZM87(VC#4\(X<OVX&
M#\U@0>!M"3P]E#[?LN"BEK?27A+B4$2.>Q3G+;@ IH<EZD+L+HCOSGMM> 0\
M($V2J,PKU5B0_A!-;619I/?+?9-KHJ["!/</3F!A;T+M5KX-GHUOC.$N+M]2
MKM#\*;!,:,/OFMHAD 1R!$L&ZW['2+E\:?DV>='\\0X&"D.*L39?.=@VBSO8
M4%1C6M1+$NW']*%X#?[ H78$W%:=SBSW3)[/'%LH8$ A5U@3/[OP9GGC_-GC
M=I7-'K'D51P!JW4*V$Y8_TS.IP,,J1&S% ]MH.16WEPBEW,+.6RP-5T01KR/
M>:JP"H,%@MT&P@>*E0O8R47)=@((0O+&"*&/4""P%MPE,UZ9;#8!AGZ9(#MR
M4?5 N5] =;?X8^VZ^?3\_1T'%F"M.V7ELGJ"AYWPM%J!0\ZSG@CO=?P;.ZJO
M'Y[Z_0GF\^E;8 D*&T%U6V#NB.V8NN>9H>[95B@,;KD6,Y_ @E4[O+8=%J9C
M4AF:(43H-"*!SL* Z X'*]4)B&LZUHNWG70*3DU]H+%RJ8?B95RL@"A/>2PE
MBU3+/9#[LM'T>-04!<Q(#G IEBW2T) PY"-1!LQ6G5(!B:*7=3 M/T/](N.R
MH*ECU#+XHUMJ'A!,*8RMO*P'"K&I[:#0O^AH9[+^ONG*!3(:4J7] 0P(RWR)
MK8U!09>]-ROEG8'B_Q%GO5P[C,.&]EDDL8CDNIX IZ;MF&N7@O< )_6U0]"N
M+W%U3>/-T>'GDTO\1/Y-WKRJM@!6,I<7XFF(C@:X*\/:3GU-U(_+ 9?U$G@A
M0(@;!HI88CC8BZ07PKUYMSYRT:E4-^"Z&ZFR\B(3G6L8=V?6M.3S^_*V"( [
MJ*52#-P"L$14DF9%%: '*DOD$TJL@O1U=/'GZ;%._*;V5RM.1+DX]13+ ^]R
M<+="='%PLJ&!Q!$2+<&D00&"ZH07R%NKQ\$<.Z& 63? $@"E6,'7=IJ-X8_A
MB?I<NVW%V$ !+BCQ3*5YYP.N",1=!S@IT63O:@2Z>;V<,+!V"@ +7URS5Q*W
MXX*5S(72N0!L_6MP @8A%W "X#:<9I("X,H;^#@,H,F9PQ#P8T#=6=9'0PF8
M&B-HDG<&+Y$WXL@CA((EU^'63#RI1/9]O+!LH#*%1AHH 6X%L"Y"C79%'/5[
M1A:N6MMN)G[$:2\'3%=3.J@%[:A7V1._IX$DT $HD?@<\0S, E:J6ND*@0X7
MMY9(#=QL,"[D"ZN5@M<W-)P]RUM:A,=_1E'3&"WM(I8$L3(X@[&X9.E(VU<N
MPF$7]@E,IXKJ8!D:%9T#$A#8.@?6'Z#\X 16!=:KOX>,*$6%A)%Y=6Q/KC"0
M2IR-VT^5S36]L[D6]H9\>O<HIZE@A,60F.I=QKKC0/(]((V)#9X^U#BRY=4J
MVQ0WNZ*OU_*9P#35(:O*HS5R5T4AQO 6%L L>L7\6\9I2V[[K.-CFR NWYQ8
ML)&?. ,)PUS7L#S+(8)32MW "X0)0,0'Z6UQQR?!-V(9+^J[6MGP!-"UT*7^
MT%D$4WS-DEO6SU\<C"\.K$PU)!_'O/@BSE^R*%K;DI4[!V@X+47/:U!V(L.K
M8#AL:\:BM3*$^/^Z?^]<L%;EN474PV@= '?]^X"]75!26ALAYJDC1)*83WX
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M(E%:?IN$SB,=7)Y] +N1"):+ 38PB5)(BC9FT,8'_'4ZR%]Y._W&757%;-/
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MEJP$)N7^4 /Q[J:M3B7B[A3/T,<?_@502P,$%     @ .HAC5$G@>IR1*
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M^);S+671\SH/K9%99'IZL8+IC*J6/M8+EV@M)I"V4YWAD[G5V(L&>^YXO]C
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M#O@,#ERQZ)B309/A(9!!_9)[+D-,7%CLDQAZ/ZXA:,MN'-I"76XKHO;*DHM
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M%2L(*D;+/-G:3+@@%"1KR5UZ? YN<X-TJ/C;,+BWDR ?CW-G^272QP @,L.
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MPN'DLN&MZ?K[]8]('L3?_O3_ 5!+ P04    "  ZB&-4[XDHL;-^  #ME 4
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MG'="HY!D(TMRI1R]*9'6#$H661->&(]M:CEW!/HH0@V[\&1-OE$SQ;0XHKJ
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MM@TGM*; +H)NTB+Q/.%MK;-;-S>MDP?&LB=G5WH(R7LZO.B7LS9&^#:'PAW
M#F\@[*N[&VYF?X)O40BVB+-A'H;I]_=AA%?X;RW+14@H)M?PA\G@)/G%0H9
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M*9-M4P.U \@':X+3A"1;Y[#OIZP&M5&W0+T >GGD[Q9PF_:_V1'PPS3#:4:
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M^K;'>+"JGM;4::261U2-LVE1OW[_/?S79/I\%&:S+HDB811T$ 7PV>C:YZ!
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M"/SL(_=)3T([Z%WXS;Q.QY,7EEG@!@M!M0D"&3K@,_/>LAJT/'B"[./+^3^
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MR=X3O6T6X#9RAFXP;Y?7TQ.ZQ_[Z(2QQ]>IJ3398':IQ@9HSE,*"0,-!\:+
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M(X0BLY<I\V(:5H1/R^P+6BWCPW6L+@H38>V4^HKL/4=WL<POF*KA*A$@)&9
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M. ^7W>#I>:ZUV4M<K;MV^9@O5/88=5%@="CDGM26Z"@#\&*=HZW5&>:;8.5
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MM#?)]8_KEQA6^+__V_\'4$L#!!0    ( #J(8U2)WY:7YZ$  !-^ 0 4
M96]L<RTR,#(Q,3(S,5]G,2YJ<&?L? D@E%W?]YD9C'7L0L80(K)7QCHD6XNM
M4$@8HJQCIQA+(60M%;)6J)"2+87($-E#498A6W:RSWSCON_GN7O>]WF_[_WN
M^[F?^WG?IY,?_Z[K7.=<YYS_^6_G7(?<1QX"+$>U];0!! H!+91_@#S">%I/
M4_.<H;&!MMYQ+0"! ,"H>_R"JQN4!0 75R\/8YW# J?/F O 6P$4T $:( N
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M<8@QY S$&N( <85X0RY#PB#1D$1("B0+D@\IAE1 :B%-D [(!\@P9!*R"-F
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M5P0C_.8UIC]$$ES'U=[?*.WEE[OQUCU!L*;5)P_=B/KL[!'@TP1S+'AA$)Y
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M.Z>^X>=TULMV/CI4V8<3]J4MSJ@:E&F%<"L*VSG A"^UPW//WSAY]HKU,Q;
M(SP/D--7WV^=E?R:?N+!X:&XFQXS4SH\_'VULX$ [J]%<6L_')3 ?/ZB6;9=
M+&JE-FN!N85T.E:G)N>4;'%A_;PH<\WX$Z&0K[3?N.?4D=Z<G.]K2K5O5NY)
M1D\'RUOR)UA?-A)ZIYSPS(U>&=D'4ZSA7E;<6%+G#]-R5TBHOO+ +#(Y2J/1
M5I%@1,"EA<7*Q_JW>3..V+-)B]>P!$8V3JNS&9OZO"B0NLGC$>1!J]$K.DF
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MLM?Y?J0J=_W=<HG> 8(L]=9L@FV+;<PT+,#4Y 'E6H<T8'$$">YQH$HDD@5
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MOY3,O7^+E+BPWBY!/^E?C9X5(WL:)PO0D.R"M13@W;(._.*^^KDJX'D8Q[9
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MIVJWE:7>_W:KBG"-/7TI?[]1.3T/H*4BGKIV',Z->^,96H[PU-7#5M0M+@\
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MW?W/7-44V<#.- 4%^ $8V$;]4'>53.0=JIE()MXQ ;=L_5H U%;_5YH4_ 6
MJ=^W0,NV6!Y S^W-:E3[J=/56!1V>'=!:0AZK)59"%O;E)'>(._!Q_4P&7/*
MANLP,4# L04G-1IW<U0_]TB7@V.\"#E?MS7UI-F.@!<RW;L)!$'$BX:>+]RC
M\UC!DU>./?LZJ+5+^C/L5H0&5L>1823?:PI69KI/54+]7G'[MXYB85[ Q/P?
M=20$%#N8O_:6!;1GI+:4-FFS +-$%J J_\5'@07$]"RL"_'K1&CJ^6:K1O[:
M![W68+!$/'\X&3Z%&GM2P @)P[H+B2,JRW7\<,=GLX*-ZQL-507NX 2/?\8H
M (3>Y2;#A)WY[RX%R-N[@T)I32Q S'\"([B0N'5W="CO@^A.'IE17<@,Y_L[
MCJ(\J:+X  5VD?D:#S(F5.PX;YKZB5(7RZTZ,O[^/0HDCT^2%9UYD1)WUIH.
M:%CT4S0:\6M:1&A>SOP1057+KQ?WQ/)!RZ!<XUJB?A?)/@8>9$-%'^3)X(@)
M=N&MBE'H1WFJ%%O(1Q$APA+/+)NJQ+Y!#<&:JUMUE;T<O!: %EU$YVL@6 AU
M&@_S$TRL,E+]USZPAE+4@-LI!FE%Q@1!66'$,R2:GFH27;%S\W!?<Z+#]5T8
MBK32;%T"K<W)!FSX;?Y0ZY?(@+1ONGD.*%TX1!['1.<;8* .7D&"*JLYZ-A7
MJ&N=%L4K^Y0N:*G&3^?O(<@V]=)>8(0^N53W%ET !"@0@]KHR7+PC !PHT0Z
M8*V8>/JUZ)9>GNBVK9JKTPGMF>_[5DW[C,>3=FSEX1"5IJC#U*L5QOP)7@OE
MU)-]ES1[.C->UQSYW.U%B$](QO/YG@4N^ZBOOTWT0B,+N)9I*F6X96>'Z$2
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M;:+0TJTB9-]PR+K?AI*LFCQ'-0.^]&*=CY4+.M6I "U4]UG'@('O8/\GE&Y
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MU: 55%JO1&8]:%&JX*.E[A:C&B>%?U08K=Y,38T4<Q4'SX%SP1T<5@G*LK(
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M%-+A>*Z_)*2J"'Y<X_K&$[UMM/EQ5!G@%ZXT/;6HJ3(]L$,K]'.6:P)8GR
MD8]#F4QH(3,EE[>>7ZO!3%JER*>-$=9L)'/&]O6#M[>/FBC65PZ0[L:G,<HU
M!E8%NHZ]W"[T[-LP3_S>%MW_@+Y6?V$7A2Q:"%KDZ8O1\7?AQ5W,7T_:U.#^
M35FQJH-CG^+E0Y9YOIMD9\XI(4\X9#B<90/[V,#B ALH4 "U#C^K$.QL#!$S
MDG;AY;GWKM1I)H6'P^1L8-G@(AM@5+".)C,50/D/BBJ^_P$;N'R>#;!"V,#
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MW1+;V3")NGY:GIV;$K#+7K%JH@UK$^8]U/DQ6?:\56R7W"1B,%H>00$5<8A
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MVD1-0U56X;$,  (! *[\8ULG9Q0" '!T\G#3D).BTWNB3X<Q"*  6  ZP T
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M^V9LZ9"#+, M)"# P</)_;N!^O]\^&\,-W/[&W>D_FO.0'?Z_Y+V1_F<\P!
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M  ?  SP$1  )0 90!%0!+> )8 Q8 #: (^ &> //@& @'(@$XH D(!W( 0J
M$J "^ #4 Q^!=J +Z .&@0E@!E@ 5H%M8!\X 2Y!(! &Z!:("$0.H@4Q@MA!
M/"!!D#A(!O08I %Z C(%68.<0)Z@9Z!04"0H 90.>@,J 56!&D'MH%[0".@[
M:!&T"3H$7:" 47!1B%&H49A0N% $4211E%"T4(Q0K%%<4?Q0GJ/$H*2BY*&\
M0ZE#:4?I0YE 64#91H&! 3 .^ [X+I@#+ B6!JN"]<%/P6[@0' $.!F<!ZX
M-X&[P6/@!? .^!P5'94(E0Z5 U4$51Y5&]4"U14U$#4*-1VU&+4.]0OJ&.HB
MZCXJ'.T6&A4:.YHPF@*:'IHUFC=:.%HRVENT6K1.M FT5;03='3T.^C,Z _1
MY=&?H-NA^Z-'H6>A5Z*WH8^@+Z/#,# PR#'8,<0P5#',,#PPPC'2,-YAM&*,
M8JQBG&'B8-)B\F#*8NIC.F&&8"9CEF)^PAS%7,>\Q"+ 8L02QE+%LL3RQ8K%
M*L!JPAK"6L6ZQ";$9L86P];"ML,.QD[%KL#NQ)[%/L+!P;F'(X2CCF.+$X23
MBO,>IP=G$><<]S8N&ZXTKB&N)VX,;A%N&^YWW*-;MVXQW9*XI7_+XU;,K9);
M';=^W#K#(\+CQ%/ L\2#XF7@U>&-XNWA8^$SXDOB&^/[X2?C5^,/X>\08!$P
M$4@3F!$$$F00-!),$< (B0BY"54)'0FC"$L)>PDW;F/<9KHM<]OR]O/;^;<[
M;B\3@8GHB:2)+(A"B0J(.HE6B=&)F8D5B.V((XG+B0>)]TEND_"1Z)#XD&20
MM) LW '?8;JC<,?A3NR=#W<F[UR04I-*DEJ1OB*M(!TE/26C)),@LR*+(*LD
MFR"[(*<CER&W)X\GKR>?HT"E8*-0I_"FR*;HI-BA)*84H;2@C*#\0#E-A4+%
M1J5!Y4^53]5/!:.FH9:C=J%.H^Z@WJ&Y0R-!8T?SFN83S28M$:TXK2WM:]I6
MVBTZ$CI).@>Z5+HO=/MWJ>[*W_6\^^;NX-W+>\SWM.^%W*N\-T>/32](_Y3^
M-?UG^GT&6@9EAF<,90S3C%B,@HPVC"F,W8RG3,Q,NDPOF.J9-IC)F!68_9C+
MF&=9;K% 6%Q9\EC&6=%9!5GM6;-8A]E0V/C9;-@RV(;84=@%V&W9L]A'[J/=
M%[KO=#_O_A0'+H<DAQ='&<<BYQW.QYPAG/6<>UP,7/I<\5S=7/ '_ \<'A0\
MF.&^S:W('<+=Q'W(P\9CP9/!,\Y[BU>6%\K;P'O Q\YGQ9?-]XV?B%^9_P7_
M9_YK@8<";@(5 IL/&1Z:/LQ\."5(+*@F&"78(X0F)"4$%?HH="XL(.PA_$'X
MIPB'B+U(J<B&*+.HE6B!Z++8/3$SL3=B"^)TXJ;BN>(+D+L0,T@>9$F"7L)2
MXJW$NB2KI)WD.\D]J0=2;E*U4J?2PM(!TFV/P(_D'D4\&I2Y+:,MDR[S0_:>
MK+5LF>R^'+^<OUR;/)J\DGR\_)0"M8*%0HG"ON)#Q0#%+TJX2II*Z4I+C]D>
MNSUN4D915E1.5)Y5851Q4JE7!5055!-5Y]28U5S5FM71U=74,]37-+@UGFET
M:Q)IFFB6:IYH26G%:LUHLVA[:G_6P=<QU"G1.=5]I)N@NZ#'I1>@U_>$XHGM
MDP9]#'T=_;?Z, ,9@R2#54-^PW##22-F(Q^C7F,*8P?C%A-\$S.3:E,T4UW3
M4M,K,U6S/#.8N8)YIOF^A;1%BL6VI83E:\M-*S&K!*OUIV)/$YYN6(M9)UIO
MVD!LDFUV;*5MTVT/[.3M<NQ.[57MB^P1#KH.E8Z8CJ:.C4ZWG>R=OCC3./LX
MC[BPNX2[++@*NR:Y[KLIN;UU![D;N3=X$"/!5+\GBV>8YZ*7N%>&UYFWCG>U
M#Z&/DT^_+YOO*]]U/UF_0G]4?PO_S\_N/@M^MA@@&? F$!1H'O@92@]]#ET-
MD@LJ#L8.M@\>"'D0DA!R'*H;VO2<^GG0\^4PN;"R<+QPM_"I%R(O<EZBOK1]
M.?B*]U7:*WB$9<37R >1R9%741917Z.YHU.C$3%/8P9C!6*SX]#CG.(FXR'Q
MQ0F$"7X)RXG*B76OZ5Y'O#Y.,DGJ3>9+SDG!3O%,64A]G-J0QI 6EW:5;I,^
MD2&549E)E?DJ\S3+,FLT6R*[(H<Z)S+G(M<V]]L;N3=U>4QYR?GH^5[Y:P4Z
M!=V%@H4E;RG>1KZ]+G(J6BC6*/Y2\K"DI)2J-+8,I<RS;/.=X;OA\D?E#14<
M%6\J[U1&O@?>>[[?JC*MFOR@].%SM6!U10UC368M46U$':C.MVZ_WJ9^H>%)
MPTBC8N/G)I&FVF;.YJ*/=S]FM)"TQ'["_O3\$Z+5KQ76YM*VTV[=OOS9Y/-,
MAU['^!?U+X.=2IT]7;)='=V2W:T]8CT?>X5[&[\*?JWO$^BKZ^?OKQW@'Z@=
M%!BL&WHXU# L--PT(CKR:10RVC[V:*QK7&&\;T)E8F12>_+;E.'4PC?+;QO?
M';X?3'M-7\X$S:+-1LP1S"7_H/J1-\\Z7[D@L-"R^&BQ?TES:6;98GE[Q7WE
M:O7YVJVUY'7:]9(-GHV/F[*;PUL&6ZO;+MN7.^&[A+N9>RQ[-3\E?O;OZ^VO
M'K@=( ZCCLB/BH[YCC_#U& _3AQ/+D\CSLC/BL\%S[LO="_6+[VO,*Y2KUFO
MF^!*\%F$(P*!V /P)"V=S:T RU_X 3$#2 .XF)CXF/B4A,24]%14I!1T#$Q,
M5'0,=(Q\7'0,+,SL[$+LS"RL#WCX>1ZP/A1!AE\?OPLWE8!NX> 0X!$@+3 #
M#\M=%AX1/AX>'I&_#1(WX;?/OPTWE:#\W96T 828*!IH0V#@'@ B!*$0HB"^
M +1(0=% O\*_H"00"A@5#1T#$PL;!YFAE@!  8'!**A@-#14)$@"!2"? ZB$
M:+?O<DNB$ZF;8=QS)>8)CG^#22]5U4ZB,;+/P&ON%H*%?8>4C)R"D0DY/&Q\
M_ (/!86$I1_)R,K)*RAJ:FGKZ"+1FX6EU5-K&UL[=P]/+V\?7[_0YV'A+UZ^
MBDA(?)V4G)*:EIZ77U#XMJBXI/1#=4UM77U#8]/GCB^=7=T]O5]'Q\8G)J>^
M?9]>7%I>65U;W]C<.C@\.H:=G)Z=7]S(!0+ H'\)?R@7(5(N%%14,"K&C5P@
M%.^;#(2H:'>YT6]+JF.8N1+=XPG&)):*?U/5CD7/J[%/8NXV@GV'@6^1\>!&
MM%^2_=L$"_EW2?9GP?XBUS2 "T8*0HA""$  F#Y+7A#V/^E_)BEB=6IG:-76
M"_H2JKXQ9:%0WC'(*T8 CM^A0S8(X&<5G _J].3/? 7$FK._148=/OL! 62/
M((!YBRN;OXHT^ MY66VQQ9ZLIER=Q,(O:9?E_L+*='SOJ^92UX+6WV]=KX&>
M?D, %)#?\9PT@T9I?A'YUXU6"$ L'P%\ZCX;^:N(RXG;3M^X-NUN']?Y+NWU
M":0K]B]LY(OJE*?&-]W_79=_WWU#L<QF'AB)W*5;']Q?#@$$Q![D_X[/6]Q9
M_9Y27 J9238YFH9<[D"C:?_"DN+_4_9_RO[?4G:CPM_W':S_010K\7=M*^O@
M\>!)'I>.;=75#=0IJ*OF"X=>I%LF;R!+U4&.?G!=GK4BN[P;>W4:"8=SG0VC
MW0CSY^C(=;,%LC=+"* U$LX'NNGK[Q.@3D@QAGQ:?R+CT<!OT_"[%-J_-"%!
M6OS/%O_9XO]K+4)_WV"T4V<,Z@'2;G0BUW[#.S)+]^-<#'498N ?2:_590"4
M")9<)&U+H-WEBUE$5W;+OGL@'\LM,]5X7,C*DF]'YCN9E,!A_X-1Z8&ZD-T2
M)Z?Q[FEC;_%*W-?.U)5TQ=4L%8O-]SYDBU.IZC(D:=^(D57^9Q,)8^M%.ZQX
M2PD*"]U6=I)1#<LN*D( Q:JG]H.BC@B =C[,3SP'_@8R5REX4'\%#229C8TL
M.>!%BOV6+B^"!?@O((+<)*$A_LDSBRXNIT>\F;&:AM'4-N#IQ31KM2VW6^(?
M.SH^L:4HFE9XWX7M&L=:!=QY0Y; &V>+6RU#K ;Z1Y""DH($&K$ZDEZKH:SE
MIUL%>W.WD9"L+CUY\U2P@LCH@'*+H\I'_]6 #+6>(=7![3'S^9>B:E.HW:2J
M^FL*S(DR)'U"C;3*X9\_/W<(B6 I%KX9W7](3_]/I&&  -[1ZL<4U", /?&:
MR16MLR=;^M"+, 3@]7&]:_[@^DPWWQ8!;)%>3Q_E4$*[3Q>-^BR6MIX];LN+
M8'W)DA<!_.=000@6I^$]UJ=B*"&J5,?$(&KB37J;U#(43 8"64SZ6H%_0>/!
MO^;%SB;]:IHO#8-]EJ(O+SB[I<#^P=;!GO20JS[)LI]3D4 *73R^ZM<6=HD#
M/N'/>"X=%;:@>H5T861)#D:._^ UIY .L&S+4+. ,$N%DTMH,C-2X21X517=
M;UGW?B2M7X07,KU=S3R8KLZ2(6I%2_G:W'RF1-%5RU1\QKQZ_&X$J2JL0KR;
MK.K1C%^1JE+"CY0Q]3?=^QOR"J3>OT[:31A@LXK9R>H7YJ9^N6MHY8<?#EDA
M;D6"M.%H>QEF^H&!+15BS4C['P;/OII8[Y^6(LVH!C1:9SQWY,Y<O^!\S>YY
MYM%9IBZK#)?M2F2,"</82>+EYXB143YR6(B72WX93<ZUN\&+-@S:[48$X(X
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MW%2"EGU%0!?/RG6/N<@ER_H="V1#7!' _14R9JI]GZ$5=K?I:1'Y298V;0D
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MGU ]_A::BSN.X42.30?(?#I=(@G>:F_7]4VJJF3'>C7@C7JK/2XPD+NF2A/
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MGWA6*N-C'_M';DW57)0?9AX<8-HQ---V.3X4/+S%D6LU6+ADLGTPK-_A/!1
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M*4E_H:"*N7VSWRT.*W88=E(X"F&&V)?[1AZ93CN<LF/=DCGN@@Q%))TNYD(
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MQNS-,Z[@IZ+D0HZ,Q-2YIC6%%R++$B\F.JTA@4\Z]O^#&1<M2<B/[Q3A74A
M8L[MQ%\0PREHYP;N":AH& ZOB*]=XMG7Q?!K]&14W)  S71 B1K[I*J(QT/F
M$AQP87 8$80]'\2G.G=ZQ[(SESZWR/8+'85$\)$;VUL'OA9!C&4RG0]KAG31
MGPM?'^,;/7Y\JWF)4TID/61I0+)^MJKC8M,@D\)(RLL<T#=I00SC/S3TS/5V
M^$3)Q]W;95)4IU,JAAZQ"D<"EQ-(TMBQ\I/*Q;LT&AFN8'J5*KUTPB+#T+4(
M::\;]!$P*$GM-VS\]+&],A!W-#@(B/W#(]\=6Y(K \4KBQI/"X7Q1)C"_* "
M^E'/9FSE=(I"%DKP>ULK/EM(=HM.B=_'A?4].&*(XXVP7U 0N.=^I?)>1(^=
MP@H$!:'T"6]Y1H=LL COQ'E9QEF:'G?Z..%)A'A^PQ3K-]"W]L6*%;T>/S$N
M7Z];Z\[K-1_NZ?5M+MX13']*YA=(3?9'9A'D^!Q>F%\T>=/HG^AMVGLA4@??
M+--&F.:[\"V-G->< F]?PDP>OZ<>(\'VL;%HJKWN@Z].=:4SP?FYX62@JJK1
M3A"PG)''H%NM8YYHR2]S'>>>E-S\35CB\=I*[+(WWRS5B9(EFUJ)_UC'R 77
M$]%6&)$G>QXO$FCTC"KSW(,\U+JTN5W'Q/">7LY0C-0W$F-,39]E;*-HAN-R
M"68$>+VX^B$F_A'V26%/GDV%+"G0\%96YK^<]/M/39DH2,U:E5O$V0X>,]H(
MD3,DL;>ND &<W+1O7U=XVR6!<W.MFGT^3Q9\.KK$L OZRYBBH_2 @:N?=<1E
MA<>$DT;Y/;<\(U>VVP4X0R3&LSQ9T\UP_YXCH8J3ZD]0*0/< +,'Q57&Z<RM
MP;Z<,,9!S4K?N/E1.2MVHE+L-X7Q=.P:RPXV[U]_H6E^_D#P./4R'PMW@TA/
M>OOT@.0RAH3^W;&-1)KM]O&7>Q/$T*T!@R9G!KK-URME1%ZN-Q(=&FBK, 9"
M%\:Q_#CK7DM<?9)O).U(B( T _7=.A<^=(3@B_X(^6")6?9*-6Q6G)HV@%/S
MREH4%1)H"7 G?S-K3]0TJWOAL2(_77((#!&O??' N3$:?\^]6I4[F +XT:*Z
M\0P%&WT% >_;UVS6%<T6#.>>K>W(0\/(QX?M_#]*S8P_LJ>4:F/+9$.]>O_;
MN&W>SO?Z2E1X\3V6=CZ- 'JI>@1G54YQ GO?^S'"F%[;J3M;Y18C!4*]P[>"
MUNWS<D)')U*RI(E2"/W?ZK"M)6; B"V4-F_G1670[,Z8&46)[!2[UX]]9O0E
MF8,D$(YLY"W$?MF)R0V=HF^YAP1XO9YIVM:RIA;?$<]@U0N@XJ3,I#]D"NT(
M]8RH%S.;*--8'6%72Z?2_!'\K!<)5 (]AL488R.7-WL01J"U;T@ 4O3M!^7D
M0="BI?ES66;J"Y@WG=_D)B"!:.DF\QB+39R/@H'7PX<7RLQP%!-4),7#VJBI
MEE#]1,('"3#9A.[K( %I2.$,R2&V'G2$#*'5MF;('-VB]OHB7N+CX%NM<P2
MZ'K"W(BDWR(J+@H-?).G3+', GUC)OMC<;$\%--[+"VM):.\!0&Z<:!CKX\3
MX\7XO*0C(T^EL<J>C[[<,,<Q8=HC^"@(6#EY^+$X.QX)]% @M(P^/]:3*^O9
M5UWN>H"XM:4<.RI9K<[]J5N8LUDZ,2YX*[%A<'@Z +[47[S\$%K]4F!7(NS@
M"IBF^ ].T#B#+N7FV;N4!EVPX%UYF\P&;'3?AFG+1"7.OK;1Y&LCQ>L#O[;L
M)@,P6%5!FS>:RR3,,JQIM"HG($ ][?[K,C;[_)D0WXIU+<I9PW#;D_YYX=N+
M U6W8YI!=+-^O ?2C=.;X7J%KE^YE4M&ID<2GK1(]S[3TS%:33P=1F@U'>#@
MPY1J5,S8RPCU><4Q.^49-[E)$#56!SK-:A[E'50OTSZ+??@<V+H*U.^=6F(F
M?DD\Q&8\^HX$VJQ5@QBW\4"[?:"8G$0B&_QO#\P&[)U>+U*\V0O'DW#KT2?Y
MV.TH%R0TN)4MEZ:[L"]BX9/"CK46$M-V G1;8E4.@.:&;QPM)A[A96NV&E]B
MDNH#8VW.)OZA%1-TLME(@-DU_=2K;#OVC='2EAE,$KN*L>4*-( F_^3-<.+N
MQG2[M7WPJSXA+V4U?[X,O@HLD>Z9Q+:>!3!]EP,2(+[]X,>@"R4="8JP?2G;
MJ#9*@WRVV.D+Y,<LX/8I' '-#]]J\'I ,>7U%6>ZN%T?:YG?&=XFB/%5AV2S
M[#VO7D6Y! +KQ,9>:NM-],M%CX<\E7R)[TV815KGMUK7GNDO/7?%J^9ZXIP^
M>3/4I:HO,8!I:W"K%6N7#*-DBUK:LNCX"?2(3VXW5Y6HT%9X-&$/??Y412CC
MP=,IQ,CQ[:_/^[N7^:B)_*ANJ84-$JS!JU2_'^O"UA9D7R,![PS&_O/YU?^;
MDY:DDGS)\!73K6P_CPDQ'Q*U ZUV=BQ:Y<W F!10#"%GCACI@Y='%&R, 8_[
M_OA,*;G\<JG,2<]UR>FI[1%0@H".)0P35EKXM.,:B^:$DQN[?J)&L'EZDA]3
MY:? 0[?VH+F^P9NGS@HV)MA^XZ2<)'?O)\.;=/\X@&?O2!KK<8O.B8D5&LNM
M*,=UI^H&O=S+OD6Q-?DQ1(8PYZ8T('5"I"0#/)3[ILS (5%O5['/+7>ZK1O:
M7Z9U)QCC\[H*BN>Y])#H+G=OZS5>3EF5]2VG9L,:?:A1HDS0HP?HR^:'/-^4
MF[T)A?2B>&UQ_L65(V;[L@"MFB?F)Z,1D.+_#3[7]>_T[_3_<V)$?OW_ %!+
M P04    "  ZB&-4P.E>6BS*   KLP$ %    &5O;',M,C R,3$R,S%?9S,N
M:G!G['P'7%1)MO=M,DB4)D<E@V203(,("(CD*$%RSCFV@H*V! 4!17(0R:(@
M08*2D9Q!D9R3Y-S=7Z/.C#-O9G>_M]_WW-UG\:OF=-T*YYPZ=>I_SZW;R!'D
M)$"LK*"D (#00$ 'Z@] 3N/K*\G)F:IKJBDH794'0"  P+]RU<[9!8T8 )R<
M/=TU%2\QZAL8,F)W 6@ +H %\ . F86'JZJ6@C: 2DKR<HP>J$K []+>$  Z
M_=_/?46=D1'XOTLD%J[NG@  4D?1@I96'A8H^C:*=O3Q=#TMWT#18'.'4QH-
MXY1V1S&(HBE/:9NO](4O=;[2,J>TI9.S)8H^Y=G5TLGRE&Y$T7>]O:Q0-/I5
M%!WF;6?E@Z('4#2SHY>3'8H^.&WK9&7F 0 8^*?EGE86MBB:#T7CNVMKRJ%H
M20# P;?YCC;_CO:T\O4\%4K.Q=7/W<[&UI.1W8*#D5],3)3QBI6/HY6G)[>Z
MF86#F;LEHYR+DZN9LQ\ ?)7Y2SI[JEM&E)(O\HM=O,@MP,/_G:+^YL5_,)W.
M[5=J6^/+G('(.WXK^[-Z+AD (+J+TLV#W\K,GP! ^1T H/SP6QES&@ 0H>;M
M=?=W\I"?VHNMIZ>K."^OCX\/CYV5!<^I0G]-?[?"/Y"^&X_GM+M?U<-XV<K:
MS,O1D_%4;Q8NCBY>[HP>KF865HS<?S3B_W;#/^?C@J:5M96[E3.JA2[*RNR<
M;5#3[6QIYVGGXLQHY_Q7D_C?;/:']-6N48DT"P& 37D XFXP@+[6 6"0G@'0
MC5)05T"_SMM57%W@=.7I,2Q\M?LO"?1?>T6+/OWPL+/YTDY.4YO1PLO=^^NU
MTV4)8 )X !$ !J@ >H )8 >X 0% !)  9 !Y0!E0 [0! \ $L !L 2? '? !
M H%;0!AP'W@ Q &)0"J0!>0"1<!+H!RH!MX!S4 [T ,, A^!26 .6 $V@#W@
M& 0"88,(0*0@*A #B 7$!1( B8*D0?*@JR!-D 'H!L@&Y SR @6"0D'W03&@
M1% Z*!=4 JH$O0.U@7I!HZ IT!)H"W2$AHZ&CP9&HT-C1>-%$T6315-!TT8S
M1K-!<T/S1[N-%H7V&"T#K0#M-=H[M':T0;1)M!6T770 _0PZ.?HY=&YT470Y
M=#5T0W1K='?T8'08>CQZ!GH1>A5Z"WH_^B3Z*OHA!A8&*08C!C>&!,85#!T,
M"PPWC&","(Q$C.<8KS$:,?HQIC V,!"8!)BTF%R8XIA*F/J8-I@^F&&8\9C/
M,,LPFS ',><P]["PL,BQV+!$L*Y@&6#98P5@16 E8Q5CO<7JQ9K!VL7&QJ;"
MYL*6PE;#-L/VQ [#?H)=@%V'W8<]AWV <P:' 4< 1P''$,<9)P0G'B</IQ:G
M#V<!YQB7&)<%5QQ7#=<2UP\W&C<+MPJW&W<.]QB/!(\-3PI/&\\>[Q;>8[PB
MO":\,;SM,V?.G#\C=D;CC-V9FV<>GWEQIO7,U)E#_+/XG/AR^$;X7OA1^#GX
M;_%'\;<)" A8"60(# D\":((<@D:",8)#@A)"7D(E0@M":&$3PE?$_81KA/A
M$K$0R1*9$/D3Q1.](NHF6B7&)68EEB,V(PXF?DI<23Q,O$M"2L)/HD;B1!)!
MDD?21K)X%OLLZUGYLY9G;Y_-/-MP=H84G92)5([4@C24-(NTB70.C 5F RN!
M[<'WP87@+O &V5DR(3)=,E^RIV0U9)/DZ.2LY$KDCN31Y"_)A\B/*.@H9"FL
M*.Y1%%'T4>Q3TE#*4%I1PBB+*0<ICZ@8J>2I'*@>4I53?:+&H.:DUJ#VH4ZA
M;J)>I0'32-!8T,!H7M)\H$6CY:35I V@S:3MH-VEHZ=3I'.E>T+70+=*3TXO
M0V]/_XB^EGZ)@91!FL&.X1%#'<,R(QFC+*,CXV/&1L:-<[3GKISS.I=^KNO<
M\7FV\SKG0\X7G__$A,<DRF3-](BIGFF#F8%9E3F0.9_Y PLNBRB++4L"2PO+
M/BL;JQYK.&LYZR(;)9L2FS];/ML8.P$[A-V-/8-]@ .+0Y3#@2.9HX<3C5.8
MTY;S*6<W%QK712X[KF2NW@N8%\0N.%_(N##,C<\MR^W-G<\]Q4/.<Y4GA*><
M9YV7F=>0]R%O"R^"3YC/D2^+[R/_67YE_A#^*OXM 4X!"X&G @."!((*@E#!
M"L%-(2XA*Z$4H1%A4F%5X7#A>F'X19&+[A>++BZ),(O<$$D2&18%BZJ+1HBV
MBF&*71*#BE6+'8I?%/<4?RG^68);PD$B3V)1DDW22C)+<D;JO)295+K4I#2C
M] WI-.E)R#F(&20#,BW#)&,I\TQF099#UEZV0';]$M\E]TMEE_;EQ.6"Y-Y>
M1K^L>!EVN4O^K+R.?*+\N,)Y!1N%?(4-16'% ,6W5S"OJ%QY>&58B4[)0BE7
M:4-91#E(N5$%7T5+)5%E^BKG5?>K5:IHJLJJL:ICUUBN.5\K5P/4E-1BU3ZI
MLZF[J;_1P-)0UWBJ,:_)KQFHV:)%JF6JE:>UIWU).UK[HPZ[CI=.O2Z1KI%N
MKNZ^WF6]&+U)?5[](/UV VH#.X,*0VQ#7<-GAKO7Y:_'79\S$C8*,QHR9C/V
M-6XSH39Q-*DQ)3(U,WUU _.&WHV\&R=F:F899KOF2N9)YAL6<A8)%BN6,I:/
M+)>LI*QBK!:LI:QCK!=MI&QB;99L(;;QMJMV<G:)=IOV5^Q3[?<=U!QR')".
M>H[%3CA.-YPJG<\Z.S@WNM"[^+KTNG*YAKE.NHF[Q;EMN*NX/_, >1A[5'B"
M46"JPXO=ZX[7E+>T]U/O Q]=GU>^)+[.OAU^G'[W_!;\%?RS S "+ +J \\%
MW@J<"I(-2@\&!9L'UT.9H+>A<S<5;SZ_A7?+X59G"%](3,A.J%YHU6VZVS=O
MS]Q1O),?1ACF'C8<+A&>>A?CKMW=KGN"]Y[<0\ L8>_O\]V/OW\281'Q/I(_
M\G$D,LHZJBOZ8G3* ZP'S@^&'D(>/H\AB?&/F8E5C7W]B/$1[-%.G&E<6[Q0
M?&H"7H)7PN3CJX\KGC _>?#D)-$V<?#II:?%2;1)]Y+VDRV3^U)D4HI2Z5+O
MIQZEV:6-I"NFO\Y@S8C/Q,KTSIS/TLUJR1;-SGU&_>S^,WB.<\[D<\WGC;DB
MN;EYM'G1^6CY7OE+!48%/867"RN*N(O2B\F+[[\ 7GB]6"ZY43+T4N5E_2O1
M5T6E+*5)9:1EL->@UWZO-\IMRR<K#"IZ*Y4KZZLDJLK>\+S)J3Y7_;2&K":Z
M%J_V=BVRSK]N]ZWKV]5W-N]FZDWK/S;H-PPT:C1V-:DTM38K-#>TR+;4M4JU
M5K>)MU6^%WU?WGZQ_76'<$=9IW!G6=?%KM?=(MT5/6(]5;V2O;5]D+YW_9?[
MFP>4!MH'KPWV#ND,C0P;#4^.6(XLCCJ.;G[P_G#\\>88YACL$_&G^'':\8P)
MCHGBR8N3-5.7ISJFM:8_SEC,K,QZS)[,W9XGF(]?8%C(7118K%Y26.I9OKX\
MM^*Z<KP:MD:REK3.OE[Z6>9SQX;^QMRF^R9R*V*;:CMG1VBG?E=]=WS/:>]X
M'W9 =?#\4/2PY4CO:.'8YP3[Y#&< UZ%4$&,(9V02.0Z0"AKZ6)N!5A^P0_(
MCX <@(^#0X-'<YZ$@IF3F9:&D9F+G9V1F8.%A9^7A8.'DXM+C(N3AU=(6%A8
MB%?BS])I)R"",V>("8E1'IA9@/T<NX"$D(" P'^I*7.:OG[^,9UV@O9/=_(6
M(,'!(,<)0P?. R 2$!H)&K(18$ )B@GZDGY!22 T= Q,+&P<7+PSJ IEQ  :
M"!T=#0,=$Q,#!9) 0:CK  8)YMES_+)8I!IFV.?=P *W'J;C,%TJ>4>FV;O!
M+&CN'H*+1TY!247-PLK&SL$I)'Q11%1,7.ZRO(+B%25E+6T=73T4>K.PM+*V
ML;6S]_#T\O;Q]?,/O7TG+/SN/5A,[*.X^(3'3Q(S,K.RG^4\S\U[^:JT['5Y
M1655?4-C4W-+:]O[OOZ!P:'AD=$/4],SLW/S"XM+RYM;VSN[>_L'AT>G<H$
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MW+NKY]3-L:"AZ1"71.*HE?\&"=P.'C)!XPG*9]#;R(G'?Q'C-AB@Z>OCOK@
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MTQTI7EA'],)D*K)N235EP/AE,+G//2L$%19)PP25Y&])W*%*P^,X3G?M!&O
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M8\IK!(.TBO!FZ.&0?\3@FLFL44<?X6TDP)E/:ZU)XI\XG[B_&FV*/\:N^#3
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M-*;[];B&:QTY9&8<<K0,V2$O2JBOVUS"AKNKP3'TA#<M$%(SJ/E"+2M9^Z5
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MFKLW*4[\NU%*LT0Y,0*W5-RZN3KX2R0PNO+JKZXLHO<L_F"NN?Z ;%8=_E
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MM\<^+:2-&342!<VCK:8JJ0R-P$WQC\QOHUO J]PM(+$DI&E3_&9C2ME1TLL
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MX4T"V'Z =3([9OTK^W4%Q"Q*G%IKR7;\L4^T%8YP(2%JURT@P9  (51VX1;
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MY]D:$EFP!4CBI3]@'TKJ(2N>N8EG&)&UBDP>&AD90YCWC$='1 S'N%^]$23
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MHN'TA\<CE_6^\E'IRF:>Z1=NW<5!2$Y/[YREG"WC.\LE'HPIU'V?,[X%K"8
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M>OUJVW#NR&LAEHC.0AD=$ %&VH9^UT;YGHV8Q:F+M&RX 6W:X&LD2][W=6S
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MBX\J']4OOA*FD;5X+X)V[D0=TXT4V*D%1C"F,WT<A.:^?8I^5/B,_=)9<FI
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M9Q$Y_.J9X!@%3W!+S;#Y)M#5OL$B_M/I+<RA6DGZE16GJGG=CYM [0NQO9M
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M%%[M#D<XJR)#+NEYLB4GA^[KYR_(,%A,JA6D"G(W-;$O ;0B5*.,)AFG,SR
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M2;K&(Q.>$] M+)"Q:8@%OM1 D+52Z=188."P&#)GV(0V^H$._HG]$_LG]C^
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M(/5PR)H?# SG-<'P1O]F-\W#6NE>R+^%%_J)_1/[?QK[=GW0+<7QIGEQ&-F
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M^4?)^2^AJVEQ1OU8?:^(A0#'L%KP9B%$>289([V$!3RP %<S7!W].A-36W4
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M0P].%?D_SO@>-?KO *X'-*UVC>Q1+"\U[),TB1;U:&)B'HM]IPEC9Z^&&FE
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M6,"Z_^3Z*RQ@4@91/GB->SD7IG"Z0(>1KY\]"L"Q4S?]\%3TX /Y[_NP_UG
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MP!T;\MEA1^<]T*N[JD:OJW4YD[_@X0;)$."BL"[2,V"I(1!U(K"".CE8=T5
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M%I=4W+TXGV"QFRI;F9=&XZB0@0$B#QDR37WEC>P[2E!FA$+TMP$,/8TWR==
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M,WX#?8O(\5D('I>0-.FVAP/(/,I@:K-U5&JT0<EJK'#Y!Z08^%SK'*"<N^9
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MY\.>C%GIO25U#<C*,"[=(+_NC+UA=5)D47="L6K)SH5@-[YX6K8_D_-";$.
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M_B*OK8<B.Q&=U(R_=DP.R#'28,1$]J8<DV:J<\YDNPNCWDFRN@PT2IL@=^/
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M%%*/)31A X>52O PAJ!3I<34>XHNBD5REO'Q$4M-.ZONC4W8PMM8S4\FPC'
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MH!U6QC[/C-ORUR?:F[;&]7G#]PI9&]PR3$,^DV]O"L&SZ@TIBF>9%SII3KV
MM/ %%8RG/HQ3)"'B:H*%];(.9JGOL2@((C^TD9#C3<U-0?0":P,5]+&VJZN6
MSL\)ALTDQ UO(RO(4,JL9>,\&TY5XT1SDXK&>;-?:H;!'<,DX]W#XS)_%N*3
M$J*,B2.IN99U5]:!D1\%R^]7>M^\B9RLSX5N5S"QY%[ $JI<%4(A"A&"-$ "
MIC0)TR2(0L02&YUQC&]NXG0PL][V-,U5E\FA24/>"UJX M</.C[A@O5HUUUO
M)H"OV*%C;^]-TY?6(CL2XTZ5V37&2>5\)()?C@%C-3-PX&CSKZE'=T@RMH@3
M'TM?EY]'5.\>A@2F(@TAEG'DR3!F ;9R,P^V,C<1_U548)F7O9+O5X!JH$[J
MP1\FVE!L+Z5O[*EJET11 6RRS%Z!&J-#]3M%@5L-.]C2M$ITRM@]/3EY\<4I
M/9I@ADV*B@_J ^D[K^6G-?U/P:K/N1H6LZ*6K$60("]!2B]B'(00"<R@<B.I
M+F 3"<))2HC50M=E<.:F,[UT'UIM6!_^%2@; W2A8[$Q87#ZCR&]9Z9)T_7)
MR.)U((1+Y\/N^DA;LS-]5K_]M.VC=^?[Z)(4(A=0.U9>D2&07BO9R 7TG<A
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MD*"(03\.4X1(DD:!4>&RHRW,S<]H0((-2M# -).&XSR>U@,G[(PL K;$&,O
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MCVS5*0>B$*04Y4=1KI?ZG=8Y!]K _.8XDKKZ+B^SNBCLPB=)P#PA(:9II,-
M*$PQDI#'/.4R)6'"K#*NNH$U-[W8P->;\ZQ!#9X%*?1\"3QVL.V<"4<]:.9Y
M3-\O(XO4B>B*SBBP,:J)BFS-ZLY@ZIONSG:=M6/CEFFG7I C:).Z3&[I?.E?
M.7[ZP*,2V2JKQ(?L28<45NHEUR5.KW56^_*#&BIN*O%0+M*(IBC!/O1UO -"
M7@*IX QZJJ^)Y#*DR&K69M+HW&2XP0QKT&"+&C2PP>\:.*B16^Y_&O6 F="Z
MYG5D&75!J?W)"PN.W![!,&EXVK,8%E3L'<JPN7?@6<QM78#K%:^7\K_D2WTD
M6I<%J)X7@4AHS#&%,?>HGCCZD(8IAD1-&@6B?BC]U.I\YID&K21I@C.;=<%E
ML-RBKI=MRQ[N__D/./"3?P*BQ@]^X'6=ZLJR#NG9CC!3)Y?TCJQ,'UYPV@!T
M>-33D JWQS_/-3KMD5!#"O:.B9K>=W&-I$;-=&A(^[,VA?I."<\5WP2J/CPN
M\V>Q\^N%]*4,/"E@&L0)1 GA$(<RA)X(I,_2A*I)KHWGY!;>W'RL:\:*M?(%
M6 _CX'I*+KK/3-A>KU-&EL&=:DR-:5=- %OWBTU%DYU:REHR>P<.6B-WKAFE
M8I-#]L<JZ.0"XFO5>W)([XER4"Y;&38&W%9?1-%J46^XZ=+F""\)?1DED-.4
M012A!*8ITJF,=,ED[/F(&"7M,VMN;AI=HP6D56HQJ##4&8+-5-<=;2.K:,-8
M-[;M%+5SGH7(C!2GXG:FR4G%RLS\E^)C>-<P,=%%/74T\=^RZLN;M9J</8BB
M:^2Y>^-C%$>4!#%D.(P@4O] 0OT(^BCV,19QY".C+5";1N<F+-T'4H@GL5J+
MNO:ZMJ$_P;63&2/JS<3&-:$C2TX'%WQ5>$$'^&HC/L\C2(\-14X%R*CA267(
MAHJ78F1UKYTDE46UJ".^="C')R96I,CRZV]9N<!I1!+A88A2AB#B.(0I]E.8
MJ!^R1%+,&#?1GZ,MS$UL.FS@=XW.<,7^.'^G1<0)*R,KABDAQK)PUNA3&J!N
M[GW_ZF\OO_WC3Y_D0S]K7/=5G[]P8(3E%U*(GTDI^,ZTJ"A4G]9ME3\_;Z^Y
M(\_Z9]?Z6/3M8[UM^.Z;S@"K//>;-E'LWT1V_Z42_/I)%.1>=+^_*S(F%MAC
MJ?),?(@8]R#2]6,P01X4"4EB1B0C(;$*VYP4_MS$IP/'P0_9"O!\N21%"1[5
M)*'4-ENNSD_\*ICY2_/MX+%U5!L%J;9J=TVL;[O.W-2_L+4?U 1<@98"G:JC
M)0&H]Z2AX0IT1("6B<U5H.;"893LJ_2AV]#;:4V8-I[W5;IG+TCX=5 ,'#5%
M\:2>TH;-2R\,J')LH2>(&MEH$$$:^3'T0B;CQ(\)]D.K0:W_]+F-.2VX;G9M
M.<3L\&8X @QE8VR!;HD8X53!(8O=RME."].JS2'C]L3@X$7#OM5KSNL -[*\
M(QF_6;TACUE%E@L4>!%GO@=]D>K"8B2!-$88IA[F+!9(^KY5WHTC[<SM^]W"
M!(\*)U0. 6N0VGW*QV@U^Z@=D#7RY]WC24/4CM.;,SQ9?^AG6'#ZR1]K:]*/
M_XS!+V7@W.7CA(-MDL8(X7L>5@,Y]76T:AK$$'./01J&7HPQ"TAJM)AEV_#<
M)./#S?7/-Q]N/M^\^P2N?WT+/GV^??/O_W;[X>V[CY^ZP+!W_]]O-Y__PVTX
MF&7VGC'H'5ED#H>'C9++QY:=22/&7B?+CRTEMA%DCK+H=G'\;T7SWYO5-6MJ
M:;253!:,,4H(EA!QB=6_TA12IOX:QH(E*8^5?%F50SK;XMP4JH/753^RSO%P
MAF S 7)*V\C*LSE>]$.']D?MXFR(O#M#Y) $#6;DN$[)<*;5J9,PF)%P(.V"
MX8T#)TF[3U-R=CRJ)I%"A#*@,/(CY19AYD$<\!!&(0T9Y9QXGE6TO$7;5KHS
M0>#\]4712S:D&TZKQJ%R[*G6"]&I7:%IPIP&$.9V5F;1_K0S-7MB]F9O QXQ
M,,[RL<[&M;IO(SRWY3QXG+"("5\Y141 )(, $AR&$%,>DY#[' NKL/FC+<W-
M(]H W6C3/UJ&5A[EU$R*G# ULO!L2>I CC+U.DN%VS#*HZU-&T%YSNB]X,FS
M-PS-$G.S4E]<74-(O"45Z8;4P$->$$<2^H&:,"'?EY F7@QC+N*(AR)* Z,%
MX',-S4T:VLPH/;! HST[N-JQ>UHE7'(VLD@,I6M 2IG37%R86^;(PR=.,G/:
MQ/UL,V>NO[PXZR^D6A>U+_)1/#:[RN6MO"NR%<L>R?):JO;_0Y#BO4*P($$2
MI)'2B,3'RIV( PQ3'T5*,N*8^XA%GK3:Z1T*9&Z2\OF+4--2C7!X+5>KCC!<
M$9Z WK%7B'6-V,]=C5B=%;@VX_D*U'0##1EHS..4CQW"VFBE9JW O%I9VB&4
MG2IA.^AYSG.X7#_HY'+_50?EM Y:W:AZT1<)QX$7)REDF.G(;^SKL\D,^D1(
MRKGT*;(J93D,QMPT4;W0D;,$+J?H-]/"\4D=60E/)GFYJF=PK(YF[%ESU>JC
M C%)XA<#)J=*!7,*RER2PQC099$NQN1IPW2QB3[X]VS%:W=4E-4BE5Y*!(^@
MC(0'$?-"2*(H@#2(&$(Q3E!BM>6VW\3<].RNB1:"?RB,(&M!@GRES]<]"<6\
M_AA7>66Y^7: 6S-!NXRQD<6J(TO# QT^=Q)TW':G\G*@F4FEX[B9+V7AQ)7V
M1]M^41KSL'YHHU13YK,PP @&05UC5N>L8R&!<1C'E 8D]#VCY*)[3Y[;!]Z"
M,S_"MLO3Z:_V(NM'_EA;7 XC>8]:>_%9M=VG3G9&[: Q_;-IAR\84O!*A]'<
ME.5:\/?Y]C!]E=TWA09$52WK\P#M$+_@@OL)2Q+("4H@0AC#-. !E&$:H)#Z
MPC".=U#K<_N&-72B>E/7/6'YPX,:GNLT;CJV0WQC7_1A"B#S BPW-H%R8U2W
M5V13Q<FVNT[+Q.B=,+*4U-!!@UU7.>YM8V_XWN+OMIW&Y-NF>-:(O$]50\LM
M_Y:EM ;R=[JBENU#)RRL-=#>W?I:0Q\R,%2@N">K=I*H"WGERXQWF:#NU)O8
MO:*W4LTTE9)F9+DY=EUN2SM^%M^JGQ41?RQ8Z(5(^FKFES("441#2$,4PB!1
M/F,8TS"T.T;B&N#<1JBWHF1%]MC5ES];F6&:7C2;<KYFWXP\</5-NP([QM7A
M6'WSZJ)JG8%@:^%..5IM)*BM=!E),5('N W < URVKB-D2C>"_<8JYUAXT*G
M0V_R!ZK::U'I<!35WD[%Q_Z1Y#>U0WVS:JK9W<HCMVS2[OB+R(]2A%$*4<("
MB @6D 94PB1)O"CT1<B)-*O2.S%R&ZV:ILSO1_%$ENN-(K&-!:#(G\FR>@8Y
M779.7Y6#=T_Y<EWJS8"5/J-A-^),]7Z8#40S[/.1QZ?.8M SN1ZGNC[?+9/;
M-UM=ULQ[]?F&VG3]NAR[M9?;S-VX-7%_.1W.IL(^Z2@W<8>\'/RF;GY@F)1"
M*,0F+O.#/GBR>7B;@:-\NZYWV3Y_S1=4,B12C\,D]G3R21Q!$@4(2H28#!#'
M ?.LHJ/LVI_;3$=]3Z%E.)0EX6:#Q8@TCBSZ#7*=QZB+TZ[![Z2?5 ,[%?41
M_7:S7YG@,!9J&'=N0Z L,4P;^32,H+V IX&/&:TV0YW*=R$3GW,<,QAQSO51
MMP02S ED@<=9P#V1"JO"@J8-STW*FLS3O$O63VKLS@LJ-)R;B=H83(ZL9A9%
M$&KHDU8VV"%KZIH%3>-SJT:P0\F .@.[]P]--+94O[W_BU@I95SJ(W3\(5ME
M^F",#HGO-GGB@ 7"#Q+H!WZ@=(KJ3"4R@;&@J0P#(;&P\KS,FIV;2K6HK\!]
M@[M>N"0[R&W3E1FQ;Z98[CD=>R^SH_,O/3IW0;O;0!O&DN.D:$9-3YPMS8:.
M_31J5G</#(XLLKQH,BY^%&RI?(-,9JR9O/+_7)>5]MUZNSZ+@"'&!=*;91A!
MY$4I3).(0=^/PP"%293:I56R!3 WV7H)VM*QLN;?3*[&9'5DX7J)MRDJ18IV
M.@&V^,'O=_DR8\]@E-VJH12ZC>&T!3%MA.= BO;B/X<^9ZCFM:Y>';U0IZ4M
MK]?5E[S0-9@7L8?"R/<HC#T<*X4+ D@C2:"NSB(I\5%"?#N%.]7<W/1L@[8)
M/;MJDI&7@&P0U^G*FY]:YB@_0[RIM+FB<V0AVS+YJ6&RP0JV8%V*E0DICJ7I
M9),3"Y&)^?NR8W37,)$Y4M9]$:! TH SB%*J)GN!3V&J*X,&/$!Q$H0DYO'B
ML=;"3Q4I*C.-.=*:S=?PLLT1=P/%?;9:Z05A2I8ZWM5.18XQ&R$J@D"_J#@4
M$#'!( F0\E$1B26+/5](VC+[;L4GYK5K<3Q650O.*3539 <DC2S%?83UHEV'
MT9T"GR'!J?0>:VM2S3UC\$NQ/7?YX.R:^8/0RWB-;E?/;_,'DJT67'J>+^,0
M!M17$A SG0<X]2'QXY1+I;AI(BR3:AYL:&[N6X.S6:3ND(+?&ZR&]:W.<FNF
M"BX8&UD6AI$U)'GF229<Y\P\W-C4J3)/FGP@0^;IZX=FCWI3'Z/I.7BWZZJL
M2#U6+D@J8\89@1Z/U$Q/O2\0$]^#DD688T:B2$B['%*GFIN;5+2ID1K(+^8H
M/=BV&:5.,GY:.MSS.+* 7$KA@"Q3)LQ<F&OJ9!,39YPR,7<_[Y3170-S[3Z1
M;*DS8K[/BT]D*722ET^"M4E>KAE;/ZR7I!+\+T5>EMKK(4OM\_Q%J=G/0N:%
M5KE%$,5,HB11<[]8IZ(*L5Y%3R".4Q&1.$0TL$I X 35W 1*@[--RNND=\P<
MG,DY'UG,-'ZP-> *; R$"BPLE8E7H&<6J.T"6\. MNP*T-HV[54YS/3KDFNW
M.8"=()LV.[!+,O?R!CM]^%"W[YIS]6F4]9F3V^*NR)\R18T^;<YPJ!37\R,"
MD60(4LH\& >2<8PYXLQH5GBNH;DI:>NGM&"OFE-?BE+0 ;9U\H[P:^K>7<[:
M-([= ,(&N'2GV;C0F3OR\(G=N-,F[CMP9ZX?DIE"^X%=@H7K^T+44?EW0KTP
MJXK<BUM97_$V*Q_S4MPU6?D6J5XM\KD/TSA2?EKHAY"BF,( RY"'G&"$C*(=
MAD.8FY34$$'69:H@G1E7NG)Q:X@^H5-O$ +>V%)7-7Y6UMCD2AC48:<5:)IN
M&%F;FA[8Y JYWO; W4X/-->U9NC?U1'VH_> 3<J*L7MBJKP5X_2(9?Z*2\@\
MG<1BT),GS&1QB>6[Z2PN>M+%!0W;_-B;6@TX5<XIQQ1Z7AKJ30P=B>+%,$T)
M#X-(^; ^&UC"\$53<QME6GC]^C&#JQ.^9-5L=N^&JY&'@D/E=<:N/WB$C;$J
M#KYL[K5J#!XQ^T15P6-WC)[U_F:UR2Y,*6&(Q2D,(XZ4_XH1Q)(Q&*3J'\QD
M+%.K;=!!*.8F+O:YG8>1;R@T8U,ZM@8=S7$_0O;FB\AZK=3V/21SS6N_3]8%
M2>T//&S@^:EM=K&WJL'5?1,C_%>R7(M?Q=?Z-^4B%32((^;#@ L,48(EI#+"
M,$ X%"R* AJE5L>G3%J=FZ8=2QUI>63*B' S77-.X]C3ZG[RP08Q:"!?@1KT
M%5"PFPL<QHU9T>3VQ)11R],>F+(A8^^\E-7-0\^>T^I0!CH_""C# 8*^YTOE
M9Z4I))%/8>CAF)"0I$B$BY4PC.8]THK1QY(V'TO7UGC?2SWD?\B)[1;M,0I%
M%*>,IEB]J4RYJL(GD(2,PRBA">=A2+6,6^76NH3&27-AO27B:Z[&5YW+:).,
M_U?K9/S'F#73:P=L3;%!/7J6PC,\.#Y=?[BMB0_3GS1X_^S\Z<L'[,U<L[^O
MLT+PICS(\D!YD$;*;^6[;Y58E75B0:T_Y<^D%/QV]49]-"1;J:MD7CQH/^BC
MJ!]9NZ8++$F(I">5)O,(HB"*8)J&RD/$@: IY0GWC>+\I@ [-\=R8P1H#C)8
M[!^,W:T&>STSZJR1Q;&S%+25EI9'*BTU]H);";8]J_Y2VPQJH\'M"K1F@Y[=
MH&_XC-X"B_VF&;T-$^U,S>2ML-O)FJB;3NYYC8UANMVQB=C<V4>;JLV!RTKL
MB^#KI= Y&!\>\U6S?+4Y@M FUFA/*'W6L6Q;7SKAH0R1'T.6B@ BA!A,U;\A
MP])C,6:,>5:'PR_ ,C=/H3.ER<_:&5/_K=V9TBEH-NFR>H=OK IIN.A%PQ6L
M:?IF['6MH]VRWP/@A]::']7D2ALT3FH-!\2Z70F[ ,^TZV.7$[>W:N;@D0-E
M6(=2U'JO6U:MO$R9^_/S]I(VB^3U5U+PVSH)2/GNFRA85FI(?Q/9_9=*\.LG
M49![T?Y&W!49$PO*.6+Z &B*I=X#C0FD<2BA'],@3*3/O8182?8TN.<F[QU6
MT((%'5I0P[T"/;OJ%"$\7RY)4=:Q?W4TH&6VD*G>#\/!8'Z]/O; H<V!M';^
M^S;WT[,#^@SZU[6&@]IRG?JWMGWGW;@"9]XDA^/,M'WF=DR:"/NTX]>T';(W
MUDW<_, Z[B0KZDVKF]7CNBH_B">Q#-LRG1&EP@N(A%' 4GUBF4/*4 @Q1X%4
M\P^>>HE5L?;C;<UM_*FQ <N<[*>X---]1PR-K-4:9;=+W0"] BUA#@NC6G#B
MME#ZB?:FK89^WO"]DN<&MUQ2X*%.MEXVB1"W$UPBDRB.,(4280\BCU%(PE"-
MTE&:)$C@Q!=6=>U.M#4_G= @AY1N.$REF4PX(FADF>A*,C0XQ\V?:<#("(46
M#K?W"D453AI^N(#"Z5L&[*NJ67RAG_E6-/^]61VNT9")<I$D'N&A1R&5Q(<H
MX!1BG4?-YY*3B"G'@R/C/5*+AN<F']MJ)4N-%"QM3R!8,V^PC3D2GR.K38<:
M_-#A_E$Y)R_KP=B?\;!FV&*+<"2F)]KN<\BXW9;= -I.;K_9/&^ZK;0!5NYL
MBPVY?X#LZXTT'9CWGK Z978[WV%Q)+%,"$1(1\&$PH>I9!+Z0K P(BS!PFCN
M>**-N8GY)D81=#@M%.8(C09R?3DY(ROS/B_G9XG&!%FH[>5$322L0PBS4]#3
M5)P4RR.W3J>+I['O2."92P?FY&),UU34(=_:>=9Y9KK#G@'V&2)!  E!"41Q
MJOZ4>@1*3X9IE#*!@L JT=;1IN:F?5NDH(-J<C34EF"SZ;$;VD96Q8&,V2>S
M.DN&VPQ5QYN;-NW46;/W<DF=O^."K6=Z?B. 'MD(Z*43?+$1\%'HM*7JY[J\
MJT:Z)DNM><&"$^Z%?L!4#R4I1-+'D$@<0QS[*/$)(BBRJ_(UO0USDSCK+*6O
MV?\6V\SS[=7O:,NYQ\2!+><-&Z!'1QWOZGC[^77ZTOU6],1V3+\M_3H==7"+
M^I6@#!M+>X^[I<OLOIGV$1G& :(1%*&N%9?$(4Q)$D(9^2Q!A(B4AC:CW<%6
MYC8>;4NZ@R)_)DLU2\PW8,$C>:YCHZH<O'O*E^M2YT98*:(M-ZL.$VXVO%Q,
MX\@#0%^,MP#=2?))^YV*YN&6)I6UD\:^%)[3%P\LM+;)#;$YFZU#^=_D954N
MO#0@$2<$JO]0B'P_@"GR!&1))&GDA\0GT6(E[G6NV,\6U=9.M&GTHF\.4+]H
M>;R7OH,,9%Z 7$I1YQY@&K%E?;53?)L)Q,7T351;K:-,9]7;)&ZH#R2].<F;
M?64U T+<UE4[U>"T5=4,3-^KJ69RC]-L,$V"_VUV$A$% 25Q#!.68HB$3@<3
M4@8%]H,P8E$<8.H@'<R+9N?FBAS+!S.\>*,A_8;37.>DCCTS/9$=ID$]:7J8
M(T1-D1_F9=-S2!!SA [###''[AZ2R6#-L^IF51]:K"=N9LOD)^^=T5=00P0]
MC-8["J=9LCG+[8"MJ0YAOV3-U3GI,Q2</N!\[.8)3R:?P;][I/C<Q8.W#@LE
M!W=%+D6ISR&3Y7NQR=VY8,)/4ADK;>21<B;\6$*2QBE,:(1BRA#AW&K1_G1S
M<W,B6K3@L0<7E*)XRIAMA.T9GHUW$1VQ-_Y.8DU<'RG04#=9>IWN)AJ0XGI'
M\5234^\J&IA_8&?1Y*X!'H!Z)!."E^\5TFXR]#XO.G^\/F;;U2:[6;W)5RO!
MM)[]+:N^O/O[.JN>;U8ZVWCV).[4.[6@OI]B1CB40E<*0TJ+TI3Z4"#?EZD?
M(AD;1?*/ 6YN>G5TTJ/F/&QC#/BJK %99P@0M6'@43W*PH=QW<\&#N(K]M[8
MRSFM94";!G[8K.XHZW[<KNS<RIU*BSJR=6LDT%:"QDRPL1/<O6ZO6CBTK]B[
M$_G!K]3+=D[U2-UPTA=WW>9T+OQ(;.UX_F.U,7"[LW$1W@MU"UGN9<A8L,2+
MF?35 !T3#Z*013 - P_Z(9721VF,J54VZC/MS6T(;G%:[FB>X=1P;],=4V/O
M<K;YD%JHAS/P.-ST-"/&[?;GF3:GW0@U(V!O2]3PMF%"<OCHQ_-")BGS I9
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M7Z62>DDS+9E&-Y7^8?N[-LK_I*)P6TFXVF>6/GS N.O-9:8RR D"-,V%\8"
M $N< ?W;A$K,8DZ</"!""#FUQ:QQA^('4KIQ:9"!M"/;UQZ>P&R\5:5QVJ@5
MG-4_[_[0*CD[+JAJ_(ZWBLZBSKJK1EM_K!UR++S2>A!!1^7]D%"?+@Q!^[K1
M^^WM#_J]7-;-?I)+NC#[)"W -E"XW43-*<)(+P(0T"+A>@.3,T 4S$#,$6-9
M+G.26!6+&MC_U/A^N\_?Y6PP=/&XE5_O:!9TTQ1W*1N7L8UFG.]T8V0;Z%!G
M.5!VI!\0_L!\?N""=R"[R3RP!=\,Q2[[0*M  .\\-^3"N.U9RO Z_GQN '4Z
M^CDV,R!IC2GJN5HV^6^$*$U/=/&&/I8;NJ@)N/HL*[E^ED*MUN^>-D]KN2W/
M-\<TSU4"&>",0@ 3D@/=@000(I$5(H4HMW(&O%60R1'D3OZHJB77G-B(7I?J
MW&6W_*E<M@_\[)"*Y981ZR?(,<<A,%,V6FS=TPX&I-6D,6JKZ//AP#3:[ J"
MCC0F#OER1AJ;D1+H!!TCMYPZ'H#M3;)S2_OC9=WQ@,)1&AX?[0W-RU-W4OYO
MLW=XTJS_9:4V?^D^MY)4<UC(%!8D RB3"8 4*L 2FH&$P5SE"G&9.5UEVG0Z
MM:7J0.;Z!,<('56MU*Z9>2PPM[/0?2,9>K$Y '$K;[05>,]L/A.[.@#D.1./
M1<<C)^*QA^(\#X_#NP.,Z[=*26YJ\>P,^L]Z:_Q9&M7*15FOK_=*E5S/],,S
MCGG,5:HR#7\1IPA P@A@N=),)5F<HR*E&;6O-CA4BJEQU5;&?QEPUGS;<%B8
MS6. ')C&=BI$!^<,1HOH6(U9M!^)-R./A(.Q/,:(C&0I!QL9-ROY5D1[3>3!
MC8]G']^J_Y%Q?'-C RWCQ@WHX(2I/H)OS]S-U6VY?"J7#VWV);T [FK?*%*0
M-(L10 2;8W!6 (8E 3)#19*9FU/L5/Q\N"A36YE:34RLX7-9:4G_S=%T'CXH
ME@;U*%"'-K-;E(].P6L]HI]:37ZN0Q%;9:*]-E[K'OD#U:]I/ER<<0WVFV$[
M,^-O;_'V=.]KV68M-^$/5>N#KV(1YP5#@*L" QBK'% H8\"Y0C'CF-#4RIW$
MML.I$>-YCNR=U%$MMF.0@S7P%A:[9SB#NW*\$I+#T[G?BNBKY7%W1O:F!.Y]
M,+ED;K_8SJNE;._3JB]7>^][ UCZ_H?2SYK&/JSH\AWE=1+1IOSZG E&9)RF
M@$JA (29 H3E"B!(DJS@)(>*6M-S7T]3X^5&UOKSCHRTT59<!_+H1=:"?WWA
M%9AX.Z&*_FQD=2'<7LP<F-87=B-1;#>&C<B>B-4&E5Y&[6U@/"JUT>.(0ZU>
M&'9>\/;[XV+U(F5]BW?_:+Z3]G/-<)9)Q;5M:X)*H(H-C68,I#D5-%9<<;L:
M1E=[FAIYMO?6;2JAQ_ZK'4=0[;;S7J *S)N'7L-MM97H;KW6C\C&S&KDOLZB
MSOORJ^AXW79W]S;JKOJJTJ>;YNLO#"2,.EGE[GR*(90IB E(-"\ F,40X(QQ
M(!7)>$X3A953;>/CYJ=&#6T*6(O3)AOL+,E@,"*A[Y.LP7"?XA=U]CNOC[L8
M=S)?5.]L!E]^:F 2+EJN_X,NGN0O+[L?_]]2KG5#WUX^R&>MK\D=16,D.4P$
MH$(R/9U-=5.E&* )E2R67,'$:L?DUNW4IKD1-:IEC7;"UJ[7'^_^8UBJ+COT
M[0C!/Z:!B>(6.-T3>CFAXS>_EUW7XZ;[<H+C+/N7V]N> CWWE6%65?6&KM<O
M>OOS%UV+ZN-J\^6)_9?DFZ^KMS\>R^:X?XYP03$5&8ASDFC6,@5<6%H 1) 2
M@NF_"J< GILEFAJA[6LM+;0"$3_48!8M5YNH:I0P43URI\:-<9[.XVC'?Z..
M3O!C_PL1G >5L<QHO3D>+:U3]&4_6F^OC];MH9I#$0X;E^DLU>L&80X%\6K$
MY>"&A_'U[Y)63^MZE_]^^?BT,=5PVLND6!"A25<"R-)4$W%" *:$ B&%S%6&
M:(J<TH=W=S4UACV0-*I%C8RLCI=V%@C;4:0?W )SWU#(G.GL.AI>>:JGNU$)
MZ+K:I\QB\<8PRM \)*M/],64-KG??)/K]N=J>S7"TX04F=EVYKGFC9P#6J09
MH'F1,T()P[%3*N@K_4V-/!H7E@<S$=:K%[K8O$0KMB@?FC0,CXWL]6+_O%H\
M5=&[U=-2.$=;7QL$.VKQ"&U@?JDEC5KQM%5EA-W^LPIP+FV)C%>NN=;GJ(1C
M"< IZ]B^-M A=A^DUG[GD-*"9B0#,$\UV7#" ,DS"8I40$)HSBEVRC)]UL/T
MZ&4?B.GHN'H&GAU)W 1)8%HX1", "W2J[M<9]*R7<7T\NY0\<]WL?'#8;/X/
MNBX--QA?^OK(%!/!99HQ0&-LDD\*!(A@VI!("B12DIN\T2Z3^;2#J<WEK7Q-
M>,B0L^@S".VF]"W !)[13I@X3^@NQ;W.Y[-.1IW.72J>SN;.YX9-YGJQ_[A:
MKK;G%XV'=^O>O;LF-6XH#%$"6&(6;<X)H!G$(!%%&DO">0R=[J3LNIW:Q&_,
MUS;CTD]MENJ?'0-1+!&W8P3_. ;FB0;"0XFWL28_M4+_'.0VVPTHK[QBV?6H
M;.,&QRD'.;X]D)F.&S?GJG,H52P@1P GF  88PIHRG. 82*@2F5:9T,RB9\M
M:>B\#R?.V?44;L+4UP]UJM_5+K3&D7 N &G)+K?!$YI*SAC$"-B=YLF=,[K5
M]TL0%_H9EPVZ%3V;^CV/#JQ#Q;])\61*X7U:FT]\\_))#_/F;BF,\\UC':=0
M5T]G>1ZG$'&]K\ %@&D, :&R !S')$TD0PFR2MC@VO'4K)"MM+.HEK?VXMA)
M/+#*O>T8V/%&"&0#D\EMH+I7N')$R&_-*]O.QZV"Y0C)65TLU_=O-$L^2*JG
M>EO\XV5;:H:((L\82P$AL=(62@$!RQ$%!592*D0SEKIME'J[FQHU'?BX&'&C
MQ;XVRD";Y3+*CN;+S=B-9LG4DLYVY7U> A3WL4,EC(%SN<O7L75ZU>\T>_K?
MNCG$_9V4=]]73\O-WZDI 3R7G(J\4 Q(F&8F'T@&F$@IR'.)XS1-J+*KZW.]
MJZE121TR7.Z+SFKZC&@M;YV::EU6/5F776'NYQ._X 7FDI-0ZTA+&C6B1HVL
MWD ;'+5^ WBO$Z_N .(M8>H=N#@$J)^V\%JAZ1V:] 2E=[TQL+;B,RT7QMA[
MMUJ;,NNFKR^2/ZUK4^2.ZX_HJ<Z@_]M:;V#_6*YEDZ'0;&=_D6JU-BE.YCGE
M*A,Y!RE"VI8K1*)MN8(#E8M<99!DN>3SI7PP#7UU*,?H0SBK24.:27,F8MC3
M*N>ZC5X&R\XD' _[$=E^K\ LVBD(M+"@HL;KYD"MJ-8KVBM6NS?/(E;KYK=$
MF%>L_5:<]"+9N-4I?8)Y5LG2:^,#@^/*9;G1EK4F__=Z?5\^E%J>QK=:+PSK
M3?F_]9K?WC'\IZ3KKW^MYIASDF5Y#%*9$  53P$E6 *,"<^YWG#G;DZ+@Z28
MFNFLO_K,,39N$/AVE!L<TL 4V\@/:@6BO09-I,BL3H_'#;,>*C.+C!Z15L1C
M4-TM./J-L1LDR;@A=[> =1:!=U-C@^MGK<U1PZ^R^=_WC0/7M]7".!TW8<F?
M5XO%NR;*9(Y(6N1*Y #23 (H8@682;B409@3EB=,*.Q8/\NE_ZE1X%;\Z*>M
M C]'9>MPV.KP+]$V>-[H$;6*.%Z<N Z3'64&!#\P60; ?4@%K2'H^:Z@Y23#
MV!6TA@!TH8+6H&;<"%'(<OYK>^KSKJPX71B"?:=_4\U9$>>8:>LO21 SY;9C
M0$SYP$S;@0RG*4FQU>EH3Q]3([:MF%$C9V-GU)+:$5<?G/WDY FDT!MB=WRL
M"<8"@0LD4DG^MX?5\[_JMVO^^!]H?@3-CS5I]+4["C%8*+:=_#:/#O0#N5B*
M=$YEQHN\R$!!4W.ABA.]PXL1$(HE>982F>30R>OC8C=3F^8UD[:9O897?>Z
MU,X(N1VHP%/]:O:SC_JKI]6W;09SC]X;O=#X]=6XW-6XGAF]ZI[Y8?0_?7O,
MR3;O-U88PXR"F,G,9#U# *M"4P0SGNJ(0(R=W,'.NY@:*9S$6 P*:[\ I!T=
MW 9/8"IP1.:F^). 4>L7NGFU&)3^*/6>)P?>V.V*%WZBI7B_;,N&M1&/,1.4
M(QD#55 ,8"Z-&P1G@*-,%B1-DH(Z)1?J[6UJT_Z@:J>1-GJ_W%;O=+QGZX78
M\O[,%W"!">$$,U#N, L0;FH%BM\+K-X>Q[V8LE'^[,+)ZJ6A=4FK;W=+8?['
MG$$\TX4V!JN[39V4IUP^U G4YA"J+#=^Y 5&"8!2[RUPKF) !,6((\05==I6
M6/4Z-68QTM:>SK69+/=RNU8EM4'<CF"\XQB8:'80UC\<B#R+Z";:2MUD7O19
MF]0!)<_%26UZ'KDZJ0,8Y^5)75X>QDB?M_4VJGMEKM;G.2,YS%D!!%>:?%(3
M*Y^E$! H(<G21!9QNG4LLJ.?TRX&N <%YIJ]A-%*149&-Y(Y ]&.3P8!,PYU
M."#B3!!=:GOE@K-.1IWV72J>SO#.YX9.YMH3YA-=;UZ^KNFRHMQ8,HWSHN[B
MX'=S*&+$J*1 *$D A%Q/\2R5()5YJD0&B<3<Q<APZ'MJID8K>O1H9(\V>T&W
M3MW:0G^4ZW)EZ9\\9#AL&2,(R,')I,&W%CLZD''6.B[7)'/P>Y]<XPR89QJR
M[W]DAG(&YIR\W)L8$(1R6M;&-,N_R?NE;$\'DCQ/8X(*H$FK ) G"-!<%  3
M*F)!M-F"K9**6O4V->YZ5ZZK3<U96DJ'\(FKJ/83DG>L E/0>>FI6=2*&VEY
MA]3RNHJ@0PR*3R1'"D.Y&5&W:!1;A'H#4JXV,EY,BJT^1V$IUB\-,Q\_K)8/
MFK.^&TOT(*4PX[Q@E%.0%(4$$+%$6XH* ZKAU?S*XD00%TOQ<C=3(U8C)3!B
MUKN?V2WIFCMPM3/Y;D<K,+4. \K9DNO'P:O1UM'5J/99O[JGIMB5IWVY^=YQ
MOGZ2XL,^<GZ.9 (+#H7>1AIR8 4&#)(4**+-+H*9*E*GFVZ;3J=&%:V$49MT
MS?&$V@IF.Z[P#5Y@YNAPR-W"^<$B08,'!]QNB )[W5[H^)5=;;NAN.Y?V_/N
MK;F7+GOM?);59EV:\);:(>V/9;FI[HPS[YW><CX;Z\@X 7R5/S:_:*W_6S,5
MA%PD&<!9!@',4 XP3Q*@&":,JY@3(N;/<LU6[DF:O$CH,C,/Y0PW0;<*FN.9
MSU_^J**MX$,S./D923LR?,71"<R;5YT+]ZJU::R-<K/=Z+4IHR*C6U0K%R1[
ME%?8 R69\B/C*^6B\@IP=\HJO]T,MD57WTTD[V=I8-(K3"W$FV_FHW^_?+ND
M1A+S=[J1\YP5.:*2@5P#;.J]Z1TK8A@44"1(0?U?Z51FR*GWJ5FGC93&L*HV
MQ@-Q0W]$:_V#LY7J, #6YFH86 /S[UNEI/G(Y3:YIRG.5GMW'BLRB_;8M\KL
M'MU>?7BU;-W1]&WB.D@PMJWK#LX%HW= (UX)[^-J*30MZZ]/DVL;.W"9G]^L
MJLU<ZH<A$1!(AC)@V,_XH7,]@$+&F&=4H<(#$;I)-36";$RDX9$L?H;J)LH,
M-P"3H=(C%;=A,[/HJBT\$LT.&X$QZ-=1LBG0\C P+>EZ8.,A2EC,59(0B2 &
M,$T1@"I. 8Y5!D0<LPP7(B7*B9_[NYL:\;Y?ZE[T-F)[<.JS5H67&A43(DJ+
MVA1C%:0(0EY7NIQ0 8HNNK%\:_C5[-?V@F=7:7W.LA3R7&E[CM-<FW<I!!1K
M-LD%2;.4"J:(4X:IB[U,C37V]XVBOF]46M#HN=>'W0%2^TO9FX :^4[6R.C;
MS[\7 ^_WL><]C7X=VZGLI=O8[H>'$4!KVU9?5W?\?Y[*M>Q,)#^/\R3+*5,@
M20K-"@P:#WY$ *=)AG-:Q*P8DAK47@*KB3!^_L]/NJ%OVL:KO4T?6^'K^!BY
ME=R-01S&Q(Y6/$,\4G6*;:# 9A6U8D<G%2MFQR4K_'&0.V!>B<FA^U'9RAV6
M4PH;T((;KU7KS?QW^J/\_O1]Z\9+I$PR*4 F4@E@1B6@"4J!R#-$B=X;94+9
M&#-G+4_-@&F%L^.:<YSZJ>0F[0,S12N71]?03FW[IKE^Z6"*ZW^=3N_S5D>9
MO9W*;"=G]P,#-Q4'#D8$IU*R H(LC?7LDT4&2&+"@5(]&Y' 1<)BE^IU0]VU
M1JA:]]7T,;S\B[M;UC2]KX*X5X7VHGHU9RD+GRA_KD]ZL>52BNJ=%N-WNFES
M77]:[Z(%ZZC@Q:(RE_.K]<;L]-XOGV6UJ?\ZCU,:IYR8B!AHB@/$&-!"(I#P
M#/(L*VB1.15ZNE&>Z2W 6Q7,3J R$C>;Y7(OL^-.X,8!L]P>C#<,H?<,K29-
M\="]+GJ_L->F35V@]3'#]&4_3.\MALE]*^$'7+_[BQME&G?3X0? LYV(IV8'
MIGXR'DW&H]Z4,Y_3M* 9HYI7I<0 0B(!@YI<68*D@$D:*RZ<4CT=MCXUEJR%
M:Z,YC'R.02_'R-D1W& \ M.5/13N^9DNJ>PW']-1#^/F7[JDW%F^I8L/C5&H
MXZ/\L?GZEUP\R]]7R\VW:JZ0B#.$!,B9R=E,BA10I;=#&10PSI(BUKN@<!4[
M3L69&B'H[RL-6;KC;#CL2&,\D .SS W%/.Z7'B]V_ #ZBE4]SD2:<'F/+OAN
MJ_/1V:K/]-<';E;5+R_[9]JSXYK7[Q_-D]5O^LE-]7[YJ<ZB\G=9/GS37_+=
MLUS3!_GVAUSSLI*?UB67\S2->9IQK#\!& /(>0Q(HF*0TR2'/(9$">48IC.>
M]"YL,DX(3RV[)HV?RF4D5HL%75<FEXW>]6J%NUU&7OTSL./^B0YMX(7BT.?Q
M4.]#Q\<J8B^7G2.-]K.HU7\6-0@8%_4&@UFT12%J88BV.$0U$*%3E0<=O1'R
MGX>1?P))U8,.C%VF]K B#$A.=%Q[^[/I9*7^J)J5^7!AGC.J).(I!8IRI-<U
M# %+I "29 KF12H5MTKJZM;MU/80A[*94[V]-^.BC@1?&U7 2H$G_0]:FS<.
M*7GL1Z-_>0F'<>"582=S5 L]BSYO\=2";S<2A[(' =<A\5$0D$?*@.0/;+=4
M2,Z8]>9$LF]MO.1(SAH>94ER?SO0KNC*"G7_M*GT3D[4KL*;=;FL2MXXH>8Y
MI7HYX( *H?= *D> 8D4 B@M5)"07:5+,FXR47S9TO?&T#QHJK\O</)4ZW/3\
M13Z4RZ69GHSJ/_08KB./;@8YD1#F #-3%Q@7$! J)5 RS:B">N1EWH[NVZ5E
MCN4)C>U6YG C^[:6<VK#ZFG'.L9 36!_:KL]/=!W%NTT]NW+'GQ4QMUW#I9V
M6KO,6T%WWE/>W.% /SRI+1-Y;+9LG8E>VCOOTQPX!(D,4LH BU,.((T+;2*8
MJVB$15[P7!'NY.(S0(:I[2T/LQ5M)38_G]CI5GG%O(V3W:H0&/W ?-](/SL%
M>K9#^F6V'Y"0N8=N@-&OE^( .<;U9AP.U)G7XPU-#:/+WW473^N:L-\O'Y\V
M.R<35#">J*PP1=@8@'$: RP34XXM+5*2IB1.K"((KG4T->([D#.J!1WNM=.)
MK1V/^4 L,%D- \N9BJXAX95O.CL;E52NJ7S*'%>?'W@L<U;H?<Z82I#"&9"8
MFII&D $"<P@PRA24",-8*9?@AO,NG"AAM!B'ZD#.__M_<)H4_U['.NIE^"<A
M5<G+C>L5\#FXA40HYCD!"&4:7"2U$4H* >(X5KQ@N4IB.."PZB:(_W%.F<[Q
M%!GCN8R-VT,B $QB#IA,4L QRO7OE4()<SX>\H#FQ,]USH&T/)"Y"9K0)RD'
MPOU+U(@7W6WTWI,];6H[>K,R976\!M5V(^+W%..\FW&/'SK5/#LWZ'YR8%:@
MG;6\JJJZFI]:K<U!0S5/2"X5UO29,FZ*+7!HJ@E+D.0R(3161$&GU)7=74W-
MBOUX_R'BAP(ZI@/JQM2."/P@-=X%KY8R>F.%EWO^GZM0^,W]T]W=N'E_KJI]
MEO/G^AO#&.+-ZOOWU;(FGOI(LGI?54]2S"66:<8E :1((8!,I@";K(X(%HI"
MR2"13A[J'?U,C1L:,1M[=M;X+E:SJ*QEK5T;FU\Y&K-=(-OQA0?H I-%B]J7
M!K4O+6J-F![K_?;CX+?";T=?X];T[5?XK(KOE<>'A@A+)=?K-OOVT>>;Q2)6
MU-3#HYFY7S91:DJD0!2:(!()J6!.)D1W5U.CB9VDQTQQ,U'T@&W'%7X@#$P7
M>_2.&,,[85P'PW,0;6=W(\?'7E/[//3UZAMNY"%D.7^CMR]W:TG?K(2<8YRD
MJL FTTZ& (29 HS$"N $0<8*%,O4*H'@:<-3(X8W];Y9"Q<9Z>PF_QE8_5/]
M%@A"VP%VVEM/Y"Y5+TS;2O*_/:R>_U6_4L_8_X'F1]#\6$_3L\9&F91=*FRG
M8.??!\:E;K, 'IQY_[W<?/MCN6*57#^;HYSZ#+PZSE6L__6T7NO]Q2^T*JO=
MM=H7N=DL&B_X>9&EDJ8I!H@@O2,PCF0,P1PPO1V($2&$L2'9_L));#4Q7B$[
M8)M.P#'"-=S VED6KSQ.(T7&[M*7SJ+#^[N_M*+1H:;-C5YUECQ^IVU4JWOD
MF7"@LL<8VN##XC>^-IRXX\;>!H?]+"XW?(\W>*>SZ\YNK,/9K0V1:N0_='9+
MYDF<YI@43"\T/#&'4 3@3.H5""&)%$X4CYW23H<3=6IVZ-W#P[I>TDY=66?1
M@1(#/)K##+3E#=HDAB_T39Q'G^8#A4/[- <=%O].S6'$'=^K.2CL%]V:P_8X
M; GZ;;42?Y6+Q=WR+&?%KV7%%RNS8-ZQ:K.FW-2J@GF>B@)D69[KC0R3 ,L4
M LP(YC(C.$?2955QZGUJ"\56^#H'WFDNF"K:*Q#]N57!T=//;7#L5H)@D <F
M=Z]H.Q/U(-2\<J^;!*/2Z2!P3AER6"-^O).W:9M,08@V@S=)L<AXBH#D$&G[
M&1- DYB F,H")R8'6>9D/U_O<FKT=N:$>Y#>RDA]F]/R!<CM^,LOD(%)ZQJ&
M'M.LN^,3U+WY0K>OZNC<#<,UE^>>-]UO=MXN-^;$6@C]E57F\/I^_77UUW+.
MTY3I/;D$199C  M! 65<[]EAJA)!."NDE6'5T\?4^*41,VKEG$7U#<AJ'1E9
M[6]_N@"]?A'D :; [#$((:<;HBL8#+XLZFIWM'NC*XH=7B%=>W28B6'J2KU9
M+9_U1*JK5)J?-B8OH#9@ZL0G3<W39"X+%J-$<L"QGN\PS@E@HM S'R40YSC+
MB5W.(=>.IT8'>YE-/"AOY*XM_.5J4_M0-U$1;F:']3#8&1\AP U,(D;D:"_S
M+-I)'>W%]E^"UQ4IK\:(=>>CFB2ND)P:)L[O#SP1HN6R,KZRLKI?OOUA/&>?
MRNJ;Z>!>&1GF>8&%H# #60&Y\4@QQ>ND "DG3+,99XF;@^O5'J?&5;5?=UT6
M01Y):YC+%+S4:_52.A:JNPZ[BHM,TD2:K]YDOLYS0%-&]2CP))5,*B+B 5X$
M?M ?WQG@=0;!\I#-YQ<=^F!-RQK]9(3].=*+[]LS,(V\'D_2;*'Q>WIVM==Q
M3\QL03@[);-^<4"BS+?/J\53]7[)M]7^&"L()3F(<R@,X6! 8L0 0IAC&(L,
M)=@Z'>9)XU.C]$8\<]7'_^:0</$4LGYZN!6(T/O-/0;7#Z:N8^&08O(&3$9*
M).F$C5NNR [E>S-"GKXS7M['#FF/LCMV/3.XTMKELJ9_5%(]+3Z42LX)EJG(
M408H-ZF6N(H!2U@&5%IHNTC_1S.68S6U:WU.C<'V]7P?C=#'19-GT5,M>+30
MDCO73;L*OYU5Y!G4P&QX4A_YN#SR+&IDCC[TX3FDP)DM0KZ+F%WM=^Q"9;9
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M*4ARQC.H.,F%DTOE]2ZG1ID'$D9M.+C;[M4"Y0QEN1)Z.5))H0#,,VUP(YR
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MOU/$YT5=!X=Z'K<V6HSG124.@SLO/W!CA:"FI(>Y,5HMC9%1'^N+K.#Z_Z5
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MCTNGDR2)<B=W]+@3/%)21K0_,<IP[/O9(Q2B8W#)7N1H+W.DA6[]/691(W<
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MGQ**S2L>JU)^E>OOU?Z?OS\M-N7C0MXO/^D]/"\?Z:+QB9K+@J:89Z8:=UX
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M7*N6#SR \6N1]PR?U#]]EH&SVT(,-A21EWZCV0UHQN'-+OQ;W<%FD Y_MO-
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M!C!V@,X0H"T!K2E>T7?^@^$0?#;(H P4GA9O<-RBV:[&M#?>S?_MPT7$78W
M7LS<]6_S[*7>BEN^G2_>:S]ZNJVTLIS0C%"&N( %*5.(2(D@14D%TY)4N<K+
MJDB94U/U\[+&=G*P5A6H^0),C;)@N=76L<%Z#\1V7GL@X"*O&WN8-7KNU%<*
MV #0 HVP;=A[Y W;C_VRX4>-V2T>"7'NL-/DFTB3V%IJ-U5@"A'FB?9:LPI*
M2FB.2BIYSEU8XYR@L5'&T8;TBL;J9\'UV>6/LE6Z)UI7;L@C-SX_*^P9M]"7
M6YE?_+SGO;EVA1NF:0,OL4AD01B#!>5EFP5/"--[6YQBG/*L%&[1K/NO'QL9
M;+3S"UX]P,[R;M@;D=BWN=9@N%^ZGK0Y[#7IOHAA+S9/FG=T%7GZ4W[3MND&
MTV94K\LI,;V:HX1J9+#24S=)$T@*0J%("$O2%%.<.K6L/!8QMNG;-II:EZ9J
M^^VZS> 3,-K-XNO B3R36UQ:[2*4I3IO>] 9?4+,H+/ZO)F',[OGDQXGT>]F
M*SF=2KYZI-./"]-F=?7TNEX^/*[D\G_*QQ^2/G:9G4DA,U.9!I8)PA#EG$":
M<PP9(U25)I"@**VSB*W%CHT%=A4':\W!6O4;T"GO<-QI/P(69\U1<(U,():0
M^F0IVV/K<'0<!>.!CHJO_?JZ'0@[(]5[ &S_MN$.?)TMW#O@=7_:SW^[%3_T
MJ^ME/?O6]<*:<*X*SC#7KAO1_Q&J@)3*%&8JDXA7),'"*<CX6,38F'M'0Y]8
MC!,8VCEOUR$3F7MW0>FT"^>ZG;<\J.MV0LR@KMMY,P]=MYY/^DWL#_+G+6]B
M%?0K-8/,]%]Y>Y3[<3ZM^5/[WR_RU^JE5OF?$U;F2<E+"7%557KN5R4D0G"(
M22%+G'"6V=4=]%5@;*3P2?(F/GQC ]@WPHTCG(?#CD%B@AR97[3JY\&] :WB
MX&OWI[$ -"8$/ [R12\H1SDK,2B#^4)TR&_>[_&IPF=BXTU,EA2O'Q=&7M.:
MN(FO7[ZO5_6WQI7>7FY-,L:J,J<5S#*1:.[+.*1<,8AX66*4"(KM:BW[B1\;
M\VU"'N=*NT/W]_,96#9),/5,_WL3._+3Q(Y,-_;LW'@W79_:3"J7MD_NXV:Q
M[8TZ&M%/P@WJK?*@U;YK6]^F,BW!UH"=R_.HD+M4)8P)_5!E"R\-P8WC&#@6
M-O2%L+_RH?-;!RR-Z&OQ?NU$[[?XAC<<EI<U1[$31E*$4YQ"G*0Y1%*DVJ=.
M"L@QQC(K<XZ08W##*3%C6S\:I6[ K"=2W@5$.T_X>F@BD_F)TM WH%$R9/A"
M'PB!@Q=.BAHX=*'/W./ A=Y/>YZ?3?6,FC6]Y-_-?LCERI#)'Y(N'Q>R#<Q\
M>%Q->)JCBI,<2I)AB%*40%91!"FN*"L%8I0Y\8"5U+'1PHY^VI/4"CJ>LEDA
M;7GP%AJ_V&=Q6WW!5N$;L OINUY(W4_H7" *>VAG)7G8<SP7,(Z.]IP>#E$3
M\$GOME]-:7V_?%M/I?CPV-QC,5H)3)B$&<5F:RMS2)@JH,AE(1561#*K6UH'
MF6.CH*8.'M]MZ3J3/P%OU ;*Z*U_TFA^3?7 T_#;,5-@4"/STG&+7'.JUVH,
MWK9X?NC'\\HZ@[T(12PZ>%KN,U8@[ 6BOQQA_Z-NA+1<K":?3$V+VU_U<I*4
M99:EA=*48_R>/*.09I1"+/.4F8T1JZQ"P?;>.C92,?%T]7)5FWH(NPOR5Z.L
M94C"/FS]5.$-1O33*B\<K G@I-U]4UP_L#.]];\.I_;^&P>9O">-6$_/T[^\
M.E/K\URM?M*%G$BNRI)4)I0Z%1!)TX@F3S#,"EJ: XF\Y(5'\883HJR^EL,7
M9+@5HFZJPYGJB)P^U"LZ;2H +#N]O5.U-AC;+?.^D#U#:M;G2]!<DY%U:'RL
M3*R-G.?*P#HTM"?SZNBC?@3P;L;G]_(+_?5)&G7K:=T<>6Y^W(49O)0SJ>K5
M[>JMU.^F4\/BCWK\GK;/F^)%*E,)3:G>/""*("(,0ZQP 5-5)@4ND4@JIWR,
MH-J-S2-HE0,K^@O0%5BN=08+ZT)2<0;1CIN>;6@BL]H;I<S-97.$THR/.8@U
M.H)]0\V8=3:!C5&'S]R VWMSFQV.%:/ 'I1/PVHX*!-' ?>0P^,(\4RG>V1+
M^:]'O:2\^2$W+9BP0DCE2$*2X02BPKB"ICLA3Q,B<Y:FJ;!J1]@K96QLO%42
M-%HZYM:=!-*.2:^&)_:.[0"9@&WYK" (FWAW4M*P^7=]QAZEX?5^V'/3M^CN
MN-KRH.OLG*JLJ,*PXC(U1:,)I%QS ,I0HK*,XJ2PZO'7)V1L<WZC8UN^UW%;
M=PI%RWW=E=C$WMCMPQ)AOO<!$'9S=TK0L+N['E./MG=]G_6;ZV_K6;V2[[4_
M*][-5GJ4:S:5[<6V*? H495Q10QNC$ D4@I90LRI3T)X620("SQ9S5=T:C?K
M^\4YS?^-T'A?=*T2>#F?__-";PL?8.V((!Q<D2FA510VFH*MJIL(E:#U+NU0
M"<H3%T0.RAAVYA]RA^53?BSR^WPN?M;3Z41DM"IDFL$R*;1O4)4*8IKF4!9Y
M@814994X5>]:OWALGL%:+S=.V,"$-*FFFC\A)US#)(L"XESJO13GIN(F(2G-
M[(IL7@/4,&4SKX3*CBA]S(],B1?M=N:]0R.#,MSFY8-RV:%)AZQU]'N?KN7[
MI8::>^D[]65!9_R[7$Y(6:89RQ2LE+E=YH1"7.0)S!C-,%*<)\HJ4=5"UMA8
MK-7/)&BL.@U=&G3WP]H_;P.#%7DJ']<-VP#W)3AP+@W.@P$X5)_S*X!T;'QN
M!4U___/^5PS8!MW*EOUNZ':/>+#IYOYC[YQY_ZSZXZ;C]X?Y2AI=UA7/)TP(
MKC@E,%.TTFR+4\@P3B"AA9 I9A)1:<VVU^DR-C;^>- G'>YW>W!@F"O'R(*Z
MAT-^)-=Y-V!G>(P]-VUCA]>#CX[#^C#<* VT?D0?+;=%)@R^O8O0E2*&6Z3"
M8+&WB 5ZI6_@B[E/T>\]+*F J%ZK"I7!I. I1(+H%4R*#&:R*(G"V-0J<XMA
M.2UH;,O36L_:UMF]B*3=UCX$/I$7D8V*PQ2<N(1(X'"-,\(&CKSH-_DXB.+"
MY]WCT3]S.:.+>O[G;/D@>:UJ*;KZV(FJ4F8N27B)%40Y)I B5C1Y,5*A+"5Y
M81N??E;*V.A@K:ACL?%^)/L9(1@^D>G 'AJGJ/6+IE\=Q7Y>PF!1[1>-W(UR
MO_QAWW)V__>Q3;!;?IFO_0WY0:Y:1\3DO7R9OZ++[]K[^%$+*5X^_;DT]RIW
M#W)!33[,K?%;ZI5>*V^9WH53OIH4N2P8K4I89:J **TPI)()*%-4\@R3B@JK
MG6],)<=&,CLVFEC[Q=I*4Q4 3$W:F/ZI^3O7=H)'TY&YGH'YVD! -Q;^FVLQ
MO@C? #M_Y[G'-3(Y'@SIQD!S1;S>U;TP1OYF?FWL!&M#3?/M%W^V@_P;V)@+
MMO:"KVN+ [I;,0<D<)W""(H.7.DP'M3'M1(CR@H2;OM%OZ7)Y$,I+U@E&%05
MY1 QC,VM>@ES23G&*,MRMUOU,W+&QOY'@:5&4:>$R$O VC%R +AB>YP^2%T;
MA7N(0\PXW(VLYXS$/33X0BSNT<<]>V.LZ>:]I,NF.>R$IQDN*\D@+Y($HA(+
M2 2A>O_)BISQE*O,Z0CJ6,38J.!M_4LO^UO';FH4!?)"06%;/.UHX#J4(C/
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MU$YK8O'T[/U#%!R&D(ZSH8.)MR>8O%VLUF'V_TX_;WTIQ9(5S$9@R"DH"ZC
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MY3793"R/:9OYBMZ[6G);^ZK6COV* EJ=//W?0\G XU%SFY9QVABW@\R)TNX
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MA=1^T.^EX&).4@EM(9DD0<5"9WTD1@P*[F,0SJHV?5'O):F3LVX8,S:,X#M
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MMGFE=2<Y(Y<'#J?NQ="R[P! 5UI<[BTQFHRF%B20099UC@X';TA"#+F3GME
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M]AW"#D/5CW9E,*0V.@#7;_C'%4$M%W/Z,N&5R]Y;:1J?A2-C"Q:=(=<3RV[
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M^>HY$3#=ODI_&[YM>WU.HK8N*@)$2L24*IHV$2.F9+"!V>P8=S=N..]YL'+
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MRZU)^'9KJHO0R!@J"5&6.H(A1'#!*&#6JU1*45*TR:_=3].XV!L/)XLF2NL
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M#EV''3N*9&]D#L) R($T1ML]D);J+3Q4(60=F>DK;7>XH]B^C<*K6EKCX>=
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MKY]T\8_N"W&6E.;).XKX,1L2E!00"RIR@*7VTLJ<8YN*B<E8'K;$3N@<^33
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M9Q17;$L2 _>A#K&F2,+H>G J:6],!81TR*W*W.C.[J<-9Z[SO6!DO!ZCFO4
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MMW,]'8^Y]C>H25:LE4=J&]=Z<A-"18,8P#4NL3^.T'XW$QM =1!MC5TH<\R
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MA>E?OR[^^#=Z]-: _$/7CVSW<0N,)UXZ[N;J]5S2I?(>&2H[JO=KQ1FRGTD
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M4Z.C7]D+2LY5[:*YG#N(9NJMS7?SU7JYJ1'?=D$95)@P5B%)2D@M22I$BO6
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MTMKOE(W;_.WZ+FY038T=8A]@9G<[[F/Y0BMU.M]?G?IYNERMZPX\+M,49K\
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M@\AA%->^@<#^'^J7""O\]W_Y/U!+ P04    "  ZB&-486OY=T(L  !B$ $
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M3,Z.128OBZ)0=\L!65WA=\S+%3?LW12L^5$,]""#<5))F.Q4\"(=HF\"0K
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M5(S.8>BCL7@%'4 S+P=7\.'%N7U8$X8K<?'^7/SWN]/7. IJ\_QBC \.SC_
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MZSS)X+&-')VK6WDO3'7+VVKR0[JK//>4G9J8GY_^[;JK]\.^U'=T)IA4Z/#
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M5LKMXUUVON]9?/I+J>YZ[/O_ 5!+ P04    "  ZB&-40+FH^J (  "**0
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M(4&#Y7?7YYUNGPP^=<E5MWW=[PUZ(-S]K?VI=?Y+E[3: W+QD03O:O7BR_5
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M0R]L5M[L!6^KQYO7#C=@-/C3I:FO![N(&32BF=F]"Z:R(8? Y2/YY*@R#0J
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ME5KNR&UQ /$H1.0EM=^R/L!)E$%'PY>4M!4]>8$&70 "4$<5?78UD%I--H$
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M73J!L<$[Y,R\"!J\Y(N1LO,BPD-AA$4*]'Z4_B45)3,YO/4NT"<5 Z</+$@
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M*K-5Z\NV2_3:W+G&**1&84)69'I--9DQF6K79I9#!&M^";>6"5[$+G.&+1W
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M,#(Q,3(S,2YX<V102P$"% ,4    "  ZB&-42>!ZG)$H  !GF $ %0
M        @ $Z< , 96]L<RTR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @
M.HAC5.^)*+&S?@  [90% !4              ( !_I@# &5O;',M,C R,3$R
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( #J(8U2)WY:7YZ$  !-^ 0 4
M      "  >07! !E;VQS+3(P,C$Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( #J(
M8U18WUY/:W<  &ZS   4              "  ?VY! !E;VQS+3(P,C$Q,C,Q
M7V<R+FIP9U!+ 0(4 Q0    ( #J(8U3 Z5Y:+,H  "NS 0 4
M  "  9HQ!0!E;VQS+3(P,C$Q,C,Q7V<S+FIP9U!+ 0(4 Q0    ( #J(8U2C
MXCUWZ*D  .HT 0 4              "  ?C[!0!E;VQS+3(P,C$Q,C,Q7V<T
M+FIP9U!+ 0(4 Q0    ( #J(8U2027Z[OA,! #V-"P 5              "
M 1*F!@!E;VQS+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  ZB&-4:V6
MD(.U  "^10@ %0              @ $#N@< 96]L<RTR,#(Q,3(S,5]P<F4N
M>&UL4$L! A0#%     @ .HAC5&%K^7="+   8A ! !@              ( !
MN6\( &5X:&EB:70Q,#(P,3(S,3(Q,3!K+FAT;5!+ 0(4 Q0    ( #J(8U3N
M,->D.@,  *\0   7              "  3&<" !E>&AI8FET,C$Q,3(S,3(Q
M,3!K+FAT;5!+ 0(4 Q0    ( #J(8U3L?+"*.@0  +L4   7
M  "  :"?" !E>&AI8FET,C,Q,3(S,3(Q,3!K+FAT;5!+ 0(4 Q0    ( #J(
M8U26^D0<H0@  'DK   7              "  0^D" !E>&AI8FET,S$Q,3(S
M,3(Q,3!K+FAT;5!+ 0(4 Q0    ( #J(8U1 N:CZH @  (HI   7
M      "  >6L" !E>&AI8FET,S$R,3(S,3(Q,3!K+FAT;5!+ 0(4 Q0    (
M #J(8U0P4T UE 4  (4=   7              "  ;JU" !E>&AI8FET,S(Q
M,3(S,3(Q,3!K+FAT;5!+ 0(4 Q0    ( #J(8U3R1_&4EQ\  ."O   6
M          "  8.[" !E>&AI8FET-#,Q,C,Q,C$Q,&LN:'1M4$L%!@     1
- !$ =00  $[;"     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
